← Back to topics

Kras G12C Inhibitors In Nsclc Efficacy Resistance

demo

1. Documents

1943

1220 papers 534 patents 189 theses

Full text available

Paper What Evidence Is There for the Reimbursement of Personalised Medicine?

P. Hall, C. McCabe · 2013 · PharmacoEconomics (Auckland) · DOI

Full title: What Evidence Is There for the Reimbursement of Personalised Medicine?

Authors: P. Hall, C. McCabe

Year: 2013

Venue: PharmacoEconomics (Auckland)

DOI: https://doi.org/10.1007/s40273-013-0025-x

Paper A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021

Kayki‐Mutlu, Gizem; Aksoyalp, Zinnet Şevval; Wojnowski, Leszek et al. · 2022 · Naunyn-Schmiedeberg s Archives of Pharmacology · DOI

Full title: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021

Authors: Kayki‐Mutlu, Gizem; Aksoyalp, Zinnet Şevval; Wojnowski, Leszek; Michel, Martin C.

Year: 2022

Venue: Naunyn-Schmiedeberg s Archives of Pharmacology

DOI: https://doi.org/10.1007/s00210-022-02250-2

Paper KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Chen, Nan; Fang, Wenfeng; Zhong, Lin et al. · 2017 · Cancer Immunology Immunotherapy · DOI

Full title: KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Authors: Chen, Nan; Fang, Wenfeng; Zhong, Lin; Peng, Peijian; Wang, Juan; Zhan, Jianhua; Hong, Shaodong; Huang, Jiaxing; Liu, Lin; Jin, Sheng; Zhou, Ting; Chen, Ying; Zhang, Hongyu; Zhang, Li

Year: 2017

Venue: Cancer Immunology Immunotherapy

DOI: https://doi.org/10.1007/s00262-017-2005-z

Paper A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

S. Piha-Paul; C. Tseng; H. Tran et al. · 2023 · Cancer Chemotherapy and Pharmacology · DOI

Full title: A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

Authors: S. Piha-Paul; C. Tseng; H. Tran; Meng Gao; D. Karp; V. Subbiah; A. Tsimberidou; J. Kawedia; S. Fu; S. Pant; T. Yap; V. Morris; B. Kee; Mariela Blum Murphy; Joann Lim; F. Meric-Bernstam

Year: 2023

Venue: Cancer Chemotherapy and Pharmacology

DOI: https://doi.org/10.1007/s00280-023-04545-4

Paper Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

Heinrich, Kathrin; Miller‐Phillips, Lisa; Ziemann, Frank et al. · 2022 · Journal of Cancer Research and Clinical Oncology · DOI

Full title: Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

Authors: Heinrich, Kathrin; Miller‐Phillips, Lisa; Ziemann, Frank; Hasselmann, Korbinian; Rühlmann, Katharina; Flach, Madeleine; Biro, Dorottya; Bergwelt‐Baildon, Michael von; Holch, Julian Walter; Herold, Tobias; Baumgarten, Louisa von; Greif, Philipp A.; Jeremias, Irmela; Wuerstlein, Rachel; Casuscelli, Jozefina; Spitzweg, Christine; Seidensticker, Max; Renz, Bernhard W.; Corradini, Stefanie; Baumeister, Philipp; Goni, Elisabetta; Tufman, Amanda; Jung, Andreas; Kumbrink, Jörg; Kirchner, Thomas; Klauschen, Frederick; Metzeler, Klaus H.; Heinemann, Volker; Westphalen, C. Benedikt

Year: 2022

Venue: Journal of Cancer Research and Clinical Oncology

DOI: https://doi.org/10.1007/s00432-022-04165-0

Paper Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

Boonstra, Pieter A.; Wind, Thijs T.; Kruchten, Michel van et al. · 2020 · Cancer and Metastasis Reviews · DOI

Full title: Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

Authors: Boonstra, Pieter A.; Wind, Thijs T.; Kruchten, Michel van; Schuuring, Ed; Hospers, Geke A.P.; Wekken, Anthonie J. van der; Groot, Derk-Jan de; Schröder, Carolien P.; Fehrmann, Rudolf S.N.; Reyners, Anna K.L.

Year: 2020

Venue: Cancer and Metastasis Reviews

DOI: https://doi.org/10.1007/s10555-020-09876-9

Paper Current therapy of KRAS-mutant lung cancer

Ghimessy, Áron; Radeczky, Péter; László, Viktória et al. · 2020 · Cancer and Metastasis Reviews · DOI

Full title: Current therapy of KRAS-mutant lung cancer

Authors: Ghimessy, Áron; Radeczky, Péter; László, Viktória; Hegedűs, Balázs; Rényi-Vámos, F; Fillinger, János; Klepetko, Walter; Lang, Christian; Döme, Balázs; Megyesfalvi, Zsolt

Year: 2020

Venue: Cancer and Metastasis Reviews

DOI: https://doi.org/10.1007/s10555-020-09903-9

Paper Structure-based inhibitor design of mutant RAS proteins—a paradigm shift

Nyíri, Kinga; Koppány, Gergely; Vértessy, Beáta G. · 2020 · Cancer and Metastasis Reviews · DOI

Full title: Structure-based inhibitor design of mutant RAS proteins—a paradigm shift

Authors: Nyíri, Kinga; Koppány, Gergely; Vértessy, Beáta G.

Year: 2020

Venue: Cancer and Metastasis Reviews

DOI: https://doi.org/10.1007/s10555-020-09914-6

Paper Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

Francescangeli, Federica; Angelis, Maria Laura De; Rossi, Rachele et al. · 2023 · Cancer and Metastasis Reviews · DOI

Full title: Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

Authors: Francescangeli, Federica; Angelis, Maria Laura De; Rossi, Rachele; Cuccu, Adriano; Giuliani, Alessandro; Maria, Ruggero De; Zeuner, Ann

Year: 2023

Venue: Cancer and Metastasis Reviews

DOI: https://doi.org/10.1007/s10555-023-10092-4

Paper Advancements in gene therapies targeting mutant KRAS in cancers

Wang, Yuhang; Bùi, Thuỳ Anh; Yang, Xinpu et al. · 2025 · Cancer and Metastasis Reviews · DOI

Full title: Advancements in gene therapies targeting mutant KRAS in cancers

Authors: Wang, Yuhang; Bùi, Thuỳ Anh; Yang, Xinpu; Hutvàgner, György; Deng, Wei

Year: 2025

Venue: Cancer and Metastasis Reviews

DOI: https://doi.org/10.1007/s10555-025-10243-9

Paper Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.

Ku, Bo Mi; Bae, Yeon Hee; Lee, Kyoung Young et al. · 2020 · Investigational new drugs · DOI

Full title: Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.

Authors: Ku, Bo Mi; Bae, Yeon Hee; Lee, Kyoung Young; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Park, Keunchil; Ahn, Myung-Ju

Year: 2020

Venue: Investigational new drugs

DOI: https://doi.org/10.1007/s10637-019-00795-3

Paper Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer

Lee, Arnold · 2022 · Targeted Oncology · DOI

Full title: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer

Authors: Lee, Arnold

Year: 2022

Venue: Targeted Oncology

DOI: https://doi.org/10.1007/s11523-022-00922-w

Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

Dorman, Klara; Zhang, Danmei; Heinrich, Kathrin et al. · 2023 · Targeted Oncology · DOI

Full title: Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

Authors: Dorman, Klara; Zhang, Danmei; Heinrich, Kathrin; Reeh, Laurens; Weiss, Lena; Haas, Michael; Beyer, Georg; Rössler, Daniel; Goni, Elisabetta; Renz, Bernhard W.; DʼHaese, Jan; Kunz, Wolfgang G.; Seidensticker, Max; Corradini, Stefanie; Niyazi, Maximilian; Ormanns, Steffen; Kumbrink, Jörg; Jung, Andreas; Klauschen, Frederick; Werner, Jens; Mayerle, Julia; Bergwelt‐Baildon, Michael von; Boeck, Stefan; Heinemann, Volker; Westphalen, C. Benedikt

Year: 2023

Venue: Targeted Oncology

DOI: https://doi.org/10.1007/s11523-023-00950-0

Paper Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Danielle Brazel; Misako Nagasaka · 2024 · Targeted oncology · DOI

Full title: Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Authors: Danielle Brazel; Misako Nagasaka

Year: 2024

Venue: Targeted oncology

DOI: https://doi.org/10.1007/s11523-024-01055-y

Paper New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Isla, Dolores; Lozano, María D.; Paz‐Ares, Luis et al. · 2022 · Clinical & Translational Oncology · DOI

Full title: New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Authors: Isla, Dolores; Lozano, María D.; Paz‐Ares, Luis; Salas, Clara; Castro, Javier de; Conde, Esther; Felip, Enriqueta; Gómez‐Román, Javier; Garrido, Pilar; Enguita, Ana B.

Year: 2022

Venue: Clinical & Translational Oncology

DOI: https://doi.org/10.1007/s12094-022-03046-9

Paper Unraveling (K)RAS in pancreatic ductal adenocarcinoma

Bernhard Doleschal · 2024 · memo - Magazine of European Medical Oncology · DOI

Full title: Unraveling (K)RAS in pancreatic ductal adenocarcinoma

Authors: Bernhard Doleschal

Year: 2024

Venue: memo - Magazine of European Medical Oncology

DOI: https://doi.org/10.1007/s12254-024-01003-6

Paper Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review

Mansinho, André; Fernandes, Ricardo M.; Carneiro, António Vaz · 2022 · Advances in Therapy · DOI

Full title: Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review

Authors: Mansinho, André; Fernandes, Ricardo M.; Carneiro, António Vaz

Year: 2022

Venue: Advances in Therapy

DOI: https://doi.org/10.1007/s12325-022-02362-4

Paper Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Khasraw, Mustafa; Yalamanchili, Priyanka; Santhanagopal, Anu et al. · 2024 · Advances in Therapy · DOI

Full title: Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Authors: Khasraw, Mustafa; Yalamanchili, Priyanka; Santhanagopal, Anu; Wu, Chuntao; Salas, Maribel; Meng, Jie; Karnoub, Maha; Esker, Stephen; Felip, Enriqueta

Year: 2024

Venue: Advances in Therapy

DOI: https://doi.org/10.1007/s12325-024-02799-9

Paper Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion

C. Bestvina; Chul Kim; Nathalie Daaboul · 2025 · Advances in Therapy · DOI

Full title: Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion

Authors: C. Bestvina; Chul Kim; Nathalie Daaboul

Year: 2025

Venue: Advances in Therapy

DOI: https://doi.org/10.1007/s12325-025-03195-7

Paper Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.

Chopra, Divyan; Lan, Zhiyi; Waterhouse, David M et al. · 2025 · Advances in therapy · DOI

Full title: Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.

Authors: Chopra, Divyan; Lan, Zhiyi; Waterhouse, David M; Wolf, Jürgen; Felip, Enriqueta; Moradian, Hoora; Karim, Nadia; Obiozor, Cynthia; Stollenwerk, Björn

Year: 2025

Venue: Advances in therapy

DOI: https://doi.org/10.1007/s12325-025-03259-8

Paper Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines

Plangger, Adelina; Rath, Barbara H.; Stickler, Sandra et al. · 2022 · Discover Oncology · DOI

Full title: Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines

Authors: Plangger, Adelina; Rath, Barbara H.; Stickler, Sandra; Hochmair, Maximilian J.; Lang, Clemens; Weigl, Lukas; Funovics, Martin; Hamilton, Gerhard

Year: 2022

Venue: Discover Oncology

DOI: https://doi.org/10.1007/s12672-022-00550-w

Paper Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors

Wang, Lihao; Wei, Dandan; Li, Shanshan et al. · 2025 · Discover Oncology · DOI

Full title: Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors

Authors: Wang, Lihao; Wei, Dandan; Li, Shanshan; Jiang, Shiqing

Year: 2025

Venue: Discover Oncology

DOI: https://doi.org/10.1007/s12672-025-03569-x

Paper Modern therapies of nonsmall cell lung cancer

Jachowski, Andrzej; Marcinkowski, Mikołaj; Szydłowski, Jakub et al. · 2023 · Journal of Applied Genetics · DOI

Full title: Modern therapies of nonsmall cell lung cancer

Authors: Jachowski, Andrzej; Marcinkowski, Mikołaj; Szydłowski, Jakub; Grabarczyk, Oskar; Nogaj, Zuzanna; Marcin, L. Pekalski; Pławski, Andrzej; Jagodzińśki, Paweł P.; Słowikowski, Bartosz

Year: 2023

Venue: Journal of Applied Genetics

DOI: https://doi.org/10.1007/s13353-023-00786-4

Paper Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Kleij, Maud B. A. van der; Guchelaar, Niels A.D.; Mathijssen, Ron H.J. et al. · 2023 · Clinical Pharmacokinetics · DOI

Full title: Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Authors: Kleij, Maud B. A. van der; Guchelaar, Niels A.D.; Mathijssen, Ron H.J.; Versluis, Jurjen; Huitema, Alwin D. R.; Koolen, Stijn L.W.; Steeghs, Neeltje

Year: 2023

Venue: Clinical Pharmacokinetics

DOI: https://doi.org/10.1007/s40262-023-01293-9

Paper Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Wilcox, Jessica; Boire, Adrienne · 2022 · CNS Drugs · DOI

Full title: Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Authors: Wilcox, Jessica; Boire, Adrienne

Year: 2022

Venue: CNS Drugs

DOI: https://doi.org/10.1007/s40263-022-00975-5

Paper Sotorasib: First Approval

Blair, Hannah A. · 2021 · Drugs · DOI

Full title: Sotorasib: First Approval

Authors: Blair, Hannah A.

Year: 2021

Venue: Drugs

DOI: https://doi.org/10.1007/s40265-021-01574-2

Paper External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges

Carrigan, Gillis; Bradbury, Brian D.; Brookhart, M. Alan et al. · 2022 · Current Epidemiology Reports · DOI

Full title: External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges

Authors: Carrigan, Gillis; Bradbury, Brian D.; Brookhart, M. Alan; Capra, William B.; Chia, Victoria; Rothman, Kenneth J.; Sarsour, Khaled; Taylor, Michael D.; Brown, Jefferey S.

Year: 2022

Venue: Current Epidemiology Reports

DOI: https://doi.org/10.1007/s40471-022-00305-9

Paper Metabolic reprogramming in non-small cell lung cancer: unraveling therapeutic vulnerabilities and resistance mechanisms

T. Addissouky · 2026 · Journal of Rare Diseases · DOI

Full title: Metabolic reprogramming in non-small cell lung cancer: unraveling therapeutic vulnerabilities and resistance mechanisms

Authors: T. Addissouky

Year: 2026

Venue: Journal of Rare Diseases

DOI: https://doi.org/10.1007/s44162-026-00147-9

Paper Innovative drugs promote precision cancer therapy

Huang, Xuan; Zhu, Mengxuan; Chen, Ruoxue et al. · 2023 · Clinical Cancer Bulletin · DOI

Full title: Innovative drugs promote precision cancer therapy

Authors: Huang, Xuan; Zhu, Mengxuan; Chen, Ruoxue; Ni, Junjie; Zhao, Wenrui; Li, Song; Lü, Xiaoling; Jiao, Heng; Cao, Xin

Year: 2023

Venue: Clinical Cancer Bulletin

DOI: https://doi.org/10.1007/s44272-023-00002-8

Paper Oncogenic KRAS signalling in pancreatic cancer

EŞER, Serap; Schnieke, Angelika; Schneider, Günter et al. · 2014 · British Journal of Cancer · DOI

Full title: Oncogenic KRAS signalling in pancreatic cancer

Authors: EŞER, Serap; Schnieke, Angelika; Schneider, Günter; Saur, Dieter

Year: 2014

Venue: British Journal of Cancer

DOI: https://doi.org/10.1038/bjc.2014.215

Paper Targeting molecular addictions in cancer

Vivanco, Igor · 2014 · British Journal of Cancer · DOI

Full title: Targeting molecular addictions in cancer

Authors: Vivanco, Igor

Year: 2014

Venue: British Journal of Cancer

DOI: https://doi.org/10.1038/bjc.2014.461

Paper Combining targeted therapeutics in the era of precision medicine

D. Papadatos-Pastos; M. J. De Miguel Luken; T. Yap · 2015 · British Journal of Cancer · DOI

Full title: Combining targeted therapeutics in the era of precision medicine

Authors: D. Papadatos-Pastos; M. J. De Miguel Luken; T. Yap

Year: 2015

Venue: British Journal of Cancer

DOI: https://doi.org/10.1038/bjc.2014.558

Paper Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Jänne, Pasi A.; Smith, Ian C. P.; McWalter, Gael et al. · 2015 · British Journal of Cancer · DOI

Full title: Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Authors: Jänne, Pasi A.; Smith, Ian C. P.; McWalter, Gael; Mann, Helen; Dougherty, Brian; Walker, Jill; Orr, Maria; Hodgson, Darren; Shaw, Alice T.; Pereira, José Rodrigues; Jeannin, G.; Vansteenkiste, Johan; Barrios, C.H.; Franke, Fábio; Crinò, Lucio; Smith, Paul D.

Year: 2015

Venue: British Journal of Cancer

DOI: https://doi.org/10.1038/bjc.2015.215

Paper Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

Chen, J; Bi, Hong‐Yan; Hou, Jincai et al. · 2013 · Cell Death and Disease · DOI

Full title: Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

Authors: Chen, J; Bi, Hong‐Yan; Hou, Jincai; Zhang, X; Zhang, C; Yue, Liling; Wen, Xinyu; Liu, D; H, Shi; Yuan, Jingping; Liu, Jingke; Liu, B

Year: 2013

Venue: Cell Death and Disease

DOI: https://doi.org/10.1038/cddis.2013.312

Paper Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

Wang, Jieqiong; Hu, Kewen; Guo, Jiawei et al. · 2016 · Nature Communications · DOI

Full title: Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

Authors: Wang, Jieqiong; Hu, Kewen; Guo, Jiawei; Cheng, Feixiong; Lv, Jing; Jiang, Wenhao; Lü, Weiqiang; Liu, Jinsong; Pang, Xiufeng; Liu, Mingyao

Year: 2016

Venue: Nature Communications

DOI: https://doi.org/10.1038/ncomms11363

Paper Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

Shin, Seungmin; Choi, Dong-Ki; Jung, Keun‐Ok et al. · 2017 · Nature Communications · DOI

Full title: Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

Authors: Shin, Seungmin; Choi, Dong-Ki; Jung, Keun‐Ok; Bae, Jeomil; Kim, Ji‐Sun; Park, Seong‐Wook; Song, Ki‐Hoon; Kim, Yong‐Sung

Year: 2017

Venue: Nature Communications

DOI: https://doi.org/10.1038/ncomms15090

Paper Molecular targeted therapy for anticancer treatment

H. Min; Ho Young Lee · 2022 · Experimental and Molecular Medicine · DOI

Full title: Molecular targeted therapy for anticancer treatment

Authors: H. Min; Ho Young Lee

Year: 2022

Venue: Experimental and Molecular Medicine

DOI: https://doi.org/10.1038/s12276-022-00864-3

Paper Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

Shin, Dong Hoon; Jo, Jeong Yeon; Choi, Minyoung et al. · 2023 · Experimental & Molecular Medicine · DOI

Full title: Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

Authors: Shin, Dong Hoon; Jo, Jeong Yeon; Choi, Minyoung; Kim, Kyung‐Hee; Bae, Young‐Ki; Kim, Sang Soo

Year: 2023

Venue: Experimental & Molecular Medicine

DOI: https://doi.org/10.1038/s12276-023-01091-0

Paper Targeting TGF-β–Smad2/3–JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer

Dongcheon Shin; Min-Gew Choi; Chungyong Han et al. · 2025 · Experimental and Molecular Medicine · DOI

Full title: Targeting TGF-β–Smad2/3–JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer

Authors: Dongcheon Shin; Min-Gew Choi; Chungyong Han; Sang Soo Kim

Year: 2025

Venue: Experimental and Molecular Medicine

DOI: https://doi.org/10.1038/s12276-025-01536-8

Paper Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics

Sorolla, Anabel; Wang, Edina; Golden, Emily et al. · 2019 · Oncogene · DOI

Full title: Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics

Authors: Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Henriques, Sónia Troeira; Redfern, Andrew; Blancafort, Pilar

Year: 2019

Venue: Oncogene

DOI: https://doi.org/10.1038/s41388-019-1056-3

Paper Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Yu, Chune; Luo, Dan; Yu, Jing et al. · 2021 · Oncogene · DOI

Full title: Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Authors: Yu, Chune; Luo, Dan; Yu, Jing; Zhang, Min; Zheng, Xiaobo; Xu, Guangchao; Wang, Jiaxin; Wang, Huiling; Xu, Yufei; Jiang, Ke; Xu, Jie; Ma, Xuelei; Jing, Jing; Shi, Hubing

Year: 2021

Venue: Oncogene

DOI: https://doi.org/10.1038/s41388-021-02077-w

Paper Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Feng, Juanjuan; Hu, Zhongwei; Xia, Xinting et al. · 2023 · Oncogene · DOI

Full title: Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Authors: Feng, Juanjuan; Hu, Zhongwei; Xia, Xinting; Liu, Xiaogu; Lian, Zhengke; Wang, Hui; Wang, Liren; Wang, Cun; Zhang, Xueli; Pang, Xiufeng

Year: 2023

Venue: Oncogene

DOI: https://doi.org/10.1038/s41388-023-02676-9

Paper Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer

Yu Zhang; Liang Liu; Jinpeng Pei et al. · 2024 · Oncogene · DOI

Full title: Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer

Authors: Yu Zhang; Liang Liu; Jinpeng Pei; Zhiqiang Ren; Yan Deng; Ker Yu

Year: 2024

Venue: Oncogene

DOI: https://doi.org/10.1038/s41388-023-02924-y

Paper The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Yuan, Min; Huang, Lili; Chen, Jianhua et al. · 2019 · Signal Transduction and Targeted Therapy · DOI

Full title: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Authors: Yuan, Min; Huang, Lili; Chen, Jianhua; Wu, Jie; Xu, Qing

Year: 2019

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-019-0099-9

Paper Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Zhong, Lei; Li, Yueshan; Xiong, Liang et al. · 2021 · Signal Transduction and Targeted Therapy · DOI

Full title: Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Authors: Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong

Year: 2021

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-021-00572-w

Paper The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

Wang, Shun; Zheng, Yan; Feng, Yang et al. · 2021 · Signal Transduction and Targeted Therapy · DOI

Full title: The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

Authors: Wang, Shun; Zheng, Yan; Feng, Yang; Zhu, Le; Zhu, Xiaoqiang; Wang, Zhefang; Wu, Xiao‐Lin; Zhou, Chenghui; Yan, Jiayan; Hu, Beiyuan; Kong, Bo; Fu, Deliang; Bruns, Christiane J.; Zhao, Yue; Qin, Lun–Xiu; Dong, Qiongzhu

Year: 2021

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-021-00659-4

Paper Insights from the degradation mechanism of cyclin D into targeted therapy of the cancer cell cycle

Maïwen Caudron-Herger; S. Diederichs · 2021 · Signal Transduction and Targeted Therapy · DOI

Full title: Insights from the degradation mechanism of cyclin D into targeted therapy of the cancer cell cycle

Authors: Maïwen Caudron-Herger; S. Diederichs

Year: 2021

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-021-00732-y

Paper KRAS mutation: from undruggable to druggable in cancer

Lamei Huang; Zhixing Guo; Fang Wang et al. · 2021 · Signal Transduction and Targeted Therapy · DOI

Full title: KRAS mutation: from undruggable to druggable in cancer

Authors: Lamei Huang; Zhixing Guo; Fang Wang; Liwu Fu

Year: 2021

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-021-00780-4

Paper PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, Ming; Cao, Chao-Guo; Ni, Zhihao et al. · 2022 · Signal Transduction and Targeted Therapy · DOI

Full title: PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

Authors: He, Ming; Cao, Chao-Guo; Ni, Zhihao; Liu, Yongbo; Song, Peilu; Hao, Shuang; He, Yuna; Sun, Xiuyun; Rao, Yu

Year: 2022

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-022-00999-9

Paper Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Yang, Yang; Li, Shuo; Wang, Yujiao et al. · 2022 · Signal Transduction and Targeted Therapy · DOI

Full title: Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Authors: Yang, Yang; Li, Shuo; Wang, Yujiao; Zhao, Yi; Li, Qiu

Year: 2022

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-022-01168-8

Paper Patient-derived xenograft models in cancer therapy: technologies and applications

Liu, Yihan; Wu, Wantao; Cai, Changjing et al. · 2023 · Signal Transduction and Targeted Therapy · DOI

Full title: Patient-derived xenograft models in cancer therapy: technologies and applications

Authors: Liu, Yihan; Wu, Wantao; Cai, Changjing; Zhang, Hao; Shen, Hong; Han, Ying

Year: 2023

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-023-01419-2

Paper Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Guowei Yin; Jing Huang; Johnny Petela et al. · 2023 · Signal Transduction and Targeted Therapy · DOI

Full title: Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Authors: Guowei Yin; Jing Huang; Johnny Petela; Hongmei Jiang; Yuetong Zhang; Siqi Gong; Jiaxin Wu; Bei Liu; Jianyou Shi; Yijun Gao

Year: 2023

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-023-01441-4

Paper Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, Xin; Yu, Tingting; Li, Xiang et al. · 2023 · Signal Transduction and Targeted Therapy · DOI

Full title: Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Authors: Xie, Xin; Yu, Tingting; Li, Xiang; Zhang, Nan; Foster, Leonard J.; Peng, Cheng; Huang, Wei; He, Gu

Year: 2023

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-023-01589-z

Paper Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Bahar, Md Entaz; Kim, Hyun Joon; Kim, Deok Ryong · 2023 · Signal Transduction and Targeted Therapy · DOI

Full title: Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Authors: Bahar, Md Entaz; Kim, Hyun Joon; Kim, Deok Ryong

Year: 2023

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-023-01705-z

Paper New clinical trial design in precision medicine: discovery, development and direction

Duan, Xiao-Peng; Qin, Bao‐Dong; Jiao, Xiao‐Dong et al. · 2024 · Signal Transduction and Targeted Therapy · DOI

Full title: New clinical trial design in precision medicine: discovery, development and direction

Authors: Duan, Xiao-Peng; Qin, Bao‐Dong; Jiao, Xiao‐Dong; Liu, Ke; Wang, Zhan; Zang, Yuan‐Sheng

Year: 2024

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-024-01760-0

Paper Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Khalil Choucair; Hafsa Imtiaz; Md. Hafiz Uddin et al. · 2025 · Signal Transduction and Targeted Therapy · DOI

Full title: Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Authors: Khalil Choucair; Hafsa Imtiaz; Md. Hafiz Uddin; M. Nagasaka; M. N. Al-Hallak; P. Philip; B. El-Rayes; Boris C. Pasche; A. Azmi

Year: 2025

Venue: Signal Transduction and Targeted Therapy

DOI: https://doi.org/10.1038/s41392-025-02473-8

Paper Direct Ras G12C inhibitors: crossing the rubicon

Lindsay, Colin R.; Blackhall, Fiona · 2019 · British Journal of Cancer · DOI

Full title: Direct Ras G12C inhibitors: crossing the rubicon

Authors: Lindsay, Colin R.; Blackhall, Fiona

Year: 2019

Venue: British Journal of Cancer

DOI: https://doi.org/10.1038/s41416-019-0499-1

Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Geel, Robin M.J.M. van; Brummelen, Emilie M.J. van; Eskens, Ferry A.L.M. et al. · 2020 · British Journal of Cancer · DOI

Full title: Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Authors: Geel, Robin M.J.M. van; Brummelen, Emilie M.J. van; Eskens, Ferry A.L.M.; Huijberts, Sanne C.F.A.; Vos, Filip De; Lolkema, Martijn P.; Devriese, Lot A.; Opdam, Frans L.; Marchetti, Serena; Steeghs, Neeltje; Monkhorst, Kim; Thijssen, Bas; Rosing, Hilde; Huitema, Alwin D. R.; Beijnen, Jos H.; Bernards, René; Schellens, Jan H.M.

Year: 2020

Venue: British Journal of Cancer

DOI: https://doi.org/10.1038/s41416-020-0776-z

Paper Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors

Baranyi, Marcell; Molnár, Eszter; Hegedüs, Luca et al. · 2024 · British Journal of Cancer · DOI

Full title: Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors

Authors: Baranyi, Marcell; Molnár, Eszter; Hegedüs, Luca; Gábriel, Zsófia; Petényi, Flóra Gréta; Bordás, Fanni; Léner, Violetta; Ranđelović, Ivan; Cserepes, Mihály; Tóvári, József; Hegedűs, Balázs; Tı́már, József

Year: 2024

Venue: British Journal of Cancer

DOI: https://doi.org/10.1038/s41416-024-02586-x

Paper The KRAS-G12C inhibitor: activity and resistance.

Liu, Jiao; Kang, Rui; Tang, Daolin · 2022 · Cancer gene therapy · DOI

Full title: The KRAS-G12C inhibitor: activity and resistance.

Authors: Liu, Jiao; Kang, Rui; Tang, Daolin

Year: 2022

Venue: Cancer gene therapy

DOI: https://doi.org/10.1038/s41417-021-00383-9

Paper Glimmers of hope for targeting oncogenic KRAS-G12D

Tang, Daolin; Kang, Rui · 2022 · Cancer Gene Therapy · DOI

Full title: Glimmers of hope for targeting oncogenic KRAS-G12D

Authors: Tang, Daolin; Kang, Rui

Year: 2022

Venue: Cancer Gene Therapy

DOI: https://doi.org/10.1038/s41417-022-00561-3

Paper Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity

Leung, Elaine Lai Han; Luo, Lian Xiang; Liu, Zhong Qiu et al. · 2018 · Cell Death and Disease · DOI

Full title: Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity

Authors: Leung, Elaine Lai Han; Luo, Lian Xiang; Liu, Zhong Qiu; Wong, Vincent Kam Wai; Lu, Linlin; Xie, Ying; Zhang, Ni; Qu, Yuan Qing; Fan, Xing; Li, Ying; Huang, Min; Xiao, Dai; Huang, Jun; Zhou, Yan Ling; He, Jian Xing; Ding, Jian; Yao, Xiao; Ward, David C.; Liu, Liang

Year: 2018

Venue: Cell Death and Disease

DOI: https://doi.org/10.1038/s41419-017-0065-9

Paper MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer

Zhang, Yuanzhou; Liang, Shunshun; Xiao, Bowen et al. · 2022 · Cell Death and Disease · DOI

Full title: MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer

Authors: Zhang, Yuanzhou; Liang, Shunshun; Xiao, Bowen; Hu, Jingying; Pang, Yechun; Liu, Yuling; Yang, Juan; Ao, Junpin; Wei, Lin; Luo, Xiaoying

Year: 2022

Venue: Cell Death and Disease

DOI: https://doi.org/10.1038/s41419-022-04709-9

Paper Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells.

Lee, Chaeyoung; Yi, Jawoon; Park, Jihwan et al. · 2024 · Cell death & disease · DOI

Full title: Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells.

Authors: Lee, Chaeyoung; Yi, Jawoon; Park, Jihwan; Ahn, Byungyong; Won, Young-Wook; Jeon, JiHeung; Lee, Byung Ju; Cho, Wha Ja; Park, Jeong Woo

Year: 2024

Venue: Cell death & disease

DOI: https://doi.org/10.1038/s41419-024-06436-9

Paper Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer.

Liu, Hongyu; Zhou, Chao; Lu, Jun et al. · 2025 · Cell death & disease · DOI

Full title: Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer.

Authors: Liu, Hongyu; Zhou, Chao; Lu, Jun; Liu, Yuqing; Zou, Peichen; Zhu, Liang; Lei, Huimin; Han, Baohui

Year: 2025

Venue: Cell death & disease

DOI: https://doi.org/10.1038/s41419-025-07687-w

Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells

Maj-Britt Paulsohn; Klara Henrike Frahnert; Denise Schlösser et al. · 2025 · Cell Death and Disease · DOI

Full title: Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells

Authors: Maj-Britt Paulsohn; Klara Henrike Frahnert; Denise Schlösser; Joana Oschwald; Waltraut Kopp; Xin Fang; Carolin Schneider; Constanza Tapia Contreras; Adi Danieli-Mackay; Fabian Ludewig; Martina Bleyer; Gabriela Salinas; Günter Schneider; E. Hessmann; Matthias Dobbelstein

Year: 2025

Venue: Cell Death and Disease

DOI: https://doi.org/10.1038/s41419-025-08362-w

Paper TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer

Ben Zhao; L. Dierichs; J. Gu et al. · 2020 · Cell Death Discovery · DOI

Full title: TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer

Authors: Ben Zhao; L. Dierichs; J. Gu; M. Trajkovic-Arsic; R. Axel Hilger; Konstantinos Savvatakis; S. Vega-Rubín-de-Celis; S. Liffers; Samuel Peña-Llopis; D. Behrens; S. Hahn; J. Siveke; Smiths S. Lueong

Year: 2020

Venue: Cell Death Discovery

DOI: https://doi.org/10.1038/s41420-020-0246-7

Paper An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer

Karstedt, Silvia von; Walczak, Henning · 2020 · Cell Death Discovery · DOI

Full title: An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer

Authors: Karstedt, Silvia von; Walczak, Henning

Year: 2020

Venue: Cell Death Discovery

DOI: https://doi.org/10.1038/s41420-020-0249-4

Paper Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer

Zhu, Jialong; Ji, Linlin; Chen, Yitian et al. · 2023 · Cell Death Discovery · DOI

Full title: Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer

Authors: Zhu, Jialong; Ji, Linlin; Chen, Yitian; Li, Huiyu; Huang, Mengxi; Dai, Zhe; Wang, Jing; Xiang, Dan; Fu, Gongbo; Lei, Zengjie; Chu, Xiaoyuan

Year: 2023

Venue: Cell Death Discovery

DOI: https://doi.org/10.1038/s41420-023-01354-9

Paper KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

Mao, Zhongwei; Xiao, Hongying; Shen, Pan‐Pan et al. · 2022 · Cell Discovery · DOI

Full title: KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

Authors: Mao, Zhongwei; Xiao, Hongying; Shen, Pan‐Pan; Yang, Yu; Xue, Jing; Yang, Yunyun; Shang, Yanguo; Zhang, Lilan; Li, Xin; Zhang, Yuying; Du, Yanan; Chen, Chun‐Chi; Guo, Rey‐Ting; Zhang, Yonghui

Year: 2022

Venue: Cell Discovery

DOI: https://doi.org/10.1038/s41421-021-00368-w

Paper MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation

Wang, Yuan; Jia, Zhenchang; Liang, Chenxi et al. · 2023 · Cell Discovery · DOI

Full title: MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation

Authors: Wang, Yuan; Jia, Zhenchang; Liang, Chenxi; He, Yunfei; Cong, Min; Wu, Qiuyao; Tian, Pu; He, Dasa; Xiang, Miao; Sun, Beibei; Yin, Yue; Peng, Chao; Yao, Feng; Fu, Da; Liang, Yajun; Zhang, Peiyuan; Xiong, Hua; Hu, Guohong

Year: 2023

Venue: Cell Discovery

DOI: https://doi.org/10.1038/s41421-022-00507-x

Paper Assembling defined DNA nanostructures with anticancer drugs: a metformin/DNA complex nanoplatform with a synergistic antitumor effect for KRAS-mutated lung cancer therapy

Qian, Hang; Wang, Dong; He, Binfeng et al. · 2022 · NPG Asia Materials · DOI

Full title: Assembling defined DNA nanostructures with anticancer drugs: a metformin/DNA complex nanoplatform with a synergistic antitumor effect for KRAS-mutated lung cancer therapy

Authors: Qian, Hang; Wang, Dong; He, Binfeng; Liu, Qian; Xu, Yü; Wu, Di; Chen, Chunfa; Zhang, Wen; Leong, David Tai; Wang, Guansong

Year: 2022

Venue: NPG Asia Materials

DOI: https://doi.org/10.1038/s41427-022-00427-y

Paper Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

Quevedo, Camilo; Cruz-Migoni, Abimael; Béry, Nicolas et al. · 2018 · Nature Communications · DOI

Full title: Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

Authors: Quevedo, Camilo; Cruz-Migoni, Abimael; Béry, Nicolas; Miller, Ami; Tanaka, Tomoyuki; Petch, Donna; Bataille, Carole J. R.; Lee, Lydia Y. W.; Fallon, Phillip S.; Tulmin, Hanna; Ehebauer, M.T.; Fernández‐Fuentes, Narcís; Russell, Angela J.; Carr, S.B.; Phillips, Simon E. V.; Rabbitts, Terence H.

Year: 2018

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-018-05707-2

Paper GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Kazi, Aslamuzzaman; Xiang, Shengyan; Yang, Hua et al. · 2018 · Nature Communications · DOI

Full title: GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Authors: Kazi, Aslamuzzaman; Xiang, Shengyan; Yang, Hua; Delitto, Daniel; Treviño, José G.; Jiang, Rays H. Y.; Ayaz, Muhammad; Lawrence, Harshani R.; Kennedy, Perry; Sebti, Saı̈d M.

Year: 2018

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-018-07644-6

Paper SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Jones, Greg G.; Río, Isabel Boned del; Sarı, Sibel et al. · 2019 · Nature Communications · DOI

Full title: SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Authors: Jones, Greg G.; Río, Isabel Boned del; Sarı, Sibel; Sekerim, Aysen; Young, Lucy C.; Hartig, Nicole; Zubiaur, Itziar Areso; El‐Bahrawy, Mona; Hynds, Robert E.; Lei, Winnie; Molina‐Arcas, Míriam; Downward, Julian; Rodriguez‐Viciana, Pablo

Year: 2019

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-019-10367-x

Paper A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS

Béry, Nicolas; Miller, Ami; Rabbitts, Terence H. · 2020 · Nature Communications · DOI

Full title: A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS

Authors: Béry, Nicolas; Miller, Ami; Rabbitts, Terence H.

Year: 2020

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-020-17022-w

Paper Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

Lundin, Anders; Porritt, Michelle J.; Jaiswal, Himjyot et al. · 2020 · Nature Communications · DOI

Full title: Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

Authors: Lundin, Anders; Porritt, Michelle J.; Jaiswal, Himjyot; Seeliger, Frank; Johansson, Camilla; Bidar, Abdel Wahad; Badertscher, Lukas; Wimberger, Sandra; Davies, Emma Jane; Hardaker, Elizabeth; Martins, Carla P.; James, Emily; Admyre, Therése; Taheri‐Ghahfarokhi, Amir; Bradley, Jenna; Schantz, Anna; Alaei-Mahabadi, Babak; Clausen, Maryam; Xu, Xiufeng; Mayr, Lorenz M.; Nitsch, Roberto; Bohlooly‐Y, Mohammad; Barry, Simon T.; Maresca, Marcello

Year: 2020

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-020-18548-9

Paper Immune modulatory effects of oncogenic KRAS in cancer

Hamarsheh, Shaima’a; Groß, Olaf; Brummer, Tilman et al. · 2020 · Nature Communications · DOI

Full title: Immune modulatory effects of oncogenic KRAS in cancer

Authors: Hamarsheh, Shaima’a; Groß, Olaf; Brummer, Tilman; Zeiser, Robert

Year: 2020

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-020-19288-6

Paper CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer

Zhang, Man; Yang, Wei; Wang, Peng et al. · 2020 · Nature Communications · DOI

Full title: CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer

Authors: Zhang, Man; Yang, Wei; Wang, Peng; Deng, Yu; Dong, Yuting; Liu, Fangfang; Huang, Rui; Zhang, Peng; Duan, Yaqi; Liu, Xindong; Lin, Dandan; Chu, Qian; Zhong, Bo

Year: 2020

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-020-19973-6

Paper Selective and noncovalent targeting of RAS mutants for inhibition and degradation

Teng, Kai Wen; Tsai, Steven T.; Hattori, Takamitsu et al. · 2021 · Nature Communications · DOI

Full title: Selective and noncovalent targeting of RAS mutants for inhibition and degradation

Authors: Teng, Kai Wen; Tsai, Steven T.; Hattori, Takamitsu; Fedele, Carmine; Koide, Akiko; Yang, Chao; Hou, Xuben; Zhang, Yingkai; Neel, Benjamin G.; O’Bryan, John P.; Koide, Shohei

Year: 2021

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-021-22969-5

Paper MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

Brägelmann, Johannes; Lorenz, Carina; Borchmann, Sven et al. · 2021 · Nature Communications · DOI

Full title: MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

Authors: Brägelmann, Johannes; Lorenz, Carina; Borchmann, Sven; Nishii, Kazuya; Wegner, Julia; Meder, Lydia; Ostendorp, Jenny; Ast, David; Heimsoeth, Alena; Nakasuka, Takamasa; Hirabae, Atsuko; Okawa, Sachi; Dammert, Marcel A.; Plenker, Dennis; Klein, Sebastian; Lohneis, Philipp; Gu, Jianing; Godfrey, Laura; Förster, Jan; Trajkovic‐Arsic, Marija; Zillinger, Thomas; Haarmann, Mareike; Quaas, Alexander; Lennartz, S; Schmiel, Marcel; D’Rozario, Joshua; Thomas, Emily; Li, Henry; Schmitt, Clemens A.; George, Julie; Thomas, Roman K.; Karstedt, Silvia von; Hartmann, Gunther; Büttner, Reinhard; Ullrich, Roland T.; Siveke, Jens T.; Ohashi, Kadoaki; Schlee, Martin; Sos, Martin L.

Year: 2021

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-021-25728-8

Paper Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry

Maldegem, Febe van; Valand, Karishma; Cole, Megan et al. · 2021 · Nature Communications · DOI

Full title: Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry

Authors: Maldegem, Febe van; Valand, Karishma; Cole, Megan; Patel, Harshil; Angelova, Mihaela; Rana, Sareena; Colliver, Emma; Enfield, Katey S.S.; Bah, Nourdine; Kelly, Gavin; Tsang, Victoria; Mugarza, Edurne; Moore, Christopher; Hobson, Philip; Levi, Dina; Molina‐Arcas, Míriam; Swanton, Charles; Downward, Julian

Year: 2021

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-021-26214-x

Paper ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Radia M. Johnson; X. Qu; Chu-Fang Lin et al. · 2022 · Nature Communications · DOI

Full title: ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Authors: Radia M. Johnson; X. Qu; Chu-Fang Lin; L. Huw; A. Venkatanarayan; E. Sokol; F. Ou; Nnamdi E. Ihuegbu; Oliver A. Zill; O. Kabbarah; Lisa Wang; R. Bourgon; F. de Sousa e Melo; C. Bolen; A. Daemen; A. Venook; F. Innocenti; H. Lenz; C. Bais

Year: 2022

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-022-33172-5

Paper Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine

Wang, Kai‐Bo; Liu, Yushuang; Li, Jinzhu et al. · 2022 · Nature Communications · DOI

Full title: Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine

Authors: Wang, Kai‐Bo; Liu, Yushuang; Li, Jinzhu; Xiao, Cheng‐Mei; Wang, Yingying; Gu, Wei; Li, Yipu; Xia, Yuan‐Zheng; Yan, Tingdong; Yang, Minghua; Kong, Lingyi

Year: 2022

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-022-33761-4

Paper Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity

Nguyen, Kim; Malik, Turnee N.; Chaput, John C. · 2023 · Nature Communications · DOI

Full title: Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity

Authors: Nguyen, Kim; Malik, Turnee N.; Chaput, John C.

Year: 2023

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-023-38100-9

Paper UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma

Kostyrko, Kaja; Román, Marta; Lee, Alex G. et al. · 2023 · Nature Communications · DOI

Full title: UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma

Authors: Kostyrko, Kaja; Román, Marta; Lee, Alex G.; Simpson, David R.; Dinh, Phuong; Leung, Stanley G.; Marini, Kieren D.; Kelly, Marcus R.; Broyde, Joshua; Califano, Andrea; Jackson, Peter K.; Sweet‐Cordero, E. Alejandro

Year: 2023

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-023-39591-2

Paper Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen

Wright, Katharine M.; DiNapoli, Sarah R.; Miller, Michelle S. et al. · 2023 · Nature Communications · DOI

Full title: Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen

Authors: Wright, Katharine M.; DiNapoli, Sarah R.; Miller, Michelle S.; Azurmendi, P. Aitana; Zhao, Xiaowei; Yu, Zhiheng; Chakrabarti, Mayukh; Shi, Wuxian; Douglass, Jacqueline; Hwang, Michael S.; Hsiue, Emily Han-Chung; Mog, Brian J.; Pearlman, Alexander H.; Paul, Suman; Konig, Maximilian F.; Pardoll, Drew M.; Bettegowda, Chetan; Papadopoulos, Nickolas; Kinzler, Kenneth W.; Vogelstein, Bert; Zhou, Shibin; Gabelli, Sandra B.

Year: 2023

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-023-40821-w

Paper Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma

Baltanás, Fernando C.; García‐Navas, Rósula; Rodríguez-Ramos, Pablo et al. · 2023 · Nature Communications · DOI

Full title: Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma

Authors: Baltanás, Fernando C.; García‐Navas, Rósula; Rodríguez-Ramos, Pablo; Calzada, Nuria; Cuesta, Cristina; Borrajo, Javier; Fuentes‐Mateos, Rocío; Juan, Andrea Olarte-San; Vidaña, Nerea; Castellano, Esther; Santos, Eugenio

Year: 2023

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-023-41583-1

Paper Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Macaya, Irati; Román, Marta; Welch, Connor et al. · 2023 · Nature Communications · DOI

Full title: Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Authors: Macaya, Irati; Román, Marta; Welch, Connor; Entrialgo‐Cadierno, Rodrigo; Salmón, Marina; Santos, Alba; Feliu, Iker; Kovalski, Joanna; López, Inés; Rodríguez‐Remírez, María; Palomino‐Echeverría, Sara; Lonfgren, Shane M.; Ferrero, Macarena; Calabuig‐Fariñas, Silvia; Ludwig, Iziar A.; Lara‐Astiaso, David; Jantus‐Lewintre, Eloísa; Guruceaga, Elizabeth; Narayanan, Shruthi; Ponz‐Sarvisé, Mariano; Pineda‐Lucena, Antonio; Lecanda, Fernando; Ruggero, Davide; Khatri, Purvesh; Santamaría, Enrique; Fernández‐Irigoyen, Joaquín; Ferrer, Irene; Paz‐Ares, Luis; Drosten, Matthias; Barbacid, Mariano; Gil‐Bazo, Ignacio; Vicent, Silvestre

Year: 2023

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-023-41828-z

Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

Bulle, Ashenafi; Liu, Peng; Seehra, Kuljeet et al. · 2024 · Nature Communications · DOI

Full title: Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

Authors: Bulle, Ashenafi; Liu, Peng; Seehra, Kuljeet; Bansod, Sapana; Chen, Yali; Zahra, Kiran; Somani, Vikas; Khawar, Iftikhar Ali; Chen, Hung-Po; Dodhiawala, Paarth B.; Li, Lin; Geng, Yutong; Mo, Chia-Kuei; Mahsl, Jay; Ding, Li; Govindan, Ramaswamy; Davies, Sherri R.; Mudd, Jacqueline L.; Hawkins, William G.; Fields, Ryan C.; DeNardo, David G.; Knoerzer, Deborah; Held, Jason M.; Grierson, Patrick; Wang‐Gillam, Andrea; Ruzinova, Marianna B.; Lim, Kian‐Huat

Year: 2024

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-024-46811-w

Paper RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

M. Nokin; Alessia Mira; Enrico Patrucco et al. · 2024 · Nature Communications · DOI

Full title: RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

Authors: M. Nokin; Alessia Mira; Enrico Patrucco; B. Ricciuti; S. Cousin; Isabelle Soubeyran; Sonia San José; Serena Peirone; Livia Caizzi; Sandra Vietti Michelina; A. Bourdon; Xinan Wang; Daniel Álvarez-Villanueva; M. Martínez-Iniesta; August Vidal; Telmo Rodrigues; Carmen García-Macías; Mark M Awad; E. Nadal; Alberto Villanueva; A. Italiano; Matteo Cereda; David Santamaría; Chiara Ambrogio

Year: 2024

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-024-51828-2

Paper Precision drugging of the MAPK pathway in head and neck cancer

Ngan, Hoi-Lam; Law, Chun-Ho; Choi, Yannie Chung Yan et al. · 2022 · npj Genomic Medicine · DOI

Full title: Precision drugging of the MAPK pathway in head and neck cancer

Authors: Ngan, Hoi-Lam; Law, Chun-Ho; Choi, Yannie Chung Yan; Chan, Jenny Yu-Sum; Lui, Vivian Wai Yan

Year: 2022

Venue: npj Genomic Medicine

DOI: https://doi.org/10.1038/s41525-022-00293-1

Paper Defining subpopulations of differential drug response to reveal novel target populations

N. Keshava; T. S. Toh; H. Yuan et al. · 2019 · npj Systems Biology and Applications · DOI

Full title: Defining subpopulations of differential drug response to reveal novel target populations

Authors: N. Keshava; T. S. Toh; H. Yuan; Bingxun Yang; Michael P. Menden; Dennis Wang

Year: 2019

Venue: npj Systems Biology and Applications

DOI: https://doi.org/10.1038/s41540-019-0113-4

Paper A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses

Arbelaez, Carlos; Estrada, Juan; Gessner, Melissa A. et al. · 2020 · npj Vaccines · DOI

Full title: A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses

Authors: Arbelaez, Carlos; Estrada, Juan; Gessner, Melissa A.; Glaus, Charles; Morales, Agnieszka B.; Mohn, Deanna; Phee, Hyewon; Lipford, J. Russell; Johnston, James A.

Year: 2020

Venue: npj Vaccines

DOI: https://doi.org/10.1038/s41541-020-00253-9

Paper A view on drug resistance in cancer

Vasan, Neil; Baselga, José; Hyman, David M. · 2019 · Nature · DOI

Full title: A view on drug resistance in cancer

Authors: Vasan, Neil; Baselga, José; Hyman, David M.

Year: 2019

Venue: Nature

DOI: https://doi.org/10.1038/s41586-019-1730-1

Paper Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing et al. · 2024 · Nature · DOI

Full title: Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

Authors: Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing; Tomlinson, Aidan; Seamon, Kyle J; Mira, Alessia; Patrucco, Enrico; Goodhart, Grace; Dilly, Julien; Gindin, Yevgeniy; Dinglasan, Nuntana; Wang, Yingyun; Lai, Lick Pui; Cai, Shurui; Jiang, Lingyan; Nasholm, Nicole; Shifrin, Nataliya; Blaj, Cristina; Shah, Harshit; Evans, James W; Montazer, Nilufar; Lai, Oliver; Shi, Jade; Ahler, Ethan; Quintana, Elsa; Chang, Stephanie; Salvador, Anthony; Marquez, Abby; Cregg, Jim; Liu, Yang; Milin, Anthony; Chen, Anqi; Ziv, Tamar Bar; Parsons, Dylan; Knox, John E; Klomp, Jennifer E; Roth, Jennifer; Rees, Matthew; Ronan, Melissa; Cuevas-Navarro, Antonio; Hu, Feng; Lito, Piro; Santamaria, David; Aguirre, Andrew J; Waters, Andrew M; Der, Channing J; Ambrogio, Chiara; Wang, Zhengping; Gill, Adrian L; Koltun, Elena S; Smith, Jacqueline A M; Wildes, David; Singh, Mallika

Year: 2024

Venue: Nature

DOI: https://doi.org/10.1038/s41586-024-07205-6

Paper Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types

Gurung, Hem R.; Heidersbach, Amy; Darwish, Martine et al. · 2023 · Nature Biotechnology · DOI

Full title: Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types

Authors: Gurung, Hem R.; Heidersbach, Amy; Darwish, Martine; Chan, Pamela Pui Fung; Li, Jenny; Beresini, Maureen H.; Zill, Oliver A.; Wallace, Andrew J.; Tong, Ann-Jay; Hascall, Dan; Torres, Eric; Chang, Andy; Lou, Kenny “Hei-Wai”; Abdolazimi, Yassan; Hammer, Christian; Xavier‐Magalhães, Ana; Marcu, Ana; Vaidya, Samir; Le, Daniel D.; Akhmetzyanova, Ilseyar; Oh, Soyoung; Moore, Amanda J.; Uche, Uzodinma; Laur, Melanie; Notturno, Richard J.; Ebert, Peter; Blanchette, Craig; Haley, Benjamin; Rose, Christopher M.

Year: 2023

Venue: Nature Biotechnology

DOI: https://doi.org/10.1038/s41587-023-01945-y

Paper Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Jayesh Desai; G. Alonso; Se Hyun Kim et al. · 2023 · Nature Medicine · DOI

Full title: Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Authors: Jayesh Desai; G. Alonso; Se Hyun Kim; A. Cervantes; T. Karasic; Laura Medina; E. Shacham-Shmueli; Rasha Cosman; A. Falcon; Eelke H. Gort; T. Guren; E. Massarelli; Wilson H Miller; Luis Paz-Ares; H. Prenen; A. Amatu; C. Cremolini; Tae Won Kim; Víctor Moreno; Sai-Hong Ignatius Ou; A. Passardi; A. Sacher; Armando Santoro; Rafal Stec; S. Ulahannan; K. Arbour; P. Lorusso; Jia Luo; Manish R. Patel; Yoonha Choi; Zhen Shi; Sandhya Mandlekar; Mark T. Lin; S. Royer-Joo; Julie Chang; Tomi Jun; N. Dharia; J. Schutzman; Sae-Won Han

Year: 2023

Venue: Nature Medicine

DOI: https://doi.org/10.1038/s41591-023-02696-8

Paper Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Skoulidis, Ferdinandos; Li, Bob T; de Langen, Adrianus Johannes et al. · 2025 · Nature medicine · DOI

Full title: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Authors: Skoulidis, Ferdinandos; Li, Bob T; de Langen, Adrianus Johannes; Hong, David S; Lena, Herve; Wolf, Juergen; Dy, Grace K; Curioni Fontecedro, Alessandra; Tomasini, Pascale; Velcheti, Vamsidhar; van der Wekken, Anthonie J; Dooms, Christophe; Paz-Ares Rodriguez, Luis; Mountzios, Giannis; Sacher, Adrian; Nadal, Ernest; Couraud, Sebastien; Kim, Sang-We; O'Byrne, Kenneth; Rocco, Danilo; Toyozawa, Ryo; Chmielewska, Izabela; Lindsay, Colin R; Hindoyan, Antreas; Mukundan, Lata; Wilmanski, Tomasz; Anderson, Abraham; Ardito-Abraham, Christine; Pati, Amrita; Reddy, Anita; Mehta, Bhakti; Schuler, Martin

Year: 2025

Venue: Nature medicine

DOI: https://doi.org/10.1038/s41591-025-03732-5

Paper Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

Caiola, Elisa; Frapolli, Roberta; Tomanelli, Michele et al. · 2018 · Scientific Reports · DOI

Full title: Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

Authors: Caiola, Elisa; Frapolli, Roberta; Tomanelli, Michele; Valerio, Rossana; Iezzi, Alice; Garassino, Marina Chiara; Broggini, Massimo; Marabese, Mirko

Year: 2018

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-017-18900-y

Paper Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation

Weng, Tzu‐Yang; Wu, Hsuan Franziska; Li, Chung-Yen et al. · 2018 · Scientific Reports · DOI

Full title: Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation

Authors: Weng, Tzu‐Yang; Wu, Hsuan Franziska; Li, Chung-Yen; Hung, Yu-Hsuan; Chang, Yu‐Wei; Chen, Yi‐Ling; Hsu, Hui‐Ping; Chen, Yu‐Hung; Wang, Chih‐Yang; Chang, Jang‐Yang; Lai, Ming-Derg

Year: 2018

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-018-26454-w

Paper An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

Hansen, Rasmus; Firdaus, Sarah J.; Li, Shuangwei et al. · 2018 · Scientific Reports · DOI

Full title: An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

Authors: Hansen, Rasmus; Firdaus, Sarah J.; Li, Shuangwei; Janes, Matthew R.; Zhang, Jingchuan; Liu, Yi; Zarrinkar, Patrick P.

Year: 2018

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-018-32683-w

Paper KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations

Pantsar, Tatu · 2020 · Scientific Reports · DOI

Full title: KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations

Authors: Pantsar, Tatu

Year: 2020

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-020-68950-y

Paper The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer

Moerland, Jessica A.; Zhang, Di; Reich, Lyndsey A. et al. · 2020 · Scientific Reports · DOI

Full title: The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer

Authors: Moerland, Jessica A.; Zhang, Di; Reich, Lyndsey A.; Carapellucci, Sarah; Lockwood, Beth; Leal, Ana S.; Krieger-Burke, Teresa; Aleiwi, Bilal; Ellsworth, Edmund L.; Liby, Karen T.

Year: 2020

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-020-79260-8

Paper Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Pairawan, Seyed; Akçakanat, Argun; Kopetz, Scott et al. · 2022 · Scientific Reports · DOI

Full title: Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Authors: Pairawan, Seyed; Akçakanat, Argun; Kopetz, Scott; Tapia, Coya; Zheng, Xiaofeng; Chen, Huiqin; Ha, Min Jin; Rizvi, Yasmeen Q.; Holla, Vijaykumar; Wang, Jing; Evans, Kurt W.; Zhao, Ming; Busaidy, Naifa L.; Fang, Bingliang; Roth, Jack A.; Dumbrava, Ecaterina Ileana; Meric‐Bernstam, Funda

Year: 2022

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-022-05193-z

Paper Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

Vaclová, Tereza; Chakraborty, Atanu; Sherwood, James et al. · 2022 · Scientific Reports · DOI

Full title: Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

Authors: Vaclová, Tereza; Chakraborty, Atanu; Sherwood, James; Ross, Sarah J.; Carroll, Danielle; Barrett, J. Carl; Downward, Julian; Bruin, Elza C. de

Year: 2022

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-022-06369-3

Paper The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors

Sakamoto, Kotaro; Lin, Bangzhong; Nunomura, Kazuto et al. · 2022 · Scientific Reports · DOI

Full title: The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors

Authors: Sakamoto, Kotaro; Lin, Bangzhong; Nunomura, Kazuto; Izawa, Takeshi; Nakagawa, Shinsaku

Year: 2022

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-022-12401-3

Paper Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis

Zhou, Chu; Jing, Zhongying; Liu, Wei et al. · 2023 · Scientific Reports · DOI

Full title: Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis

Authors: Zhou, Chu; Jing, Zhongying; Liu, Wei; Ma, Zihuan; Liu, Siyao; Fang, Yueyu

Year: 2023

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-023-42851-2

Paper CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Cheng, Ke; Zhou, Zijian; Chen, Qiangxing et al. · 2024 · Scientific Reports · DOI

Full title: CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Authors: Cheng, Ke; Zhou, Zijian; Chen, Qiangxing; Chen, Zixin; Cai, Yu; Cai, He; Wu, Shangdi; Gao, Pan; Cai, Yunqiang; Zhou, Jin; Wang, Xin; Zhong, Wu; Peng, Bing

Year: 2024

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-024-57417-z

Paper KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential

Metin Eser; Gulam Hekimoğlu; M. Yarar et al. · 2024 · Scientific Reports · DOI

Full title: KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential

Authors: Metin Eser; Gulam Hekimoğlu; M. Yarar; Sezin Canbek; M. Ozcelik

Year: 2024

Venue: Scientific Reports

DOI: https://doi.org/10.1038/s41598-024-75208-4

Paper A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Gurule, Natalia J.; McCoach, Caroline E.; Hinz, Trista K. et al. · 2021 · npj Precision Oncology · DOI

Full title: A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Authors: Gurule, Natalia J.; McCoach, Caroline E.; Hinz, Trista K.; Merrick, Daniel T.; Bokhoven, Adriaan Van; Kim, Jihye; Patil, Tejas; Calhoun, Jacob; Nemenoff, Raphael A.; Tan, Aik Choon; Doebele, Robert C.; Heasley, Lynn E.

Year: 2021

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-021-00181-4

Paper Comprehensive molecular profiling of pulmonary pleomorphic carcinoma

Nagano, Masaaki; Kohsaka, Shinji; Hayashi, Takuo et al. · 2021 · npj Precision Oncology · DOI

Full title: Comprehensive molecular profiling of pulmonary pleomorphic carcinoma

Authors: Nagano, Masaaki; Kohsaka, Shinji; Hayashi, Takuo; Ueno, Toshihide; Kojima, Shinya; Shinozaki‐Ushiku, Aya; Morita, Shigeki; Tsuda, Masumi; Tanaka, Shinya; Shinohara, Toshiya; Omori, Yuko; Sugaya, Fumiko; Kato, Hiroaki; Narita, Yoshiaki; Nakajima, Jun; Suzuki, Kenji; Takamochi, Kazuya; Mano, Hiroyuki

Year: 2021

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-021-00201-3

Paper Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes

Gabriela Palma; Faisal Khurshid; K. Lu et al. · 2021 · npj Precision Oncology · DOI

Full title: Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes

Authors: Gabriela Palma; Faisal Khurshid; K. Lu; Brian D. Woodward; H. Husain

Year: 2021

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-021-00237-5

Paper MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.

Farnsworth, Dylan A; Inoue, Yusuke; Johnson, Fraser D et al. · 2022 · NPJ precision oncology · DOI

Full title: MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.

Authors: Farnsworth, Dylan A; Inoue, Yusuke; Johnson, Fraser D; de Rappard-Yuswack, Georgia; Lu, Daniel; Shi, Rocky; Ma, Lok In Josephine; Mattar, Marissa S; Somwar, Romel; Ladanyi, Marc; Unni, Arun M; Lockwood, William W

Year: 2022

Venue: NPJ precision oncology

DOI: https://doi.org/10.1038/s41698-022-00328-x

Paper Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

Lee, Jessica; Sivakumar, Smruthy; Schrock, Alexa B. et al. · 2022 · npj Precision Oncology · DOI

Full title: Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

Authors: Lee, Jessica; Sivakumar, Smruthy; Schrock, Alexa B.; Madison, Russell W.; Fabrizio, David; Gjoerup, Ole; Ross, Jeffrey S.; Frampton, Garrett M.; Napalkov, Pavel; Montesion, Meagan; Schutzman, Jennifer L.; Ye, Xin; Hegde, Priti S.; Nagasaka, Misako; Oxnard, Geoffrey R.; Sokol, Ethan; Ou, Sai‐Hong Ignatius; Shi, Zhen

Year: 2022

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-022-00334-z

Paper Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

Priest, Katherine; Le, Anh T.; Gebregzabheir, Amanuail et al. · 2023 · npj Precision Oncology · DOI

Full title: Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

Authors: Priest, Katherine; Le, Anh T.; Gebregzabheir, Amanuail; Nijmeh, Hala; Reis, Gregory B.; Mandell, Melanie; Davies, Kurtis D.; Lawrence, Carolyn A.; O’Donnell, Emily; Doebele, Robert C.; Bao, Liming; Aisner, Dara L.; Schenk, Erin L.

Year: 2023

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-023-00349-0

Paper Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

B. Nelson; N. Reddy; J. Huse et al. · 2023 · npj Precision Oncology · DOI

Full title: Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

Authors: B. Nelson; N. Reddy; J. Huse; B. Amini; M. Nardo; M. Gouda; S. Weathers; V. Subbiah

Year: 2023

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-023-00398-5

Paper Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma

Zhao, Ruiying; Xu, Yunhua; Chen, Yedan et al. · 2023 · npj Precision Oncology · DOI

Full title: Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma

Authors: Zhao, Ruiying; Xu, Yunhua; Chen, Yedan; Zhang, Jiajun; Teng, Fei; Liao, Sha; Chen, Shengnan; Wu, Qian; Xiang, Chan; Pang, Jiaohui; Shang, Zhanxian; Zhao, Jikai; Bao, Hairong; Bao, Hua; Shao, Yang; Lü, Shun; Han, Yuchen

Year: 2023

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-023-00430-8

Paper ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

Timofeev, Oleg; Giron, Philippe; Lawo, Steffen et al. · 2024 · npj Precision Oncology · DOI

Full title: ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

Authors: Timofeev, Oleg; Giron, Philippe; Lawo, Steffen; Pichler, Martin; Noeparast, Amir

Year: 2024

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-024-00554-5

Paper Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization

Kohei Maruyama; Yuki Shimizu; Yumi Nomura et al. · 2025 · npj Precision Oncology · DOI

Full title: Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization

Authors: Kohei Maruyama; Yuki Shimizu; Yumi Nomura; Tomoko Oh-hara; Yuki Takahashi; Satoshi Nagayama; Naoya Fujita; Ryohei Katayama

Year: 2025

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-024-00793-6

Paper Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A

H. Yanada; Ryohei Yoshida; Ryotaro Kida et al. · 2025 · npj Precision Oncology · DOI

Full title: Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A

Authors: H. Yanada; Ryohei Yoshida; Ryotaro Kida; K. Nitanai; Maya Ikeda; Kazunori Nagasue; Taeka Naraoka; Masashi Ueda; Takashi Watanabe; Ryota Shigaki; Yasuhiro Umekage; Yoshinori Minami; T. Nagato; Manami Hayashi; S. Yuzawa; M. Tanino; Takaaki Sasaki

Year: 2025

Venue: npj Precision Oncology

DOI: https://doi.org/10.1038/s41698-025-00953-2

Paper Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Maroni, Giorgia; Bassal, Mahmoud A.; Krishnan, Indira et al. · 2021 · Communications Biology · DOI

Full title: Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Authors: Maroni, Giorgia; Bassal, Mahmoud A.; Krishnan, Indira; Fhu, Chee Wai; Savova, Virginia; Žilionis, Rapolas; Maymi, Valerie A.; Pandell, Nicole; Csizmadia, Eva; Zhang, Junyan; Storti, Barbara; Castaño, Julio; Panella, Riccardo; Li, Jia; Gustafson, Corinne E.; Fox, Sam; Levy, Rachel D.; Meyerovitz, Claire V.; Tramontozzi, Peter J.; Vermilya, Kimberly; Rienzo, Assunta De; Crucitta, Stefania; Bassères, Daniela S. Daniela Sanchez; Weetall, Marla; Branstrom, Art; Giorgetti, Alessandra; Ciampi, Raffaele; Re, Marzia Del; Danesi, Romano; Bizzarri, Ranieri; Yang, Henry; Kocher, Olivier; Klein, Allon M.; Welner, Robert S.; Bueno, Raphael; Magli, Maria Cristina; Clohessy, John G.; Ali, Azhar; Tenen, Daniel G.; Levantini, Elena

Year: 2021

Venue: Communications Biology

DOI: https://doi.org/10.1038/s42003-021-01897-6

Paper Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform

Xia, Yifeng; X, Ji; Jang, In Sock et al. · 2021 · Communications Biology · DOI

Full title: Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform

Authors: Xia, Yifeng; X, Ji; Jang, In Sock; Surka, Christine; Hsu, Christy; Wang, Kai; Rolfe, Mark; Bence, Neil; Lu, Gang

Year: 2021

Venue: Communications Biology

DOI: https://doi.org/10.1038/s42003-021-02352-2

Paper Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Chapeau, Emilie A.; Sansregret, Laurent; Galli, Giorgio Giacomo et al. · 2024 · Nature Cancer · DOI

Full title: Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Authors: Chapeau, Emilie A.; Sansregret, Laurent; Galli, Giorgio Giacomo; Chêne, Patrick; Wartmann, Markus; Mourikis, Thanos; Jaaks, Patricia; Baltschukat, Sabrina; Barbosa, Inês Amorim Monteiro; Bauer, Daniel; Brachmann, Saskia M.; Delaunay, Clara; Estadieu, Claire; Faris, Jason E.; Furet, Pascal; Harlfinger, Stefanie; Hueber, Andreas; Núñez, Eloísa Jiménez; Kodack, David P.; Mandon, Emeline; Martin, Typhaine; Mesrouze, Yannick; Romanet, Vincent; Scheufler, Clemens; Sellner, Holger; Stamm, Christelle; Sterker, Dario; Tordella, Luca; Hofmann, Francesco; Soldermann, Nicolas; Schmelzle, Tobias

Year: 2024

Venue: Nature Cancer

DOI: https://doi.org/10.1038/s43018-024-00754-9

Paper Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Riediger, Anja Lisa; Dietz, Steffen; Schirmer, Uwe et al. · 2016 · Scientific Reports · DOI

Full title: Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Authors: Riediger, Anja Lisa; Dietz, Steffen; Schirmer, Uwe; Meister, Michael; Heinzmann-Groth, Ingrid; Schneider, Marc A.; Muley, Thomas; Thomas, Michael; Sültmann, Holger

Year: 2016

Venue: Scientific Reports

DOI: https://doi.org/10.1038/srep33505

Paper Fragment-based covalent ligand discovery

Lu, Wenchao; Kostić, Milka; Zhang, Tinghu et al. · 2021 · RSC Chemical Biology · DOI

Full title: Fragment-based covalent ligand discovery

Authors: Lu, Wenchao; Kostić, Milka; Zhang, Tinghu; Che, Jianwei; Patricelli, Matthew P.; Jones, Lyn H.; Chouchani, Edward T.; Gray, Nathanael S.

Year: 2021

Venue: RSC Chemical Biology

DOI: https://doi.org/10.1039/d0cb00222d

Paper KRasG12C inhibitors in clinical trials: a short historical perspective

Goebel, Lisa; Müller, Matthias; Goody, Roger S. et al. · 2020 · RSC Medicinal Chemistry · DOI

Full title: KRasG12C inhibitors in clinical trials: a short historical perspective

Authors: Goebel, Lisa; Müller, Matthias; Goody, Roger S.; Rauh, Daniel

Year: 2020

Venue: RSC Medicinal Chemistry

DOI: https://doi.org/10.1039/d0md00096e

Paper Covalent inhibitors: a rational approach to drug discovery

Sutanto, Fandi; Konstantinidou, Markella; Dömlingꝉ, Alexander · 2020 · RSC Medicinal Chemistry · DOI

Full title: Covalent inhibitors: a rational approach to drug discovery

Authors: Sutanto, Fandi; Konstantinidou, Markella; Dömlingꝉ, Alexander

Year: 2020

Venue: RSC Medicinal Chemistry

DOI: https://doi.org/10.1039/d0md00154f

Paper Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation

Bond, Michael J.; Crews, Craig M. · 2021 · RSC Chemical Biology · DOI

Full title: Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation

Authors: Bond, Michael J.; Crews, Craig M.

Year: 2021

Venue: RSC Chemical Biology

DOI: https://doi.org/10.1039/d1cb00011j

Paper Monobodies as tool biologics for accelerating target validation and druggable site discovery

Akkapeddi, Padma; Teng, Kai Wen; Koide, Shohei · 2021 · RSC Medicinal Chemistry · DOI

Full title: Monobodies as tool biologics for accelerating target validation and druggable site discovery

Authors: Akkapeddi, Padma; Teng, Kai Wen; Koide, Shohei

Year: 2021

Venue: RSC Medicinal Chemistry

DOI: https://doi.org/10.1039/d1md00188d

Paper Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling

Lim, Shuhui; Boyer, N.; Boo, Nicole et al. · 2021 · Chemical Science · DOI

Full title: Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling

Authors: Lim, Shuhui; Boyer, N.; Boo, Nicole; Huang, Chunhui; Venkatachalam, Gireedhar; Juang, Yu‐Chi; Garrigou, Michael; Kaan, Hung Yi Kristal; Duggal, Ruchia; Peh, Khong Ming; Sadruddin, Ahmad; Gopal, Pooja; Yuen, Tsz Ying; Ng, Simon; Kannan, Srinivasaraghavan; Brown, Christopher J.; Verma, Chandra; Orth, Peter; Peier, Andrea; Ge, Lan; Yu, Xiang; Bhatt, Bhavana; Chen, Feifei; Wang, Erjia; Li, Nianyu Jason; Gonzales, Raymond J.; Stoeck, Alexander; Henry, Brian; Sawyer, Tomi K.; Lane, David P.; Johannes, Charles W.; Biswas, Kaustav; Partridge, Anthony W.

Year: 2021

Venue: Chemical Science

DOI: https://doi.org/10.1039/d1sc05187c

Paper The era of high-quality chemical probes

Licciardello, Marco P.; Workman, Paul · 2022 · RSC Medicinal Chemistry · DOI

Full title: The era of high-quality chemical probes

Authors: Licciardello, Marco P.; Workman, Paul

Year: 2022

Venue: RSC Medicinal Chemistry

DOI: https://doi.org/10.1039/d2md00291d

Paper Medicinal chemistry perspective of pyrido[2,3- d ]pyrimidines as anticancer agents

Kumar, Adarsh; Bhagat, Kuber Kumar; Singh, Ankit Kumar et al. · 2023 · RSC Advances · DOI

Full title: Medicinal chemistry perspective of pyrido[2,3- d ]pyrimidines as anticancer agents

Authors: Kumar, Adarsh; Bhagat, Kuber Kumar; Singh, Ankit Kumar; Singh, Harshwardhan; Angre, Tanuja; Verma, Amita; Khalilullah, Habibullah; Jaremko, Mariusz; Emwas, Abdul‐Hamid; Kumar, Pradeep

Year: 2023

Venue: RSC Advances

DOI: https://doi.org/10.1039/d3ra00056g

Paper Management of Brain Metastases: A Review of Novel Therapies

Bellur, Shreyas; Khosla, Atulya Aman; Ozair, Ahmad et al. · 2023 · Seminars in Neurology · DOI

Full title: Management of Brain Metastases: A Review of Novel Therapies

Authors: Bellur, Shreyas; Khosla, Atulya Aman; Ozair, Ahmad; Kotecha, Rupesh; McDermott, Michael; Ahluwalia, Manmeet S.

Year: 2023

Venue: Seminars in Neurology

DOI: https://doi.org/10.1055/s-0043-1776782

Paper The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12C

Vincent L. Cannataro; S. Gaffney; Carly Stender et al. · 2017 · bioRxiv · DOI

Full title: The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12C

Authors: Vincent L. Cannataro; S. Gaffney; Carly Stender; Zi-Ming Zhao; M. Philips; A. Greenstein; J. Townsend

Year: 2017

Venue: bioRxiv

DOI: https://doi.org/10.1101/149724

Paper SHP2 Inhibition Abrogates Adaptive Resistance to KRAS G12C -Inhibition and Remodels the Tumor Microenvironment of KRAS -Mutant Tumors

Fedele, Carmine; Li, Shuai; Teng, Kai Wen et al. · 2020 · DOI

Full title: SHP2 Inhibition Abrogates Adaptive Resistance to KRAS G12C -Inhibition and Remodels the Tumor Microenvironment of KRAS -Mutant Tumors

Authors: Fedele, Carmine; Li, Shuai; Teng, Kai Wen; Foster, Connor; Peng, David H.; Ran, Hao; Mita, Paolo; Geer, Mitchell J.; Hattori, Takamitsu; Koide, Akiko; Wang, Yubao; Tang, Kwan Ho; Leinwand, Joshua; Wang, Wei; Diskin, Brian; Deng, Jiehui; Chen, Ting; Dolgalev, Igor; Özerdem, Uğur; Miller, George; Koide, Shohei; Wong, Kwok‐Kin; Neel, Benjamin G.

Year: 2020

DOI: https://doi.org/10.1101/2020.05.30.125138

Paper Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer

Y. Inoue; A. Nikolić; D. Farnsworth et al. · 2020 · bioRxiv · DOI

Full title: Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer

Authors: Y. Inoue; A. Nikolić; D. Farnsworth; A-L Liu; M. Ladanyi; R. Somwar; M. Gallo; W. Lockwood

Year: 2020

Venue: bioRxiv

DOI: https://doi.org/10.1101/2020.11.12.368522

Paper An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

Boumelha, Jesse; Trécesson, Sophie de Carné; Law, Emily K. et al. · 2020 · DOI

Full title: An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

Authors: Boumelha, Jesse; Trécesson, Sophie de Carné; Law, Emily K.; Romero-Clavijo, Pablo; Coelho, Matthew A.; Ng, TP; Mugarza, Edurne; Moore, Christopher; Rana, Sareena; Caswell, Deborah R.; Murillo, Miguel; Hancock, David C.; Argyris, Prokopios P.; Brown, William L.; Durfee, Cameron; Larson, Lindsay K.; Vogel, Rachel I.; Suárez‐Bonnet, Alejandro; Priestnall, Simon L.; East, Philip; Ross, Sarah J.; Kassiotis, George; Molina‐Arcas, Míriam; Swanton, Charles; Harris, Reuben S.; Downward, Julian

Year: 2020

DOI: https://doi.org/10.1101/2020.12.22.423126

Paper Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

Tang, Kwan Ho; Li, Shuai; Khodadadi‐Jamayran, Alireza et al. · 2021 · DOI

Full title: Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

Authors: Tang, Kwan Ho; Li, Shuai; Khodadadi‐Jamayran, Alireza; Jen, Jayu; Han, Han; Guidry, Kayla; Chen, Ting; Yuan, Hao; Fedele, Carmine; Zebala, John A.; Maeda, Dean Y.; Christensen, James G.; Olson, Peter; Athanas, Argus; Wong, Kwok‐Kin; Neel, Benjamin G.

Year: 2021

DOI: https://doi.org/10.1101/2021.03.21.436338

Paper A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Haderk, Franziska; Fernández-Méndez, Celia; Čech, Lauren et al. · 2021 · DOI

Full title: A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Authors: Haderk, Franziska; Fernández-Méndez, Celia; Čech, Lauren; Yu, Johnny; Meraz, Ismail M.; Olivas, Victor; Rabago, Dora Barbosa; Kerr, D. Lucas; Gómez, Carlos F.; Allegakoen, David V.; Guan, Juan; Shah, Khyati N.; Herrington, Kari A.; Gbenedio, Oghenekevwe M.; Nanjo, Shigeki; Majidi, Mourad; Tamaki, Whitney; Rotow, Julia; McCoach, Caroline E.; Riess, Jonathan W.; Gutkind, J. Silvio; Tang, Tracy; Post, Leonard; Huang, Bo; Santisteban, Pilar; Goodarzi, Hani; Bandyopadhyay, Sourav; Kuo, Calvin J.; Roose, Jeroen P.; Wu, Wei; Blakely, Collin M.; Roth, Jack A.; Bivona, Trever G.

Year: 2021

DOI: https://doi.org/10.1101/2021.10.23.465573

Paper Combined KRAS G12C and SOS1 inhibition enhances and extends the anti-tumor response in KRAS G12C -driven cancers by addressing intrinsic and acquired resistance

Thatikonda, Venu; Lu, Hengyu; Jurado, Sabine et al. · 2023 · DOI

Full title: Combined KRAS G12C and SOS1 inhibition enhances and extends the anti-tumor response in KRAS G12C -driven cancers by addressing intrinsic and acquired resistance

Authors: Thatikonda, Venu; Lu, Hengyu; Jurado, Sabine; Kostyrko, Kaja; Bristow, Christopher A.; Bosch, Karin; Feng, Ningping; Gao, Sisi; Gerlach, Daniel; Gmachl, Michael; Lieb, Simone; Jeschko, Astrid; Machado, Annette A.; Marszalek, Ethan D.; Mahendra, Mikhila; Jaeger, Philipp A.; Sorokin, Alexey V.; Strauss, Sandra J.; Trapani, Francesca; Kopetz, Scott; Vellano, Christopher P.; Petronczki, Mark; Kraut, Norbert; Heffernan, Timothy P.; Marszalek, Joseph R.; Pearson, Mark; Waizenegger, Irene C.; Hofmann, Marco H.

Year: 2023

DOI: https://doi.org/10.1101/2023.01.23.525210

Paper Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro et al. · 2023 · DOI

Full title: Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

Authors: Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro; Alkhalili, Osama; Uddin, Md. Hafiz; Bannoura, Sahar F.; Mzannar, Yousef; Azar, Ibrahim; Beal, Eliza W.; Tobon, Miguel E.; Kim, Steve; Beydoun, Rafic; Baloglu, Erkan; Senapedis, William; El‐Rayes, Bassel F.; Philip, Philip A.; Mohammad, Ramzi M.; Shields, Anthony F.; Hallak, Mohammed Najeeb Al; Azmi, Asfar S.

Year: 2023

DOI: https://doi.org/10.1101/2023.03.27.534309

Paper A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer

J. Foote; Tyler E Mattox; A. Keeton et al. · 2024 · bioRxiv · DOI

Full title: A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer

Authors: J. Foote; Tyler E Mattox; A. Keeton; Xi Chen; Forrest T Smith; Kristy Berry; Thomas W Holmes; Junwei Wang; Chung-Hui Huang; Antonio Ward; Amit K Mitra; Veronica Ramirez-Alcantara; Cherlene Hardy; Karrianne G. Fleten; K. Flatmark; K. Yoon; Sujith Sarvesh; G. Nagaraju; D. S. Bandi; Y. Maxuitenko; J. Valiyaveettil; Julienne L. Carstens; D. Buchsbaum; Jennifer Yang; Gang Zhou; Elmar Nurmemmedov; I. Babic; V. Gaponenko; Hazem Abdelkarim; M. Boyd; Gregory S. Gorman; U. Manne; Sejong Bae; B. El-Rayes; G. Piazza

Year: 2024

Venue: bioRxiv

DOI: https://doi.org/10.1101/2023.05.17.541233

Paper Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

Vida Tajiknia; Maximilian Pinho-Schwermann; Praveen R Srinivasan et al. · 2023 · bioRxiv · DOI

Full title: Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

Authors: Vida Tajiknia; Maximilian Pinho-Schwermann; Praveen R Srinivasan; Liz Hernandez Borrero; Leiqing Zhang; K. Huntington; W. El-Deiry

Year: 2023

Venue: bioRxiv

DOI: https://doi.org/10.1101/2023.09.13.557593

Paper Targeting cancer with small molecule pan-KRAS degraders

Popow, Johannes; Farnaby, William; Gollner, Andreas et al. · 2023 · DOI

Full title: Targeting cancer with small molecule pan-KRAS degraders

Authors: Popow, Johannes; Farnaby, William; Gollner, Andreas; Kofink, Christiane; Fischer, Gerhard W.; Wurm, Melanie; Zollman, David; Wijaya, Andre; Mischerikow, Nikolai; Hasenoehrl, Carina; Prokofeva, Polina; Arnhof, Heribert; Arce-Solano, Silvia; Bell, Sammy; Boeck, Georg; Diers, Emelyne; Frost, Aileen B.; Goodwin‐Tindall, Jake; Karolyi‐Oezguer, Jale; Khan, Shakil; Klawatsch, Theresa; Koegl, Manfred; Kousek, Roland; Kratochvil, Barbara; Kropatsch, Katrin; Lauber, Arnel A.; McLennan, Ross; Olt, Sabine; Peter, Daniel; Petermann, Oliver; Roessler, Vanessa; Stolt-Bergner, Peggy; Strack, Patrick; Strauss, Eva; Trainor, Nicole; Vetma, Vesna; Whitworth, Claire; Zhong, Siying; Quant, Jens; Weinstabl, Harald; Küster, Bernhard; Ettmayer, Peter; Ciulli, Alessio

Year: 2023

DOI: https://doi.org/10.1101/2023.10.24.563163

Paper SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma

Daley, Brianna R.; Sealover, Nancy E.; Sheffels, Erin et al. · 2023 · DOI

Full title: SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma

Authors: Daley, Brianna R.; Sealover, Nancy E.; Sheffels, Erin; Hughes, Jacob M.; Gerlach, Daniel; Hofmann, Marco H.; Kostyrko, Kaja; Mair, Barbara; Linke, Amanda J.; Beckley, Zaria; Frank, Andrew; Dalgard, Clifton L.; Kortum, Robert L.

Year: 2023

DOI: https://doi.org/10.1101/2023.12.07.570642

Paper Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling

Rachel Nakagawa; Andrew Beardsley; Sophia Durney et al. · 2024 · bioRxiv · DOI

Full title: Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling

Authors: Rachel Nakagawa; Andrew Beardsley; Sophia Durney; M. Hayward; Vishvak Subramanyam; Nathaniel P. Meyer; Harrison Wismer; Hani Goodarzi; Valerie M. Weaver; Daniel Van de Mark; Andrei Goga

Year: 2024

Venue: bioRxiv

DOI: https://doi.org/10.1101/2024.09.26.615226

Paper Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells

Maj-Britt Paulsohn; Klara Henrike Frahnert; Xin Fang et al. · 2025 · bioRxiv · DOI

Full title: Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells

Authors: Maj-Britt Paulsohn; Klara Henrike Frahnert; Xin Fang; Carolin Schneider; Constanza Tapia Contreras; Günter Schneider; E. Hessmann; Matthias Dobbelstein

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.01.11.632518

Paper CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma

Kathleen M. McAndrews; Krishnan K. Mahadevan; Bingrui Li et al. · 2025 · bioRxiv · DOI

Full title: CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma

Authors: Kathleen M. McAndrews; Krishnan K. Mahadevan; Bingrui Li; Amari M. Sockwell; Sami J. Morse; Patience J. Kelly; Sarah I. Patel; Michelle L Kirtley; Barbara A. Moreno Diaz; Hengyu Lyu; David H Peng; Xunian Zhou; Hikaru Sugimoto; Aaron A. Bickert; Lakshmi Kavitha Sthanam; Meagan R. Conner; Shreyasee V. Kumbhar; Kent A. Arian; Yasaman Barekatain; Francesca Paradiso; Paola A. Guerrero; V. Bernard; Navid Sobhani; Alondra N. Camacho-Acevedo; Kiara E. Bornes; Phuong Thao Tran; Anirban Maitra; T. Heffernan; R. Kalluri

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.01.29.635543

Paper RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors

Beau Baars; Ana Orive-Ramos; Ziyue Kou et al. · 2025 · bioRxiv · DOI

Full title: RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors

Authors: Beau Baars; Ana Orive-Ramos; Ziyue Kou; Bijaya Gaire; Mathieu Desaunay; Christos Adamopoulos; Stuart A. Aaronson; Shaomeng Wang; E. Gavathiotis; Poulikos I. Poulikakos

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.02.14.638317

Paper Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models

Daniela D. De Nobrega; Logan C. Eiler; Parmanand Ahirwar et al. · 2025 · bioRxiv · DOI

Full title: Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models

Authors: Daniela D. De Nobrega; Logan C. Eiler; Parmanand Ahirwar; Urvi P. Rawal; Chelsea L. Crawford; D. Buchsbaum; A. Keeton; Y. Maxuitenko; Xi Chen; G. Piazza; Allan Tsung; Karim I. Budhwani

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.02.25.640132

Paper Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1, a regulator of cap-dependent translation

I. Meraz; Shuhong Wu; Yi Xu et al. · 2025 · bioRxiv · DOI

Full title: Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1, a regulator of cap-dependent translation

Authors: I. Meraz; Shuhong Wu; Yi Xu; Lihui Gao; Meng Feng; Chenghui Ren; R. Song; Ran Zhang; Qi Wang; Yuanxin Xi; Sung Yun Jung; Jing Wang; Bingliang Fang; M. Majidi; Jack A Roth

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.03.18.643954

Paper Mechanisms of resistance to active state selective tri-complex RAS inhibitors

Ben Sang; Ling Feng Ye; Feng Hu et al. · 2025 · bioRxiv · DOI

Full title: Mechanisms of resistance to active state selective tri-complex RAS inhibitors

Authors: Ben Sang; Ling Feng Ye; Feng Hu; Yasin Pourfarjam; Antonio Cuevas-Navarro; Shijie Fan; Zheng Fu; Aaliyah Washington; Diego J. Rodriguez; Alberto Vides; Sumit Kar; Ethan Ahler; Kevin K. Lin; A. Hegde; J. Smith; B. Wolpin; Salman R Punekar; A. Spira; I. Garrido-Laguna; David S. Hong; A. Dar; R. Yaeger; K. Arbour; P. Lito

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.04.24.649345

Paper Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.

Daniel R. Principe; Jeffrey H Becker; Anastasia E. Metropulos et al. · 2026 · Molecular Cancer Therapeutics · DOI

Full title: Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.

Authors: Daniel R. Principe; Jeffrey H Becker; Anastasia E. Metropulos; Alejandra M Marinelarena; Thao D Pham; A. Aissa; H. Munshi

Year: 2026

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-25-0483

Paper Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRC.

Alonso, Salvador; Chu, Kevan; Parsons, Marie J et al. · 2025 · bioRxiv : the preprint server for biology · DOI

Full title: Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRC.

Authors: Alonso, Salvador; Chu, Kevan; Parsons, Marie J; Granowsky, Elizabeth; Gunasinghe, Himari; Shia, Jinru; Yaeger, Rona; Dow, Lukas E

Year: 2025

Venue: bioRxiv : the preprint server for biology

DOI: https://doi.org/10.1101/2025.08.05.668666

Paper VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation

Sung-Hyun Hwang; Mingyun Bae; Ji-Won Kim et al. · 2025 · bioRxiv · DOI

Full title: VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation

Authors: Sung-Hyun Hwang; Mingyun Bae; Ji-Won Kim; Seung Yoon Hyun; Kui-Jin Kim; Joshua H Choe; Min Jung Kim; Ji Won Park; Seung-Yong Jeong; Songji Choi; Woochan Park; Jeongmin Seo; Heejung Chae; Minsu Kang; E. Jung; K. J. Suh; Se Hyun Kim; Jin Won Kim; Yu Jung Kim; Jeehyoung Kim; Haeseong Park; A. Aguirre; E. A. Lee; Ja-Lok Ku; Keun-Wook Lee

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.09.16.676456

Paper Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development

Estape, Anna Arnal; Foggetti, Giorgia; Starrett, Jacqueline H. et al. · 2021 · Cold Spring Harbor Perspectives in Medicine · DOI

Full title: Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development

Authors: Estape, Anna Arnal; Foggetti, Giorgia; Starrett, Jacqueline H.; Nguyen, Don X.; Politi, Katerina

Year: 2021

Venue: Cold Spring Harbor Perspectives in Medicine

DOI: https://doi.org/10.1101/cshperspect.a037820

Paper Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47

Hu, Huanhuan; Cheng, Rongjie; Wang, Yanbo et al. · 2022 · Journal of Clinical Investigation · DOI

Full title: Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47

Authors: Hu, Huanhuan; Cheng, Rongjie; Wang, Yanbo; Wang, Xiaojun; Wu, Jianzhuang; Kong, Yan; Zhan, Shoubin; Zhou, Zhen; Zhu, Hongyu; Yu, Ranran; Liang, Gaoli; Wang, Qingyan; Zhu, Xiaoju; Zhang, Chenyu; Yin, Rong; Yan, Chao; Chen, Xi

Year: 2022

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci153470

Paper Targeting mutations in cancer

Waarts, Michael R.; Stonestrom, Aaron J.; Park, Young C. et al. · 2022 · Journal of Clinical Investigation · DOI

Full title: Targeting mutations in cancer

Authors: Waarts, Michael R.; Stonestrom, Aaron J.; Park, Young C.; Levine, Ross L.

Year: 2022

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci154943

Paper Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition

Yihsuan S. Tsai; M. Woodcock; S. Azam et al. · 2022 · Journal of Clinical Investigation · DOI

Full title: Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition

Authors: Yihsuan S. Tsai; M. Woodcock; S. Azam; L. Thorne; K. Kanchi; J. Parker; B. Vincent; C. Pecot

Year: 2022

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci155523

Paper Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

F. Nardi; N. Perurena; Amy E. Schade et al. · 2023 · Journal of Clinical Investigation · DOI

Full title: Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Authors: F. Nardi; N. Perurena; Amy E. Schade; Zecang Li; K. Ngo; E. Ivanova; Aisha Saldanha; Chendi Li; P. Gokhale; A. Hata; D. Barbie; C. Paweletz; P. Janne; K. Cichowski

Year: 2023

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci167651

Paper Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

Vaccaro, Kyle; Allen, Juliet; Whitfield, Troy W. et al. · 2024 · Journal of Clinical Investigation · DOI

Full title: Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

Authors: Vaccaro, Kyle; Allen, Juliet; Whitfield, Troy W.; Maoz, Asaf; Reeves, Sarah; Velarde, José; Yang, Dian; Meglan, Anna; Ribeiro, Juliano; Blandin, Jasmine; Phan, Nicole; Bell, George W.; Hata, Aaron N.; Weiskopf, Kipp

Year: 2024

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci169315

Paper Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS–mutant cancer models

Shihui Shen; Qiansen Zhang; Yuhan Wang et al. · 2025 · Journal of Clinical Investigation · DOI

Full title: Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS–mutant cancer models

Authors: Shihui Shen; Qiansen Zhang; Yuhan Wang; Hui Chen; Shuangming Gong; Yun Liu; Conghao Gai; Hansen Chen; Enhao Zhu; Bo Yang; Lin Liu; Siyuan Cao; Mengting Zhao; Wenjie Ren; Mengjuan Li; Zhuoya Peng; Lu Zhang; Shaoying Zhang; Juwen Shen; Bianhong Zhang; Patrick K.H. Lee; Kun Li; Lei Li; Huaiyu Yang

Year: 2025

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci185278

Paper Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer

Padhye, Aparna; Konen, Jessica; Rodriguez, B. Leticia et al. · 2021 · JCI Insight · DOI

Full title: Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer

Authors: Padhye, Aparna; Konen, Jessica; Rodriguez, B. Leticia; Fradette, Jared J.; Ochieng, Joshua K.; Diao, Lixia; Wang, Jing; Lü, Wei; Solis, Luisa S.; Batra, Harsh Vardhan; Raso, Maria Gabriela; Peoples, Michael; Minelli, Rosalba; Carugo, Alessandro; Bristow, Christopher A.; Gibbons, Don L.

Year: 2021

Venue: JCI Insight

DOI: https://doi.org/10.1172/jci.insight.148392

Paper Targeting the undruggable oncogenic KRAS: the dawn of hope

Asimgil, Hande; Ertetik, Utku; Çevik, Nedim Can et al. · 2022 · JCI Insight · DOI

Full title: Targeting the undruggable oncogenic KRAS: the dawn of hope

Authors: Asimgil, Hande; Ertetik, Utku; Çevik, Nedim Can; Ekizce, Menar; Doğruöz, Alper; Gökalp, Muazzez; Arık-Sever, Elif; Istvánffy, Rouzanna; Friess, Helmut; Ceyhan, Güralp O.; Demir, İhsan Ekin

Year: 2022

Venue: JCI Insight

DOI: https://doi.org/10.1172/jci.insight.153688

Paper Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report

H. H. Rossing; M. Grauslund; E. Urbanska et al. · 2013 · BMC Research Notes · DOI

Full title: Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report

Authors: H. H. Rossing; M. Grauslund; E. Urbanska; L. C. Melchior; C. K. Rask; Junia C. Costa; B. Skov; J. Sørensen; E. Santoni-Rugiu

Year: 2013

Venue: BMC Research Notes

DOI: https://doi.org/10.1186/1756-0500-6-489

Paper Oncogenic driver mutations in lung cancer

S. Luo; D. C. Lam · 2013 · Translational Respiratory Medicine · DOI

Full title: Oncogenic driver mutations in lung cancer

Authors: S. Luo; D. C. Lam

Year: 2013

Venue: Translational Respiratory Medicine

DOI: https://doi.org/10.1186/2213-0802-1-6

Paper MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis

Chungui Xu; Weihao Lin; Qi Zhang et al. · 2024 · Molecular Medicine · DOI

Full title: MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis

Authors: Chungui Xu; Weihao Lin; Qi Zhang; Yarui Ma; Xue Wang; Ai Guo; Guiling Zhu; Zhendiao Zhou; Weiwei Song; Ziyi Zhao; Yuchen Jiao; Xiaobing Wang; Chunxia Du

Year: 2024

Venue: Molecular Medicine

DOI: https://doi.org/10.1186/s10020-024-00972-y

Paper Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma

Sixian Chen; Aizhen Fu; Yuanli Lu et al. · 2022 · BMC Genomics · DOI

Full title: Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma

Authors: Sixian Chen; Aizhen Fu; Yuanli Lu; W. Lu; Yongfeng Chen; S.-H. Hong; Suli Zhou; Tianmin Xiang; Zhenzhen Zhang; Yongguang Cai

Year: 2022

Venue: BMC Genomics

DOI: https://doi.org/10.1186/s12864-021-08289-4

Paper Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

Araujo, Luiz H.; Souza, Bianca Mendes; Leite, Laura Rabelo et al. · 2021 · BMC Cancer · DOI

Full title: Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

Authors: Araujo, Luiz H.; Souza, Bianca Mendes; Leite, Laura Rabelo; Parma, Sabrina A. F.; Lopes, Natália P.; Malta, Frederico Scott Varella; Freire, Maíra Cristina Menezes

Year: 2021

Venue: BMC Cancer

DOI: https://doi.org/10.1186/s12885-021-07884-8

Paper A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice

Liu, Yanxia; Gao, Yuan; Wang, Ying et al. · 2022 · BMC Cancer · DOI

Full title: A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice

Authors: Liu, Yanxia; Gao, Yuan; Wang, Ying; Zhao, Cong; Zhang, Zhiyun; Li, Baolan; Zhang, Tongmei

Year: 2022

Venue: BMC Cancer

DOI: https://doi.org/10.1186/s12885-022-10236-9

Paper Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

Julián, Cristina; Pal, Navdeep; Gershon, Anda et al. · 2023 · BMC Cancer · DOI

Full title: Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

Authors: Julián, Cristina; Pal, Navdeep; Gershon, Anda; Evangelista, Marie; Purkey, Hans E.; Lambert, Peter; Shi, Zhen; Zhang, Qing

Year: 2023

Venue: BMC Cancer

DOI: https://doi.org/10.1186/s12885-023-10778-6

Paper Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis

Teppei Yamaguchi; J. Shimizu; Reiko Matsuzawa et al. · 2024 · BMC Cancer · DOI

Full title: Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis

Authors: Teppei Yamaguchi; J. Shimizu; Reiko Matsuzawa; Naohiro Watanabe; Y. Horio; Yutaka Fujiwara

Year: 2024

Venue: BMC Cancer

DOI: https://doi.org/10.1186/s12885-024-12554-6

Paper The complex journey of targeting RAS in oncology

Katarzyna Wasiak; Damian Ciunowicz; Amelia Kierasińska-Kałka et al. · 2025 · BMC Cancer · DOI

Full title: The complex journey of targeting RAS in oncology

Authors: Katarzyna Wasiak; Damian Ciunowicz; Amelia Kierasińska-Kałka; Marta Węgierska; Marcin Pacholczyk; Piotr Rieske; Ewelina Stoczyńska-Fidelus

Year: 2025

Venue: BMC Cancer

DOI: https://doi.org/10.1186/s12885-025-14033-y

Paper Comprehensive tumor molecular profile analysis in clinical practice

Özdoğan, Mustafa; Papadopoulou, Eirini; Τσούλος, Νικόλαος et al. · 2021 · BMC Medical Genomics · DOI

Full title: Comprehensive tumor molecular profile analysis in clinical practice

Authors: Özdoğan, Mustafa; Papadopoulou, Eirini; Τσούλος, Νικόλαος; Tsantikidi, Aikaterini; Mariatou, Vasiliki-Metaxa; Tsaousis, Georgios; Kapeni, Evgenia; Bourkoula, Evgenia; Fotiou, Dimitrios; Kapetsis, Georgios; Boukovinas, Ioannis; Touroutoglou, Nikolaos; Fassas, Athanasios; Adamidis, Achilleas; Kosmidis, Paraskevas; Trafalis, Dimitrios T.; Galani, Eleni; Lypas, Georgios; Orhan, Bülent; Tansan, Sualp; Özatlı, Tahsin; Kırca, Önder; Çakır, Okan; Nasioulas, George

Year: 2021

Venue: BMC Medical Genomics

DOI: https://doi.org/10.1186/s12920-021-00952-9

Paper CRISPR and KRAS: a match yet to be made

Bender, Guzide; Yamaci, Rezan Fahrioglu; Taneri, Bahar · 2021 · Journal of Biomedical Science · DOI

Full title: CRISPR and KRAS: a match yet to be made

Authors: Bender, Guzide; Yamaci, Rezan Fahrioglu; Taneri, Bahar

Year: 2021

Venue: Journal of Biomedical Science

DOI: https://doi.org/10.1186/s12929-021-00772-0

Paper DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer

Chiou, Li-Wen; Chan, Chien-Hui; Jhuang, Yu‐Ling et al. · 2023 · Journal of Biomedical Science · DOI

Full title: DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer

Authors: Chiou, Li-Wen; Chan, Chien-Hui; Jhuang, Yu‐Ling; Yang, Ching‐Yao; Jeng, Yung‐Ming

Year: 2023

Venue: Journal of Biomedical Science

DOI: https://doi.org/10.1186/s12929-023-00940-4

Paper Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

Kotani, Hiroshi; Oshima, Hiroko; Boucher, Justin C. et al. · 2024 · Journal of Biomedical Science · DOI

Full title: Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

Authors: Kotani, Hiroshi; Oshima, Hiroko; Boucher, Justin C.; Yamano, Tomoyoshi; Sakaguchi, Hiroyuki; Sato, Shigeki; Fukuda, Koji; Nishiyama, Akihiro; Yamashita, Kaname; Ohtsubo, Koushiro; Takeuchi, Shinji; Nishiuchi, Takumi; Oshima, Masanobu; Davila, Marco L.; Yano, Seiji

Year: 2024

Venue: Journal of Biomedical Science

DOI: https://doi.org/10.1186/s12929-024-01060-3

Paper Recent advances in non-small cell lung cancer targeted therapy; an update review

Araghi, Mahmood; Mannani, Reza; Maleki, Ali Heidarnejad et al. · 2023 · Cancer Cell International · DOI

Full title: Recent advances in non-small cell lung cancer targeted therapy; an update review

Authors: Araghi, Mahmood; Mannani, Reza; Maleki, Ali Heidarnejad; Hamidi, A.; Rostami, Samaneh; Safa, Salar Hozhabri; Faramarzi, Fatemeh; Khorasani, Sahar; Alimohammadi, Mina; Tahmasebi, Safa; Akhavan‐Sigari, Reza

Year: 2023

Venue: Cancer Cell International

DOI: https://doi.org/10.1186/s12935-023-02990-y

Paper The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis

Rui Zhao; Yang Shu; Wei Xu et al. · 2024 · Cancer Cell International · DOI

Full title: The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis

Authors: Rui Zhao; Yang Shu; Wei Xu; Fengxian Jiang; Pancen Ran; Liying Pan; Jingliang Wang; Weihao Wang; Jing Zhao; Yahui Wang; Guobin Fu

Year: 2024

Venue: Cancer Cell International

DOI: https://doi.org/10.1186/s12935-024-03498-9

Paper Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Xu, Ke; Park, Dongkyoo; Magis, Andrew T. et al. · 2019 · Molecular Cancer · DOI

Full title: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Authors: Xu, Ke; Park, Dongkyoo; Magis, Andrew T.; Zhang, Jun; Zhou, Wei; Sica, Gabriel; Ramalingam, Suresh S.; Curran, Walter J.; Deng, Xingming

Year: 2019

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-019-1012-4

Paper RNA-based therapies: A cog in the wheel of lung cancer defense

Κhan, Parvez; Siddiqui, Jawed A.; Lakshmanan, Imayavaramban et al. · 2021 · Molecular Cancer · DOI

Full title: RNA-based therapies: A cog in the wheel of lung cancer defense

Authors: Κhan, Parvez; Siddiqui, Jawed A.; Lakshmanan, Imayavaramban; Ganti, Apar Kishor; Salgia, Ravi; Jain, Maneesh; Batra, Surinder K.; Nasser, Mohd W.

Year: 2021

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-021-01338-2

Paper An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

F. Reggiani; E. Sauta; F. Torricelli et al. · 2021 · Molecular Cancer · DOI

Full title: An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

Authors: F. Reggiani; E. Sauta; F. Torricelli; E. Zanetti; E. Tagliavini; G. Santandrea; G. Gobbi; G. Damia; R. Bellazzi; D. Ambrosetti; A. Ciarrocchi; V. Sancisi

Year: 2021

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-021-01357-z

Paper Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Tang, Daolin; Kroemer, Guido; Kang, Rui · 2021 · Molecular Cancer · DOI

Full title: Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Authors: Tang, Daolin; Kroemer, Guido; Kang, Rui

Year: 2021

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-021-01422-7

Paper Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Chunxi Zhu; Xiaoqing Guan; Xinuo Zhang et al. · 2022 · Molecular Cancer · DOI

Full title: Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Authors: Chunxi Zhu; Xiaoqing Guan; Xinuo Zhang; X. Luan; Zhengbo Song; Xiangdong Cheng; Weidong Zhang; Jiangjiang Qin

Year: 2022

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-022-01629-2

Paper Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

Zhu, Zhi; McGray, AJ Robert; Jiang, Weijian et al. · 2022 · Molecular Cancer · DOI

Full title: Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

Authors: Zhu, Zhi; McGray, AJ Robert; Jiang, Weijian; Lu, Binfeng; Kaliński, Paweł; Guo, Zong Sheng

Year: 2022

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-022-01664-z

Paper Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Wang, Penglei; Laster, Kyle Vaughn; Jia, Xuechao et al. · 2023 · Molecular Cancer · DOI

Full title: Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Authors: Wang, Penglei; Laster, Kyle Vaughn; Jia, Xuechao; Dong, Zigang; Liu, Kangdong

Year: 2023

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-023-01903-x

Paper Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Puyalto, A.; Rodríguez‐Remírez, María; López, Inés et al. · 2024 · Molecular Cancer · DOI

Full title: Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Authors: Puyalto, A.; Rodríguez‐Remírez, María; López, Inés; Macaya, Irati; Guruceaga, Elizabeth; Olmedo, María; Vilalta, A.; Welch, Connor; Sandiego, Sergio; Vicent, Silvestre; Valencia, Karmele; Calvo, Alfonso; Pı́o, Rubén; Raez, Luis E.; Rolfo, Christian; Ajona, Daniel; Gil‐Bazo, Ignacio

Year: 2024

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-024-01991-3

Paper Targeting KRAS: from metabolic regulation to cancer treatment

Shi, Yanyan; Zheng, Huiling; Wang, Tianzhen et al. · 2025 · Molecular Cancer · DOI

Full title: Targeting KRAS: from metabolic regulation to cancer treatment

Authors: Shi, Yanyan; Zheng, Huiling; Wang, Tianzhen; Zhou, Shaonan; Zhao, Shiqing; Li, Mo; Cao, Baoshan

Year: 2025

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-024-02216-3

Paper The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy

Ma, Qinglong; Zhang, Wenyang; Wu, Kongming et al. · 2025 · Molecular Cancer · DOI

Full title: The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy

Authors: Ma, Qinglong; Zhang, Wenyang; Wu, Kongming; Shi, Lei

Year: 2025

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-024-02218-1

Paper Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs

Xia Wang; Jing Wu; Aotian Xiao et al. · 2025 · Molecular Cancer · DOI

Full title: Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs

Authors: Xia Wang; Jing Wu; Aotian Xiao; Jie Wang; Jun Tian

Year: 2025

Venue: Molecular Cancer

DOI: https://doi.org/10.1186/s12943-025-02364-0

Paper Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation

Dim, Nneka; Perepelyuk, Maryna; Gomes, Olukayode et al. · 2015 · Journal of Nanobiotechnology · DOI

Full title: Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation

Authors: Dim, Nneka; Perepelyuk, Maryna; Gomes, Olukayode; Thangavel, Chellappagounder; Liu, Yi; Den, Robert B.; Lakshmikuttyamma, Ashakumary; Shoyele, Sunday

Year: 2015

Venue: Journal of Nanobiotechnology

DOI: https://doi.org/10.1186/s12951-015-0124-2

Paper Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo

Yuchen Zhang; Cheukfai Li; Chenglai Xia et al. · 2022 · Cell Communication and Signaling · DOI

Full title: Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo

Authors: Yuchen Zhang; Cheukfai Li; Chenglai Xia; Keneth Kin Wah To; Zhixing Guo; C. Ren; L. Wen; Fang Wang; Liwu Fu; N. Liao

Year: 2022

Venue: Cell Communication and Signaling

DOI: https://doi.org/10.1186/s12964-022-00955-8

Paper Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions

Watterson, Alex; Coelho, Matthew A. · 2023 · Cell Communication and Signaling · DOI

Full title: Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions

Authors: Watterson, Alex; Coelho, Matthew A.

Year: 2023

Venue: Cell Communication and Signaling

DOI: https://doi.org/10.1186/s12964-023-01063-x

Paper KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

Rosell, R.; Jantus‐Lewintre, Eloísa; Cao, Peng et al. · 2024 · Cell Communication and Signaling · DOI

Full title: KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

Authors: Rosell, R.; Jantus‐Lewintre, Eloísa; Cao, Peng; Cai, Xueting; Xing, B.; Ito, Masaoki; Gomez-Vazquez, Jose Luis; Marco-Jordán, Mireia; Calabuig‐Fariñas, Silvia; Cardona, Andrés F.; Codony‐Servat, Jordi; González, Jessica; València-Clua, K.; Aguilar, Andrés; Pedraz‐Valdunciel, Carlos; Dantes, Zahra; Jain, Anisha; Shivamallu, Chandan; Molina‐Vila, Miguel Ángel; Arrieta, Óscar; Ferrero, Macarena; Camps, Carlos; González‐Cao, María

Year: 2024

Venue: Cell Communication and Signaling

DOI: https://doi.org/10.1186/s12964-024-01667-x

Paper Off-target engagement of sotorasib with PPARγ via FABP4: a novel mechanism driving interstitial lung disease.

Zhang, Jiaqi; Li, Jinjin; Cheng, Mengting et al. · 2025 · Cell communication and signaling : CCS · DOI

Full title: Off-target engagement of sotorasib with PPARγ via FABP4: a novel mechanism driving interstitial lung disease.

Authors: Zhang, Jiaqi; Li, Jinjin; Cheng, Mengting; Zhou, Haiyang; Zhang, Xiaochen; Yan, Hao; Xu, Zhifei; Yang, Bo; He, Qiaojun; Gao, Zizheng; Chen, Xueqin; Luo, Peihua

Year: 2025

Venue: Cell communication and signaling : CCS

DOI: https://doi.org/10.1186/s12964-025-02425-3

Paper RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment

Liu, Yongting; Xie, Bin; Chen, Qiong · 2023 · Journal of Translational Medicine · DOI

Full title: RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment

Authors: Liu, Yongting; Xie, Bin; Chen, Qiong

Year: 2023

Venue: Journal of Translational Medicine

DOI: https://doi.org/10.1186/s12967-023-04486-9

Paper KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner

Laurent, Pierre-Antoine; Milić, Marina; Quevrin, Clément et al. · 2023 · Journal of Translational Medicine · DOI

Full title: KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner

Authors: Laurent, Pierre-Antoine; Milić, Marina; Quevrin, Clément; Meziani, Lydia; Liu, Winchygn; Morel, Daphné; Signolle, Nicolas; Clémenson, Céline; Lévy, Antonin; Mondini, Michele; Deutsch, Éric

Year: 2023

Venue: Journal of Translational Medicine

DOI: https://doi.org/10.1186/s12967-023-04619-0

Paper KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors

Tian, Linyan; Liu, Chengming; Zheng, Sufei et al. · 2025 · Journal of Translational Medicine · DOI

Full title: KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors

Authors: Tian, Linyan; Liu, Chengming; Zheng, Sufei; Shi, Huiyang; Fang, Wei; Jiang, Wenxin; Dong, Yucheng; Xu, Haiyan; Yin, Enzhi; Sun, Nan; He, Jie; Wang, Yan

Year: 2025

Venue: Journal of Translational Medicine

DOI: https://doi.org/10.1186/s12967-025-06089-y

Paper Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

Shen, Fangfang; Guo, Wei; Song, Xia et al. · 2023 · Diagnostic Pathology · DOI

Full title: Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

Authors: Shen, Fangfang; Guo, Wei; Song, Xia; Wang, Bei

Year: 2023

Venue: Diagnostic Pathology

DOI: https://doi.org/10.1186/s13000-023-01349-1

Paper Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Majeed, Umair; Manochakian, Rami; Zhao, Yujie et al. · 2021 · Journal of Hematology & Oncology · DOI

Full title: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Authors: Majeed, Umair; Manochakian, Rami; Zhao, Yujie; Lou, Yanyan

Year: 2021

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-021-01121-2

Paper Emerging strategies to target RAS signaling in human cancer therapy

Chen, Kun; Zhang, Yalei; Qian, Ling et al. · 2021 · Journal of Hematology & Oncology · DOI

Full title: Emerging strategies to target RAS signaling in human cancer therapy

Authors: Chen, Kun; Zhang, Yalei; Qian, Ling; Wang, Peng

Year: 2021

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-021-01127-w

Paper BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Sajid Khan; Janet S. Wiegand; Peiyi Zhang et al. · 2022 · Journal of Hematology & Oncology · DOI

Full title: BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Authors: Sajid Khan; Janet S. Wiegand; Peiyi Zhang; Wanyi Hu; Dinesh Thummuri; Vivekananda Budamagunta; Nan Hua; Lingtao Jin; C. Allegra; S. Kopetz; M. Zajac-Kaye; F. Kaye; Guangrong Zheng; Daohong Zhou

Year: 2022

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-022-01241-3

Paper Tumor organoids: applications in cancer modeling and potentials in precision medicine

Xu, Hanxiao; Jiao, Dechao; Liu, Aiguo et al. · 2022 · Journal of Hematology & Oncology · DOI

Full title: Tumor organoids: applications in cancer modeling and potentials in precision medicine

Authors: Xu, Hanxiao; Jiao, Dechao; Liu, Aiguo; Wu, Kongming

Year: 2022

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-022-01278-4

Paper Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Wu, Qing; Qian, Wei; Sun, Xiaoli et al. · 2022 · Journal of Hematology & Oncology · DOI

Full title: Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Authors: Wu, Qing; Qian, Wei; Sun, Xiaoli; Jiang, Shaojie

Year: 2022

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-022-01362-9

Paper Drugging KRAS: current perspectives and state-of-art review

Parikh, Kaushal; Banna, Giuseppe Luigi; Liu, Stephen V. et al. · 2022 · Journal of Hematology & Oncology · DOI

Full title: Drugging KRAS: current perspectives and state-of-art review

Authors: Parikh, Kaushal; Banna, Giuseppe Luigi; Liu, Stephen V.; Friedlaender, Alex; Desai, Aakash; Subbiah, Vivek; Addeo, Alfredo

Year: 2022

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-022-01375-4

Paper RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Xiaojuan Yang; Hong Wu · 2024 · Journal of Hematology & Oncology · DOI

Full title: RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Authors: Xiaojuan Yang; Hong Wu

Year: 2024

Venue: Journal of Hematology & Oncology

DOI: https://doi.org/10.1186/s13045-024-01631-9

Paper The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.

Kwan, Albert K; Piazza, Gary A; Keeton, Adam B et al. · 2022 · Journal of experimental & clinical cancer research : CR · DOI

Full title: The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.

Authors: Kwan, Albert K; Piazza, Gary A; Keeton, Adam B; Leite, Caio A

Year: 2022

Venue: Journal of experimental & clinical cancer research : CR

DOI: https://doi.org/10.1186/s13046-021-02225-w

Paper Research progress on non-protein-targeted drugs for cancer therapy

Zhang, Yiwen; Lu, Lu; Song, Feifeng et al. · 2023 · Journal of Experimental & Clinical Cancer Research · DOI

Full title: Research progress on non-protein-targeted drugs for cancer therapy

Authors: Zhang, Yiwen; Lu, Lu; Song, Feifeng; Zou, Xiaozhou; Liu, Yujia; Zheng, Xiaowei; Qian, Jinjun; Gu, Chunyan; Huang, Ping; Yang, Ye

Year: 2023

Venue: Journal of Experimental & Clinical Cancer Research

DOI: https://doi.org/10.1186/s13046-023-02635-y

Paper Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2

Kim, Dasom; Min, Dongwha; Kim, Joohee et al. · 2023 · Journal of Experimental & Clinical Cancer Research · DOI

Full title: Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2

Authors: Kim, Dasom; Min, Dongwha; Kim, Joohee; Kim, Jong Min; Seo, Yerim; Jung, Byung Hwa; Kwon, Seung‐Hae; Ro, Hyunju; Lee, Seoee; Jason, K.; Lee, Ji-Yun

Year: 2023

Venue: Journal of Experimental & Clinical Cancer Research

DOI: https://doi.org/10.1186/s13046-023-02922-8

Paper RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer

Jianzhuang Wu; Kexin Xie; Yixuan Zhang et al. · 2025 · Journal of experimental & clinical cancer research : CR · DOI

Full title: RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer

Authors: Jianzhuang Wu; Kexin Xie; Yixuan Zhang; Weiyi Zhang; Rongjie Cheng; Yaliang Zhang; Yugui Xia; Tongyan Liu; Rong Yin; Yudong Qiu; Tao Xu; Rutian Li; Qi Sun; Chao Yan

Year: 2025

Venue: Journal of experimental & clinical cancer research : CR

DOI: https://doi.org/10.1186/s13046-025-03369-9

Paper Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target

Ajmal, Amar; Alkhatabi, Hind Ali; Alreemi, Roaa M. et al. · 2024 · BMC Chemistry · DOI

Full title: Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target

Authors: Ajmal, Amar; Alkhatabi, Hind Ali; Alreemi, Roaa M.; Alamri, Mubarak A.; Khalid, Asaad; Abdalla, Ashraf N.; Alotaibi, Bader S.; Wadood, Abdul

Year: 2024

Venue: BMC Chemistry

DOI: https://doi.org/10.1186/s13065-024-01152-z

Paper Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

Chan, Lok Seng; Liu, Jianzhong; Li, Molly et al. · 2023 · Clinical Epigenetics · DOI

Full title: Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

Authors: Chan, Lok Seng; Liu, Jianzhong; Li, Molly; Li, Lili; Tao, Qian; Mok, Tony

Year: 2023

Venue: Clinical Epigenetics

DOI: https://doi.org/10.1186/s13148-023-01454-4

Paper Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.

Boby, Jeffrey Mathew; Mohd Ghazali, Nurul Nadia; Mani, Anita et al. · 2022 · Journal of medical case reports · DOI

Full title: Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.

Authors: Boby, Jeffrey Mathew; Mohd Ghazali, Nurul Nadia; Mani, Anita; George, Mathew

Year: 2022

Venue: Journal of medical case reports

DOI: https://doi.org/10.1186/s13256-022-03593-3

Paper The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC

Firas Batrash; Mahmoud Kutmah; Jun Zhang · 2023 · Experimental Hematology & Oncology · DOI

Full title: The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC

Authors: Firas Batrash; Mahmoud Kutmah; Jun Zhang

Year: 2023

Venue: Experimental Hematology & Oncology

DOI: https://doi.org/10.1186/s40164-023-00453-8

Paper Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling

Wang, Ya‐Fang; Yao, Mingyue; Li, Cheng et al. · 2023 · Experimental Hematology and Oncology · DOI

Full title: Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling

Authors: Wang, Ya‐Fang; Yao, Mingyue; Li, Cheng; Yang, Kexin; Qin, Xiaolong; Xu, Lansong; Shi, Shangxuan; Yu, Chengcheng; Meng, Xiangjun; Xie, Chengying

Year: 2023

Venue: Experimental Hematology and Oncology

DOI: https://doi.org/10.1186/s40164-023-00466-3

Paper Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

Qiao, Meng; Zhou, Fei; Liu, Xinyu et al. · 2024 · Experimental Hematology and Oncology · DOI

Full title: Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

Authors: Qiao, Meng; Zhou, Fei; Liu, Xinyu; Jiang, Tao; Wang, Haowei; Li, Xuefei; Zhao, Chao; Cheng, Lei; Chen, Xiaoxia; Ren, Shengxiang; Wang, Zaiqi; Zhou, Caicun

Year: 2024

Venue: Experimental Hematology and Oncology

DOI: https://doi.org/10.1186/s40164-023-00471-6

Paper Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer

Jeffrey Xiao; Joshua Kim; Brandon Park et al. · 2025 · Experimental Hematology & Oncology · DOI

Full title: Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer

Authors: Jeffrey Xiao; Joshua Kim; Brandon Park; David J. Baylink; Cedric Kwon; Victoria Tran; Scott Lee; Kevin Codorniz; Laren D Tan; Pamela Lobo Moreno; Amy Schill-Depew; S. Mirshahidi; David de Semir; D. Hanna; Kiran Naqvi; H. Cao; Chien-Shing Chen; Joanne Xiu; H. Lenz; Hamid Mirshahidi; Mark E. Reeves; Yi Xu

Year: 2025

Venue: Experimental Hematology & Oncology

DOI: https://doi.org/10.1186/s40164-025-00669-w

Paper Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Liu, Si‐Yang Maggie; Sun, Hao; Zhou, Jiaying et al. · 2020 · Biomarker Research · DOI

Full title: Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Authors: Liu, Si‐Yang Maggie; Sun, Hao; Zhou, Jiaying; Jie, Guang‐Ling; Xie, Zhi; Shao, Yang; Zhang, Xian; Ye, Junyi; Chen, Chunxiang; Zhang, Xu‐Chao; Zhou, Qing; Yang, Jin‐Ji; Wu, Yi‐Long

Year: 2020

Venue: Biomarker Research

DOI: https://doi.org/10.1186/s40364-020-00199-z

Paper Oncogenic alterations in advanced NSCLC: a molecular super-highway

Friedlaender, Alex; Pérol, M.; Banna, Giuseppe Luigi et al. · 2024 · Biomarker Research · DOI

Full title: Oncogenic alterations in advanced NSCLC: a molecular super-highway

Authors: Friedlaender, Alex; Pérol, M.; Banna, Giuseppe Luigi; Parikh, Kaushal; Addeo, Alfredo

Year: 2024

Venue: Biomarker Research

DOI: https://doi.org/10.1186/s40364-024-00566-0

Paper A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Pang, Xiufeng; Liu, Mingyao · 2016 · Chinese Journal of Cancer · DOI

Full title: A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Authors: Pang, Xiufeng; Liu, Mingyao

Year: 2016

Venue: Chinese Journal of Cancer

DOI: https://doi.org/10.1186/s40880-016-0154-7

Paper Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Zixi Wang; Yurou Xing; Bingjie Li et al. · 2022 · Molecular Biomedicine · DOI

Full title: Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Authors: Zixi Wang; Yurou Xing; Bingjie Li; Xiaoyu Li; Bin Liu; Yongsheng Wang

Year: 2022

Venue: Molecular Biomedicine

DOI: https://doi.org/10.1186/s43556-022-00107-x

Paper KRASG12C inhibitors in lung cancer therapy

Maciej Jędrak; Karolina Niekurzak; Joanna Kania et al. · 2023 · Journal of Education, Health and Sport · DOI

Full title: KRASG12C inhibitors in lung cancer therapy

Authors: Maciej Jędrak; Karolina Niekurzak; Joanna Kania; Maciej Józefiak; Piotr Sobkiewicz; Krzysztof Kania

Year: 2023

Venue: Journal of Education, Health and Sport

DOI: https://doi.org/10.12775/jehs.2023.17.01.015

Paper Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies

Valeryia Milasheuskaya; Katsiaryna Miraniuk; Mykola Sobchynskyi et al. · 2025 · Quality in Sport · DOI

Full title: Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies

Authors: Valeryia Milasheuskaya; Katsiaryna Miraniuk; Mykola Sobchynskyi; Andrii Myrnyi; Dmytro Kowalczuk; Viktoryia Kasianik; Darya Lazitskaya; Kamil Turlej; Iga Kiełbaszewska; Natalia Surosz; Dawid Wiczkowski

Year: 2025

Venue: Quality in Sport

DOI: https://doi.org/10.12775/qs.2025.43.61191

Paper Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

Perkins, Géraldine; Yap, Timothy A.; Pope, Lorna et al. · 2012 · PLoS ONE · DOI

Full title: Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

Authors: Perkins, Géraldine; Yap, Timothy A.; Pope, Lorna; Mulick, Amy; Dukes, Juliet; Riisnaes, Ruth; Massard, Christophe; Cassier, Philippe A.; Miranda, Susana; Clark, Jeremy; Denholm, Katie Ann; Thway, Khin; Castro, David González de; Attard, Gerhardt; Molife, L Rhoda; Kaye, Stan B.; Banerji, Udai; Bono, Johann S. de

Year: 2012

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0047020

Paper Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome

Kerner, Gerald S. M. A.; Schuuring, Ed; Sietsma, Johanna et al. · 2013 · PLoS ONE · DOI

Full title: Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome

Authors: Kerner, Gerald S. M. A.; Schuuring, Ed; Sietsma, Johanna; Hiltermann, T. Jeroen N.; Pieterman, Remge M.; Leede, Gerard P. J. de; Putten, John W.G. van; Liesker, Jeroen J.W.; Renkema, Tineke E. J.; Hengel, Peter van; Platteel, Inge; Timens, Wim; Groen, Harry J.M.

Year: 2013

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0070346

Paper EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

R. Terragni; A. Casadei Gardini; S. Sabattini et al. · 2014 · PLoS ONE · DOI

Full title: EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

Authors: R. Terragni; A. Casadei Gardini; S. Sabattini; G. Bettini; D. Amadori; C. Talamonti; M. Vignoli; L. Capelli; J. Saunders; M. Ricci; P. Ulivi

Year: 2014

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0085388

Paper A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein

Carver, Joseph O.; Dexheimer, Thomas S.; Hsu, Dennis et al. · 2014 · PLoS ONE · DOI

Full title: A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein

Authors: Carver, Joseph O.; Dexheimer, Thomas S.; Hsu, Dennis; Weng, Meng‐Tzu; Smith, Jordan L.; Guha, Rajarshi; Jadhav, Ajit; Simeonov, Anton; Luo, Ji

Year: 2014

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0103836

Paper The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

Wada, Makoto; Horinaka, Mano; Yamazaki, Toshikazu et al. · 2014 · PLoS ONE · DOI

Full title: The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

Authors: Wada, Makoto; Horinaka, Mano; Yamazaki, Toshikazu; Katoh, Norito; Sakai, Toshiyuki

Year: 2014

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0113217

Paper A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress

Lee, Jong Woo; Park, Hee Sun; Park, Sin‐Aye et al. · 2015 · PLoS ONE · DOI

Full title: A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress

Authors: Lee, Jong Woo; Park, Hee Sun; Park, Sin‐Aye; Ryu, Seung-Hee; Meng, Wuyi; Jürgensmeier, Juliane M.; Kurie, Jonathan M.; Hong, Waun Ki; Boyer, Julie L.; Herbst, Roy S.; Koo, Ja Seok

Year: 2015

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0122628

Paper Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression

Sato, Katsuaki; Suda, Kenichi; Shimizu, Shigeki et al. · 2016 · PLoS ONE · DOI

Full title: Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression

Authors: Sato, Katsuaki; Suda, Kenichi; Shimizu, Shigeki; Sakai, Kazuko; Mizuuchi, Hiroshi; Tomizawa, Kenji; Takemoto, Toshiki; Nishio, Kazuto; Mitsudomi, Tetsuya

Year: 2016

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0154186

Paper Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers

Diána Brauswetter; Bianka Gurbi; A. Varga et al. · 2017 · PLoS ONE · DOI

Full title: Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers

Authors: Diána Brauswetter; Bianka Gurbi; A. Varga; E. Várkondi; R. Schwáb; G. Bánhegyi; O. Fábián; G. Kéri; I. Vályi-Nagy; I. Peták

Year: 2017

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0185687

Paper Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy

Fomchenko, Elena I.; Bayley, James C.; Alvarez‐Breckenridge, Christopher et al. · 2022 · Neurospine · DOI

Full title: Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy

Authors: Fomchenko, Elena I.; Bayley, James C.; Alvarez‐Breckenridge, Christopher; Rhines, Laurence D.; Tatsui, Claudio E.

Year: 2022

Venue: Neurospine

DOI: https://doi.org/10.14245/ns.2244290.145

Paper ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer

Saad, Mohamed I.; Alhayyani, Sultan; McLeod, Louise et al. · 2019 · EMBO Molecular Medicine · DOI

Full title: ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer

Authors: Saad, Mohamed I.; Alhayyani, Sultan; McLeod, Louise; Liang, Yu; Alanazi, Mohammad; Deswaerte, Virginie; Tang, Ke; Jardé, Thierry; Smith, Julian A.; Prodanovic, Zdenka; Tate, Michelle D.; Balic, Jesse J.; Watkins, D. Neil; Cain, Jason E.; Bozinovski, Steven; Algar, Elizabeth M.; Kohmoto, Tomohiro; Ebi, Hiromichi; Ferlin, Walter; Garbers, Christoph; Ruwanpura, Saleela M.; Sagi, Irit; Rose‐John, Stefan; Jenkins, Brendan J.

Year: 2019

Venue: EMBO Molecular Medicine

DOI: https://doi.org/10.15252/emmm.201809976

Paper Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS ‐mutant cancer

Zhang, Yang; Liang, Shun‐Qing; Saliakoura, Maria et al. · 2021 · EMBO Molecular Medicine · DOI

Full title: Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS ‐mutant cancer

Authors: Zhang, Yang; Liang, Shun‐Qing; Saliakoura, Maria; Yang, Haitang; Vassella, Erik; Konstantinidou, Georgia; Tschan, Mario P.; Hegedűs, Balázs; Zhao, Liang; Gao, Yanyun; Xu, Duo; Deng, Haibin; Marti, Thomas M.; Kocher, Gregor J.; Wang, Wenxiang; Schmid, Ralph A.; Peng, Ren‐Wang

Year: 2021

Venue: EMBO Molecular Medicine

DOI: https://doi.org/10.15252/emmm.202013193

Paper Targeting rare tumors: new focus for clinical research in China

Wang, Shuhang; Jiang, Yale; Miao, Huilei et al. · 2022 · EMBO Molecular Medicine · DOI

Full title: Targeting rare tumors: new focus for clinical research in China

Authors: Wang, Shuhang; Jiang, Yale; Miao, Huilei; Fang, Yuan; Jiang, Ning; Yu, Yue; Ma, Peiwen; Tang, Qiyu; Cui, Dandan; Fang, Hong; Huang, Huiyao; Fan, Qi; Sun, Chao; Yu, Anqi; Miao, Shuangman; Du, Jingting; Zhu, Jingxiao; Wang, Yuning; Li, Ning

Year: 2022

Venue: EMBO Molecular Medicine

DOI: https://doi.org/10.15252/emmm.202216415

Paper [Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice.]

L. Belluomini; Sara Pilotto · 2025 · Recenti progressi in medicina · DOI

Full title: [Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice.]

Authors: L. Belluomini; Sara Pilotto

Year: 2025

Venue: Recenti progressi in medicina

DOI: https://doi.org/10.1701/4619.46290

Paper Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma

Peng, Xinyi; Xia, Zhenqi; Guo, Yong et al. · 2023 · Aging · DOI

Full title: Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma

Authors: Peng, Xinyi; Xia, Zhenqi; Guo, Yong; Li, Yan

Year: 2023

Venue: Aging

DOI: https://doi.org/10.18632/aging.204770

Paper Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells

A. Rouhi; Christina R. Miller; Sarah Grasedieck et al. · 2016 · OncoTarget · DOI

Full title: Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells

Authors: A. Rouhi; Christina R. Miller; Sarah Grasedieck; Stefanie Reinhart; B. Stolze; H. Döhner; F. Kuchenbauer; L. Bullinger; S. Fröhling; C. Scholl

Year: 2016

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.13841

Paper The proto-oncogene KRAS is targeted by miR-200c

Kopp, Florian; Wagner, Ernst; Roidl, Andreas · 2013 · Oncotarget · DOI

Full title: The proto-oncogene KRAS is targeted by miR-200c

Authors: Kopp, Florian; Wagner, Ernst; Roidl, Andreas

Year: 2013

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.1427

Paper In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics

Grundberg, Ida; Kiflemariam, Sara; Mignardi, Marco et al. · 2013 · Oncotarget · DOI

Full title: In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics

Authors: Grundberg, Ida; Kiflemariam, Sara; Mignardi, Marco; Imgenberg‐Kreuz, Juliana; Edlund, Karolina; Micke, Patrick; Sundström, Magnus; Sjöblom, Tobias; Botling, Johan; Nilsson, Mats

Year: 2013

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.1527

Paper Molecular pathways and therapeutic targets in lung cancer

Shtivelman, Emma; Hensing, Thomas A.; Simon, George R. et al. · 2014 · Oncotarget · DOI

Full title: Molecular pathways and therapeutic targets in lung cancer

Authors: Shtivelman, Emma; Hensing, Thomas A.; Simon, George R.; Dennis, Phillip A.; Otterson, Gregory A.; Bueno, Raphael; Salgia, Ravi

Year: 2014

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.1891

Paper Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

Jun Zhang; S. Nannapaneni; Dongsheng Wang et al. · 2017 · OncoTarget · DOI

Full title: Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

Authors: Jun Zhang; S. Nannapaneni; Dongsheng Wang; Fakeng Liu; Xu Wang; R. Jin; Xiuju Liu; M. Rahman; Xiang-hong Peng; G. Qian; Z. Chen; Kwok-kin Wong; F. Khuri; Wei Zhou; D. Shin

Year: 2017

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.19779

Paper Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

Said, Rabih; Yang, Ye; Falchook, Gerald S. et al. · 2014 · Oncotarget · DOI

Full title: Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

Authors: Said, Rabih; Yang, Ye; Falchook, Gerald S.; Jankú, Filip; Naing, Aung; Zinner, Ralph; Blumenschein, George R.; Fu, Siqing; Hong, David S.; Piha‐Paul, Sarina A.; Wheler, Jennifer J.; Kurzrock, Razelle; Palmer, Gary A.; Aldape, Kenneth; Hess, Kenneth R.; Tsimberidou, Apostolia M.

Year: 2014

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.2339

Paper Implications of KRAS mutations in acquired resistance to treatment in NSCLC

Re, Marzia Del; Rofi, Eleonora; Restante, Giuliana et al. · 2017 · Oncotarget · DOI

Full title: Implications of KRAS mutations in acquired resistance to treatment in NSCLC

Authors: Re, Marzia Del; Rofi, Eleonora; Restante, Giuliana; Crucitta, Stefania; Arrigoni, E.; Fogli, Stefano; Maïo, Massimo Di; Petrini, Iacopo; Danesi, Romano

Year: 2017

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.23553

Paper Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials

Wilkins, Jon F.; Cannataro, Vincent L.; Hu, Hai et al. · 2018 · Oncotarget · DOI

Full title: Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials

Authors: Wilkins, Jon F.; Cannataro, Vincent L.; Hu, Hai; Townsend, Jeffrey P.

Year: 2018

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.25155

Paper Targeted drug combination therapy design based on driver genes

Zsákai, Lilian; Sipos, Anna; Dobos, Judit et al. · 2019 · Oncotarget · DOI

Full title: Targeted drug combination therapy design based on driver genes

Authors: Zsákai, Lilian; Sipos, Anna; Dobos, Judit; Erös, Dániel; Szántai-Kis, Csaba; Bánhegyi, Péter; Pató, János; Őrfi, László; Matula, Zsolt; Mikala, Gábor; Kéri, Gÿorgý; Peták, István; Vályi‐Nagy, István

Year: 2019

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.26985

Paper Circulating tumor DNA analysis in the era of precision oncology

R. Said; N. Guibert; G. Oxnard et al. · 2020 · OncoTarget · DOI

Full title: Circulating tumor DNA analysis in the era of precision oncology

Authors: R. Said; N. Guibert; G. Oxnard; A. Tsimberidou

Year: 2020

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.27418

Paper Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations

Joshi, Asim; Mishra, Rohit; Desai, Sanket et al. · 2021 · Oncotarget · DOI

Full title: Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations

Authors: Joshi, Asim; Mishra, Rohit; Desai, Sanket; Chandrani, Pratik; Kore, Hitesh; Sunder, Roma; Hait, Supriya; Iyer, Prajish; Trivedi, Vaishakhi; Choughule, Anuradha; Noronha, Vanita; Joshi, Amit; Patil, Vijay; Menon, Nandini; Kumar, Rajiv; Prabhash, Kumar; Dutt, Amit

Year: 2021

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.27905

Paper Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Kaczmarczyk, Jan; Roberts, Rhonda R.; Luke, Brian T. et al. · 2021 · Oncotarget · DOI

Full title: Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Authors: Kaczmarczyk, Jan; Roberts, Rhonda R.; Luke, Brian T.; Chan, King C.; Wagoner, Carly M. Van; Felder, Robin A.; Saul, Richard G.; Colantonio, Simona; Blonder, Josip

Year: 2021

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.28072

Paper Activation of RAS family members confers resistance to ROS1 targeting drugs

M. Cargnelutti; S. Corso; M. Pergolizzi et al. · 2014 · OncoTarget · DOI

Full title: Activation of RAS family members confers resistance to ROS1 targeting drugs

Authors: M. Cargnelutti; S. Corso; M. Pergolizzi; L. Mevellec; D. Aisner; R. Dziadziuszko; M. Varella-Garcia; P. Comoglio; R. Doebele; J. Vialard; S. Giordano

Year: 2014

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.3311

Paper Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade

Umelo, Ijeoma Adaku; Wever, Olivier De; Kronenberger, Peter et al. · 2015 · Oncotarget · DOI

Full title: Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade

Authors: Umelo, Ijeoma Adaku; Wever, Olivier De; Kronenberger, Peter; Deun, Jan Van; Noor, Alfiah; Singh, Kshitiz; Teugels, Erik; Chen, Gang; Bracke, Marc; Grève, Jacques De

Year: 2015

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.3853

Paper Mutant HRAS as novel target for MEK and mTOR inhibitors

Kießling, Michael K.; Curioni‐Fontecedro, Alessandra; Samaras, Panagiotis et al. · 2015 · Oncotarget · DOI

Full title: Mutant HRAS as novel target for MEK and mTOR inhibitors

Authors: Kießling, Michael K.; Curioni‐Fontecedro, Alessandra; Samaras, Panagiotis; Atrott, Kirstin; Cosín‐Roger, Jesús; Lang, Silvia; Scharl, Michael; Rogler, Gerhard

Year: 2015

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.5619

Paper Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

Baldelli, Elisa; Bellezza, Guido; Haura, Eric B. et al. · 2015 · Oncotarget · DOI

Full title: Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

Authors: Baldelli, Elisa; Bellezza, Guido; Haura, Eric B.; Crinò, Lucio; Cress, W. Douglas; Deng, Jianghong; Ludovini, Vienna; Sidoni, Angelo; Schabath, Matthew B.; Puma, Francesco; Vannucci, Jacopo; Siggillino, Annamaria; Liotta, Lance A.; Petricoin, Emanuel F.; Pierobon, Mariaelena

Year: 2015

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.5941

Paper Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts

C. Lieu; Peter J. Klauck; Patrick K. Henthorn et al. · 2015 · OncoTarget · DOI

Full title: Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts

Authors: C. Lieu; Peter J. Klauck; Patrick K. Henthorn; J. Tentler; A. Tan; A. Spreafico; H. Selby; Blair C. Britt; S. Bagby; J. Arcaroli; W. Messersmith; T. Pitts; S. Eckhardt

Year: 2015

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.5949

Paper Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression

Wang, Qun; Tan, Rong; Zhu, Xin et al. · 2016 · Oncotarget · DOI

Full title: Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression

Authors: Wang, Qun; Tan, Rong; Zhu, Xin; Zhang, Yi; Tan, Zhiping; Su, Bing; Li, Yu

Year: 2016

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.7134

Paper Inhibiting the molecular evolution of cancer through HSP90

A. Martins; F. Davies; P. Workman · 2012 · OncoTarget · DOI

Full title: Inhibiting the molecular evolution of cancer through HSP90

Authors: A. Martins; F. Davies; P. Workman

Year: 2012

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.738

Paper KRAS above and beyond – EGFR in pancreatic cancer

J. Siveke; H. Crawford · 2012 · OncoTarget · DOI

Full title: KRAS above and beyond – EGFR in pancreatic cancer

Authors: J. Siveke; H. Crawford

Year: 2012

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.750

Paper Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model

B. Danysh; Erin Y. Rieger; Deepankar Sinha et al. · 2016 · OncoTarget · DOI

Full title: Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model

Authors: B. Danysh; Erin Y. Rieger; Deepankar Sinha; Caitlin Evers; G. Cote; M. Cabanillas; M. Hofmann

Year: 2016

Venue: OncoTarget

DOI: https://doi.org/10.18632/oncotarget.9023

Paper Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment

Cordover, Emma; Minden, Audrey · 2020 · Journal of Cancer Metastasis and Treatment · DOI

Full title: Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment

Authors: Cordover, Emma; Minden, Audrey

Year: 2020

Venue: Journal of Cancer Metastasis and Treatment

DOI: https://doi.org/10.20517/2394-4722.2020.101

Paper Research progress on KRAS mutations in colorectal cancer

Cefalì, Marco; Epistolio, Samantha; Palmarocchi, Maria Celeste et al. · 2021 · Journal of Cancer Metastasis and Treatment · DOI

Full title: Research progress on KRAS mutations in colorectal cancer

Authors: Cefalì, Marco; Epistolio, Samantha; Palmarocchi, Maria Celeste; Frattini, Milo; Dosso, Sara De

Year: 2021

Venue: Journal of Cancer Metastasis and Treatment

DOI: https://doi.org/10.20517/2394-4722.2021.61

Paper Emerging RAS-directed therapies for cancer

Conroy, Michael; Cowzer, Darren; Kölch, Walter et al. · 2021 · Cancer Drug Resistance · DOI

Full title: Emerging RAS-directed therapies for cancer

Authors: Conroy, Michael; Cowzer, Darren; Kölch, Walter; Duffy, Austin G.

Year: 2021

Venue: Cancer Drug Resistance

DOI: https://doi.org/10.20517/cdr.2021.07

Paper Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study

Guo, Xiaojin; He, Du; Li, Jiayu et al. · 2022 · Cancer Drug Resistance · DOI

Full title: Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study

Authors: Guo, Xiaojin; He, Du; Li, Jiayu; Yang, Meng‐Hang; Xiong, Anweng; Zhang, Haiping; Wu, Fengying

Year: 2022

Venue: Cancer Drug Resistance

DOI: https://doi.org/10.20517/cdr.2021.85

Paper Emerging insights to lung cancer drug resistance

Su, Chunxia · 2022 · Cancer Drug Resistance · DOI

Full title: Emerging insights to lung cancer drug resistance

Authors: Su, Chunxia

Year: 2022

Venue: Cancer Drug Resistance

DOI: https://doi.org/10.20517/cdr.2022.61

Paper From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers

Saliani, Mahsa; Jalal, Razieh; Ahmadian, Mohammad Reza · 2019 · Cancer Biology and Medicine · DOI

Full title: From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers

Authors: Saliani, Mahsa; Jalal, Razieh; Ahmadian, Mohammad Reza

Year: 2019

Venue: Cancer Biology and Medicine

DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0530

Paper Biological insights in non-small cell lung cancer

Rosell, Rafael; Jain, Anisha; Codony‐Servat, Jordi et al. · 2023 · Cancer Biology and Medicine · DOI

Full title: Biological insights in non-small cell lung cancer

Authors: Rosell, Rafael; Jain, Anisha; Codony‐Servat, Jordi; Jantus‐Lewintre, Eloísa; Morrison, Blake; Ginesta, Jordi Barretina; González‐Cao, María

Year: 2023

Venue: Cancer Biology and Medicine

DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0108

Paper Cutting-Edge Therapies for Lung Cancer

La’ah, Anita Silas; Chiou, Shih‐Hwa · 2024 · Cells · DOI

Full title: Cutting-Edge Therapies for Lung Cancer

Authors: La’ah, Anita Silas; Chiou, Shih‐Hwa

Year: 2024

Venue: Cells

DOI: https://doi.org/10.3390/cells13050436

Paper KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer

Kılgöz, Havva Ö.; Bender, Guzide; Scandura, Joseph M. et al. · 2016 · Molecular Medicine · DOI

Full title: KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer

Authors: Kılgöz, Havva Ö.; Bender, Guzide; Scandura, Joseph M.; Viale, Agnès; Taneri, Bahar

Year: 2016

Venue: Molecular Medicine

DOI: https://doi.org/10.2119/molmed.2016.00151

Paper Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer

Y. Jing; Ruixin Cheng; H. Zeng et al. · 2024 · International Journal of General Medicine · DOI

Full title: Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer

Authors: Y. Jing; Ruixin Cheng; H. Zeng; Qin Huang; Dongyu He; Jiayi Sun; P. Tian; Yalun Li

Year: 2024

Venue: International Journal of General Medicine

DOI: https://doi.org/10.2147/ijgm.s484435

Paper Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer

Shannon S Zhang; M. Nagasaka · 2021 · Lung Cancer · DOI

Full title: Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer

Authors: Shannon S Zhang; M. Nagasaka

Year: 2021

Venue: Lung Cancer

DOI: https://doi.org/10.2147/lctt.s334623

Paper A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Brazel, Danielle; Arter, Zhaohui; Nagasaka, Misako · 2022 · Lung Cancer Targets and Therapy · DOI

Full title: A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Authors: Brazel, Danielle; Arter, Zhaohui; Nagasaka, Misako

Year: 2022

Venue: Lung Cancer Targets and Therapy

DOI: https://doi.org/10.2147/lctt.s383662

Paper CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code.

Zhang, Shannon S; Lee, Alexandria; Nagasaka, Misako · 2023 · Lung Cancer (Auckland, N.Z.) · DOI

Full title: CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code.

Authors: Zhang, Shannon S; Lee, Alexandria; Nagasaka, Misako

Year: 2023

Venue: Lung Cancer (Auckland, N.Z.)

DOI: https://doi.org/10.2147/LCTT.S403461

Paper CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

Brazel, Danielle; Kim, Jennifer; Ou, Sai‐Hong Ignatius · 2023 · Lung Cancer Targets and Therapy · DOI

Full title: CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

Authors: Brazel, Danielle; Kim, Jennifer; Ou, Sai‐Hong Ignatius

Year: 2023

Venue: Lung Cancer Targets and Therapy

DOI: https://doi.org/10.2147/lctt.s403614

Paper Adagrasib in KRYSTAL-12 has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma.

Luo, Faustine X; Arter, Zhaohui Liao · 2024 · Lung Cancer (Auckland, N.Z.) · DOI

Full title: Adagrasib in KRYSTAL-12 has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma.

Authors: Luo, Faustine X; Arter, Zhaohui Liao

Year: 2024

Venue: Lung Cancer (Auckland, N.Z.)

DOI: https://doi.org/10.2147/LCTT.S490942

Paper The Role Of Circulating Tumor DNA In Therapeutic Resistance

Xu, Chenxin; Cao, Haixia; Chen, Shi et al. · 2019 · OncoTargets and Therapy · DOI

Full title: The Role Of Circulating Tumor DNA In Therapeutic Resistance

Authors: Xu, Chenxin; Cao, Haixia; Chen, Shi; Feng, Jifeng

Year: 2019

Venue: OncoTargets and Therapy

DOI: https://doi.org/10.2147/ott.s226202

Paper Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments.

Ji, Jingran; Wang, Chongkai; Fakih, Marwan · 2022 · OncoTargets and therapy · DOI

Full title: Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments.

Authors: Ji, Jingran; Wang, Chongkai; Fakih, Marwan

Year: 2022

Venue: OncoTargets and therapy

DOI: https://doi.org/10.2147/OTT.S340392

Paper Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer

Yanning Sun; Li Ma; Xiaofei Zhang et al. · 2024 · OncoTargets and Therapy · DOI

Full title: Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer

Authors: Yanning Sun; Li Ma; Xiaofei Zhang; Zhaoxia Wang

Year: 2024

Venue: OncoTargets and Therapy

DOI: https://doi.org/10.2147/ott.s487870

Paper The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

Zheng, Difan; Chen, Haiquan; Wang, Rui et al. · 2016 · OncoTargets and Therapy · DOI

Full title: The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

Authors: Zheng, Difan; Chen, Haiquan; Wang, Rui; Zhang, Yang; Pan, Yunjian; Cheng, Xinghua; Cheng, Chao; Zheng, Shanbo; Li, Hang; Gong, Ranxia; Li, Yuan; Shen, Xuxia; Sun, Yihua

Year: 2016

Venue: OncoTargets and Therapy

DOI: https://doi.org/10.2147/ott.s96834

Paper Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Whitsett, Timothy G.; Richer, Amanda L.; Friel, Jacqueline M. et al. · 2015 · Pharmacogenomics and Personalized Medicine · DOI

Full title: Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Authors: Whitsett, Timothy G.; Richer, Amanda L.; Friel, Jacqueline M.; Carson, Vashti M.; Inge, Landon J.

Year: 2015

Venue: Pharmacogenomics and Personalized Medicine

DOI: https://doi.org/10.2147/pgpm.s52845

Paper Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators

Check, Jerome H.; PORETTA, TRINA; Check, Diane et al. · 2023 · Anticancer Research · DOI

Full title: Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators

Authors: Check, Jerome H.; PORETTA, TRINA; Check, Diane; Srivastava, Maya D.

Year: 2023

Venue: Anticancer Research

DOI: https://doi.org/10.21873/anticanres.16240

Paper Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment

Kataoka, Masahiro; Kitazawa, Masato; Nakamura, Satoshi et al. · 2023 · Anticancer Research · DOI

Full title: Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment

Authors: Kataoka, Masahiro; Kitazawa, Masato; Nakamura, Satoshi; Koyama, Makoto; Yamamoto, Yuta; Miyazaki, Satoru; Hondo, Nao; Tanaka, Hirokazu; Soejima, Yuji

Year: 2023

Venue: Anticancer Research

DOI: https://doi.org/10.21873/anticanres.16629

Paper KRASMutations in Cholangiocarcinoma: Prevalence, Prognostic Value, andKRASG12/G13 Detection in Cell-Free DNA

THONGYOO, PITCHASAK; Chindaprasirt, Jarin; Aphivatanasiri, Chaiwat et al. · 2024 · Cancer Genomics & Proteomics · DOI

Full title: KRASMutations in Cholangiocarcinoma: Prevalence, Prognostic Value, andKRASG12/G13 Detection in Cell-Free DNA

Authors: THONGYOO, PITCHASAK; Chindaprasirt, Jarin; Aphivatanasiri, Chaiwat; Intarawichian, Piyapharom; Kunprom, Waritta; Kongpetch, Sarinya; Techasen, Anchalee; Loilome, Watcharin; Namwat, Nisana; Titapun, Attapol; Jusakul, Apinya

Year: 2024

Venue: Cancer Genomics & Proteomics

DOI: https://doi.org/10.21873/cgp.20492

Paper STABILITY INDICATING AND COST-EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SOTORASIB BY USING RP-HPLC

Yarlagadda, Subba Rao; Mannam, Subba Rao; Jampani, Baby Padmini · 2021 · International Journal of Applied Pharmaceutics · DOI

Full title: STABILITY INDICATING AND COST-EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SOTORASIB BY USING RP-HPLC

Authors: Yarlagadda, Subba Rao; Mannam, Subba Rao; Jampani, Baby Padmini

Year: 2021

Venue: International Journal of Applied Pharmaceutics

DOI: https://doi.org/10.22159/ijap.2021v13i5.42659

Paper LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology

Irene A. Retmana · DOI

Full title: LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology

Authors: Irene A. Retmana

DOI: https://doi.org/10.33540/2425

Paper Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach

Kumar, S. Udhaya; Varghese, Rinku Polachirakkal; Preethi, V. Anu et al. · 2023 · Frontiers in Bioscience-Landmark · DOI

Full title: Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach

Authors: Kumar, S. Udhaya; Varghese, Rinku Polachirakkal; Preethi, V. Anu; Doss, C. George Priya; Zayed, Hatem

Year: 2023

Venue: Frontiers in Bioscience-Landmark

DOI: https://doi.org/10.31083/j.fbl2811288

Paper Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer

Shi, Jiajian; Chen, Yuchen; Peng, Chentai et al. · 2022 · ONCOLOGIE · DOI

Full title: Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer

Authors: Shi, Jiajian; Chen, Yuchen; Peng, Chentai; Kuang, Linwu; Zhang, Zitong; Li, Yangkai; Huang, Kun

Year: 2022

Venue: ONCOLOGIE

DOI: https://doi.org/10.32604/oncologie.2022.027545

Paper Targeting KRAS in pancreatic cancer

Stickler, Sandra; Rath, Barbara H.; Hamilton, Gerhard · 2024 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · DOI

Full title: Targeting KRAS in pancreatic cancer

Authors: Stickler, Sandra; Rath, Barbara H.; Hamilton, Gerhard

Year: 2024

Venue: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

DOI: https://doi.org/10.32604/or.2024.045356

Paper p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors

Grassilli, Emanuela; Cerrito, Maria Grazia; Bonomo, Sara et al. · 2021 · Frontiers in Cell and Developmental Biology · DOI

Full title: p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors

Authors: Grassilli, Emanuela; Cerrito, Maria Grazia; Bonomo, Sara; Giovannoni, Roberto; Conconi, Donatella; Lavitrano, Marialuisa

Year: 2021

Venue: Frontiers in Cell and Developmental Biology

DOI: https://doi.org/10.3389/fcell.2021.690365

Paper Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Sun, Guoqiang; Rong, Dawei; Li, Zhouxiao et al. · 2021 · Frontiers in Cell and Developmental Biology · DOI

Full title: Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Authors: Sun, Guoqiang; Rong, Dawei; Li, Zhouxiao; Sun, Guangshun; Wu, Fan; Li, Xiao; Cao, Hongyong; Cheng, Ye; Tang, Weiwei; Sun, Yangbai

Year: 2021

Venue: Frontiers in Cell and Developmental Biology

DOI: https://doi.org/10.3389/fcell.2021.694363

Paper The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

Cáceres-Gutiérrez, Rodrigo E.; Alfaro‐Mora, Yair; Andonegui, Marco A. et al. · 2022 · Frontiers in Cell and Developmental Biology · DOI

Full title: The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

Authors: Cáceres-Gutiérrez, Rodrigo E.; Alfaro‐Mora, Yair; Andonegui, Marco A.; Díaz‐Chávez, José; Herrera, Luis A.

Year: 2022

Venue: Frontiers in Cell and Developmental Biology

DOI: https://doi.org/10.3389/fcell.2022.751367

Paper KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

Zhang, Zining; Zhang, Heng; Liao, Xiang et al. · 2023 · Frontiers in Cell and Developmental Biology · DOI

Full title: KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

Authors: Zhang, Zining; Zhang, Heng; Liao, Xiang; Tsai, Hsiang‐i

Year: 2023

Venue: Frontiers in Cell and Developmental Biology

DOI: https://doi.org/10.3389/fcell.2023.1147676

Paper Targeting alternative splicing in cancer immunotherapy

Han, Nan; Liu, Zhaoqi · 2023 · Frontiers in Cell and Developmental Biology · DOI

Full title: Targeting alternative splicing in cancer immunotherapy

Authors: Han, Nan; Liu, Zhaoqi

Year: 2023

Venue: Frontiers in Cell and Developmental Biology

DOI: https://doi.org/10.3389/fcell.2023.1232146

Paper Transcription and Translation Inhibitors in Cancer Treatment

Laham-Karam, Nihay; Pinto, Gaspar; Poso, Antti et al. · 2020 · Frontiers in Chemistry · DOI

Full title: Transcription and Translation Inhibitors in Cancer Treatment

Authors: Laham-Karam, Nihay; Pinto, Gaspar; Poso, Antti; Kokkonen, Piia

Year: 2020

Venue: Frontiers in Chemistry

DOI: https://doi.org/10.3389/fchem.2020.00276

Paper The Role of Glutamine and Glutaminase in Pulmonary Hypertension

Wang, Shang; Yan, Yi; Xu, Weijie et al. · 2022 · Frontiers in Cardiovascular Medicine · DOI

Full title: The Role of Glutamine and Glutaminase in Pulmonary Hypertension

Authors: Wang, Shang; Yan, Yi; Xu, Weijie; Gong, Su‐Gang; Zhong, Xiu-Jun; An, Qin-Yan; Zhao, Ya‐Lin; Liu, Jinming; Wang, Lan; Yuan, Ping; Jiang, Rong

Year: 2022

Venue: Frontiers in Cardiovascular Medicine

DOI: https://doi.org/10.3389/fcvm.2022.838657

Paper Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic

L. Quiñones; Kuen S. Lee · 2015 · Frontiers in Genetics · DOI

Full title: Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic

Authors: L. Quiñones; Kuen S. Lee

Year: 2015

Venue: Frontiers in Genetics

DOI: https://doi.org/10.3389/fgene.2015.00195

Paper Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer

Gao, Liyuan; Shen, Weizhang · 2022 · Frontiers in Genetics · DOI

Full title: Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer

Authors: Gao, Liyuan; Shen, Weizhang

Year: 2022

Venue: Frontiers in Genetics

DOI: https://doi.org/10.3389/fgene.2022.890247

Paper Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates

Alcaráz-Sanabria, Ana; Morafraile, Esther Cabañas; Fernández-Hinojal, G. et al. · 2022 · Frontiers in Immunology · DOI

Full title: Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates

Authors: Alcaráz-Sanabria, Ana; Morafraile, Esther Cabañas; Fernández-Hinojal, G.; Velasco, Guillermo; Pérez‐Segura, Pedro; Pandiella, Atanasio; Győrffy, Balázs; Ocaña, Alberto

Year: 2022

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2021.786069

Paper Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

Chen, Xun; Keller, S.; Hafner, Philipp et al. · 2024 · Frontiers in Immunology · DOI

Full title: Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

Authors: Chen, Xun; Keller, S.; Hafner, Philipp; Alrawashdeh, Asma; Avery, Thomas Yul; Norona, Johana; Zhou, Jinxue; Ruess, Dietrich Alexander

Year: 2024

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2024.1340726

Paper Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Xiang, Yuchu; Liu, Xudong; Wang, Yifan et al. · 2024 · Frontiers in Immunology · DOI

Full title: Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Authors: Xiang, Yuchu; Liu, Xudong; Wang, Yifan; Zheng, Dawei; Meng, Qiuxing; Jiang, Lingling; Yang, Sha; Zhang, Sijia; Zhang, Xin; Liu, Yan; Wang, Bo

Year: 2024

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2024.1366260

Paper Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.

Zhang, Fan; Wang, Banglu; Wu, Menghuan et al. · 2025 · Frontiers in immunology · DOI

Full title: Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.

Authors: Zhang, Fan; Wang, Banglu; Wu, Menghuan; Zhang, Liwen; Ji, Mei

Year: 2025

Venue: Frontiers in immunology

DOI: https://doi.org/10.3389/fimmu.2025.1509173

Paper Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy

Li Peng; Hongmei Li; Wencai Yan et al. · 2025 · Frontiers in Immunology · DOI

Full title: Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy

Authors: Li Peng; Hongmei Li; Wencai Yan; Yingjie Liu; Haihao Zhu; Yingcai Hong

Year: 2025

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2025.1649445

Paper Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma

Ramalingam, Prasanna Srinivasan; Priyadharshini, A.; Emerson, Isaac Arnold et al. · 2023 · Frontiers in Medicine · DOI

Full title: Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma

Authors: Ramalingam, Prasanna Srinivasan; Priyadharshini, A.; Emerson, Isaac Arnold; Arumugam, Sivakumar

Year: 2023

Venue: Frontiers in Medicine

DOI: https://doi.org/10.3389/fmed.2023.1107128

Paper A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer

Hofmarcher, Thomas; Malmberg, Chiara; Lindgren, Peter · 2023 · Frontiers in Medicine · DOI

Full title: A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer

Authors: Hofmarcher, Thomas; Malmberg, Chiara; Lindgren, Peter

Year: 2023

Venue: Frontiers in Medicine

DOI: https://doi.org/10.3389/fmed.2023.1119506

Paper Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Linehan, Anna; O’Reilly, Mary; McDermott, Ray et al. · 2024 · Frontiers in Medicine · DOI

Full title: Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Authors: Linehan, Anna; O’Reilly, Mary; McDermott, Ray; O’Kane, Grainne M.

Year: 2024

Venue: Frontiers in Medicine

DOI: https://doi.org/10.3389/fmed.2024.1369136

Paper Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity

Henkels, Karen M.; Rehl, Kristen M.; Cho, Kwang‐Jin · 2021 · Frontiers in Molecular Biosciences · DOI

Full title: Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity

Authors: Henkels, Karen M.; Rehl, Kristen M.; Cho, Kwang‐Jin

Year: 2021

Venue: Frontiers in Molecular Biosciences

DOI: https://doi.org/10.3389/fmolb.2021.673096

Paper KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients

Wang, Shuhang; Li, Qin; Ma, Peiwen et al. · 2022 · Frontiers in Molecular Biosciences · DOI

Full title: KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients

Authors: Wang, Shuhang; Li, Qin; Ma, Peiwen; Fang, Yuan; Yu, Yue; Jiang, Ning; Miao, Huilei; Tang, Qiyu; Yang, Yuqi; Xing, Shujun; Chen, Rongrong; Yi, Xin; Li, Ning

Year: 2022

Venue: Frontiers in Molecular Biosciences

DOI: https://doi.org/10.3389/fmolb.2022.831382

Paper New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, Haitang; Liang, Shun‐Qing; Schmid, Ralph A. et al. · 2019 · Frontiers in Oncology · DOI

Full title: New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Authors: Yang, Haitang; Liang, Shun‐Qing; Schmid, Ralph A.; Peng, Ren‐Wang

Year: 2019

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2019.00953

Paper Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models

Wan, Yuhua; Zhang, Yan; Wang, Gengchong et al. · 2020 · Frontiers in Oncology · DOI

Full title: Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models

Authors: Wan, Yuhua; Zhang, Yan; Wang, Gengchong; Mwangi, Patrick Malonza; Cai, Huaman; Li, Rongxiu

Year: 2020

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2020.01326

Paper Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations

M. Colombo; M. Marabese; Giulia Vargiu et al. · 2020 · Frontiers in Oncology · DOI

Full title: Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations

Authors: M. Colombo; M. Marabese; Giulia Vargiu; M. Broggini; E. Caiola

Year: 2020

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2020.532292

Paper A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

Xiang, Luochengling; Fu, Xiao; Wang, Xiao et al. · 2020 · Frontiers in Oncology · DOI

Full title: A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

Authors: Xiang, Luochengling; Fu, Xiao; Wang, Xiao; Li, Wenyuan; Zheng, Xiaoqiang; Nan, Kejun; Tian, Tao

Year: 2020

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2020.559896

Paper DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer

Rayees Padder; Z. I. Bhat; Zaki Ahmad et al. · 2021 · Frontiers in Oncology · DOI

Full title: DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer

Authors: Rayees Padder; Z. I. Bhat; Zaki Ahmad; Neetu Singh; M. Husain

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2020.592130

Paper Targeting KRAS: The Elephant in the Room of Epithelial Cancers

V. Merz; M. Gaule; C. Zecchetto et al. · 2021 · Frontiers in Oncology · DOI

Full title: Targeting KRAS: The Elephant in the Room of Epithelial Cancers

Authors: V. Merz; M. Gaule; C. Zecchetto; A. Cavaliere; S. Casalino; Camilla Pesoni; Serena Contarelli; Fabio Sabbadini; M. Bertolini; Domenico Mangiameli; M. Milella; V. Fedele; D. Melisi

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.638360

Paper Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

Zhao, Yiming; Wang, Shuyuan; Yang, Zhengyu et al. · 2021 · Frontiers in Oncology · DOI

Full title: Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

Authors: Zhao, Yiming; Wang, Shuyuan; Yang, Zhengyu; Dong, Yu; Wang, Yanan; Zhang, Lele; Hu, Hai; Han, Baohui

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.665484

Paper KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

M. Xie; Xiaoling Xu; Yun Fan · 2021 · Frontiers in Oncology · DOI

Full title: KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

Authors: M. Xie; Xiaoling Xu; Yun Fan

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.672612

Paper The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience

Karol, Dalia; McKinnon, Mathieu; Mukhtar, Lenah E. et al. · 2021 · Frontiers in Oncology · DOI

Full title: The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience

Authors: Karol, Dalia; McKinnon, Mathieu; Mukhtar, Lenah E.; Awan, Arif; Lo, Bernard; Wheatley‐Price, Paul

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.687730

Paper Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

Giampieri, Riccardo; Lupi, Alessio; Ziranu, Pina et al. · 2021 · Frontiers in Oncology · DOI

Full title: Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

Authors: Giampieri, Riccardo; Lupi, Alessio; Ziranu, Pina; Bittoni, Alessandro; Pretta, Andrea; Pecci, Federica; Persano, Mara; Giglio, Enrica; Copparoni, Cecilia; Crocetti, Sonia; Mandolesi, Alessandra; Faa, Gavino; Coni, Pierpaolo; Scartozzi, Mario; Berardi, Rossana

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.736104

Paper Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway

Jain, Anisha; Prasad, Ashwini; Pradeep, Sushma et al. · 2021 · Frontiers in Oncology · DOI

Full title: Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway

Authors: Jain, Anisha; Prasad, Ashwini; Pradeep, Sushma; Dharmashekar, Chandan; Achar, Raghu Ram; Silina, Ekaterina; Stupin, Victor; Amachawadi, Raghavendra G.; Prasad, Shashanka K.; Reddy, Pruthvish; Syed, Asad; Shivamallu, Chandan; Kollur, Shiva Prasad

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.741326

Paper Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Mo Shen; Rong-Xin Qi; Justin Ren et al. · 2022 · Frontiers in Oncology · DOI

Full title: Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Authors: Mo Shen; Rong-Xin Qi; Justin Ren; D. Lv; Haihua Yang

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.780655

Paper Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer.

Blaquier, Juan Bautista; Cardona, Andrés Felipe; Recondo, Gonzalo · 2021 · Frontiers in oncology · DOI

Full title: Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer.

Authors: Blaquier, Juan Bautista; Cardona, Andrés Felipe; Recondo, Gonzalo

Year: 2021

Venue: Frontiers in oncology

DOI: https://doi.org/10.3389/fonc.2021.787585

Paper KRAS Mutations in Squamous Cell Carcinomas of the Lung

Acker, Fabian; Stratmann, Jan; Aspacher, Lukas et al. · 2021 · Frontiers in Oncology · DOI

Full title: KRAS Mutations in Squamous Cell Carcinomas of the Lung

Authors: Acker, Fabian; Stratmann, Jan; Aspacher, Lukas; Nguyen, Thu; Wagner, Sebastian; Serve, Hubert; Wild, Peter J.; Sebastian, Martin

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.788084

Paper The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

Ferrara, Miriam Grazia; Stefani, Alessio; Pilotto, Sara et al. · 2021 · Frontiers in Oncology · DOI

Full title: The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

Authors: Ferrara, Miriam Grazia; Stefani, Alessio; Pilotto, Sara; Carbone, Carmine; Vita, Emanuele; Salvatore, Mariantonietta Di; D’Argento, Ettore; Sparagna, Ileana; Monaca, Federico; Valente, Giustina; Vitale, Antonio; Piro, Geny; Belluomini, Lorenzo; Milella, Michèle; Tortora, Giampaolo; Bria, Emilio

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.792385

Paper Targeting KRAS in Non-Small Cell Lung Cancer

Elena Corral de la Fuente; M. E. Olmedo García; Ana Gómez Rueda et al. · 2022 · Frontiers in Oncology · DOI

Full title: Targeting KRAS in Non-Small Cell Lung Cancer

Authors: Elena Corral de la Fuente; M. E. Olmedo García; Ana Gómez Rueda; Yolanda Lage; P. Garrido

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.792635

Paper Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

Cucurull, Marc; Notario, L.; Sánchez‐Céspedes, Montse et al. · 2022 · Frontiers in Oncology · DOI

Full title: Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

Authors: Cucurull, Marc; Notario, L.; Sánchez‐Céspedes, Montse; Hierro, Cinta; Estival, Anna; Carcereny, Enric; Saigí, Maria

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.793121

Paper Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit

Ning, Wenjuan; Marti, Thomas M.; Dorn, Patrick et al. · 2022 · Frontiers in Oncology · DOI

Full title: Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit

Authors: Ning, Wenjuan; Marti, Thomas M.; Dorn, Patrick; Peng, Ren‐Wang

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.1004669

Paper KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Bannoura, Sahar F.; Khan, Husain Yar; Azmi, Asfar S. · 2022 · Frontiers in Oncology · DOI

Full title: KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Authors: Bannoura, Sahar F.; Khan, Husain Yar; Azmi, Asfar S.

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.1013902

Paper Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population

L. Peng; Jun Guo; L. Kong et al. · 2023 · Frontiers in Oncology · DOI

Full title: Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population

Authors: L. Peng; Jun Guo; L. Kong; Yong Huang; N. Tang; Juguang Zhang; Minglei Wang; Xiaohan He; Zhenzhen Li; Yonggang Peng; Zhehai Wang; Xiao Han

Year: 2023

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.1070761

Paper Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Hou, Jue; He, Zongsheng; Liu, Tian et al. · 2022 · Frontiers in Oncology · DOI

Full title: Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Authors: Hou, Jue; He, Zongsheng; Liu, Tian; Chen, Dongfeng; Wang, Bin; Wen, Qinglian; Zheng, Xi

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.755053

Paper Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.

Désage, Anne-Laure; Léonce, Camille; Swalduz, Aurélie et al. · 2022 · Frontiers in oncology · DOI

Full title: Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.

Authors: Désage, Anne-Laure; Léonce, Camille; Swalduz, Aurélie; Ortiz-Cuaran, Sandra

Year: 2022

Venue: Frontiers in oncology

DOI: https://doi.org/10.3389/fonc.2022.796832

Paper Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma

Gupta, Kshama; Jones, Jeremy; Farias, Virgínea et al. · 2022 · Frontiers in Oncology · DOI

Full title: Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma

Authors: Gupta, Kshama; Jones, Jeremy; Farias, Virgínea; Mackeyev, Yuri; Singh, Pankaj K.; Quiñones‐Hinojosa, Alfredo; Krishnan, Sunil

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.840241

Paper LKB1: Can We Target an Hidden Target? Focus on NSCLC

Ndembe, Gloriana; Intini, Ilenia; Perin, Elisa et al. · 2022 · Frontiers in Oncology · DOI

Full title: LKB1: Can We Target an Hidden Target? Focus on NSCLC

Authors: Ndembe, Gloriana; Intini, Ilenia; Perin, Elisa; Marabese, Mirko; Caiola, Elisa; Mendogni, Paolo; Rosso, Lorenzo; Broggini, Massimo; Colombo, Marika

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.889826

Paper Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C.

Zhuang, Haiming; Fan, Jigang; Li, Mingyu et al. · 2022 · Frontiers in oncology · DOI

Full title: Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C.

Authors: Zhuang, Haiming; Fan, Jigang; Li, Mingyu; Zhang, Hao; Yang, Xiuyan; Lin, Ligen; Lu, Shaoyong; Wang, Qing; Liu, Yaqin

Year: 2022

Venue: Frontiers in oncology

DOI: https://doi.org/10.3389/fonc.2022.915512

Paper Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation

Avery, Thomas Yul; Köhler, Natalie; Zeiser, Robert et al. · 2022 · Frontiers in Oncology · DOI

Full title: Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation

Authors: Avery, Thomas Yul; Köhler, Natalie; Zeiser, Robert; Brummer, Tilman; Ruess, Dietrich Alexander

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.931774

Paper Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer

Mussafi, Ofek; Mei, Jie; Mao, Wenjun et al. · 2022 · Frontiers in Oncology · DOI

Full title: Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer

Authors: Mussafi, Ofek; Mei, Jie; Mao, Wenjun; Wan, Yuan

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.948405

Paper State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer

Yao, Yongfang; Fareed, Rameesha; Zafar, Aliya et al. · 2022 · Frontiers in Oncology · DOI

Full title: State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer

Authors: Yao, Yongfang; Fareed, Rameesha; Zafar, Aliya; Saleem, Kalsoom; Huang, Tao; Duan, Yongtao; Rehman, Masood ur

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.958505

Paper KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population

Fancelli, Sara; Caliman, Enrico; Mazzoni, Francesca et al. · 2022 · Frontiers in Oncology · DOI

Full title: KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population

Authors: Fancelli, Sara; Caliman, Enrico; Mazzoni, Francesca; Paglialunga, Luca; Michelet, Marta Rita Gatta; Lavacchi, Daniele; Berardi, Rossana; Mentrasti, Giulia; Metro, Giulio; Birocchi, Ilaria; Delmonte, Angelo; Priano, Ilaria; Comin, Camilla; Castiglione, Franca; Bartoli, Caterina; Voltolini, Luca; Pillozzi, Serena; Antonuzzo, Lorenzo

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.968064

Paper Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 <50%

I. Attili; C. Valenza; C. Santoro et al. · 2022 · Frontiers in Oncology · DOI

Full title: Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 <50%

Authors: I. Attili; C. Valenza; C. Santoro; G. Antonarelli; P. Trillo Aliaga; E. Del Signore; C. Catania; G. Spitaleri; A. Passaro; F. de Marinis

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.980765

Paper Utilization of macrocyclic peptides to target protein-protein interactions in cancer

Yang, Jiawen; Zhu, Qiaoliang; Wu, Yifan et al. · 2022 · Frontiers in Oncology · DOI

Full title: Utilization of macrocyclic peptides to target protein-protein interactions in cancer

Authors: Yang, Jiawen; Zhu, Qiaoliang; Wu, Yifan; Xiao-juan, QU; Liu, Haixia; Jiang, Biao; Ge, Di; Song, Xiaoling

Year: 2022

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2022.992171

Paper Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models

Meike Kaehler; Pia Osteresch; A. Künstner et al. · 2023 · Frontiers in Oncology · DOI

Full title: Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models

Authors: Meike Kaehler; Pia Osteresch; A. Künstner; Stella Juliane Vieth; Daniela Esser; Marius Möller; Hauke Busch; I. Vater; M. Spielmann; I. Cascorbi; I. Nagel

Year: 2023

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2023.1200897

Paper Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

Notario, L.; Cucurull, Marc; Cerdà, Gabriela et al. · 2023 · Frontiers in Oncology · DOI

Full title: Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

Authors: Notario, L.; Cucurull, Marc; Cerdà, Gabriela; Sanz, Carolina; Carcereny, Enric; Muñoz‐Mármol, Ana M; Hernández, Ainhoa; Doménech, Marta; Morán, Teresa; Sánchez‐Céspedes, Montse; Costa, Marta; Mate, José Luís; Esteve, Anna; Saigí, Maria

Year: 2023

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2023.1239000

Paper Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer

Qunaj, Lindor; May, Michael; Neugut, Alfred I. et al. · 2023 · Frontiers in Oncology · DOI

Full title: Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer

Authors: Qunaj, Lindor; May, Michael; Neugut, Alfred I.; Herzberg, Benjamin

Year: 2023

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2023.1252516

Paper Lung cancer organoids: models for preclinical research and precision medicine

Liu, Yajing; Zhou, Yanbing; Chen, Pu · 2023 · Frontiers in Oncology · DOI

Full title: Lung cancer organoids: models for preclinical research and precision medicine

Authors: Liu, Yajing; Zhou, Yanbing; Chen, Pu

Year: 2023

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2023.1293441

Paper Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer.

Chour, Ali; Toffart, Anne-Claire; Berton, Elodie et al. · 2024 · Frontiers in oncology · DOI

Full title: Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer.

Authors: Chour, Ali; Toffart, Anne-Claire; Berton, Elodie; Duruisseaux, Michael

Year: 2024

Venue: Frontiers in oncology

DOI: https://doi.org/10.3389/fonc.2024.1328728

Paper KRAS G12C inhibitor combination therapies: current evidence and challenge.

Miyashita, Hirotaka; Kato, Shumei; Hong, David S · 2024 · Frontiers in oncology · DOI

Full title: KRAS G12C inhibitor combination therapies: current evidence and challenge.

Authors: Miyashita, Hirotaka; Kato, Shumei; Hong, David S

Year: 2024

Venue: Frontiers in oncology

DOI: https://doi.org/10.3389/fonc.2024.1380584

Paper Assessment of KRASG12C inhibitors for colorectal cancer

G. Piazza; Preethi Chandrasekaran; Y. Maxuitenko et al. · 2024 · Frontiers in Oncology · DOI

Full title: Assessment of KRASG12C inhibitors for colorectal cancer

Authors: G. Piazza; Preethi Chandrasekaran; Y. Maxuitenko; Karim I. Budhwani

Year: 2024

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2024.1412435

Paper Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

Aliki Ntzifa; Theodoros Marras; G. Kallergi et al. · 2024 · Frontiers in Oncology · DOI

Full title: Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

Authors: Aliki Ntzifa; Theodoros Marras; G. Kallergi; Athanasios Kotsakis; V. Georgoulias; E. Lianidou

Year: 2024

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2024.1435537

Paper KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

Alessandro Tubita; S. Fancelli; Lorenzo Anela et al. · 2025 · Frontiers in Oncology · DOI

Full title: KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

Authors: Alessandro Tubita; S. Fancelli; Lorenzo Anela; Giulia Petroni; E. Caliman; Francesca Mazzoni; F. Scolari; Brunella Napolitano; Beatrice Menicacci; Camilla Eva Comin; Luca Voltolini; S. Pillozzi; L. Antonuzzo

Year: 2025

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2025.1654491

Paper Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer

Jean Cabon; D. Lerouge; S. Thureau et al. · 2025 · Frontiers in Oncology · DOI

Full title: Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer

Authors: Jean Cabon; D. Lerouge; S. Thureau; Jacques Balosso; M. Guigo; R. Gervais; C. Dubos; P. Dô; P. Demontrond; H. Curcio; S. Deshayes; J. Madelaine; Dimitri Leite Ferreira; Leonard Jacson; Kilian Lecrosnier; François Chevalier; F. Guisier; E. Dantoing; A. Leconte; François Christy; M. Césaire

Year: 2025

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2025.1675825

Paper Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors

Saeed Aslani; Owen McKay; L. Lipton et al. · 2025 · Frontiers in Oncology · DOI

Full title: Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors

Authors: Saeed Aslani; Owen McKay; L. Lipton; Vinod Ganju; Daniel Croagh

Year: 2025

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2025.1691760

Paper Regulation of the Ras-Related Signaling Pathway by Small Molecules Containing an Indole Core Scaffold: A Potential Antitumor Therapy

Chen, Feiyu; Li, Xiang; Zhu, Hongping et al. · 2020 · Frontiers in Pharmacology · DOI

Full title: Regulation of the Ras-Related Signaling Pathway by Small Molecules Containing an Indole Core Scaffold: A Potential Antitumor Therapy

Authors: Chen, Feiyu; Li, Xiang; Zhu, Hongping; Huang, Wei

Year: 2020

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2020.00280

Paper 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells

A. Poloznikov; Sergey Nikulin; L. Bolotina et al. · 2021 · Frontiers in Pharmacology · DOI

Full title: 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells

Authors: A. Poloznikov; Sergey Nikulin; L. Bolotina; A. Kachmazov; M. Raigorodskaya; A. Kudryavtseva; I. Bakhtogarimov; S. Rodin; I. Gaisina; M. Topchiy; A. Asachenko; V. Novosad; A. Tonevitsky; B. Alekseev

Year: 2021

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2021.777114

Paper Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells

Xingduo Dong; Meng Zhang; Chaoyun Cai et al. · 2022 · Frontiers in Pharmacology · DOI

Full title: Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells

Authors: Xingduo Dong; Meng Zhang; Chaoyun Cai; Q. Teng; Jing-Quan Wang; Yigong Fu; Qingbin Cui; Ketankumar Patel; Dong-Tao Wang; Zhe-Sheng Chen

Year: 2022

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2022.843829

Paper Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Li, Jiaxin; Li, Runze; Ma, Lin-Rui et al. · 2022 · Frontiers in Pharmacology · DOI

Full title: Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Authors: Li, Jiaxin; Li, Runze; Ma, Lin-Rui; Wang, Peng; Xu, Donghan; Huang, Jie; Li, Li-Qi; Tang, Ling; Xie, Ying; Leung, Elaine Lai‐Han; Yan, Peiyu

Year: 2022

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2022.875330

Paper Recent progress in targeted therapy for non-small cell lung cancer

Yao Xiao; Pu Liu; Jie Wei et al. · 2023 · Frontiers in Pharmacology · DOI

Full title: Recent progress in targeted therapy for non-small cell lung cancer

Authors: Yao Xiao; Pu Liu; Jie Wei; Xin Zhang; Jun Guo; Yajun Lin

Year: 2023

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2023.1125547

Paper Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Li, Furong; Lin, Yanping; Li, Rong et al. · 2023 · Frontiers in Pharmacology · DOI

Full title: Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Authors: Li, Furong; Lin, Yanping; Li, Rong; Shen, Xin; Xiang, Mengying; Xiong, Guangrui; Zhang, Ke; Xia, Tingrong; Guo, Jiangyan; Miao, Zhonghui; Liao, Yedan; Zhang, Xuan; Xie, Lin

Year: 2023

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2023.1165666

Paper Roles and inhibitors of FAK in cancer: current advances and future directions

Hu, Hui-Hui; Wang, Saiqi; Shang, Hai-Li et al. · 2024 · Frontiers in Pharmacology · DOI

Full title: Roles and inhibitors of FAK in cancer: current advances and future directions

Authors: Hu, Hui-Hui; Wang, Saiqi; Shang, Hai-Li; Lv, Huifang; Chen, Beibei; Gao, Shegan; Chen, Xiaobing

Year: 2024

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2024.1274209

Paper Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond.

Huang, Renjie; Gong, Xian; Du, Jianting et al. · 2025 · Frontiers in pharmacology · DOI

Full title: Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond.

Authors: Huang, Renjie; Gong, Xian; Du, Jianting; Xu, Guobing; Qian, Jiekun; Liao, Guoliang; Lin, Yuxing; Pan, Maojie; Zheng, Bin; Yuan, Wenjie; Huang, Qinzhao; Chen, Chun; Yang, Zhang

Year: 2025

Venue: Frontiers in pharmacology

DOI: https://doi.org/10.3389/fphar.2025.1704347

Paper The Research Progress of Direct KRAS G12C Mutation Inhibitors

Yang, Ai Li; Li, Min; Fang, Mingzhi · 2021 · Pathology & Oncology Research · DOI

Full title: The Research Progress of Direct KRAS G12C Mutation Inhibitors

Authors: Yang, Ai Li; Li, Min; Fang, Mingzhi

Year: 2021

Venue: Pathology & Oncology Research

DOI: https://doi.org/10.3389/pore.2021.631095

Paper Targeted therapeutic options in early and metastatic NSCLC-overview

Gálffy, Gabriella; Mórocz, Éva; Korompay, Réka et al. · 2024 · Pathology & Oncology Research · DOI

Full title: Targeted therapeutic options in early and metastatic NSCLC-overview

Authors: Gálffy, Gabriella; Mórocz, Éva; Korompay, Réka; Hécz, Réka; Bujdosó, Réka; Puskás, Rita; Lovas, Tímea; Gáspár, Eszter; Yahya, Kamel; Király, Péter Attila; Lohinai, Zoltán

Year: 2024

Venue: Pathology & Oncology Research

DOI: https://doi.org/10.3389/pore.2024.1611715

Paper Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions

Böldicke, Thomas · 2022 · Antibodies · DOI

Full title: Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions

Authors: Böldicke, Thomas

Year: 2022

Venue: Antibodies

DOI: https://doi.org/10.3390/antib11030049

Paper An In Vivo Inflammatory Loop Potentiates KRAS Blockade

Arendt, Kristina A. M.; Ntaliarda, Giannoula; Armenis, Vasileios et al. · 2022 · Biomedicines · DOI

Full title: An In Vivo Inflammatory Loop Potentiates KRAS Blockade

Authors: Arendt, Kristina A. M.; Ntaliarda, Giannoula; Armenis, Vasileios; Kati, Danai; Henning, Christin; Giotopoulou, Georgia A.; Pepe, Mario; Klotz, Laura V.; Lamort, Anne‐Sophie; Hatz, Rudolf; Kobold, Sebastian; Schamberger, Andrea C.; Stathopoulos, Georgios T.

Year: 2022

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines10030592

Paper Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience

Anna K Rekowska; Piotr Rola; Agnieszka Kwiatkowska et al. · 2024 · Biomedicines · DOI

Full title: Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience

Authors: Anna K Rekowska; Piotr Rola; Agnieszka Kwiatkowska; M. Wójcik-Superczyńska; Michał Gil; P. Krawczyk; Janusz Milanowski

Year: 2024

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines12020325

Paper Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

Nollmann, Friederike I.; Ruess, Dietrich Alexander · 2020 · Biomedicines · DOI

Full title: Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

Authors: Nollmann, Friederike I.; Ruess, Dietrich Alexander

Year: 2020

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines8080281

Paper Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR

Palacín-Aliana, Irina; Garcia‐Romero, Noemí; Asensi-Puig, Adriá et al. · 2021 · Biomedicines · DOI

Full title: Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR

Authors: Palacín-Aliana, Irina; Garcia‐Romero, Noemí; Asensi-Puig, Adriá; Carrión-Navarro, Josefa; González‐Rumayor, Víctor; Ayuso‐Sacido, Ángel

Year: 2021

Venue: Biomedicines

DOI: https://doi.org/10.3390/biomedicines9080906

Paper A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer

M. Grzes; Magdalena Oroń; Z. Staszczak et al. · 2020 · Cancers · DOI

Full title: A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer

Authors: M. Grzes; Magdalena Oroń; Z. Staszczak; A. Jaiswar; M. Nowak-Niezgoda; Dawid Walerych

Year: 2020

Venue: Cancers

DOI: https://doi.org/10.3390/cancers12061532

Paper Mechanisms of Resistance to KRASG12C Inhibitors

V. Dunnett-Kane; P. Nicola; F. Blackhall et al. · 2021 · Cancers · DOI

Full title: Mechanisms of Resistance to KRASG12C Inhibitors

Authors: V. Dunnett-Kane; P. Nicola; F. Blackhall; C. Lindsay

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13010151

Paper Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

D. König; S. Savic Prince; S. Rothschild · 2021 · Cancers · DOI

Full title: Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

Authors: D. König; S. Savic Prince; S. Rothschild

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13040804

Paper Targeting KRAS in Cancer: Promising Therapeutic Strategies

Mustachio, Lisa Maria; Chelariu-Raicu, Anca; Székvölgyi, Lóránt et al. · 2021 · Cancers · DOI

Full title: Targeting KRAS in Cancer: Promising Therapeutic Strategies

Authors: Mustachio, Lisa Maria; Chelariu-Raicu, Anca; Székvölgyi, Lóránt; Roszik, Jason

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13061204

Paper KRAS G12C Mutations in NSCLC: From Target to Resistance

A. Addeo; G. Banna; A. Friedlaender · 2021 · Cancers · DOI

Full title: KRAS G12C Mutations in NSCLC: From Target to Resistance

Authors: A. Addeo; G. Banna; A. Friedlaender

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13112541

Paper Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cabanos, Heidie Frisco; Hata, Aaron N. · 2021 · Cancers · DOI

Full title: Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Authors: Cabanos, Heidie Frisco; Hata, Aaron N.

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13112666

Paper Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation

Pardo-Sánchez, José Miguel; Mancheño, Nuria; Cerón, J. M. Castro et al. · 2021 · Cancers · DOI

Full title: Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation

Authors: Pardo-Sánchez, José Miguel; Mancheño, Nuria; Cerón, J. M. Castro; Aragón, Carlos Jordá; Ansótegui, Emilio; Juan, Óscar; Palanca, Sarai; Cremades, Antonio; Gandía, Carolina; Farrás, Rosa

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13122980

Paper Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma

Gow, Chien‐Hung; Hsieh, Min‐Shu; Liu, Yi-Nan et al. · 2021 · Cancers · DOI

Full title: Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma

Authors: Gow, Chien‐Hung; Hsieh, Min‐Shu; Liu, Yi-Nan; Lee, Yi‐Hsuan; Shih, Jin‐Yuan

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13164103

Paper Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Rodak, Olga; Peris‐Díaz, Manuel David; Olbromski, Mateusz et al. · 2021 · Cancers · DOI

Full title: Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Authors: Rodak, Olga; Peris‐Díaz, Manuel David; Olbromski, Mateusz; Podhorska‐Okołów, Marzenna; Dzięgiel, Piotr

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13184705

Paper Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

Yuta Adachi; Ryo Kimura; K. Hirade et al. · 2021 · Cancers · DOI

Full title: Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

Authors: Yuta Adachi; Ryo Kimura; K. Hirade; H. Ebi

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13205081

Paper Oncogenic KRAS: Signaling and Drug Resistance

Kim, Hyeon Jin; Lee, Han Na; Jeong, Mi Suk et al. · 2021 · Cancers · DOI

Full title: Oncogenic KRAS: Signaling and Drug Resistance

Authors: Kim, Hyeon Jin; Lee, Han Na; Jeong, Mi Suk; Jang, Se Bok

Year: 2021

Venue: Cancers

DOI: https://doi.org/10.3390/cancers13225599

Paper A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished.

Ning, Wenjuan; Yang, Zhang; Kocher, Gregor J et al. · 2022 · Cancers · DOI

Full title: A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished.

Authors: Ning, Wenjuan; Yang, Zhang; Kocher, Gregor J; Dorn, Patrick; Peng, Ren-Wang

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14020390

Paper Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets

Karagiannakos, Alexandros; Adamaki, Maria; Tsintarakis, Antonis et al. · 2022 · Cancers · DOI

Full title: Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets

Authors: Karagiannakos, Alexandros; Adamaki, Maria; Tsintarakis, Antonis; Vojtěšek, Bořivoj; Fåhræus, Robin; Zoumpourlis, Vassilis; Karakostis, Konstantinos

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14030664

Paper Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Reita, Damien; Pabst, Lucile; Pencreach, Erwan et al. · 2022 · Cancers · DOI

Full title: Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Authors: Reita, Damien; Pabst, Lucile; Pencreach, Erwan; Guérin, Eric; Dano, Laurent; Rimelen, Valérie; Voegeli, Anne-Claire; Vallat, Laurent; Mascaux, Céline; Beau-Faller, Michèle

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14051321

Paper Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

Bontoux, Christophe; Hofman, Véronique; Brest, Patrick et al. · 2022 · Cancers · DOI

Full title: Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

Authors: Bontoux, Christophe; Hofman, Véronique; Brest, Patrick; Ilié, Marius; Mograbi, Baharia; Hofman, Paul

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14071628

Paper Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients

Ulivi, Paola; Urbini, Milena; Petracci, Elisabetta et al. · 2022 · Cancers · DOI

Full title: Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients

Authors: Ulivi, Paola; Urbini, Milena; Petracci, Elisabetta; Canale, Matteo; Dubini, Alessandra; Bartolini, Daniela; Calistri, Daniele; Cravero, Paola; Fonzi, Eugenio; Martinelli, Giovanni; Priano, Ilaria; Andrikou, Kalliopi; Bronte, Giuseppe; Crinò, Lucio; Delmonte, Angelo

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14102352

Paper Synthetic Vulnerabilities in the KRAS Pathway

Román, Marta; Hwang, Elizabeth; Sweet‐Cordero, E. Alejandro · 2022 · Cancers · DOI

Full title: Synthetic Vulnerabilities in the KRAS Pathway

Authors: Román, Marta; Hwang, Elizabeth; Sweet‐Cordero, E. Alejandro

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14122837

Paper A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting

I. Terrenato; Cristiana Ercolani; A. di Benedetto et al. · 2022 · Cancers · DOI

Full title: A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting

Authors: I. Terrenato; Cristiana Ercolani; A. di Benedetto; E. Gallo; E. Melucci; B. Casini; F. Rollo; Aldo Palange; P. Visca; E. Pescarmona; E. Melis; F. Gallina; A. Sacconi; F. Cecere; L. Landi; F. Cappuzzo; G. Ciliberto; S. Buglioni

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14122971

Paper Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

E. Cekani; Samantha Epistolio; Giulia Dazio et al. · 2022 · Cancers · DOI

Full title: Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

Authors: E. Cekani; Samantha Epistolio; Giulia Dazio; M. Cefalì; L. Wannesson; M. Frattini; P. Froesch

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14174103

Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines

Yixuan Ma; Benjamin Schulz; N. Trakooljul et al. · 2022 · Cancers · DOI

Full title: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines

Authors: Yixuan Ma; Benjamin Schulz; N. Trakooljul; Moosheer Al Ammar; Anett Sekora; S. Sender; F. Hadlich; D. Zechner; F. Weiss; M. Lerch; R. Jaster; Christian Junhanss; H. Murua Escobar

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14184467

Paper KRAS in NSCLC: State of the Art and Future Perspectives

Cascetta, Priscilla; Marinello, Arianna; Lazzari, Chiara et al. · 2022 · Cancers · DOI

Full title: KRAS in NSCLC: State of the Art and Future Perspectives

Authors: Cascetta, Priscilla; Marinello, Arianna; Lazzari, Chiara; Gregorc, Vanesa; Planchard, David; Bianco, Roberto; Normanno, Nicola; Morabito, Alessandro

Year: 2022

Venue: Cancers

DOI: https://doi.org/10.3390/cancers14215430

Paper Advances in the Molecular Landscape of Lung Cancer Brain Metastasis

Souza, Vanessa G. P.; Araújo, Rachel Paes de; Santesso, Mariana R. et al. · 2023 · Cancers · DOI

Full title: Advances in the Molecular Landscape of Lung Cancer Brain Metastasis

Authors: Souza, Vanessa G. P.; Araújo, Rachel Paes de; Santesso, Mariana R.; Seneda, Ana Laura; Minutentag, Iael Weissberg; Felix, Tainara F.; Filho, Pedro Tadao Hamamoto; Pewarchuk, Michelle E.; Brockley, Liam J.; Marchi, Fábio Albuquerque; Lam, Wan L.; Drigo, Sandra A.; Reis, Patrícia P.

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15030722

Paper Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

Éabha O’Sullivan; A. Keogh; Brian Henderson et al. · 2023 · Cancers · DOI

Full title: Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

Authors: Éabha O’Sullivan; A. Keogh; Brian Henderson; S. Finn; S. Gray; K. Gately

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15061635

Paper Precision Oncology: Evolving Clinical Trials across Tumor Types

Song, I-Wen; Vo, Henry Hiep; Chen, Ying‐Shiuan et al. · 2023 · Cancers · DOI

Full title: Precision Oncology: Evolving Clinical Trials across Tumor Types

Authors: Song, I-Wen; Vo, Henry Hiep; Chen, Ying‐Shiuan; Baysal, Mehmet A.; Kahle, Michael; Johnson, Amber M.; Tsimberidou, Apostolia M.

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15071967

Paper Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Li, Shenduo; Correia, Guilherme Sacchi de Camargo; Wang, Jing et al. · 2023 · Cancers · DOI

Full title: Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Authors: Li, Shenduo; Correia, Guilherme Sacchi de Camargo; Wang, Jing; Manochakian, Rami; Zhao, Yujie; Lou, Yanyan

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15112899

Paper New Actions on Actionable Mutations in Lung Cancers

Le, Xiuning; Elamin, Yasir Y.; Zhang, Jianjun · 2023 · Cancers · DOI

Full title: New Actions on Actionable Mutations in Lung Cancers

Authors: Le, Xiuning; Elamin, Yasir Y.; Zhang, Jianjun

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15112917

Paper Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment

Restrepo, Juan Carlos; Dueñas, Diana; Corredor, Zuray et al. · 2023 · Cancers · DOI

Full title: Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment

Authors: Restrepo, Juan Carlos; Dueñas, Diana; Corredor, Zuray; Liscano, Yamil

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15133474

Paper Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience

Chmielewska, Izabela; Krawczyk, Paweł; Grenda, Anna et al. · 2023 · Cancers · DOI

Full title: Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience

Authors: Chmielewska, Izabela; Krawczyk, Paweł; Grenda, Anna; Wójcik-Superczyńska, Magdalena; Krzyżanowska, Natalia; Gil, Michał; Milanowski, Janusz

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15143732

Paper Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib

A. Nolan; C. Raso; W. Kolch et al. · 2023 · Cancers · DOI

Full title: Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib

Authors: A. Nolan; C. Raso; W. Kolch; A. Kriegsheim; Kieran Wynne; D. Matallanas

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15164141

Paper Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams

Serra, Massimo; Rubes, Davide; Schinelli, Sergio et al. · 2023 · Cancers · DOI

Full title: Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams

Authors: Serra, Massimo; Rubes, Davide; Schinelli, Sergio; Paolillo, Mayra

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15164173

Paper Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure

Jesus, Victor Hugo Fonseca de; Mathias-Machado, Maria Cecília; Farias, João Paulo Fogacci de et al. · 2023 · Cancers · DOI

Full title: Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure

Authors: Jesus, Victor Hugo Fonseca de; Mathias-Machado, Maria Cecília; Farias, João Paulo Fogacci de; Aruquipa, Marcelo Porfírio Sunagua; Jácome, Alexandre A.; Peixoto, Renata D’Alpino

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15205015

Paper New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations

Attili, Ilaria; Corvaja, Carla; Spitaleri, Gianluca et al. · 2023 · Cancers · DOI

Full title: New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations

Authors: Attili, Ilaria; Corvaja, Carla; Spitaleri, Gianluca; Signore, Ester Del; Aliaga, Pamela Trillo; Passaro, Antonio; Marinis, Filippo de

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15205079

Paper Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

Cian O’Leary; Grace Murphy; Yong Yeung et al. · 2023 · Cancers · DOI

Full title: Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

Authors: Cian O’Leary; Grace Murphy; Yong Yeung; Ming Tang; Vikram Jain; C.G. O’Leary

Year: 2023

Venue: Cancers

DOI: https://doi.org/10.3390/cancers15235582

Paper KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

Fujimoto, Kazushi; Ikeda, Satoshi; Tabata, Erina et al. · 2024 · Cancers · DOI

Full title: KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

Authors: Fujimoto, Kazushi; Ikeda, Satoshi; Tabata, Erina; Kaneko, Taichi; Sagawa, Shinobu; Yamada, Chieri; Kumagai, Kosumi; Fukushima, Takashi; Haga, Sanshiro; Watanabe, Masayuki; Muraoka, Tatsuya; Sekine, Akimasa; Baba, Tomohisa; Ogura, Takashi

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16071327

Paper Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

Anastasia Karachaliou; E. Kotteas; O. Fiste et al. · 2024 · Cancers · DOI

Full title: Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

Authors: Anastasia Karachaliou; E. Kotteas; O. Fiste; Konstantinos N. Syrigos

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16081447

Paper Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials

T. Peng; Ta-Wei Wu; Tai-Yung Yi et al. · 2024 · Cancers · DOI

Full title: Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials

Authors: T. Peng; Ta-Wei Wu; Tai-Yung Yi; An-Jan Wu

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16213676

Paper Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer

Dekker, Simone E.; Deng, Lei · 2024 · Cancers · DOI

Full title: Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer

Authors: Dekker, Simone E.; Deng, Lei

Year: 2024

Venue: Cancers

DOI: https://doi.org/10.3390/cancers16223885

Paper Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways

Šereš, Mário; Spacayova, Katarina; Sulová, Zdena et al. · 2025 · Cancers · DOI

Full title: Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways

Authors: Šereš, Mário; Spacayova, Katarina; Sulová, Zdena; Špaldová, Jana; Breier, Albert; Pavlíková, Lucia

Year: 2025

Venue: Cancers

DOI: https://doi.org/10.3390/cancers17020248

Paper Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)

Mina, Syeda A.; Shanshal, Mohamed; Leventakos, Konstantinos et al. · 2025 · Cancers · DOI

Full title: Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)

Authors: Mina, Syeda A.; Shanshal, Mohamed; Leventakos, Konstantinos; Parikh, Kaushal

Year: 2025

Venue: Cancers

DOI: https://doi.org/10.3390/cancers17030353

Paper Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

Soumavo Mukherjee; D. Suresh; Ajit P. Zambre et al. · 2025 · Cancers · DOI

Full title: Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

Authors: Soumavo Mukherjee; D. Suresh; Ajit P. Zambre; Sairam Yadavilli; Shreya Ghoshdastidar; Anandhi Upendran; R. Kannan

Year: 2025

Venue: Cancers

DOI: https://doi.org/10.3390/cancers17030490

Paper KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges

P. P. Vitiello; A. A. Valsecchi; Eleonora Duregon et al. · 2025 · Cancers · DOI

Full title: KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges

Authors: P. P. Vitiello; A. A. Valsecchi; Eleonora Duregon; Paola Francia di Celle; P. Cassoni; M. Papotti; A. Bardelli; M. Di Maio

Year: 2025

Venue: Cancers

DOI: https://doi.org/10.3390/cancers17172803

Paper Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?

Krzyżanowska, Natalia; Krawczyk, Paweł; Wojas‐Krawczyk, Kamila et al. · 2022 · Cells · DOI

Full title: Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?

Authors: Krzyżanowska, Natalia; Krawczyk, Paweł; Wojas‐Krawczyk, Kamila; Kucharczyk, Tomasz; Milanowski, Janusz

Year: 2022

Venue: Cells

DOI: https://doi.org/10.3390/cells11203280

Paper Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

Lam, Kuen Kuen; Wong, Siew Heng; Cheah, Peh Yean · 2023 · Cells · DOI

Full title: Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

Authors: Lam, Kuen Kuen; Wong, Siew Heng; Cheah, Peh Yean

Year: 2023

Venue: Cells

DOI: https://doi.org/10.3390/cells12040631

Paper Cutting-Edge Therapies for Lung Cancer

La’ah, Anita Silas; Chiou, Shih‐Hwa · 2024 · Cells · DOI

Full title: Cutting-Edge Therapies for Lung Cancer

Authors: La’ah, Anita Silas; Chiou, Shih‐Hwa

Year: 2024

Venue: Cells

DOI: https://doi.org/10.3390/cells13050436

Paper The Role of Oxidative Stress in Tumorigenesis and Progression

Li, Kexin; Deng, Zhangyuzi; Lei, Chunran et al. · 2024 · Cells · DOI

Full title: The Role of Oxidative Stress in Tumorigenesis and Progression

Authors: Li, Kexin; Deng, Zhangyuzi; Lei, Chunran; Ding, Xiaoqing; Li, Jing; Wang, Changshan

Year: 2024

Venue: Cells

DOI: https://doi.org/10.3390/cells13050441

Paper Hippo Signaling at the Hallmarks of Cancer and Drug Resistance

Kumar, Ramesh; Hong, Wanjin · 2024 · Cells · DOI

Full title: Hippo Signaling at the Hallmarks of Cancer and Drug Resistance

Authors: Kumar, Ramesh; Hong, Wanjin

Year: 2024

Venue: Cells

DOI: https://doi.org/10.3390/cells13070564

Paper Genetic Signature of Human Pancreatic Cancer and Personalized Targeting

Reshkin, Stephan J.; Cardone, Rosa Angela; Koltai, Tomas · 2024 · Cells · DOI

Full title: Genetic Signature of Human Pancreatic Cancer and Personalized Targeting

Authors: Reshkin, Stephan J.; Cardone, Rosa Angela; Koltai, Tomas

Year: 2024

Venue: Cells

DOI: https://doi.org/10.3390/cells13070602

Paper Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Degirmenci, Ufuk; Wang, Mei; Hu, Jiancheng · 2020 · Cells · DOI

Full title: Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Authors: Degirmenci, Ufuk; Wang, Mei; Hu, Jiancheng

Year: 2020

Venue: Cells

DOI: https://doi.org/10.3390/cells9010198

Paper Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond

Shetu, Shaila A.; James, Nneoma; Rivera, Gildardo et al. · 2023 · Current Issues in Molecular Biology · DOI

Full title: Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond

Authors: Shetu, Shaila A.; James, Nneoma; Rivera, Gildardo; Bandyopadhyay, Debasish

Year: 2023

Venue: Current Issues in Molecular Biology

DOI: https://doi.org/10.3390/cimb45030124

Paper Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery

Ramalingam, Prasanna Srinivasan; Balakrishnan, Purushothaman; Rajendran, Senthilnathan et al. · 2023 · Current Issues in Molecular Biology · DOI

Full title: Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery

Authors: Ramalingam, Prasanna Srinivasan; Balakrishnan, Purushothaman; Rajendran, Senthilnathan; Arunachalam, J.; Rajasekaran, R.; Arumugam, Sivakumar

Year: 2023

Venue: Current Issues in Molecular Biology

DOI: https://doi.org/10.3390/cimb45030137

Paper Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Mithoowani, Hamid; Febbraro, Michela · 2022 · Current Oncology · DOI

Full title: Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Authors: Mithoowani, Hamid; Febbraro, Michela

Year: 2022

Venue: Current Oncology

DOI: https://doi.org/10.3390/curroncol29030150

Paper Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Cho, Byoung Chul; Loong, Herbert H.; Tsai, Chun‐Ming et al. · 2022 · Current Oncology · DOI

Full title: Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Authors: Cho, Byoung Chul; Loong, Herbert H.; Tsai, Chun‐Ming; Teo, Man Lung P.; Kim, Hye Ryun; Lim, Sun Min; Jain, Suyog; Olsen, Steve; Park, Keunchil

Year: 2022

Venue: Current Oncology

DOI: https://doi.org/10.3390/curroncol29030174

Paper The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis

McGuire, Anna; McConechy, Melissa K.; Melosky, Barbara et al. · 2022 · Current Oncology · DOI

Full title: The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis

Authors: McGuire, Anna; McConechy, Melissa K.; Melosky, Barbara; English, John C.; Choi, James J.; Peng, Defen; Yee, John; Furman, Benjamin L. S.; Hernandez, Rosalia Aguirre; Feijão, Pedro; Mulder, David T.; Hughesman, Curtis; Yip, Stephen

Year: 2022

Venue: Current Oncology

DOI: https://doi.org/10.3390/curroncol29040215

Paper Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Cheema, Parneet; Banerji, Shantanu; Blais, Normand et al. · 2023 · Current Oncology · DOI

Full title: Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Authors: Cheema, Parneet; Banerji, Shantanu; Blais, Normand; Chu, Quincy S.; Juergens, Rosalyn A.; Leighl, Natasha B.; Sacher, Adrian G.; Sheffield, Brandon S.; Snow, Stephanie; Vincent, Mark; Wheatley‐Price, Paul F.; Yip, Stephen; Melosky, Barbara

Year: 2023

Venue: Current Oncology

DOI: https://doi.org/10.3390/curroncol30070476

Paper Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer

Kano, Yoshihito; Suenaga, Mitsukuni; Uetake, Hiroyuki · 2023 · Current Oncology · DOI

Full title: Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer

Authors: Kano, Yoshihito; Suenaga, Mitsukuni; Uetake, Hiroyuki

Year: 2023

Venue: Current Oncology

DOI: https://doi.org/10.3390/curroncol30070480

Paper KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance

Leonard J. Ash; Ottavia Busia-Bourdain; Daniel Okpattah et al. · 2024 · Current Oncology · DOI

Full title: KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance

Authors: Leonard J. Ash; Ottavia Busia-Bourdain; Daniel Okpattah; Avrosina Kamel; Ariel N. Liberchuk; Andrew L. Wolfe

Year: 2024

Venue: Current Oncology

DOI: https://doi.org/10.3390/curroncol31040150

Paper Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches.

Karki, Ramesh; Chen, Ru; Pan, Sheng · 2025 · Current oncology (Toronto, Ont.) · DOI

Full title: Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches.

Authors: Karki, Ramesh; Chen, Ru; Pan, Sheng

Year: 2025

Venue: Current oncology (Toronto, Ont.)

DOI: https://doi.org/10.3390/curroncol32110614

Paper Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Wankhede, Durgesh; Bontoux, Christophe; Grover, Sandeep et al. · 2023 · Diagnostics · DOI

Full title: Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Authors: Wankhede, Durgesh; Bontoux, Christophe; Grover, Sandeep; Hofman, Paul

Year: 2023

Venue: Diagnostics

DOI: https://doi.org/10.3390/diagnostics13193043

Paper Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

Baldelli, Elisa; Gazzah, Emna El; Moran, John Conor et al. · 2021 · Genes · DOI

Full title: Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

Authors: Baldelli, Elisa; Gazzah, Emna El; Moran, John Conor; Hodge, K. Alex; Manojlovic, Zarko; Bassiouni, Rania; Carpten, John D.; Ludovini, Vienna; Baglivo, Sara; Crinò, Lucio; Bianconi, Fortunato; Dong, Ting; Loffredo, Jeremy; Petricoin, Emanuel F.; Pierobon, Mariaelena

Year: 2021

Venue: Genes

DOI: https://doi.org/10.3390/genes12091402

Paper Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges

Meira, Débora Dummer; Caetano, Maria Clara de Castro e; Casotti, Matheus Correia et al. · 2023 · Genes · DOI

Full title: Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges

Authors: Meira, Débora Dummer; Caetano, Maria Clara de Castro e; Casotti, Matheus Correia; Zetum, Aléxia Stefani Siqueira; Gonçalves, André Felipe Monteiro; Moreira, André Rodrigues; Oliveira, Augusto Henrique de; Pesente, Fellipe; Santana, Gabriel Mendonça; Duque, Daniel de Almeida; Pereira, Gierleson Santos Cangussu; Castro, Giulia de Souza Cupertino de; Pavan, Isabele Pagani; Chagas, João Pedro Sarcinelli; Bourguignon, José Henrique Borges; Oliveira, Juliana Ribeiro de; Barbosa, Karen Ruth Michio; Altoé, Lorena Souza Castro; Louro, Luana Santos; Merigueti, Luiza Poppe; Alves, Lyvia Neves Rebello; Machado, Marlon Ramos Rosado; Roque, Maria Luísa Rodrigues Oliveira; Prates, Pedro Santana; Segáua, Sayuri Honorio de Paula; Uchiya, Taissa dos Santos; Louro, Thomas Erik Santos; Daleprane, Vinicius Eduardo; Guaitolini, Yasmin Moreto; Vicente, Creuza Rachel; Trabach, Raquel Silva dos Reis; Araújo, Bruno Cancian de; Santos, Eldamária de Vargas Wolfgramm dos; Paula, Flavia; Lopes, Tiago José S.; Carvalho, Elizeu Fagundes de; Louro, Iúri Drumond

Year: 2023

Venue: Genes

DOI: https://doi.org/10.3390/genes14101906

Paper Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation

Ni, Duan; Song, Kun; Zhang, Jian et al. · 2017 · International Journal of Molecular Sciences · DOI

Full title: Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation

Authors: Ni, Duan; Song, Kun; Zhang, Jian; Lu, Shaoyong

Year: 2017

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms18112249

Paper Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

Rebuzzi, Sara Elena; Zullo, Lodovica; Rossi, Giovanni et al. · 2021 · International Journal of Molecular Sciences · DOI

Full title: Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

Authors: Rebuzzi, Sara Elena; Zullo, Lodovica; Rossi, Giovanni; Grassi, Massimiliano; Murianni, Veronica; Tagliamento, Marco; Prelaj, Arsela; Coco, Simona; Longo, Luca; Bello, Maria Giovanna Dal; Alama, Angela; Dellepiane, Chiara; Bennicelli, E.; Malapelle, Umberto; Genova, Carlo

Year: 2021

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms22052625

Paper If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer

Köhler, Jens; Jänne, Pasi A. · 2021 · International Journal of Molecular Sciences · DOI

Full title: If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer

Authors: Köhler, Jens; Jänne, Pasi A.

Year: 2021

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms22063025

Paper Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives

Aleksakhina, Svetlana N.; Imyanitov, Evgeny N. · 2021 · International Journal of Molecular Sciences · DOI

Full title: Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives

Authors: Aleksakhina, Svetlana N.; Imyanitov, Evgeny N.

Year: 2021

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms222010931

Paper Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer

Lee, Jennifer J.; Jain, Vaibhav; Amaravadi, Ravi K. · 2021 · International Journal of Molecular Sciences · DOI

Full title: Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer

Authors: Lee, Jennifer J.; Jain, Vaibhav; Amaravadi, Ravi K.

Year: 2021

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms222212402

Paper The Role of EREG/EGFR Pathway in Tumor Progression

Cheng, Wanli; Feng, Po‐Hao; Lee, Kang‐Yun et al. · 2021 · International Journal of Molecular Sciences · DOI

Full title: The Role of EREG/EGFR Pathway in Tumor Progression

Authors: Cheng, Wanli; Feng, Po‐Hao; Lee, Kang‐Yun; Chen, Kuan-Yuan; Sun, Wei-Lun; Hiệp, Nguyễn Văn; Luo, Ching-Shan; Wu, Sheng‐Ming

Year: 2021

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms222312828

Paper KRAS: A Druggable Target in Colon Cancer Patients

F. Negri; L. Bottarelli; G. de’Angelis et al. · 2022 · International Journal of Molecular Sciences · DOI

Full title: KRAS: A Druggable Target in Colon Cancer Patients

Authors: F. Negri; L. Bottarelli; G. de’Angelis; L. Gnetti

Year: 2022

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms23084120

Paper Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer

Calabrese, Fiorella; Pezzuto, Federica; Lunardi, Francesca et al. · 2022 · International Journal of Molecular Sciences · DOI

Full title: Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer

Authors: Calabrese, Fiorella; Pezzuto, Federica; Lunardi, Francesca; Fortarezza, Francesco; Tzorakoleftheraki, Sofia‐Eleni; Resi, Maria Vittoria; Tinè, Mariaenrica; Pasello, Giulia; Hofman, Paul

Year: 2022

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms23084164

Paper Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines

Oliveira, Renato José da Silva; Gomes, Izabela Natália Faria; Silva, Luciane Sussuchi da et al. · 2022 · International Journal of Molecular Sciences · DOI

Full title: Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines

Authors: Oliveira, Renato José da Silva; Gomes, Izabela Natália Faria; Silva, Luciane Sussuchi da; Lengert, André van Helvoort; Laus, Ana Carolina; Melendez, Matias Eliseo; Munari, Carla Carolina; Cury, Fernanda de Paula; Longato, Giovanna Barbarini; Reis, Rui Manuel

Year: 2022

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms23147774

Paper KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges

Serena Ceddia; L. Landi; F. Cappuzzo · 2022 · International Journal of Molecular Sciences · DOI

Full title: KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges

Authors: Serena Ceddia; L. Landi; F. Cappuzzo

Year: 2022

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms23169391

Paper In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis.

Tu, Gao; Liu, Qing; Qiu, Yue et al. · 2022 · International journal of molecular sciences · DOI

Full title: In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis.

Authors: Tu, Gao; Liu, Qing; Qiu, Yue; Leung, Elaine Lai-Han; Yao, Xiaojun

Year: 2022

Venue: International journal of molecular sciences

DOI: https://doi.org/10.3390/ijms232213845

Paper Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study

Srisongkram, Tarapong; Weerapreeyakul, Natthida · 2022 · International Journal of Molecular Sciences · DOI

Full title: Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study

Authors: Srisongkram, Tarapong; Weerapreeyakul, Natthida

Year: 2022

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms24010669

Paper A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition

Barrios‐Bernal, Pedro; Lucio-Lozada, José; Ramos-Ramírez, Maritza et al. · 2023 · International Journal of Molecular Sciences · DOI

Full title: A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition

Authors: Barrios‐Bernal, Pedro; Lucio-Lozada, José; Ramos-Ramírez, Maritza; Hernández‐Pedro, Norma; Arrieta, Óscar

Year: 2023

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms24054331

Paper KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy

E. Gurreri; G. Genovese; Luigi Perelli et al. · 2023 · International Journal of Molecular Sciences · DOI

Full title: KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy

Authors: E. Gurreri; G. Genovese; Luigi Perelli; Antonio Agostini; G. Piro; C. Carbone; G. Tortora

Year: 2023

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms24119313

Paper The Future of Precision Oncology

Rulten, Stuart L.; Grose, Richard; Gatz, Susanne A. et al. · 2023 · International Journal of Molecular Sciences · DOI

Full title: The Future of Precision Oncology

Authors: Rulten, Stuart L.; Grose, Richard; Gatz, Susanne A.; Jones, J. Louise; Cameron, Angus J.M.

Year: 2023

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms241612613

Paper Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers

Kim, Jimi · 2023 · International Journal of Molecular Sciences · DOI

Full title: Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers

Authors: Kim, Jimi

Year: 2023

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms242316933

Paper Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development

Ranđelović, Ivan; Nyíri, Kinga; Koppány, Gergely et al. · 2024 · International Journal of Molecular Sciences · DOI

Full title: Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development

Authors: Ranđelović, Ivan; Nyíri, Kinga; Koppány, Gergely; Baranyi, Marcell; Tóvári, József; Kígyós, Attila; Tı́már, József; Vértessy, Beáta G.; Grolmusz, Vince

Year: 2024

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms25052572

Paper Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer

Xuan Wang; Johanna Breuer; S. Garbe et al. · 2024 · International Journal of Molecular Sciences · DOI

Full title: Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer

Authors: Xuan Wang; Johanna Breuer; S. Garbe; Frank Giordano; Peter Brossart; Georg Feldmann; S. Bisht

Year: 2024

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms25116249

Paper Emerging Targets in Non-Small Cell Lung Cancer

Liu, Louisa; Soler, Joshua; Reckamp, Karen L. et al. · 2024 · International Journal of Molecular Sciences · DOI

Full title: Emerging Targets in Non-Small Cell Lung Cancer

Authors: Liu, Louisa; Soler, Joshua; Reckamp, Karen L.; Sankar, K. Nathan

Year: 2024

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms251810046

Paper The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer

Ki Lui; Kwok-Kuen Cheung; Winnie Wing Man Ng et al. · 2024 · International Journal of Molecular Sciences · DOI

Full title: The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer

Authors: Ki Lui; Kwok-Kuen Cheung; Winnie Wing Man Ng; Yanping Wang; Doreen W. H. Au; W. C. Cho

Year: 2024

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms252211954

Paper Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

M. Cefalì; Samantha Epistolio; Giulia Ramelli et al. · 2022 · Journal of Clinical Medicine · DOI

Full title: Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

Authors: M. Cefalì; Samantha Epistolio; Giulia Ramelli; Dylan Mangan; F. Molinari; V. Martin; Stefania Freguia; L. Mazzucchelli; P. Froesch; M. Frattini; L. Wannesson

Year: 2022

Venue: Journal of Clinical Medicine

DOI: https://doi.org/10.3390/jcm11061627

Paper KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration

Yunchen Yang; Huan Zhang; Shanshan Huang et al. · 2023 · Journal of Clinical Medicine · DOI

Full title: KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration

Authors: Yunchen Yang; Huan Zhang; Shanshan Huang; Q. Chu

Year: 2023

Venue: Journal of Clinical Medicine

DOI: https://doi.org/10.3390/jcm12020709

Paper Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer

Stein, Matthew K.; Oluoha, Oluchukwu; Patel, Kruti et al. · 2021 · Journal of Personalized Medicine · DOI

Full title: Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer

Authors: Stein, Matthew K.; Oluoha, Oluchukwu; Patel, Kruti; Vanderwalde, Ari M.

Year: 2021

Venue: Journal of Personalized Medicine

DOI: https://doi.org/10.3390/jpm11060518

Paper Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

Šutić, Maja; Vukić, Ana; Baranašić, Jurica et al. · 2021 · Journal of Personalized Medicine · DOI

Full title: Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

Authors: Šutić, Maja; Vukić, Ana; Baranašić, Jurica; Försti, Asta; Džubur, Feđa; Samaržija, Miroslav; Jakopović, Marko; Brčić, Luka; Knežević, Jelena

Year: 2021

Venue: Journal of Personalized Medicine

DOI: https://doi.org/10.3390/jpm11111102

Paper A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer

Manolakos, Peter; Ward, Linda · 2023 · Journal of Personalized Medicine · DOI

Full title: A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer

Authors: Manolakos, Peter; Ward, Linda

Year: 2023

Venue: Journal of Personalized Medicine

DOI: https://doi.org/10.3390/jpm13061010

Paper Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors

Sara Cherri; Laura Melocchi; L. Gandolfi et al. · 2023 · Life · DOI

Full title: Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors

Authors: Sara Cherri; Laura Melocchi; L. Gandolfi; G. Rossi; A. Zaniboni

Year: 2023

Venue: Life

DOI: https://doi.org/10.3390/life13020395

Paper FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021

Sochacka-Ćwikła, Aleksandra; Mą̨czyński, Marcin; Regiec, Andrzej · 2022 · Molecules · DOI

Full title: FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021

Authors: Sochacka-Ćwikła, Aleksandra; Mą̨czyński, Marcin; Regiec, Andrzej

Year: 2022

Venue: Molecules

DOI: https://doi.org/10.3390/molecules27072259

Paper New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine

Wang, Nana; Mei, Haibo; Dhawan, Gagan et al. · 2023 · Molecules · DOI

Full title: New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine

Authors: Wang, Nana; Mei, Haibo; Dhawan, Gagan; Zhang, Wei; Han, Jianlin; Soloshonok, Vadim A.

Year: 2023

Venue: Molecules

DOI: https://doi.org/10.3390/molecules28093651

Paper A Deep-Learning Proteomic-Scale Approach for Drug Design

Overhoff, Brennan; Falls, Zackary; Mangione, William et al. · 2021 · Pharmaceuticals · DOI

Full title: A Deep-Learning Proteomic-Scale Approach for Drug Design

Authors: Overhoff, Brennan; Falls, Zackary; Mangione, William; Samudrala, Ram

Year: 2021

Venue: Pharmaceuticals

DOI: https://doi.org/10.3390/ph14121277

Paper Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Lee, Jesang; Park, Seung Bum · 2022 · Pharmaceuticals · DOI

Full title: Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Authors: Lee, Jesang; Park, Seung Bum

Year: 2022

Venue: Pharmaceuticals

DOI: https://doi.org/10.3390/ph15121478

Paper TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.

Tammaccaro, Salvina Laura; Prigent, Philippe; Le Bail, Jean-Christophe et al. · 2023 · Pharmaceuticals (Basel, Switzerland) · DOI

Full title: TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.

Authors: Tammaccaro, Salvina Laura; Prigent, Philippe; Le Bail, Jean-Christophe; Dos-Santos, Odette; Dassencourt, Laurent; Eskandar, Myriam; Buzy, Armelle; Venier, Olivier; Guillemot, Jean-Claude; Veeranagouda, Yaligara; Didier, Michel; Spanakis, Emmanuel; Kanno, Tokuwa; Cesaroni, Matteo; Mathieu, Stephane; Canard, Luc; Casse, Alhassan; Windenberger, Fanny; Calvet, Loreley; Noblet, Laurence; Sidhu, Sukhvinder; Debussche, Laurent; Moll, Jurgen; Valtingojer, Iris

Year: 2023

Venue: Pharmaceuticals (Basel, Switzerland)

DOI: https://doi.org/10.3390/ph16040553

Paper Recent Advances in Covalent Drug Discovery

Schaefer, D. M.; Cheng, Xinlai · 2023 · Pharmaceuticals · DOI

Full title: Recent Advances in Covalent Drug Discovery

Authors: Schaefer, D. M.; Cheng, Xinlai

Year: 2023

Venue: Pharmaceuticals

DOI: https://doi.org/10.3390/ph16050663

Paper Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise.

Alanazi, Fawaz E; Alatawi, Yasser; Alattar, Abdullah et al. · 2025 · Pharmaceuticals (Basel, Switzerland) · DOI

Full title: Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise.

Authors: Alanazi, Fawaz E; Alatawi, Yasser; Alattar, Abdullah; Alshaman, Reem; Kotb, Ahmed A; Hetta, Helal F

Year: 2025

Venue: Pharmaceuticals (Basel, Switzerland)

DOI: https://doi.org/10.3390/ph18121788

Paper Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

A. Indini; E. Rijavec; M. Ghidini et al. · 2021 · Pharmaceutics · DOI

Full title: Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

Authors: A. Indini; E. Rijavec; M. Ghidini; A. Cortellini; F. Grossi

Year: 2021

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics13050653

Paper Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer

Leone, Gian Marco; Candido, Saverio; Lavoro, Alessandro et al. · 2023 · Pharmaceutics · DOI

Full title: Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer

Authors: Leone, Gian Marco; Candido, Saverio; Lavoro, Alessandro; Vivarelli, Silvia; Gattuso, Giuseppe; Călina, Daniela; Libra, Massimo; Falzone, Luca

Year: 2023

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics15041252

Paper The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers

Andrade, Fernanda; German-Cortés, Júlia; Montero‐Herradón, Sara et al. · 2023 · Pharmaceutics · DOI

Full title: The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers

Authors: Andrade, Fernanda; German-Cortés, Júlia; Montero‐Herradón, Sara; Carcavilla, Pilar; Baranda-Martínez-Abascal, Diego; Moltó‐Abad, Marc; Seras‐Franzoso, Joaquin; Díaz‐Riascos, Zamira V.; Rafael, Diana; Abasolo, Ibane

Year: 2023

Venue: Pharmaceutics

DOI: https://doi.org/10.3390/pharmaceutics15061686

Paper Emerging Treatment Options in Lung Cancer

Addeo, Alfredo · 2022 · healthbook TIMES Oncology Hematology · DOI

Full title: Emerging Treatment Options in Lung Cancer

Authors: Addeo, Alfredo

Year: 2022

Venue: healthbook TIMES Oncology Hematology

DOI: https://doi.org/10.36000/hbt.oh.2022.13.076

Paper Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer

Caputo, Vincenza; Ciardiello, Fortunato; Corte, Carminia M. Della et al. · 2023 · Exploration of Targeted Anti-tumor Therapy · DOI

Full title: Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer

Authors: Caputo, Vincenza; Ciardiello, Fortunato; Corte, Carminia M. Della; Martini, Giulia; Troiani, Teresa; Napolitano, Stefania

Year: 2023

Venue: Exploration of Targeted Anti-tumor Therapy

DOI: https://doi.org/10.37349/etat.2023.00125

Paper Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies

Malik, Parth; Rani, Ruma; Solanki, Raghu et al. · 2023 · Exploration of Targeted Anti-tumor Therapy · DOI

Full title: Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies

Authors: Malik, Parth; Rani, Ruma; Solanki, Raghu; Patel, Vishal Haribhai; Mukherjee, Tapan K.

Year: 2023

Venue: Exploration of Targeted Anti-tumor Therapy

DOI: https://doi.org/10.37349/etat.2023.00171

Paper Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer

Wu, Jingbo; Li, Xiaojing; Liu, Hui et al. · 2023 · Biomedical Reports · DOI

Full title: Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer

Authors: Wu, Jingbo; Li, Xiaojing; Liu, Hui; Liu, Yong-Juan; Liu, Xiuping

Year: 2023

Venue: Biomedical Reports

DOI: https://doi.org/10.3892/br.2023.1686

Paper Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis

Liu, Xiaofeng; Hai, Yang; Dong, Jinqu et al. · 2022 · International Journal of Oncology · DOI

Full title: Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis

Authors: Liu, Xiaofeng; Hai, Yang; Dong, Jinqu; Xu, Lan; Hou, Wenqian; Su, Jing; Ren, Weiyu; Liu, Dongling

Year: 2022

Venue: International Journal of Oncology

DOI: https://doi.org/10.3892/ijo.2022.5447

Paper Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL‑XL

Kitazawa, Masato; Miyagawa, Yusuke; Koyama, Makoto et al. · 2021 · Molecular and Clinical Oncology · DOI

Full title: Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL‑XL

Authors: Kitazawa, Masato; Miyagawa, Yusuke; Koyama, Makoto; Nakamura, Satoshi; Hondo, Nao; Miyazaki, Satoru; Muranaka, Futoshi; Tokumaru, Shigeo; Yamamoto, Yuta; Ehara, Takehito; Kuroiwa, Masatsugu; Tanaka, Hirokazu; Komatsu, Daisuke; Takeoka, Michiko; Soejima, Yuji

Year: 2021

Venue: Molecular and Clinical Oncology

DOI: https://doi.org/10.3892/mco.2021.2310

Paper Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.

Baoyin Zhao; Jing Wang; B. Song et al. · 2015 · Molecular Medicine Reports · DOI

Full title: Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.

Authors: Baoyin Zhao; Jing Wang; B. Song; Hong Wei; Weipeng Lv; L. Tian; Mei Li; Shen Lv

Year: 2015

Venue: Molecular Medicine Reports

DOI: https://doi.org/10.3892/mmr.2014.3058

Paper Phenotypic screening using large‑scale genomic libraries to identify drug targets for the treatment of cancer (Review)

Sato, Mitsuo · 2020 · Oncology Letters · DOI

Full title: Phenotypic screening using large‑scale genomic libraries to identify drug targets for the treatment of cancer (Review)

Authors: Sato, Mitsuo

Year: 2020

Venue: Oncology Letters

DOI: https://doi.org/10.3892/ol.2020.11512

Paper Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta‑analysis

Li, Shu; Wang, Xiaotong; Li, Qiuhong et al. · 2022 · Oncology Letters · DOI

Full title: Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta‑analysis

Authors: Li, Shu; Wang, Xiaotong; Li, Qiuhong; Li, Chunli

Year: 2022

Venue: Oncology Letters

DOI: https://doi.org/10.3892/ol.2022.13605

Paper Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model

Hsu, Ping‐Chih; Tian, Bo; Yang, Yi‐Lin et al. · 2019 · Oncology Reports · DOI

Full title: Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model

Authors: Hsu, Ping‐Chih; Tian, Bo; Yang, Yi‐Lin; Wang, Yucheng; Liu, Shu; Urisman, Anatoly; Yang, Cheng‐Ta; Xu, Zhidong; Jablons, David M.; You, Liang

Year: 2019

Venue: Oncology Reports

DOI: https://doi.org/10.3892/or.2019.7207

Paper Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)

Zhang, Joshua; Darman, Lily; Hassan, Mohammad Rashedul et al. · 2023 · Oncology Reports · DOI

Full title: Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)

Authors: Zhang, Joshua; Darman, Lily; Hassan, Mohammad Rashedul; Holzen, Urs von; Awasthi, Niranjan

Year: 2023

Venue: Oncology Reports

DOI: https://doi.org/10.3892/or.2023.8643

Paper Advances in targeting KRAS mutations: A promising approach for the treatment of non-small cell lung cancer (Review)

Upesh Sharma; Jincheng Song; Hemraj Kandu et al. · 2026 · Oncology Report · DOI

Full title: Advances in targeting KRAS mutations: A promising approach for the treatment of non-small cell lung cancer (Review)

Authors: Upesh Sharma; Jincheng Song; Hemraj Kandu; Yue Zhu; Zhaoxia Dai

Year: 2026

Venue: Oncology Report

DOI: https://doi.org/10.3892/or.2026.9044

Paper Therapeutic Progress in Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer

Liu, Yi; HUANG, Zhen; CHEN, Lulu et al. · 2025 · SHILAP Revista de lepidopterología · DOI

Full title: Therapeutic Progress in Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer

Authors: Liu, Yi; HUANG, Zhen; CHEN, Lulu; Song, Qibin

Year: 2025

Venue: SHILAP Revista de lepidopterología

DOI: https://doi.org/10.3971/j.issn.1000-8578.2025.25.0438

Paper Using Artificial Intelligence to select drug targets in oncology

Tudor I Oprea; Virgil Păunescu · 2024 · Journal of Medical and Radiation Oncology · DOI

Full title: Using Artificial Intelligence to select drug targets in oncology

Authors: Tudor I Oprea; Virgil Păunescu

Year: 2024

Venue: Journal of Medical and Radiation Oncology

DOI: https://doi.org/10.53011/jmro.2024.01.01

Paper From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC

Hongyu Liu · 2025 · Highlights in Science Engineering and Technology · DOI

Full title: From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC

Authors: Hongyu Liu

Year: 2025

Venue: Highlights in Science Engineering and Technology

DOI: https://doi.org/10.54097/0trsfx05

Paper Sotorasib and other drugs comparison in treating non-small cell lung cancer

Yueting Ren · 2022 · Highlights in Science Engineering and Technology · DOI

Full title: Sotorasib and other drugs comparison in treating non-small cell lung cancer

Authors: Yueting Ren

Year: 2022

Venue: Highlights in Science Engineering and Technology

DOI: https://doi.org/10.54097/hset.v8i.1256

Paper Advancements in Targeted Therapies Based on the EGFR, and KRAS Genetic Mutations in Lung Cancer

Weiting Feng · 2024 · Theoretical and Natural Science · DOI

Full title: Advancements in Targeted Therapies Based on the EGFR, and KRAS Genetic Mutations in Lung Cancer

Authors: Weiting Feng

Year: 2024

Venue: Theoretical and Natural Science

DOI: https://doi.org/10.54254/2753-8818/2024.18031

Paper A Novel Integrated Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma Based on Synergistic siRNA and Intelligent Nanocarriers

Yibing Li · 2026 · Theoretical and Natural Science · DOI

Full title: A Novel Integrated Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma Based on Synergistic siRNA and Intelligent Nanocarriers

Authors: Yibing Li

Year: 2026

Venue: Theoretical and Natural Science

DOI: https://doi.org/10.54254/2753-8818/2026.pj31652

Paper KRAS Inhibition in Colorectal Cancer: Current Insights, Clinical Successes, and Ongoing Challenges

Furqan Memon; Momina Nadeem; C. Bah et al. · 2024 · Asian Journal of Health Research · DOI

Full title: KRAS Inhibition in Colorectal Cancer: Current Insights, Clinical Successes, and Ongoing Challenges

Authors: Furqan Memon; Momina Nadeem; C. Bah; Muhammad Sulaiman; Umm-E- Hani; Ceaser Wankumbu Silumbwe; Muhammad Ali Amin Khan; Julius Mulumba; Jianjun Zou; Shengtao Yuan

Year: 2024

Venue: Asian Journal of Health Research

DOI: https://doi.org/10.55561/ajhr.v3i3.180

Paper Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human plasma: Implications for therapeutic drug monitoring

Hikita, Eri; Gando, Yoshito; Chubachi, Hideo et al. · 2023 · Drug Discoveries & Therapeutics · DOI

Full title: Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human plasma: Implications for therapeutic drug monitoring

Authors: Hikita, Eri; Gando, Yoshito; Chubachi, Hideo; Shirota, Mikio; Kushiyama, Akifumi; Yasu, Takeo

Year: 2023

Venue: Drug Discoveries & Therapeutics

DOI: https://doi.org/10.5582/ddt.2023.01043

Paper PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Barua, Amrita; Kundu, Samrat T; Garza, Sofia G et al. · 2025 · bioRxiv : the preprint server for biology · DOI

Full title: PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Authors: Barua, Amrita; Kundu, Samrat T; Garza, Sofia G; Fradette, Jared J; Choudhary, Bhagya Shree; Peng, David H; Diao, Lixia; Wang, Jing; Gibbons, Don L

Year: 2025

Venue: bioRxiv : the preprint server for biology

DOI: https://doi.org/10.64898/2025.12.22.696060

Paper Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

Lu, Yuqing; Yang, Yuewen; Zhu, Guanghao et al. · 2023 · International Journal of Biological Sciences · DOI

Full title: Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

Authors: Lu, Yuqing; Yang, Yuewen; Zhu, Guanghao; Zeng, Hairong; Fan, Yi‐Ming; Guo, Fujia; Xu, Dongshu; Wang, Boya; Chen, Dapeng; Ge, Guang‐Bo

Year: 2023

Venue: International Journal of Biological Sciences

DOI: https://doi.org/10.7150/ijbs.83026

Paper Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks

Stravopodis, Dimitrios J.; Papavassiliou, Kostas A.; Papavassiliou, Athanasios G. · 2023 · International Journal of Biological Sciences · DOI

Full title: Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks

Authors: Stravopodis, Dimitrios J.; Papavassiliou, Kostas A.; Papavassiliou, Athanasios G.

Year: 2023

Venue: International Journal of Biological Sciences

DOI: https://doi.org/10.7150/ijbs.83574

Paper S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance

Saptadwipa Ganguly; R. Burikhanov; Vitaliy M. Sviripa et al. · 2025 · International Journal on Biological Sciences · DOI

Full title: S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance

Authors: Saptadwipa Ganguly; R. Burikhanov; Vitaliy M. Sviripa; Sally Ellingson; Jieyun Jiang; Christian M. Gosser; David Orren; Eva M. Goellner; G.G. Shenoy; Mahadev Rao; John A. D’Orazio; C. Brainson; Chang-Guo Zhan; Peter H. Spielmann; David S. Watt; Vivek M. Rangnekar

Year: 2025

Venue: International Journal on Biological Sciences

DOI: https://doi.org/10.7150/ijbs.96672

Paper Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma

Wu, Xiaonan; Zhao, Jun; Yang, Ling et al. · 2022 · Journal of Cancer · DOI

Full title: Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma

Authors: Wu, Xiaonan; Zhao, Jun; Yang, Ling; Nie, Xin; Wang, Zheng; Zhang, Ping; Li, Chao; Hu, Xueqing; Tang, Min; Yi, Yuting; Du, Xinhua; Xia, Xuefeng; Guan, Yanfang; Yu, Zicheng; Gu, Wenguang; Quan, Xiangming; Li, Lin; Shi, Hong

Year: 2022

Venue: Journal of Cancer

DOI: https://doi.org/10.7150/jca.65370

Paper Conquering oncogenic KRAS and its bypass mechanisms

Hou, Pingping; Wang, Yingshuang · 2022 · Theranostics · DOI

Full title: Conquering oncogenic KRAS and its bypass mechanisms

Authors: Hou, Pingping; Wang, Yingshuang

Year: 2022

Venue: Theranostics

DOI: https://doi.org/10.7150/thno.71260

Paper KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review

Fatima, Sheereen; Pansuriya, Nirav; Lakhani, Alisha et al. · 2024 · Cureus · DOI

Full title: KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review

Authors: Fatima, Sheereen; Pansuriya, Nirav; Lakhani, Alisha; Madhuri, S.; Ajmal, Reshma; Clementina, Ruchira; Lakdawala, Zahabiya; Shah, Kinjal J.; Dilshana, Husna; Andrea, Maya; Mathew, Bejoi; Raheja, Aashna

Year: 2024

Venue: Cureus

DOI: https://doi.org/10.7759/cureus.60061

Thesis Adaptive resistance to EGFR-targeted therapy by calcium signaling in NSCLC cells

Mulder, Celine; Prust, Nadine; Van Doorn, Sander et al. · 2018 · Utrecht University · DOI

Full title: Adaptive resistance to EGFR-targeted therapy by calcium signaling in NSCLC cells

Authors: Mulder, Celine; Prust, Nadine; Van Doorn, Sander; Reinecke, Maria; Kuster, Bernhard; Van Bergen En Henegouwen, Paul; Lemeer, Simone

Year: 2018

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/374409

Thesis Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription

Kulkarni, A; Mohan, V; Tang, TT et al. · 2025 · University of Melbourne · DOI

Full title: Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription

Authors: Kulkarni, A; Mohan, V; Tang, TT; Post, L; Chan, YC; Manning, M; Thio, N; Parker, BL; Dawson, MA; Rosenbluh, J; Vissers, JHA; Harvey, KF

Year: 2025

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/358338

Thesis Identification of therapeutic targets in canine bladder cancer: a translational model for MAPK pathway-targeted and immune-based therapies

Cronise, Kathryn Elizabeth, author; Duval, Dawn, advisor; Gustafson, Daniel, advisor et al. · 2021 · Colorado State University · DOI

Full title: Identification of therapeutic targets in canine bladder cancer: a translational model for MAPK pathway-targeted and immune-based therapies

Authors: Cronise, Kathryn Elizabeth, author; Duval, Dawn, advisor; Gustafson, Daniel, advisor; DeLuca, Jennifer, committee member; Page, Rodney, committee member; Thamm, Douglas, committee member

Year: 2021

Venue: Colorado State University

DOI: https://hdl.handle.net/10217/232608

Thesis Aktuelle patientenindividuelle Behandlungsansätze beim metastasierten nicht-kleinzelligen Lungenkarzinom

Frost, Nikolaj · 2022 · Freie Universität Berlin (Refubium) · DOI

Full title: Aktuelle patientenindividuelle Behandlungsansätze beim metastasierten nicht-kleinzelligen Lungenkarzinom

Authors: Frost, Nikolaj

Year: 2022

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/33608

Thesis Hochdurchsatz-Sequenz-Analyse zur Identifikation von prädisponierenden sowie

Isau, Melanie · 2015 · Freie Universität Berlin (Refubium) · DOI

Full title: Hochdurchsatz-Sequenz-Analyse zur Identifikation von prädisponierenden sowie

Authors: Isau, Melanie

Year: 2015

Venue: Freie Universität Berlin (Refubium)

DOI: https://refubium.fu-berlin.de/handle/fub188/2221

Thesis Perfil molecular do câncer de pulmão de não pequenas células em um hospital terciário no sul do Brasil

Andreis, Tiago Finger · 2023 · Universidade Federal do Rio Grande do Sul – LUME · DOI

Full title: Perfil molecular do câncer de pulmão de não pequenas células em um hospital terciário no sul do Brasil

Authors: Andreis, Tiago Finger

Year: 2023

Venue: Universidade Federal do Rio Grande do Sul – LUME

DOI: http://hdl.handle.net/10183/265098

Thesis Carcinoma de pulmón no celula pequeña, con mutación de KRas: diferenciación y caracterización de subtipos, así como de los diferentes mecanismos de resistencia, para la elaboración de tratamientos dirigidos

Gil Moreno, María de los Llanos · 2019 · Universitat Autònoma de Barcelona (TDX) · DOI

Full title: Carcinoma de pulmón no celula pequeña, con mutación de KRas: diferenciación y caracterización de subtipos, así como de los diferentes mecanismos de resistencia, para la elaboración de tratamientos dirigidos

Authors: Gil Moreno, María de los Llanos

Year: 2019

Venue: Universitat Autònoma de Barcelona (TDX)

DOI: http://hdl.handle.net/10803/665499

Thesis FASTING-MIMICKING DIET-BASED NON-TOXIC COMBINATION THERAPY IN CANCER TREATMENT: FROM MOLECULES TO BEDSIDE

DI TANO, MAIRA · 2019 · Università degli Studi di Milano (AIR) · DOI

Full title: FASTING-MIMICKING DIET-BASED NON-TOXIC COMBINATION THERAPY IN CANCER TREATMENT: FROM MOLECULES TO BEDSIDE

Authors: DI TANO, MAIRA

Year: 2019

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/609110

Thesis SMAC-MIMETIC- AND TRAIL- BASED COMBINATIONS AS THERAPEUTIC STRATEGIES FOR KRAS-MUTATED CANCERS

A. Conti · 2015 · Università degli Studi di Milano (AIR) · DOI

Full title: SMAC-MIMETIC- AND TRAIL- BASED COMBINATIONS AS THERAPEUTIC STRATEGIES FOR KRAS-MUTATED CANCERS

Authors: A. Conti

Year: 2015

Venue: Università degli Studi di Milano (AIR)

DOI: http://hdl.handle.net/2434/249662

Thesis Mechanisms of Resistance to MAPK Pathway Inhibition in RAS-Mutant Cancers

Wang, Belinda · 2017 · Harvard University - DASH · DOI

Full title: Mechanisms of Resistance to MAPK Pathway Inhibition in RAS-Mutant Cancers

Authors: Wang, Belinda

Year: 2017

Venue: Harvard University - DASH

DOI: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33493475

Thesis Loss of Insulin Receptor Substrates 1 and 2 Suppresses Kras-Driven Non-Small Cell Lung Cancer

Xu, He (Clare) · 2019 · Harvard University - DASH · DOI

Full title: Loss of Insulin Receptor Substrates 1 and 2 Suppresses Kras-Driven Non-Small Cell Lung Cancer

Authors: Xu, He (Clare)

Year: 2019

Venue: Harvard University - DASH

DOI: http://nrs.harvard.edu/urn-3:HUL.InstRepos:39987870

Thesis Co-targeting Translation Initiation and the RAS/ERK Pathway for the Treatment of KRAS-mutant Lung Cancer

Nardi, Francesca · 2024 · Harvard University - DASH · DOI

Full title: Co-targeting Translation Initiation and the RAS/ERK Pathway for the Treatment of KRAS-mutant Lung Cancer

Authors: Nardi, Francesca

Year: 2024

Venue: Harvard University - DASH

DOI: https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37377848

Thesis Mapping the molecular mechanism of GTPases KRAS and RIT1 in lung cancer

Holmes, Kristin Dannielle · 2021 · University of Washington - ResearchWorks · DOI

Full title: Mapping the molecular mechanism of GTPases KRAS and RIT1 in lung cancer

Authors: Holmes, Kristin Dannielle

Year: 2021

Venue: University of Washington - ResearchWorks

DOI: http://hdl.handle.net/1773/47110

Thesis The Molecular Epidemiology of Non-Small Cell Lung Cancer

Isaksson, Johan · 2023 · Uppsala University · DOI

Full title: The Molecular Epidemiology of Non-Small Cell Lung Cancer

Authors: Isaksson, Johan

Year: 2023

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-497493

Thesis Development of Combination Therapy with Anti-Cancer Drugs

Leijen, S. · 2013 · Utrecht University · DOI

Full title: Development of Combination Therapy with Anti-Cancer Drugs

Authors: Leijen, S.

Year: 2013

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/267996

Thesis Understanding Resistance to Targeted Anticancer Therapies

Sun, C. · 2015 · Utrecht University · DOI

Full title: Understanding Resistance to Targeted Anticancer Therapies

Authors: Sun, C.

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/304110

Thesis Mutation and immune profiling of non-small cell lung cancer

La Fleur, Linnéa · 2019 · Uppsala University · DOI

Full title: Mutation and immune profiling of non-small cell lung cancer

Authors: La Fleur, Linnéa

Year: 2019

Venue: Uppsala University

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-390321

Thesis Clinical Pharmacology of Genotype-Directed Anticancer Therapy: Towards Rational Combination Strategies

van Geel, Robin M J M · 2016 · Utrecht University · DOI

Full title: Clinical Pharmacology of Genotype-Directed Anticancer Therapy: Towards Rational Combination Strategies

Authors: van Geel, Robin M J M

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/341138

Thesis Early clinical development of targeted anticancer agents

van Brummelen, E.M.J. · 2017 · Utrecht University · DOI

Full title: Early clinical development of targeted anticancer agents

Authors: van Brummelen, E.M.J.

Year: 2017

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/356786

Thesis A one-two punch model for cancer therapy

Wang, Liqin · 2018 · Utrecht University · DOI

Full title: A one-two punch model for cancer therapy

Authors: Wang, Liqin

Year: 2018

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/364638

Thesis From resistance to sensitivity and back – the full circle of resisting the inescapable

Šuštić, Tonći · 2020 · Utrecht University · DOI

Full title: From resistance to sensitivity and back – the full circle of resisting the inescapable

Authors: Šuštić, Tonći

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/396923

Thesis Translational research of combined anticancer therapies targeting the MAPK pathway

Huijberts, Sanne Cornelia Francina Adriana · 2020 · Utrecht University · DOI

Full title: Translational research of combined anticancer therapies targeting the MAPK pathway

Authors: Huijberts, Sanne Cornelia Francina Adriana

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/406730

Thesis Precision medicine in non-small cell lung cancer: Improving dosing strategies

Boosman, René Johan · 2022 · Utrecht University · DOI

Full title: Precision medicine in non-small cell lung cancer: Improving dosing strategies

Authors: Boosman, René Johan

Year: 2022

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/420491

Thesis All roads lead to SHP2

Mulero-Sánchez, Antonio · 2023 · Utrecht University · DOI

Full title: All roads lead to SHP2

Authors: Mulero-Sánchez, Antonio

Year: 2023

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/430725

Thesis Combine and conquer as a strategy to treat RAS-driven cancers

Jansen, Robin Alexandra · 2024 · Utrecht University · DOI

Full title: Combine and conquer as a strategy to treat RAS-driven cancers

Authors: Jansen, Robin Alexandra

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/437416

Thesis Biomarker-driven treatment strategies in solid tumors: Insights from clinical and translational research

Embaby, Alaa · 2024 · Utrecht University · DOI

Full title: Biomarker-driven treatment strategies in solid tumors: Insights from clinical and translational research

Authors: Embaby, Alaa

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/451613

Thesis LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology

Retmana, Irene Anindyajati · 2024 · Utrecht University · DOI

Full title: LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology

Authors: Retmana, Irene Anindyajati

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/455646

Thesis Tumor cell-intrinsic signals promoting tolerance and adaptation to oncogenic kinase inhibition

Flower, Cameron Timothy · 2024 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Tumor cell-intrinsic signals promoting tolerance and adaptation to oncogenic kinase inhibition

Authors: Flower, Cameron Timothy

Year: 2024

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/156951

Thesis Cross-species evaluation of Pan-RAF inhibitor LY3009120 or SOS1::KRAS inhibitor BI-3406 in human, canine, and equine malignant melanoma

Gao, Yu · 2024 · University of Veterinary Medicine Hannover (TiHo) · DOI

Full title: Cross-species evaluation of Pan-RAF inhibitor LY3009120 or SOS1::KRAS inhibitor BI-3406 in human, canine, and equine malignant melanoma

Authors: Gao, Yu

Year: 2024

Venue: University of Veterinary Medicine Hannover (TiHo)

DOI: https://nbn-resolving.org/urn:nbn:de:gbv:95-120575

Thesis Investigating therapeutic chemotypes by merging functional genomics and drug design

Lou, Kevin · 2022 · University of California, San Francisco (UCSF) · DOI

Full title: Investigating therapeutic chemotypes by merging functional genomics and drug design

Authors: Lou, Kevin

Year: 2022

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/14s7p5tg

Thesis Analysis of the initiation, progression and therapy of BRAF(V600E) and KRAS(G12D)- driven non-small cell lung adenocarcinoma using conditional mouse models

Trejo, Christy · 2012 · University of California, San Francisco (UCSF) · DOI

Full title: Analysis of the initiation, progression and therapy of BRAF(V600E) and KRAS(G12D)- driven non-small cell lung adenocarcinoma using conditional mouse models

Authors: Trejo, Christy

Year: 2012

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/1bv4t8kc

Thesis Development of a scalable in-vivo drug discovery platform allows for deep interrogation of mechanisms of KRAS.G12C inhibitors.

Yu, John Xuzong · 2022 · University of California, San Francisco (UCSF) · DOI

Full title: Development of a scalable in-vivo drug discovery platform allows for deep interrogation of mechanisms of KRAS.G12C inhibitors.

Authors: Yu, John Xuzong

Year: 2022

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/17w596v6

Thesis Investigation of Notch3-dependent mechanisms in KRAS-mutant lung adenocarcinoma

Hwang, Elizabeth Eujin · 2022 · University of California, San Francisco (UCSF) · DOI

Full title: Investigation of Notch3-dependent mechanisms in KRAS-mutant lung adenocarcinoma

Authors: Hwang, Elizabeth Eujin

Year: 2022

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/3204n09b

Thesis Development of an Irreversible Mutant-Specific Inhibitor of Oncogenic K-Ras G12C

Ostrem, Jonathan Michael · 2013 · University of California, San Francisco (UCSF) · DOI

Full title: Development of an Irreversible Mutant-Specific Inhibitor of Oncogenic K-Ras G12C

Authors: Ostrem, Jonathan Michael

Year: 2013

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/23h9s068

Thesis The cooperation of PIK3CA[H1047R] with BRAF[V600E] and KRAS[G12D] in lung tumorigenesis

Green, Shon · 2015 · University of California, San Francisco (UCSF) · DOI

Full title: The cooperation of PIK3CA[H1047R] with BRAF[V600E] and KRAS[G12D] in lung tumorigenesis

Authors: Green, Shon

Year: 2015

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/8fs8784n

Thesis Tumor-Specific Therapies Targeting Antigen Presentation and Misregulated Proteolysis

Rohweder, Peter James · 2022 · University of California, San Francisco (UCSF) · DOI

Full title: Tumor-Specific Therapies Targeting Antigen Presentation and Misregulated Proteolysis

Authors: Rohweder, Peter James

Year: 2022

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/6nc3b40b

Thesis Discovery and Design of Next Generation Inhibitors Targeting the HER2/HER3 heterodimer and K-Ras

Novotny, Chris J · 2016 · University of California, San Francisco (UCSF) · DOI

Full title: Discovery and Design of Next Generation Inhibitors Targeting the HER2/HER3 heterodimer and K-Ras

Authors: Novotny, Chris J

Year: 2016

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/8zz805wx

Thesis Targeting oncogenic K-Ras G12C and G13C via covalent drug design

Nnadi, Chimno · 2019 · University of California, San Francisco (UCSF) · DOI

Full title: Targeting oncogenic K-Ras G12C and G13C via covalent drug design

Authors: Nnadi, Chimno

Year: 2019

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/8np2j0vr

Thesis CHARACTERIZATION OF THE TUMOR AND SYSTEMIC IMMUNOMODULATORY EFFECTS OF MEK1 INHIBITION

Dennison, Lauren · 2021 · Johns Hopkins University · DOI

Full title: CHARACTERIZATION OF THE TUMOR AND SYSTEMIC IMMUNOMODULATORY EFFECTS OF MEK1 INHIBITION

Authors: Dennison, Lauren

Year: 2021

Venue: Johns Hopkins University

DOI: http://jhir.library.jhu.edu/handle/1774.2/64286

Thesis Identification of drug resistance mechanisms induced in response to KRAS therapeutics

Warren, Hannah · 2021 · University of Liverpool · DOI

Full title: Identification of drug resistance mechanisms induced in response to KRAS therapeutics

Authors: Warren, Hannah

Year: 2021

Venue: University of Liverpool

DOI: https://livrepository.liverpool.ac.uk/3140729/1/201218160_Sep2021.pdf

Thesis 103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)

Barlesi, F; Felip, E; Popat, S et al. · 2024 · University of Melbourne · DOI

Full title: 103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)

Authors: Barlesi, F; Felip, E; Popat, S; Solomon, B; Wolf, J; Li, BT; Wu, Y-L; Kerr, KM; Akamatsu, H; Camidge, DR; Gupta, R; Meloni, A; Dai, T; Borghaei, H

Year: 2024

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/351906

Thesis A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

Roth, S; Wilson, KC; Ramsay, RG et al. · 2025 · University of Melbourne · DOI

Full title: A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

Authors: Roth, S; Wilson, KC; Ramsay, RG; Mitchell, C; Sampurno, S; Pham, TD; Huei Kong, JC; Wong, SQ; Heriot, AG; Deva, S; Burge, M; Sverdrup, C; Moller, AS; Kuryk, L; Eriksen, JA; Jaderberg, M; Zalcberg, JR; Michael, M

Year: 2025

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/359449

Thesis Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J; Alonso, G; Kim, SH et al. · 2025 · University of Melbourne · DOI

Full title: Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Authors: Desai, J; Alonso, G; Kim, SH; Cervantes, A; Karasic, T; Medina, L; Shacham-Shmueli, E; Cosman, R; Falcon, A; Gort, E; Guren, T; Massarelli, E; Miller, WH; Paz-Ares, L; Prenen, H; Amatu, A; Cremolini, C; Kim, TW; Moreno, V; Ou, SHI; Passardi, A; Sacher, A; Santoro, A; Stec, R; Ulahannan, S; Arbour, K; Lorusso, P; Luo, J; Patel, MR; Choi, Y; Shi, Z; Mandlekar, S; Lin, MT; Royer-Joo, S; Chang, J; Jun, T; Dharia, NV; Schutzman, JL; Han, SW

Year: 2025

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/358247

Thesis The importance of Ras in drug resistance in cancer

Healy, Fiona M; Prior, Ian A; MacEwan, David J · 2022 · University of Liverpool · DOI

Full title: The importance of Ras in drug resistance in cancer

Authors: Healy, Fiona M; Prior, Ian A; MacEwan, David J

Year: 2022

Venue: University of Liverpool

DOI: https://livrepository.liverpool.ac.uk/3116829/1/Healy%20et%20al%20BJP%20clean.pdf

Thesis The Frequency of Ras Mutations in Cancer

Prior, Ian A; Hood, Fiona E; Hartley, James L · 2020 · University of Liverpool · DOI

Full title: The Frequency of Ras Mutations in Cancer

Authors: Prior, Ian A; Hood, Fiona E; Hartley, James L

Year: 2020

Venue: University of Liverpool

DOI: https://livrepository.liverpool.ac.uk/3093548/1/Prior%20CR2020.pdf

Thesis Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Warren, Hannah R; Ross, Sarah J; Smith, Paul D et al. · 2022 · University of Liverpool · DOI

Full title: Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Authors: Warren, Hannah R; Ross, Sarah J; Smith, Paul D; Coulson, Judy M; Prior, Ian A

Year: 2022

Venue: University of Liverpool

DOI: https://livrepository.liverpool.ac.uk/3164900/1/bcj-2022-0440.pdf

Thesis Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Branstrom, Art · 2021 · Universidade de São Paulo – USP Digital Library · DOI

Full title: Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Authors: Branstrom, Art

Year: 2021

Venue: Universidade de São Paulo – USP Digital Library

DOI: https://doi.org/10.1038/s42003-021-01897-6

Thesis Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

Verissimo, Carla S; Overmeer, René M; Ponsioen, Bas et al. · 2016 · Utrecht University · DOI

Full title: Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

Authors: Verissimo, Carla S; Overmeer, René M; Ponsioen, Bas; Drost, Jarno; Mertens, Sander; Verlaan-Klink, Ingrid; Gerwen, Bastiaan van; van der Ven, Marieke; van de Wetering, Marc; Egan, David A; Bernards, René; Clevers, Hans; Bos, Johannes L; Snippert, Hugo J

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/343547

Thesis Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

Subbiah, Vivek; Kreitman, Robert J; Wainberg, Zev A et al. · 2018 · Utrecht University · DOI

Full title: Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

Authors: Subbiah, Vivek; Kreitman, Robert J; Wainberg, Zev A; Cho, Jae Yong; Schellens, Jan H M; Soria, Jean Charles; Wen, Patrick Y; Zielinski, Christoph; Cabanillas, Maria E; Urbanowitz, Gladys; Mookerjee, Bijoyesh; Wang, Dazhe; Rangwala, Fatima; Keam, Bhumsuk

Year: 2018

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/362469

Thesis Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Retmana, Irene A; Loos, Nancy H C; Schinkel, Alfred H et al. · 2021 · Utrecht University · DOI

Full title: Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Authors: Retmana, Irene A; Loos, Nancy H C; Schinkel, Alfred H; Beijnen, Jos H; Sparidans, Rolf W

Year: 2021

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/412114

Thesis Pharmacokinetics of the KRAS G12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

Loos, Nancy H C; Retmana, Irene A; Rijmers, Jamie et al. · 2023 · Utrecht University · DOI

Full title: Pharmacokinetics of the KRAS G12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

Authors: Loos, Nancy H C; Retmana, Irene A; Rijmers, Jamie; Wang, Yaogeng; Gan, Changpei; Lebre, Maria C; Sparidans, Rolf W; Beijnen, Jos H; Schinkel, Alfred H

Year: 2023

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/432858

Thesis Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study

Retmana, Irene A.; Çelebi, Nefise; Rijmers, Jamie et al. · 2024 · Utrecht University · DOI

Full title: Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study

Authors: Retmana, Irene A.; Çelebi, Nefise; Rijmers, Jamie; Schinkel, Alfred H.; Beijnen, Jos H.; Sparidans, Rolf W.

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/437527

Thesis Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

Retmana, Irene A; Loos, Nancy H C; Schinkel, Alfred H et al. · 2023 · Utrecht University · DOI

Full title: Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

Authors: Retmana, Irene A; Loos, Nancy H C; Schinkel, Alfred H; Beijnen, Jos H; Sparidans, Rolf W

Year: 2023

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/432864

Thesis ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure

Rijmers, Jamie; Retmana, Irene A; Bui, Viët et al. · 2024 · Utrecht University · DOI

Full title: ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure

Authors: Rijmers, Jamie; Retmana, Irene A; Bui, Viët; Arguedas, Davinia; Lebre, Maria C; Sparidans, Rolf W; Beijnen, Jos H; Schinkel, Alfred H

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/452188

Thesis A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells

Hoang, Trish T.; Tanrikulu, Ismet Caglar; Vatland, Quinn A. et al. · 2020 · Massachusetts Institute of Technology (MIT) · DOI

Full title: A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells

Authors: Hoang, Trish T.; Tanrikulu, Ismet Caglar; Vatland, Quinn A.; Hoang, Trieu M.; Raines, Ronald T

Year: 2020

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/123520

Thesis KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Krall, Elsa B; Munoz, Diana M; Ilic, Nina et al. · 2017 · Massachusetts Institute of Technology (MIT) · DOI

Full title: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Authors: Krall, Elsa B; Munoz, Diana M; Ilic, Nina; Niederst, Matthew J; Yu, Kristine; Ruddy, David A; Redig, Amanda J; Gainor, Justin F; Williams, Juliet A; Asara, John M; Janne, Pasi A; Shaw, Alice T; McDonald III, Robert E; Engelman, Jeffrey A; Stegmeier, Frank; Schlabach, Michael R; Wang, Belinda; Raghavan, Srivatsan; Aguirre, Andrew J.; Kim, Jong Wook; Doench, John Gerard; Hahn, William

Year: 2017

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/109867

Thesis A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer

Gu, Li; Deng, Zhou J.; Roy, Sweta et al. · 2021 · Massachusetts Institute of Technology (MIT) · DOI

Full title: A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer

Authors: Gu, Li; Deng, Zhou J.; Roy, Sweta; Hammond, Paula T

Year: 2021

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/130536

Thesis The metabolic landscape of RAS-driven cancers from biology to therapy

Mukhopadhyay, Suman; Vander Heiden, Matthew G; McCormick, Frank · 2022 · Massachusetts Institute of Technology (MIT) · DOI

Full title: The metabolic landscape of RAS-driven cancers from biology to therapy

Authors: Mukhopadhyay, Suman; Vander Heiden, Matthew G; McCormick, Frank

Year: 2022

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/136166.2

Thesis Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

Liu, Qingsong; Xu, Chunxiao; Kirubakaran, Sivapriya et al. · 2015 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

Authors: Liu, Qingsong; Xu, Chunxiao; Kirubakaran, Sivapriya; Zhang, Xin; Hur, Wooyoung; Kwiatkowski, Nicholas P.; Wang, Jinhua; Westover, Kenneth D.; Gao, Peng; Ercan, Dalia; Niepel, Mario; Thoreen, Carson C.; Kang, Seong A.; Patricelli, Matthew P.; Wang, Yuchuan; Tupper, Tanya; Altabef, Abigail; Kawamura, Hidemasa; Held, Kathryn D.; Chou, Danny M.; Elledge, Stephen J.; Janne, Pasi A.; Wong, Kwok-Kin; Gray, Nathanael S.; Sabatini, David; Liu, Yan

Year: 2015

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/96764

Thesis Selective Killing of K-ras Mutant Cancer Cells by Novel Small Molecule Inducers of Oxidative Stress

Shaw, Alice; Winslow, Monte Meier; Magendantz, Margaret et al. · 2011 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Selective Killing of K-ras Mutant Cancer Cells by Novel Small Molecule Inducers of Oxidative Stress

Authors: Shaw, Alice; Winslow, Monte Meier; Magendantz, Margaret; Ouyang, Chensi; Dowdle, James; Subramanian, Aravind; Lewis, Timothy A.; Maglathin, Rebecca L.; Tolliday, Nicola; Jacks, Tyler E

Year: 2011

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/67456

Thesis Systematic identification of signaling pathways with potential to confer anticancer drug resistance

Martz, C. A.; Ottina, Kathleen; Singleton, K. R. et al. · 2015 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Systematic identification of signaling pathways with potential to confer anticancer drug resistance

Authors: Martz, C. A.; Ottina, Kathleen; Singleton, K. R.; Jasper, J. S.; Wardell, S. E.; Peraza-Penton, A.; Anderson, G. R.; Winter, P. S.; Alley, H. M.; Kwong, L. N.; Cooper, Z. A.; Tetzlaff, M.; Chen, P.-L.; Rathmell, J. C.; Flaherty, K. T.; Wargo, J. A.; McDonnell, D. P.; Wood, K. C.; Wang, Tim; Sabatini, David

Year: 2015

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/97538

Thesis Systems Biology Approaches for Identifying Synthetic Lethal Targets in Cancer

Ku, Angel Alejandro · 2019 · University of California, San Francisco (UCSF) · DOI

Full title: Systems Biology Approaches for Identifying Synthetic Lethal Targets in Cancer

Authors: Ku, Angel Alejandro

Year: 2019

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/0gj863n2

Thesis DIRECT PP2A ACTIVATION FOR THE TREATMENT OF KRAS- AND EGFR-DRIVEN LUNG ADENOCARCINOMA

Tohme, Rita · 2018 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: DIRECT PP2A ACTIVATION FOR THE TREATMENT OF KRAS- AND EGFR-DRIVEN LUNG ADENOCARCINOMA

Authors: Tohme, Rita

Year: 2018

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=case1526073628472942

Thesis Discovery of small molecules blocking oncogenic K-Ras activity

Kovar, Sarah E. · 2018 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: Discovery of small molecules blocking oncogenic K-Ras activity

Authors: Kovar, Sarah E.

Year: 2018

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=wright1533299266181661

Thesis SENSITIZATION TO TRAIL-INDUCED APOPTOSIS IN K-RAS 12 MUTANT PANCREATIC CANCER CELLS BY BITC

Wicker, Christina Ann · 2008 · OhioLINK Electronic Theses and Dissertations · DOI

Full title: SENSITIZATION TO TRAIL-INDUCED APOPTOSIS IN K-RAS 12 MUTANT PANCREATIC CANCER CELLS BY BITC

Authors: Wicker, Christina Ann

Year: 2008

Venue: OhioLINK Electronic Theses and Dissertations

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=wright1215556518

Thesis Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)

Mian, Afsar Ali; Haberbosch, Isabella; Khamaisie, Hazem et al. · 2021 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)

Authors: Mian, Afsar Ali; Haberbosch, Isabella; Khamaisie, Hazem; Agbarya, Abed; Pietsch, Larissa; Eshel, Elizabeh; Najib, Dally; Chiriches, Claudia; Ottmann, Oliver Gerhard; Hantschel, Oliver; Biondi, Ricardo M.; Ruthardt, Martin; Mahajna, Jamal

Year: 2021

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/179752

Thesis Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors

Desai, J; Gan, H; Barrow, C et al. · 2020 · University of Melbourne · DOI

Full title: Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors

Authors: Desai, J; Gan, H; Barrow, C; Jameson, M; Atkinson, V; Haydon, A; Millward, M; Begbie, S; Brown, M; Markman, B; Patterson, W; Hill, A; Horvath, L; Nagrial, A; Richardson, G; Jackson, C; Friedlander, M; Parente, P; Tran, B; Wang, L; Chen, Y; Tang, Z; Huang, W; Wu, J; Zeng, D; Luo, L; Solomon, B

Year: 2020

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/245843

Thesis PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Tutuka, CSA; Andrews, MC; Mariadason, JM et al. · 2021 · University of Melbourne · DOI

Full title: PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Authors: Tutuka, CSA; Andrews, MC; Mariadason, JM; Ioannidis, P; Hudson, C; Cebon, J; Behren, A

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/259639

Thesis P21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

Wang, K; Baldwin, GS; Nikfarjam, M et al. · 2021 · University of Melbourne · DOI

Full title: P21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

Authors: Wang, K; Baldwin, GS; Nikfarjam, M; He, H

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/271165

Thesis Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway

Wormald, S; Milla, L; O'Connor, L · 2021 · University of Melbourne · DOI

Full title: Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway

Authors: Wormald, S; Milla, L; O'Connor, L

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/261432

Thesis Landscape of KRAS G12C, Associated Genomic Alterations, and Interrelation with Immuno-Oncology Biomarkers in KRAS -Mutated Cancers

Salem, ME; El-Refai, SM; Sha, W et al. · 2022 · University of Melbourne · DOI

Full title: Landscape of KRAS G12C, Associated Genomic Alterations, and Interrelation with Immuno-Oncology Biomarkers in KRAS -Mutated Cancers

Authors: Salem, ME; El-Refai, SM; Sha, W; Puccini, A; Grothey, A; George, TJ; Hwang, JJ; O'Neil, B; Barrett, AS; Kadakia, KC; Musselwhite, LW; Raghavan, D; Van Cutsem, E; Tabernero, J; Tie, J

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/307179

Thesis ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer

Saad, MI; Alhayyani, S; McLeod, L et al. · 2022 · University of Melbourne · DOI

Full title: ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer

Authors: Saad, MI; Alhayyani, S; McLeod, L; Yu, L; Alanazi, M; Deswaerte, V; Tang, K; Jarde, T; Smith, JA; Prodanovic, Z; Tate, MD; Balic, JJ; Watkins, DN; Cain, JE; Bozinovski, S; Algar, E; Kohmoto, T; Ebi, H; Ferlin, W; Garbers, C; Ruwanpura, S; Sagi, I; Rose-John, S; Jenkins, BJ

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/304295

Thesis Developments in systemic therapies for the management of lung cancer

Heynemann, S; Mitchell, P · 2023 · University of Melbourne · DOI

Full title: Developments in systemic therapies for the management of lung cancer

Authors: Heynemann, S; Mitchell, P

Year: 2023

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/338045

Thesis Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Choi, Y; Dharia, NV; Jun, T et al. · 2025 · University of Melbourne · DOI

Full title: Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Authors: Choi, Y; Dharia, NV; Jun, T; Chang, J; Royer-Joo, S; Yau, KK; Assaf, ZJ; Aimi, J; Sivakumar, S; Montesion, M; Sacher, A; LoRusso, P; Desai, J; Schutzman, JL; Shi, Z

Year: 2025

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/358323

Thesis CRAF dimerization with ARAF regulates KRAS-driven tumor growth

Venkatanarayan, A; Liang, J; Yen, I et al. · 2022 · University of Melbourne · DOI

Full title: CRAF dimerization with ARAF regulates KRAS-driven tumor growth

Authors: Venkatanarayan, A; Liang, J; Yen, I; Shanahan, F; Haley, B; Phu, L; Verschueren, E; Hinkle, TB; Kan, D; Segal, E; Long, JE; Lima, T; Liau, NPD; Sudhamsu, J; Li, J; Klijn, C; Piskol, R; Junttila, MR; Shaw, AS; Merchant, M; Chang, MT; Kirkpatrick, DS; Malek, S

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/322098

Thesis Major milestones in translational oncology.

Dragani, Tommaso A; Castells, Antoni; Kulasingam, Vathany et al. · 2016 · University of Cambridge · DOI

Full title: Major milestones in translational oncology.

Authors: Dragani, Tommaso A; Castells, Antoni; Kulasingam, Vathany; Diamandis, Eleftherios P; Earl, Helena; Iams, Wade T; Lovly, Christine M; Sedelaar, JP Michiel; Schalken, Jack A

Year: 2016

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/260591

Thesis DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.

Majrashi, Taghreed A; Sabt, Ahmed; Almahli, Hadia et al. · 2024 · University of Cambridge · DOI

Full title: DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.

Authors: Majrashi, Taghreed A; Sabt, Ahmed; Almahli, Hadia; El Hassab, Mahmoud A; Noamaan, Mahmoud A; Elkaeed, Eslam B; Hamissa, Mohamed Farouk; Maslamani, Abdalkareem Nael; Shaldam, Moataz A; Eldehna, Wagdy M

Year: 2024

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/365512

Thesis The influence of the EGFR pathway in modulating the efficacy of gemcitabine

Luk, Peter Ping-Kit · 2011 · UNSW Sydney · DOI

Full title: The influence of the EGFR pathway in modulating the efficacy of gemcitabine

Authors: Luk, Peter Ping-Kit

Year: 2011

Venue: UNSW Sydney

DOI: http://hdl.handle.net/1959.4/50384

Thesis Small RNA combination therapy for lung cancer

Tammela, Tuomas; Xue, Wen; Dahlman, James E. et al. · 2015 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Small RNA combination therapy for lung cancer

Authors: Tammela, Tuomas; Xue, Wen; Dahlman, James E.; Sood, Sabina; Dave, Apeksha; Cai, Wenxin; Chirino, Leilani M.; Yang, Gillian R.; Bronson, Roderick T.; Crowley, Denise G.; Sahay, Gaurav; Anderson, Daniel Griffith; Khan, Omar Fizal; Schroeder, Avraham Dror; Langer, Robert S; Jacks, Tyler E

Year: 2015

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/95771

Thesis Vývoj a validace nové metodiky pro obohacení a detekci cirkulující nádorové DNA u onkologických pacientů

Pláničková, Lenka · 2017 · Charles University Prague (Univerzita Karlova) · DOI

Full title: Vývoj a validace nové metodiky pro obohacení a detekci cirkulující nádorové DNA u onkologických pacientů

Authors: Pláničková, Lenka

Year: 2017

Venue: Charles University Prague (Univerzita Karlova)

DOI: http://hdl.handle.net/20.500.11956/91800

Thesis The validity and predictive value of blood-based biomarkers in prediction of response in the treatment of metastatic non-small cell lung cancer: A systematic review

van Delft, F; Koffijberg, H; Retèl, V et al. · 2020 · University of Melbourne · DOI

Full title: The validity and predictive value of blood-based biomarkers in prediction of response in the treatment of metastatic non-small cell lung cancer: A systematic review

Authors: van Delft, F; Koffijberg, H; Retèl, V; van den Heuvel, M; Ijzerman, M

Year: 2020

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/246343

Thesis Current highlights in lung cancer in 2021

Lim, KHJ; Solomon, BJ · 2021 · University of Melbourne · DOI

Full title: Current highlights in lung cancer in 2021

Authors: Lim, KHJ; Solomon, BJ

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/287770

Thesis Circulating tumour DNA to guide precision medicine in solid malignancies

Tan, Lavinia Tsia Yi · 2023 · University of Melbourne · DOI

Full title: Circulating tumour DNA to guide precision medicine in solid malignancies

Authors: Tan, Lavinia Tsia Yi

Year: 2023

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/326332

Thesis Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Basu, B; Krebs, MG; Sundar, R et al. · 2018 · University of Liverpool · DOI

Full title: Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Authors: Basu, B; Krebs, MG; Sundar, R; Wilson, RH; Spicer, J; Jones, R; Brada, M; Talbot, DC; Steele, N; Garces, AH Ingles; Brugger, W; Harrington, EA; Evans, J; Hall, E; Tovey, H; de Oliveira, FM; Carreira, S; Swales, K; Ruddle, R; Raynaud, FI; Purchase, B; Dawes, JC; Parmar, M; Turner, AJ; Tunariu, N; Banerjee, S; de Bono, JS; Banerji, U

Year: 2018

Venue: University of Liverpool

DOI: https://livrepository.liverpool.ac.uk/3027571/1/Vistusertib%20%28dual%20m-TORC1/2%20inhibitor%29%20in%20combination%20with%20paclitaxel%20in%20patients%20with%20high-grade%20serous%20ovarian%20and%20squamous%20non-small-cell%20lung%20cancer.pdf

Thesis Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

Earl, Helena; Molica, Stefano; Rutkowski, Piotr · 2017 · University of Cambridge · DOI

Full title: Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

Authors: Earl, Helena; Molica, Stefano; Rutkowski, Piotr

Year: 2017

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/264598

Patent us-2023346790-a1

· 2023

Full title: us-2023346790-a1

Year: 2023

Patent us-2023373999-a1

· 2023

Full title: us-2023373999-a1

Year: 2023

Patent us-2023372340-a1

· 2023

Full title: us-2023372340-a1

Year: 2023

Patent us-2023310436-a1

· 2023

Full title: us-2023310436-a1

Year: 2023

Patent us-2023357277-a1

· 2023

Full title: us-2023357277-a1

Year: 2023

Patent us-2023374042-a1

· 2023

Full title: us-2023374042-a1

Year: 2023

Patent us-2024016781-a1

· 2024

Full title: us-2024016781-a1

Year: 2024

Patent us-2023374036-a1

· 2023

Full title: us-2023374036-a1

Year: 2023

Patent us-2024025907-a1

· 2024

Full title: us-2024025907-a1

Year: 2024

Patent us-2024058321-a1

· 2024

Full title: us-2024058321-a1

Year: 2024

Patent us-2023383359-a1

· 2023

Full title: us-2023383359-a1

Year: 2023

Patent us-2023406860-a1

· 2023

Full title: us-2023406860-a1

Year: 2023

Patent us-2024108630-a1

· 2024

Full title: us-2024108630-a1

Year: 2024

Patent us-2024058441-a1

· 2024

Full title: us-2024058441-a1

Year: 2024

Patent us-2024050430-a1

· 2024

Full title: us-2024050430-a1

Year: 2024

Patent us-2024059703-a1

· 2024

Full title: us-2024059703-a1

Year: 2024

Patent us-2024082218-a1

· 2024

Full title: us-2024082218-a1

Year: 2024

Patent us-2024101553-a1

· 2024

Full title: us-2024101553-a1

Year: 2024

Patent us-2024091230-a1

· 2024

Full title: us-2024091230-a1

Year: 2024

Patent us-2024083913-a1

· 2024

Full title: us-2024083913-a1

Year: 2024

Patent us-2024101573-a1

· 2024

Full title: us-2024101573-a1

Year: 2024

Patent us-2024124478-a1

· 2024

Full title: us-2024124478-a1

Year: 2024

Patent us-2024140948-a1

· 2024

Full title: us-2024140948-a1

Year: 2024

Patent us-2024141353-a1

· 2024

Full title: us-2024141353-a1

Year: 2024

Patent us-2024159756-a1

· 2024

Full title: us-2024159756-a1

Year: 2024

Patent us-2024173392-a1

· 2024

Full title: us-2024173392-a1

Year: 2024

Patent us-2024148733-a1

· 2024

Full title: us-2024148733-a1

Year: 2024

Patent us-2024158446-a1

· 2024

Full title: us-2024158446-a1

Year: 2024

Patent us-2024165208-a1

· 2024

Full title: us-2024165208-a1

Year: 2024

Patent us-2024190885-a1

· 2024

Full title: us-2024190885-a1

Year: 2024

Patent us-2024173328-a1

· 2024

Full title: us-2024173328-a1

Year: 2024

Patent us-2024139196-a1

· 2024

Full title: us-2024139196-a1

Year: 2024

Patent us-2024101557-a1

· 2024

Full title: us-2024101557-a1

Year: 2024

Patent us-2024174660-a1

· 2024

Full title: us-2024174660-a1

Year: 2024

Patent us-2024182470-a1

· 2024

Full title: us-2024182470-a1

Year: 2024

Patent us-2024238294-a1

· 2024

Full title: us-2024238294-a1

Year: 2024

Patent us-2024190862-a1

· 2024

Full title: us-2024190862-a1

Year: 2024

Patent us-2024173329-a1

· 2024

Full title: us-2024173329-a1

Year: 2024

Patent us-2024238397-a1

· 2024

Full title: us-2024238397-a1

Year: 2024

Patent us-2024197711-a1

· 2024

Full title: us-2024197711-a1

Year: 2024

Patent us-2024156821-a1

· 2024

Full title: us-2024156821-a1

Year: 2024

Patent us-2024216546-a1

· 2024

Full title: us-2024216546-a1

Year: 2024

Patent us-2024246954-a1

· 2024

Full title: us-2024246954-a1

Year: 2024

Patent us-2024219403-a1

· 2024

Full title: us-2024219403-a1

Year: 2024

Patent us-2024247000-a1

· 2024

Full title: us-2024247000-a1

Year: 2024

Patent us-2024228510-a1

· 2024

Full title: us-2024228510-a1

Year: 2024

Patent us-2024263146-a1

· 2024

Full title: us-2024263146-a1

Year: 2024

Patent us-2024287066-a1

· 2024

Full title: us-2024287066-a1

Year: 2024

Patent us-2024261289-a1

· 2024

Full title: us-2024261289-a1

Year: 2024

Patent us-2024293558-a1

· 2024

Full title: us-2024293558-a1

Year: 2024

Patent us-2024254122-a1

· 2024

Full title: us-2024254122-a1

Year: 2024

Patent us-2024279206-a1

· 2024

Full title: us-2024279206-a1

Year: 2024

Patent us-2024327425-a1

· 2024

Full title: us-2024327425-a1

Year: 2024

Patent us-2024358702-a1

· 2024

Full title: us-2024358702-a1

Year: 2024

Patent us-2024245686-a1

· 2024

Full title: us-2024245686-a1

Year: 2024

Patent us-2024352028-a1

· 2024

Full title: us-2024352028-a1

Year: 2024

Patent us-2024344136-a1

· 2024

Full title: us-2024344136-a1

Year: 2024

Patent us-2024343742-a1

· 2024

Full title: us-2024343742-a1

Year: 2024

Patent us-2024299392-a1

· 2024

Full title: us-2024299392-a1

Year: 2024

Patent us-2024287068-a1

· 2024

Full title: us-2024287068-a1

Year: 2024

Patent us-2024325363-a1

· 2024

Full title: us-2024325363-a1

Year: 2024

Patent us-2024307395-a1

· 2024

Full title: us-2024307395-a1

Year: 2024

Patent us-2024343735-a1

· 2024

Full title: us-2024343735-a1

Year: 2024

Patent us-2024374525-a1

· 2024

Full title: us-2024374525-a1

Year: 2024

Patent us-2024300964-a1

· 2024

Full title: us-2024300964-a1

Year: 2024

Patent us-2024335447-a1

· 2024

Full title: us-2024335447-a1

Year: 2024

Patent us-2024343813-a1

· 2024

Full title: us-2024343813-a1

Year: 2024

Patent us-2024374597-a1

· 2024

Full title: us-2024374597-a1

Year: 2024

Patent us-2024390340-a1

· 2024

Full title: us-2024390340-a1

Year: 2024

Patent us-2024368192-a1

· 2024

Full title: us-2024368192-a1

Year: 2024

Patent us-2024383922-a1

· 2024

Full title: us-2024383922-a1

Year: 2024

Patent us-2024400557-a1

· 2024

Full title: us-2024400557-a1

Year: 2024

Patent us-2024366567-a1

· 2024

Full title: us-2024366567-a1

Year: 2024

Patent us-2024376127-a1

· 2024

Full title: us-2024376127-a1

Year: 2024

Patent us-2024398815-a1

· 2024

Full title: us-2024398815-a1

Year: 2024

Patent us-2025032497-a1

· 2025

Full title: us-2025032497-a1

Year: 2025

Patent us-2024368156-a1

· 2024

Full title: us-2024368156-a1

Year: 2024

Patent us-2024366608-a1

· 2024

Full title: us-2024366608-a1

Year: 2024

Patent us-2024408098-a1

· 2024

Full title: us-2024408098-a1

Year: 2024

Patent us-2024417408-a1

· 2024

Full title: us-2024417408-a1

Year: 2024

Patent us-2024398814-a1

· 2024

Full title: us-2024398814-a1

Year: 2024

Patent us-2025009748-a1

· 2025

Full title: us-2025009748-a1

Year: 2025

Patent us-2025009753-a1

· 2025

Full title: us-2025009753-a1

Year: 2025

Patent us-2025049810-a1

· 2025

Full title: us-2025049810-a1

Year: 2025

Patent us-2024423987-a1

· 2024

Full title: us-2024423987-a1

Year: 2024

Patent us-2025108055-a1

· 2025

Full title: us-2025108055-a1

Year: 2025

Patent us-2025019387-a1

· 2025

Full title: us-2025019387-a1

Year: 2025

Patent us-2025082648-a1

· 2025

Full title: us-2025082648-a1

Year: 2025

Patent us-2025032494-a1

· 2025

Full title: us-2025032494-a1

Year: 2025

Patent us-2025099461-a1

· 2025

Full title: us-2025099461-a1

Year: 2025

Patent us-2025109147-a1

· 2025

Full title: us-2025109147-a1

Year: 2025

Patent us-2025042922-a1

· 2025

Full title: us-2025042922-a1

Year: 2025

Patent us-2025057817-a1

· 2025

Full title: us-2025057817-a1

Year: 2025

Patent us-2025049792-a1

· 2025

Full title: us-2025049792-a1

Year: 2025

Patent us-2025136582-a1

· 2025

Full title: us-2025136582-a1

Year: 2025

Patent us-2025136609-a1

· 2025

Full title: us-2025136609-a1

Year: 2025

Patent us-2025122210-a1

· 2025

Full title: us-2025122210-a1

Year: 2025

Patent us-2025108050-a1

· 2025

Full title: us-2025108050-a1

Year: 2025

Patent us-2025101042-a1

· 2025

Full title: us-2025101042-a1

Year: 2025

Patent us-2025127782-a1

· 2025

Full title: us-2025127782-a1

Year: 2025

Patent us-2025059208-a1

· 2025

Full title: us-2025059208-a1

Year: 2025

Patent us-2025136615-a1

· 2025

Full title: us-2025136615-a1

Year: 2025

Patent us-2025051365-a1

· 2025

Full title: us-2025051365-a1

Year: 2025

Patent us-2025129103-a1

· 2025

Full title: us-2025129103-a1

Year: 2025

Patent us-2025136621-a1

· 2025

Full title: us-2025136621-a1

Year: 2025

Patent us-2025154156-a1

· 2025

Full title: us-2025154156-a1

Year: 2025

Patent us-2025145589-a1

· 2025

Full title: us-2025145589-a1

Year: 2025

Patent us-2025188162-a1

· 2025

Full title: us-2025188162-a1

Year: 2025

Patent us-2025177399-a1

· 2025

Full title: us-2025177399-a1

Year: 2025

Patent us-2025154133-a1

· 2025

Full title: us-2025154133-a1

Year: 2025

Patent us-2025179077-a1

· 2025

Full title: us-2025179077-a1

Year: 2025

Patent us-2025205238-a1

· 2025

Full title: us-2025205238-a1

Year: 2025

Patent us-2025213579-a1

· 2025

Full title: us-2025213579-a1

Year: 2025

Patent us-2025188085-a1

· 2025

Full title: us-2025188085-a1

Year: 2025

Patent us-2025215087-a1

· 2025

Full title: us-2025215087-a1

Year: 2025

Patent us-2025249019-a1

· 2025

Full title: us-2025249019-a1

Year: 2025

Patent us-2025250286-a1

· 2025

Full title: us-2025250286-a1

Year: 2025

Patent us-2025221989-a1

· 2025

Full title: us-2025221989-a1

Year: 2025

Patent us-2025228834-a1

· 2025

Full title: us-2025228834-a1

Year: 2025

Patent us-2025262211-a1

· 2025

Full title: us-2025262211-a1

Year: 2025

Patent us-2025206759-a1

· 2025

Full title: us-2025206759-a1

Year: 2025

Patent us-2025213563-a1

· 2025

Full title: us-2025213563-a1

Year: 2025

Patent us-2025270206-a1

· 2025

Full title: us-2025270206-a1

Year: 2025

Patent us-2025282799-a1

· 2025

Full title: us-2025282799-a1

Year: 2025

Patent us-2025262213-a1

· 2025

Full title: us-2025262213-a1

Year: 2025

Patent us-2025268900-a1

· 2025

Full title: us-2025268900-a1

Year: 2025

Patent us-2025276982-a1

· 2025

Full title: us-2025276982-a1

Year: 2025

Patent us-2025276968-a1

· 2025

Full title: us-2025276968-a1

Year: 2025

Patent us-2025312333-a1

· 2025

Full title: us-2025312333-a1

Year: 2025

Patent us-2025295665-a1

· 2025

Full title: us-2025295665-a1

Year: 2025

Patent us-2025295664-a1

· 2025

Full title: us-2025295664-a1

Year: 2025

Patent us-2025270225-a1

· 2025

Full title: us-2025270225-a1

Year: 2025

Patent us-2025312343-a1

· 2025

Full title: us-2025312343-a1

Year: 2025

Patent us-9029089-b2

· 2015

Full title: us-9029089-b2

Year: 2015

Patent us-2018118757-a1

· 2018

Full title: us-2018118757-a1

Year: 2018

Patent us-2017197945-a1

· 2017

Full title: us-2017197945-a1

Year: 2017

Patent us-2018015087-a1

· 2018

Full title: us-2018015087-a1

Year: 2018

Patent us-2018273523-a1

· 2018

Full title: us-2018273523-a1

Year: 2018

Patent us-2018086753-a1

· 2018

Full title: us-2018086753-a1

Year: 2018

Patent us-2018155348-a1

· 2018

Full title: us-2018155348-a1

Year: 2018

Patent us-2018273515-a1

· 2018

Full title: us-2018273515-a1

Year: 2018

Patent us-2018127396-a1

· 2018

Full title: us-2018127396-a1

Year: 2018

Patent us-2018141927-a1

· 2018

Full title: us-2018141927-a1

Year: 2018

Patent us-2018194748-a1

· 2018

Full title: us-2018194748-a1

Year: 2018

Patent us-2018319775-a1

· 2018

Full title: us-2018319775-a1

Year: 2018

Patent us-2019070191-a1

· 2019

Full title: us-2019070191-a1

Year: 2019

Patent us-2018334454-a1

· 2018

Full title: us-2018334454-a1

Year: 2018

Patent us-2018273577-a1

· 2018

Full title: us-2018273577-a1

Year: 2018

Patent us-2018153919-a1

· 2018

Full title: us-2018153919-a1

Year: 2018

Patent us-2019055211-a1

· 2019

Full title: us-2019055211-a1

Year: 2019

Patent us-2019092767-a1

· 2019

Full title: us-2019092767-a1

Year: 2019

Patent us-2019270743-a1

· 2019

Full title: us-2019270743-a1

Year: 2019

Patent us-2019262342-a1

· 2019

Full title: us-2019262342-a1

Year: 2019

Patent us-2019062314-a1

· 2019

Full title: us-2019062314-a1

Year: 2019

Patent us-2018282308-a1

· 2018

Full title: us-2018282308-a1

Year: 2018

Patent us-2019077801-a1

· 2019

Full title: us-2019077801-a1

Year: 2019

Patent us-2018282307-a1

· 2018

Full title: us-2018282307-a1

Year: 2018

Patent us-2019367489-a1

· 2019

Full title: us-2019367489-a1

Year: 2019

Patent us-2019160148-a1

· 2019

Full title: us-2019160148-a1

Year: 2019

Patent us-2019345158-a1

· 2019

Full title: us-2019345158-a1

Year: 2019

Patent us-2019062330-a1

· 2019

Full title: us-2019062330-a1

Year: 2019

Patent us-2019343838-a1

· 2019

Full title: us-2019343838-a1

Year: 2019

Patent us-2019284144-a1

· 2019

Full title: us-2019284144-a1

Year: 2019

Patent us-2019144444-a1

· 2019

Full title: us-2019144444-a1

Year: 2019

Patent us-2019389796-a1

· 2019

Full title: us-2019389796-a1

Year: 2019

Patent us-2019375749-a1

· 2019

Full title: us-2019375749-a1

Year: 2019

Patent us-2019345169-a1

· 2019

Full title: us-2019345169-a1

Year: 2019

Patent us-2020010454-a1

· 2020

Full title: us-2020010454-a1

Year: 2020

Patent us-2019367534-a1

· 2019

Full title: us-2019367534-a1

Year: 2019

Patent us-2019389851-a1

· 2019

Full title: us-2019389851-a1

Year: 2019

Patent us-2019336514-a1

· 2019

Full title: us-2019336514-a1

Year: 2019

Patent us-2020181123-a1

· 2020

Full title: us-2020181123-a1

Year: 2020

Patent us-2020033346-a1

· 2020

Full title: us-2020033346-a1

Year: 2020

Patent us-2020010904-a1

· 2020

Full title: us-2020010904-a1

Year: 2020

Patent us-2020115363-a1

· 2020

Full title: us-2020115363-a1

Year: 2020

Patent us-2020069657-a1

· 2020

Full title: us-2020069657-a1

Year: 2020

Patent us-2020207766-a1

· 2020

Full title: us-2020207766-a1

Year: 2020

Patent us-2019374542-a1

· 2019

Full title: us-2019374542-a1

Year: 2019

Patent us-2020055845-a1

· 2020

Full title: us-2020055845-a1

Year: 2020

Patent us-2020308170-a1

· 2020

Full title: us-2020308170-a1

Year: 2020

Patent us-2020165231-a1

· 2020

Full title: us-2020165231-a1

Year: 2020

Patent us-2020239479-a1

· 2020

Full title: us-2020239479-a1

Year: 2020

Patent us-2020253868-a1

· 2020

Full title: us-2020253868-a1

Year: 2020

Patent us-2020222407-a1

· 2020

Full title: us-2020222407-a1

Year: 2020

Patent us-2020237758-a1

· 2020

Full title: us-2020237758-a1

Year: 2020

Patent us-2020262837-a1

· 2020

Full title: us-2020262837-a1

Year: 2020

Patent us-2021009577-a1

· 2021

Full title: us-2021009577-a1

Year: 2021

Patent us-2020325234-a1

· 2020

Full title: us-2020325234-a1

Year: 2020

Patent us-2020339554-a1

· 2020

Full title: us-2020339554-a1

Year: 2020

Patent us-2020331911-a1

· 2020

Full title: us-2020331911-a1

Year: 2020

Patent us-2021024501-a1

· 2021

Full title: us-2021024501-a1

Year: 2021

Patent us-2021115063-a1

· 2021

Full title: us-2021115063-a1

Year: 2021

Patent us-2021230162-a1

· 2021

Full title: us-2021230162-a1

Year: 2021

Patent us-2021032293-a1

· 2021

Full title: us-2021032293-a1

Year: 2021

Patent us-2021085683-a1

· 2021

Full title: us-2021085683-a1

Year: 2021

Patent us-2021188869-a1

· 2021

Full title: us-2021188869-a1

Year: 2021

Patent us-2021177844-a1

· 2021

Full title: us-2021177844-a1

Year: 2021

Patent us-2021198255-a1

· 2021

Full title: us-2021198255-a1

Year: 2021

Patent us-2021269434-a1

· 2021

Full title: us-2021269434-a1

Year: 2021

Patent us-2021355125-a1

· 2021

Full title: us-2021355125-a1

Year: 2021

Patent us-2021269432-a1

· 2021

Full title: us-2021269432-a1

Year: 2021

Patent us-2021230170-a1

· 2021

Full title: us-2021230170-a1

Year: 2021

Patent us-2021355141-a1

· 2021

Full title: us-2021355141-a1

Year: 2021

Patent us-2021261532-a1

· 2021

Full title: us-2021261532-a1

Year: 2021

Patent us-2021355121-a1

· 2021

Full title: us-2021355121-a1

Year: 2021

Patent us-10125134-b2

· 2018

Full title: us-10125134-b2

Year: 2018

Patent us-10111874-b2

· 2018

Full title: us-10111874-b2

Year: 2018

Patent us-10246424-b2

· 2019

Full title: us-10246424-b2

Year: 2019

Patent us-10144724-b2

· 2018

Full title: us-10144724-b2

Year: 2018

Patent us-10273207-b2

· 2019

Full title: us-10273207-b2

Year: 2019

Patent us-10414757-b2

· 2019

Full title: us-10414757-b2

Year: 2019

Patent us-10633381-b2

· 2020

Full title: us-10633381-b2

Year: 2020

Patent us-10428064-b2

· 2019

Full title: us-10428064-b2

Year: 2019

Patent us-10519146-b2

· 2019

Full title: us-10519146-b2

Year: 2019

Patent us-10398696-b2

· 2019

Full title: us-10398696-b2

Year: 2019

Patent us-10351550-b2

· 2019

Full title: us-10351550-b2

Year: 2019

Patent us-10640504-b2

· 2020

Full title: us-10640504-b2

Year: 2020

Patent us-10689377-b2

· 2020

Full title: us-10689377-b2

Year: 2020

Patent us-10829458-b2

· 2020

Full title: us-10829458-b2

Year: 2020

Patent us-10646488-b2

· 2020

Full title: us-10646488-b2

Year: 2020

Patent us-10723738-b2

· 2020

Full title: us-10723738-b2

Year: 2020

Patent us-10441587-b2

· 2019

Full title: us-10441587-b2

Year: 2019

Patent us-10711014-b2

· 2020

Full title: us-10711014-b2

Year: 2020

Patent us-10875842-b2

· 2020

Full title: us-10875842-b2

Year: 2020

Patent us-10858343-b2

· 2020

Full title: us-10858343-b2

Year: 2020

Patent us-10882847-b2

· 2021

Full title: us-10882847-b2

Year: 2021

Patent us-10647715-b2

· 2020

Full title: us-10647715-b2

Year: 2020

Patent us-10689356-b2

· 2020

Full title: us-10689356-b2

Year: 2020

Patent us-10919850-b2

· 2021

Full title: us-10919850-b2

Year: 2021

Patent us-11045484-b2

· 2021

Full title: us-11045484-b2

Year: 2021

Patent us-10730867-b2

· 2020

Full title: us-10730867-b2

Year: 2020

Patent us-11053226-b2

· 2021

Full title: us-11053226-b2

Year: 2021

Patent us-11090304-b2

· 2021

Full title: us-11090304-b2

Year: 2021

Patent us-10975071-b2

· 2021

Full title: us-10975071-b2

Year: 2021

Patent us-11096939-b2

· 2021

Full title: us-11096939-b2

Year: 2021

Patent us-10888559-b2

· 2021

Full title: us-10888559-b2

Year: 2021

Patent us-10888568-b2

· 2021

Full title: us-10888568-b2

Year: 2021

Patent us-10982287-b2

· 2021

Full title: us-10982287-b2

Year: 2021

Patent us-11091481-b2

· 2021

Full title: us-11091481-b2

Year: 2021

Patent us-10988485-b2

· 2021

Full title: us-10988485-b2

Year: 2021

Patent us-11285156-b2

· 2022

Full title: us-11285156-b2

Year: 2022

Patent us-11155879-b2

· 2021

Full title: us-11155879-b2

Year: 2021

Patent us-11352370-b2

· 2022

Full title: us-11352370-b2

Year: 2022

Patent us-11285135-b2

· 2022

Full title: us-11285135-b2

Year: 2022

Patent us-11439645-b2

· 2022

Full title: us-11439645-b2

Year: 2022

Patent us-11306087-b2

· 2022

Full title: us-11306087-b2

Year: 2022

Patent us-11390626-b2

· 2022

Full title: us-11390626-b2

Year: 2022

Patent us-11267812-b2

· 2022

Full title: us-11267812-b2

Year: 2022

Patent us-11548888-b2

· 2023

Full title: us-11548888-b2

Year: 2023

Patent us-11274093-b2

· 2022

Full title: us-11274093-b2

Year: 2022

Patent us-11434231-b2

· 2022

Full title: us-11434231-b2

Year: 2022

Patent us-11739102-b2

· 2023

Full title: us-11739102-b2

Year: 2023

Patent us-2022040182-a1

· 2022

Full title: us-2022040182-a1

Year: 2022

Patent us-2021290633-a1

· 2021

Full title: us-2021290633-a1

Year: 2021

Patent us-2022002298-a1

· 2022

Full title: us-2022002298-a1

Year: 2022

Patent us-2022064188-a1

· 2022

Full title: us-2022064188-a1

Year: 2022

Patent us-2022054492-a1

· 2022

Full title: us-2022054492-a1

Year: 2022

Patent us-2021379007-a1

· 2021

Full title: us-2021379007-a1

Year: 2021

Patent us-2022079947-a1

· 2022

Full title: us-2022079947-a1

Year: 2022

Patent us-2022112205-a1

· 2022

Full title: us-2022112205-a1

Year: 2022

Patent us-2022040181-a1

· 2022

Full title: us-2022040181-a1

Year: 2022

Patent us-2022112178-a1

· 2022

Full title: us-2022112178-a1

Year: 2022

Patent us-2022064696-a1

· 2022

Full title: us-2022064696-a1

Year: 2022

Patent us-2022168280-a1

· 2022

Full title: us-2022168280-a1

Year: 2022

Patent us-2022054491-a1

· 2022

Full title: us-2022054491-a1

Year: 2022

Patent us-2022096482-a1

· 2022

Full title: us-2022096482-a1

Year: 2022

Patent us-2022170909-a1

· 2022

Full title: us-2022170909-a1

Year: 2022

Patent us-2021380570-a1

· 2021

Full title: us-2021380570-a1

Year: 2021

Patent us-2022112192-a1

· 2022

Full title: us-2022112192-a1

Year: 2022

Patent us-2022106309-a1

· 2022

Full title: us-2022106309-a1

Year: 2022

Patent us-2022152026-a1

· 2022

Full title: us-2022152026-a1

Year: 2022

Patent us-2022154189-a1

· 2022

Full title: us-2022154189-a1

Year: 2022

Patent us-2022152030-a1

· 2022

Full title: us-2022152030-a1

Year: 2022

Patent us-2022175782-a1

· 2022

Full title: us-2022175782-a1

Year: 2022

Patent us-2022177531-a1

· 2022

Full title: us-2022177531-a1

Year: 2022

Patent us-2022153741-a1

· 2022

Full title: us-2022153741-a1

Year: 2022

Patent us-2022184179-a1

· 2022

Full title: us-2022184179-a1

Year: 2022

Patent us-2022177603-a1

· 2022

Full title: us-2022177603-a1

Year: 2022

Patent us-2022227738-a1

· 2022

Full title: us-2022227738-a1

Year: 2022

Patent us-2022267857-a1

· 2022

Full title: us-2022267857-a1

Year: 2022

Patent us-2022257599-a1

· 2022

Full title: us-2022257599-a1

Year: 2022

Patent us-2022227883-a1

· 2022

Full title: us-2022227883-a1

Year: 2022

Patent us-2022213101-a1

· 2022

Full title: us-2022213101-a1

Year: 2022

Patent us-2022194961-a1

· 2022

Full title: us-2022194961-a1

Year: 2022

Patent us-2022273643-a1

· 2022

Full title: us-2022273643-a1

Year: 2022

Patent us-2022340641-a1

· 2022

Full title: us-2022340641-a1

Year: 2022

Patent us-2022323446-a1

· 2022

Full title: us-2022323446-a1

Year: 2022

Patent us-2022306633-a1

· 2022

Full title: us-2022306633-a1

Year: 2022

Patent us-2022306688-a1

· 2022

Full title: us-2022306688-a1

Year: 2022

Patent us-2022395504-a1

· 2022

Full title: us-2022395504-a1

Year: 2022

Patent us-2022323614-a1

· 2022

Full title: us-2022323614-a1

Year: 2022

Patent us-2022401436-a1

· 2022

Full title: us-2022401436-a1

Year: 2022

Patent us-2022331324-a1

· 2022

Full title: us-2022331324-a1

Year: 2022

Patent us-2022395507-a1

· 2022

Full title: us-2022395507-a1

Year: 2022

Patent us-2022389013-a1

· 2022

Full title: us-2022389013-a1

Year: 2022

Patent us-2022402971-a1

· 2022

Full title: us-2022402971-a1

Year: 2022

Patent us-2022389033-a1

· 2022

Full title: us-2022389033-a1

Year: 2022

Patent us-2023124492-a1

· 2023

Full title: us-2023124492-a1

Year: 2023

Patent us-2023023023-a1

· 2023

Full title: us-2023023023-a1

Year: 2023

Patent us-2023072276-a1

· 2023

Full title: us-2023072276-a1

Year: 2023

Patent us-2023000867-a1

· 2023

Full title: us-2023000867-a1

Year: 2023

Patent us-2023103007-a1

· 2023

Full title: us-2023103007-a1

Year: 2023

Patent us-2023077225-a1

· 2023

Full title: us-2023077225-a1

Year: 2023

Patent us-2023128824-a1

· 2023

Full title: us-2023128824-a1

Year: 2023

Patent us-2023061083-a1

· 2023

Full title: us-2023061083-a1

Year: 2023

Patent us-2023114765-a1

· 2023

Full title: us-2023114765-a1

Year: 2023

Patent us-2023099858-a1

· 2023

Full title: us-2023099858-a1

Year: 2023

Patent us-2023183235-a1

· 2023

Full title: us-2023183235-a1

Year: 2023

Patent us-2023099204-a1

· 2023

Full title: us-2023099204-a1

Year: 2023

Patent us-2023121955-a1

· 2023

Full title: us-2023121955-a1

Year: 2023

Patent us-2023233569-a1

· 2023

Full title: us-2023233569-a1

Year: 2023

Patent us-2023201198-a1

· 2023

Full title: us-2023201198-a1

Year: 2023

Patent us-2023192696-a1

· 2023

Full title: us-2023192696-a1

Year: 2023

Patent us-2023143938-a1

· 2023

Full title: us-2023143938-a1

Year: 2023

Patent us-2023226040-a1

· 2023

Full title: us-2023226040-a1

Year: 2023

Patent us-2023233567-a1

· 2023

Full title: us-2023233567-a1

Year: 2023

Patent us-2023203018-a1

· 2023

Full title: us-2023203018-a1

Year: 2023

Patent us-2023257374-a1

· 2023

Full title: us-2023257374-a1

Year: 2023

Patent us-2023339981-a1

· 2023

Full title: us-2023339981-a1

Year: 2023

Patent us-2023338384-a1

· 2023

Full title: us-2023338384-a1

Year: 2023

Patent us-2023285498-a1

· 2023

Full title: us-2023285498-a1

Year: 2023

Patent us-2023174555-a1

· 2023

Full title: us-2023174555-a1

Year: 2023

Patent us-2023233558-a1

· 2023

Full title: us-2023233558-a1

Year: 2023

Patent us-2023303586-a1

· 2023

Full title: us-2023303586-a1

Year: 2023

Patent us-11723891-b2

· 2023

Full title: us-11723891-b2

Year: 2023

Patent us-11766436-b2

· 2023

Full title: us-11766436-b2

Year: 2023

Patent us-11878985-b2

· 2024

Full title: us-11878985-b2

Year: 2024

Patent us-11767320-b2

· 2023

Full title: us-11767320-b2

Year: 2023

Patent us-11932633-b2

· 2024

Full title: us-11932633-b2

Year: 2024

Patent us-11918584-b2

· 2024

Full title: us-11918584-b2

Year: 2024

Patent us-11939328-b2

· 2024

Full title: us-11939328-b2

Year: 2024

Patent us-11697657-b2

· 2023

Full title: us-11697657-b2

Year: 2023

Patent us-11905281-b2

· 2024

Full title: us-11905281-b2

Year: 2024

Patent us-12016862-b2

· 2024

Full title: us-12016862-b2

Year: 2024

Patent us-11890285-b2

· 2024

Full title: us-11890285-b2

Year: 2024

Patent us-11999753-b2

· 2024

Full title: us-11999753-b2

Year: 2024

Patent us-12059421-b2

· 2024

Full title: us-12059421-b2

Year: 2024

Patent us-12049483-b2

· 2024

Full title: us-12049483-b2

Year: 2024

Patent us-11945803-b2

· 2024

Full title: us-11945803-b2

Year: 2024

Patent us-11993597-b2

· 2024

Full title: us-11993597-b2

Year: 2024

Patent us-12077539-b2

· 2024

Full title: us-12077539-b2

Year: 2024

Patent us-12083121-b2

· 2024

Full title: us-12083121-b2

Year: 2024

Patent us-12128048-b2

· 2024

Full title: us-12128048-b2

Year: 2024

Patent us-12121519-b2

· 2024

Full title: us-12121519-b2

Year: 2024

Patent us-11999752-b2

· 2024

Full title: us-11999752-b2

Year: 2024

Patent us-12168058-b2

· 2024

Full title: us-12168058-b2

Year: 2024

Patent us-12208099-b2

· 2025

Full title: us-12208099-b2

Year: 2025

Patent us-12110289-b2

· 2024

Full title: us-12110289-b2

Year: 2024

Patent us-12280055-b2

· 2025

Full title: us-12280055-b2

Year: 2025

Patent us-12291539-b2

· 2025

Full title: us-12291539-b2

Year: 2025

Patent us-12383503-b2

· 2025

Full title: us-12383503-b2

Year: 2025

Patent us-12280056-b2

· 2025

Full title: us-12280056-b2

Year: 2025

Patent us-12180220-b2

· 2024

Full title: us-12180220-b2

Year: 2024

Patent us-12409178-b2

· 2025

Full title: us-12409178-b2

Year: 2025

Patent us-12378243-b2

· 2025

Full title: us-12378243-b2

Year: 2025

Patent us-12377101-b2

· 2025

Full title: us-12377101-b2

Year: 2025

Patent us-12391692-b2

· 2025

Full title: us-12391692-b2

Year: 2025

Patent us-12441742-b2

· 2025

Full title: us-12441742-b2

Year: 2025

Patent us-12398154-b2

· 2025

Full title: us-12398154-b2

Year: 2025

Patent us-12440491-b2

· 2025

Full title: us-12440491-b2

Year: 2025

Patent us-12336995-b2

· 2025

Full title: us-12336995-b2

Year: 2025

Patent us-12421253-b2

· 2025

Full title: us-12421253-b2

Year: 2025

Patent us-2012004116-a1

· 2012

Full title: us-2012004116-a1

Year: 2012

Patent us-2011262920-a1

· 2011

Full title: us-2011262920-a1

Year: 2011

Patent us-2012064175-a1

· 2012

Full title: us-2012064175-a1

Year: 2012

Patent us-2011269640-a1

· 2011

Full title: us-2011269640-a1

Year: 2011

Patent us-2013252831-a1

· 2013

Full title: us-2013252831-a1

Year: 2013

Patent us-2014350022-a1

· 2014

Full title: us-2014350022-a1

Year: 2014

Patent us-2013029336-a1

· 2013

Full title: us-2013029336-a1

Year: 2013

Patent us-2015239900-a1

· 2015

Full title: us-2015239900-a1

Year: 2015

Patent us-2016022680-a1

· 2016

Full title: us-2016022680-a1

Year: 2016

Patent us-2016108019-a1

· 2016

Full title: us-2016108019-a1

Year: 2016

Patent us-2015238515-a1

· 2015

Full title: us-2015238515-a1

Year: 2015

Patent us-2015184250-a1

· 2015

Full title: us-2015184250-a1

Year: 2015

Patent us-2016143906-a1

· 2016

Full title: us-2016143906-a1

Year: 2016

Patent us-2016159738-a1

· 2016

Full title: us-2016159738-a1

Year: 2016

Patent us-2016297774-a1

· 2016

Full title: us-2016297774-a1

Year: 2016

Patent us-2016120876-a1

· 2016

Full title: us-2016120876-a1

Year: 2016

Patent us-2017022184-a1

· 2017

Full title: us-2017022184-a1

Year: 2017

Patent us-9862701-b2

· 2018

Full title: us-9862701-b2

Year: 2018

Patent us-9884047-b1

· 2018

Full title: us-9884047-b1

Year: 2018

Patent us-re50490-e

· 2025

Full title: us-re50490-e

Year: 2025

Patent us-re50527-e

· 2025

Full title: us-re50527-e

Year: 2025

Patent us-10053737-b2

· 2018

Full title: us-10053737-b2

Year: 2018

Patent us-10329627-b1

· 2019

Full title: us-10329627-b1

Year: 2019

Patent us-10556906-b2

· 2020

Full title: us-10556906-b2

Year: 2020

Patent us-10774082-b2

· 2020

Full title: us-10774082-b2

Year: 2020

Patent us-11007183-b2

· 2021

Full title: us-11007183-b2

Year: 2021

Patent us-11141418-b1

· 2021

Full title: us-11141418-b1

Year: 2021

Patent us-11186878-b2

· 2021

Full title: us-11186878-b2

Year: 2021

Patent us-11312724-b2

· 2022

Full title: us-11312724-b2

Year: 2022

Patent us-11510919-b2

· 2022

Full title: us-11510919-b2

Year: 2022

Patent us-11859252-b2

· 2024

Full title: us-11859252-b2

Year: 2024

Patent us-11865182-b2

· 2024

Full title: us-11865182-b2

Year: 2024

Patent us-11965162-b2

· 2024

Full title: us-11965162-b2

Year: 2024

Patent us-12122787-b2

· 2024

Full title: us-12122787-b2

Year: 2024

Patent us-12168006-b2

· 2024

Full title: us-12168006-b2

Year: 2024

Patent us-12251383-b2

· 2025

Full title: us-12251383-b2

Year: 2025

Patent us-12447152-b2

· 2025

Full title: us-12447152-b2

Year: 2025

Patent us-2009202989-a1

· 2009

Full title: us-2009202989-a1

Year: 2009

Patent us-2011081651-a1

· 2011

Full title: us-2011081651-a1

Year: 2011

Patent us-2011319415-a1

· 2011

Full title: us-2011319415-a1

Year: 2011

Patent us-2013102595-a1

· 2013

Full title: us-2013102595-a1

Year: 2013

Patent us-2013203788-a1

· 2013

Full title: us-2013203788-a1

Year: 2013

Patent us-2015197814-a1

· 2015

Full title: us-2015197814-a1

Year: 2015

Patent us-2016040252-a1

· 2016

Full title: us-2016040252-a1

Year: 2016

Patent us-2016228451-a1

· 2016

Full title: us-2016228451-a1

Year: 2016

Patent us-2016317517-a1

· 2016

Full title: us-2016317517-a1

Year: 2016

Patent us-2019117596-a1

· 2019

Full title: us-2019117596-a1

Year: 2019

Patent us-2019352723-a1

· 2019

Full title: us-2019352723-a1

Year: 2019

Patent us-2020078360-a1

· 2020

Full title: us-2020078360-a1

Year: 2020

Patent us-2020140437-a1

· 2020

Full title: us-2020140437-a1

Year: 2020

Patent us-2020190596-a1

· 2020

Full title: us-2020190596-a1

Year: 2020

Patent us-2020246338-a1

· 2020

Full title: us-2020246338-a1

Year: 2020

Patent us-2020276189-a1

· 2020

Full title: us-2020276189-a1

Year: 2020

Patent us-2020338205-a1

· 2020

Full title: us-2020338205-a1

Year: 2020

Patent us-2021040564-a1

· 2021

Full title: us-2021040564-a1

Year: 2021

Patent us-2021230174-a1

· 2021

Full title: us-2021230174-a1

Year: 2021

Patent us-2021324383-a1

· 2021

Full title: us-2021324383-a1

Year: 2021

Patent us-2021401845-a1

· 2021

Full title: us-2021401845-a1

Year: 2021

Patent us-2022213100-a1

· 2022

Full title: us-2022213100-a1

Year: 2022

Patent us-2022235356-a1

· 2022

Full title: us-2022235356-a1

Year: 2022

Patent us-2022389029-a1

· 2022

Full title: us-2022389029-a1

Year: 2022

Patent us-2022395508-a1

· 2022

Full title: us-2022395508-a1

Year: 2022

Patent us-2023011378-a1

· 2023

Full title: us-2023011378-a1

Year: 2023

Patent us-2023023009-a1

· 2023

Full title: us-2023023009-a1

Year: 2023

Patent us-2023026856-a1

· 2023

Full title: us-2023026856-a1

Year: 2023

Patent us-2023105745-a1

· 2023

Full title: us-2023105745-a1

Year: 2023

Patent us-2023118795-a1

· 2023

Full title: us-2023118795-a1

Year: 2023

Patent us-2023158019-a1

· 2023

Full title: us-2023158019-a1

Year: 2023

Patent us-2023174526-a1

· 2023

Full title: us-2023174526-a1

Year: 2023

Patent us-2023203060-a1

· 2023

Full title: us-2023203060-a1

Year: 2023

Patent us-2023212170-a1

· 2023

Full title: us-2023212170-a1

Year: 2023

Patent us-2023226061-a1

· 2023

Full title: us-2023226061-a1

Year: 2023

Patent us-2023227472-a1

· 2023

Full title: us-2023227472-a1

Year: 2023

Patent us-2023357231-a1

· 2023

Full title: us-2023357231-a1

Year: 2023

Patent us-2023365563-a1

· 2023

Full title: us-2023365563-a1

Year: 2023

Patent us-2023406849-a1

· 2023

Full title: us-2023406849-a1

Year: 2023

Patent us-2024174690-a1

· 2024

Full title: us-2024174690-a1

Year: 2024

Patent us-2024180912-a1

· 2024

Full title: us-2024180912-a1

Year: 2024

Patent us-2024200146-a1

· 2024

Full title: us-2024200146-a1

Year: 2024

Patent us-2024246968-a1

· 2024

Full title: us-2024246968-a1

Year: 2024

Patent us-2024252664-a1

· 2024

Full title: us-2024252664-a1

Year: 2024

Patent us-2024300942-a1

· 2024

Full title: us-2024300942-a1

Year: 2024

Patent us-2024325394-a1

· 2024

Full title: us-2024325394-a1

Year: 2024

Patent us-2024342285-a1

· 2024

Full title: us-2024342285-a1

Year: 2024

Patent us-2024376107-a1

· 2024

Full title: us-2024376107-a1

Year: 2024

Patent us-2024390379-a1

· 2024

Full title: us-2024390379-a1

Year: 2024

Patent us-2024409558-a1

· 2024

Full title: us-2024409558-a1

Year: 2024

Patent us-2025002504-a1

· 2025

Full title: us-2025002504-a1

Year: 2025

Patent us-2025019385-a1

· 2025

Full title: us-2025019385-a1

Year: 2025

Patent us-2025034169-a1

· 2025

Full title: us-2025034169-a1

Year: 2025

Patent us-2025051333-a1

· 2025

Full title: us-2025051333-a1

Year: 2025

Patent us-2025051361-a1

· 2025

Full title: us-2025051361-a1

Year: 2025

Patent us-2025064946-a1

· 2025

Full title: us-2025064946-a1

Year: 2025

Patent us-2025066386-a1

· 2025

Full title: us-2025066386-a1

Year: 2025

Patent us-2025122211-a1

· 2025

Full title: us-2025122211-a1

Year: 2025

Patent us-2025129096-a1

· 2025

Full title: us-2025129096-a1

Year: 2025

Patent us-2025161305-a1

· 2025

Full title: us-2025161305-a1

Year: 2025

Patent us-2025163064-a1

· 2025

Full title: us-2025163064-a1

Year: 2025

Patent us-2025255868-a1

· 2025

Full title: us-2025255868-a1

Year: 2025

Patent us-2025262194-a1

· 2025

Full title: us-2025262194-a1

Year: 2025

Patent us-2025313553-a1

· 2025

Full title: us-2025313553-a1

Year: 2025

Patent us-9861623-b1

· 2018

Full title: us-9861623-b1

Year: 2018

Metadata only

Paper Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Huang, Yan; Zhang, Li · 2023 · Cancer Innovation · DOI

Full title: Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Authors: Huang, Yan; Zhang, Li

Year: 2023

Venue: Cancer Innovation

DOI: https://doi.org/10.1002/cai2.56

Paper A protocol for systematic review and meta-analysis

Guojian He, Xiu-juan Zhang, Ting Yan, Jiayi Wang, Qi Li, PhDc Tianyu Liu, Youn-Poong Oh, PhDe · 2022

Full title: A protocol for systematic review and meta-analysis

Authors: Guojian He, Xiu-juan Zhang, Ting Yan, Jiayi Wang, Qi Li, PhDc Tianyu Liu, Youn-Poong Oh, PhDe

Year: 2022

Paper Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy

Martinov, Tijana; Greenberg, Philip D. · 2023 · Annual Review of Cancer Biology · DOI

Full title: Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy

Authors: Martinov, Tijana; Greenberg, Philip D.

Year: 2023

Venue: Annual Review of Cancer Biology

DOI: https://doi.org/10.1146/annurev-cancerbio-061521-082114

Paper Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab

Liu, Yufei; Zhang, Zhe; Rinsurongkawong, Waree et al. · 2022 · JAMA Network Open · DOI

Full title: Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab

Authors: Liu, Yufei; Zhang, Zhe; Rinsurongkawong, Waree; Gay, Carl M.; Le, Xiuning; Ning, Matthew S.; Lewis, Jeff; Rinsurongkawong, Vadeerat; Lee, J. Jack; Roth, Jack A.; Swisher, Stephen G.; Gandhi, Saumil; Lee, Percy P.; Gibbons, Don L.; Vaporciyan, Ara A.; Heymach, John V.; Zhang, Jianjun; Lin, Steven H.

Year: 2022

Venue: JAMA Network Open

DOI: https://doi.org/10.1001/jamanetworkopen.2022.15589

Paper KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

Paniagua, Guillem; Jacob, Harrys K.C.; Brehey, Oksana et al. · 2022 · Molecular Oncology · DOI

Full title: KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

Authors: Paniagua, Guillem; Jacob, Harrys K.C.; Brehey, Oksana; García‐Alonso, Sara; Lechuga, Carmen G.; Pons, Tirso; Musteanu, Mónica; Guerra, Carmen; Drosten, Matthias; Barbacid, Mariano

Year: 2022

Venue: Molecular Oncology

DOI: https://doi.org/10.1002/1878-0261.13213

Paper KRAS inhibitors: going noncovalent

Drosten, Matthias; Barbacid, Mariano · 2022 · Molecular Oncology · DOI

Full title: KRAS inhibitors: going noncovalent

Authors: Drosten, Matthias; Barbacid, Mariano

Year: 2022

Venue: Molecular Oncology

DOI: https://doi.org/10.1002/1878-0261.13341

Paper Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node

Scardaci, Rossella; Berlinska, Ewa; Scaparone, Pietro et al. · 2024 · Molecular Oncology · DOI

Full title: Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node

Authors: Scardaci, Rossella; Berlinska, Ewa; Scaparone, Pietro; Michelina, Sandra Vietti; Garbo, Edoardo; Novello, Silvia; Santamarı́a, David; Ambrogio, Chiara

Year: 2024

Venue: Molecular Oncology

DOI: https://doi.org/10.1002/1878-0261.13605

Paper Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling

Baoyuan Zhang; Yan Zhang; Jiangwei Zhang et al. · 2021 · Advancement of science · DOI

Full title: Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling

Authors: Baoyuan Zhang; Yan Zhang; Jiangwei Zhang; Ping Liu; B. Jiao; Zaiqi Wang; R. Ren

Year: 2021

Venue: Advancement of science

DOI: https://doi.org/10.1002/advs.202100250

Paper Targeting the Small GTPase Superfamily through Their Regulatory Proteins

Gray, Janine L.; Delft, F. von; Brennan, Paul E. · 2019 · Angewandte Chemie International Edition · DOI

Full title: Targeting the Small GTPase Superfamily through Their Regulatory Proteins

Authors: Gray, Janine L.; Delft, F. von; Brennan, Paul E.

Year: 2019

Venue: Angewandte Chemie International Edition

DOI: https://doi.org/10.1002/anie.201900585

Paper Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy

Yawen Zheng; Qinghua Lai; Han-xi Zhao et al. · 2021 · Cancer Communications · DOI

Full title: Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy

Authors: Yawen Zheng; Qinghua Lai; Han-xi Zhao; Xiaoling Li; Xiaorong Sun; L. Xing

Year: 2021

Venue: Cancer Communications

DOI: https://doi.org/10.1002/cac2.12227

Paper KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

Chengming Liu; Sufei Zheng; Zhanyu Wang et al. · 2022 · Cancer Communications · DOI

Full title: KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

Authors: Chengming Liu; Sufei Zheng; Zhanyu Wang; Sihui Wang; Xinfeng Wang; Lu Yang; Haiyan Xu; Z. Cao; Xiaoli Feng; Q. Xue; Yan Wang; N. Sun; Jie He

Year: 2022

Venue: Cancer Communications

DOI: https://doi.org/10.1002/cac2.12327

Paper Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Jian Li; Ting Deng; Yanhong Gu et al. · 2025 · Cancer Communications · DOI

Full title: Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Authors: Jian Li; Ting Deng; Yanhong Gu; A. C. Blanco; Zhihua Li; C. Bai; Lin Wu; Jingjing Huang; Xingya Li; Yu Yao; Zhengbo Song; Yongsheng Li; Lian Liu; Ligang Xing; Wenming Wu; Julia Martínez-Pérez; A. Hubert; J. Zugazagoitia; Jian Zhang; Yongsheng Wang; Yanqiu Zhao; Guilan Wen; Guohao Xia; Diansheng Zhong; Xueqin Chen; K. Jiang; A. Wang-Gillam; Yuli Ding; Sumei Liu; Z. Rao; Xinghu Liu; L. Shen

Year: 2025

Venue: Cancer Communications

DOI: https://doi.org/10.1002/cac2.70056

Paper Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective

Misra, Pragya; Singh, Shailza · 2019 · Cancer Medicine · DOI

Full title: Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective

Authors: Misra, Pragya; Singh, Shailza

Year: 2019

Venue: Cancer Medicine

DOI: https://doi.org/10.1002/cam4.2112

Paper Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Nogová, Lucia; Mattonet, Christian; Scheffler, Matthias et al. · 2020 · Cancer Medicine · DOI

Full title: Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Authors: Nogová, Lucia; Mattonet, Christian; Scheffler, Matthias; Taubert, Max; Gardizi, Masyar; Sos, Martin L.; Michels, Sebastian; Fischer, Rieke; Limburg, Meike; Abdulla, Diana S.Y.; Persigehl, Thorsten; Kobe, Carsten; Merkelbach‐Bruse, Sabine; Franklin, Jeremy; Backes, Heiko; Schnell, Roland; Behringer, Dirk; Kaminsky, Britta; Eichstaedt, Martina; Stelzer, Christoph; Kinzig, Martina; Sörgel, Fritz; Tian, Yingying; Junge, Lisa; Suleiman, Ahmed A.; Frechen, Sebastian; Rokitta, Dennis; Ouyang, Dongsheng; Fuhr, Uwe; Buettner, Reinhard; Wolf, Jürgen

Year: 2020

Venue: Cancer Medicine

DOI: https://doi.org/10.1002/cam4.3131

Paper Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study

Shirota, Hidekazu; Komine, Keigo; Takahashi, Masanobu et al. · 2022 · Cancer Medicine · DOI

Full title: Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study

Authors: Shirota, Hidekazu; Komine, Keigo; Takahashi, Masanobu; Takahashi, Shin; Miyauchi, Eisaku; Niizuma, Hidetaka; Tada, Hiroshi; Shimada, Muneaki; Niihori, Tetsuya; Aoki, Yoko; Sugiyama, Ikuko; Kawamura, Maako; Yasuda, Jun; Suzuki, Shuhei; Iwaya, Takeshi; Saito, Motonobu; Saito, Tsuyoshi; Shibata, Hiroyuki; Furukawa, Toru; Ishioka, Chikashi

Year: 2022

Venue: Cancer Medicine

DOI: https://doi.org/10.1002/cam4.5349

Paper Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients

Liu, Feiwen; Wang, Fang; He, Jianbo et al. · 2023 · Cancer Medicine · DOI

Full title: Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients

Authors: Liu, Feiwen; Wang, Fang; He, Jianbo; Zhou, Shaozhang; Luo, Min

Year: 2023

Venue: Cancer Medicine

DOI: https://doi.org/10.1002/cam4.5995

Paper Targeted single‐cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis‐resistant state in hematologic malignancies

Xiaohui Shen; Peiyuan Dong; Jingjing Kong et al. · 2023 · Cell Biochemistry and Function · DOI

Full title: Targeted single‐cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis‐resistant state in hematologic malignancies

Authors: Xiaohui Shen; Peiyuan Dong; Jingjing Kong; Nannan Sun; Fang Wang; Lina Sang; Yan Xu; Mengmeng Zhang; Xiaoli Chen; Rongqun Guo; Shuya Wang; Quande Lin; Zhongxing Jiang; Shan Xu; Congli Zhang; Zhilei Bian; Weimin Wang; Rongqun Guo

Year: 2023

Venue: Cell Biochemistry and Function

DOI: https://doi.org/10.1002/cbf.3869

Paper Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief report

Jiao, Yang; Huang, Jie; Yuan, Gongjun et al. · 2024 · Clinical Case Reports · DOI

Full title: Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief report

Authors: Jiao, Yang; Huang, Jie; Yuan, Gongjun; Lin, Xiao‐Cheng; Chen, Hua‐Jun; Yang, Jin‐Ji; Yang, Jin‐Ji; Yang, Jin‐Ji

Year: 2024

Venue: Clinical Case Reports

DOI: https://doi.org/10.1002/ccr3.8866

Paper Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma‐first” approach?

M. Makarem; N. Leighl · 2020 · Cancer · DOI

Full title: Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma‐first” approach?

Authors: M. Makarem; N. Leighl

Year: 2020

Venue: Cancer

DOI: https://doi.org/10.1002/cncr.32875

Paper Advances in the treatment of KRAS G12C mutant non–small cell lung cancer

Khvaramze Shaverdashvili; Timothy F. Burns · 2025 · Cancer · DOI

Full title: Advances in the treatment of KRAS G12C mutant non–small cell lung cancer

Authors: Khvaramze Shaverdashvili; Timothy F. Burns

Year: 2025

Venue: Cancer

DOI: https://doi.org/10.1002/cncr.35783

Paper Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer

F. Passiglia; F. Pepe; G. Russo et al. · 2025 · Cancer · DOI

Full title: Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer

Authors: F. Passiglia; F. Pepe; G. Russo; E. Garbo; A. Listì; F. Benso; C. Scimone; Lucia Palumbo; M. Pluchino; R. Minari; P. Bordi; Massimiliano Cani; Antonio Ungaro; Chiara Ambrogio; Riccardo Taulli; E. Capelletto; Maurizio Balbi; Luisella Righi; Marcello Tiseo; D. Giannarelli; G. Troncone; S. Novello; U. Malapelle

Year: 2025

Venue: Cancer

DOI: https://doi.org/10.1002/cncr.35917

Paper Persistent lineage plasticity driving lung cancer development and progression

Fanchen Meng; Jianyu Li; Zhijun Xia et al. · 2025 · Clinical and Translational Medicine · DOI

Full title: Persistent lineage plasticity driving lung cancer development and progression

Authors: Fanchen Meng; Jianyu Li; Zhijun Xia; Qinglin Wang; Qinhong Sun; Siwei Wang; Lin Xu; Rong Yin

Year: 2025

Venue: Clinical and Translational Medicine

DOI: https://doi.org/10.1002/ctm2.70458

Paper Drugging “undruggable” genes for cancer treatment: Are we making progress?

Duffy, Michael J.; Crown, John · 2020 · International Journal of Cancer · DOI

Full title: Drugging “undruggable” genes for cancer treatment: Are we making progress?

Authors: Duffy, Michael J.; Crown, John

Year: 2020

Venue: International Journal of Cancer

DOI: https://doi.org/10.1002/ijc.33197

Paper Fast proliferating and slowly migrating non‐small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment

Giulia Pelos; M. Riester; Jagriti Pal et al. · 2023 · International Journal of Cancer · DOI

Full title: Fast proliferating and slowly migrating non‐small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment

Authors: Giulia Pelos; M. Riester; Jagriti Pal; Ksenia Myacheva; Isabelle Moneke; J. Rotondo; Michael Lübbert; S. Diederichs

Year: 2023

Venue: International Journal of Cancer

DOI: https://doi.org/10.1002/ijc.34783

Paper Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Jing Yang; Qing Qiao; N. Lin et al. · 2025 · Journal of biochemical and molecular toxicology · DOI

Full title: Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Authors: Jing Yang; Qing Qiao; N. Lin; Miaomiao Niu; Lin Su; Boshu Yin

Year: 2025

Venue: Journal of biochemical and molecular toxicology

DOI: https://doi.org/10.1002/jbt.70427

Paper Ultrasensitive DNA Origami Plasmon Sensor for Accurate Detection in Circulating Tumor DNAs

Chen, Zhi; Meng, Changle; Wang, Xueliang et al. · 2024 · Laser & Photonics Review · DOI

Full title: Ultrasensitive DNA Origami Plasmon Sensor for Accurate Detection in Circulating Tumor DNAs

Authors: Chen, Zhi; Meng, Changle; Wang, Xueliang; Chen, Jiajie; Deng, Jiefeng; Fan, Taojian; Wang, Lude; Lin, Huiling; Huang, Hao; Li, Shuang; Sun, Shuo; Qu, Junle; Fan, Dianyuan; Zhang, Xueji; Liu, Yingxia; Shao, Yonghong; Zhang, Han

Year: 2024

Venue: Laser & Photonics Review

DOI: https://doi.org/10.1002/lpor.202400035

Paper Translational relevance of SOS1 targeting for KRAS‐mutant colorectal cancer

Diego Alem; Xinrui Yang; F. Beato et al. · 2023 · Molecular Carcinogenesis · DOI

Full title: Translational relevance of SOS1 targeting for KRAS‐mutant colorectal cancer

Authors: Diego Alem; Xinrui Yang; F. Beato; Bhaswati Sarcar; Alexandra F Tassielli; Ruifan Dai; Tara L Hogenson; Margaret A. Park; Kun Jiang; Jianfeng Cai; Yu Yuan; M. Fernandez-Zapico; A. Tan; J. Fleming; Hao Xie

Year: 2023

Venue: Molecular Carcinogenesis

DOI: https://doi.org/10.1002/mc.23543

Paper Differential Response and Resistance to KRAS-Targeted Therapy.

Liu, Zhaojin; Lenz, Heinz-Josef; Yu, Jian et al. · 2025 · Molecular carcinogenesis · DOI

Full title: Differential Response and Resistance to KRAS-Targeted Therapy.

Authors: Liu, Zhaojin; Lenz, Heinz-Josef; Yu, Jian; Zhang, Lin

Year: 2025

Venue: Molecular carcinogenesis

DOI: https://doi.org/10.1002/mc.23908

Paper Adagrasib: A landmark in the KRAS G12C ‐mutated NSCLC

Tian, He; Yang, Zhenlin; He, Jie · 2022 · MedComm · DOI

Full title: Adagrasib: A landmark in the KRAS G12C ‐mutated NSCLC

Authors: Tian, He; Yang, Zhenlin; He, Jie

Year: 2022

Venue: MedComm

DOI: https://doi.org/10.1002/mco2.190

Paper Understanding and targeting resistance mechanisms in cancer

Lei, Zi‐Ning; Qin, Tian; Teng, Qiu‐Xu et al. · 2023 · MedComm · DOI

Full title: Understanding and targeting resistance mechanisms in cancer

Authors: Lei, Zi‐Ning; Qin, Tian; Teng, Qiu‐Xu; Wurpel, John N.D.; Zeng, Leli; Pan, Yihang; Chen, Zhe‐Sheng

Year: 2023

Venue: MedComm

DOI: https://doi.org/10.1002/mco2.265

Paper RAS‐targeted cancer therapy: Advances in drugging specific mutations

Liu, Cen; Ye, Danyang; Yang, Hongliu et al. · 2023 · MedComm · DOI

Full title: RAS‐targeted cancer therapy: Advances in drugging specific mutations

Authors: Liu, Cen; Ye, Danyang; Yang, Hongliu; Chen, Xu; Su, Zhijun; Li, Xia; Ding, Mei; Liu, Yonggang

Year: 2023

Venue: MedComm

DOI: https://doi.org/10.1002/mco2.285

Paper Epigenetic regulation in lung cancer

Ramazi, Shahin; Dadzadi, Maedeh; Sahafnejad, Zahra et al. · 2023 · MedComm · DOI

Full title: Epigenetic regulation in lung cancer

Authors: Ramazi, Shahin; Dadzadi, Maedeh; Sahafnejad, Zahra; Allahverdi, Abdollah

Year: 2023

Venue: MedComm

DOI: https://doi.org/10.1002/mco2.401

Paper 2020 Innovation-Based Optimism for Lung Cancer Outcomes

Schenk, Erin L.; Patil, Tejas; Pacheco, Jose M. et al. · 2020 · The Oncologist · DOI

Full title: 2020 Innovation-Based Optimism for Lung Cancer Outcomes

Authors: Schenk, Erin L.; Patil, Tejas; Pacheco, Jose M.; Bunn, Paul A.

Year: 2020

Venue: The Oncologist

DOI: https://doi.org/10.1002/onco.13590

Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

Brummelen, Emilie M.J. van; Huijberts, Sanne C.F.A.; Herpen, Carla M.L. van et al. · 2020 · The Oncologist · DOI

Full title: Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

Authors: Brummelen, Emilie M.J. van; Huijberts, Sanne C.F.A.; Herpen, Carla M.L. van; Desar, Ingrid M.E.; Opdam, Frans L.; Geel, Robin M.J.M. van; Marchetti, Serena; Steeghs, Neeltje; Monkhorst, Kim; Thijssen, Bas; Rosing, Hilde; Huitema, Alwin D. R.; Beijnen, Jos H.; Bernards, René; Schellens, Jan H.M.

Year: 2020

Venue: The Oncologist

DOI: https://doi.org/10.1002/onco.13631

Paper A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer

Heppner, David E.; Eck, Michael J. · 2021 · Protein Science · DOI

Full title: A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer

Authors: Heppner, David E.; Eck, Michael J.

Year: 2021

Venue: Protein Science

DOI: https://doi.org/10.1002/pro.4125

Paper Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors

E. Stites; A. Shaw · 2017 · bioRxiv · DOI

Full title: Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors

Authors: E. Stites; A. Shaw

Year: 2017

Venue: bioRxiv

DOI: https://doi.org/10.1002/psp4.12291

Paper Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer

Sayama, Hiroyuki; Marcantonio, Diana H.; Nagashima, Takeyuki et al. · 2021 · CPT Pharmacometrics & Systems Pharmacology · DOI

Full title: Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer

Authors: Sayama, Hiroyuki; Marcantonio, Diana H.; Nagashima, Takeyuki; Shimazaki, Masashi; Minematsu, Tsuyoshi; Apgar, Joshua F.; Burke, John M.; Wille, Lucia; Nagasaka, Yasuhisa; Kirouac, Daniel C.

Year: 2021

Venue: CPT Pharmacometrics & Systems Pharmacology

DOI: https://doi.org/10.1002/psp4.12661

Paper Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.

F. Facchinetti; C. Proto; R. Minari et al. · 2018 · Handbook of Experimental Pharmacology · DOI

Full title: Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.

Authors: F. Facchinetti; C. Proto; R. Minari; M. Garassino; M. Tiseo

Year: 2018

Venue: Handbook of Experimental Pharmacology

DOI: https://doi.org/10.1007/164_2017_16

Paper Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.

Landre, Thierry; Justeau, Gregoire; Assié, Jean-Baptiste et al. · 2022 · Cancer immunology, immunotherapy : CII · DOI

Full title: Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.

Authors: Landre, Thierry; Justeau, Gregoire; Assié, Jean-Baptiste; Chouahnia, Kader; Davoine, Claire; Taleb, Chérifa; Chouaïd, Christos; Duchemann, Boris

Year: 2022

Venue: Cancer immunology, immunotherapy : CII

DOI: https://doi.org/10.1007/s00262-021-03031-1

Paper Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Hofman, Paul; Berezowska, Sabina; Kazdal, Daniel et al. · 2023 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · DOI

Full title: Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Authors: Hofman, Paul; Berezowska, Sabina; Kazdal, Daniel; Mograbi, Baharia; Ilié, Marius; Stenzinger, Albrecht; Hofman, Véronique

Year: 2023

Venue: Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin

DOI: https://doi.org/10.1007/s00428-023-03651-1

Paper Targeting KRAS in pancreatic cancer: new drugs on the horizon

Sahar F. Bannoura; Md. Hafiz Uddin; M. Nagasaka et al. · 2021 · Cancer Metastasis Review · DOI

Full title: Targeting KRAS in pancreatic cancer: new drugs on the horizon

Authors: Sahar F. Bannoura; Md. Hafiz Uddin; M. Nagasaka; Farzeen Fazili; M. Al-Hallak; P. Philip; B. El-Rayes; A. Azmi

Year: 2021

Venue: Cancer Metastasis Review

DOI: https://doi.org/10.1007/s10555-021-09990-2

Paper Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.

M. Bungaro; S. Novello; F. Passiglia · 2022 · Current Treatment Options in Oncology · DOI

Full title: Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.

Authors: M. Bungaro; S. Novello; F. Passiglia

Year: 2022

Venue: Current Treatment Options in Oncology

DOI: https://doi.org/10.1007/s11864-022-01033-4

Paper Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.

Di Federico, Alessandro; Ricciotti, Ilaria; Favorito, Valentina et al. · 2023 · Current oncology reports · DOI

Full title: Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.

Authors: Di Federico, Alessandro; Ricciotti, Ilaria; Favorito, Valentina; Michelina, Sandra Vietti; Scaparone, Pietro; Metro, Giulio; De Giglio, Andrea; Pecci, Federica; Lamberti, Giuseppe; Ambrogio, Chiara; Ricciuti, Biagio

Year: 2023

Venue: Current oncology reports

DOI: https://doi.org/10.1007/s11912-023-01436-y

Paper An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health

Subhrojyoti Ghosh; Tiyasa Bhuniya; Anuvab Dey et al. · 2023 · Applied Biochemistry and Biotechnology · DOI

Full title: An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health

Authors: Subhrojyoti Ghosh; Tiyasa Bhuniya; Anuvab Dey; Madhurima Koley; Preeti Roy; Aishi Bera; Debarshi Gol; Ankita Chowdhury; Rajanyaa Chowdhury; Shinjini Sen

Year: 2023

Venue: Applied Biochemistry and Biotechnology

DOI: https://doi.org/10.1007/s12010-023-04748-8

Paper Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment

Ke Wang; Manyi Xu; Yanhua Wang et al. · 2024 · Clinical and Translational Oncology · DOI

Full title: Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment

Authors: Ke Wang; Manyi Xu; Yanhua Wang; Chunwei Xu; Yue Hao; Zhengbo Song

Year: 2024

Venue: Clinical and Translational Oncology

DOI: https://doi.org/10.1007/s12094-024-03485-6

Paper Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.

Torres-Jiménez, Javier; Espinar, Javier Baena; de Cabo, Helena Bote et al. · 2024 · Drugs · DOI

Full title: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.

Authors: Torres-Jiménez, Javier; Espinar, Javier Baena; de Cabo, Helena Bote; Berjaga, María Zurera; Esteban-Villarrubia, Jorge; Fraile, Jon Zugazagoitia; Paz-Ares, Luis

Year: 2024

Venue: Drugs

DOI: https://doi.org/10.1007/s40265-024-02030-7

Paper Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

Khan, Sajid; Budamagunta, Vivekananda; Zhou, Daohong · 2023 · Advances in cancer research · DOI

Full title: Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

Authors: Khan, Sajid; Budamagunta, Vivekananda; Zhou, Daohong

Year: 2023

Venue: Advances in cancer research

DOI: https://doi.org/10.1016/bs.acr.2023.02.004

Paper Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance.

H. Ellis; Chiara Braconi; Juan W. Valle et al. · 2024 · American Journal of Pathology · DOI

Full title: Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance.

Authors: H. Ellis; Chiara Braconi; Juan W. Valle; N. Bardeesy

Year: 2024

Venue: American Journal of Pathology

DOI: https://doi.org/10.1016/j.ajpath.2024.11.005

Paper The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Saturno, G.; Lopes, Filipa M.; Niculescu‐Duvaz, Ion et al. · 2020 · Annals of Oncology · DOI

Full title: The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Authors: Saturno, G.; Lopes, Filipa M.; Niculescu‐Duvaz, Ion; Niculescu‐Duvaz, Dan; Zambon, Alfonso; Davies, Lawrence; Johnson, L.; Preece, Natasha; Lee, Rebecca; Virós, Amaya; Holovanchuk, Denys; Pedersen, Malin; McLeary, Robert; Lorigan, Paul; Dhomen, Nathalie; Fisher, Cyril; Banerji, Udai; Dean, E.; Krebs, Matthew; Gore, Martin; Larkin, James; Marais, Richard; Springer, Caroline J.

Year: 2020

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2020.10.483

Paper Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.

M. Reck; D. Carbone; M. Garassino et al. · 2021 · Annals of Oncology · DOI

Full title: Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.

Authors: M. Reck; D. Carbone; M. Garassino; F. Barlesi

Year: 2021

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2021.06.001

Paper 1116P United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review

Julve, M.; Kennedy, O.; Lindsay, Colin R. et al. · 2022 · Annals of Oncology · DOI

Full title: 1116P United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review

Authors: Julve, M.; Kennedy, O.; Lindsay, Colin R.; Walters-Davies, Rhiannon; Button, M.; Steele, Nicola; McGeogh, Adam; Georgiou, A.; Goranov, Bojidar; Farrugia, David; Gorf, L.; Remer, Marcus; Shah, R.; Baijal, Shobhit; Gennatas, S.; Geldart, T.; Daniels, E.; Watts, L.; Greystoke, Alastair; Newsom‐Davis, Tom

Year: 2022

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2022.07.1241

Paper 459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

Patel, Manish R.; Lee, JS; Miguel, Maria J. de et al. · 2022 · Annals of Oncology · DOI

Full title: 459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

Authors: Patel, Manish R.; Lee, JS; Miguel, Maria J. de; Burns, Timothy F.; Falcón, Alejandro; Kim, T.W.; Krebs, Matthew; Prenen, Hans; Shmueli, Einat; Desai, Jayesh; LoRusso, Patricia; Sacher, Adrian G.; Choi, Yoonha; Dharia, N.; Lin, M.T.; Mandlekar, S.; Royer-Joo, S.; Schutzman, J.L.; Garralda, Elena

Year: 2022

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2022.07.588

Paper Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Hendriks, Lizza; Kerr, Keith M.; Menis, Jessica et al. · 2023 · Annals of Oncology · DOI

Full title: Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Authors: Hendriks, Lizza; Kerr, Keith M.; Menis, Jessica; Mok, Tony; Nestle, Ursula; Passaro, Antonio; Peters, Solange; Planchard, David; Smit, Egbert F.; Solomon, Benjamin; Veronesi, Giulia; Reck, Martin

Year: 2023

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2022.12.009

Paper Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

Boiarsky, Daniel; Lydon, Christine; Chambers, Emily S. et al. · 2023 · Annals of Oncology · DOI

Full title: Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

Authors: Boiarsky, Daniel; Lydon, Christine; Chambers, Emily S.; Sholl, Lynette M.; Nishino, Mizuki; Skoulidis, Ferdinandos; Heymach, John V.; Luo, Junhang; Awad, Mark M.; Jänne, Pasi A.; Allen, Eliezer M. Van; Barbie, David A.; Vokes, Natalie I.

Year: 2023

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2023.04.514

Paper 653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors

Wang, Juan; Zhao, Jun; Zhong, Jia et al. · 2023 · Annals of Oncology · DOI

Full title: 653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors

Authors: Wang, Juan; Zhao, Jun; Zhong, Jia; Li, Xingang; Fang, Jian; Yu, Yan; Li, X.; Fang, Xinyi; Chang, J.; Liu, Zhonghua; Zhao, Yajie; Song, Qibin; Bai, Chunmei; Wang-Gillam, A.; Ding, Yi; Rao, Zihe; Bi, Changlong

Year: 2023

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2023.09.1839

Paper 663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

C. Rojas; I. Lugowska; R. Juergens et al. · 2023 · Annals of Oncology · DOI

Full title: 663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

Authors: C. Rojas; I. Lugowska; R. Juergens; A. Sacher; S. Weindler; M. Şendur; R. Dziadziuszko; A. Pal; E. Castanon Alvarez; E.S. Ahern; N. Lakhani; L-C. Chen; T. Jemielita; Y. Choi; A. Stathis

Year: 2023

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2023.09.1849

Paper 665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

Heymach, John V.; Kotecki, Nuria; Prenen, Hans et al. · 2023 · Annals of Oncology · DOI

Full title: 665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

Authors: Heymach, John V.; Kotecki, Nuria; Prenen, Hans; Alonso, Guzmán; Lindsay, Colin R.; Barve, Minal; Thamer, Claus; Eigenbrod-Giese, Sabina; Marotti, Marcelo; Lancker, Griet Van

Year: 2023

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2023.09.1851

Paper 1409P DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)

Li, H-S.; Xu, Hongbo; Duan, Jianchun et al. · 2023 · Annals of Oncology · DOI

Full title: 1409P DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)

Authors: Li, H-S.; Xu, Hongbo; Duan, Jianchun; Wang, Zhiqiang; Zhong, Jim; Cui, Y-Y.; Fang, Qiang; Lei, S-Y.; Wang, Yuan

Year: 2023

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2023.09.2441

Paper LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Garassino, Marina Chiara; Theelen, Willemijn S.M.E.; Jotte, Robert M. et al. · 2023 · Annals of Oncology · DOI

Full title: LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Authors: Garassino, Marina Chiara; Theelen, Willemijn S.M.E.; Jotte, Robert M.; Laskin, Janessa; Marinis, Filippo de; Aguado, Carlos; Badin, Firas; Chmielewska, Izabela; Hochmair, Maximilian J.; Lu, Shun; Nadal, Ernest; Ostoros, Gyula; Felip, Enriqueta; Spira, Alexander I.; Lane, Conor M.; He, Jinghua; Chao, Richard C.; Jänne, Pasi A.

Year: 2023

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2023.10.066

Paper Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.

Riedl, J M; Fece de la Cruz, F; Lin, J J et al. · 2025 · Annals of oncology : official journal of the European Society for Medical Oncology · DOI

Full title: Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.

Authors: Riedl, J M; Fece de la Cruz, F; Lin, J J; Parseghian, C; Kim, J E; Matsubara, H; Barnes, H; Caughey, B; Norden, B L; Morales-Giron, A A; Kushner, E W; Ehnstrom, S; Nakamura, H; Patel, P S; Ellis, H; Pappas, L; Vakaris, A; Gainor, J F; Kopetz, S; Klempner, S J; Parikh, A R; Hata, A N; Heist, R S; Corcoran, R B

Year: 2025

Venue: Annals of oncology : official journal of the European Society for Medical Oncology

DOI: https://doi.org/10.1016/j.annonc.2025.01.020

Paper 1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases

P. Cassier; J. Schneider; A. Italiano et al. · 2025 · Annals of Oncology · DOI

Full title: 1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases

Authors: P. Cassier; J. Schneider; A. Italiano; A. Hollebecque; R. Heist; T. Shimizu; S. Kim; A. Spira; R. Cosman; G. Sherwood; S.A. Patel; Y-C. Kim; W. Iams; M. Khalil; A. Fink; Y. Lin; M. Willard; M. Socinski

Year: 2025

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2025.08.2470

Paper 1989P Efficacy and safety of fulzerasib in patients (pts) with KRAS G12C-mutant non-small cell lung cancer (NSCLC): Updated results from phase I/II studies

Y. Wu; Q. Zhou; D. Huang et al. · 2025 · Annals of Oncology · DOI

Full title: 1989P Efficacy and safety of fulzerasib in patients (pts) with KRAS G12C-mutant non-small cell lung cancer (NSCLC): Updated results from phase I/II studies

Authors: Y. Wu; Q. Zhou; D. Huang; L. Sun; X. Meng; Y. Yu; M. Zhao; N. Yang; T. Zhang; Y. Yuan; Q. Chu; J. Shan; M. Sun; J. Zhao; X. Li; L. Liu; Y. Pan; M. Huang; J. Huang; S. Zhang

Year: 2025

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2025.08.2613

Paper 977MO Safety and efficacy of elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C NSCLC

D. Tan; E. Pons-Tostivint; A. Amatu et al. · 2025 · Annals of Oncology · DOI

Full title: 977MO Safety and efficacy of elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C NSCLC

Authors: D. Tan; E. Pons-Tostivint; A. Amatu; B. Pellini; F. Bigot; L. Verlingue; P. Jänne; E. Rodriguez; O. Saavedra; A. Zivi; A. Artal; B. Doger de Spéville; P. Ascierto; F. Agustoni; C-C. Lin; R. Dua; M. Yang; G. An; S.H. Wong; K. Arbour

Year: 2025

Venue: Annals of Oncology

DOI: https://doi.org/10.1016/j.annonc.2025.10.689

Paper Resistance mutations and the blood–brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer

Rijmers, Jamie; Lebre, Maria C.; Beijnen, Jos H. et al. · 2025 · Acta Pharmaceutica Sinica B · DOI

Full title: Resistance mutations and the blood–brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer

Authors: Rijmers, Jamie; Lebre, Maria C.; Beijnen, Jos H.; Schinkel, Alfred H.

Year: 2025

Venue: Acta Pharmaceutica Sinica B

DOI: https://doi.org/10.1016/j.apsb.2025.06.002

Paper Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer.

Ye, Wei; Lu, Xin; Qiao, Yue et al. · 2024 · Biochimica et biophysica acta. Reviews on cancer · DOI

Full title: Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer.

Authors: Ye, Wei; Lu, Xin; Qiao, Yue; Ou, Wen-Bin

Year: 2024

Venue: Biochimica et biophysica acta. Reviews on cancer

DOI: https://doi.org/10.1016/j.bbcan.2024.189108

Paper Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors.

Kale, Ramesh; Samant, Charudatt; Nandakumar, Krishnadas et al. · 2025 · Biochemical and biophysical research communications · DOI

Full title: Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors.

Authors: Kale, Ramesh; Samant, Charudatt; Nandakumar, Krishnadas; Ranganath Pai, K Sreedhara; Bhonde, Mandar

Year: 2025

Venue: Biochemical and biophysical research communications

DOI: https://doi.org/10.1016/j.bbrc.2025.151688

Paper Unveiling the role of KRAS in tumor immune microenvironment.

Miao Xu; Xing Zhao; Ti Wen et al. · 2024 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · DOI

Full title: Unveiling the role of KRAS in tumor immune microenvironment.

Authors: Miao Xu; Xing Zhao; Ti Wen; Xiujuan Qu

Year: 2024

Venue: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

DOI: https://doi.org/10.1016/j.biopha.2023.116058

Paper TTP enhances the sensitivity of KRASG12C-mutated lung cancer cells to KRASG12C inhibitors by downregulating SLC7A11 and promoting ferroptosis.

Park, Ki Ra; Le, Minh-Xuan; Sul, Ok Joo et al. · 2025 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · DOI

Full title: TTP enhances the sensitivity of KRASG12C-mutated lung cancer cells to KRASG12C inhibitors by downregulating SLC7A11 and promoting ferroptosis.

Authors: Park, Ki Ra; Le, Minh-Xuan; Sul, Ok Joo; Jeon, JiHeung; Kwon, Min Sung; Lee, Haebin; Ra, Seung Won; Kwon, Hyuk Nam; Cho, Wha Ja; Park, Jeong Woo

Year: 2025

Venue: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

DOI: https://doi.org/10.1016/j.biopha.2025.118772

Paper Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.

Imaizumi, Tomoyoshi; Shimada, Itsuro; Satake, Yoshiki et al. · 2024 · Bioorganic & medicinal chemistry · DOI

Full title: Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.

Authors: Imaizumi, Tomoyoshi; Shimada, Itsuro; Satake, Yoshiki; Yamaki, Susumu; Koike, Takanori; Nigawara, Takahiro; Kaneko, Osamu; Amano, Yasushi; Mori, Kenichi; Yamanaka, Yosuke; Nakayama, Ayako; Nishizono, Yoshihiro; Shimazaki, Masashi; Nagashima, Takeyuki; Kuramoto, Kazuyuki

Year: 2024

Venue: Bioorganic & medicinal chemistry

DOI: https://doi.org/10.1016/j.bmc.2023.117581

Paper The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer

Fiala, Ondřej; Pešek, Miloš; Fínek, Jindřich et al. · 2013 · Cancer Genetics · DOI

Full title: The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer

Authors: Fiala, Ondřej; Pešek, Miloš; Fínek, Jindřich; Benešová, Lucie; Belšánová, Barbora; Minárik, Marek

Year: 2013

Venue: Cancer Genetics

DOI: https://doi.org/10.1016/j.cancergen.2012.12.003

Paper AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

Morimoto, Kenji; Yamada, Tadaaki; Hirai, Soichi et al. · 2024 · Cancer letters · DOI

Full title: AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

Authors: Morimoto, Kenji; Yamada, Tadaaki; Hirai, Soichi; Katayama, Yuki; Fukui, Sarina; Sawada, Ryo; Tachibana, Yusuke; Matsui, Yohei; Nakamura, Ryota; Ishida, Masaki; Kawachi, Hayato; Kunimasa, Kei; Sasaki, Takaaki; Nishida, Makoto; Furuya, Naoki; Watanabe, Satoshi; Shiotsu, Shinsuke; Nishioka, Naoya; Horinaka, Mano; Sakai, Toshiyuki; Uehara, Hisanori; Yano, Seiji; Son, Bo-Kyung; Tokuda, Shinsaku; Takayama, Koichi

Year: 2024

Venue: Cancer letters

DOI: https://doi.org/10.1016/j.canlet.2024.216692

Paper WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.

Yamamoto, Gaku; Tanaka, Kosuke; Kamata, Ryo et al. · 2024 · Cancer letters · DOI

Full title: WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.

Authors: Yamamoto, Gaku; Tanaka, Kosuke; Kamata, Ryo; Saito, Hitoshi; Yamamori-Morita, Tomoko; Nakao, Takehiro; Liu, Jie; Mori, Shunta; Yagishita, Shigehiro; Hamada, Akinobu; Shinno, Yuki; Yoshida, Tatsuya; Horinouchi, Hidehito; Ohe, Yuichiro; Watanabe, Shun-Ichi; Yatabe, Yasushi; Kitai, Hidenori; Konno, Satoshi; Kobayashi, Susumu S; Ohashi, Akihiro

Year: 2024

Venue: Cancer letters

DOI: https://doi.org/10.1016/j.canlet.2024.217414

Paper Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.

Wang, Yujue; Liu, Sixue; Yang, Zhentao et al. · 2021 · Cancer cell · DOI

Full title: Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.

Authors: Wang, Yujue; Liu, Sixue; Yang, Zhentao; Algazi, Alain P; Lomeli, Shirley H; Wang, Yan; Othus, Megan; Hong, Aayoung; Wang, Xiaoyan; Randolph, Chris E; Jones, Alexis M; Bosenberg, Marcus W; Byrum, Stephanie D; Tackett, Alan J; Lopez, Henry; Yates, Clayton; Solit, David B; Ribas, Antoni; Piva, Marco; Moriceau, Gatien; Lo, Roger S

Year: 2021

Venue: Cancer cell

DOI: https://doi.org/10.1016/j.ccell.2021.07.023

Paper A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Zhang, Ziyang; Rohweder, Peter J.; Ongpipattanakul, Chayanid et al. · 2022 · Cancer Cell · DOI

Full title: A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Authors: Zhang, Ziyang; Rohweder, Peter J.; Ongpipattanakul, Chayanid; Basu, Koli; Bohn, Markus‐Frederik; Dugan, Eli; Steri, Veronica; Hann, Byron; Shokat, Kevan M.; Craik, Charles S.

Year: 2022

Venue: Cancer Cell

DOI: https://doi.org/10.1016/j.ccell.2022.07.005

Paper MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.

Yu Qian; Ana Galán-Cobo; I. Guijarro et al. · 2023 · Cancer Cell · DOI

Full title: MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.

Authors: Yu Qian; Ana Galán-Cobo; I. Guijarro; M. Dang; D. Molkentine; A. Poteete; Fahao Zhang; Qi Wang; Jing Wang; E. Parra; Apekshya Panda; Jacy Fang; F. Skoulidis; I. Wistuba; Svena Verma; T. Merghoub; J. Wolchok; Kwok-kin Wong; R. Deberardinis; J. Minna; N. Vokes; C. Meador; J. Gainor; Linghua Wang; A. Reuben; J. Heymach

Year: 2023

Venue: Cancer Cell

DOI: https://doi.org/10.1016/j.ccell.2023.05.015

Paper Emerging landscape of KRAS inhibitors in cancer treatment.

Riedl, Jakob M; Matsubara, Hiroyuki; McNeil, Reid et al. · 2026 · Cancer cell · DOI

Full title: Emerging landscape of KRAS inhibitors in cancer treatment.

Authors: Riedl, Jakob M; Matsubara, Hiroyuki; McNeil, Reid; Patel, Parasvi S; Fece de la Cruz, Ferran; Gulhan, Doga C; Corcoran, Ryan B

Year: 2026

Venue: Cancer cell

DOI: https://doi.org/10.1016/j.ccell.2026.01.001

Paper Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System

Simpson, Luke M.; Macartney, Thomas; Nardin, Alice et al. · 2020 · Cell chemical biology · DOI

Full title: Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System

Authors: Simpson, Luke M.; Macartney, Thomas; Nardin, Alice; Fulcher, Luke J.; Röth, Sascha; Testa, Andrea; Maniaci, Chiara; Ciulli, Alessio; Ganley, Ian G.; Sapkota, Gopal P.

Year: 2020

Venue: Cell chemical biology

DOI: https://doi.org/10.1016/j.chembiol.2020.06.013

Paper Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Goldman, Jonathan W.; Shi, Peipei; Reck, Martin et al. · 2015 · Clinical Lung Cancer · DOI

Full title: Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Authors: Goldman, Jonathan W.; Shi, Peipei; Reck, Martin; Paz‐Ares, Luis; Koustenis, Andrew; Hurt, Karla

Year: 2015

Venue: Clinical Lung Cancer

DOI: https://doi.org/10.1016/j.cllc.2015.08.003

Paper Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report

Sproat, Michelle R.; Hofherr, Mara; Devarakonda, Siddhartha · 2022 · Clinical Lung Cancer · DOI

Full title: Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report

Authors: Sproat, Michelle R.; Hofherr, Mara; Devarakonda, Siddhartha

Year: 2022

Venue: Clinical Lung Cancer

DOI: https://doi.org/10.1016/j.cllc.2022.04.007

Paper KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry

Isaksson, Johan; Berglund, Anders; Louie, Karly S. et al. · 2023 · Clinical Lung Cancer · DOI

Full title: KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry

Authors: Isaksson, Johan; Berglund, Anders; Louie, Karly S.; Willén, Linda; Hamidian, Arash; Edsjö, Anders; Enlund, Fredrik; Planck, Maria; Vikström, Anders; Johansson, Mikael; Hallqvist, Andreas; Wagenius, Gunnar; Botling, Johan

Year: 2023

Venue: Clinical Lung Cancer

DOI: https://doi.org/10.1016/j.cllc.2023.05.002

Paper KRAS mutations in non-small cell lung cancer: Translational aspects, current therapies and challenges for future research.

Colombino, Maria; Palomba, Grazia; Casula, Milena et al. · 2025 · Critical reviews in oncology/hematology · DOI

Full title: KRAS mutations in non-small cell lung cancer: Translational aspects, current therapies and challenges for future research.

Authors: Colombino, Maria; Palomba, Grazia; Casula, Milena; Pisano, Marina; Tore, Silvia; Serra, Riccardo; Putzu, Carlo; Fadda, Giovanni Maria; Maestrale, Giovanni Battista; Casula, Stefania; Paliogiannis, Panagiotis; Cossu, Antonio; Palmieri, Giuseppe

Year: 2025

Venue: Critical reviews in oncology/hematology

DOI: https://doi.org/10.1016/j.critrevonc.2025.104925

Paper Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Remón, Jordi; Hendriks, Lizza; Cabrera, C. et al. · 2018 · Cancer Treatment Reviews · DOI

Full title: Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Authors: Remón, Jordi; Hendriks, Lizza; Cabrera, C.; Reguart, Noemı́; Besse, Benjamin

Year: 2018

Venue: Cancer Treatment Reviews

DOI: https://doi.org/10.1016/j.ctrv.2018.10.006

Paper KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Nagasaka, Misako; Li, Yiwei; Sukari, Ammar et al. · 2020 · Cancer Treatment Reviews · DOI

Full title: KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Authors: Nagasaka, Misako; Li, Yiwei; Sukari, Ammar; Ou, Sai‐Hong Ignatius; Hallak, Mohammed Najeeb Al; Azmi, Asfar S.

Year: 2020

Venue: Cancer Treatment Reviews

DOI: https://doi.org/10.1016/j.ctrv.2020.101974

Paper MEK inhibitor resistance mechanisms and recent developments in combination trials.

E. Kun; Y. Tsang; C. Ng et al. · 2020 · Cancer Treatment Reviews · DOI

Full title: MEK inhibitor resistance mechanisms and recent developments in combination trials.

Authors: E. Kun; Y. Tsang; C. Ng; D. Gershenson; K. Wong

Year: 2020

Venue: Cancer Treatment Reviews

DOI: https://doi.org/10.1016/j.ctrv.2020.102137

Paper Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions.

Attili, Ilaria; Corvaja, Carla; Trillo Aliaga, Pamela et al. · 2025 · Cancer treatment reviews · DOI

Full title: Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions.

Authors: Attili, Ilaria; Corvaja, Carla; Trillo Aliaga, Pamela; Del Signore, Ester; Spitaleri, Gianluca; Passaro, Antonio; de Marinis, Filippo

Year: 2025

Venue: Cancer treatment reviews

DOI: https://doi.org/10.1016/j.ctrv.2025.102957

Paper Anticancer drug resistance: An update and perspective.

R. Nussinov; Chung-Jung Tsai; Hyunbum Jang · 2021 · Drug resistance updates · DOI

Full title: Anticancer drug resistance: An update and perspective.

Authors: R. Nussinov; Chung-Jung Tsai; Hyunbum Jang

Year: 2021

Venue: Drug resistance updates

DOI: https://doi.org/10.1016/j.drup.2021.100796

Paper Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma

Liu, Ke; Guo, Jintao; Liu, Kuai et al. · 2018 · EBioMedicine · DOI

Full title: Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma

Authors: Liu, Ke; Guo, Jintao; Liu, Kuai; Fan, Peiyang; Zeng, Yuanyuan; Xu, Chaoqun; Zhong, Jiaxin; Li, Qiyuan; Zhou, Ying

Year: 2018

Venue: EBioMedicine

DOI: https://doi.org/10.1016/j.ebiom.2018.09.034

Paper An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer

Wang, Haiyun; Lv, Qi; Xu, Yue et al. · 2019 · EBioMedicine · DOI

Full title: An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer

Authors: Wang, Haiyun; Lv, Qi; Xu, Yue; Cai, Zhaoqing; Zheng, Jie; Cheng, Xiaojie; Dai, Yao; Jänne, Pasi A.; Ambrogio, Chiara; Köhler, Jens

Year: 2019

Venue: EBioMedicine

DOI: https://doi.org/10.1016/j.ebiom.2019.10.012

Paper Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis

Ernst, Sophie M.; Hofman, Maaike M.; Horst, Tessa E. van der et al. · 2024 · EBioMedicine · DOI

Full title: Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis

Authors: Ernst, Sophie M.; Hofman, Maaike M.; Horst, Tessa E. van der; Paats, Marthe S.; Heijboer, Frank W J; Aerts, Joachim G.J.V.; Dumoulin, Daphne W.; Cornelissen, Robin; Thüsen, Jan H. von der; Bruijn, Peter de; Hoop, Esther Oomen‐de; Mathijssen, Ron H.J.; Koolen, Stijn L.W.; Dingemans, Anne‐Marie C.

Year: 2024

Venue: EBioMedicine

DOI: https://doi.org/10.1016/j.ebiom.2024.105074

Paper HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2.

Ho, Cassandra S L; Tüns, Alicia I; Schildhaus, Hans-Ulrich et al. · 2021 · European journal of cancer (Oxford, England : 1990) · DOI

Full title: HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2.

Authors: Ho, Cassandra S L; Tüns, Alicia I; Schildhaus, Hans-Ulrich; Wiesweg, Marcel; Grüner, Barbara M; Hegedus, Balazs; Schuler, Martin; Schramm, Alexander; Oeck, Sebastian

Year: 2021

Venue: European journal of cancer (Oxford, England : 1990)

DOI: https://doi.org/10.1016/j.ejca.2021.10.003

Paper Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

Stratmann, Jan; Althoff, Friederike C.; Doebel, Paula et al. · 2024 · European Journal of Cancer · DOI

Full title: Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

Authors: Stratmann, Jan; Althoff, Friederike C.; Doebel, Paula; Rauh, Jacqueline; Trummer, Arne; Hünerlitürkoglu, A; Frost, Nikolaj; Yildirim, Hüsameddin; Christopoulos, Petros; Burkhard, Oswald; Büschenfelde, Christian Meyer zum; Rose, Aaron Becker von; Alt, Jürgen; Aries, Sven Philip; Webendörfer, Maximilian; Kaldune, Stefan; Uhlenbruch, Mark; Tritchkova, Guergana; Waller, Cornelius F.; Rittmeyer, Achim; Hoffknecht, Petra; Braess, Jan; Kopp, Hans‐Georg; Grohé, Christian; Schäfer, Monica; Schumann, Christian; Griesinger, Frank; Kuon, Jonas; Sebastian, Martin; Reinmuth, Niels

Year: 2024

Venue: European Journal of Cancer

DOI: https://doi.org/10.1016/j.ejca.2024.113911

Paper Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers

Pandey, Divya; Chauhan, Subhash C.; Kashyap, Vivek K. et al. · 2024 · European Journal of Medicinal Chemistry · DOI

Full title: Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers

Authors: Pandey, Divya; Chauhan, Subhash C.; Kashyap, Vivek K.; Roy, Kuldeep K.

Year: 2024

Venue: European Journal of Medicinal Chemistry

DOI: https://doi.org/10.1016/j.ejmech.2024.116771

Paper Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy.

Jiang, Min; Ma, Shaowei; Xuan, Ying et al. · 2025 · European journal of medicinal chemistry · DOI

Full title: Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy.

Authors: Jiang, Min; Ma, Shaowei; Xuan, Ying; Chen, Kuanbing

Year: 2025

Venue: European journal of medicinal chemistry

DOI: https://doi.org/10.1016/j.ejmech.2025.117626

Paper Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards

Danesi, Romano; Fogli, Stefano; Indraccolo, Stefano et al. · 2021 · ESMO Open · DOI

Full title: Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards

Authors: Danesi, Romano; Fogli, Stefano; Indraccolo, Stefano; Re, Marzia Del; Tos, Angelo Paolo Dei; Leoncini, Lorenzo; Antonuzzo, Lorenzo; Bonanno, Laura; Guarneri, Valentina; Pierini, Andrea; Amunni, Gianni; Conté, Pierfranco

Year: 2021

Venue: ESMO Open

DOI: https://doi.org/10.1016/j.esmoop.2020.100040

Paper Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine

Bhamidipati, Deepak; Subbiah, Vivek · 2023 · ESMO Open · DOI

Full title: Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine

Authors: Bhamidipati, Deepak; Subbiah, Vivek

Year: 2023

Venue: ESMO Open

DOI: https://doi.org/10.1016/j.esmoop.2023.101591

Paper 103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)

Barlési, Fabrice; Felip, Enriqueta; Popat, Sanjay et al. · 2024 · ESMO Open · DOI

Authors: Barlési, Fabrice; Felip, Enriqueta; Popat, Sanjay; Solomon, Benjamin; Wolf, Jennifer Moriatis; Li, B.T.; Wu, Yi‐Long; Kerr, Keith M.; Akamatsu, Hiroko; Camidge, D. Ross; Gupta, Ravi; Meloni, A.; Dai, Tian; Borghaei, Hossein

Year: 2024

Venue: ESMO Open

DOI: https://doi.org/10.1016/j.esmoop.2024.102682

Paper Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Li, Huiyu; Qi, Wei-liang; Wang, Yuxiang et al. · 2021 · Genes & Diseases · DOI

Full title: Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Authors: Li, Huiyu; Qi, Wei-liang; Wang, Yuxiang; Meng, Linghua

Year: 2021

Venue: Genes & Diseases

DOI: https://doi.org/10.1016/j.gendis.2021.08.011

Paper Screening and Validation of Molecular Targeted Radiosensitizers

Willers, Henning; Pan, Xiao; Borgeaud, Nathalie et al. · 2021 · International Journal of Radiation Oncology*Biology*Physics · DOI

Full title: Screening and Validation of Molecular Targeted Radiosensitizers

Authors: Willers, Henning; Pan, Xiao; Borgeaud, Nathalie; Korovina, Irina; Koi, Lydia; Egan, Regina K.; Greninger, Patricia; Rosenkranz, Aliza; Kung, Jong; Liss, Andrew S.; Parsels, Leslie A.; Morgan, Meredith A.; Lawrence, Theodore S.; Lin, Steven H.; Hong, Theodore S.; Yeap, Beow Y.; Wirth, Lori J.; Hata, Aaron N.; Ott, Christopher J.; Benes, Cyril H.; Baumann, Michaël; Krause, Mechthild

Year: 2021

Venue: International Journal of Radiation Oncology*Biology*Physics

DOI: https://doi.org/10.1016/j.ijrobp.2021.07.1694

Paper KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

P. Cassier; C. Dooms; A. Gazzah et al. · 2024 · International Journal of Radiation Oncology, Biology, Physics · DOI

Full title: KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Authors: P. Cassier; C. Dooms; A. Gazzah; E. Felip; N. Steeghs; K. Rohrberg; F. de Braud; B. Solomon; M. Schuler; D. Tan; N. Yamamoto; H. Loong; B. C. Cho; J. Wolf; C. Lin; M. Negrao; L. Werner; X. Cui; A. Farago; M. de Miguel

Year: 2024

Venue: International Journal of Radiation Oncology, Biology, Physics

DOI: https://doi.org/10.1016/j.ijrobp.2023.10.053

Paper KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.

F. Cappuzzo; G. Castro; J. Kang et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.

Authors: F. Cappuzzo; G. Castro; J. Kang; Yi‐Long Wu; O. Brustugun; P. Cheema; T. Owonikoko; A. Longin; A. Boran; Jiawei Duan; R. Caparica; H. Loong

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.tps9144

Paper Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A549 cells

Alturki, Mansour S.; Tawfeeq, Nada; Alissa, Amal et al. · 2025 · Informatics in Medicine Unlocked · DOI

Full title: Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A549 cells

Authors: Alturki, Mansour S.; Tawfeeq, Nada; Alissa, Amal; Ahbail, Zahra; Gomaa, Mohamed S.; Khzem, Abdulaziz H. Al; Rants’o, Thankhoe A.; Akbar, Md.; Alharbi, Waleed S.; Alshehri, Bayan Y.; Alotaibi, Amjad N.; Almughem, Fahad A.; Alshehri, Abdullah A.

Year: 2025

Venue: Informatics in Medicine Unlocked

DOI: https://doi.org/10.1016/j.imu.2024.101612

Paper LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Jänne, P.A.; Smit, E.F.; Marinis, F. de et al. · 2022 · Immuno-Oncology Technology · DOI

Full title: LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Authors: Jänne, P.A.; Smit, E.F.; Marinis, F. de; Laskin, J.; Gómez, M. Dómine; Gadgeel, S.; Garassino, M.C.; Lu, Shen-qi; Spira, A.S.; Kang, V.; Roshan, S.; Yan, X.; Felip, E.

Year: 2022

Venue: Immuno-Oncology Technology

DOI: https://doi.org/10.1016/j.iotech.2022.100360

Paper Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer.

Zhu, Linsha; Jia, Xiangbo; Xu, Lei et al. · 2026 · iScience · DOI

Full title: Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer.

Authors: Zhu, Linsha; Jia, Xiangbo; Xu, Lei; Chen, Li; Fu, Xiangning; Yan, Hua; Ai, Bo; Peng, Shu

Year: 2026

Venue: iScience

DOI: https://doi.org/10.1016/j.isci.2025.114429

Paper Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin

Chang, Wen-Hsuan; Liu, Yinzhe; Hammes, Emma A. et al. · 2022 · Journal of Biological Chemistry · DOI

Full title: Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin

Authors: Chang, Wen-Hsuan; Liu, Yinzhe; Hammes, Emma A.; Bryant, Kirsten L.; Cerione, Richard A.; Antonyak, Marc A.

Year: 2022

Venue: Journal of Biological Chemistry

DOI: https://doi.org/10.1016/j.jbc.2022.102842

Paper Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells.

Hindul, Naushin L; Abbott, Lauren R; Adan, Sumaya M D et al. · 2024 · The Journal of biological chemistry · DOI

Full title: Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells.

Authors: Hindul, Naushin L; Abbott, Lauren R; Adan, Sumaya M D; Straatman, Kornelis R; Fry, Andrew M; Hirota, Kouji; Tanaka, Kayoko

Year: 2024

Venue: The Journal of biological chemistry

DOI: https://doi.org/10.1016/j.jbc.2024.107409

Paper Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer

Wang, Xiaodong; Lin, Jia-Hong; Hu, Ming-Hao · 2025 · Journal of Biological Chemistry · DOI

Full title: Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer

Authors: Wang, Xiaodong; Lin, Jia-Hong; Hu, Ming-Hao

Year: 2025

Venue: Journal of Biological Chemistry

DOI: https://doi.org/10.1016/j.jbc.2025.108164

Paper Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors

Anthiya, Shubaash; Öztürk, Süleyman Can; Yanık, Hamdullah et al. · 2023 · Journal of Controlled Release · DOI

Full title: Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors

Authors: Anthiya, Shubaash; Öztürk, Süleyman Can; Yanık, Hamdullah; Tavukçuoğlu, Ece; Şahin, Adem; Datta, Dhrubajyoti; Charissé, Klaus; Moreira, David; Loza, Marı́a Isabel; Calvo, Alfonso; Sulheim, Einar; Loevenich, Simon; Klinkenberg, Geir; Schmid, Ruth; Manoharan, Muthiah; Esendağlı, Güneş; Alonso, Marı́a José

Year: 2023

Venue: Journal of Controlled Release

DOI: https://doi.org/10.1016/j.jconrel.2023.03.016

Paper Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report

Christofyllakis, Konstantinos; Monteiro, Ana Raquel; Cetin, Onur et al. · 2022 · Journal of Geriatric Oncology · DOI

Full title: Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report

Authors: Christofyllakis, Konstantinos; Monteiro, Ana Raquel; Cetin, Onur; Kos, Igor Age; Greystoke, Alastair; Luciani, Andrea

Year: 2022

Venue: Journal of Geriatric Oncology

DOI: https://doi.org/10.1016/j.jgo.2022.04.013

Paper KRAS G12C–Mutant Non–Small Cell Lung Cancer

Veluswamy, Rajwanth; Mack, Philip C.; Houldsworth, Jane et al. · 2021 · Journal of Molecular Diagnostics · DOI

Full title: KRAS G12C–Mutant Non–Small Cell Lung Cancer

Authors: Veluswamy, Rajwanth; Mack, Philip C.; Houldsworth, Jane; Elkhouly, Ehab; Hirsch, Fred R.

Year: 2021

Venue: Journal of Molecular Diagnostics

DOI: https://doi.org/10.1016/j.jmoldx.2021.02.002

Paper Prognostic and Predictive Value of KRAS Mutation in NSCLC

Yamamoto, Satomi; Washington, Laurie; Komiya, Takefumi · 2016 · Journal of Thoracic Oncology · DOI

Full title: Prognostic and Predictive Value of KRAS Mutation in NSCLC

Authors: Yamamoto, Satomi; Washington, Laurie; Komiya, Takefumi

Year: 2016

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2016.04.035

Paper KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.

M. Niemantsverdriet; E. Schuuring; A. Elst et al. · 2018 · Journal of Thoracic Oncology · DOI

Full title: KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.

Authors: M. Niemantsverdriet; E. Schuuring; A. Elst; A. J. van der Wekken; L. V. van Kempen; A. van den Berg; H. Groen

Year: 2018

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2018.07.103

Paper K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Scheffler, Matthias; Ihle, Michaela A.; Hein, Rebecca et al. · 2018 · Journal of Thoracic Oncology · DOI

Full title: K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Authors: Scheffler, Matthias; Ihle, Michaela A.; Hein, Rebecca; Merkelbach‐Bruse, Sabine; Scheel, Andreas H.; Siemanowski, Janna; Brägelmann, Johannes; Kron, Anna; Abedpour, Nima; Roth, Rebecca; Schüller, Merle; Koleczko, Sophia; Michels, Sebastian; Fassunke, Jana; Pasternack, Helen; Heydt, Carina; Serke, Monika; Fischer, Rieke; Schulte, Wolfgang; Gerigk, Ulrich; Nogová, Lucia; Ko, Yon‐Dschun; Abdulla, Diana S.Y.; Riedel, Richard; Kambartel, K; Lorenz, J.; Sauerland, Imke; Randerath, Winfried; Kaminsky, Britta; Hagmeyer, Lars; Grohé, Christian; Eisert, Anna; Frank, Rieke; Gogl, Leonie; Schaepers, Carsten; Holzem, Alessandra; Hellmich, Martin; Thomas, Roman K.; Peifer, Martin; Sos, Martin L.; Büttner, Reinhard; Wolf, Jürgen

Year: 2018

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2018.12.013

Paper Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

Jeanson, A.; Tomasini, Pascale; Souquet-Bressand, M. et al. · 2019 · Journal of Thoracic Oncology · DOI

Full title: Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

Authors: Jeanson, A.; Tomasini, Pascale; Souquet-Bressand, M.; Brandone, Nicolas; Boucékine, Mohamed; Grangeon, M.; Chaléat, S.; Khobta, Natalyia; Milia, Julie; Mhanna, Laurent; Greillier, Laurent; Biemar, Julie; Nanni, Isabelle; Ouafik, L’Houcine; Garcia, Stéphane; Mazières, Julien; Barlési, Fabrice; Mascaux, Céline

Year: 2019

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2019.01.011

Paper IBS05.01 KRAS Mutant Lung Cancer

Jänne, Pasi A. · 2019 · Journal of Thoracic Oncology · DOI

Full title: IBS05.01 KRAS Mutant Lung Cancer

Authors: Jänne, Pasi A.

Year: 2019

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2019.08.208

Paper MO01.30 Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)

Fakih, Marwan; Durm, Greg Andrew; Govindan, Ramaswamy et al. · 2021 · Journal of Thoracic Oncology · DOI

Full title: MO01.30 Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)

Authors: Fakih, Marwan; Durm, Greg Andrew; Govindan, Ramaswamy; Falchook, Gerald S.; Soman, N.; Henary, Haby; Hong, David S.

Year: 2021

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2020.10.135

Paper ES28.05 Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors

Molina‐Arcas, Míriam · 2021 · Journal of Thoracic Oncology · DOI

Full title: ES28.05 Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors

Authors: Molina‐Arcas, Míriam

Year: 2021

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2021.01.064

Paper Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project

Finn, Stephen P.; Addeo, Alfredo; Dafni, Urania et al. · 2021 · Journal of Thoracic Oncology · DOI

Full title: Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project

Authors: Finn, Stephen P.; Addeo, Alfredo; Dafni, Urania; Thunnissen, Erik; Bubendorf, Lukas; Madsen, Line Bille; Biernat, Wojciech; Verbeken, Eric; Hernández‐Losa, Javier; Marchetti, Antonio; Cheney, Richard; Warth, Arne; Speel, Ernst‐Jan M.; Quinn, Anne Marie; Monkhorst, Kim; Jantus‐Lewintre, Eloísa; Tischler, Verena; Marti, Nesa; Dimopoulou, Georgia; Molina‐Vila, Miguel Ángel; Kammler, Roswitha; Kerr, Keith M.; Peters, Solange; Stahel, Rolf A.

Year: 2021

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2021.02.016

Paper KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.

Koga, Takamasa; Suda, Kenichi; Fujino, Toshio et al. · 2021 · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · DOI

Full title: KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.

Authors: Koga, Takamasa; Suda, Kenichi; Fujino, Toshio; Ohara, Shuta; Hamada, Akira; Nishino, Masaya; Chiba, Masato; Shimoji, Masaki; Takemoto, Toshiki; Arita, Takeo; Gmachl, Michael; Hofmann, Marco H; Soh, Junichi; Mitsudomi, Tetsuya

Year: 2021

Venue: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

DOI: https://doi.org/10.1016/j.jtho.2021.04.015

Paper OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial

Lu, Shan-Shan; Jian, Hongtao; Zhang, Yanmei et al. · 2022 · Journal of Thoracic Oncology · DOI

Full title: OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial

Authors: Lu, Shan-Shan; Jian, Hongtao; Zhang, Yanmei; Song, Ziwei; Zhao, Y.; Wang, Pinzhi; Jiang, L.; Gong, Yuqiao; Zhou, Jian; Dong, Xianghu; Yang, Nuan; Fang, J.; Zhuang, Wenchen; Cang, S.; Ma, Ruoyan; Shi, J.; Wu, Peipei; Lu, Jinxian; Xiang, Zongqin; Shi, Zumin; Zhang, L.; Wang, Yu

Year: 2022

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2022.07.026

Paper EP08.01-026 Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients

Swart, Esther M.; Noordhof, Anneloes L.; Damhuis, R.A.M. et al. · 2022 · Journal of Thoracic Oncology · DOI

Full title: EP08.01-026 Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients

Authors: Swart, Esther M.; Noordhof, Anneloes L.; Damhuis, R.A.M.; Kunst, P.W.A.; Ruysscher, Dirk K.M. De; Hendriks, L.E.L.; Geffen, Wouter H. van; Aarts, M.J.

Year: 2022

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2022.07.598

Paper PP01.41 Efficacy of Sotorasib Versus Standard Chemotherapy + Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data

Haddad, P.; Hammoud, D. · 2023 · Journal of Thoracic Oncology · DOI

Full title: PP01.41 Efficacy of Sotorasib Versus Standard Chemotherapy + Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data

Authors: Haddad, P.; Hammoud, D.

Year: 2023

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2022.09.067

Paper Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Chour, Ali; Denis, Julie; Mascaux, Céline et al. · 2023 · Journal of Thoracic Oncology · DOI

Full title: Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Authors: Chour, Ali; Denis, Julie; Mascaux, Céline; Zysman, M.; Bigay-Gamé, L.; Swalduz, Aurélie; Gounant, V.; Cortot, Alexis B.; Darrason, Marie; Fallet, Vincent; Auclin, Édouard; Basse, Clémence; Tissot, Claire; Decroisette, C.; Bombaron, P.; Giroux‐Leprieur, Etienne; Odier, L.; Brosseau, Solenn; Creusot, Quentin; Gueçamburu, M.; Meersseman, Corentin; Rochand, Adrien; Costantini, Adrien; Gaillard, Claire Marine; Wasielewski, Eric; Girard, Nicolas; Cadranel, Jacques; Lafitte, Claire; Lebossé, Fanny; Duruisseaux, M.

Year: 2023

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2023.05.013

Paper Toxicity From Sotorasib After Immune Checkpoint Inhibitors: A Note of Caution and Reflections of Future Advancements in the Field

Desai, Aakash; Dimou, Anastasios · 2023 · Journal of Thoracic Oncology · DOI

Full title: Toxicity From Sotorasib After Immune Checkpoint Inhibitors: A Note of Caution and Reflections of Future Advancements in the Field

Authors: Desai, Aakash; Dimou, Anastasios

Year: 2023

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2023.07.013

Paper MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

Negrão, Marcelo V.; Cassier, Philippe A.; Solomon, Benjamin et al. · 2023 · Journal of Thoracic Oncology · DOI

Full title: MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

Authors: Negrão, Marcelo V.; Cassier, Philippe A.; Solomon, Benjamin; Schüler, Martin; Rohrberg, K.; Cresta, Sara; Dooms, Christophe; Tan, Daniel Shao-Weng; Loong, Herbert H.; Amatu, Alessio; Assmann, K. Krueger; Fairchild, Lauren; Sansregret, Laurent; Fan, Li; Farago, Anna F.; Cho, Byoung Chul

Year: 2023

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2023.09.151

Paper MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC

J. Clarke; E. Felip; B.T. Li et al. · 2023 · Journal of Thoracic Oncology · DOI

Full title: MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC

Authors: J. Clarke; E. Felip; B.T. Li; J. Ruffinelli; P. Garrido; J. Zugazagoitia; S. Goldberg; S. Ramalingam; I. Victoria; S. Puri; D. Gandara; T. Varrieur; S. Edmonds; K. Palmer; W. Snyder; R. Govindan; I. Rybkin

Year: 2023

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2023.09.153

Paper P2.09-15 Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer

Zhou, Katherine I.; Lin, Chieh‐Yu; Tseng, Chi‐Lung et al. · 2023 · Journal of Thoracic Oncology · DOI

Full title: P2.09-15 Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer

Authors: Zhou, Katherine I.; Lin, Chieh‐Yu; Tseng, Chi‐Lung; Ramnath, Nithya; Dowell, Jonathan E.; Kelley, Michael J.

Year: 2023

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2023.09.589

Paper OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC

Y. Fujiwara; N. Reddy Ammakkanavar; A. Hollebecque et al. · 2024 · Journal of Thoracic Oncology · DOI

Full title: OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC

Authors: Y. Fujiwara; N. Reddy Ammakkanavar; A. Hollebecque; Y. Murciano-Goroff; D.H. Lee; T. Burns; P. Cassier; J. Han; A. Italiano; T. Koyama; B. Shim; R. Heist; J. Sabari; A. Spira; J. Bodor; Q. Chu; G. Durm; N. Singhal; M. Chisamore; A. Fink; A. Chen; M. Willard; G. Oxnard; K. Dragnev

Year: 2024

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2024.09.073

Paper OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

M. Negrao; J.V. Uyeki; I. Cicin et al. · 2025 · Journal of Thoracic Oncology · DOI

Full title: OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

Authors: M. Negrao; J.V. Uyeki; I. Cicin; Y. Chen; B. Shim; M. Yamaguchi; T. Burns; G. Sherwood; J. Bodor; J. Sakakibara-Konishi; K. Dragnev; N. Ammakkanavar; V. Lin; S. Kim; Y. Zhou; N. Fasnacht; A. Fink; M. Willard; C. Visseren-Grul; S. Peters

Year: 2025

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2025.09.055

Paper MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

M.L. Johnson; L.L. Mateos; T. Yamada et al. · 2025 · Journal of Thoracic Oncology · DOI

Full title: MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

Authors: M.L. Johnson; L.L. Mateos; T. Yamada; N. Makani; B. Chan; W.T. Huang; D. Spyratos; J. Roubec; N. Reinmuth; A. Sacher; A. Spira; N. Singhal; S. Takeuchi; Y.R. Murciano-Goroff; Y. Zhou; A. Fink; A. Merced; M. Willard; C. Visseren-Grul; S. Peters

Year: 2025

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2025.09.109

Paper Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC.

Timothy F. Burns; N. Ammakkanavar; A. Hollebecque et al. · 2025 · Journal of Thoracic Oncology · DOI

Full title: Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC.

Authors: Timothy F. Burns; N. Ammakkanavar; A. Hollebecque; Dae Ho Lee; T. Koyama; P. Cassier; A. Italiano; Ji-Youn Han; Nimit Singhal; Shinji Takeuchi; R. Heist; Dustin Deming; A. Spira; Q.S-C. Chu; A. Sacher; Yutaka Fujiwara; M. Chisamore; Arthur Xintian You; S. Mcneely; A. Fink; Aaron Chen; G. Oxnard; Melinda D Willard; Y. Murciano-Goroff; Konstantin Dragnev

Year: 2025

Venue: Journal of Thoracic Oncology

DOI: https://doi.org/10.1016/j.jtho.2025.11.018

Paper Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

Ruppert, Anne-Marie; Beau‐Faller, Michèle; Debieuvre, D. et al. · 2020 · JTO Clinical and Research Reports · DOI

Full title: Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

Authors: Ruppert, Anne-Marie; Beau‐Faller, Michèle; Debieuvre, D.; Ouafik, L’Houcine; Westeel, Virginie; Rouquette, Isabelle; Mazières, Julien; Bringuier, Pierre‐Paul; Monnet, Isabelle; Escande, Fabienne; Ricordel, Charles; Merlio, Jean‐Philippe; Janicot, Henri; Lemoine, Antoinette; Foucher, Pascal; Poudenx, M.; Morin, Franck; Langlais, Alexandra; Souquet, Pierre-Jean; Barlési, Fabrice; Wislez, Marie

Year: 2020

Venue: JTO Clinical and Research Reports

DOI: https://doi.org/10.1016/j.jtocrr.2020.100052

Paper Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan

Wu, Shang‐Gin; Liao, Wei‐Yu; Su, Kang‐Yi et al. · 2020 · JTO Clinical and Research Reports · DOI

Full title: Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan

Authors: Wu, Shang‐Gin; Liao, Wei‐Yu; Su, Kang‐Yi; Yu, Sung‐Liang; Huang, Yen-Lin; Yu, Chong‐Jen; Yang, James Chih‐Hsin; Shih, Jin‐Yuan

Year: 2020

Venue: JTO Clinical and Research Reports

DOI: https://doi.org/10.1016/j.jtocrr.2020.100140

Paper Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

Arbour, Kathryn C.; Manchado, Eusebio; Bott, Matthew J. et al. · 2021 · JTO Clinical and Research Reports · DOI

Full title: Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

Authors: Arbour, Kathryn C.; Manchado, Eusebio; Bott, Matthew J.; Ahn, Linda S.; Tobi, Yosef Y.; Ni, Andy Ai; Yu, Helena A.; Shannon, Alyssa; Ladanyi, Marc; Perron, Victoria; Ginsberg, Michelle S.; Johnson, Amanda; Holodny, Andrei I.; Kris, Mark G.; Rudin, Charles M.; Lito, Piro; Rosen, Neal; Lowe, Scott W.; Riely, Gregory J.

Year: 2021

Venue: JTO Clinical and Research Reports

DOI: https://doi.org/10.1016/j.jtocrr.2021.100256

Paper Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

Lee, Jiyun; Tan, Aaron C.; Zhou, Siqin et al. · 2021 · JTO Clinical and Research Reports · DOI

Full title: Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

Authors: Lee, Jiyun; Tan, Aaron C.; Zhou, Siqin; Yoon, Shinkyo; Liu, Si‐Yang Maggie; Masuda, Ken; Hayashi, Hidetoshi; Batra, Ullas; Kim, Dong‐Wan; Goto, Yasushi; Tan, Sze Huey; Wu, Yi‐Long; Lee, Dae Ho; Tan, Daniel S.W.; Ahn, Myung‐Ju

Year: 2021

Venue: JTO Clinical and Research Reports

DOI: https://doi.org/10.1016/j.jtocrr.2021.100261

Paper Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Cui, Wanyuan; Franchini, Fanny; Alexander, Marliese et al. · 2020 · Lung Cancer · DOI

Full title: Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Authors: Cui, Wanyuan; Franchini, Fanny; Alexander, Marliese; Officer, Ann; Wong, Hui‐Li; IJzerman, Maarten J.; Desai, Jayesh; Solomon, Benjamin

Year: 2020

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2020.06.030

Paper The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

K. Kerr; F. Bibeau; E. Thunnissen et al. · 2021 · Lung Cancer · DOI

Full title: The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

Authors: K. Kerr; F. Bibeau; E. Thunnissen; J. Botling; A. Ryška; J. Wolf; K. Öhrling; P. Burdon; U. Malapelle; R. Büttner

Year: 2021

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2021.02.026

Paper Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

Noordhof, Anneloes L.; Damhuis, Ronald; Hendriks, Lizza et al. · 2021 · Lung Cancer · DOI

Full title: Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

Authors: Noordhof, Anneloes L.; Damhuis, Ronald; Hendriks, Lizza; Langen, Adrianus J. de; Timens, Wim; Venmans, Ben J.W.; Geffen, Wouter H. van

Year: 2021

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2021.04.001

Paper On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

Lindsay, Colin R.; Garassino, Marina Chiara; Nadal, Ernest et al. · 2021 · Lung Cancer · DOI

Full title: On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

Authors: Lindsay, Colin R.; Garassino, Marina Chiara; Nadal, Ernest; Öhrling, Katarina; Scheffler, Matthias; Mazières, Julien

Year: 2021

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2021.07.005

Paper Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice

Steeghs, Elisabeth M. P.; Groen, Harry J.M.; Schuuring, Ed et al. · 2022 · Lung Cancer · DOI

Full title: Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice

Authors: Steeghs, Elisabeth M. P.; Groen, Harry J.M.; Schuuring, Ed; Aarts, Mieke J.; Damhuis, Ronald; Voorham, Quirinus J.M.; Ligtenberg, Marjolijn J. L.; Grünberg, Katrien

Year: 2022

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2022.04.001

Paper Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome

Mogenet, Alice; Barlési, Fabrice; Besse, Benjamin et al. · 2022 · Lung Cancer · DOI

Full title: Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome

Authors: Mogenet, Alice; Barlési, Fabrice; Besse, Benjamin; Michiels, Stefan; Karimi, Maryam; Tran-Dien, Alicia; Girard, Nicolas; Mazières, Julien; Audigier-Valette, Clarisse; Locatelli-Sanchez, M.; Kamal, Maud; Gestraud, Pierre; Hamza, Abderaouf; Jacquet, Alexandra; Jimenez, Marta; Yara, Sabrina; Greillier, Laurent; Bertucci, François; Planchard, David; Soria, Jean‐Charles; Bièche, Ivan; Tomasini, Pascale

Year: 2022

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2022.05.004

Paper KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study

Frost, Matilde Grupe; Jensen, Kristoffer Jarlov; Gotfredsen, Ditte Resendal et al. · 2023 · Lung Cancer · DOI

Full title: KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study

Authors: Frost, Matilde Grupe; Jensen, Kristoffer Jarlov; Gotfredsen, Ditte Resendal; Sørensen, Anne Mette Skov; Ankarfeldt, Mikkel Zöllner; Louie, Karly S.; Sroczynski, Nicholas; Jakobsen, Erik; Andersen, Jon Lykkegaard; Jimenez‐Solem, Espen; Petersen, Tonny Studsgaard

Year: 2023

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2023.02.021

Paper Clinical application of the AMOY 9-in-1 panel to lung cancer patients

Kunimasa, Kei; Matsumoto, Shingo; Kawamura, Takahisa et al. · 2023 · Lung Cancer · DOI

Full title: Clinical application of the AMOY 9-in-1 panel to lung cancer patients

Authors: Kunimasa, Kei; Matsumoto, Shingo; Kawamura, Takahisa; Inoue, Takako; Tamiya, Motohiro; Kanzaki, Ryu; Maniwa, Tomohiro; Okami, Jiro; Honma, Keiichiro; Goto, Kōichi; Nishino, Kazumi

Year: 2023

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2023.107190

Paper KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing

Lim, Tony Kiat Hon; Skoulidis, Ferdinandos; Kerr, Keith M. et al. · 2023 · Lung Cancer · DOI

Full title: KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing

Authors: Lim, Tony Kiat Hon; Skoulidis, Ferdinandos; Kerr, Keith M.; Ahn, Myung‐Ju; Kapp, Joshua; Soares, Fernando Augusto; Yatabe, Yasushi

Year: 2023

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2023.107293

Paper Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program

Passiglia, Francesco; Reale, Maria Lucia; Russo, Giuseppe Lo et al. · 2023 · Lung Cancer · DOI

Full title: Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program

Authors: Passiglia, Francesco; Reale, Maria Lucia; Russo, Giuseppe Lo; Pasello, Giulia; Minuti, Gabriele; Bulotta, Alessandra; Galetta, Domenico; Pelizzari, Giacomo; Sini, Claudio; Bria, Emilio; Roca, Elisa; Pilotto, Sara; Genova, Carlo; Metro, Giulio; Citarella, Fabrizio; Chiari, Rita; Cortinovis, Diego; Delmonte, Angelo; Russo, Alessandro; Tiseo, Marcello; Cerea, Giulio; Carta, Annamaria; Scotti, Vieri; Vavalà, Tiziana; Brambilla, Marta; Buffoni, L; Buosi, Roberta; Catania, Chiara; Gori, Stefania; Grisanti, Salvatore; Agustoni, Francesco; Garbo, Edoardo; Malapelle, Umberto; Novello, Silvia

Year: 2023

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2023.107444

Paper The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

Oya, Yuko; Imaizumi, Kazuyoshi; Mitsudomi, Tetsuya · 2024 · Lung Cancer · DOI

Full title: The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

Authors: Oya, Yuko; Imaizumi, Kazuyoshi; Mitsudomi, Tetsuya

Year: 2024

Venue: Lung Cancer

DOI: https://doi.org/10.1016/j.lungcan.2024.107886

Paper Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.

Waterhouse, David M; Rothschild, Sacha; Dooms, Christophe et al. · 2024 · Lung cancer (Amsterdam, Netherlands) · DOI

Full title: Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.

Authors: Waterhouse, David M; Rothschild, Sacha; Dooms, Christophe; Mennecier, Bertrand; Bozorgmehr, Farastuk; Majem, Margarita; van den Heuvel, Michel H; Linardou, Helena; Chul Cho, Byoung; Roberts-Thomson, Rachel; Tanaka, Kentaro; Blais, Normand; Schvartsman, Gustavo; Holmskov Hansen, Karin; Chmielewska, Izabela; Forster, Martin D; Giannopoulou, Christina; Stollenwerk, Björn; Obiozor, Cynthia C; Wang, Yang; Novello, Silvia

Year: 2024

Venue: Lung cancer (Amsterdam, Netherlands)

DOI: https://doi.org/10.1016/j.lungcan.2024.107921

Paper Recent advances in therapeutic targeting of the KRAS pathway in cancer.

Hitchen, Nadia; Williams, Sarah; Desai, Jayesh · 2025 · Pharmacology & therapeutics · DOI

Full title: Recent advances in therapeutic targeting of the KRAS pathway in cancer.

Authors: Hitchen, Nadia; Williams, Sarah; Desai, Jayesh

Year: 2025

Venue: Pharmacology & therapeutics

DOI: https://doi.org/10.1016/j.pharmthera.2025.108889

Paper ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability

Loos, Nancy H.C.; Retmana, Irene A.; Li, Wenlong et al. · 2022 · Pharmacological Research · DOI

Full title: ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability

Authors: Loos, Nancy H.C.; Retmana, Irene A.; Li, Wenlong; Martins, Margarida L.F.; Lebre, Maria C.; Sparidans, Rolf W.; Beijnen, Jos H.; Schinkel, Alfred H.

Year: 2022

Venue: Pharmacological Research

DOI: https://doi.org/10.1016/j.phrs.2022.106137

Paper Cyclopeptide RA-V from Rubia yunnanensis restores activity of Adagrasib against colorectal cancer by reducing the expression of Nrf2.

Jiang, Zhuangzhuang; Ye, Shuqing; Wu, Yingwei et al. · 2024 · Pharmacological research · DOI

Full title: Cyclopeptide RA-V from Rubia yunnanensis restores activity of Adagrasib against colorectal cancer by reducing the expression of Nrf2.

Authors: Jiang, Zhuangzhuang; Ye, Shuqing; Wu, Yingwei; Zhou, Chen; Cao, Feng; Tan, Ninghua

Year: 2024

Venue: Pharmacological research

DOI: https://doi.org/10.1016/j.phrs.2024.107252

Paper Traitement par sotorasib en autorisation d’accès précoce dans le cancer pulmonaire non à petites cellules mutées KRAS G12C : expérience du centre hospitalier régional universitaire de Tours

Bessy, C.; Blin, Timothée; Pichon, Éric et al. · 2022 · Revue des Maladies Respiratoires · DOI

Full title: Traitement par sotorasib en autorisation d’accès précoce dans le cancer pulmonaire non à petites cellules mutées KRAS G12C : expérience du centre hospitalier régional universitaire de Tours

Authors: Bessy, C.; Blin, Timothée; Pichon, Éric; Marchand‐Adam, S.; Carmier, D.

Year: 2022

Venue: Revue des Maladies Respiratoires

DOI: https://doi.org/10.1016/j.rmr.2022.12.002

Paper Stopping the beating heart of cancer: KRAS reviewed.

Herdeis, Lorenz; Gerlach, Daniel; McConnell, Darryl B et al. · 2021 · Current opinion in structural biology · DOI

Full title: Stopping the beating heart of cancer: KRAS reviewed.

Authors: Herdeis, Lorenz; Gerlach, Daniel; McConnell, Darryl B; Kessler, Dirk

Year: 2021

Venue: Current opinion in structural biology

DOI: https://doi.org/10.1016/j.sbi.2021.06.013

Paper Exploiting metabolic vulnerabilities of Non small cell lung carcinoma

Majem, Blanca; Nadal, Ernest; Muñoz‐Pinedo, Cristina · 2019 · Seminars in Cell and Developmental Biology · DOI

Full title: Exploiting metabolic vulnerabilities of Non small cell lung carcinoma

Authors: Majem, Blanca; Nadal, Ernest; Muñoz‐Pinedo, Cristina

Year: 2019

Venue: Seminars in Cell and Developmental Biology

DOI: https://doi.org/10.1016/j.semcdb.2019.06.004

Paper Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Langen, Adrianus J. de; Johnson, Melissa L.; Mazières, Julien et al. · 2023 · The Lancet · DOI

Full title: Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Authors: Langen, Adrianus J. de; Johnson, Melissa L.; Mazières, Julien; Dingemans, Anne‐Marie C.; Mountzios, Giannis; Pless, Miklos; Wolf, Jürgen; Schüler, Martin; Léna, H.; Skoulidis, Ferdinandos; Yoneshima, Yasuto; Kim, Sang‐We; Linardou, Helena; Novello, Silvia; Wekken, Anthonie J. van der; Chen, Yuanbin; Peters, Solange; Felip, Enriqueta; Solomon, Benjamin; Ramalingam, Suresh S.; Dooms, Christophe; Lindsay, Colin R.; Ferreira, Carlos Gil; Blais, Normand; Obiozor, Cynthia C.; Wang, Yang; Mehta, Bhakti; Varrieur, Tracy; Ngarmchamnanrith, Gataree; Stollenwerk, Björn; Waterhouse, David; Paz‐Ares, Luis

Year: 2023

Venue: The Lancet

DOI: https://doi.org/10.1016/s0140-6736(23)00221-0

Paper The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.

Goldberg, Sarah B; Herbst, Roy S · 2023 · Lancet (London, England) · DOI

Full title: The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.

Authors: Goldberg, Sarah B; Herbst, Roy S

Year: 2023

Venue: Lancet (London, England)

DOI: https://doi.org/10.1016/S0140-6736(23)00288-X

Paper Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer

Milner-Watts, Charlotte; O’Sullivan, Hazel; Stewart, James T. et al. · 2023 · Lung Cancer · DOI

Full title: Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer

Authors: Milner-Watts, Charlotte; O’Sullivan, Hazel; Stewart, James T.; Idaikkadar, Praveena; Tokaca, Nadza; Davidson, Michael; Yousaf, Nadia; Bhosle, Jaishree; Popat, Sanjay; O’Brien, Mary; Minchom, Anna

Year: 2023

Venue: Lung Cancer

DOI: https://doi.org/10.1016/s0169-5002(23)00499-3

Paper Ornithine decarboxylase as a new target for improving the effect of KRAS-G12C inhibitors in non-small cell lung cancer cells

Martín, Alejandro San; Buelvas, Neudo; Guzmán, Claudia García et al. · 2022 · European Journal of Cancer · DOI

Full title: Ornithine decarboxylase as a new target for improving the effect of KRAS-G12C inhibitors in non-small cell lung cancer cells

Authors: Martín, Alejandro San; Buelvas, Neudo; Guzmán, Claudia García; Guzman, S.; Mansilla, Matías; Muñoz, R. Lopez

Year: 2022

Venue: European Journal of Cancer

DOI: https://doi.org/10.1016/s0959-8049(22)00963-7

Paper Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagement kinetics

Zhang, Junhuai; Lu, J.; Zheng, Z. et al. · 2022 · European Journal of Cancer · DOI

Full title: Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagement kinetics

Authors: Zhang, Junhuai; Lu, J.; Zheng, Z.; Lu, J.; Wang, An‐Min; Wang, Jia‐jia; CHEN, JIAOLING; Rui, H.; Chen, C.; Chen, Guobi

Year: 2022

Venue: European Journal of Cancer

DOI: https://doi.org/10.1016/s0959-8049(22)00998-4

Paper Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides

Trinh, Thi B.; Upadhyaya, Punit; Qian, Ziqing et al. · 2015 · ACS Combinatorial Science · DOI

Full title: Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides

Authors: Trinh, Thi B.; Upadhyaya, Punit; Qian, Ziqing; Pei, Dehua

Year: 2015

Venue: ACS Combinatorial Science

DOI: https://doi.org/10.1021/acscombsci.5b00164

Paper Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors.

Tao Jiang; Chonglan Lin; Siyuan Le et al. · 2025 · Journal of Medicinal Chemistry · DOI

Full title: Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors.

Authors: Tao Jiang; Chonglan Lin; Siyuan Le; Leitao Zhang; Tao Liang; Lijian Cai; Xiaoling Lan; Mei Ge; Zhubo Liu; Wan He; Ling Peng; Yanhui Zhao; Jinmin Ren; Feng Yan; Qiang Lu; Jiong Lan; Fusheng Zhou

Year: 2025

Venue: Journal of Medicinal Chemistry

DOI: https://doi.org/10.1021/acs.jmedchem.4c03183

Paper Emerging RAS Inhibitors: Heterocyclic and Spirocyclic Compounds in Cancer Therapeutics.

Robert B. Kargbo · 2025 · ACS Medicinal Chemistry Letters · DOI

Full title: Emerging RAS Inhibitors: Heterocyclic and Spirocyclic Compounds in Cancer Therapeutics.

Authors: Robert B. Kargbo

Year: 2025

Venue: ACS Medicinal Chemistry Letters

DOI: https://doi.org/10.1021/acsmedchemlett.5c00028

Paper Preclinical Evaluation of [124I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors.

R. Artschwager; T. Kalidindi; Delissa S. Johnson et al. · 2024 · ACS Pharmacology & Translational Science · DOI

Full title: Preclinical Evaluation of [124I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors.

Authors: R. Artschwager; T. Kalidindi; Delissa S. Johnson; Christopher Brennan; Zachary V. Samuels; P. Lito; N. Pillarsetty

Year: 2024

Venue: ACS Pharmacology & Translational Science

DOI: https://doi.org/10.1021/acsptsci.4c00425

Paper The Renaissance of Ras

Milroy, L.‐G.; Ottmann, Christian · 2014 · ACS Chemical Biology · DOI

Full title: The Renaissance of Ras

Authors: Milroy, L.‐G.; Ottmann, Christian

Year: 2014

Venue: ACS Chemical Biology

DOI: https://doi.org/10.1021/cb500555h

Paper Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors

Gregory S. Ducker; C. Atreya; J. Simko et al. · 2013 · Oncogene · DOI

Full title: Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors

Authors: Gregory S. Ducker; C. Atreya; J. Simko; Y. Hom; M. Matli; C. Benes; B. Hann; E. Nakakura; E. Bergsland; D. Donner; J. Settleman; K. Shokat; R. Warren

Year: 2013

Venue: Oncogene

DOI: https://doi.org/10.1038/onc.2013.92

Paper Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R.

Qi, Wei-Liang; Li, Hui-Yu; Wang, Yi et al. · 2023 · Acta pharmacologica Sinica · DOI

Full title: Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R.

Authors: Qi, Wei-Liang; Li, Hui-Yu; Wang, Yi; Xu, Lan; Deng, Jie-Ting; Zhang, Xi; Wang, Yu-Xiang; Meng, Ling-Hua

Year: 2023

Venue: Acta pharmacologica Sinica

DOI: https://doi.org/10.1038/s41401-022-01015-0

Paper High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

J. Álvarez-Pérez; Juan Sanjuan-Hidalgo; Alberto M. Arenas et al. · 2025 · Nature Communications · DOI

Full title: High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

Authors: J. Álvarez-Pérez; Juan Sanjuan-Hidalgo; Alberto M. Arenas; Iván Hernández-Navas; Maria S. Benitez‑Cantos; Á. Andrades; S. Calabuig-Fariñas; E. Jantus-Lewintre; Luis Paz-Ares; Irene Ferrer; Pedro P Medina

Year: 2025

Venue: Nature Communications

DOI: https://doi.org/10.1038/s41467-025-62350-4

Paper Uncovering adagrasib resistance

Diana Romero · 2021 · Nature Reviews Clinical Oncology · DOI

Full title: Uncovering adagrasib resistance

Authors: Diana Romero

Year: 2021

Venue: Nature Reviews Clinical Oncology

DOI: https://doi.org/10.1038/s41571-021-00545-6

Paper The current state of the art and future trends in RAS-targeted cancer therapies

Punekar, Salman R.; Velcheti, Vamsidhar; Neel, Benjamin G. et al. · 2022 · Nature Reviews Clinical Oncology · DOI

Full title: The current state of the art and future trends in RAS-targeted cancer therapies

Authors: Punekar, Salman R.; Velcheti, Vamsidhar; Neel, Benjamin G.; Wong, Kwok‐Kin

Year: 2022

Venue: Nature Reviews Clinical Oncology

DOI: https://doi.org/10.1038/s41571-022-00671-9

Paper At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

I. Otano; A. Ucero; J. Zugazagoitia et al. · 2023 · Nature Reviews Clinical Oncology · DOI

Full title: At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

Authors: I. Otano; A. Ucero; J. Zugazagoitia; L. Paz-Ares

Year: 2023

Venue: Nature Reviews Clinical Oncology

DOI: https://doi.org/10.1038/s41571-022-00718-x

Paper A prime editor mouse to model a broad spectrum of somatic mutations in vivo

Ely, Zackery A.; Mathey‐Andrews, Nicolas; Naranjo, Santiago et al. · 2023 · Nature Biotechnology · DOI

Full title: A prime editor mouse to model a broad spectrum of somatic mutations in vivo

Authors: Ely, Zackery A.; Mathey‐Andrews, Nicolas; Naranjo, Santiago; Gould, Samuel I.; Mercer, Kim L.; Newby, Gregory A.; Cabana, Christina M.; Rideout, William M.; Jaramillo, Grissel Cervantes; Khirallah, Jennifer; Holland, Katie; Randolph, Peyton B.; Freed-Pastor, William A.; Davis, Jessie R.; Kulstad, Zachary; Westcott, Peter M.K.; Lin, Lin; Anzalone, Andrew V.; Horton, Brendan; Pattada, Nimisha B.; Shanahan, Sean-Luc; Ye, Zhongfeng; Spranger, Stefani; Xu, Qiaobing; Sánchez‐Rivera, Francisco J.; Liu, David R.; Jacks, Tyler

Year: 2023

Venue: Nature Biotechnology

DOI: https://doi.org/10.1038/s41587-023-01783-y

Paper Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Warren, Hannah R.; Ross, Sarah J.; Smith, Paul D. et al. · 2022 · Biochemical Journal · DOI

Full title: Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Authors: Warren, Hannah R.; Ross, Sarah J.; Smith, Paul D.; Coulson, Judy M.; Prior, Ian A.

Year: 2022

Venue: Biochemical Journal

DOI: https://doi.org/10.1042/bcj20220440

Paper KRASG12C inhibitor: combing for combination.

A. Chakraborty · 2020 · Biochemical Society Transactions · DOI

Full title: KRASG12C inhibitor: combing for combination.

Authors: A. Chakraborty

Year: 2020

Venue: Biochemical Society Transactions

DOI: https://doi.org/10.1042/bst20200473

Paper Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC

Y. Fujiwara; N. Ammakkanavar; A. Hollebecque et al. · 2025 · Pneumologie · DOI

Full title: Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC

Authors: Y. Fujiwara; N. Ammakkanavar; A. Hollebecque; Y. Goroff; D. Lee; T. Burns; P. Cassier; J. Youn Han; A. Italiano; T. Koyama; B. Yong Shim; R. Heist; J. Sabari; A. Spira; J. Bodor; Q. Chu; G. Durm; N. Singhal; M. Chisamore; A. Fink; M. Willard; G. Oxnard; K. Dragnev; M. Thomas

Year: 2025

Venue: Pneumologie

DOI: https://doi.org/10.1055/s-0045-1804654

Paper Acquired Resistance to KRASG12C Inhibition in Cancer.

Awad, Mark M; Liu, Shengwu; Rybkin, Igor I et al. · 2021 · The New England journal of medicine · DOI

Full title: Acquired Resistance to KRASG12C Inhibition in Cancer.

Authors: Awad, Mark M; Liu, Shengwu; Rybkin, Igor I; Arbour, Kathryn C; Dilly, Julien; Zhu, Viola W; Johnson, Melissa L; Heist, Rebecca S; Patil, Tejas; Riely, Gregory J; Jacobson, Joseph O; Yang, Xiaoping; Persky, Nicole S; Root, David E; Lowder, Kristen E; Feng, Hanrong; Zhang, Shannon S; Haigis, Kevin M; Hung, Yin P; Sholl, Lynette M; Wolpin, Brian M; Wiese, Julie; Christiansen, Jason; Lee, Jessica; Schrock, Alexa B; Lim, Lee P; Garg, Kavita; Li, Mark; Engstrom, Lars D; Waters, Laura; Lawson, J David; Olson, Peter; Lito, Piro; Ou, Sai-Hong I; Christensen, James G; Jänne, Pasi A; Aguirre, Andrew J

Year: 2021

Venue: The New England journal of medicine

DOI: https://doi.org/10.1056/NEJMoa2105281

Paper Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

Jänne, Pasi A; Riely, Gregory J; Gadgeel, Shirish M et al. · 2022 · The New England journal of medicine · DOI

Full title: Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

Authors: Jänne, Pasi A; Riely, Gregory J; Gadgeel, Shirish M; Heist, Rebecca S; Ou, Sai-Hong I; Pacheco, Jose M; Johnson, Melissa L; Sabari, Joshua K; Leventakos, Konstantinos; Yau, Edwin; Bazhenova, Lyudmila; Negrao, Marcelo V; Pennell, Nathan A; Zhang, Jun; Anderes, Kenna; Der-Torossian, Hirak; Kheoh, Thian; Velastegui, Karen; Yan, Xiaohong; Christensen, James G; Chao, Richard C; Spira, Alexander I

Year: 2022

Venue: The New England journal of medicine

DOI: https://doi.org/10.1056/NEJMoa2204619

Paper Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Yaeger, Rona; Weiss, Jared; Pelster, Meredith et al. · 2022 · New England Journal of Medicine · DOI

Full title: Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Authors: Yaeger, Rona; Weiss, Jared; Pelster, Meredith; Spira, Alexander I.; Barve, Minal; Ou, Sai‐Hong Ignatius; Leal, Ticiana; Bekaii‐Saab, Tanios; Paweletz, Cloud P.; Heavey, Grace A.; Christensen, James G.; Velastegui, Karen; Kheoh, Thian; Der‐Torossian, Hirak; Klempner, Samuel J.

Year: 2022

Venue: New England Journal of Medicine

DOI: https://doi.org/10.1056/nejmoa2212419

Paper Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Sacher, Adrian G.; LoRusso, Patricia; Patel, Manish R. et al. · 2023 · New England Journal of Medicine · DOI

Full title: Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Authors: Sacher, Adrian G.; LoRusso, Patricia; Patel, Manish R.; Miller, Wilson H.; Garralda, Elena; Förster, Martin; Santoro, Armando; Falcón, Alejandro; Kim, Tae Won; Paz‐Ares, Luis; Bowyer, Samantha; Miguel, Maria J. de; Han, Sae‐Won; Krebs, Matthew; Lee, Jong Seok; Cheng, Michael L.; Arbour, Kathryn C.; Massarelli, Erminia; Choi, Yoonha; Shi, Zhen; Mandlekar, Sandhya; Lin, Mark T.; Royer‐Joo, Stephanie; Chang, Julie; Dharia, Neekesh V.; Schutzman, Jennifer L.; Desai, Jayesh

Year: 2023

Venue: New England Journal of Medicine

DOI: https://doi.org/10.1056/nejmoa2303810

Paper A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors

Siyu Feng; M. Callow; J. Fortin et al. · 2022 · Proceedings of the National Academy of Sciences of the United States of America · DOI

Full title: A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors

Authors: Siyu Feng; M. Callow; J. Fortin; Z. Khan; David Bray; Michael R. Costa; Zhen Shi; Weiru Wang; M. Evangelista

Year: 2022

Venue: Proceedings of the National Academy of Sciences of the United States of America

DOI: https://doi.org/10.1073/pnas.2120512119

Paper Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling

Amar Ajmal; Y. Ali; Ajmal Khan et al. · 2022 · Journal of Biomolecular Structure and Dynamics · DOI

Full title: Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling

Authors: Amar Ajmal; Y. Ali; Ajmal Khan; A. Wadood; A. Rehman

Year: 2022

Venue: Journal of Biomolecular Structure and Dynamics

DOI: https://doi.org/10.1080/07391102.2022.2138550

Paper Investigation of EGFR/pi3k/Akt signaling pathway in seminomas

F. Guerra; S. Quintana; S. Giustina et al. · 2020 · Biotechnic & Histochemistry · DOI

Full title: Investigation of EGFR/pi3k/Akt signaling pathway in seminomas

Authors: F. Guerra; S. Quintana; S. Giustina; G. Mendeluk; L. Jufe; M. Avagnina; L. Díaz; L. Palaoro

Year: 2020

Venue: Biotechnic & Histochemistry

DOI: https://doi.org/10.1080/10520295.2020.1776393

Paper Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.

Chia-Yu Kuo; Tzu-Wen Wang; A. Lieu et al. · 2025 · Journal of chemotherapy · DOI

Full title: Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.

Authors: Chia-Yu Kuo; Tzu-Wen Wang; A. Lieu; Chih-Jen Yang

Year: 2025

Venue: Journal of chemotherapy

DOI: https://doi.org/10.1080/1120009x.2025.2503052

Paper Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021).

Xu, Qifu; Zhang, Guozhen; Liu, Qian et al. · 2022 · Expert opinion on therapeutic patents · DOI

Full title: Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021).

Authors: Xu, Qifu; Zhang, Guozhen; Liu, Qian; Li, Shunda; Zhang, Yingjie

Year: 2022

Venue: Expert opinion on therapeutic patents

DOI: https://doi.org/10.1080/13543776.2022.2032648

Paper Inhibition of GTPase KRASG12D: a review of patent literature

Yuhang Li; Le Yang; Xiaoran Li et al. · 2024 · Expert Opinion on Therapeutic Patents · DOI

Full title: Inhibition of GTPase KRASG12D: a review of patent literature

Authors: Yuhang Li; Le Yang; Xiaoran Li; Xiaojin Zhang

Year: 2024

Venue: Expert Opinion on Therapeutic Patents

DOI: https://doi.org/10.1080/13543776.2024.2369630

Paper Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective.

Nadia Karim; David M. Waterhouse; S. Jones et al. · 2025 · Journal of Medical Economics · DOI

Full title: Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective.

Authors: Nadia Karim; David M. Waterhouse; S. Jones; Björn Stollenwerk

Year: 2025

Venue: Journal of Medical Economics

DOI: https://doi.org/10.1080/13696998.2025.2604968

Paper An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations

G. Strohbehn; K. Sankar; A. Qin et al. · 2022 · Expert Opinion on Pharmacotherapy · DOI

Full title: An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations

Authors: G. Strohbehn; K. Sankar; A. Qin; G. Kalemkerian

Year: 2022

Venue: Expert Opinion on Pharmacotherapy

DOI: https://doi.org/10.1080/14656566.2022.2134777

Paper Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC).

Herrmann, Amanda; Azenkot, Tali; Hilburn, Van et al. · 2025 · Expert opinion on pharmacotherapy · DOI

Full title: Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC).

Authors: Herrmann, Amanda; Azenkot, Tali; Hilburn, Van; Bazhenova, Lyudmila

Year: 2025

Venue: Expert opinion on pharmacotherapy

DOI: https://doi.org/10.1080/14656566.2025.2536352

Paper KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications

Anita Emami; Pouya Mahdavi Sharif; N. Rezaei · 2025 · Expert opinion on therapeutic targets · DOI

Full title: KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications

Authors: Anita Emami; Pouya Mahdavi Sharif; N. Rezaei

Year: 2025

Venue: Expert opinion on therapeutic targets

DOI: https://doi.org/10.1080/14728222.2025.2500426

Paper Molecular therapeutic targets in non-small cell lung cancer

K. Sankar; S. Gadgeel; A. Qin · 2020 · Expert Review of Anticancer Therapy · DOI

Full title: Molecular therapeutic targets in non-small cell lung cancer

Authors: K. Sankar; S. Gadgeel; A. Qin

Year: 2020

Venue: Expert Review of Anticancer Therapy

DOI: https://doi.org/10.1080/14737140.2020.1787156

Paper Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis

Luo, Wei; Zhu, Jing; Zhang, Wenxue et al. · 2023 · Expert Review of Anticancer Therapy · DOI

Full title: Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis

Authors: Luo, Wei; Zhu, Jing; Zhang, Wenxue; Yu, Airu; Zhou, Wei; Xu, Ke

Year: 2023

Venue: Expert Review of Anticancer Therapy

DOI: https://doi.org/10.1080/14737140.2023.2282606

Paper Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.

Higgins, Jordyn P; Carlisle, Jennifer W; Moniri, Nader H et al. · 2025 · Future oncology (London, England) · DOI

Full title: Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.

Authors: Higgins, Jordyn P; Carlisle, Jennifer W; Moniri, Nader H; Gupta, Shruti; Oduah, Eziafa I; Leal, Ticiana

Year: 2025

Venue: Future oncology (London, England)

DOI: https://doi.org/10.1080/14796694.2024.2430172

Paper Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.

Anchisi, Sandro; Wolfer, Anita; Bisig, Bettina et al. · 2023 · Cancer biology & therapy · DOI

Full title: Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.

Authors: Anchisi, Sandro; Wolfer, Anita; Bisig, Bettina; Missiglia, Edoardo; Tiab, Amine; Kamel, Ehab Mohamed; Michielin, Olivier; Coukos, George; Homicsko, Krisztian

Year: 2023

Venue: Cancer biology & therapy

DOI: https://doi.org/10.1080/15384047.2023.2193116

Paper Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.

Zhang, Yuda; Zeng, Fanxu; Peng, Shixuan et al. · 2023 · Expert review of respiratory medicine · DOI

Full title: Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.

Authors: Zhang, Yuda; Zeng, Fanxu; Peng, Shixuan; Chen, Yangqian; Jiang, Wenjuan; Wang, Zhan; Deng, Li; Huang, Zhe; Qin, Haoyue; Yan, Huan; Zhang, Xing; Zhang, Lin; Yang, Nong; Gong, Qian; Zeng, Liang; Zhang, Yongchang

Year: 2023

Venue: Expert review of respiratory medicine

DOI: https://doi.org/10.1080/17476348.2023.2265810

Paper Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer

Kitai, Hidenori; Ebi, Hiromichi · 2016 · Small GTPases · DOI

Full title: Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer

Authors: Kitai, Hidenori; Ebi, Hiromichi

Year: 2016

Venue: Small GTPases

DOI: https://doi.org/10.1080/21541248.2016.1210369

Paper A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors

T. McFall; E. Stites · 2020 · Molecular & Cellular Oncology · DOI

Full title: A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors

Authors: T. McFall; E. Stites

Year: 2020

Venue: Molecular & Cellular Oncology

DOI: https://doi.org/10.1080/23723556.2019.1701914

Paper SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Fedele, Carmine; Li, Shuai; Teng, Kai Wen et al. · 2020 · The Journal of Experimental Medicine · DOI

Full title: SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Year: 2020

Venue: The Journal of Experimental Medicine

DOI: https://doi.org/10.1084/jem.20201414

Paper DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity

Valencia, Karmele; Echepare, Mirari; Teijeira, Álvaro et al. · 2022 · The Journal of Experimental Medicine · DOI

Full title: DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity

Authors: Valencia, Karmele; Echepare, Mirari; Teijeira, Álvaro; Pasquier, Andrea; Bértolo, Cristina; Sainz, Cristina; Tamayo, Ibón; Picabea, Beñat; Bosco, Graziella; Thomas, Roman K.; Agorreta, Jackeline; López-Picazo, José M.; Frigola, Joan; Amat, Ramon; Calvo, Alfonso; Felip, Enriqueta; Melero, Ignacio; Montuenga, Luis M.

Year: 2022

Venue: The Journal of Experimental Medicine

DOI: https://doi.org/10.1084/jem.20220726

Paper Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

Garassino, Marina Chiara; Marabese, Mirko; Rusconi, P et al. · 2011 · Annals of Oncology · DOI

Full title: Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

Authors: Garassino, Marina Chiara; Marabese, Mirko; Rusconi, P; Rulli, Eliana; Martelli, Olga; Farina, Gabriella; Scanni, A.; Broggini, Massimo

Year: 2011

Venue: Annals of Oncology

DOI: https://doi.org/10.1093/annonc/mdq680

Paper Academically led clinical trials: challenges and opportunities

S. Turajlic; J. Larkin; C. Swanton · 2015 · Annals of Oncology · DOI

Full title: Academically led clinical trials: challenges and opportunities

Authors: S. Turajlic; J. Larkin; C. Swanton

Year: 2015

Venue: Annals of Oncology

DOI: https://doi.org/10.1093/annonc/mdv332

Paper Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

B.T. Li; F. Janku; B. Jung et al. · 2019 · Annals of Oncology · DOI

Full title: Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

Authors: B.T. Li; F. Janku; B. Jung; C. Hou; K. Madwani; R. Alden; P. Razavi; J. Reis-Filho; R. Shen; J. Isbell; A. Blocker; N. Eattock; S. Gnerre; R. Satya; H. Xu; C. Zhao; M. Hall; Y. Hu; A. Sehnert; D. Brown; M. Ladanyi; C. Rudin; N. Hunkapiller; N. Feeney; G. Mills; C. Paweletz; P. Janne; D. Solit; Gregory Riely; A. Aravanis; G. Oxnard

Year: 2019

Venue: Annals of Oncology

DOI: https://doi.org/10.1093/annonc/mdz046

Paper Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases

F. Pietrantonio; J. Lee; L. Boussemart et al. · 2019 · Annals of Oncology · DOI

Full title: Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases

Authors: F. Pietrantonio; J. Lee; L. Boussemart; C. Schinke; G. Srkalović; R. Madison; J. Ross; V. Miller; B. Alexander; Siraj M. Ali; A. Schrock; G. Daniels

Year: 2019

Venue: Annals of Oncology

DOI: https://doi.org/10.1093/annonc/mdz268.005

Paper Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2

R. Doebele; R. Dziadziuszko; A. Drilon et al. · 2019 · Annals of Oncology · DOI

Full title: Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2

Authors: R. Doebele; R. Dziadziuszko; A. Drilon; A. Shaw; J. Wolf; A. Farago; L. Dennis; T. Riehl; B. Simmons; C. Wu; C-W. Chang; V. Choeurng; T. Wilson

Year: 2019

Venue: Annals of Oncology

DOI: https://doi.org/10.1093/annonc/mdz394.017

Paper A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)

D. Enrico; L. Lacroix; E. Rouleau et al. · 2019 · Annals of Oncology · DOI

Full title: A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)

Authors: D. Enrico; L. Lacroix; E. Rouleau; J. Scoazec; Y. Loriot; L. Tselikas; C. Jovelet; D. Planchard; A. Gazzah; L. Mezquita; M. Ngo; S. Michiels; A. Maillard; C. Massard; F. Facchinetti; J. Soria; F. André; G. Vassal; L. Friboulet; B. Besse

Year: 2019

Venue: Annals of Oncology

DOI: https://doi.org/10.1093/annonc/mdz413.031

Paper The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer

J-H. Chen; X. Chu; Jia‐Tao Zhang et al. · 2019 · Annals of Oncology · DOI

Full title: The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer

Authors: J-H. Chen; X. Chu; Jia‐Tao Zhang; Q. Nie; J. Su; Hong-Hong Yan; H-P Zheng; Xiao Chen; M. Song; Lisheng Chang; P-S Li; Y. Guan; Y. Wu; W. Zhong

Year: 2019

Venue: Annals of Oncology

DOI: https://doi.org/10.1093/annonc/mdz431.026

Paper LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

R. Herbst; G. Lopes; D. Kowalski et al. · 2019 · DOI

Full title: LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

Authors: R. Herbst; G. Lopes; D. Kowalski; K. Kasahara; Y. Wu; G. D. Castro; B. Cho; H. Turna; R. Cristescu; D. Aurora-Garg; J. Lunceford; J. Kobie; M. Ayers; M. Pietanza; B. Piperdi; T. Mok

Year: 2019

DOI: https://doi.org/10.1093/annonc/mdz453.001

Paper KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

S. Gadgeel; D. Rodríguez-Abreu; E. Felip et al. · 2019 · DOI

Full title: KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

Authors: S. Gadgeel; D. Rodríguez-Abreu; E. Felip; E. Esteban; G. Speranza; M. Reck; R. Hui; M. Boyer; E. Garon; H. Horinouchi; R. Cristescu; D. Aurora-Garg; J. Lunceford; J. Kobie; M. Ayers; B. Piperdi; M. Pietanza; M. Garassino

Year: 2019

DOI: https://doi.org/10.1093/annonc/mdz453.002

Paper Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers

Liam Donnelly; Tyler Hogan; Sean M. Lenahan et al. · 2021 · Carcinogenesis · DOI

Full title: Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers

Authors: Liam Donnelly; Tyler Hogan; Sean M. Lenahan; Gopika Nandagopal; Jenna G Eaton; Meagan A Lebeau; Cai L McCann; Hailey M. Sarausky; K. Hampel; Jordan D Armstrong; M. Cameron; N. Sidiropoulos; Paula B Deming; D. Seward

Year: 2021

Venue: Carcinogenesis

DOI: https://doi.org/10.1093/carcin/bgab104

Paper Editorial of special issue on pharmacotherapeutics of digestive tumors

Liwu Fu · 2020 · Gastroenterology Report · DOI

Full title: Editorial of special issue on pharmacotherapeutics of digestive tumors

Authors: Liwu Fu

Year: 2020

Venue: Gastroenterology Report

DOI: https://doi.org/10.1093/gastro/goaa038

Paper Targeting KRAS G12C mutations in colorectal cancer

Mingde Zhao; A. Wu · 2022 · Gastroenterology Report · DOI

Full title: Targeting KRAS G12C mutations in colorectal cancer

Authors: Mingde Zhao; A. Wu

Year: 2022

Venue: Gastroenterology Report

DOI: https://doi.org/10.1093/gastro/goac083

Paper The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling

Umemoto, Kumiko; Yamamoto, Hiroyuki; Oikawa, Ritsuko et al. · 2022 · JNCI Journal of the National Cancer Institute · DOI

Full title: The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling

Authors: Umemoto, Kumiko; Yamamoto, Hiroyuki; Oikawa, Ritsuko; Takeda, Hiroyuki; Doi, Ayako; Horie, Yoshiki; Arai, Hiroyuki; Ogura, Takashi; Mizukami, Takuro; Izawa, Naoki; Moore, Jay A.; Sokol, Ethan; Sunakawa, Yu

Year: 2022

Venue: JNCI Journal of the National Cancer Institute

DOI: https://doi.org/10.1093/jnci/djac106

Paper Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides

Juliano, Rudolph L. · 2020 · NAR Cancer · DOI

Full title: Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides

Authors: Juliano, Rudolph L.

Year: 2020

Venue: NAR Cancer

DOI: https://doi.org/10.1093/narcan/zcaa025

Paper RADT-67. EVALUATING THE EFFICACY OF G12C-INHIBITORS IN CONJUNCTION WITH GAMMA KNIFE RADIOSURGERY FOR KRAS-MUTANT NSCLC BRAIN METASTASES

M. Mureb; A. A. D. de Moura; Nilay Karaman et al. · 2025 · Neuro-Oncology · DOI

Full title: RADT-67. EVALUATING THE EFFICACY OF G12C-INHIBITORS IN CONJUNCTION WITH GAMMA KNIFE RADIOSURGERY FOR KRAS-MUTANT NSCLC BRAIN METASTASES

Authors: M. Mureb; A. A. D. de Moura; Nilay Karaman; Cindy Liu; B. Donahue; K. Bernstein; Benjamin Cooper; Douglas Kondziolka

Year: 2025

Venue: Neuro-Oncology

DOI: https://doi.org/10.1093/neuonc/noaf201.0436

Paper Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

Wang, Judy; Martín-Romano, Patricia; Cassier, Philippe A. et al. · 2022 · The Oncologist · DOI

Full title: Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

Authors: Wang, Judy; Martín-Romano, Patricia; Cassier, Philippe A.; Johnson, Melissa L.; Haura, Eric B.; Lenox, Laurie; Guo, Yue; Bandyopadhyay, Nibedita; Russell, Michael J.; Shearin, Elizabeth; Lauring, Josh; Dahan, Laëtitia

Year: 2022

Venue: The Oncologist

DOI: https://doi.org/10.1093/oncolo/oyab080

Paper Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases

Huang, Richard S.P.; Harries, Lukas; Decker, Brennan et al. · 2022 · The Oncologist · DOI

Full title: Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases

Authors: Huang, Richard S.P.; Harries, Lukas; Decker, Brennan; Hiemenz, Matthew; Murugesan, Karthikeyan; Creeden, James; Tolba, Khaled; Stabile, Laura P.; Ramkissoon, Shakti; Burns, Timothy F.; Ross, Jeffrey S.

Year: 2022

Venue: The Oncologist

DOI: https://doi.org/10.1093/oncolo/oyac094

Paper KRAS : Druggable at Last

Herzberg, Benjamin; Manji, Gulam A. · 2023 · The Oncologist · DOI

Full title: KRAS : Druggable at Last

Authors: Herzberg, Benjamin; Manji, Gulam A.

Year: 2023

Venue: The Oncologist

DOI: https://doi.org/10.1093/oncolo/oyad014

Paper Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

Elkrief, Arielle; Ricciuti, Biagio; Alessi, Joao V. et al. · 2023 · The Oncologist · DOI

Full title: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

Authors: Elkrief, Arielle; Ricciuti, Biagio; Alessi, Joao V.; Fei, Teng; Kalvin, Hannah L.; Egger, Jacklynn V.; Rizvi, Hira; Thummalapalli, Rohit; Lamberti, Giuseppe; Plodkowski, Andrew J.; Hellmann, Matthew D.; Kris, Mark G.; Arcila, Maria E.; Baine, Marina K.; Rudin, Charles M.; Lito, Piro; Ladanyi, Marc; Schoenfeld, Adam J.; Riely, Gregory J.; Awad, Mark M.; Arbour, Kathryn C.

Year: 2023

Venue: The Oncologist

DOI: https://doi.org/10.1093/oncolo/oyad197

Paper Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report.

Vitale, Antonio; Vita, Emanuele; Stefani, Alessio et al. · 2025 · The oncologist · DOI

Full title: Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report.

Authors: Vitale, Antonio; Vita, Emanuele; Stefani, Alessio; Cancellieri, Alessandra; Lococo, Filippo; Tortora, Giampaolo; Bria, Emilio

Year: 2025

Venue: The oncologist

DOI: https://doi.org/10.1093/oncolo/oyaf030

Paper Regulation of ferroptosis in KRas mutant cancer cells

B. Choi; T. Colon; J. Jiang et al. · 2020 · The FASEB Journal · DOI

Full title: Regulation of ferroptosis in KRas mutant cancer cells

Authors: B. Choi; T. Colon; J. Jiang; Eunji Lee; W. Dai

Year: 2020

Venue: The FASEB Journal

DOI: https://doi.org/10.1096/fasebj.2020.34.s1.09236

Paper Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells

Booth, Laurence; Poklepovic, Andrew; Hancock, John F. et al. · 2023 · Anti-Cancer Drugs · DOI

Full title: Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells

Authors: Booth, Laurence; Poklepovic, Andrew; Hancock, John F.; Dent, Paul

Year: 2023

Venue: Anti-Cancer Drugs

DOI: https://doi.org/10.1097/cad.0000000000001442

Paper A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development

Peng Yue; C. Hon; Xiaoping Zhao et al. · 2025 · Anti-Cancer Drugs · DOI

Full title: A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development

Authors: Peng Yue; C. Hon; Xiaoping Zhao; Fayaz Ali; Jiayi Sun; Jiyou Kou

Year: 2025

Venue: Anti-Cancer Drugs

DOI: https://doi.org/10.1097/cad.0000000000001773

Paper The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.

Daniel F Pilco-Janeta; Myriam De la Cruz-Puebla · 2025 · Anti-Cancer Drugs · DOI

Full title: The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.

Authors: Daniel F Pilco-Janeta; Myriam De la Cruz-Puebla

Year: 2025

Venue: Anti-Cancer Drugs

DOI: https://doi.org/10.1097/cad.0000000000001801

Paper Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance

Xiyuan Luo; Feihan Zhou; Yuemeng Tang et al. · 2025 · Chinese Medical Journal · DOI

Full title: Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance

Authors: Xiyuan Luo; Feihan Zhou; Yuemeng Tang; Xiaohong Liu; Ruiling Xiao; Minzhi Gu; Jialu Bai; Decheng Jiang; Gang Yang; Lei You; Yupei Zhao

Year: 2025

Venue: Chinese Medical Journal

DOI: https://doi.org/10.1097/cm9.0000000000003776

Paper Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

Abdelmonem, Ahmed; Bikram Shah, Bidhan; Shebli, Mouza Al et al. · 2025 · American journal of clinical oncology · DOI

Full title: Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

Authors: Abdelmonem, Ahmed; Bikram Shah, Bidhan; Shebli, Mouza Al; Tabbara, Imad A

Year: 2025

Venue: American journal of clinical oncology

DOI: https://doi.org/10.1097/COC.0000000000001275

Paper Non–Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB)

L. Tafe · 2019 · Advances in Anatomic Pathology · DOI

Full title: Non–Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB)

Authors: L. Tafe

Year: 2019

Venue: Advances in Anatomic Pathology

DOI: https://doi.org/10.1097/pap.0000000000000244

Paper The Ever Changing Landscape of Anatomic Pathology Practice.

G. Netto · 2020 · Advances in Anatomic Pathology · DOI

Full title: The Ever Changing Landscape of Anatomic Pathology Practice.

Authors: G. Netto

Year: 2020

Venue: Advances in Anatomic Pathology

DOI: https://doi.org/10.1097/pap.0000000000000255

Paper Genetic mechanisms of resistance to targeted KRAS inhibition

Bianca J. Diaz; Max Kops; Sara Bernardo et al. · 2025 · bioRxiv · DOI

Full title: Genetic mechanisms of resistance to targeted KRAS inhibition

Authors: Bianca J. Diaz; Max Kops; Sara Bernardo; Henri Schmidt; Elizabeth Grankowsky; Adrian Vega; Chen Zhang; Matthew Bott; Maria Skamagki; A. Tomlinson; Nicole A Vita; Alyna Katti; Mark P Labrecque; Ida Aronchik; Mallika Singh; Lukas E. Dow

Year: 2025

Venue: bioRxiv

DOI: https://doi.org/10.1101/2025.08.04.668444

Paper The ERBB network facilitates KRAS-driven lung tumorigenesis

Kruspig, Björn; Monteverde, Tiziana; Neidler, Sarah et al. · 2018 · DOI

Full title: The ERBB network facilitates KRAS-driven lung tumorigenesis

Authors: Kruspig, Björn; Monteverde, Tiziana; Neidler, Sarah; Hock, Andreas; Kerr, Emma; Nixon, Colin; Clark, William; Hedley, Ann; Dick, Craig; Vousden, Karen H.; Martins, Carla P.; Murphy, Daniel J.

Year: 2018

DOI: https://doi.org/10.1101/290700

Paper KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)

Hanxiao Chen; Jun Zhao · 2020 · Thoracic Cancer · DOI

Full title: KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)

Authors: Hanxiao Chen; Jun Zhao

Year: 2020

Venue: Thoracic Cancer

DOI: https://doi.org/10.1111/1759-7714.13538

Paper High SHP2 expression determines the efficacy of PD ‐1/ PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

Feng, Hui‐Bo; Chen, Yu; Xie, Zhi et al. · 2021 · Thoracic Cancer · DOI

Full title: High SHP2 expression determines the efficacy of PD ‐1/ PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

Authors: Feng, Hui‐Bo; Chen, Yu; Xie, Zhi; Jiang, Jie; Zhong, Yumin; Guo, Wei‐Bang; Yan, Wenqing; Lv, Zhiyi; Lu, Danxia; Liang, Hong‐Ling; Xu, Fangping; Yang, Jin‐Ji; Yang, Xue‐Ning; Zhou, Qing; Zhang, Dong‐Kun; Zhang, Zhou; Chuai, Shaokun; Zhang, Henghui; Wu, Yi‐Long; Zhang, Xu‐Chao

Year: 2021

Venue: Thoracic Cancer

DOI: https://doi.org/10.1111/1759-7714.14137

Paper Not just g RAS ping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Ebi, Hiromichi; Faber, Anthony C.; Engelman, Jeffrey A. et al. · 2014 · Cancer Science · DOI

Full title: Not just g RAS ping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Authors: Ebi, Hiromichi; Faber, Anthony C.; Engelman, Jeffrey A.; Yano, Seiji

Year: 2014

Venue: Cancer Science

DOI: https://doi.org/10.1111/cas.12383

Paper Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Koga, Takamasa; Suda, Kenichi; Mitsudomi, Tetsuya · 2022 · Cancer science · DOI

Full title: Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Authors: Koga, Takamasa; Suda, Kenichi; Mitsudomi, Tetsuya

Year: 2022

Venue: Cancer science

DOI: https://doi.org/10.1111/cas.15263

Paper D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity

Shi, Zhe; Weng, Jifang; Niu, Haotao et al. · 2023 · Cancer Science · DOI

Full title: D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity

Authors: Shi, Zhe; Weng, Jifang; Niu, Haotao; Yang, Hong; Liu, Rongfeng; Weng, Yan; Zhu, Qingqing; Zhang, Yihong; Tao, Liangshan; Wang, Zhenwu; Huh, Seok Jae; Jiang, Yueheng; Mei, Hong; Dai, Xing; Zhang, Ling; Wang, Yaolin

Year: 2023

Venue: Cancer Science

DOI: https://doi.org/10.1111/cas.15829

Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer

Lee, Mi Rim; Woo, Sang Myung; Kim, Min Kyeong et al. · 2024 · Cancer Science · DOI

Full title: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer

Authors: Lee, Mi Rim; Woo, Sang Myung; Kim, Min Kyeong; Han, Sung‐Sik; Park, Sang‐Jae; Lee, Woo Jin; Lee, Dong-Eun; Choi, Sung Yong; Choi, Wonyoung; Yoon, Kyong‐Ah; Chun, Jung Won; Kim, Yun‐Hee; Kong, Sun‐Young

Year: 2024

Venue: Cancer Science

DOI: https://doi.org/10.1111/cas.16104

Paper Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt

Noritaka Tanaka; Hiromichi Ebi · 2024 · Cancer Science · DOI

Full title: Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt

Authors: Noritaka Tanaka; Hiromichi Ebi

Year: 2024

Venue: Cancer Science

DOI: https://doi.org/10.1111/cas.16441

Paper Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer

Kai Song; Haibo Lu; Liangliang Jin et al. · 2020 · The FEBS Journal · DOI

Full title: Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer

Authors: Kai Song; Haibo Lu; Liangliang Jin; Kai Wang; Wenbing Guo; Hailong Zheng; Keru Li; C. He; Tianyi You; Yelin Fu; Jing Yang; Wenyuan Zhao; Zheng Guo

Year: 2020

Venue: The FEBS Journal

DOI: https://doi.org/10.1111/febs.15306

Paper Developments in systemic therapies for the management of lung cancer

Heynemann, Sarah; Mitchell, Paul · 2021 · Internal Medicine Journal · DOI

Full title: Developments in systemic therapies for the management of lung cancer

Authors: Heynemann, Sarah; Mitchell, Paul

Year: 2021

Venue: Internal Medicine Journal

DOI: https://doi.org/10.1111/imj.15609

Paper B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy

Yu Zhao; Yuejiao Cao; Yiqi Chen et al. · 2021 · Immunology · DOI

Full title: B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy

Authors: Yu Zhao; Yuejiao Cao; Yiqi Chen; Lei Wu; H. Hang; Chenxia Jiang; Xiaorong Zhou

Year: 2021

Venue: Immunology

DOI: https://doi.org/10.1111/imm.13384

Paper Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model

Hsu, Ping‐Chih; Miao, Jinbai; Huang, Zhen et al. · 2018 · Journal of Cellular and Molecular Medicine · DOI

Full title: Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model

Authors: Hsu, Ping‐Chih; Miao, Jinbai; Huang, Zhen; Yang, Yi‐Lin; Xu, Zhidong; You, Joanna; Dai, Yuyuan; Yeh, Che‐Chung; Chan, Geraldine; Liu, Shu; Urisman, Anatoly; Yang, Cheng‐Ta; Jablons, David M.; You, Liang

Year: 2018

Venue: Journal of Cellular and Molecular Medicine

DOI: https://doi.org/10.1111/jcmm.13582

Paper Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.

Mohanty, Atish; Nam, Arin; Srivastava, Saumya et al. · 2023 · Science advances · DOI

Full title: Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.

Authors: Mohanty, Atish; Nam, Arin; Srivastava, Saumya; Jones, Jeff; Lomenick, Brett; Singhal, Sharad S; Guo, Linlin; Cho, Hyejin; Li, Aimin; Behal, Amita; Mirzapoiazova, Tamara; Massarelli, Erminia; Koczywas, Marianna; Arvanitis, Leonidas D; Walser, Tonya; Villaflor, Victoria; Hamilton, Stanley; Mambetsariev, Isa; Sattler, Martin; Nasser, Mohd W; Jain, Maneesh; Batra, Surinder K; Soldi, Raffaella; Sharma, Sunil; Fakih, Marwan; Mohanty, Saswat Kumar; Mainan, Avijit; Wu, Xiwei; Chen, Yihong; He, Yanan; Chou, Tsui-Fen; Roy, Susmita; Orban, John; Kulkarni, Prakash; Salgia, Ravi

Year: 2023

Venue: Science advances

DOI: https://doi.org/10.1126/sciadv.ade3816

Paper SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition

Xinxin Song; Zhuan Zhou; Ammar D. Elmezayen et al. · 2024 · Science Advances · DOI

Full title: SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition

Authors: Xinxin Song; Zhuan Zhou; Ammar D. Elmezayen; Runliu Wu; Chunhua Yu; B. Gao; John D. Minna; Kenneth D Westover; Herbert J Zeh; Guido Kroemer; Lynn E. Heasley; Rui Kang; D. Tang

Year: 2024

Venue: Science Advances

DOI: https://doi.org/10.1126/sciadv.adq4274

Paper Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer

Jennifer E. Klomp; J. Diehl; Jeffrey A. Klomp et al. · 2024 · Science · DOI

Full title: Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer

Authors: Jennifer E. Klomp; J. Diehl; Jeffrey A. Klomp; A. C. Edwards; Run-Wei Yang; Alexis J. Morales; Khalilah E Taylor; Kristina Drizyte-Miller; Kirsten L. Bryant; Antje Schaefer; Jared L. Johnson; Emily M Huntsman; Tomer M. Yaron; M. Pierobon; E. Baldelli; Alex W. Prevatte; Natalie K Barker; Laura E. Herring; Emanuel F. PetricoinIII; Lee M. Graves; Lewis C Cantley; Adrienne D. Cox; C. Der; Clint A. Stalnecker; Emanuel F. Petricoin

Year: 2024

Venue: Science

DOI: https://doi.org/10.1126/science.adk0850

Paper The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells.

Kurimchak, Alison M; Herrera-Montávez, Carlos; Montserrat-Sangrà, Sara et al. · 2022 · Science signaling · DOI

Full title: The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells.

Authors: Kurimchak, Alison M; Herrera-Montávez, Carlos; Montserrat-Sangrà, Sara; Araiza-Olivera, Daniela; Hu, Jianping; Neumann-Domer, Ryan; Kuruvilla, Mathew; Bellacosa, Alfonso; Testa, Joseph R; Jin, Jian; Duncan, James S

Year: 2022

Venue: Science signaling

DOI: https://doi.org/10.1126/scisignal.abn2707

Paper ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

D. Peng; S. Kundu; Jared J. Fradette et al. · 2019 · Science Translational Medicine · DOI

Full title: ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

Authors: D. Peng; S. Kundu; Jared J. Fradette; L. Diao; P. Tong; L. Byers; Jing Wang; J. R. Canales; P. Villalobos; B. Mino; Yanan Yang; R. Minelli; M. Peoples; C. Bristow; T. Heffernan; A. Carugo; I. Wistuba; D. Gibbons

Year: 2019

Venue: Science Translational Medicine

DOI: https://doi.org/10.1126/scitranslmed.aaq1238

Paper Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells

Moiez Ali; Min Lu; H. Ang et al. · 2022 · Science Translational Medicine · DOI

Full title: Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells

Authors: Moiez Ali; Min Lu; H. Ang; R. Soderquist; C. Eyler; Haley M. Hutchinson; C. Glass; Christopher F. Bassil; Omar M. Lopez; D. Kerr; C. Falcon; H. Yu; A. Hata; C. Blakely; C. McCoach; T. Bivona; K. Wood

Year: 2022

Venue: Science Translational Medicine

DOI: https://doi.org/10.1126/scitranslmed.abc7480

Paper Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.

Hailei Huang; Qing Deng; Lei Guo et al. · 2026 · Science Translational Medicine · DOI

Full title: Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.

Authors: Hailei Huang; Qing Deng; Lei Guo; Teresa Gorria; Federica Pecci; Daniella Yang; S. Rodig; Luis De Las Casas; Jill Hallin; James G Christensen; Mark M Awad; Lin Xu; B. Ricciuti; Esra A. Akbay

Year: 2026

Venue: Science Translational Medicine

DOI: https://doi.org/10.1126/scitranslmed.adq6647

Paper KRAS-targeted therapies in cancer: novel approaches and overcoming resistance

Daolin Tang; Guido Kroemer; Rui Kang · 2025 · BMJ Oncology · DOI

Full title: KRAS-targeted therapies in cancer: novel approaches and overcoming resistance

Authors: Daolin Tang; Guido Kroemer; Rui Kang

Year: 2025

Venue: BMJ Oncology

DOI: https://doi.org/10.1136/bmjonc-2025-000946

Paper Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice

Sherwood, James; Brown, Helen; Rettino, Alessandro et al. · 2017 · ESMO Open · DOI

Full title: Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice

Authors: Sherwood, James; Brown, Helen; Rettino, Alessandro; Schreieck, Amelie; Clark, Graeme M.; Claes, Bart; Agrawal, Bhuwnesh; Chaston, Ria; Kong, Benjamin S.G.; Choppa, Paul; Nygren, Anders O.H.; Deras, Ina L.; Kohlmann, Alexander

Year: 2017

Venue: ESMO Open

DOI: https://doi.org/10.1136/esmoopen-2017-000235

Paper 15 Identification of new combination therapies for lung cancer tumours harbouring KRAS mutations

M. Molina-Arcas; C. Moore; S. Rana et al. · 2018 · ESMO Open · DOI

Full title: 15 Identification of new combination therapies for lung cancer tumours harbouring KRAS mutations

Authors: M. Molina-Arcas; C. Moore; S. Rana; F. van Maldegem; S. Horswell; D. Hancock; J. Downward

Year: 2018

Venue: ESMO Open

DOI: https://doi.org/10.1136/esmoopen-2018-eacr25.15

Paper PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment

C. Ambrogio; P. Jänne · 2018 · DOI

Full title: PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment

Authors: C. Ambrogio; P. Jänne

Year: 2018

DOI: https://doi.org/10.1136/esmoopen-2018-eacr25.244

Paper PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment

C. Ambrogio; P. Jänne · 2018 · DOI

Full title: PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment

Authors: C. Ambrogio; P. Jänne

Year: 2018

DOI: https://doi.org/10.1136/esmoopen-2018-eacr25.244

Paper Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients

Malapelle, Umberto; Vigliar, Elena; Sgariglia, Roberta et al. · 2014 · Journal of Clinical Pathology · DOI

Full title: Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients

Authors: Malapelle, Umberto; Vigliar, Elena; Sgariglia, Roberta; Bellevicine, Claudio; Colarossi, Lorenzo; Vitale, Domenico; Pallante, Pierlorenzo; Troncone, Giancarlo

Year: 2014

Venue: Journal of Clinical Pathology

DOI: https://doi.org/10.1136/jclinpath-2014-202691

Paper Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice

D. Moore; K. Balbi; A. Ingham et al. · 2018 · Journal of Clinical Pathology · DOI

Full title: Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice

Authors: D. Moore; K. Balbi; A. Ingham; H. Arkenau; P. Bennett

Year: 2018

Venue: Journal of Clinical Pathology

DOI: https://doi.org/10.1136/jclinpath-2018-205319

Paper RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications

Saeed, Omer; López-Beltrán, Antonio; Fisher, Kurt W. et al. · 2018 · Journal of Clinical Pathology · DOI

Full title: RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications

Authors: Saeed, Omer; López-Beltrán, Antonio; Fisher, Kurt W.; Scarpelli, Marina; Montironi, Rodolfo; Cimadamore, Alessia; Massari, Francesco; Santoni, Matteo; Cheng, Liang

Year: 2018

Venue: Journal of Clinical Pathology

DOI: https://doi.org/10.1136/jclinpath-2018-205471

Paper Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms

Neuwelt, Alexander; Kimball, Abigail K.; Johnson, Amber M. et al. · 2020 · Journal for ImmunoTherapy of Cancer · DOI

Full title: Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms

Authors: Neuwelt, Alexander; Kimball, Abigail K.; Johnson, Amber M.; Arnold, Benjamin W; Bullock, Bonnie; Kaspar, Rachael E.; Kleczko, Emily K.; Kwak, Jeff; Wu, Meng‐Han; Heasley, Lynn E.; Doebele, Robert C.; Li, Howard; Nemenoff, Raphael A.; Clambey, Eric T.

Year: 2020

Venue: Journal for ImmunoTherapy of Cancer

DOI: https://doi.org/10.1136/jitc-2019-000441

Paper Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Negrão, Marcelo V.; Skoulidis, Ferdinandos; Montesion, Meagan et al. · 2021 · Journal for ImmunoTherapy of Cancer · DOI

Full title: Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Authors: Negrão, Marcelo V.; Skoulidis, Ferdinandos; Montesion, Meagan; Schulze, Katja; Bāra, Ilze; Shen, Vincent K.; Xu, Hao; Hu, Sylvia; Sui, Dawen; Elamin, Yasir Y.; Le, Xiuning; Goldberg, Michael E.; Murugesan, Karthikeyan; Wu, Chang‐Jiun; Zhang, Jianhua; Barreto, David S; Robichaux, Jacqulyne; Reuben, Alexandre; Cascone, Tina; Gay, Carl M.; Mitchell, K. G.; Hong, Lingzhi; Rinsurongkawong, Waree; Roth, Jack A.; Swisher, Stephen G.; Lee, J. Jack; Tsao, Anne S.; Papadimitrakopoulou, Vassiliki A.; Gibbons, Don L.; Glisson, Bonnie S.; Singal, Gaurav; Miller, Vincent A.; Alexander, Brian M.; Frampton, Garrett M.; Albacker, Lee A.; Shames, David S.; Zhang, Jianjun; Heymach, John V.; Zhang, Jianjun; Heymach, John V

Year: 2021

Venue: Journal for ImmunoTherapy of Cancer

DOI: https://doi.org/10.1136/jitc-2021-002891

Paper Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers

Hu, Chunhong; Zhao, Lishu; Liu, Wenliang et al. · 2021 · Journal for ImmunoTherapy of Cancer · DOI

Full title: Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers

Authors: Hu, Chunhong; Zhao, Lishu; Liu, Wenliang; Fan, Songqing; Liu, Junqi; Liu, Yuxuan; Liu, Xiaohan; Shu, Long; Liu, Xianling; Liu, Ping; Deng, Chao; Qiu, Zhenhua; Chen, Chen; Jiang, Yi; Liang, Qingchun; Yang, Lingling; Shao, Yang; He, Qiongzhi; Yu, Danlei; Zeng, Yue; Li, Yizheng; Pan, Yue; Zhang, Sujuan; Shi, Shenghao; Peng, Yurong; Wu, Fang

Year: 2021

Venue: Journal for ImmunoTherapy of Cancer

DOI: https://doi.org/10.1136/jitc-2021-003773

Paper 1403 Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status – A real world analysis in patients with advanced NSCLC

Aggarwal, Charu; Nimeiri, Halla; Chen, James et al. · 2022 · Regular and Young Investigator Award Abstracts · DOI

Full title: 1403 Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status – A real world analysis in patients with advanced NSCLC

Authors: Aggarwal, Charu; Nimeiri, Halla; Chen, James; Huerga, Iker; Horn, Leora; Trunova, Nataliya; Patel, Jyoti D.

Year: 2022

Venue: Regular and Young Investigator Award Abstracts

DOI: https://doi.org/10.1136/jitc-2022-sitc2022.1403

Paper 388 A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combination with a PD1–41BB armoring and enhancement costimulatory switch receptor

Schendel, Dolores J.; Longinotti, Giulia; Catarinella, Mario et al. · 2023 · Regular and Young Investigator Award Abstracts · DOI

Full title: 388 A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combination with a PD1–41BB armoring and enhancement costimulatory switch receptor

Authors: Schendel, Dolores J.; Longinotti, Giulia; Catarinella, Mario; Salvermoser, Melanie; Bittmann, Julia; Crame, Kirsty; Davari, Kathrin

Year: 2023

Venue: Regular and Young Investigator Award Abstracts

DOI: https://doi.org/10.1136/jitc-2023-sitc2023.0388

Paper 466 Combined inhibition of KRAS G12C and PD-1 boosts the therapeutic efficacy via conditioning of tumor microenvironment in pre-clinical humanized NSCLC mouse models

Ting Ni; Tongxin Huo; Yawen Zhang et al. · 2023 · Regular and Young Investigator Award Abstracts · DOI

Full title: 466 Combined inhibition of KRAS G12C and PD-1 boosts the therapeutic efficacy via conditioning of tumor microenvironment in pre-clinical humanized NSCLC mouse models

Authors: Ting Ni; Tongxin Huo; Yawen Zhang; Panpan Wang; Huacheng He; Jingjing Wang; Wenting Shi; Xiangnan Qiang; Qingyang Gu

Year: 2023

Venue: Regular and Young Investigator Award Abstracts

DOI: https://doi.org/10.1136/jitc-2023-sitc2023.0466

Paper Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance

T. Sewastianik; Christian Roy; Michael V. Gormally et al. · 2025 · Journal for ImmunoTherapy of Cancer · DOI

Full title: Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance

Authors: T. Sewastianik; Christian Roy; Michael V. Gormally; M. Montesion; Patrick Halvey; Aastha Jindal; Hubert Lam; A. Schoenfeld; Christopher A. Klebanoff; G. Opiteck; Dirk Nagorsen

Year: 2025

Venue: Journal for ImmunoTherapy of Cancer

DOI: https://doi.org/10.1136/jitc-2025-012435

Paper Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.

Liu, Shougeng; Jiang, Yiting; Fu, Yudong et al. · 2026 · Journal for immunotherapy of cancer · DOI

Full title: Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.

Authors: Liu, Shougeng; Jiang, Yiting; Fu, Yudong; Wang, Simeng; Fu, Rao; Gao, Minmin; Zhao, Yingxi; Chen, Sihong; Yang, Yuan; Yang, Weiming; Jia, Lina; Qin, Mingze; Zhang, Xiaohui; Cui, Wei; Wang, Lihui

Year: 2026

Venue: Journal for immunotherapy of cancer

DOI: https://doi.org/10.1136/jitc-2025-012886

Paper Transfiguring Novel Marine Natural Product as oncogenic KRAS G12C Mutant Inhibitors via

Nausheen Nazir, M. Husnain, Arbaz Waqar, Munazza Kanwal, Tariq Aziz, Nawal Al‐Hoshani, Rania Ali EL HADI MOHAMED, M. S. Alwethaynani, F. Al-Joufi, Reem Nabil Hassan · 2025 · Journal of Computational Biophysics and Chemistry · DOI

Full title: Transfiguring Novel Marine Natural Product as oncogenic KRAS G12C Mutant Inhibitors via

Authors: Nausheen Nazir, M. Husnain, Arbaz Waqar, Munazza Kanwal, Tariq Aziz, Nawal Al‐Hoshani, Rania Ali EL HADI MOHAMED, M. S. Alwethaynani, F. Al-Joufi, Reem Nabil Hassan

Year: 2025

Venue: Journal of Computational Biophysics and Chemistry

DOI: https://doi.org/10.1142/s2737416526500353

Paper Therapeutics Targeting Mutant KRAS.

K. Thein; A. Biter; D. Hong · 2020 · Annual Review of Medicine · DOI

Full title: Therapeutics Targeting Mutant KRAS.

Authors: K. Thein; A. Biter; D. Hong

Year: 2020

Venue: Annual Review of Medicine

DOI: https://doi.org/10.1146/annurev-med-080819-033145

Paper Clinical Relevance of KRAS in Human Cancers

S. Jančík; J. Drábek; D. Radzioch et al. · 2010 · Journal of Biomedicine and Biotechnology · DOI

Full title: Clinical Relevance of KRAS in Human Cancers

Authors: S. Jančík; J. Drábek; D. Radzioch; M. Hajdůch

Year: 2010

Venue: Journal of Biomedicine and Biotechnology

DOI: https://doi.org/10.1155/2010/150960

Paper Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors

N. Saba; S. Yom; M. Haigentz et al. · 2012 · Chemotherapy Research and Practice · DOI

Full title: Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors

Authors: N. Saba; S. Yom; M. Haigentz; B. El-Rayes

Year: 2012

Venue: Chemotherapy Research and Practice

DOI: https://doi.org/10.1155/2012/291421

Paper Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90

Liu, Ying; Wu, Lei; Lü, Hong et al. · 2021 · Journal of Oncology · DOI

Full title: Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90

Authors: Liu, Ying; Wu, Lei; Lü, Hong; En, Wu; Ni, Jun; Zhou, Xiaorong

Year: 2021

Venue: Journal of Oncology

DOI: https://doi.org/10.1155/2021/2721466

Paper The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

Wei Chen; Ling Li; Sheng Cheng et al. · 2022 · Disease Markers · DOI

Full title: The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

Authors: Wei Chen; Ling Li; Sheng Cheng; Junxian Yu

Year: 2022

Venue: Disease Markers

DOI: https://doi.org/10.1155/2022/2631852

Paper Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation

Bana Antonios; Oyepeju Abioye; Seon Jo Park et al. · 2025 · Case Reports in Oncological Medicine · DOI

Full title: Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation

Authors: Bana Antonios; Oyepeju Abioye; Seon Jo Park; G. Finley

Year: 2025

Venue: Case Reports in Oncological Medicine

DOI: https://doi.org/10.1155/crom/7966703

Paper PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

S. Wee; Zainab Jagani; K. Xiang et al. · 2009 · Cancer Research · DOI

Full title: PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

Authors: S. Wee; Zainab Jagani; K. Xiang; Alice T. Loo; M. Dorsch; Yung-mae M. Yao; W. Sellers; C. Lengauer; F. Stegmeier

Year: 2009

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-08-4765

Paper MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors

Yang, Bin; Li, Xi; Fu, Yu et al. · 2021 · Cancer Research · DOI

Full title: MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors

Authors: Yang, Bin; Li, Xi; Fu, Yu; Guo, Ensong; Ye, Youqiong; Li, Fuxia; Liu, Si; Xiao, Rourou; Liu, Chen; Lu, Funian; Huang, Jia; Qin, Tianyu; Han, Leng; Peng, Guang; Mills, Gordon B.; Sun, Chaoyang; Chen, Gang

Year: 2021

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-20-2370

Paper CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Prahallad, Anirudh; Weiss, Andreas; Voshol, Hans et al. · 2023 · Cancer Research · DOI

Full title: CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Authors: Prahallad, Anirudh; Weiss, Andreas; Voshol, Hans; Kerr, Gráinne; Sprouffske, Kathleen; Yuan, Tina L.; Ruddy, David A.; Meistertzheim, Morgane; Kazic-Legueux, Malika; Kottarathil, Tina; Piquet, Michelle; Cao, Yichen; Martinuzzi-Duboc, Laetitia; Buhles, Alexandra; Adler, Flavia; Mannino, Salvatore; Tordella, Luca; Sansregret, Laurent; Maira, Sauveur-Michel; Porta, Diana Graus; Fedele, Carmine; Brachmann, Saskia M.

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-23-1127

Paper Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy

Petroni, Giulia; Pillozzi, Serena; Antonuzzo, Lorenzo · 2024 · Cancer Research · DOI

Full title: Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy

Authors: Petroni, Giulia; Pillozzi, Serena; Antonuzzo, Lorenzo

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-23-3325

Paper RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer.

Hitendra S Solanki; Harshit Shah; Denis Imbody et al. · 2025 · Cancer Research · DOI

Full title: RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer.

Authors: Hitendra S Solanki; Harshit Shah; Denis Imbody; Bina Desai; Ryoji Kato; Daria Miroshnychenko; Yaakov E. Stern; A. Majumder; Bhaswati Sarcar; Aobuli Xieraili; Paul A. Stewart; Bin Fang; Yonghong Zhang; Jiqiang Yao; L. Darville; John M. Koomen; Uwe Rix; James W Evans; Y. C. Yang; Ethan Ahler; A. Marusyk; Mallika Singh; Ida Aronchik; E. Haura

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-25-0600

Paper CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

Szu-Aun Long; Haley Todd; Grace Goodhart et al. · 2025 · Cancer Research · DOI

Full title: CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

Authors: Szu-Aun Long; Haley Todd; Grace Goodhart; Wen-Hsuan Chang; Amber M. Amparo; Rachel Bridgens; Julien Dilly; Se Jun Park; Robert M Beal; Sara M Shehadeh; Megan A Satyadi; Vidushi K Trivedi; Sarah E Ackermann; Raivath Mukherjee; Craig M. Goodwin; A. C. Edwards; Clint A. Stalnecker; Kenneth D. Greis; Andrew J. Aguirre; G. A. Hobbs; Kirsten L. Bryant; Syed A Ahmad; Adrienne D. Cox; C. Der; Andrew M. Waters

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/0008-5472.can-25-1835

Paper Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition

T. Troiani; S. Napolitano; D. Vitagliano et al. · 2014 · Clinical Cancer Research · DOI

Full title: Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition

Authors: T. Troiani; S. Napolitano; D. Vitagliano; F. Morgillo; A. Capasso; V. Sforza; A. Nappi; D. Ciardiello; F. Ciardiello; E. Martinelli

Year: 2014

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-13-2181

Paper KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

S. Misale; J. Fatherree; E. Cortez et al. · 2018 · Clinical Cancer Research · DOI

Full title: KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Authors: S. Misale; J. Fatherree; E. Cortez; Chendi Li; S. Bilton; Daria Timonina; David T Myers; Dana Lee; María Gomez-Caraballo; Max Greenberg; Varuna Nangia; Patricia Greninger; Regina K. Egan; Joseph McClanaghan; Giovanna T. Stein; Ellen Murchie; P. Zarrinkar; M. R. Janes; Lian-Sheng Li; Yi Liu; A. Hata; C. Benes

Year: 2018

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-18-0368

Paper Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

K. Suzawa; M. Offin; D. Lu et al. · 2018 · Clinical Cancer Research · DOI

Full title: Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Authors: K. Suzawa; M. Offin; D. Lu; Christopher Kurzatkowski; M. Vojnic; Roger S Smith; J. Sabari; Huichun Tai; M. Mattar; I. Khodos; E. de Stanchina; C. Rudin; M. Kris; M. Arcila; W. Lockwood; A. Drilon; M. Ladanyi; R. Somwar

Year: 2018

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-18-1640

Paper A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer

Qianwen Zhang; Yan Zhang; Ya-qing Chen et al. · 2019 · Clinical Cancer Research · DOI

Full title: A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer

Authors: Qianwen Zhang; Yan Zhang; Ya-qing Chen; Jianchang Qian; Xue-sai Zhang; Ker Yu

Year: 2019

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-18-2548

Paper Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition

Meagan B. Ryan; F. Fece de la Cruz; S. Phat et al. · 2019 · Clinical Cancer Research · DOI

Full title: Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition

Authors: Meagan B. Ryan; F. Fece de la Cruz; S. Phat; David T Myers; Edmond Wong; Heather A. Shahzade; Catriona B. Hong; R. Corcoran

Year: 2019

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-19-3523

Paper Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.

Adachi, Yuta; Ito, Kentaro; Hayashi, Yuko et al. · 2020 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.

Authors: Adachi, Yuta; Ito, Kentaro; Hayashi, Yuko; Kimura, Ryo; Tan, Tuan Zea; Yamaguchi, Rui; Ebi, Hiromichi

Year: 2020

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2077

Paper Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Liu, Chen; Lu, Hengyu; Wang, Hongyun et al. · 2020 · Clinical Cancer Research · DOI

Full title: Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Authors: Liu, Chen; Lu, Hengyu; Wang, Hongyun; Loo, Alice; Zhang, Xiamei; Yang, Guizhi; Kowal, Colleen; Delach, Scott; Wang, Ye; Goldoni, Silvia; Hastings, William D.; Wong, Karrie; Gao, Hui; Meyer, Matthew J.; Moody, Susan E.; LaMarche, Matthew J.; Engelman, Jeffrey A.; Williams, Juliet; Hammerman, Peter S.; Abrams, Tinya J.; Mohseni, Morvarid; Caponigro, Giordano; Hao, Huai‐Xiang

Year: 2020

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-20-2718

Paper Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Kato, Shumei; Adashek, Jacob J.; Shaya, Justin et al. · 2021 · Clinical Cancer Research · DOI

Full title: Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Authors: Kato, Shumei; Adashek, Jacob J.; Shaya, Justin; Okamura, Ryosuke; Jimenez, Rebecca E.; Lee, Suzanna; Sicklick, Jason K.; Kurzrock, Razelle

Year: 2021

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-20-3761

Paper KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.

Suzuki, Shinichiro; Yonesaka, Kimio; Teramura, Takeshi et al. · 2021 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.

Authors: Suzuki, Shinichiro; Yonesaka, Kimio; Teramura, Takeshi; Takehara, Toshiyuki; Kato, Ryoji; Sakai, Hitomi; Haratani, Koji; Tanizaki, Junko; Kawakami, Hisato; Hayashi, Hidetoshi; Sakai, Kazuko; Nishio, Kazuto; Nakagawa, Kazuhiko

Year: 2021

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-21-0856

Paper Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma

Yajing Gao; Pekka Päivinen; S. Tripathi et al. · 2021 · Clinical Cancer Research · DOI

Full title: Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma

Authors: Yajing Gao; Pekka Päivinen; S. Tripathi; Eva Domènech-Moreno; Iris P. L. Wong; Kari Vaahtomeri; A. Nagaraj; S. Talwelkar; M. Foretz; E. Verschuren; B. Viollet; Yan Yan; T. Mäkelä

Year: 2021

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-21-2049

Paper Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy

Boumelha, Jesse; Molina‐Arcas, Míriam; Downward, Julian · 2023 · Clinical Cancer Research · DOI

Full title: Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy

Authors: Boumelha, Jesse; Molina‐Arcas, Míriam; Downward, Julian

Year: 2023

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-22-3655

Paper Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042).

S. Gadgeel; Jieling Miao; J. Riess et al. · 2023 · Clinical Cancer Research · DOI

Full title: Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042).

Authors: S. Gadgeel; Jieling Miao; J. Riess; J. Moon; P. Mack; G. Gerstner; T. Burns; A. Taj; W. Akerley; K. Dragnev; N. Laudi; M. Redman; J. Gray; D. Gandara; K. Kelly

Year: 2023

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-22-3947

Paper The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer

Choudhury, Noura J.; Lavery, Jessica A.; Brown, Samantha et al. · 2023 · Clinical Cancer Research · DOI

Full title: The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer

Authors: Choudhury, Noura J.; Lavery, Jessica A.; Brown, Samantha; Bruijn, Ino de; Jee, Justin; Tran, Thinh Ngoc; Rizvi, Hira; Arbour, Kathryn C.; Whiting, Karissa; Shen, Ronglai; Hellmann, Matthew D.; Bédard, Philippe L.; Yu, Celeste; Leighl, Natasha B.; Lenoue-Newton, Michele L.; Micheel, Christine; Warner, Jeremy L.; Ginsberg, Michelle S.; Plodkowski, Andrew J.; Girshman, Jeffrey; Sawan, Peter; Pillai, Shirin; Sweeney, Shawn M.; Kehl, Kenneth L.; Panageas, Katherine S.; Schultz, Nikolaus; Schrag, Deborah; Riely, Gregory J.; Team, on behalf of the AACR GENIE BPC Core

Year: 2023

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-23-0580

Paper Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations

Linette, Gerald P.; Bear, Adham S.; Carreno, Beatriz M. · 2024 · Clinical Cancer Research · DOI

Full title: Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations

Authors: Linette, Gerald P.; Bear, Adham S.; Carreno, Beatriz M.

Year: 2024

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-23-1212

Paper Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Corcoran, Ryan B.; Khanh, T.; Kim, Jeong Eun et al. · 2024 · Clinical Cancer Research · DOI

Full title: Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Authors: Corcoran, Ryan B.; Khanh, T.; Kim, Jeong Eun; Cleary, James M.; Parikh, Aparna R.; Yeku, Oladapo; Xiong, Niya; Weekes, Colin D.; Veneris, Jennifer; Ahronian, Leanne G.; Mauri, Gianluca; 上田, 俊彦; Norden, Bryanna L.; Michel, Alexa; Seventer, Emily E. Van; Siravegna, Giulia; Camphausen, Kyle; Chi, Gary; Fetter, Isobel J.; Brugge, Joan S.; Chen, Helen X.; Takebe, Naoko; Penson, Richard T.; Juric, Dejan; Flaherty, Keith T.; Sullivan, Ryan J.; Clark, Jeffrey W.; Heist, Rebecca S.; Matulonis, Ursula A.; Liu, Joyce F.; Shapiro, Geoffrey I.

Year: 2024

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-23-3135

Paper Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.

Harrold, Emily; Keane, Fergus; Walch, Henry et al. · 2024 · Clinical cancer research : an official journal of the American Association for Cancer Research · DOI

Full title: Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.

Authors: Harrold, Emily; Keane, Fergus; Walch, Henry; Chou, Joanne F; Sinopoli, Jenna; Palladino, Silvia; Al-Rawi, Duaa H; Chadalavada, Kalyani; Manca, Paolo; Chalasani, Sree; Yang, Jessica; Cercek, Andrea; Shia, Jinru; Capanu, Marinela; Bakhoum, Samuel F; Schultz, Nikolaus; Chatila, Walid K; Yaeger, Rona

Year: 2024

Venue: Clinical cancer research : an official journal of the American Association for Cancer Research

DOI: https://doi.org/10.1158/1078-0432.CCR-23-4005

Paper Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Negrão, Marcelo V.; Paula, Alvaro G.; Molkentine, David et al. · 2025 · Clinical Cancer Research · DOI

Full title: Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Authors: Negrão, Marcelo V.; Paula, Alvaro G.; Molkentine, David; Hover, Laura D.; Nilsson, Monique B.; Vokes, Natalie I.; Engstrom, Lars D.; Calinisan, Andrew; Briere, David M.; Waters, Laura; Hallin, Jill; Diao, Lixia; Altan, Mehmet; Blumenschein, George R.; Skoulidis, Ferdinandos; Wang, Jing; Kopetz, Scott; Hong, David S.; Gibbons, Don L.; Olson, Peter; Christensen, James G.; Heymach, John V.

Year: 2025

Venue: Clinical Cancer Research

DOI: https://doi.org/10.1158/1078-0432.ccr-24-2310

Paper Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Lee, Catherine; Jiang, Ziyue Karen; Planken, Simon et al. · 2024 · DOI

Full title: Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Authors: Lee, Catherine; Jiang, Ziyue Karen; Planken, Simon; Manzuk, Lisa K.; Ortiz, Roberto; Hall, Michael; Noorbehesht, Kavon; Ram, Sripad; Affolter, Timothy; Troche, Gabriel E.; Ihle, Nathan T.; Johnson, Theodore; Ahn, Youngwook; Kraus, Manfred; Giddabasappa, Anand

Year: 2024

DOI: https://doi.org/10.1158/1535-7163.c.6727175.v2

Paper Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Lee, Catherine; Jiang, Ziyue Karen; Planken, Simon et al. · 2024 · DOI

Full title: Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Year: 2024

DOI: https://doi.org/10.1158/1535-7163.c.6727175.v2

Paper Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Lee, Catherine; Jiang, Ziyue Karen; Planken, Simon et al. · 2024 · DOI

Full title: Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Year: 2024

DOI: https://doi.org/10.1158/1535-7163.c.6727175.v2

Paper Data from Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers

Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro et al. · 2023 · DOI

Full title: Data from Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers

Year: 2023

DOI: https://doi.org/10.1158/1535-7163.c.6960454.v1

Paper Data from Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers

Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro et al. · 2023 · DOI

Year: 2023

DOI: https://doi.org/10.1158/1535-7163.c.6960454.v1

Paper Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Young-Kwang Yoon; Hwang-Phill Kim; Sae-Won Han et al. · 2009 · Molecular Cancer Therapeutics · DOI

Full title: Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Authors: Young-Kwang Yoon; Hwang-Phill Kim; Sae-Won Han; H. Hur; D. Oh; S. Im; Y. Bang; Tae‐You Kim

Year: 2009

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-09-0300

Paper ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer

Köhler, Jens; Zhao, Yutong; Li, Jiaqi et al. · 2021 · Molecular Cancer Therapeutics · DOI

Full title: ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer

Authors: Köhler, Jens; Zhao, Yutong; Li, Jiaqi; Gokhale, Prafulla C.; Tiv, Hong L.; Knott, Aine; Wilkens, Margaret K.; Soroko, Kara M.; Lin, Mika; Ambrogio, Chiara; Musteanu, Mónica; Ogino, Atsuko; Choi, Jihyun; Bahcall, Magda; Bertram, Arrien A.; Chambers, Emily S.; Paweletz, Cloud P.; Bhagwat, Shripad V.; Manro, Jason R.; Tiu, Ramón V.; Jänne, Pasi A.

Year: 2021

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-20-0531

Paper Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Adashek, Jacob J; Desai, Aakash P; Andreev-Drakhlin, Alexander Y et al. · 2021 · Molecular cancer therapeutics · DOI

Full title: Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Authors: Adashek, Jacob J; Desai, Aakash P; Andreev-Drakhlin, Alexander Y; Roszik, Jason; Cote, Gilbert J; Subbiah, Vivek

Year: 2021

Venue: Molecular cancer therapeutics

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0329

Paper Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Coker, Elizabeth A.; Stewart, Adam; Özer, Buğra et al. · 2022 · Molecular Cancer Therapeutics · DOI

Full title: Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Authors: Coker, Elizabeth A.; Stewart, Adam; Özer, Buğra; Minchom, Anna; Pickard, Lisa; Ruddle, Ruth; Carreira, Suzanne; Popat, Sanjay; O’Brien, Mary; Raynaud, Florence I.; Bono, Johann S. de; Al‐Lazikani, Bissan; Banerji, Udai

Year: 2022

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-21-0442

Paper AZD4625 is a Potent and Selective Inhibitor of KRASG12C

Chakraborty, Atanu; Hanson, Lyndsey; Robinson, David M. et al. · 2022 · Molecular Cancer Therapeutics · DOI

Full title: AZD4625 is a Potent and Selective Inhibitor of KRASG12C

Authors: Chakraborty, Atanu; Hanson, Lyndsey; Robinson, David M.; Lewis, Hilary; Bickerton, Sue; Davies, Michael; Polański, Radosław; Whiteley, Rebecca; Koers, Alex; Atkinson, James; Baker, Tamara; Barrantes, Iván del Barco; Ciotta, Giovanni; Kettle, Jason G.; Magiera, Łukasz; Martins, Carla P.; Peter, Alison; Wigmore, Eleanor M.; Underwood, Zoe; Cosulich, Sabina; Niedbala, Michael; Ross, Sarah J.

Year: 2022

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-22-0241

Paper The Next Generation of KRAS Targeting: Reasons for Excitement and Concern

Akhave, Neal S.; Biter, Amadeo B.; Hong, David S. · 2022 · Molecular Cancer Therapeutics · DOI

Full title: The Next Generation of KRAS Targeting: Reasons for Excitement and Concern

Authors: Akhave, Neal S.; Biter, Amadeo B.; Hong, David S.

Year: 2022

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-22-0356

Paper Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Catherine Lee; Z. Jiang; Simon Planken et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Authors: Catherine Lee; Z. Jiang; Simon Planken; Lisa K Manzuk; Roberto Ortiz; Michael Hall; Kavon Noorbehesht; S. Ram; T. Affolter; Gabriel E Troche; Nathan T Ihle; Theodore Johnson; Youngwook Ahn; M. Kraus; A. Giddabasappa

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-22-0810

Paper AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weng, Weining; Meng, Tao; Pu, Junyi et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Authors: Weng, Weining; Meng, Tao; Pu, Junyi; Ma, Linjie; Shen, Yi; Wang, Zhaohui; Pan, Rong; Wang, Mingqiao; Chen, Caiwei; Wang, Lijun; Zhang, Jianjian; Zhou, Biao; Shao, Siyuan; Qian, Yu; Liu, Shu-Hui; Hu, Wenhao; Meng, Xun

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-23-0198

Paper Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers

Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1101/2023.03.27.534309

Paper The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Sudhakar, Niranjan; Yan, Larry; Qiryaqos, Fadia et al. · 2024 · Molecular Cancer Therapeutics · DOI

Full title: The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Authors: Sudhakar, Niranjan; Yan, Larry; Qiryaqos, Fadia; Engstrom, Lars D.; Laguer, Jade; Calinisan, Andrew; Hebbert, Allan; Waters, Laura; Moya, Krystal; Bowcut, Vickie; Vegar, Laura; Ketcham, John M.; Ivetac, Anthony; Smith, Christopher R.; Lawson, J. David; Rahbæk, Lisa; Clarine, Jeffrey; Nguyen, Natalie; Saechao, Barbara; Parker, Cody; ELLIOTT, A. J.; Vanderpool, Darin; He, Leo; Hover, Laura D.; Fernandez-Banet, Julio; Coma, Sílvia; Pachter, Jonathan A.; Hallin, Jill; Marx, Matthew A.; Briere, David M.; Christensen, James G.; Olson, Peter; Haling, Jacob R.; Khare, Shilpi

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-23-0870

Paper Dual Inhibitors of KRASG12D and HSP90 are Effective Against KRASG12D Inhibitor Resistance.

I. Pulido; Laura C Gunder; Chenghao Ying et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Dual Inhibitors of KRASG12D and HSP90 are Effective Against KRASG12D Inhibitor Resistance.

Authors: I. Pulido; Laura C Gunder; Chenghao Ying; Yaya Wang; Yan-Qing Dai; Zimo Yang; Ali Rahnama; Jinhua Li; Yuetong Sun; Chuhe Liu; H. Zhou; Guoqiang Wang; Kevin P Foley; K. Abdelhady; Malek G Massad; Thomas L Prince; Ian Papautsky; Weiwen Ying; T. Shimamura

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-24-1173

Paper Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.

Daniel R. Principe; Jeffrey H Becker; Anastasia E. Metropulos et al. · 2026 · Molecular Cancer Therapeutics · DOI

Full title: Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.

Authors: Daniel R. Principe; Jeffrey H Becker; Anastasia E. Metropulos; Alejandra M Marinelarena; Thao D Pham; A. Aissa; H. Munshi

Year: 2026

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.mct-25-0483

Paper Abstract A029: Biomarker analysis of patients withMETΔex14 mutated non-small-cell lung cancer (NSCLC) treated with capmatinib in the GEOMETRY mono-1 study

R. Heist; E. Garon; D. Tan et al. · 2019 · Biomarkers · DOI

Full title: Abstract A029: Biomarker analysis of patients withMETΔex14 mutated non-small-cell lung cancer (NSCLC) treated with capmatinib in the GEOMETRY mono-1 study

Authors: R. Heist; E. Garon; D. Tan; H. Groen; T. Seto; E. Smit; L. Fairchild; A. Balbín; M. Yan; M. Giovannini; M. Akimov; B. Sankaran; N. Nwana; J. Wolf

Year: 2019

Venue: Biomarkers

DOI: https://doi.org/10.1158/1535-7163.targ-19-a029

Paper Abstract A084: Use of the natural nucleotide, GTP, is essential for the identification of potent, active-state KRASG12C inhibitors that bind in the switch II pocket

Bin Wang; Alok K. Sharma; J. Stice et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A084: Use of the natural nucleotide, GTP, is essential for the identification of potent, active-state KRASG12C inhibitors that bind in the switch II pocket

Authors: Bin Wang; Alok K. Sharma; J. Stice; Brian Smith; Marcin Dyba; Devansh Singh; J. Denson; Dana Rabara; Erik K. Larsen; Yue Yang; F. Lightstone; Andrew G Stephen; Dwight Nissley; F. McCormick; Eli Wallace; A. Maciag; Pedro J Beltran

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-a084

Paper Abstract A097: HBI-2438, HUYABIO selective KRASG12C inhibitor with BBB penetration, inhibited tumor growth in a metastatic brain model as single agent and also displayed synergy in combination with HBI-2376 (HUYABIO SHP2 inhibitor) in a CRC PDX model

F. Shojaei; Jill M Ricono; Che Fang et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A097: HBI-2438, HUYABIO selective KRASG12C inhibitor with BBB penetration, inhibited tumor growth in a metastatic brain model as single agent and also displayed synergy in combination with HBI-2376 (HUYABIO SHP2 inhibitor) in a CRC PDX model

Authors: F. Shojaei; Jill M Ricono; Che Fang; John Ning; Gloria Lee; M. Gillings

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-a097

Paper Abstract A098: HBI-2376, HUYABIO clinical stage SHP2 inhibitor, displays efficacy signal in patients with KRAS mutations in early clinical studies

F. Shojaei; Jill M Ricono; Che Fang et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A098: HBI-2376, HUYABIO clinical stage SHP2 inhibitor, displays efficacy signal in patients with KRAS mutations in early clinical studies

Authors: F. Shojaei; Jill M Ricono; Che Fang; Yan Xing; John Ning; Gloria Lee; M. Gillings

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-a098

Paper Abstract A099: Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS driven tumors

Balakrishna Lakhavath; M. Pothuganti; Githavani Kummari et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A099: Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS driven tumors

Authors: Balakrishna Lakhavath; M. Pothuganti; Githavani Kummari; Hemasankar Pathange; Rajan Sekar; S. Viswanadha

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-a099

Paper Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)

H.L. Robbins; Peter Fletcher; J. Savage et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)

Authors: H.L. Robbins; Peter Fletcher; J. Savage; M. Mehmi; Yvonne Summers; A. Greystoke; Noelle O’Rourke; Sanjay Popat; Pooja Jain; James Spicer; Judith Cave; Paul Shaw; David Gilligan; Danielle Power; Dean Fennel; A. D. Beggs; Lucinda Billingham; Gary Middleton

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-a115

Paper Abstract A144: HM99462, a Novel & potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inhibitor, MEK inhibitor, or EGFR mutant inhibitor

Jaeyul Choi; S. Jung; Wongi Park et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A144: HM99462, a Novel & potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inhibitor, MEK inhibitor, or EGFR mutant inhibitor

Authors: Jaeyul Choi; S. Jung; Wongi Park; Joo-Yun Byun; Semi Lim; Youngjoo Lee; Soye Jeon; Yu-Yon Kim; Y. Ahn; Y. H. Kim; K. Suh

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-a144

Paper Abstract B074: Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor

Matthew L. Maddess; D. Sloman; Xiaoshen Ma et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B074: Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor

Authors: Matthew L. Maddess; D. Sloman; Xiaoshen Ma; Anandan Palani; Alexander Stoeck; Aaron C Sather; Nicolas Solban; Ruchia Duggal; Jeanine E Ballard; Erik V Munsell; Lin-Chi Chen; Yongxin Han; Richard Miller; Symon Gathiaka; Christopher Brynczka; Hongming Li; Ruojing Yang; Christopher Brynczka; Phil J Day

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b074

Paper Abstract B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

Chendi Li; Christopher J. Graser; Qian Qin et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

Authors: Chendi Li; Christopher J. Graser; Qian Qin; Usman M Syed; Barbara Karakyriakou; Sarah Clark; A. Y. Saiki; Paul E Hughes; Christopher J Ott; Luca Pinello; Franziska Michor; Aaron N. Hata

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b080

Paper Abstract B082: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal DNA (ecDNA) amplification-mediated resistance to KRASG12C inhibitor in colorectal cancer (CRC)

Sudhir Chowdhry; Ryan J. Hansen; Jacques Mauger et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B082: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal DNA (ecDNA) amplification-mediated resistance to KRASG12C inhibitor in colorectal cancer (CRC)

Authors: Sudhir Chowdhry; Ryan J. Hansen; Jacques Mauger; A. Pferdekamper; Edison Tse; Ben Norman; Jafar Moininazeri; Salvador Garcia; Yen Truong; Debbie Liao; Joshua Lange; Evan Holmes; Anthony Celeste; Dave Solis; Auzon Steffy; Joshua Plum; Julie Wiese; Julius Apuy; Ardalan Ardeshiri; S. Milutinovic; Deepti Wilkinson; Anthony B Pinkerton; Christian A Hassig; S. Kasibhatla

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b082

Paper Abstract B083: Secondary KRAS mutations lead to acquired resistance to KRASG12D inhibitor in colorectal cancer

Simone Lieb; Sabine Jurado; Sergej Nowoshilow et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B083: Secondary KRAS mutations lead to acquired resistance to KRASG12D inhibitor in colorectal cancer

Authors: Simone Lieb; Sabine Jurado; Sergej Nowoshilow; Krzysztof M. Zak; M. H. Hofmann

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b083

Paper Abstract B084: Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C amplification

Hitendra S Solanki; Denis Imbody; Bina Desai et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B084: Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C amplification

Authors: Hitendra S Solanki; Denis Imbody; Bina Desai; Ryoji Kato; Paul A. Stewart; Yaakov E. Stern; A. Majumder; Liznair Bridenstine; Bhaswati Sarca; Daria Miroshnychenko; Ida Aronchik; A. Marusyk; E. Haura

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b084

Paper Abstract B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and P13K/AKT/mTOR pathways

Tracy T Tang; L. Post · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and P13K/AKT/mTOR pathways

Authors: Tracy T Tang; L. Post

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b088

Paper Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers

Koichi Ito; M. Hulse; Anjana Agarwal et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers

Authors: Koichi Ito; M. Hulse; Anjana Agarwal; Jack Carter; Monisha Sivakumar; K. Vykuntam; Min Wang; M. Cowart; Joy Cote; W. Gowen-MacDonald; Brian Vidal Torres; Justin Kurian; Neha Bhagwat; Norman Fultang; Alexander Grego; Andrew Moore; Ashley M. Schwab; J. Burtell; O. Osinubi; Jacob Spruance; Liang Lu; P. Pitis; C. Basch; Klare Bersch; Chaofeng Dai; Raul Leal; Artem Shvartsbart; Ganfeng Cao; Bo Shen; Patrick Y. Wen; J. Rager; Ross Kuskovsky; Bob Landman; Tom Emm; Stefan Ruepp; Chunhua Qin; Gina Paris; Jennifer Xavier; R. Chiaverelli; Sang Hyun Lee; S. Geeganage; Hong Lin; Diane Heiser; Bruce Ruggeri; Naveen Babbar; Andrew Combs; P. Scherle

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-b113

Paper Abstract C026: Initial safety, pharmacokinetics, and recommended Phase 2 dose from RAMP 203: A Phase 1/2 study of Avutometinib + Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer

M. Awad; Jerome Goldschmidt; A. Spira et al. · 2023 · Molecular Cancer Therapeutics · DOI

Full title: Abstract C026: Initial safety, pharmacokinetics, and recommended Phase 2 dose from RAMP 203: A Phase 1/2 study of Avutometinib + Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer

Authors: M. Awad; Jerome Goldschmidt; A. Spira; Rajat Malhotra; Jeffrey Yorio; Vijeta Bhambhani; Yaofeng Cheng; Pablo S Lee; R. Govindan

Year: 2023

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-23-c026

Paper Abstract A048: PRC2 inhibition enhances KRAS inhibitor response to delay treatment relapse in KRAS-mutant preclinical lung and colorectal cancer models

Stephanie W Ni; Natalie Yuen; Livia Ulicna et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A048: PRC2 inhibition enhances KRAS inhibitor response to delay treatment relapse in KRAS-mutant preclinical lung and colorectal cancer models

Authors: Stephanie W Ni; Natalie Yuen; Livia Ulicna; Denise F. Reyes; Michal Pawlak; Frank L. Duong; Jason E Long; A. Pankov; Lori S Friedman; Anneleen Daemen; M. Junttila

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a048

Paper Abstract A066: SOS1-panKRAS modulator, HM101207: A top candidate to control KRAS-MAPK-driven cancers through strong synergy with vertical inhibitors

S. Jung; Jaeyul Choi; Wongi Park et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A066: SOS1-panKRAS modulator, HM101207: A top candidate to control KRAS-MAPK-driven cancers through strong synergy with vertical inhibitors

Authors: S. Jung; Jaeyul Choi; Wongi Park; Soye Jeon; Heesun Moon; Jooyun Byun; Young Gil Ahn

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a066

Paper Abstract A080: Systematic PDX-based drug screening reveals genotype-specific vulnerabilities and therapeutic combinatorial opportunities in colorectal cancer

Alexey Sorokin; Preeti Kanikarla; Jay Saynonh et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A080: Systematic PDX-based drug screening reveals genotype-specific vulnerabilities and therapeutic combinatorial opportunities in colorectal cancer

Authors: Alexey Sorokin; Preeti Kanikarla; Jay Saynonh; Christian Y. Beke Onana; Fengqin Gao; Zhensheng Liu; Fangyang Wang; Christopher Bristow; S. Kopetz

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a080

Paper Abstract A084: Establishment of KRAS G12C Mutant Brain Metastasis Models for Pre-clinical Evaluation of KRAS G12C Targeted Anti-Cancer Therapy

Takashi Willebrand; Amanda K Miles; Yinfei Yin et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A084: Establishment of KRAS G12C Mutant Brain Metastasis Models for Pre-clinical Evaluation of KRAS G12C Targeted Anti-Cancer Therapy

Authors: Takashi Willebrand; Amanda K Miles; Yinfei Yin; Guilan Wang; Min Liu; Zichun Wang; Yuzhou Xu; Qikuan Chen; Yinfei Yin

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a084

Paper Abstract A100: AXL Inhibitor AB801 Increases the Anti-Tumor Efficacy of KRAS Inhibition

Jhansi L. Leslie; Logan Chinn; Umida Djakbarova et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A100: AXL Inhibitor AB801 Increases the Anti-Tumor Efficacy of KRAS Inhibition

Authors: Jhansi L. Leslie; Logan Chinn; Umida Djakbarova; Ruben Flores; Gonzalo Barajas; Ester Fernandez-Salas; S. Paprcka

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a100

Paper Abstract A101: Inhibition of ULK1/2-Mediated Autophagy Enhances Responses to RAS Inhibition and Augments Antigen-Specific T Cell Cytotoxicity

Umida Djakbarova; Jhansi L. Leslie; Jenna L Pappalardo et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract A101: Inhibition of ULK1/2-Mediated Autophagy Enhances Responses to RAS Inhibition and Augments Antigen-Specific T Cell Cytotoxicity

Authors: Umida Djakbarova; Jhansi L. Leslie; Jenna L Pappalardo; Yihong Guan; Ferdie Soriano; Jamison Buendia; Xuelei Yan; Hyunyoung Moon; Jenna L. Jeffrey; Ester Fernandez-Salas; S. Paprcka

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-a101

Paper Abstract B083: Transcription factors enhancing anti-tumor chemokine expression and lymphocyte infiltration in KRAS G12C inhibitor-resistant non-small cell lung cancer

Chendi Li; Anahita Nimbalkar; Melissa D. Vieira et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B083: Transcription factors enhancing anti-tumor chemokine expression and lymphocyte infiltration in KRAS G12C inhibitor-resistant non-small cell lung cancer

Authors: Chendi Li; Anahita Nimbalkar; Melissa D. Vieira; Usman M Syed; Barbara Karakyriakou; James Heather; Christopher Ott; Aaron N. Hata

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-b083

Paper Abstract B108: NTS231 is a novel covalent allosteric molecular glue of the KEAP1-CUL3 E3-ligase complex that selectively degrades NRF2 and inhibits tumors with aberrant NRF2 activation

Qiang Li; Chengyi Zhang; Chengxiang Wang et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B108: NTS231 is a novel covalent allosteric molecular glue of the KEAP1-CUL3 E3-ligase complex that selectively degrades NRF2 and inhibits tumors with aberrant NRF2 activation

Authors: Qiang Li; Chengyi Zhang; Chengxiang Wang; Xiao-tian Ma; Guoqiang Zhou

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-b108

Paper Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia

K. Sinkevicius; J. Stice; Rui Xu et al. · 2025 · Molecular Cancer Therapeutics · DOI

Full title: Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia

Authors: K. Sinkevicius; J. Stice; Rui Xu; Cathy Zhang; Siyu Feng; E. Riegler; Carlos Stahlhut; Kanchan Singh; D. Czyzyk; J. Denson; Yue Yang; Sofia Donovan; Ming Chen; Cindy Feng; Kyle Sullivan; Nadege Gitego; Michela Ranieri; Magdalena A Ploszaj; Katie Parker; Samar Ghorbanpoorvalukolaie; Marcin Dyba; Brian P Smith; Lijuan Fu; Ken Lin; Felice C. Lightstone; A. Maciag; Keshi Wang; Aaron N. Hata; K. Wong; D. Nissley; Eli Wallace; D. Simanshu; F. McCormick; Pedro J Beltran

Year: 2025

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1535-7163.targ-25-c082

Paper Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer

Nathan T Ihle; R. Herbst; Edward S. Kim et al. · 2011 · DOI

Full title: Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer

Authors: Nathan T Ihle; R. Herbst; Edward S. Kim; I. Wistuba; J. Lee; G. Blumenschein; A. Tsao; Lu Chen; Shuxing Zhang; C. Alden; Ximing Tang; Suyu Liu; D. Stewart; V. Papadimitrakopoulou; J. Heymach; H. Tran; M. Hicks; J. Erasmus; Sanjay Gupta; J. Minna; Jill Larsen; S. Lippman; W. Hong; G. Powis

Year: 2011

DOI: https://doi.org/10.1158/1538-7445.am2011-955

Paper Abstract 1137: Expression of specific apoptotic mediators predicts sensitivity to combined MEK and PI3K inhibition in KRAS mutant non-small cell lung cancer according to TP53 mutational status.

A. Hata; A. Faber; Alan T Yeo et al. · 2013 · DOI

Full title: Abstract 1137: Expression of specific apoptotic mediators predicts sensitivity to combined MEK and PI3K inhibition in KRAS mutant non-small cell lung cancer according to TP53 mutational status.

Authors: A. Hata; A. Faber; Alan T Yeo; Zhao Chen; Kwok-kin Wong; J. Engelman

Year: 2013

DOI: https://doi.org/10.1158/1538-7445.am2013-1137

Paper Abstract 4410: KRAS mutation status is associated with enhanced dependency on purine biosynthesis and related pathways in non small cell lung cancer cells

Diarmuid Moran; P. Trusk; Karen Pry et al. · 2014 · DOI

Full title: Abstract 4410: KRAS mutation status is associated with enhanced dependency on purine biosynthesis and related pathways in non small cell lung cancer cells

Authors: Diarmuid Moran; P. Trusk; Karen Pry; D. Sidransky; K. Paz; S. Bacus

Year: 2014

DOI: https://doi.org/10.1158/1538-7445.am2014-4410

Paper Abstract 318: Enhancing drug discovery and development throughput without sacrificing predictivity: ex vivo 3D drug response profiling (DRP) using patient-derived xenografts (PDX)

DesRochers, Tessa; Mattingly, Christina; Shuford, Stephen et al. · 2015 · Cancer Research · DOI

Full title: Abstract 318: Enhancing drug discovery and development throughput without sacrificing predictivity: ex vivo 3D drug response profiling (DRP) using patient-derived xenografts (PDX)

Authors: DesRochers, Tessa; Mattingly, Christina; Shuford, Stephen; Gevaert, Matthew; Orr, David; Bult, Carol J.; Airhart, Susie; Cheng, Mingshan; Wang, Minan; Keck, James; Crosswell, Howland E.

Year: 2015

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2015-318

Paper Abstract 5343: The effect of horizontal and vertical inhibition of nodes within the MAPK and PI3K-AKT pathways in NSCLC models

S. Broutin; A. Stewart; P. Thavasu et al. · 2015 · DOI

Full title: Abstract 5343: The effect of horizontal and vertical inhibition of nodes within the MAPK and PI3K-AKT pathways in NSCLC models

Authors: S. Broutin; A. Stewart; P. Thavasu; A. Paci; J. Bidart; U. Banerji

Year: 2015

DOI: https://doi.org/10.1158/1538-7445.am2015-5343

Paper Abstract 2686: The genomic landscape of Kras mutant genetically engineered mouse models of human cancers

W. Chung; A. Daemen; J. Long et al. · 2016 · DOI

Full title: Abstract 2686: The genomic landscape of Kras mutant genetically engineered mouse models of human cancers

Authors: W. Chung; A. Daemen; J. Long; Jason H. Cheng; Christopher Tran; Z. Modrusan; O. Foreman; M. Junttila

Year: 2016

DOI: https://doi.org/10.1158/1538-7445.am2016-2686

Paper Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium

Bob T. Li; F. Janku; P. Jänne et al. · 2016 · DOI

Full title: Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium

Authors: Bob T. Li; F. Janku; P. Jänne; G. Mills; K. Madwani; R. Alden; C. Paweletz; M. Ladanyi; A. Aravanis; B. Jung; S. Gnerre; A. Sehnert; D. Solit; Gregory Riely; G. Oxnard

Year: 2016

DOI: https://doi.org/10.1158/1538-7445.am2016-4342

Paper Abstract 1826: Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping

K. Suzawa; M. Offin; Christopher Kurzatkowski et al. · 2018 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 1826: Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping

Authors: K. Suzawa; M. Offin; Christopher Kurzatkowski; Dan-dan Liu; M. Vojnic; Roger S Smith; M. Mattar; I. Khodos; E. Stanchina; J. Sabari; W. Lockwood; A. Drilon; M. Ladanyi; R. Somwar

Year: 2018

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2018-1826

Paper Abstract 2156: Lung niche factors for progenitor cell self-renewal sustain lung cancer stem cells and contribute to drug resistance to kinase inhibitors in non-small cell lung cancer

A. Mitsui; S. Yokokawa; O. Nagano et al. · 2018 · Tumor Biology · DOI

Full title: Abstract 2156: Lung niche factors for progenitor cell self-renewal sustain lung cancer stem cells and contribute to drug resistance to kinase inhibitors in non-small cell lung cancer

Authors: A. Mitsui; S. Yokokawa; O. Nagano; H. Saya

Year: 2018

Venue: Tumor Biology

DOI: https://doi.org/10.1158/1538-7445.am2018-2156

Paper Abstract 938: Detection of actionable mutations in plasma cfDNA samples from patients with non-small cell lung carcinoma using a novel amplicon-based Firefly NGS assay

Lin Wang; Li Weng; X. Chen et al. · 2018 · Clinical research · DOI

Full title: Abstract 938: Detection of actionable mutations in plasma cfDNA samples from patients with non-small cell lung carcinoma using a novel amplicon-based Firefly NGS assay

Authors: Lin Wang; Li Weng; X. Chen; Min Li; Qiaomei Guo; Wen-jun Yu; T. Wittkop; Hongyan Wang; M. Fahem; Shengrong Lin; Grace Q. Zhao; J. Lou

Year: 2018

Venue: Clinical research

DOI: https://doi.org/10.1158/1538-7445.am2018-938

Paper Abstract 1322: Maximizing the therapeutic potential of SHP2 inhibition with rational combination strategies in tumors driven by aberrant RAS-MAPK signaling

Grace J. Lee; Carlos Stahlhut; J. Evans et al. · 2019 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 1322: Maximizing the therapeutic potential of SHP2 inhibition with rational combination strategies in tumors driven by aberrant RAS-MAPK signaling

Authors: Grace J. Lee; Carlos Stahlhut; J. Evans; D. Reyes; Edward G. Lorenzana; Shao-lin Li; E. Koltun; Dong Lee; Zhengping Wang; R. Nichols; J. Smith; Mallika Singh

Year: 2019

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2019-1322

Paper Abstract 2797: Accumulation of neutrophils in the tumor microenvironment promotes resistance to immunotherapy in pancreatic cancer

Despina Siolas; E. Vucic; J. Cullis et al. · 2019 · Tumor Biology · DOI

Full title: Abstract 2797: Accumulation of neutrophils in the tumor microenvironment promotes resistance to immunotherapy in pancreatic cancer

Authors: Despina Siolas; E. Vucic; J. Cullis; Mark Choi; D. Bar-Sagi

Year: 2019

Venue: Tumor Biology

DOI: https://doi.org/10.1158/1538-7445.am2019-2797

Paper Abstract 4980: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers

A. Udyavar; Daniel Direnzo; D. Ashok et al. · 2019 · Immunology · DOI

Full title: Abstract 4980: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers

Authors: A. Udyavar; Daniel Direnzo; D. Ashok; A. Anderson; S. W. Young; M. Walters; J. Tan

Year: 2019

Venue: Immunology

DOI: https://doi.org/10.1158/1538-7445.am2019-4980

Paper Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

Gerlach, Daniel; Gmachl, Michael; Ramharter, Jürgen et al. · 2020 · Cancer Research · DOI

Full title: Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

Authors: Gerlach, Daniel; Gmachl, Michael; Ramharter, Jürgen; Teh, Jessica L.F.; Fu, Szu-Chin; Trapani, Francesca; Kessler, Dirk; Rumpel, Klaus; Botesteanu, Dana‐Adriana; Ettmayer, Peter; Arnhof, Heribert; Gerstberger, Thomas; Kofink, Christiane; Wunberg, Tobias; Vellano, Christopher P.; Heffernan, Timothy P.; Marszalek, Joseph R.; Pearson, Mark; McConnell, Darryl B.; Kraut, Norbert; Hofmann, Marco H.

Year: 2020

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2020-1091

Paper Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway

J. Smith; Mallika Singh; R. Nichols et al. · 2020 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway

Authors: J. Smith; Mallika Singh; R. Nichols; E. Koltun; Y. C. Yang; D. Wildes; Carlos Stahlhut; Dong Lee; C. Schulze; D. Reyes; Abby Marquez; Grace J. Lee; Shao-lin Li; C. Marcireau; L. Debussche; M. Goldsmith; Zhengping Wang; Adrian L Gill; S. Kelsey

Year: 2020

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2020-1943

Paper Abstract 1958: Repotrectinib increases effectiveness of KRAS-G12C inhibitors inKRAS-G12Cmutant cancer modelsviasimultaneous SRC/FAK/JAK2 inhibition

J. J. Cui; D. Zhai; W. Deng et al. · 2020 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 1958: Repotrectinib increases effectiveness of KRAS-G12C inhibitors inKRAS-G12Cmutant cancer modelsviasimultaneous SRC/FAK/JAK2 inhibition

Authors: J. J. Cui; D. Zhai; W. Deng; L. Rodón; N. Lee; B. Murray

Year: 2020

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2020-1958

Paper Abstract 5684: Drug-anchoredin vitroandin vivoCRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRASG12C-mutant models

Lars D. Engstrom; Laurie Waters; Sole Gatto et al. · 2020 · Cancer Chemistry · DOI

Full title: Abstract 5684: Drug-anchoredin vitroandin vivoCRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRASG12C-mutant models

Authors: Lars D. Engstrom; Laurie Waters; Sole Gatto; J. Fernandez-Banet; Ruth Aranda; A. Pavlícek; J. Christensen; P. Olson

Year: 2020

Venue: Cancer Chemistry

DOI: https://doi.org/10.1158/1538-7445.am2020-5684

Paper Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition

Huai-Xiang Hao; Chen Liu; Hongyun Wang et al. · 2020 · Bioinformatics, Convergence Science, and Systems Biology · DOI

Full title: Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition

Authors: Huai-Xiang Hao; Chen Liu; Hongyun Wang; Hengyu Lu; S. Delach; M. LaMarche; J. Engelman; P. Hammerman; G. Caponigro; S. Moody; Morvarid Mohseni

Year: 2020

Venue: Bioinformatics, Convergence Science, and Systems Biology

DOI: https://doi.org/10.1158/1538-7445.am2020-lb-122

Paper Abstract 1104: Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models

N. Lee; W. Deng; D. Zhai et al. · 2021 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 1104: Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models

Authors: N. Lee; W. Deng; D. Zhai; L. Rodón; Ana Parra; J. Cowell; Afsheen Banisadr; Xin Zhang; B. Murray

Year: 2021

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2021-1104

Paper Abstract 1263: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition strategy

Coma, Sílvia; Chowdhury, Sanjib; Pachter, Jonathan A. · 2021 · Cancer Research · DOI

Full title: Abstract 1263: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition strategy

Authors: Coma, Sílvia; Chowdhury, Sanjib; Pachter, Jonathan A.

Year: 2021

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2021-1263

Paper Abstract 1342: Development and preclinical evaluation of unique first-in-class small molecule inhibitors of the anti-apoptotic protein FLIP

C. Higgins; J. Fox; Jamie Z. Roberts et al. · 2021 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract 1342: Development and preclinical evaluation of unique first-in-class small molecule inhibitors of the anti-apoptotic protein FLIP

Authors: C. Higgins; J. Fox; Jamie Z. Roberts; D. Doherty; Trevor R. Perrior; R. Boffey; Tim Harrison; D. Longley

Year: 2021

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2021-1342

Paper - **DOI:** 10.1158/1538-7445.am2021-1425 - **Authors:** S. Coma, J. Paradis, J. Gutkind, J. Pachter - **Year:** 2021 - **Journal:** Experimental and Molecular Therapeutics

S. Coma; J. Paradis; J. Gutkind et al. · 2021 · Experimental and Molecular Therapeutics · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2021-1425 - **Authors:** S. Coma, J. Paradis, J. Gutkind, J. Pachter - **Year:** 2021 - **Journal:** Experimental and Molecular Therapeutics

Authors: S. Coma; J. Paradis; J. Gutkind; J. Pachter

Year: 2021

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2021-1425

Paper Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

M. Krebs; R. Shinde; R. Rahman et al. · 2021 · Clinical Trials · DOI

Full title: Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Authors: M. Krebs; R. Shinde; R. Rahman; R. Grochot; M. Little; Jenny King; Joseph Kitchin; M. Parmar; A. Turner; M. Mahmud; C. Yap; N. Tunariu; Juanita Lopez; J. Bono; U. Banerji; A. Minchom

Year: 2021

Venue: Clinical Trials

DOI: https://doi.org/10.1158/1538-7445.am2021-ct019

Paper Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

M. H. Hofmann; Hengyu Lu; Ulrich Duenzinger et al. · 2021 · Clinical Trials · DOI

Full title: Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

Authors: M. H. Hofmann; Hengyu Lu; Ulrich Duenzinger; D. Gerlach; F. Trapani; Annette A. Machado; J. Daniele; I. Waizenegger; M. Gmachl; D. Rudolph; C. Vellano; M. Marotti; Vitomir Vucenovic; T. Heffernan; J. Marszalek; M. Petronczki; N. Kraut

Year: 2021

Venue: Clinical Trials

DOI: https://doi.org/10.1158/1538-7445.am2021-ct210

Paper Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

M. Awad; Shengwu Liu; K. Arbour et al. · 2021 · Experimental and Molecular Therapeutics · DOI

Full title: Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Authors: M. Awad; Shengwu Liu; K. Arbour; V. Zhu; M. Johnson; R. Heist; T. Patil; Gregory Riely; J. Jacobson; Julien Dilly; Xiaoping Yang; N. Persky; D. Root; L. Sholl; L. Lim; K. Garg; Mark Li; Lars R. Engstrom; L. Waters; J. Lawson; P. Olson; J. Christensen; P. Lito; S. Ou; P. Jänne; A. Aguirre

Year: 2021

Venue: Experimental and Molecular Therapeutics

DOI: https://doi.org/10.1158/1538-7445.am2021-lb002

Paper Abstract 1101: CTNNB1 mutation can mediate resistance to EGFR, ALK and KRAS targeted therapies

A. Majumder; Benjamin S. Meyer; J. K. Hicks et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1101: CTNNB1 mutation can mediate resistance to EGFR, ALK and KRAS targeted therapies

Authors: A. Majumder; Benjamin S. Meyer; J. K. Hicks; T. Boyle; E. Haura

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1101

Paper Abstract 1105: MET or SHP2 inhibition enhances targeted therapies and delays the emergence of resistance in oncogene-driven NSCLC

Nadine Reischmann; Lorenz Pudelko; C. Stroh et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1105: MET or SHP2 inhibition enhances targeted therapies and delays the emergence of resistance in oncogene-driven NSCLC

Authors: Nadine Reischmann; Lorenz Pudelko; C. Stroh; N. Linde; D. Musch; Marina Keil; L. Pudelko; C. Esdar; A. Blaukat; K. Schumacher; N. Karachaliou

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1105

Paper Abstract 1107: Notch activation drives resistance to Kras(G12C) inhibition in lung adenocarcinoma

E. Hwang; Alex G. Lee; Stanley G Leung et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1107: Notch activation drives resistance to Kras(G12C) inhibition in lung adenocarcinoma

Authors: E. Hwang; Alex G. Lee; Stanley G Leung; Marcus R. Breese; A. Sweet-Cordero

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1107

Paper Abstract 1131: Pharmacogenomic insight into targetable vulnerabilities and modifiers of response to MRTX1133 in KRASG12D-mutant models

Vickie Bowcut; Andrew Calinisan; David M Briere et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1131: Pharmacogenomic insight into targetable vulnerabilities and modifiers of response to MRTX1133 in KRASG12D-mutant models

Authors: Vickie Bowcut; Andrew Calinisan; David M Briere; Lauren N. Hargis; Lars D. Engstrom; Jade Laguer; Darin Vanderpool; Xiaolun Wang; J. Lawson; N. Thomas; Robin J. Gunn; Christopher R. Smith; J. Fernandez-Banet; Leo He; A. Pavlícek; Lisa Rahbaek; M. Marx; P. Olson; J. Christensen; Jill Hallin

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1131

Paper Abstract 1300: Targeted therapies prime lung cancer cells for macrophage-mediated destruction

Kyle Vacarro; J. Allen; Asaf Maoz et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1300: Targeted therapies prime lung cancer cells for macrophage-mediated destruction

Authors: Kyle Vacarro; J. Allen; Asaf Maoz; Sarah Reeves; A. Hata; K. Weiskopf

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1300

Paper Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer

J. Boumelha; Pablo Romero-Clavijo; S. de Carné et al. · 2022 · Cancer Research · DOI

Full title: Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer

Authors: J. Boumelha; Pablo Romero-Clavijo; S. de Carné; M. Molina-Arcas; J. Downward

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-1352

Paper Abstract 3101: Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using our own collections of PDX and PDX-derived organoids

P. Yagüe; D. Gomez; A. Ucero et al. · 2022 · Cancer Research · DOI

Full title: Abstract 3101: Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using our own collections of PDX and PDX-derived organoids

Authors: P. Yagüe; D. Gomez; A. Ucero; L. García; Patricia Plaza; N. Carrizo; J. Solórzano; L. Paz-Ares; I. Ferrer

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-3101

Paper Abstract 3110: Identification of the phosphorylation network in PDX and corresponding organoid (PDXO) models upon targeted therapy treatment using deep phosphoproteomic analysis[MB1]

Xiaoxi Xu; M. Tognetti; Yuehan Feng et al. · 2022 · Cancer Research · DOI

Full title: Abstract 3110: Identification of the phosphorylation network in PDX and corresponding organoid (PDXO) models upon targeted therapy treatment using deep phosphoproteomic analysis[MB1]

Authors: Xiaoxi Xu; M. Tognetti; Yuehan Feng; L. Shang; Leilei Chen; Jessie Wang; R. Bruderer; L. Bourré; H. Li

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-3110

Paper Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor

M. H. Hofmann; S. Jurado; D. Gerlach et al. · 2022 · Cancer Research · DOI

Full title: Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor

Authors: M. H. Hofmann; S. Jurado; D. Gerlach; T. Koga; F. Trapani; M. Gmachl; D. Alpár; Simone Lieb; Astrid Jeschko; T. Mitsudomi; N. Kraut; M. Petronczki

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-3255

Paper - **DOI:** 10.1158/1538-7445.am2022-338 - **Authors:** S. García-Román, M. Molina-Vila, E. D'hondt, R. Rosell - **Year:** 2022 - **Journal:** Cancer Research

S. García-Román; M. Molina-Vila; E. D'hondt et al. · 2022 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2022-338 - **Authors:** S. García-Román, M. Molina-Vila, E. D'hondt, R. Rosell - **Year:** 2022 - **Journal:** Cancer Research

Authors: S. García-Román; M. Molina-Vila; E. D'hondt; R. Rosell

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-338

Paper Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models

M. McMahon; M. Bogdan; M. J. Timson et al. · 2022 · Cancer Research · DOI

Full title: Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models

Authors: M. McMahon; M. Bogdan; M. J. Timson; Hikmat Al-Hashimi; Phaedra C. Ghazi; Y. Zhan; Bryan D. Smith; Conan G Kinsey; D. Flynn

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-3600

Paper Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity

P. Anastasiou; E. Mugarza; J. Boumelha et al. · 2022 · Cancer Research · DOI

Full title: Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity

Authors: P. Anastasiou; E. Mugarza; J. Boumelha; S. Rana; C. Moore; M. Molina-Arcas; J. Downward

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-4029

Paper Abstract 402: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK

S. Coma; S. Chowdhury; Julien Dilly et al. · 2022 · Cancer Research · DOI

Full title: Abstract 402: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK

Authors: S. Coma; S. Chowdhury; Julien Dilly; M. Musteanu; M. Barbacid; A. Aguirre; J. Pachter

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-402

Paper Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC

K. Priest; A. Le; D. Aisner et al. · 2022 · Cancer Research · DOI

Full title: Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC

Authors: K. Priest; A. Le; D. Aisner; Amanuail Gebregzabheir; H. Nijmeh; M. Mandell; K. Davies; E. O'Donnell; R. Doebele; Liming Bao; Erin L. Schenk

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-5233

Paper Abstract 5313: A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers

S. Khan; Janet S. Wiegand; Peiyi Zhang et al. · 2022 · Cancer Research · DOI

Full title: Abstract 5313: A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers

Authors: S. Khan; Janet S. Wiegand; Peiyi Zhang; Wanyi Hu; Dinesh Thummuri; Vivekananda Budamagunta; Nan Hua; Lingtao Jin; C. Allegra; E. Kopetz; M. Zajac-Kaye; F. Kaye; Guangrong Zheng; Daohong Zhou

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-5313

Paper Abstract 5463: BPI-442096: A potent and selective inhibitor of SHP2 for the treatment of multiple cancers

Ling Li; B. Fu; Han Han et al. · 2022 · Cancer Research · DOI

Full title: Abstract 5463: BPI-442096: A potent and selective inhibitor of SHP2 for the treatment of multiple cancers

Authors: Ling Li; B. Fu; Han Han; Zhongxin Sun; Xiangdong Zhao; Xuepeng Jv; Jun Tong; Jiayu Zhao; Z. Zou; Haibo Chen; Xiaoyun Liu; W. Ren; Yinlong Li; Wenmao Wu; Jing Guo; Dan Yan; Xiangyong Liu; H. Lan; Hao Wu; L. Ding; Jiabing Wang

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-5463

Paper Abstract 6121: Correlation of tumor immune microenvironment status and driver genes alterations in Chinese non-small-cell lung cancer patients

Jindong Guo; L. Xiong; Haibin Yuan et al. · 2022 · Cancer Research · DOI

Full title: Abstract 6121: Correlation of tumor immune microenvironment status and driver genes alterations in Chinese non-small-cell lung cancer patients

Authors: Jindong Guo; L. Xiong; Haibin Yuan; Mengna Hu; Bei Zhang; Ding Zhang

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-6121

Paper Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

D. Tan; Toshio Shimizu; B. Solomon et al. · 2022 · Cancer Research · DOI

Full title: Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Authors: D. Tan; Toshio Shimizu; B. Solomon; R. Heist; M. Schuler; M. D. M. Luken; A. Gazzah; M. Wermke; C. Dooms; H. Loong; N. Steeghs; E. Felip; C. Steuer; E. Van Cutsem; R. Soo; Ashley C. Jaeger; Jaeyeon Kim; Kun Xu; Xueying Chen; Xiaoming Cui; H. Burks; A. Farago; P. Cassier

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-ct033

Paper Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress)

N. Ammakkanavar; J. Call; Toshio Shimizu et al. · 2022 · Cancer Research · DOI

Full title: Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress)

Authors: N. Ammakkanavar; J. Call; Toshio Shimizu; Y. Kuboki; Shiyao Liu; Melinda D Willard; M. Axelson; R. Heist; A. Patnaik

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-ct202

Paper Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203)

R. Govindan; J. Pachter; A. Koustenis et al. · 2022 · Cancer Research · DOI

Full title: Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203)

Authors: R. Govindan; J. Pachter; A. Koustenis; Gloria Patrick; L. Denis

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-ct204

Paper Abstract CT515: A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring KRAS or EGFR mutation

A. Saltos; B. Creelan; T. Tanvetyanon et al. · 2022 · Cancer Research · DOI

Full title: Abstract CT515: A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring KRAS or EGFR mutation

Authors: A. Saltos; B. Creelan; T. Tanvetyanon; A. Chiappori; S. Antonia; M. Shafique; Milijana Ugrenovic-Petrovic; S. Sansil; Anthony M. Neuger; Jongphil Kim; E. Haura; J. Gray

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2022-ct515

Paper Abstract 1034: Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions

M. Aldea; A. Marinello; M. Tagliamento et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1034: Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions

Authors: M. Aldea; A. Marinello; M. Tagliamento; F. Dall’Olio; D. Vasseur; A. Bayle; A. Gazzah; M. Grecea; C. Nicotra; L. Lacroix; S. Ponce; L. Friboulet; F. Barlesi; F. André; D. Planchard; E. Rouleau; A. Italiano; B. Besse

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1034

Paper Abstract 1072: Combination of 5-Fluorouracil or ONC212 plus KRAS G12D inhibitor MRTX1133 against colorectal and pancreatic cancer cells results in immune-stimulatory cytokine patterns and unexpected synergies independent of G12D mutation

Tajiknia, Vida; El‐Deiry, Wafik S.; Schwermann, Maximilian Pinho et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1072: Combination of 5-Fluorouracil or ONC212 plus KRAS G12D inhibitor MRTX1133 against colorectal and pancreatic cancer cells results in immune-stimulatory cytokine patterns and unexpected synergies independent of G12D mutation

Authors: Tajiknia, Vida; El‐Deiry, Wafik S.; Schwermann, Maximilian Pinho; Zhou, Lanlan; Huntington, Kelsey E.

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1072

Paper Abstract 1079: Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance

H. Patel; A. Smith; S. Chan et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1079: Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance

Authors: H. Patel; A. Smith; S. Chan; L. Kessler; F. Burrows; S. Malik

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1079

Paper Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C

Snahel Patel; B. Bhhatarai; Philamer C. Calses et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C

Authors: Snahel Patel; B. Bhhatarai; Philamer C. Calses; D. Erlanson; R. Everley; Susan Fong; Phil Gerken; Johannes C. Hermann; Tiep Le; Li-kai Liu; Evan McMahon; R. Neve; Tony Phan; Allison Roberts; M. Shanafelt; Sophie Siemsgluess; J. Staunton; Yan Wang; Weiru Wang; Monika Williams; K. Webster

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1142

Paper Abstract 1386: Ag5 is highly potent, mitochondrially targeted agent with a differentiated mechanism of action that promises to be efficacious in solid cancers

M. Treder · 2023 · Cancer Research · DOI

Full title: Abstract 1386: Ag5 is highly potent, mitochondrially targeted agent with a differentiated mechanism of action that promises to be efficacious in solid cancers

Authors: M. Treder

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1386

Paper Abstract 1677: ASPC-1-MRTX-1133R as a useful cell line model for KRAS-G12D inhibitor development

Guoqian Wang; Yao Tang; Tingduo Lv et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1677: ASPC-1-MRTX-1133R as a useful cell line model for KRAS-G12D inhibitor development

Authors: Guoqian Wang; Yao Tang; Tingduo Lv; Jinying Ning; F‐J Hao

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1677

Paper Abstract 1682: Bridging gaps in treatment resistance 2D models with the incorporation of 3D models

M. Gadde; E. Schwabe; Kshithija Mulam et al. · 2023 · Cancer Research · DOI

Full title: Abstract 1682: Bridging gaps in treatment resistance 2D models with the incorporation of 3D models

Authors: M. Gadde; E. Schwabe; Kshithija Mulam; Lindsay Hill; C. Bulow

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-1682

Paper Abstract 185: Global mapping of pathway modules and phosphorylation networks in PDX and corresponding organoid (PDXO) models treated with targeted therapies

Martin Mehnert; Xiaoxi Xu; T. Treiber et al. · 2023 · Cancer Research · DOI

Full title: Abstract 185: Global mapping of pathway modules and phosphorylation networks in PDX and corresponding organoid (PDXO) models treated with targeted therapies

Authors: Martin Mehnert; Xiaoxi Xu; T. Treiber; L. Shang; Leilei Chen; Jessie Wang; M. Tognetti; Christopher Below; R. Bruderer; J. Vowinckel; B. Mao; W. Qian; Shengfu Guo; L. Bourré; Yuehan Feng

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-185

Paper Abstract 257: CDX model based genome-scale CRISPR KO screens for modulators of KRAS (G12C) inhibitor sensitivity

Haixin Zhao; Fangzheng Zhai; Bin Li et al. · 2023 · Cancer Research · DOI

Full title: Abstract 257: CDX model based genome-scale CRISPR KO screens for modulators of KRAS (G12C) inhibitor sensitivity

Authors: Haixin Zhao; Fangzheng Zhai; Bin Li; Qiangqiang Fan; Zhengang Peng

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-257

Paper Abstract 2621: Characterizing MEK1/2 degradation in K-ras mutant cells

Carlos Herrera-Montávez; Alison M. Kurimchak; Jian Jin et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2621: Characterizing MEK1/2 degradation in K-ras mutant cells

Authors: Carlos Herrera-Montávez; Alison M. Kurimchak; Jian Jin; James S. Duncan

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2621

Paper Abstract 2790: Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment of advanced non-small cell lung cancer and other solid tumors

B. Zhu; Dawei Cui; Ruifeng Liu et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2790: Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment of advanced non-small cell lung cancer and other solid tumors

Authors: B. Zhu; Dawei Cui; Ruifeng Liu; W. Feng; Z. Sheng; Binhua Lv

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2790

Paper Abstract 2805: Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic response of refractory lung cancer

Charny Park; Sehwa Hong; Mihwa Hwang et al. · 2023 · Cancer Research · DOI

Full title: Abstract 2805: Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic response of refractory lung cancer

Authors: Charny Park; Sehwa Hong; Mihwa Hwang; Youngjoo Lee; B. Song; Eun-Hye Kang; Hanna Sim; B. Ahn; K. Hwang; Namhee Yu; Sunshin Kim; Ji-Youn Han

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-2805

Paper Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics

Yi Liao; Sean Chin Chan; E. Welsh et al. · 2023 · Cancer Research · DOI

Full title: Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics

Authors: Yi Liao; Sean Chin Chan; E. Welsh; B. Fang; Luxin Sun; E. Schönbrunn; J. Koomen; Derek R Duckett; E. Haura; Andrii Monastyrskyi; U. Rix

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-3839

Paper Abstract 3867: Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

Chendi Li; Qian Qin; M. U. Syed et al. · 2023 · Cancer Research · DOI

Full title: Abstract 3867: Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

Authors: Chendi Li; Qian Qin; M. U. Syed; Anahita Nimbalkar; Barbara Karakyriakou; Sarah E. Clark; A. Y. Saiki; P. Hughes; Christopher J. Ott; Luca Pinello; A. Hata

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-3867

Paper Abstract 3871: KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro

Deanna Mohn; A. Y. Saiki; Pragathi Achanta et al. · 2023 · Cancer Research · DOI

Full title: Abstract 3871: KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro

Authors: Deanna Mohn; A. Y. Saiki; Pragathi Achanta; A. P. Stapper; J. Lipford; R. Verma

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-3871

Paper Abstract 3878: Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance

N. Chatterjee; V. Olivas; Wei Wu et al. · 2023 · Cancer Research · DOI

Full title: Abstract 3878: Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance

Authors: N. Chatterjee; V. Olivas; Wei Wu; Ben J. Powell; T. Bivona

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-3878

Paper Abstract 3907: Targeting adaptive resistance to EGFR and KRAS G12C inhibitors by TT125-802, a novel and specific CBP/p300 bromodomain inhibitor

Thomas Bohnacker; Dorothea C Gruber; Sara Laudato et al. · 2023 · Cancer Research · DOI

Full title: Abstract 3907: Targeting adaptive resistance to EGFR and KRAS G12C inhibitors by TT125-802, a novel and specific CBP/p300 bromodomain inhibitor

Authors: Thomas Bohnacker; Dorothea C Gruber; Sara Laudato; Martin Schwill; C. Fabritius; Raquel Herrador; Katrin Westritschnig; Thushara Pattupara; V. Ayinampudi; S. Flückiger-Mangual

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-3907

Paper Abstract 3971: Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for anti-tumor drug discovery

Nengwei Xu; Reifeng Wang; Jian Xiang et al. · 2023 · Cancer Research · DOI

Full title: Abstract 3971: Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for anti-tumor drug discovery

Authors: Nengwei Xu; Reifeng Wang; Jian Xiang; Q. Gu; X. Qiang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-3971

Paper Abstract 412: Drug combination screen identifies pemigatinib, an FGFR inhibitor, as a mechanism to overcome KRASG12C inhibitor resistance in lung cancer

Angela Abdollahi; M. Favata; Darlise DiMatteo et al. · 2023 · Cancer Research · DOI

Full title: Abstract 412: Drug combination screen identifies pemigatinib, an FGFR inhibitor, as a mechanism to overcome KRASG12C inhibitor resistance in lung cancer

Authors: Angela Abdollahi; M. Favata; Darlise DiMatteo; Sean Schuette; E. Boarder; M. Rupar; R. Macarron; A. Gilmartin; Hong Wang; A. Amador-Arjona

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-412

Paper Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Coma, Silvia; Arcas, Miriam Molina; Downward, Julian et al. · 2023 · Cancer Research · DOI

Full title: Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Authors: Coma, Silvia; Arcas, Miriam Molina; Downward, Julian; Pachter, Jonathan A.

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-4155

Paper Abstract 429: Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer

Lei Zhang; Ao Li; Shanzhong Jian et al. · 2023 · Cancer Research · DOI

Full title: Abstract 429: Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer

Authors: Lei Zhang; Ao Li; Shanzhong Jian; Chengyi Du; W. Zhu; Y. Tao; Meiwei Wang; Wen-hua Xu; Wenshan Hao; L. Paradiso; Thomas W. Myers; K. Koya; Jintao Zhang

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-429

Paper Abstract 486: Characterization of a novel series of highly selective PARP7 inhibitors

P. Cowley; B. McGuinness; Gillian M. Campbell et al. · 2023 · Cancer Research · DOI

Full title: Abstract 486: Characterization of a novel series of highly selective PARP7 inhibitors

Authors: P. Cowley; B. McGuinness; Gillian M. Campbell; A. Wise

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-486

Paper Abstract 4984: Integrated platform enables KRAS-targeted drugs discovery

Beibei Liu; an Li; Xiangyang Zuo et al. · 2023 · Cancer Research · DOI

Full title: Abstract 4984: Integrated platform enables KRAS-targeted drugs discovery

Authors: Beibei Liu; an Li; Xiangyang Zuo; Jie Yang; Ruifeng Wang; Feifei Fan; Wenting Shi; Q. Gu

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-4984

Paper Abstract 5484: Synergistic antitumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts

S. Hou; Andrew Kwon; J. Nieva et al. · 2023 · Cancer Research · DOI

Full title: Abstract 5484: Synergistic antitumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts

Authors: S. Hou; Andrew Kwon; J. Nieva; N. Desai

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-5484

Paper Abstract 5501: Vertical inhibition of the MAPK pathway with D3S-002, a potent and selective ERK1/2 inhibitor, to improve anti-tumor activity of and overcome resistance to KRAS G12C inhibitors

Jing Zhang; Jingtao Lu; Zhiqiang Zheng et al. · 2023 · Cancer Research · DOI

Full title: Abstract 5501: Vertical inhibition of the MAPK pathway with D3S-002, a potent and selective ERK1/2 inhibitor, to improve anti-tumor activity of and overcome resistance to KRAS G12C inhibitors

Authors: Jing Zhang; Jingtao Lu; Zhiqiang Zheng; Jiang Lu; Allison E. Wang; Jia Wang; Janet Chen; Haopeng Rui; Cheng Chen; Zhi Jian Chen

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-5501

Paper Abstract 5739: Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer

Gaku Yamamoto; Kosuke Tanaka; R. Kamata et al. · 2023 · Cancer Research · DOI

Full title: Abstract 5739: Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer

Authors: Gaku Yamamoto; Kosuke Tanaka; R. Kamata; S. Mori; Jie Liu; Toyohiro Yamauchi; Yuta Sakae; A. Ohashi; Susumu S. Kobayashi

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-5739

Paper Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer

Yue Zou; Srijita Dhar; Kirsten Gallagher et al. · 2023 · Cancer Research · DOI

Full title: Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer

Authors: Yue Zou; Srijita Dhar; Kirsten Gallagher; Andrew W. Buesking; S. Pawley; R. Holmes; Xiaowei Wu; Katarina Rohlfing; Min Wang; J. Rager; T. Emm; S. Ruepp; M. Cowart; Jing Ni; Jean J. Zhao; Bruce R Ruggeri; A. Combs; K. Vaddi; S. Geeganage; Ashish Juvekar; Sang Hyun Lee; P. Scherle

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-5973

Paper Abstract 6570: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

Yoann Pradat; J. Viot; Konstantin Gunbin et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6570: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

Authors: Yoann Pradat; J. Viot; Konstantin Gunbin; Andrey A. Yurchenko; L. Cerbone; Marc Deloger; Guillaume Grisay; L. Verlingue; Veronique Scott; Ismael Padioleau; Leonardo Panunzi; S. Michiels; A. Hollebecque; Gerome Jules-Clement; Laura Mezquita; Antoine Laine; Y. Loriot; B. Besse; L. Friboulet; Fabrice André; P. Cournède; Daniel Gautheret; Sergey I. Nikolaev

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6570

Paper Abstract 6691: Paired comparison of routine molecular screening of patient samples with advanced non-small cell lung cancer in circulating cell-free DNA using OncoBEAMTM EGFR V2, targeted next-generation sequencing Plasma-SeqSensei™ Solid Cancer IVD Kit and custom-validated NGS assay

D. Barthelemy; Emmanuel Grolleau; Gaëlle Lescuyer et al. · 2023 · Cancer Research · DOI

Full title: Abstract 6691: Paired comparison of routine molecular screening of patient samples with advanced non-small cell lung cancer in circulating cell-free DNA using OncoBEAMTM EGFR V2, targeted next-generation sequencing Plasma-SeqSensei™ Solid Cancer IVD Kit and custom-validated NGS assay

Authors: D. Barthelemy; Emmanuel Grolleau; Gaëlle Lescuyer; Florence Geiguer; Arnaud Gauthier; Julie Balandier; M. Raffin; C. Bardel; B. Bouyssounouse; C. Rodriguez-Lafrasse; S. Couraud; A. Wozny; L. Payen-Gay

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-6691

Paper Abstract 940: Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer

Xue Wu; Yaru Zhang; J. Pang et al. · 2023 · Cancer Research · DOI

Full title: Abstract 940: Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer

Authors: Xue Wu; Yaru Zhang; J. Pang; Li Lin; Jiani C. Yin; Haimeng Tang; Y. Shao

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-940

Paper Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Y. Murciano-Goroff; R. Heist; Y. Kuboki et al. · 2023 · Cancer Research · DOI

Full title: Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Authors: Y. Murciano-Goroff; R. Heist; Y. Kuboki; T. Koyama; N. Ammakkanavar; A. Hollebecque; A. Patnaik; T. Shimizu; A. Spira; M. Nagasaka; Ji-Youn Han; W. Iams; D. Deming; J. Call; P. Cassier; Sae-Won Han; Quincy Siu-chung Chu; Rasha Cosman; G. Durm; T. Burns; Melinda D Willard; Shiyao Liu; S. Callies; A. Balar; J. Sabari

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-ct028

Paper Abstract LB231: Overcoming KRAS G12C inhibitor resistance with a chaperone-mediated protein degrader (CHAMP)

Ines Pulido Endrino; Qiyue Luan; Jennifer Graeber et al. · 2023 · Cancer Research · DOI

Full title: Abstract LB231: Overcoming KRAS G12C inhibitor resistance with a chaperone-mediated protein degrader (CHAMP)

Authors: Ines Pulido Endrino; Qiyue Luan; Jennifer Graeber; Brianna C. Borger; Chenghao Ying; Jinhua Li; Zi-Xuan Yang; Zhiyong Wang; Yaya Wang; Yuetong Sun; Yan-Qing Dai; I. Papautsky; T. Prince; Guoqiang Wang; K. Foley; W. Ying; T. Shimamura

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2023-lb231

Paper Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC

M. Negrão; D. Molkentine; Alvaro G Paula et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC

Authors: M. Negrão; D. Molkentine; Alvaro G Paula; Laura Hover; M. Nilsson; N. Vokes; Lars D. Engstrom; Andrew Calinisan; Laurie Waters; David M Briere; Jill Hallin; G. Blumenschein; F. Skoulidis; S. Kopetz; David S. Hong; D. Gibbons; Peter Olson; James G Christensen; J. Heymach

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1212

Paper Abstract 1669: KRAS G12X mutants display differential preferences in downstream effector binding

Leonard J. Ash; Ottavia Bourdain; Dennis Lam et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1669: KRAS G12X mutants display differential preferences in downstream effector binding

Authors: Leonard J. Ash; Ottavia Bourdain; Dennis Lam; Shlomo S. Pallas; Andrew L. Wolfe

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1669

Paper Abstract 1926: MRAS the forgotten member of the GTPase superfamily plays a role in KRASG12Ci resistance

Venu Thatikonda; K. Kostyrko; Sabine Jurado et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1926: MRAS the forgotten member of the GTPase superfamily plays a role in KRASG12Ci resistance

Authors: Venu Thatikonda; K. Kostyrko; Sabine Jurado; Simone Lieb; M. Hinkel; D. Alpar; Oliver Bergner; Astrid Jeschko; Mark Pearson; M. H. Hofmann

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1926

Paper Abstract 1927: Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS effectors

Urszula N. Wasko; Jingjing Jiang; Yingyun Wang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1927: Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS effectors

Authors: Urszula N. Wasko; Jingjing Jiang; Yingyun Wang; Lorenzo Tomassoni; Lingyan Jiang; Marie Ménard; Álvaro Curiel-García; Tanner C. Dalton; Margo Orlen; Cole Edwards; Clint A. Stalnecker; Julien Dilly; Stephanie Chang; Stephen A. Sastra; Carmine F. Palermo; T. Baslan; Sha Tian; M. Holderfield; Elsa Quintana; Zhengping Wang; J. Smith; Andrea Califano; D. Wildes; Andrew J. Aguirre; R. Vonderheide; Ben Z. Stanger; Scott W. Lowe; C. Der; Mallika Singh; K. Olive

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1927

Paper Abstract 1928: Targeting FAK to improve the therapy of KRAS G12C mutant cancers

Liu, Shuang; Shi, Junfen; Lu, Chang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1928: Targeting FAK to improve the therapy of KRAS G12C mutant cancers

Authors: Liu, Shuang; Shi, Junfen; Lu, Chang; Zhang, Miao; Xin, Ying; Zhu, Yan; Li, Jijun; Luo, Hong; Sun, Yinghui

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1928

Paper Abstract 1929: Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition and regulated by 4E-BP1

I. Meraz; Shuhong Wu; M. Majidi et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1929: Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition and regulated by 4E-BP1

Authors: I. Meraz; Shuhong Wu; M. Majidi; Chenghui Ren; Yi Xu; F. Meng; Lihui Gao; R. Song; Ran Zhang; Bingliang Fang; Qi Wang; Y. Xi; Jing Wang; Sung Yun Jung; Jack A Roth

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1929

Paper Abstract 1931: Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS- driven cancer cells

Xianwen Yang; Guiping Li; Peiling Ren et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1931: Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS- driven cancer cells

Authors: Xianwen Yang; Guiping Li; Peiling Ren; Xiaoyun Shi; Ying Yu; Baoyu Hao; Pan Wang; Min Cheng; Guangxiu Dai

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1931

Paper Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agent

Ines Pulido Endrino; Laura C Gunder; Qiyue Luan et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agent

Authors: Ines Pulido Endrino; Laura C Gunder; Qiyue Luan; Chenghao Ying; Zimo Yang; Jinhua Li; Yaya Wang; Yuetong Sun; Chuhe Liu; Yan-Qing Dai; H. Zhou; Malek G Massad; Ian Papautsky; Thomas L Prince; Guoqiang Wang; Kevin P Foley; Weiwen Ying

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1932

Paper Abstract 1933: Dissecting acquired resistance to KRASG12D inhibition in a mouse model of pancreatic ductal adenocarcinoma

Julien Dilly; Laleh Abbassi; Connor J Hennessey et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1933: Dissecting acquired resistance to KRASG12D inhibition in a mouse model of pancreatic ductal adenocarcinoma

Authors: Julien Dilly; Laleh Abbassi; Connor J Hennessey; Giselle A Uribe; Brendan D Parent; Annan Yang; Kevin S. Kapner; Ziyue Li; Kyle E Evans; Shatavisha Dasgupta; Megan T. Hoffman; Li Qiang; Felix P Hambitzer; Seema Chugh; A. Shalek; Stephanie K. Dougan; B. Wolpin; Jonathan A. Nowak; Srivatsan Raghavan; Peter S. Winter; Andrew J. Aguirre

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1933

Paper Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance

Y. Shibata; H. Udagawa; M. Nilsson et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance

Authors: Y. Shibata; H. Udagawa; M. Nilsson; J. Robichaux; Ana Galán-Cobo; M. Negrão; D. Molkentine; Junqin He; A. Poteete; Yu Qian; Qian Huang; F. Skoulidis; J. Heymach

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1935

Paper Abstract 1936: KEAP1-NRF2 mediated resistance against KRASG12D inhibitor in pancreatic ductal adenocarcinoma

Wen-Hsuan Chang; Addison G Stamey; Andrew M. Waters et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1936: KEAP1-NRF2 mediated resistance against KRASG12D inhibitor in pancreatic ductal adenocarcinoma

Authors: Wen-Hsuan Chang; Addison G Stamey; Andrew M. Waters; Kirsten L. Bryant; Adrienne D. Cox; C. Der

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1936

Paper Abstract 1938: WEE1 inhibition prevents and overcomes resistance to KRAS inhibitors in lung cancer by enhancing MCL1-mediated apoptosis

Gaku Yamamoto; Kosuke Tanaka; R. Kamata et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1938: WEE1 inhibition prevents and overcomes resistance to KRAS inhibitors in lung cancer by enhancing MCL1-mediated apoptosis

Authors: Gaku Yamamoto; Kosuke Tanaka; R. Kamata; Takehiro Nakao; Shunta Mori; Jie Liu; Susumu S. Kobayashi; Akihiro Ohashi

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1938

Paper Abstract 1940: Identifying resistant mechanisms to direct KRAS inhibitors in NSCLC

S. Kundu; David H Peng; B. L. Rodriguez et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1940: Identifying resistant mechanisms to direct KRAS inhibitors in NSCLC

Authors: S. Kundu; David H Peng; B. L. Rodriguez; Eileen L. McCarthy; D. Gibbons

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1940

Paper Abstract 1942: Characterization of a panel of CRISPR/Cas9 engineered KRAS G12C inhibitor-resistant tumor models

Jun Zhou; Li Hua; Jian Feng et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1942: Characterization of a panel of CRISPR/Cas9 engineered KRAS G12C inhibitor-resistant tumor models

Authors: Jun Zhou; Li Hua; Jian Feng; Ning Bao; Dan Zhang; Jingjing Wang; Marrit Putker; Ludovic Bourré

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1942

Paper Abstract 1943: Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models

Xousaen M Helu; Ellie Griffiths; Andrew Calinisan et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1943: Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models

Authors: Xousaen M Helu; Ellie Griffiths; Andrew Calinisan; Allan Hebbert; Larry Yan; Natalie Hoffman; David Trinh; Laura Hover; J. Fernandez-Banet; David M Briere; Ella Lifset; Peter Olson; James G Christensen; Jill Hallin

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1943

Paper Abstract 1944: Using patient-derived cancer organoids to determine the effects of the anti-EGFR therapy panitumumab in the presence or absence of KRAS mutation

Jordan N Stoecker; Shirsa Udgata; A. Gillette et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1944: Using patient-derived cancer organoids to determine the effects of the anti-EGFR therapy panitumumab in the presence or absence of KRAS mutation

Authors: Jordan N Stoecker; Shirsa Udgata; A. Gillette; Cheri A Pasch; M. Skala; D. Deming

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1944

Paper Abstract 1945: Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor osimertinib and KRAS-G12C inhibitor sotorasib in lung cancer

Yuri Yagami; Takashi Sato; Hiroki Yamamoto et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1945: Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor osimertinib and KRAS-G12C inhibitor sotorasib in lung cancer

Authors: Yuri Yagami; Takashi Sato; Hiroki Yamamoto; Masayuki Shirasawa; Y. Nakahara; Watanabe Hideo; Naoki Katsuhiko

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1945

Paper Abstract 1946: Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutations

Ting Ni; Tongxin Huo; Yawen Zhang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1946: Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutations

Authors: Ting Ni; Tongxin Huo; Yawen Zhang; Jingjing Wang; Gaoxiang Liu; Wenting Shi; Qingyang Gu

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1946

Paper Abstract 1947: Studies on pMEK inhibitors for the treatment of RAS-mutant cancers as a single agent or combinations

X. Lv; Min Xu; Yong Hu et al. · 2024 · Cancer Research · DOI

Full title: Abstract 1947: Studies on pMEK inhibitors for the treatment of RAS-mutant cancers as a single agent or combinations

Authors: X. Lv; Min Xu; Yong Hu; Lanjiao Zhao; Xiuquan Chen; Youqin Chen; Chen Yang; Jizhi Li; Chen Chen

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-1947

Paper Abstract 2101: Patient-derived cells (PDCs) and organoids (PDOs) as critical platforms for developing next therapeutic strategies for NSCLC

Sewon Park; Yunjoo Joo; Ju-hyeon Lee et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2101: Patient-derived cells (PDCs) and organoids (PDOs) as critical platforms for developing next therapeutic strategies for NSCLC

Authors: Sewon Park; Yunjoo Joo; Ju-hyeon Lee; M. Yun; Mi Ra Yu; S. Oh; E. Lee; Dong Kwon Kim; Seul Lee; Kyu-Cheol Lim; M. Hong; Sun Min Lim; Jii Bum Lee; B. C. Cho

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2101

Paper Abstract 2494: RAS-Bio a unique pan-cancer biobank for RAS-driven tumors

Mathew Carter; Katherine D. Brown; H. Adderley et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2494: RAS-Bio a unique pan-cancer biobank for RAS-driven tumors

Authors: Mathew Carter; Katherine D. Brown; H. Adderley; George Morrissey; L. Woodhouse; Jamie Weaver; K. Simpson; Jordan Roebuck; J. Rogan; Joseph Mercer; Anshuman Chaturvedi; D. Wedge; Claus Jorgensen; A. Malliri; C. Dive; Colin R. Lindsay

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2494

Paper Abstract 2499: Window-of-opportunity trial of metastatic pancreatic cancer reveals potential mechanisms of response to targeting RAS signaling

Motoyuki Tsuda; Colin J Daniel; Xiaoyan Wang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 2499: Window-of-opportunity trial of metastatic pancreatic cancer reveals potential mechanisms of response to targeting RAS signaling

Authors: Motoyuki Tsuda; Colin J Daniel; Xiaoyan Wang; C. Pelz; Hayley Zimny; Alexander Smith; John Muschler; Xi Li; T. Ozmen; Furkan Ozmen; D. Keith; Christopher L. Corless; Koei Chin; Jonathan R. Brody; Charles D Lopez; Gordon B. Mills; Rosalie C. Sears

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2499

Paper Abstract 2817: Establishment of KRAS G12C mutant brain metastasis models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy

Qikuan Chen; Guilan Wang; Yingfei Yin · 2024 · Cancer Research · DOI

Full title: Abstract 2817: Establishment of KRAS G12C mutant brain metastasis models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy

Authors: Qikuan Chen; Guilan Wang; Yingfei Yin

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-2817

Paper Abstract 3313: Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS interaction

D. Ki; Hana Yu; Donggeon Kim et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3313: Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS interaction

Authors: D. Ki; Hana Yu; Donggeon Kim; Y. Jeon; Seongin Jo; J. Nam; Eun-Jung Kim; Sungeun Kim; H. Choi; Jieun Kim; Jihyun Yu; S. Choi; Wooseok Han

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3313

Paper Abstract 3321: KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models

David H Peng; Antonio Tedeschi; Lorenz Herdeis et al. · 2024 · Cancer Research · DOI

Full title: Abstract 3321: KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models

Authors: David H Peng; Antonio Tedeschi; Lorenz Herdeis; Otmar Schaaf; F. Savarese; F. Rocchetti; J. Popow; Heinrich J. Huber; Birgit Wilding; Matthias Treu; Julian Fuchs; Joachim Bröeker; Tobias Wunberg; Firoella Schischlik; Jesse Lipp; Mariah Williams; Vaness Chandler; Charles E. Deckard; V. Ramamoorthy; Joseph R. Daniele; S. Kopetz; Michael P. Kim; D. Gibbons; C. Vellano; Joseph R. Marszalek; T. Heffernan; D. McConnell; Mark Pearson; N. Kraut; D. Rudolph

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-3321

Paper Abstract 4322: Inhibition of ULK and KRASG12C control tumor growth in preclinical models of lung cancer

Phaedra C. Ghazi; Kayla T. O'Toole; Sanjana Boggaram et al. · 2024 · Cancer Research · DOI

Full title: Abstract 4322: Inhibition of ULK and KRASG12C control tumor growth in preclinical models of lung cancer

Authors: Phaedra C. Ghazi; Kayla T. O'Toole; Sanjana Boggaram; Michael T Scherzer; M. Bogdan; Bryan D. Smith; D. Flynn; Conan G Kinsey; Martin McMahon

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-4322

Paper Abstract 447: Anti-tumor efficacy of ompenaclid, a creatine transporter inhibitor, in KRAS mutant tumors, including NSCLC

Puichi lo; Victor Sanz Chavez; Shugaku Takeda et al. · 2024 · Cancer Research · DOI

Full title: Abstract 447: Anti-tumor efficacy of ompenaclid, a creatine transporter inhibitor, in KRAS mutant tumors, including NSCLC

Authors: Puichi lo; Victor Sanz Chavez; Shugaku Takeda; M. Tavazoie; Isabel Kurth

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-447

Paper - **DOI:** 10.1158/1538-7445.am2024-5948 - **Authors:** Yan Wang, Richard M. Neve, J. Staunton, Kevin R. Webster - **Year:** 2024 - **Journal:** Cancer Research

Yan Wang; Richard M. Neve; J. Staunton et al. · 2024 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2024-5948 - **Authors:** Yan Wang, Richard M. Neve, J. Staunton, Kevin R. Webster - **Year:** 2024 - **Journal:** Cancer Research

Authors: Yan Wang; Richard M. Neve; J. Staunton; Kevin R. Webster

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-5948

Paper Abstract 6049: Cell-based PROTAC screening for cancer drug discovery

Wan, Yong; Ma, Haiqing; Wu, Jianghong · 2024 · Cancer Research · DOI

Full title: Abstract 6049: Cell-based PROTAC screening for cancer drug discovery

Authors: Wan, Yong; Ma, Haiqing; Wu, Jianghong

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-6049

Paper Abstract 617: BH-30236, a novel macrocyclic CLK inhibitor modulating RNA splicing, demonstrates potent inhibition of cancer cell growth in a broad panel of cancer cell lines

Ping Jiang; Danan Li; Nancy Ling et al. · 2024 · Cancer Research · DOI

Full title: Abstract 617: BH-30236, a novel macrocyclic CLK inhibitor modulating RNA splicing, demonstrates potent inhibition of cancer cell growth in a broad panel of cancer cell lines

Authors: Ping Jiang; Danan Li; Nancy Ling; Dayong Zhai; W. Deng; Eugene Rui; J. J. Cui

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-617

Paper Abstract 6496: Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens

Liqiong Liu; Ann Strange; Schuyler Lee et al. · 2024 · Cancer Research · DOI

Full title: Abstract 6496: Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens

Authors: Liqiong Liu; Ann Strange; Schuyler Lee; Bifeng Gao; Daniel Merrick; T. Patil; James DeGregori; D. R. Camidge; S. Pine; H. Sabaawy

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-6496

Paper Abstract 657: Discovery of a novel brain penetrant SHP2 allosteric inhibitor with anti-tumor effects

Miyeon Kim; Dongsung Kim; Y. Jeon et al. · 2024 · Cancer Research · DOI

Full title: Abstract 657: Discovery of a novel brain penetrant SHP2 allosteric inhibitor with anti-tumor effects

Authors: Miyeon Kim; Dongsung Kim; Y. Jeon; Kyeong Jin Yoon; Anna Jang; Mijung Lee; Dahye Jeon; Soyeon Jang; Jinhwan Kim; Eun-Jung Kim; Jihoon Park; Victor Hong; Hayoun Jung; S. Choi

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-657

Paper Abstract 6584: Aberrant TRIM7 expression potentiates RACO-1 mediated proliferation and dysregulated interferon responsiveness in the setting of anti-PD-1 acquired resistance in cancer

Thuy-Ai Nguyen; Marc Morra; Kevin Li et al. · 2024 · Cancer Research · DOI

Full title: Abstract 6584: Aberrant TRIM7 expression potentiates RACO-1 mediated proliferation and dysregulated interferon responsiveness in the setting of anti-PD-1 acquired resistance in cancer

Authors: Thuy-Ai Nguyen; Marc Morra; Kevin Li; Ulhas Bhatt; Joseph Mwangi; Yisel Rivera-Molina; N. Oien; Julio Medina; Taylor H Schreiber; George Fromm

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-6584

Paper Abstract 6585: Combination RASG12C(ON) and RASMULTI(ON) inhibition overcomes resistance and prolongs durability in preclinical models of mutant KRASG12C-driven cancers

Xing Wei; M. Holderfield; Y. C. Yang et al. · 2024 · Cancer Research · DOI

Full title: Abstract 6585: Combination RASG12C(ON) and RASMULTI(ON) inhibition overcomes resistance and prolongs durability in preclinical models of mutant KRASG12C-driven cancers

Authors: Xing Wei; M. Holderfield; Y. C. Yang; Kyle Seamon; Jay Dinglasan; Nilufar Montazar; Bianca J Lee; Shurui Cai; L. Lai; Ida Aronchik; Stephanie Chang; Zhican Wang; Pete Wildes; J. Smith; Jingjing Jiang; Mallika Singh

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-6585

Paper Abstract 6909: KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models

J. Rosen; N. Pham; Q. Li et al. · 2024 · Cancer Research · DOI

Full title: Abstract 6909: KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models

Authors: J. Rosen; N. Pham; Q. Li; P. Cao; Katrina Hueniken; Takamasa Koga; N. Radulovich; A. Koers; Michael Niedbala; Sarah Ross; A. Sacher; M S Tsao

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-6909

Paper Abstract CT117: A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors

B. Cho; Shun Lu; M. Lee et al. · 2024 · Cancer Research · DOI

Full title: Abstract CT117: A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors

Authors: B. Cho; Shun Lu; M. Lee; Zhengbo Song; John J. Park; Sun Min Lim; Ziming Li; Jun Zhao; G. Richardson; Yanqiao Zhang; Jun Zhang; A. Liu; Cheng Chen; Jia Wang; Jingtao Lu; Haopeng Rui; Qian Chen; Hui Wang; Jing Zhang; Zhi Jian Chen; Tony Mok

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-ct117

Paper Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)

Xiaorong Dong; Xiangjiao Meng; Yan Zhang et al. · 2024 · Cancer Research · DOI

Full title: Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)

Authors: Xiaorong Dong; Xiangjiao Meng; Yan Zhang; Yan Wang; Jianhua Chen; L. Han; Qiming Wang; Zhong Lin; Hongying Wei; Siheng Lin; Chuan-yin Li; Qiong Wu

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-ct119

Paper Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

Ziming Li; Xiaomin Dang; Dingzhi Huang et al. · 2024 · Cancer Research · DOI

Full title: Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

Authors: Ziming Li; Xiaomin Dang; Dingzhi Huang; Shi Jin; Weiwei Li; Jianhua Shi; Xicheng Wang; Yiping Zhang; Zhengbo Song; Junping Zhang; Zhuang Wu; Xuewen Liu; Liyan Jiang; Xiangjiao Meng; Mingfang Zhao; Jianying Zhou; Liangming Zhang; Pingli Wang; Hui Luo; Junquan Yang; Shundong Cang; Xiang Wang; Jing Wang; J. Cui; Yan Yu; Zhihong Zhang; Junguo Lu; Weihua Yang; Gaofeng Li; Jifeng Feng; D. Lv; Lin Wu; Yong Fang; Yan Wang; Yanqiu Zhao; Baoshan Cao; Wei Zhu; Z. Zhuang; Qingshan Li; Mingxi Wang; Huan Zhou; Xiaorong Dong; Shengxiang Hu; J. Fang; Yihong Zhang; Wenjia Wang; Ziyong Xiang; Zhe Shi; Ling Zhang; Shun Lu

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-ct246

Paper Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer

Linfeng Luo; Anlin Li; Wei Du et al. · 2024 · Cancer Research · DOI

Full title: Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer

Authors: Linfeng Luo; Anlin Li; Wei Du; Maojian Chen; Jing Li; Yixin Zhou; Li Zhang; Shaodong Hong

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-lb266

Paper Abstract LB428: Discovery of KY-001:A Direct Inhibitor of TEAD-YAP Protein-Protein Interaction for the Treatment of Advanced Solid Tumors with Abnormal Hippo Signaling Pathway

Zhao, Kehao; Zhag, Yong; Shi, Yufang et al. · 2024 · Cancer Research · DOI

Full title: Abstract LB428: Discovery of KY-001:A Direct Inhibitor of TEAD-YAP Protein-Protein Interaction for the Treatment of Advanced Solid Tumors with Abnormal Hippo Signaling Pathway

Authors: Zhao, Kehao; Zhag, Yong; Shi, Yufang; Chen, Jian

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-lb428

Paper Abstract LB451: Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer

Nilanjana Chatterjee; V. Olivas; Wei Wu et al. · 2024 · Cancer Research · DOI

Full title: Abstract LB451: Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer

Authors: Nilanjana Chatterjee; V. Olivas; Wei Wu; Tracy T Tang; Ben Powell; T. Bivona

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2024-lb451

Paper Abstract 1276: UNLOCK, a preclinical platform of PDX models resistant to innovative therapies

L. Bigot; Nobre Nobre; Alice Da Silva et al. · 2025 · Cancer Research · DOI

Full title: Abstract 1276: UNLOCK, a preclinical platform of PDX models resistant to innovative therapies

Authors: L. Bigot; Nobre Nobre; Alice Da Silva; Mélissandre Méteau; Mathis Delavigne; Miguel Soares; F. Facchinetti; L. Poiraudeau; F. Brayé; Inmaculada Inmaculada Alonso Garcia; Natalie Y. Ngoi; Alexandre Halimi; E. Natali; D. Vasseur; Kristi Beshiri; C. Nicotra; M. Ngo-Camus; L. Tselikas; Beatriz Alonso de Castro; Julieta E. Rodriguez; M. F. Mosele; Maud Kamal; Gerome Jules-Clement; K. Fizazi; C. Massard; B. Besse; L. Friboulet; Y. Loriot

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-1276

Paper Abstract 239: RCZY-690 and RCZY-680: Novel, highly potent, and orally bioavailable, tri-complex pan RAS-MULTI(ON) inhibitors with distinctive oral pharmacokinetic profiles, exhibiting broad anti-tumor activities in CDX models

X. Celia-J. Chen; Lin Wang; Yuanchao Bai et al. · 2025 · Cancer Research · DOI

Full title: Abstract 239: RCZY-690 and RCZY-680: Novel, highly potent, and orally bioavailable, tri-complex pan RAS-MULTI(ON) inhibitors with distinctive oral pharmacokinetic profiles, exhibiting broad anti-tumor activities in CDX models

Authors: X. Celia-J. Chen; Lin Wang; Yuanchao Bai; Xiaohong Liu; Qiaoni You; Jianming Bao

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-239

Paper Abstract 2766: Metabolic and tumor immune cell landscapes are significantly different amongst KRAS mutational variants in non-small cell lung cancer

F. Weinberg; Jen Godden; Denise Shieh et al. · 2025 · Cancer Research · DOI

Full title: Abstract 2766: Metabolic and tumor immune cell landscapes are significantly different amongst KRAS mutational variants in non-small cell lung cancer

Authors: F. Weinberg; Jen Godden; Denise Shieh; Stamatina Fragkogianni; Jacob Mercer; M. Stoppler; Daniel R. Principe; R. Nguyen; K. Sankar; Koosha Paydary; M. Fidler

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-2766

Paper Abstract 27: Orthotopic tumor models using luciferized patient-derived organoids for investigating EGFR-MAPK pathway inhibition in colorectal and pancreatic cancer

Krishna S. Tummala; Milind D. Chalishazar; M. Angagaw et al. · 2025 · Cancer Research · DOI

Full title: Abstract 27: Orthotopic tumor models using luciferized patient-derived organoids for investigating EGFR-MAPK pathway inhibition in colorectal and pancreatic cancer

Authors: Krishna S. Tummala; Milind D. Chalishazar; M. Angagaw; Alireza Savadipour; Qingyun Yan; Cui Long; Mark Buchanan; Panagiotis N. Lalagkas; Eric Muise; Lan Chen; Kuoyuan Cheng; Eunsil Park; Jennifer Piesvaux; Erica Leccese; Brian Long; Nicolas Solban

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-27

Paper Abstract 3706: Identifying first-in-class targets for anti-cancer therapy in KRAS mutant NSCLC using the systems biology-based drug discovery platform

Namhee Kim; J. Joo; S. Choi et al. · 2025 · Cancer Research · DOI

Full title: Abstract 3706: Identifying first-in-class targets for anti-cancer therapy in KRAS mutant NSCLC using the systems biology-based drug discovery platform

Authors: Namhee Kim; J. Joo; S. Choi; Kwang‐Hyun Cho

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-3706

Paper Abstract 3882: Patterns of genomic patient-model conservation and evolution in the Human Cancer Models Initiative (HCMI) next-generation cancer model resource

Andrew McPherson; Seongmin Choi; William F Hooper et al. · 2025 · Cancer Research · DOI

Full title: Abstract 3882: Patterns of genomic patient-model conservation and evolution in the Human Cancer Models Initiative (HCMI) next-generation cancer model resource

Authors: Andrew McPherson; Seongmin Choi; William F Hooper; Jennifer Shelton; Timothy R. Chu; Dina Elharouni; Mushriq Al-Jazrawe; Merve Dede; T. Hinoue; Sean A. Misek; Heeju Noh; Luca Zanella; Moony Tseng; Hayley E. Francies; Priya Sridevi; Rachana Agarwal; Cindy W. Kyi; Julyann Pérez-Mayoral; Megan J. Stine; Eva Y. Tonsing-Carter; James M. Clinton; The Hcmi Network; Peter W. Laird; Calvin J. Kuo; O. Elemento; David L. Spector; Andrew D. Cherniack; Kyle Ellrott; M. Ferguson; R. Beroukhim; K. Hoadley; N. Robine; Mathew J. Garnett; D. Tuveson; Andrea Califano; Paul T. Spellman; Keith L Ligon; Daniela S. Gerhard; Louis M. Staudt; Jesse S. Boehm

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-3882

Paper - **DOI:** 10.1158/1538-7445.am2025-419 - **Authors:** Dingcheng Gao, Yingzhuo Liu, Yi Ban - **Year:** 2025 - **Journal:** Cancer Research

Dingcheng Gao; Yingzhuo Liu; Yi Ban · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-419 - **Authors:** Dingcheng Gao, Yingzhuo Liu, Yi Ban - **Year:** 2025 - **Journal:** Cancer Research

Authors: Dingcheng Gao; Yingzhuo Liu; Yi Ban

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-419

Paper Abstract 421: Targeting WEE1 enhances the antitumor effect of KRAS mutated non-small cell lung cancer harboring TP53 mutations

Koji Fukuda; S. Takeuchi; Shigeki Sato et al. · 2025 · Cancer Research · DOI

Full title: Abstract 421: Targeting WEE1 enhances the antitumor effect of KRAS mutated non-small cell lung cancer harboring TP53 mutations

Authors: Koji Fukuda; S. Takeuchi; Shigeki Sato; S. Arai; S. Nanjo; Hiroaki Taniguchi; Seiji Yano

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-421

Paper Abstract 422: Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by replication stress-induced genomic instability and mitotic cell death

Chendi Li; Varuna Nangia; Christopher J. Graser et al. · 2025 · Cancer Research · DOI

Full title: Abstract 422: Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by replication stress-induced genomic instability and mitotic cell death

Authors: Chendi Li; Varuna Nangia; Christopher J. Graser; Jeremy B Chang; Anahita Nimbalkar; Mohammad U. Syed; Melissa D. Vieira; Yi Shen; Steve Altschuler; Lani Wu; Franziska Michor; Sabrina L Spencer; Aaron N. Hata

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-422

Paper Abstract 4371: PHI-501 as a potent pan-RAF/DDRs inhibitor suppresses lung cancer cell proliferation and overcomes KRAS G12C inhibitor resistance

An-Na Moon; Ji Young Kim; Hee-sun Hwang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4371: PHI-501 as a potent pan-RAF/DDRs inhibitor suppresses lung cancer cell proliferation and overcomes KRAS G12C inhibitor resistance

Authors: An-Na Moon; Ji Young Kim; Hee-sun Hwang; Gi-Jun Sung; Jinsun Kwon; Ky-Youb Nam; Kyu-Tae Kim; J. Han; Jeong-Hyeok Yoon; Ki-Young Lee

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4371

Paper Abstract 4434: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors

Veena Somasundaram; S. Krishn; Reshmi Nair et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4434: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors

Authors: Veena Somasundaram; S. Krishn; Reshmi Nair; P. Nair; Rachel Salazar

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4434

Paper Abstract 4450: Targeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitors

Xianwen Yang; Peiling Ren; Guiping Li et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4450: Targeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitors

Authors: Xianwen Yang; Peiling Ren; Guiping Li; Ying Yu; Guangxiu Dai

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4450

Paper Abstract 4559: Paired liquid biopsies analysis reveals resistance mechanisms and prognostic factors in patients treated with KRASG12C inhibitors

Kristi Beshiri; D. Vasseur; Julieta E. Rodriguez et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4559: Paired liquid biopsies analysis reveals resistance mechanisms and prognostic factors in patients treated with KRASG12C inhibitors

Authors: Kristi Beshiri; D. Vasseur; Julieta E. Rodriguez; Smolenschi Cristina; F. Facchinetti; A. Italiano; Nicotra Claudio; M. Ngo-Camus; A. Gazzah; Capucine Baldini; L. Friboulet; Y. Loriot; Fabrice Barlesi; C. Massard; A. Hollebecque

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4559

Paper Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Gaku Yamamoto; Yu Tanaka; Y. Zenke et al. · 2025 · Cancer Research · DOI

Full title: Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Authors: Gaku Yamamoto; Yu Tanaka; Y. Zenke; Jie Liu; Tetsuya Sakai; H. Izumi; E. Sugiyama; S. Umemura; Shingo Matsumoto; K. Yoh; Koichi Goto; Susumu S Kobayashi; H. Udagawa

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-4714

Paper Abstract 5329: Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer

Meihua Li; Apeng Liang; Kai Wang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5329: Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer

Authors: Meihua Li; Apeng Liang; Kai Wang; Yi Long; Rui Wu; Hui Xu; Jian Zhu; Guangbin Liu; Ling Fang; Xi Wang; Chenjie Pan; Yiming Cai; Xiang Zhang; Shengli Dong; Yu Yu; Xinlong Yang; Chao Zhou; Wei Wu; Chengshan Niu; Mingyu Jiang; Shaoqing Chen; Jun Li; Yusheng Wu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5329

Paper Abstract 534: Sotorasib-resveratrol combination induces synergistic cytotoxicity by downregulating K-RAS signaling in K-RAS mutant lung cancer cell lines

P. B. Bernal; N. Hernández-Pedro; J. Lucio-Lozada et al. · 2025 · Cancer Research · DOI

Full title: Abstract 534: Sotorasib-resveratrol combination induces synergistic cytotoxicity by downregulating K-RAS signaling in K-RAS mutant lung cancer cell lines

Authors: P. B. Bernal; N. Hernández-Pedro; J. Lucio-Lozada; E. Romero-Núñez; C. Castillo-Ruiz; Brandon Lopez; Sandra Hernández‐Sánchez; Oscar Arrieta

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-534

Paper Abstract 5362: Molecular profiling of SW-682, a pan-TEAD inhibitor, as monotherapy and in combination with other treatments across tumor types

Somdutta Saha; V. Jové; Amelia Schirmer et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5362: Molecular profiling of SW-682, a pan-TEAD inhibitor, as monotherapy and in combination with other treatments across tumor types

Authors: Somdutta Saha; V. Jové; Amelia Schirmer; L. Celentano; A. Chanelo; Connor Smith; Sarah Ahn; Jim Smothers; Wenlin Shao; Tai-An Lin; Paula L. Miliani de Marval; Lei Chen; R. DuBose

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5362

Paper Abstract 5501: An integrated end-to-end platform facilitating the evaluation of next generation KRAS inhibitors

Di Zhan; Lingling Huang; Lei Zhang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5501: An integrated end-to-end platform facilitating the evaluation of next generation KRAS inhibitors

Authors: Di Zhan; Lingling Huang; Lei Zhang; Ting Ma; Yuzhou Xu; Yinfei Yin; Zichun Wang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5501

Paper Abstract 5507: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer

Joshua H Choe; Julien Dilly; Eejung Kim et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5507: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer

Authors: Joshua H Choe; Julien Dilly; Eejung Kim; L. Lai; Nicole Sindoni; Fan Yi Kong; Dennis Gong; Jaclyn Varga-Wiles; Brendan D Parent; Junning Wang; Kyle Seamon; Jennifer A. Chan; Clint A. Stalnecker; C. Der; W. L. Hwang; B. Wolpin; D. Wildes; J. Mancias; Lewis C Cantley; A. Aguirre

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5507

Paper Abstract 5509: Mechanisms regulating resistance to KRAS inhibitor driven by DNp63/YAP regulation of tissue stiffness and metabolic alterations in lung adenocarcinoma

Santanu Adhikary; M. Napoli; Suehelay Acevedo et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5509: Mechanisms regulating resistance to KRAS inhibitor driven by DNp63/YAP regulation of tissue stiffness and metabolic alterations in lung adenocarcinoma

Authors: Santanu Adhikary; M. Napoli; Suehelay Acevedo; Christina L Carr; Jaden R. Baldwin; Nicole Hackel; Hitendra S Solanki; Yaakov E. Stern; Laxmi S. Karanam; Duy T. Nguyen; E. Haura; Elsa R. Flores

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5509

Paper Abstract 5512: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven byKRASG12C amplification or NRASG13R mutation

Hitendra S Solanki; Denis Imbody; Bina Desai et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5512: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven byKRASG12C amplification or NRASG13R mutation

Authors: Hitendra S Solanki; Denis Imbody; Bina Desai; Daria Miroshnychenko; Bhaswati Sarcar; A. Majumder; Yonghong Zhang; Uwe Rix; A. Marusyk; Mallika Singh; Ida Aronchik; E. Haura

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5512

Paper Abstract 5517: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy

I. Meraz; M. Majidi; R. Song et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5517: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy

Authors: I. Meraz; M. Majidi; R. Song; Shuhong Wu; Lihui Gao; F. Meng; Chenghui Ren; Yi Xu; Qi Wang; Yuanxin Xi; Jing Wang; Sung Yun Jung; Elizabeth J. Shpall; Jack A Roth

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5517

Paper Abstract 5518: Targeting FAK by Ifebemtinib synergizes with Pan RAS inhibitors in treating RAS mutant cancers

Baoyuan Zhang; Ran Pang; Jiaming Gao et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5518: Targeting FAK by Ifebemtinib synergizes with Pan RAS inhibitors in treating RAS mutant cancers

Authors: Baoyuan Zhang; Ran Pang; Jiaming Gao; Jingwen Cheng; Ping Zhang; Natasha Qin; Leo Liu; Zaiqi Wang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5518

Paper Abstract 5521: Integrative analysis of acquired drug resistance to KRAS(G12D) inhibitors

Ines Pulido Endrino; Laura C Gunder; Malek G Massad et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5521: Integrative analysis of acquired drug resistance to KRAS(G12D) inhibitors

Authors: Ines Pulido Endrino; Laura C Gunder; Malek G Massad; J. Carretero; T. Shimamura

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5521

Paper Abstract 5522: Cell state modulates the KRASG12C proximal proteome

A. Majumder; Liznair Bridenstine; Denis Imbody et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5522: Cell state modulates the KRASG12C proximal proteome

Authors: A. Majumder; Liznair Bridenstine; Denis Imbody; Kiah Bowers; Dalia Ercan; Bin Fang; E. Haura

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5522

Paper Abstract 5524: Developing KRASG12C inhibitor-resistant tumor models for efficacy evaluation of next-generation anticancer therapies

Jian Feng; Dan Zhang; A. Hua et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5524: Developing KRASG12C inhibitor-resistant tumor models for efficacy evaluation of next-generation anticancer therapies

Authors: Jian Feng; Dan Zhang; A. Hua; C. Nie; Jessie Wang; Ludovic Bourré; Jun Zhou; Peng Wang

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5524

Paper - **DOI:** 10.1158/1538-7445.am2025-5532 - **Authors:** Hayato Kawachi, Tadaaki Yamada, Yuki Katayama, Takayama Koichi - **Year:** 2025 - **Journal:** Cancer Research

Hayato Kawachi; Tadaaki Yamada; Yuki Katayama et al. · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.am2025-5532 - **Authors:** Hayato Kawachi, Tadaaki Yamada, Yuki Katayama, Takayama Koichi - **Year:** 2025 - **Journal:** Cancer Research

Authors: Hayato Kawachi; Tadaaki Yamada; Yuki Katayama; Takayama Koichi

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5532

Paper Abstract 5706: A patient-derived organoid screening platform as a powerful tool to study efficacy of KRAS inhibitors

Merel Derksen; Mariana Silva; Gerben ten Hag et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5706: A patient-derived organoid screening platform as a powerful tool to study efficacy of KRAS inhibitors

Authors: Merel Derksen; Mariana Silva; Gerben ten Hag; Nilofar Ehsani; Yasmine Abouleila; Vineeta Adegbenro; Annemarie Buijs; M. Doorn; Nikki van Dorp; J. F. Aldeguer; Foteini Gkogkou; Yara Hendriksen; R. Korporaal; Ka Wai La; Joris Maas; Francisco Morales-Rodrigues; Daniele Mori; Sumeyra Mucuk; César Oyarce; Nima Salehi; Anna Schepers; M. Statia; Roel Verkerk; Timo Voskuilen; Rene Overmeer; F. Pourfarzad; Sylvia F Boj

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5706

Paper Abstract 5836: Suppression of TNFα and IFNγ signaling are key molecular events in KRASG12C mutant cancer cells to confer therapeutic resistance to Sotorasib and promote immune evasion

Mohammed L Ibrahim; Xiaoqing Yu; Dana Foresman et al. · 2025 · Cancer Research · DOI

Full title: Abstract 5836: Suppression of TNFα and IFNγ signaling are key molecular events in KRASG12C mutant cancer cells to confer therapeutic resistance to Sotorasib and promote immune evasion

Authors: Mohammed L Ibrahim; Xiaoqing Yu; Dana Foresman; Zheng Hong; E. Haura; Amer A Beg

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-5836

Paper Abstract 6376: KRASmultidegrader BPI-585725 displays potent anti-tumor activity in KRAS-driven preclinical models

Zhengqing Li; Renqi Xu; Xiaofeng Yang et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6376: KRASmultidegrader BPI-585725 displays potent anti-tumor activity in KRAS-driven preclinical models

Authors: Zhengqing Li; Renqi Xu; Xiaofeng Yang; Xiaoqiang Kong; Ying Zhao; Tao Zhang; Yanju Liu; Jing Guo; Cheng Yang; Han Han; Xiaoyun Liu; Haibo Chen; Lieming Ding; Hong Lan; Quan Zhou

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6376

Paper Abstract 6997: Impact of KRASG12C oxidation state on non-small-cell lung cancer response to targeted therapeutics

Yismeilin R. Feliz Mosquea; M. L. Carneiro Buchele; D. Parsonage et al. · 2025 · Cancer Research · DOI

Full title: Abstract 6997: Impact of KRASG12C oxidation state on non-small-cell lung cancer response to targeted therapeutics

Authors: Yismeilin R. Feliz Mosquea; M. L. Carneiro Buchele; D. Parsonage; Jingyun Lee; Surbhi Mundra; Sharon L. Campbell; Leslie B. Poole; Cristina M. Furdui

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-6997

Paper Abstract CT073: A first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) in adult patients with advanced solid tumors

Chia-chi Lin; H. Yu; Dong-Wan Kim et al. · 2025 · Cancer Research · DOI

Full title: Abstract CT073: A first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) in adult patients with advanced solid tumors

Authors: Chia-chi Lin; H. Yu; Dong-Wan Kim; Daniel Tan; Dae Ho Lee; M. J. Casulleras; N. Steeghs; Fredericus Eskens; Ahmad A. Tarhini; Melissa L. Johnson; I. Braña; Giuseppe Curigliano; L. Siu; A. Ferrándiz; G. Shapiro; Victor Moreno Garcia; Hironobu Minami; Martin Klumpp; Helen Evans; T. Hengelage; Suresh B. Lakshminarayana; John Ritz; Xin Yang; David P. Kodack; Christopher Straub; Pruthvi Desireddy; Susan E Moody; Pilar Garrido

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-ct073

Paper Abstract CT138: Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study

Xiangjiao Meng; Yan Zhang; Yan Wang et al. · 2025 · Cancer Research · DOI

Full title: Abstract CT138: Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study

Authors: Xiangjiao Meng; Yan Zhang; Yan Wang; L. Han; Jianhua Chen; Qiming Wang; Zhong Lin; Shujun Feng; Zhenzhong Su; Xiaoqing Zhang; Xiaorong Dong

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-ct138

Paper Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12Cand STK11 mutations: KRYSTAL-1 phase 2 cohort

M. Negrão; Kai He; Edwin H Yau et al. · 2025 · Cancer Research · DOI

Full title: Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12Cand STK11 mutations: KRYSTAL-1 phase 2 cohort

Authors: M. Negrão; Kai He; Edwin H Yau; A. Spira; Melissa L. Johnson; S. Gadgeel; P. Jänne; J. Sabari; Muhammad K. Riaz; Erin L. Schenk; J. Misleh; Harris A. Ahmad; Nicolas Brand; Marzana Chowdhury; Laura J. Eccles; Gregory Riely

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-ct209

Paper Abstract CT266: D3S-001, a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in KRAS G12C inhibitor resistant non-small cell lung cancer

H. Loong; Ziming Li; Byoung Chul Cho et al. · 2025 · Cancer Research · DOI

Full title: Abstract CT266: D3S-001, a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in KRAS G12C inhibitor resistant non-small cell lung cancer

Authors: H. Loong; Ziming Li; Byoung Chul Cho; Jun Zhao; John J. Park; Zhengbo Song; Bowyer Samantha; Ki Hyeong Lee; Xiaorong Dong; Jianya Zhou; Cheng Chen; Yangbo Liu; Yandong Shen; Shaonan Wang; Zifei Fan; Qianqian Chen; Hui Wang; Jing Zhang; Zhi Jian Chen; Tony Mok; Shun Lu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-ct266

Paper Abstract LB290: Identifying novel mechanisms of resistance to KRAS-inhibitors in NSCLC

S. Kundu · 2025 · Cancer Research · DOI

Full title: Abstract LB290: Identifying novel mechanisms of resistance to KRAS-inhibitors in NSCLC

Authors: S. Kundu

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-lb290

Paper Abstract ND01: AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors

B. Lanman; Ryan Wurz; Rati Verma et al. · 2025 · Cancer Research · DOI

Full title: Abstract ND01: AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors

Authors: B. Lanman; Ryan Wurz; Rati Verma; T. Osgood; Kevin Gaida; Deanna Mohn; Ying-Chu Chen; Gilbert Diaz; A. Y. Saiki; Paul E Hughes; Christopher P. Mohr; Amit Vaish; Yanyan Tudor; Upendra P. Dahal; Prashant Agarwal; Christine Mollica

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.am2025-nd01

Paper Abstract IA24: Interrogating therapy response and resistance in engineered preclinical models

L. Dow · 2020 · Oral Presentations - Invited Abstracts · DOI

Full title: Abstract IA24: Interrogating therapy response and resistance in engineered preclinical models

Authors: L. Dow

Year: 2020

Venue: Oral Presentations - Invited Abstracts

DOI: https://doi.org/10.1158/1538-7445.camodels2020-ia24

Paper Abstract B016: Inhibition of KRASG12C in colon cancer illustrates a link between beta-catenin, WNK, and the GID complex

K. Nayak; Y. Hwang; LeeAnn Wang et al. · 2022 · Cancer Research · DOI

Full title: Abstract B016: Inhibition of KRASG12C in colon cancer illustrates a link between beta-catenin, WNK, and the GID complex

Authors: K. Nayak; Y. Hwang; LeeAnn Wang; D. Swaney; N. Krogan; J. Gordan

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.crc22-b016

Paper Abstract B013: Precision medicine platform to guide the treatment of NSCLC

Nathan M. Merrill; A. Udager; Angel Qin et al. · 2025 · Cancer Research · DOI

Full title: Abstract B013: Precision medicine platform to guide the treatment of NSCLC

Authors: Nathan M. Merrill; A. Udager; Angel Qin; K. Lagisetty; L. Bao; Xu Cheng; H. Madhi; Ananya Banerjee; M. S. Jahromi; L. Goo; V. Kathawate; B. Vandenburg; Mary Horn; D. Nancarrow; Tusharika Rastogi; Albert Liu; N. Gu; Zhaoping Qin; H. Serhan; M. Aikins; V. Navani; John L. Jefferies; Muhammad Sajawal Ali; Michael Monument; J. Kratz; Amber Smith; Andrew Chang; G. Kalemkerian; Stacy Fry; P. Ulintz; S. Nagrath; P. Hsu; M. Soellner; S. Merajver

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.genfunc25-b013

Paper Abstract PR009: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

Yoann Pradat; J. Viot; Konstantin Gunbin et al. · 2023 · Cancer Research · DOI

Full title: Abstract PR009: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

Authors: Yoann Pradat; J. Viot; Konstantin Gunbin; A. Iurchenko; Marc Deloger; L. Cerbone; Guillaume Grisay; L. Verlingue; V. Scott; S. Michiels; A. Hollebecque; Gerome Jules-Clement; Antoine Laine; L. Friboulet; L. Mezquita; Y. Loriot; B. Besse; F. André; P. Cournède; D. Gautheret; S. Nikolaev

Year: 2023

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.metastasis22-pr009

Paper Abstract I16: KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and therapeutic resistance

Ellen M. Langer; Yulong Su; M. M. Joly et al. · 2019 · DOI

Full title: Abstract I16: KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and therapeutic resistance

Authors: Ellen M. Langer; Yulong Su; M. M. Joly; Brittany L. Allen-Petersen; Amy S Farrell; P. Worth; Daniel F. Liefwalker; Jason M. Link; B. Sheppard; R. Sears

Year: 2019

DOI: https://doi.org/10.1158/1538-7445.panca19-i16

Paper Abstract C097: KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-driven tumors to sotorasib treatment

Yongkun Wei; Minghui Liu; Phuoc T Nguyen et al. · 2024 · Cancer Research · DOI

Full title: Abstract C097: KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-driven tumors to sotorasib treatment

Authors: Yongkun Wei; Minghui Liu; Phuoc T Nguyen; Dean N. Pan; W. Yao; H. Ying

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.panca2023-c097

Paper Abstract C116: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma

Rachael Baliira; E. L. Opsahl; Ivana Barravecchia et al. · 2024 · Cancer Research · DOI

Full title: Abstract C116: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma

Authors: Rachael Baliira; E. L. Opsahl; Ivana Barravecchia; M. P. di Magliano; Stefanie Galbán

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.panca2023-c116

Paper Abstract C067: Understanding the tumor extrinsic role of oncogenic Kras in pancreatic cancer

Monica E Bonilla · 2022 · Cancer Research · DOI

Full title: Abstract C067: Understanding the tumor extrinsic role of oncogenic Kras in pancreatic cancer

Authors: Monica E Bonilla

Year: 2022

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.panca22-c067

Paper Abstract IA-04: Targeting the oncogenic state of RAS with tri-complex inhibitors

Mallika Singh · 2024 · Cancer Research · DOI

Full title: Abstract IA-04: Targeting the oncogenic state of RAS with tri-complex inhibitors

Authors: Mallika Singh

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.pancreatic24-ia-04

Paper Abstract IA-05: Targeting KRAS for pancreatic cancer treatment

C. Der · 2024 · Cancer Research · DOI

Full title: Abstract IA-05: Targeting KRAS for pancreatic cancer treatment

Authors: C. Der

Year: 2024

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.pancreatic24-ia-05

Paper - **DOI:** 10.1158/1538-7445.pancreatic25-a095 - **Authors:** Donovan Drouillard, Marissa Davies, Donna McCallister, Michael B Dwinell - **Year:** 2025 - **Journal:** Cancer Research

Donovan Drouillard; Marissa Davies; Donna McCallister et al. · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.pancreatic25-a095 - **Authors:** Donovan Drouillard, Marissa Davies, Donna McCallister, Michael B Dwinell - **Year:** 2025 - **Journal:** Cancer Research

Authors: Donovan Drouillard; Marissa Davies; Donna McCallister; Michael B Dwinell

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.pancreatic25-a095

Paper Abstract B083: Defining a molecular basis and therapeutic approach for KEAP1-NRF2 mediated resistance to KRAS inhibition in KRAS-mutant pancreatic ductal adenocarcinoma

Wen-Hsuan Chang; Addison G Stamey; Run-Wei Yang et al. · 2025 · Cancer Research · DOI

Full title: Abstract B083: Defining a molecular basis and therapeutic approach for KEAP1-NRF2 mediated resistance to KRAS inhibition in KRAS-mutant pancreatic ductal adenocarcinoma

Authors: Wen-Hsuan Chang; Addison G Stamey; Run-Wei Yang; Ryan Robb; Jeffery A. Klomp; Clint A. Stalnecker; Andrew M. Waters; Antje Schaefer; Kirsten L. Bryant; Adrienne D. Cox; C. Der

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.pancreatic25-b083

Paper Abstract B092: Investigating combination therapies to overcome RAS inhibitor resistance in pancreatic cancer

Vasiliki I. Pantazopoulou; Casie Kubota; Satoshi Ogawa et al. · 2025 · Cancer Research · DOI

Full title: Abstract B092: Investigating combination therapies to overcome RAS inhibitor resistance in pancreatic cancer

Authors: Vasiliki I. Pantazopoulou; Casie Kubota; Satoshi Ogawa; Kassidy Curtis; Araceli Herrera Morales; Dannielle D. Engle

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.pancreatic25-b092

Paper - **DOI:** 10.1158/1538-7445.pancreatic25-ia02 - **Authors:** Mallika Singh - **Year:** 2025 - **Journal:** Cancer Research

Mallika Singh · 2025 · Cancer Research · DOI

Full title: - **DOI:** 10.1158/1538-7445.pancreatic25-ia02 - **Authors:** Mallika Singh - **Year:** 2025 - **Journal:** Cancer Research

Authors: Mallika Singh

Year: 2025

Venue: Cancer Research

DOI: https://doi.org/10.1158/1538-7445.pancreatic25-ia02

Paper Targeted therapies in non-small cell lung cancer: present and future

McLaughlin, Jessica; Berkman, Jonathan; Nana‐Sinkam, Patrick · 2023 · Faculty Reviews · DOI

Full title: Targeted therapies in non-small cell lung cancer: present and future

Authors: McLaughlin, Jessica; Berkman, Jonathan; Nana‐Sinkam, Patrick

Year: 2023

Venue: Faculty Reviews

DOI: https://doi.org/10.12703/r/12-22

Paper Abstract B011: RNA-based therapeutics to target the p53 pathway in cancer

M. Napoli; Ashley K Lu; A. Deshpande et al. · 2024 · Molecular Cancer Therapeutics · DOI

Full title: Abstract B011: RNA-based therapeutics to target the p53 pathway in cancer

Authors: M. Napoli; Ashley K Lu; A. Deshpande; Jaden R. Baldwin; Christina L Carr; Michael R Dunne; Omar K Farha; Michelle Teplensky; Elsa R Flores

Year: 2024

Venue: Molecular Cancer Therapeutics

DOI: https://doi.org/10.1158/1538-8514.rnadrivers24-b011

Paper Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance

I. Aronchik; Yumin Dai; M. Labenski et al. · 2018 · Molecular Cancer Research · DOI

Full title: Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance

Authors: I. Aronchik; Yumin Dai; M. Labenski; C. Barnés; T. Jones; L. Qiao; L. Beebe; Mehnaz Malek; Winfried Elis; T. Shi; K. Mavrommatis; G. Bray; E. Filvaroff

Year: 2018

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1541-7786.mcr-17-0554

Paper Abstract B23: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257: A prototype selective inhibitor of KRAS G12C

Hallin, Jill; Aranda, Ruth; Baer, Brian R. et al. · 2020 · Molecular Cancer Research · DOI

Full title: Abstract B23: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257: A prototype selective inhibitor of KRAS G12C

Authors: Hallin, Jill; Aranda, Ruth; Baer, Brian R.; Briere, David M.; Burkhard, Michael R.; Calinisan, Andrew; Chiang, Harrah; Engstrom, Lars D.; Fell, Jay B.; Fischer, John P.; Hargis, Lauren; Marx, Matthew A.; Olson, Pete; Sudhakar, Niranjan; Christensen, James G.

Year: 2020

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras18-b23

Paper Abstract IA19: Insight towards therapeutic susceptibility of KRAS-mutant cancers from MRTX1257, a novel KRAS G12C mutant-selective small-molecule inhibitor

J. Christensen · 2020 · DOI

Full title: Abstract IA19: Insight towards therapeutic susceptibility of KRAS-mutant cancers from MRTX1257, a novel KRAS G12C mutant-selective small-molecule inhibitor

Authors: J. Christensen

Year: 2020

DOI: https://doi.org/10.1158/1557-3125.ras18-ia19

Paper Abstract A001: RAS:RAF proximity ligation assay may predict response to KRASG12C inhibitors in NSCLC

R. Kato; Hitendra S Solanki; Denis Imbody et al. · 2023 · Molecular Cancer Research · DOI

Full title: Abstract A001: RAS:RAF proximity ligation assay may predict response to KRASG12C inhibitors in NSCLC

Authors: R. Kato; Hitendra S Solanki; Denis Imbody; A. Majumder; Yaakov E. Stern; Liznair Bridenstine; Joseph Johnson; E. Haura

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-a001

Paper Abstract A017: Deciphering the role of integrated stress response (ISR) in the developmental stages of mutant KRAS lung cancer

Shiqi Diao; N. Ghaddar; Jianqiu Zou et al. · 2023 · Molecular Cancer Research · DOI

Full title: Abstract A017: Deciphering the role of integrated stress response (ISR) in the developmental stages of mutant KRAS lung cancer

Authors: Shiqi Diao; N. Ghaddar; Jianqiu Zou; Shuo Wang; A. Koromilas

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-a017

Paper Abstract B004: Multi-omics profiling to identify mechanisms of resistance to KRAS inhibition: A comparative study on colorectal and lung cancer

S. Chowdhury; Vinay K Pattalachinti; V. Haridas et al. · 2023 · Molecular Cancer Research · DOI

Full title: Abstract B004: Multi-omics profiling to identify mechanisms of resistance to KRAS inhibition: A comparative study on colorectal and lung cancer

Authors: S. Chowdhury; Vinay K Pattalachinti; V. Haridas; S. Kopetz; J. Shen

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-b004

Paper Abstract B012: Effects of adagrasib on oncogenic signaling, immune cell regulation and biomarkers of response in preliminary clinical analyses

Jill Hallin; Laura D Hover; Julio Fernandez-Benet et al. · 2023 · Molecular Cancer Research · DOI

Full title: Abstract B012: Effects of adagrasib on oncogenic signaling, immune cell regulation and biomarkers of response in preliminary clinical analyses

Authors: Jill Hallin; Laura D Hover; Julio Fernandez-Benet; A. Pavlícek; K. Anderes; P. Jänne; Gregory Riely; A. Spira; Jun Zhang; Peter Olson; J. Christensen

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-b012

Paper Abstract B025: The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK.

S. Coma; M. Musteanu; C. Caffarra et al. · 2023 · Molecular Cancer Research · DOI

Full title: Abstract B025: The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK.

Authors: S. Coma; M. Musteanu; C. Caffarra; Alessia Mira; E. Patrucco; Julien Dilly; A. Aguirre; M. Barbacid; C. Ambrogio; J. Pachter

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-b025

Paper Abstract B026: Overcoming KRAS G12C inhibitor resistance with chaperone-mediated protein degrader in NSCLC

I. Pulido; Jennifer Graeber; Brianna C. Borger et al. · 2023 · Molecular Cancer Research · DOI

Full title: Abstract B026: Overcoming KRAS G12C inhibitor resistance with chaperone-mediated protein degrader in NSCLC

Authors: I. Pulido; Jennifer Graeber; Brianna C. Borger; K. Foley; W. Ying; Chenghao Ying; Jinhua Li; Yaya Wang; Yuetong Sun; Yan-Qing Dai; Guoqiang Wang; T. Prince; T. Shimamura

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-b026

Paper - **DOI:** 10.1158/1557-3125.ras23-ia06 - **Authors:** C. Der - **Year:** 2023 - **Journal:** Molecular Cancer Research

C. Der · 2023 · Molecular Cancer Research · DOI

Full title: - **DOI:** 10.1158/1557-3125.ras23-ia06 - **Authors:** C. Der - **Year:** 2023 - **Journal:** Molecular Cancer Research

Authors: C. Der

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-ia06

Paper Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer

R. Yaeger; Riccardo Mezzadra; Jenna Sinopoli et al. · 2023 · Molecular Cancer Research · DOI

Full title: Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer

Authors: R. Yaeger; Riccardo Mezzadra; Jenna Sinopoli; Yu Bian; M. Marasco; Esther Kaplun; Yijun Gao; Huiyong Zhao; A. Da Cruz Paula; Yingjie Zhu; Almudena Chaves Perez; Kalyani Chadalavada; Edison Tse; S. Chowdhry; Sydney Bowker; Q. Chang; Besnik Qeriqi; B. Weigelt; G. Nanjangud; M. Berger; H. Der-Torossian; K. Anderes; N. Socci; J. Shia; Gregory Riely; Y. Murciano-Goroff; Bob T. Li; J. Christensen; J. Reis-Filho; D. Solit; E. de Stanchina; S. Lowe; Neal Rosen; S. Misale

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-ia07

Paper Abstract IA20: The impact of RAS inhibition on tumor immune evasion

J. Downward · 2023 · Molecular Cancer Research · DOI

Full title: Abstract IA20: The impact of RAS inhibition on tumor immune evasion

Authors: J. Downward

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-ia20

Paper Abstract PR07: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma

Rachael Baliira; E. L. Opsahl; Elyse McLintock et al. · 2023 · Molecular Cancer Research · DOI

Full title: Abstract PR07: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma

Authors: Rachael Baliira; E. L. Opsahl; Elyse McLintock; Katelyn L. Donahue; Ivana Barravacchia; M. Magliano; S. Galban

Year: 2023

Venue: Molecular Cancer Research

DOI: https://doi.org/10.1158/1557-3125.ras23-pr07

Paper Abstract A31: Activity-based protein profiling reveals adaptive response to pharmacological MEK inhibition in KRAS mutant non-small cell lung cancer

Jae-Young Kim; B. Fang; E. Welsh et al. · 2014 · DOI

Full title: Abstract A31: Activity-based protein profiling reveals adaptive response to pharmacological MEK inhibition in KRAS mutant non-small cell lung cancer

Authors: Jae-Young Kim; B. Fang; E. Welsh; F. Kinose; Jiannong Li; S. Eschrich; J. Koomen; E. Haura

Year: 2014

DOI: https://doi.org/10.1158/1557-3125.rasonc14-a31

Paper Abstract A54: Studies on the molecular mechanisms responsible for cisplatin resistance associated to KRAS G12C mutation in NSCLC

E. Caiola; R. Frapolli; M. Broggini et al. · 2014 · DOI

Full title: Abstract A54: Studies on the molecular mechanisms responsible for cisplatin resistance associated to KRAS G12C mutation in NSCLC

Authors: E. Caiola; R. Frapolli; M. Broggini; M. Garassino; G. Farina; M. Marabese

Year: 2014

DOI: https://doi.org/10.1158/1557-3125.rasonc14-a54

Paper Abstract B25: KRAS mutation status is associated with enhanced dependency on purine biosynthesis and related pathways in non small cell lung cancer cells

Diarmuid Moran; P. Trusk; Karen Pry et al. · 2014 · DOI

Full title: Abstract B25: KRAS mutation status is associated with enhanced dependency on purine biosynthesis and related pathways in non small cell lung cancer cells

Authors: Diarmuid Moran; P. Trusk; Karen Pry; K. Paz; D. Sidransky; S. Bacus

Year: 2014

DOI: https://doi.org/10.1158/1557-3125.rasonc14-b25

Paper Abstract B30: Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer

Navika D. Shukla; A. Salahudeen; S. Padda et al. · 2018 · Tumor Microenvironment · DOI

Full title: Abstract B30: Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer

Authors: Navika D. Shukla; A. Salahudeen; S. Padda; J. Neal; H. Wakelee; C. Kuo

Year: 2018

Venue: Tumor Microenvironment

DOI: https://doi.org/10.1158/1557-3265.aacriaslc18-b30

Paper Data from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Amodio, Vito; Yaeger, Rona; Arcella, Pamela et al. · 2023 · DOI

Full title: Data from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Authors: Amodio, Vito; Yaeger, Rona; Arcella, Pamela; Cancelliere, Carlotta; Lamba, Simona; Lorenzato, Annalisa; Arena, Sabrina; Montone, Monica; Mussolin, Benedetta; Bian, Yu; Whaley, Adele; Pinnelli, Marika; Murciano‐Goroff, Yonina R.; Vakiani, Efsevia; Valeri, Nicola; Liao, Wei‐Li; Bhalkikar, Anuja; Thyparambil, Sheeno; Zhao, HuiYong; Stanchina, Elisa de; Marsoni, Silvia; Siena, Salvatore; Bertotti, Andrea; Trusolino, Livio; Li, Bob T.; Rosen, Neal; Nicolantonio, Federica Di; Bardelli, Alberto; Misale, Sandra

Year: 2023

DOI: https://doi.org/10.1158/2159-8290.c.6547880

Paper EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.

V. Amodio; R. Yaeger; Pamela Arcella et al. · 2020 · Cancer Discovery · DOI

Full title: EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.

Authors: V. Amodio; R. Yaeger; Pamela Arcella; Carlotta Cancelliere; S. Lamba; Annalisa Lorenzato; S. Arena; M. Montone; Benedetta Mussolin; Yu Bian; Adele Whaley; M. Pinnelli; Y. Murciano-Goroff; E. Vakiani; N. Valeri; W. Liao; A. Bhalkikar; S. Thyparambil; Huiyong Zhao; E. de Stanchina; S. Marsoni; S. Siena; A. Bertotti; L. Trusolino; Bob T. Li; N. Rosen; F. Di Nicolantonio; A. Bardelli; S. Misale

Year: 2020

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-20-0187

Paper Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown.

N. Pore; Song Wu; N. Standifer et al. · 2021 · Cancer Discovery · DOI

Full title: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown.

Authors: N. Pore; Song Wu; N. Standifer; M. Jure-Kunkel; M. de los Reyes; Y. Shrestha; R. Halpin; R. Rothstein; Kathy Mulgrew; S. Blackmore; Philip Martin; John H Meekin; M. Griffin; I. Bisha; Theresa A. Proia; Ricardo J. Miragaia; R. Herbst; A. Gupta; S. Abdullah; R. Raja; M. Frigault; J. Barrett; P. Dennis; M. Ascierto; M. Oberst

Year: 2021

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-20-1543

Paper Mechanisms of Resistance to KRASG12C-Targeted Therapy.

Neal S Akhave; A. Biter; D. Hong · 2021 · Cancer Discovery · DOI

Full title: Mechanisms of Resistance to KRASG12C-Targeted Therapy.

Authors: Neal S Akhave; A. Biter; D. Hong

Year: 2021

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-20-1616

Paper Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies

Aldea, Mihaela; André, Fabrice; Marabelle, Aurélien et al. · 2021 · Cancer Discovery · DOI

Full title: Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies

Authors: Aldea, Mihaela; André, Fabrice; Marabelle, Aurélien; Doğan, Semih; Barlési, Fabrice; Soria, Jean‐Charles

Year: 2021

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-20-1638

Paper Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance

Rudolph, Joachim; Settleman, Jeff; Malek, Shiva · 2021 · Cancer Discovery · DOI

Full title: Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance

Authors: Rudolph, Joachim; Settleman, Jeff; Malek, Shiva

Year: 2021

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-21-0260

Paper Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.

Tanaka, Noritaka; Lin, Jessica J; Li, Chendi et al. · 2021 · Cancer discovery · DOI

Full title: Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.

Authors: Tanaka, Noritaka; Lin, Jessica J; Li, Chendi; Ryan, Meagan B; Zhang, Junbing; Kiedrowski, Lesli A; Michel, Alexa G; Syed, Mohammed U; Fella, Katerina A; Sakhi, Mustafa; Baiev, Islam; Juric, Dejan; Gainor, Justin F; Klempner, Samuel J; Lennerz, Jochen K; Siravegna, Giulia; Bar-Peled, Liron; Hata, Aaron N; Heist, Rebecca S; Corcoran, Ryan B

Year: 2021

Venue: Cancer discovery

DOI: https://doi.org/10.1158/2159-8290.CD-21-0365

Paper The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRASG12C Inhibitors.

Pinnelli, Marika; Trusolino, Livio · 2021 · Cancer discovery · DOI

Full title: The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRASG12C Inhibitors.

Authors: Pinnelli, Marika; Trusolino, Livio

Year: 2021

Venue: Cancer discovery

DOI: https://doi.org/10.1158/2159-8290.CD-21-0609

Paper Can Drug Repurposing Accelerate Precision Oncology?

Schipper, Luuk J.; Zeverijn, Laurien J.; Garnett, Mathew J. et al. · 2022 · Cancer Discovery · DOI

Full title: Can Drug Repurposing Accelerate Precision Oncology?

Authors: Schipper, Luuk J.; Zeverijn, Laurien J.; Garnett, Mathew J.; Voest, Emile E.

Year: 2022

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-21-0612

Paper Classification of KRAS -Activating Mutations and the Implications for Therapeutic Intervention

Johnson, Christian W.; Burkhart, Deborah L.; Haigis, Kevin M. · 2022 · Cancer Discovery · DOI

Full title: Classification of KRAS -Activating Mutations and the Implications for Therapeutic Intervention

Authors: Johnson, Christian W.; Burkhart, Deborah L.; Haigis, Kevin M.

Year: 2022

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-22-0035

Paper Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

M. Negrão; Haniel A Araujo; G. Lamberti et al. · 2023 · Cancer Discovery · DOI

Full title: Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

Authors: M. Negrão; Haniel A Araujo; G. Lamberti; Alissa J Cooper; Neal S Akhave; Teng Zhou; Lukas Delasos; J. K. Hicks; M. Aldea; G. Minuti; J. Hines; J. Aredo; Michael J Dennis; T. Chakrabarti; S. Scott; P. Bironzo; M. Scheffler; P. Christopoulos; A. Stenzinger; J. Riess; So Yeon Kim; S. Goldberg; Mingjia Li; Qi Wang; Yun Qing; Y. Ni; Minh Truong Do; Richard Lee; B. Ricciuti; J. Alessi; Jing Wang; Blerina Resuli; L. Landi; Shu-Chi Tseng; M. Nishino; S. Digumarthy; W. Rinsurongkawong; Vadeerat Rinsurongkawong; A. Vaporciyan; G. Blumenschein; Jianjun Zhang; D. Owen; C. Blakely; G. Mountzios; C. Shu; C. Bestvina; M. Garassino; K. Marrone; J. Gray; S. Patel; A. Cummings; H. Wakelee; J. Wolf; G. Scagliotti; F. Cappuzzo; F. Barlesi; P. Patil; L. Drusbosky; D. Gibbons; F. Meric-Bernstam; J. Lee; J. Heymach; David S. Hong; R. Heist; M. Awad; F. Skoulidis

Year: 2023

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-22-1420

Paper Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047

Shiels, Meredith S.; Lipkowitz, Stanley; Campos, Nicole G. et al. · 2023 · Cancer Discovery · DOI

Full title: Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047

Authors: Shiels, Meredith S.; Lipkowitz, Stanley; Campos, Nicole G.; Schiffman, Mark; Schiller, John T.; Freedman, Neal D.; González, Amy Berrington de

Year: 2023

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-23-0208

Paper SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Drilon, Alexander; Sharma, Manish R.; Johnson, Melissa L. et al. · 2023 · Cancer Discovery · DOI

Full title: SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Authors: Drilon, Alexander; Sharma, Manish R.; Johnson, Melissa L.; Yap, Timothy A.; Gadgeel, Shirish M.; Nepert, Dale; Feng, Gang; Reddy, Micaela B.; Harney, Allison S.; Elsayed, Mohamed; Cook, Adam W.; Wong, Christina E.; Hinklin, Ronald J.; Jiang, Yutong; Brown, Eric N.; Neitzel, Nickolas A.; Laird, Ellen R.; Wu, Wen‐I; Singh, Anurag; Wei, Ping; Ching, Keith A.; Gaudino, John J.; Lee, Patrice A.; Hartley, Dylan P.; Rothenberg, S. Michael

Year: 2023

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-23-0361

Paper Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

Suehnholz, Sarah P.; Nissan, Moriah H.; Zhang, Hongxin et al. · 2023 · Cancer Discovery · DOI

Full title: Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

Authors: Suehnholz, Sarah P.; Nissan, Moriah H.; Zhang, Hongxin; Kundra, Ritika; Nandakumar, Subhiksha; Lu, Calvin; Carrero, Stephanie; Dhaneshwar, Amanda; Fernandez, Nicole; Xu, Benjamin W.; Arcila, Maria E.; Zehir, Ahmet; Syed, Aijazuddin; Brannon, A. Rose; Rudolph, Julia E.; Paraiso, Eder; Sabbatini, Paul; Levine, Ross L.; Doǧan, Ahmet; Gao, Jianjiong; Ladanyi, Marc; Drilon, Alexander; Berger, Michael F.; Solit, David B.; Schultz, Nikolaus; Chakravarty, Debyani

Year: 2023

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-23-0467

Paper Precision Oncology: 2023 in Review

Murciano‐Goroff, Yonina R.; Suehnholz, Sarah P.; Drilon, Alexander et al. · 2023 · Cancer Discovery · DOI

Full title: Precision Oncology: 2023 in Review

Authors: Murciano‐Goroff, Yonina R.; Suehnholz, Sarah P.; Drilon, Alexander; Chakravarty, Debyani

Year: 2023

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-23-1194

Paper Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jiang, Jingjing; Jiang, Lingyan; Maldonato, Benjamin J. et al. · 2024 · Cancer Discovery · DOI

Full title: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Authors: Jiang, Jingjing; Jiang, Lingyan; Maldonato, Benjamin J.; Wang, Yingyun; Holderfield, Matthew; Aronchik, Ida; Winters, Ian P.; Salman, Zeena; Blaj, Cristina; Ménard, Marie; Brodbeck, Jens; Chen, Zhe; Wei, Xing; Rosen, Michael; Gindin, Yevgeniy; Lee, Bianca J.; Evans, James W.; Chang, Stephanie; Wang, Zhican; Seamon, Kyle J.; Parsons, Dylan; Cregg, James; Marquez, Abby; Tomlinson, Aidan C.A.; Yano, Jason K.; Knox, John E.; Quintana, Elsa; Aguirre, Andrew J.; Arbour, Kathryn C.; Reed, Abby; Gustafson, W. Clay; Gill, Adrian L.; Koltun, Elena S.; Wildes, David; Smith, Jacqueline A.M.; Wang, Zhengping; Singh, Mallika

Year: 2024

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-24-0027

Paper The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers

Ryan, Meagan B.; Quade, Bradley; Schenk, Natasha et al. · 2024 · Cancer Discovery · DOI

Full title: The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers

Authors: Ryan, Meagan B.; Quade, Bradley; Schenk, Natasha; Fang, Zhong; Zingg, Marshall; Cohen, Steven E.; Swalm, Brooke M.; Li, Chun; Özen, Ayşegül; Ye, Chaoyang; Ritorto, Maria Stella; Huang, Xin; Dar, Arvin C.; Han, Yongxin; Hoeflich, Klaus P.; Hale, Michael; Hagel, Margit

Year: 2024

Venue: Cancer Discovery

DOI: https://doi.org/10.1158/2159-8290.cd-24-0139

Paper Mechanisms of KRAS Inhibitor Resistance Revealed.

· 2021 · Cancer discovery · DOI

Full title: Mechanisms of KRAS Inhibitor Resistance Revealed.

Year: 2021

Venue: Cancer discovery

DOI: https://doi.org/10.1158/2159-8290.CD-NB2021-0335

Paper Multiple Mechanisms Underlie the Acquired Resistance to KRAS G12C Inhibition.

· 2022 · Cancer discovery · DOI

Full title: Multiple Mechanisms Underlie the Acquired Resistance to KRAS G12C Inhibition.

Year: 2022

Venue: Cancer discovery

DOI: https://doi.org/10.1158/2159-8290.CD-RW2022-010

Paper Abstract B029: Investigating therapeutic strategies to promote immune rejection of KRAS G12C inhibitor-resistant sub-populations in lung cancer

M. Tomaschko; M. Molina-Arcas; C. Moore et al. · 2023 · Cancer immunology research · DOI

Full title: Abstract B029: Investigating therapeutic strategies to promote immune rejection of KRAS G12C inhibitor-resistant sub-populations in lung cancer

Authors: M. Tomaschko; M. Molina-Arcas; C. Moore; S. Rana; S. de Carné; P. Anastasiou; Claire E. Pillsbury; Andrea de Castro; J. Downward

Year: 2023

Venue: Cancer immunology research

DOI: https://doi.org/10.1158/2326-6074.tumimm23-b029

Paper Data from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

Wang, Peng; Sun, Xin; He, Xueting et al. · 2025 · DOI

Full title: Data from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

Authors: Wang, Peng; Sun, Xin; He, Xueting; Kang, Di; Liu, Xiaoyu; Liu, Dan; Li, Amin; Yang, Guiqun; Lin, Yiwei; Li, Sujing; Wang, Yinxiang; Wang, Yanping

Year: 2025

DOI: https://doi.org/10.1158/2767-9764.c.7819665

Paper Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers

H. Khan; M. Nagasaka; Yiwei Li et al. · 2022 · bioRxiv · DOI

Full title: Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers

Authors: H. Khan; M. Nagasaka; Yiwei Li; A. Aboukameel; Md. Hafiz Uddin; R. Sexton; Sahar F. Bannoura; Y. Mzannar; M. Al-Hallak; Steve H Kim; R. Beydoun; Y. Landesman; H. Mamdani; D. Uprety; P. Philip; R. Mohammad; A. Shields; A. Azmi

Year: 2022

Venue: bioRxiv

DOI: https://doi.org/10.1158/2767-9764.crc-21-0176

Paper N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma

Sofia Geroyska; Isabel Mejia; Alfred A Chan et al. · 2024 · Cancer Research Communications · DOI

Full title: N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma

Authors: Sofia Geroyska; Isabel Mejia; Alfred A Chan; Marian Navarrete; V. Pandey; Samuel Kharpatin; J. Noguti; Feng Wang; Daniel N. Srole; Tsui-Fen Chou; J. Wohlschlegel; Elizabeta Nemeth; R. Damoiseaux; D. Shackelford; Delphine J. Lee; Begoña Díaz

Year: 2024

Venue: Cancer Research Communications

DOI: https://doi.org/10.1158/2767-9764.crc-23-0428

Paper Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers

Bagnyukova, Tetyana; Egleston, Brian L.; Pavlov, Valerii A. et al. · 2024 · Cancer Research Communications · DOI

Full title: Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers

Authors: Bagnyukova, Tetyana; Egleston, Brian L.; Pavlov, Valerii A.; Serebriiskii, Ilya G.; Golemis, Erica A.; Borghaei, Hossein

Year: 2024

Venue: Cancer Research Communications

DOI: https://doi.org/10.1158/2767-9764.crc-23-0482

Paper The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models

Nathan M Jameson; Daehwan Kim; Catherine Lee et al. · 2025 · Cancer Research Communications · DOI

Full title: The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models

Authors: Nathan M Jameson; Daehwan Kim; Catherine Lee; Blake Skrable; Alexandra Shea; Xiao Guo; Hooman Izadi; Monah Abed; O. Harismendy; Jianhui Ma; Doris S Kim; M.R. Lackner

Year: 2025

Venue: Cancer Research Communications

DOI: https://doi.org/10.1158/2767-9764.crc-24-0411

Paper Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

Wang, Peng; Sun, Xin; He, Xueting et al. · 2025 · Cancer Research Communications · DOI

Full title: Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

Authors: Wang, Peng; Sun, Xin; He, Xueting; Kang, Di; Liu, Xiaoyu; Liu, Dan; Li, Amin; Yang, Guiqun; Lin, Yiwei; Li, Sujing; Wang, Yinxiang; Wang, Yanping

Year: 2025

Venue: Cancer Research Communications

DOI: https://doi.org/10.1158/2767-9764.crc-25-0001

Paper Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor

B. Ku; Yeon Jeong Kim; Donghyun Park et al. · 2022 · Oncology · DOI

Full title: Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor

Authors: B. Ku; Yeon Jeong Kim; Donghyun Park; Se-Hoon Lee; J. Ahn; Keunchil Park; M. Ahn; Jong-Mu Sun

Year: 2022

Venue: Oncology

DOI: https://doi.org/10.1159/000516813

Paper Sotorasib Shows Intracranial Activity in Patients with KRAS G12C- Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases

Koster, Kira‐Lee; Appenzeller, Christina; Lauber, Arno et al. · 2022 · Case Reports in Oncology · DOI

Full title: Sotorasib Shows Intracranial Activity in Patients with KRAS G12C- Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases

Authors: Koster, Kira‐Lee; Appenzeller, Christina; Lauber, Arno; Früh, Martin; Schmid, Sabine

Year: 2022

Venue: Case Reports in Oncology

DOI: https://doi.org/10.1159/000525341

Paper Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report

Sindu Iska; E. Alley · 2023 · Case Reports in Oncology · DOI

Full title: Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report

Authors: Sindu Iska; E. Alley

Year: 2023

Venue: Case Reports in Oncology

DOI: https://doi.org/10.1159/000529828

Paper Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases

Jonas Frederik Schmidt; Dominik Entz; Frank Brasch et al. · 2024 · Case Reports in Oncology · DOI

Full title: Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases

Authors: Jonas Frederik Schmidt; Dominik Entz; Frank Brasch; Martin Goerner

Year: 2024

Venue: Case Reports in Oncology

DOI: https://doi.org/10.1159/000540675

Paper Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

Marina Salmón; R. Álvarez-Díaz; C. Fustero-Torre et al. · 2023 · Journal of Clinical Investigation · DOI

Full title: Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

Authors: Marina Salmón; R. Álvarez-Díaz; C. Fustero-Torre; Oksana Brehey; C. Lechuga; Manuel Sanclemente; Fernando Fernández-García; Alejandra López-García; M del Carmen Martín-Guijarro; S. Rodríguez-Perales; Emily Bousquet-Mur; Lucía Morales-Cacho; F. Mulero; F. Al-Shahrour; Lola Martínez; Orlando Domínguez; E. Caleiras; S. Ortega; C. Guerra; M. Musteanu; M. Drosten; M. Barbacid

Year: 2023

Venue: Journal of Clinical Investigation

DOI: https://doi.org/10.1172/jci164413

Paper Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non–Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib

Natalie Mausey; Zachery Halford · 2023 · The Annals of Pharmacotherapy · DOI

Full title: Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non–Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib

Authors: Natalie Mausey; Zachery Halford

Year: 2023

Venue: The Annals of Pharmacotherapy

DOI: https://doi.org/10.1177/10600280231197459

Paper Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

Clement Chung; G. Umoru · 2024 · Journal of Oncology Pharmacy Practice · DOI

Full title: Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

Authors: Clement Chung; G. Umoru

Year: 2024

Venue: Journal of Oncology Pharmacy Practice

DOI: https://doi.org/10.1177/10781552241242684

Paper Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review

Sara El Zaitouni; A. Laraqui; Youssra Boustany et al. · 2025 · Clinical Medicine Insights: Oncology · DOI

Full title: Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review

Authors: Sara El Zaitouni; A. Laraqui; Youssra Boustany; Soukaina Benmokhtar; Hicham El Annaz; R. Abi; M. Tagajdid; Safae El Kochri; Elarbi Bouaiti; I. L. Amine; Rabii Ameziane El Hassani; Khalid Ennibi

Year: 2025

Venue: Clinical Medicine Insights: Oncology

DOI: https://doi.org/10.1177/11795549251331759

Paper New developments in targeted therapy for metastatic colorectal cancer

Ambrose H. N. Wong; B. Ma; Rashid N Lui · 2023 · Therapeutic Advances in Medical Oncology · DOI

Full title: New developments in targeted therapy for metastatic colorectal cancer

Authors: Ambrose H. N. Wong; B. Ma; Rashid N Lui

Year: 2023

Venue: Therapeutic Advances in Medical Oncology

DOI: https://doi.org/10.1177/17588359221148540

Paper Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

T. Seale; Brandy N. Perkins; Theodora Chatzilygeroudi et al. · 2024 · Blood · DOI

Full title: Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Authors: T. Seale; Brandy N. Perkins; Theodora Chatzilygeroudi; Soren Cole; Kareem Battah; Maximilian F. Stahl; M. Levis; A. Ambinder; S. Misale; Theodoros Karantanos

Year: 2024

Venue: Blood

DOI: https://doi.org/10.1182/blood-2024-211218

Paper Progress and applications of mouse models for human lung cancer

Seranno, Sandrine De; Meuwissen, Ralph · 2010 · European Respiratory Journal · DOI

Full title: Progress and applications of mouse models for human lung cancer

Authors: Seranno, Sandrine De; Meuwissen, Ralph

Year: 2010

Venue: European Respiratory Journal

DOI: https://doi.org/10.1183/09031936.00124709

Paper Biological therapies in nonsmall cell lung cancer

Zugazagoitia, Jon; Molina‐Pinelo, Sonia; López‐Ríos, Fernando et al. · 2017 · European Respiratory Journal · DOI

Full title: Biological therapies in nonsmall cell lung cancer

Authors: Zugazagoitia, Jon; Molina‐Pinelo, Sonia; López‐Ríos, Fernando; Paz‐Ares, Luis

Year: 2017

Venue: European Respiratory Journal

DOI: https://doi.org/10.1183/13993003.01520-2016

Paper Applications of CRISPR technology to lung cancer research

Sorolla, Anabel; Parisi, Eva; Sorolla, Maria Alba et al. · 2021 · European Respiratory Journal · DOI

Full title: Applications of CRISPR technology to lung cancer research

Authors: Sorolla, Anabel; Parisi, Eva; Sorolla, Maria Alba; Marqués, Marta; Porcel, José M.

Year: 2021

Venue: European Respiratory Journal

DOI: https://doi.org/10.1183/13993003.02610-2021

Paper Personalised medicine for nonsmall cell lung cancer

Mascaux, Céline; Tomasini, Pascale; Greillier, Laurent et al. · 2017 · European Respiratory Review · DOI

Full title: Personalised medicine for nonsmall cell lung cancer

Authors: Mascaux, Céline; Tomasini, Pascale; Greillier, Laurent; Barlési, Fabrice

Year: 2017

Venue: European Respiratory Review

DOI: https://doi.org/10.1183/16000617.0066-2017

Paper KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

Kempf, Emmanuelle; Rousseau, Benoı̂t; Besse, Benjamin et al. · 2016 · European Respiratory Review · DOI

Full title: KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

Authors: Kempf, Emmanuelle; Rousseau, Benoı̂t; Besse, Benjamin; Paz‐Ares, Luis

Year: 2016

Venue: European Respiratory Review

DOI: https://doi.org/10.1183/16000617.0071-2015

Paper Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer

Abdayem, P.; Planchard, David · 2021 · European Respiratory Review · DOI

Full title: Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer

Authors: Abdayem, P.; Planchard, David

Year: 2021

Venue: European Respiratory Review

DOI: https://doi.org/10.1183/16000617.0294-2020

Paper Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions

K. Hummelink; M. Muller; T. Linders et al. · 2019 · ERJ Open Research · DOI

Full title: Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions

Authors: K. Hummelink; M. Muller; T. Linders; V. van der Noort; P. Nederlof; P. Baas; S. Burgers; E. Smit; G. Meijer; M. M. van den Heuvel; D. van den Broek; K. Monkhorst

Year: 2019

Venue: ERJ Open Research

DOI: https://doi.org/10.1183/23120541.00016-2019

Paper KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

Bhattacharya, Saveri; Socinski, Mark A.; Burns, Timothy F. · 2015 · Clinical and Translational Medicine · DOI

Full title: KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

Authors: Bhattacharya, Saveri; Socinski, Mark A.; Burns, Timothy F.

Year: 2015

Venue: Clinical and Translational Medicine

DOI: https://doi.org/10.1186/s40169-015-0075-0

Paper New KRAS Inhibitor Induces Responses in Non&amp;#x2013;Small Cell Lung Cancer With &lt;em&gt;KRAS G12C&lt;/em&gt; Mutation

· 2022 · Default Digital Object Group · DOI

Full title: New KRAS Inhibitor Induces Responses in Non&amp;#x2013;Small Cell Lung Cancer With &lt;em&gt;KRAS G12C&lt;/em&gt; Mutation

Year: 2022

Venue: Default Digital Object Group

DOI: https://doi.org/10.1200/adn.22.201036

Paper Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities

Lee, Michael S.; Pant, Shubham · 2021 · American Society of Clinical Oncology Educational Book · DOI

Full title: Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities

Authors: Lee, Michael S.; Pant, Shubham

Year: 2021

Venue: American Society of Clinical Oncology Educational Book

DOI: https://doi.org/10.1200/edbk_321255

Paper Overcoming KRAS-Mutant Lung Cancer.

Jia Luo; J. Ostrem; B. Pellini et al. · 2022 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · DOI

Full title: Overcoming KRAS-Mutant Lung Cancer.

Authors: Jia Luo; J. Ostrem; B. Pellini; Denis Imbody; Yaakov E. Stern; Hitendra S Solanki; E. Haura; L. Villaruz

Year: 2022

Venue: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

DOI: https://doi.org/10.1200/edbk_360354

Paper Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer

Cavagna, Rodrigo de Oliveira; Paula, Flávia Escremim de; Sant'Anna, Débora et al. · 2021 · JCO Global Oncology · DOI

Full title: Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer

Authors: Cavagna, Rodrigo de Oliveira; Paula, Flávia Escremim de; Sant'Anna, Débora; Santana, Iara Viana Vidigal; Silva, Vinícius Duval da; Silva, Eduardo Caetano Albino da; Bacchi, Carlos E.; Miziara, José Elias; Dias, Josiane Mourão; Marchi, Pedro De; Leal, Letícia Ferro; Reis, Rui Manuel

Year: 2021

Venue: JCO Global Oncology

DOI: https://doi.org/10.1200/go.20.00615

Paper MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.

G. Manji; Brian W. Labadie; Shing M. Lee et al. · 2023 · JCO Global Oncology · DOI

Full title: MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.

Authors: G. Manji; Brian W. Labadie; Shing M. Lee; I. Pellicciotta; Liner Ge; Sarah Sta Ana; Naomi Sender; Isabelle Ross; W. Wong; Alexander G. Raufi

Year: 2023

Venue: JCO Global Oncology

DOI: https://doi.org/10.1200/go.2023.9.supplement_1.45

Paper Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

Bekaii‐Saab, Tanios; Phelps, Mitch A.; Li, Xiaobai et al. · 2011 · Journal of Clinical Oncology · DOI

Full title: Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

Authors: Bekaii‐Saab, Tanios; Phelps, Mitch A.; Li, Xiaobai; Saji, Motoyasu; Goff, Laura W.; Kauh, John; O’Neil, Bert H.; Balsom, Stephanie; Balint, Catherine; Liersemann, R.; Vasko, Vasily; Bloomston, Mark; Marsh, W.; Doyle, L. Austin; Ellison, Gilian; Grever, Michael R.; Ringel, Matthew D.; Villalona‐Calero, Miguel A.

Year: 2011

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2010.33.9473

Paper Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

M. Fakih; B. O'Neil; T. Price et al. · 2019 · Journal of Clinical Oncology · DOI

Full title: Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Authors: M. Fakih; B. O'Neil; T. Price; G. Falchook; J. Desai; J. Kuo; R. Govindan; E. Rasmussen; P. K. Morrow; J. Ngang; H. Henary; D. Hong

Year: 2019

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.3003

Paper Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.

T. Moss; J. Ahnert; H. Oakley et al. · 2019 · Journal of Clinical Oncology · DOI

Full title: Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.

Authors: T. Moss; J. Ahnert; H. Oakley; Michael P. Kahle; D. Karp; S. Pant; Jeena Jacob; V. Raymond; R. Lanman; L. Kwong; M. Routbort; Nital Soni; Jerry M. Huang; M. Javle; F. Meric-Bernstam

Year: 2019

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.3056

Paper Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.

Ricciuti, Biagio; Recondo, Gonzalo; Umeton, Renato et al. · 2019 · Journal of Clinical Oncology · DOI

Full title: Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.

Authors: Ricciuti, Biagio; Recondo, Gonzalo; Umeton, Renato; Nishino, Mizuki; Sholl, Lynette M.; Awad, Mark M.

Year: 2019

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.9082

Paper Molecular characterization and management of secondary resistance to serial TRK inhibitors.

M. Nathenson; Matthew L. Hemming; Karan Malik et al. · 2019 · Journal of Clinical Oncology · DOI

Full title: Molecular characterization and management of secondary resistance to serial TRK inhibitors.

Authors: M. Nathenson; Matthew L. Hemming; Karan Malik; Jia-Ren Lin; S. Santagata; Z. Du; A. Mariño-Enríquez; Timothy Hagan; Otari Chipashvili; K. Thornton; C. Raut; B. Childs; M. Bertagnolli; E. Sicinska; N. Ku; G. Demetri

Year: 2019

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.e22547

Paper Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS –mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).

Tamiya, Yutaro; Zenke, Yoshitaka; Matsumoto, Shingo et al. · 2020 · Journal of Clinical Oncology · DOI

Full title: Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS –mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).

Authors: Tamiya, Yutaro; Zenke, Yoshitaka; Matsumoto, Shingo; Furuya, Naoki; Sakamoto, Tomohiro; Kato, Terufumi; Nishino, Kazumi; Shingyoji, Masato; Miyamoto, Shingo; Shirakawa, Chigusa; Toyozawa, Ryo; Ohashi, Kadoaki; Ikeda, Takaya; Nosaki, Kaname; Udagawa, Hibiki; Kirita, Keisuke; Yoh, Kiyotaka; Niho, Seiji; Goto, Kōichi

Year: 2020

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.9589

Paper Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.

Arbour, Kathryn C.; Rizvi, Hira; Plodkowski, Andrew J. et al. · 2020 · Journal of Clinical Oncology · DOI

Full title: Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.

Authors: Arbour, Kathryn C.; Rizvi, Hira; Plodkowski, Andrew J.; Halpenny, Darragh; Hellmann, Matthew D.; Heller, Glenn; Knežević, Andrea; Yu, Helena A.; Ladanyi, Marc; Kris, Mark G.; Arcila, Maria E.; Rudin, Charles M.; Lito, Piro; Riely, Gregory J.

Year: 2020

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.9596

Paper Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS G12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).

Fakih, Marwan; Durm, Greg Andrew; Govindan, Ramaswamy et al. · 2020 · Journal of Clinical Oncology · DOI

Full title: Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS G12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).

Authors: Fakih, Marwan; Durm, Greg Andrew; Govindan, Ramaswamy; Falchook, Gerald S.; Soman, Neelesh; Henary, Haby; Hong, David S.

Year: 2020

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.tps3661

Paper Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.

K. Arbour; B. Ricciuti; H. Rizvi et al. · 2021 · Journal of Clinical Oncology · DOI

Full title: Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.

Authors: K. Arbour; B. Ricciuti; H. Rizvi; M. Hellmann; H. Yu; M. Ladanyi; M. Kris; M. Arcila; C. Rudin; P. Lito; M. Awad; Gregory Riely

Year: 2021

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.9088

Paper Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletion.

S. Graziano; Dean Pavlick; E. Sokol et al. · 2021 · Journal of Clinical Oncology · DOI

Full title: Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletion.

Authors: S. Graziano; Dean Pavlick; E. Sokol; S. Ramkissoon; E. Severson; R. Huang; Douglas A. Mata; B. Decker; K. McGregor; N. Danziger; J. Ross

Year: 2021

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.9116

Paper Molecular profiling by NGS upon progression disease in advanced stage NSCLC patients.

R. Serna; A. Sánchez; M. Julián et al. · 2021 · DOI

Full title: Molecular profiling by NGS upon progression disease in advanced stage NSCLC patients.

Authors: R. Serna; A. Sánchez; M. Julián; C. G. Girón; M. Dómine; A. Blasco; J. Torres; J. Oramas; J. Bosch-Barrera; M. Sala; M. Sereno; A. Ortega; Luis Enrique Chara Velarde; Berta Hernández; A. Padilla; J. Coves; E. J. Lewintre; M. Molina-Vila; A. Romero; M. Provencio-Pulla

Year: 2021

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.e21196

Paper A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.

Li, Jian; Zhao, Jun; Cao, Baoshan et al. · 2022 · Journal of Clinical Oncology · DOI

Full title: A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.

Authors: Li, Jian; Zhao, Jun; Cao, Baoshan; Fang, Jian; Li, Xiaoyan; Wang, Mengzhao; Ba, Yi; Li, Xingya; Li, Zhihua; LIU, Zhe; Wang, Yongsheng; Cheng, Ying; Bai, Chunmei; Shen, Lin

Year: 2022

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.3089

Paper Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

Zhou, Qing; Yang, Nong; Zhao, Jun et al. · 2022 · Journal of Clinical Oncology · DOI

Full title: Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

Authors: Zhou, Qing; Yang, Nong; Zhao, Jun; Dong, Xiaorong; Wang, Huijuan; Yuan, Ying; Yu, Yan; Zhang, Meijiang; Zhang, Sujie; Huang, Mengna; Shen, Yuping; Wu, Yi‐Long

Year: 2022

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.3110

Paper Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.

E. Nakajima; Yi Ren; Jonathon Vallejo et al. · 2022 · Journal of Clinical Oncology · DOI

Full title: Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.

Authors: E. Nakajima; Yi Ren; Jonathon Vallejo; Oladimeji Akinboro; Pallavi S Mishra-Kalyani; E. Larkins; N. Drezner; Shenghui Tang; R. Pazdur; J. Beaver; H. Singh

Year: 2022

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.9001

Paper Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).

A. Hata; N. Katakami; N. Takase et al. · 2022 · Journal of Clinical Oncology · DOI

Full title: Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).

Authors: A. Hata; N. Katakami; N. Takase; K. Kibata; Y. Yamanaka; M. Tamiya; M. Mori; T. Kijima; S. Morita; K. Sakai; K. Nishio

Year: 2022

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.9117

Paper A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non–small cell lung cancer (NSCLC).

D. Camidge; J. Reuss; A. Spira et al. · 2022 · Journal of Clinical Oncology · DOI

Full title: A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non–small cell lung cancer (NSCLC).

Authors: D. Camidge; J. Reuss; A. Spira; P. Janne; M. Rehman; J. Pachter; Gloria Patrick; L. Denis; D. Spigel

Year: 2022

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.tps9147

Paper A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non–small cell lung cancer (NSCLC) (RAMP 203).

R. Govindan; M. Awad; S. Gadgeel et al. · 2022 · Journal of Clinical Oncology · DOI

Full title: A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non–small cell lung cancer (NSCLC) (RAMP 203).

Authors: R. Govindan; M. Awad; S. Gadgeel; J. Pachter; Gloria Patrick; L. Denis

Year: 2022

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.tps9148

Paper Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data in the United States.

D. Aran; Meishar Shahoha; K. Rosenberg-Katz et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data in the United States.

Authors: D. Aran; Meishar Shahoha; K. Rosenberg-Katz; S. Amar-Farkash

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.1560

Paper The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).

S. Sakata; H. Akamatsu; K. Azuma et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).

Authors: S. Sakata; H. Akamatsu; K. Azuma; T. Uemura; Y. Tsuchiya-Kawano; H. Yoshioka; M. Osuga; Y. Koh; S. Morita; N. Yamamoto

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9006

Paper KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

P. Cassier; C. Dooms; A. Gazzah et al. · 2024 · International Journal of Radiation Oncology, Biology, Physics · DOI

Full title: KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Year: 2024

Venue: International Journal of Radiation Oncology, Biology, Physics

DOI: https://doi.org/10.1016/j.ijrobp.2023.10.053

Paper Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).

F. Skoulidis; A. D. de Langen; L. Paz-Ares et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).

Authors: F. Skoulidis; A. D. de Langen; L. Paz-Ares; G. Mountzios; A. Curioni-Fontecedro; S. Couraud; A. Janssens; D. Rocco; K. Ohashi; M. Vincent; J. Kang; G. Schvartsman; C. Lindsay; K. O'Byrne; R. Dziadziuszko; J. L. Andersen; A. Hindoyan; Tomasz Wilmanski; Yang Wang; M. Schuler

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9008

Paper Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.

K. Arbour; R. Thummalapalli; Ezra Bernstein et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.

Authors: K. Arbour; R. Thummalapalli; Ezra Bernstein; Benjamin O Herzberg; Bob T. Li; A. Iqbal; F. Santini; J. Eng; M. Ladanyi; Soo-Ryum Yang; R. Shen; P. Lito; J. Sabari; Gregory Riely

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9083

Paper A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).

H. Izumi; S. Matsumoto; K. Nishino et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).

Authors: H. Izumi; S. Matsumoto; K. Nishino; T. Kato; Satoshi Hara; A. Nakamura; J. Sakakibara-Konishi; Shoichiro Yamamoto; Y. Ohe; I. Nakachi; S. Kuyama; Tomohiro Kato; M. Kodani; Y. Shibata; H. Udagawa; T. Sakai; K. Nosaki; Y. Zenke; K. Yoh; K. Goto

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9097

Paper RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).

J. Reuss; S. Gandhi; D. Spigel et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).

Authors: J. Reuss; S. Gandhi; D. Spigel; P. Janne; L. Paz-Ares; S. Gadgeel; J. Patel; F. Passiglia; A. Spira; M. Edelman; G. Blumenschein; A. Shergill; T. Burns; Vijeta Bhambhani; Gloria Patrick; J. Pachter; L. Denis; D. Camidge

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9100

Paper FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.

Yufan Liu; Elizabeth S Duke; N. Drezner et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.

Authors: Yufan Liu; Elizabeth S Duke; N. Drezner; H. Singh; P. Kluetz; R. Pazdur; E. Larkins

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9119

Paper Analysis of survival outcomes in patients with non–small-cell lung cancer with mutations in STK11/LKB1 receiving chemoimmunotherapy.

Diana Kim; Rachel J Elsey; T. Meissner et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Analysis of survival outcomes in patients with non–small-cell lung cancer with mutations in STK11/LKB1 receiving chemoimmunotherapy.

Authors: Diana Kim; Rachel J Elsey; T. Meissner; Yuliang Sun; Bing Xu; Crystal Hattum; B. Solomon; John H. Lee; C. Williams

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e15043

Paper First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.

Rongrui Liu; X. Qu; N. Yang et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.

Authors: Rongrui Liu; X. Qu; N. Yang; X. Chai; Jianming Xu

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e15127

Paper Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.

M. Provencio-Pulla; R. Campelo; A. Azkárate et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.

Authors: M. Provencio-Pulla; R. Campelo; A. Azkárate; V. Calvo; M. Cobo; J. Mosquera; E. Nadal; D. Rodríguez-Abreu; R. Marsé Fabregat; A. Callejo; M. Dómine; Ó. Juan-Vidal; F. García-García; E. Sánchez; A. Romero

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e21015

Paper SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.

B. Ricciuti; Elinton Lee; Terri Conneran et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.

Authors: B. Ricciuti; Elinton Lee; Terri Conneran; J. King; Allison Harper; G. Lamberti; G. Brisbane; Kateřina Hošková; S. Clifford; J. Murphy; R. Huang; G. Oxnard; Anthony Addario; Richard M. Erwin; K. Tolba; M. Awad

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.tps3166

Paper ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).

S. Padda; M. Redman; D. Gerber et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).

Authors: S. Padda; M. Redman; D. Gerber; T. Stinchcombe; S. Waqar; T. Leal; K. Minichiello; K. Reckamp; R. Herbst; H. Borghaei; J. Brahmer; J. Gray; K. Kelly; S. Ramalingam; J. Neal

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.tps9143

F. Cappuzzo; G. Castro; J. Kang et al. · 2023 · Journal of Clinical Oncology · DOI

Authors: F. Cappuzzo; G. Castro; J. Kang; Yi‐Long Wu; O. Brustugun; P. Cheema; T. Owonikoko; A. Longin; A. Boran; Jiawei Duan; R. Caparica; H. Loong

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.tps9144

Paper Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).

A. Dingemans; K. Syrigos; L. Livi et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).

Authors: A. Dingemans; K. Syrigos; L. Livi; A. Paulus; Sang-We Kim; Yuanbin Chen; E. Felip; F. Griesinger; K. Ohashi; G. Zalcman; B. Hughes; J. Sørensen; N. Blais; C. Ferreira; C. Lindsay; R. Dziadziuszko; P. Ward; C. Obiozor; Yang Wang; Solange Peters

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2023.41.17_suppl.lba9016

Paper A unique model: Partnership between community oncology and pharma for clinical trial enrichment.

Shikha Prakash; Karla Polk; L. Ensley et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: A unique model: Partnership between community oncology and pharma for clinical trial enrichment.

Authors: Shikha Prakash; Karla Polk; L. Ensley; Justin Adams; Monica Lisi; Karen Poe; L. Brisbin; K. Konduri; A. Paulson

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.1535

Paper Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.

R. Heist; T. Koyama; Y. Murciano-Goroff et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.

Authors: R. Heist; T. Koyama; Y. Murciano-Goroff; A. Hollebecque; P. Cassier; Ji-Youn Han; Diego Tosi; A. Sacher; Timothy F. Burns; A. Spira; C. Gomez-Roca; T. Shimizu; N. Ammakkanavar; J. Sabari; Misako Nagasaka; A. Fink; Aaron Chen; Melinda D Willard; G. Oxnard; Y. Kuboki

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.3007

Paper Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.

Jun Zhao; Jian Fang; Yan Yu et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.

Authors: Jun Zhao; Jian Fang; Yan Yu; Q. Chu; Xiaoyan Li; Jiayan Chen; Zhe Liu; Li Zhang; Lin Wu; Zhuang Wu; Xingya Li; Yanqiu Zhao; Ligang Xing; Lian Liu; C. Bai; Xiaorong Dong; Qibin Song; P. Pan; X. Fang; Jie Wang

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.3008

Paper Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.

Yuxiang Ma; Hongyun Zhao; Jianhua Chen et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.

Authors: Yuxiang Ma; Hongyun Zhao; Jianhua Chen; Zhengbo Song; Yanqiu Zhao; Yubiao Guo; Gang Wu; Hua Yang; Xiaoqing Yu; Fangfang Gao; Ruiguang Zhang; Jian Fang; Xiaoyan Lin; GuangLin Liu; Chen Yang; L. Men; E. Liang; Dajun Yang; Li Zhang; Y. Zhai

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.3124

Paper Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.

Timothy F. Burns; Konstantin Dragnev; Yutaka Fujiwara et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.

Authors: Timothy F. Burns; Konstantin Dragnev; Yutaka Fujiwara; Y. Murciano-Goroff; Dae Ho Lee; A. Hollebecque; T. Koyama; P. Cassier; A. Italiano; R. Heist; Ji-Youn Han; Dustin Deming; A. Spira; J. Sabari; M. Chisamore; A. Fink; Aaron Chen; Melinda D Willard; G. Oxnard; N. Ammakkanavar

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8510

Paper Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.

Bob T. Li; Jeffrey M Clarke; E. Felip et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.

Authors: Bob T. Li; Jeffrey M Clarke; E. Felip; J. Ruffinelli; Pilar Garrido; J. Zugazagoitia; Sarah B. Goldberg; Suresh S. Ramalingam; Ivan Victoria; S. Puri; D. Gandara; W. Kormany; S. Edmonds; K. Palmer; Ravi G. Gupta; Ramaswamy Govindan

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8512

Paper Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).

Robert C. Hsu; A. Leyba; Denaly Chen et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).

Authors: Robert C. Hsu; A. Leyba; Denaly Chen; Harris B Krause; A. Elliott; Wendy Cozen; Evanthia T. Roussos Torres; Misako Nagasaka; H. Mamdani; Gilberto Lopes; Hossein Borghaei; Stephen V. Liu; Patrick C. Ma; A. Vanderwalde; Jorge J. Nieva

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8526

Paper Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC).

Eejung Kim; Xinyuan Tong; Ayushi S. Patel et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC).

Authors: Eejung Kim; Xinyuan Tong; Ayushi S. Patel; Shengwu Liu; Julien Dilly; Laura Hover; Suman Mukhopadhyay; Fiona Sherman; James G Christensen; Peter Olson; Andrew Aguirre; K. Wong; Hongbin Ji

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8529

Paper Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.

Corey Langer; R. Galot; H. Prenen et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.

Authors: Corey Langer; R. Galot; H. Prenen; D. Hong; Ivan Victoria; Ravi Salgia; Maxime Chénard-Poirier; M. Furqan; Emily Chan; Jane Nolte-Hippenmeyer; Caihong Xia; Bob T. Li

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8559

Paper Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).

Mitchell S. von Itzstein; Timothy F. Burns; Jonathan E Dowell et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).

Authors: Mitchell S. von Itzstein; Timothy F. Burns; Jonathan E Dowell; Leora Horn; D. R. Camidge; S. York; Keith D. Eaton; C. Walker; Song Zhang; David E. Gerber

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8597

Paper Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.

Zhengbo Song; Xingya Li; Rongbo Lin et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.

Authors: Zhengbo Song; Xingya Li; Rongbo Lin; Yuan Yuan; Huaqiu Shi; Ying Liu; Yongzhong Luo; Tangfeng Lv; Yiping Zhang; Yinxin Zhu; Zaiqi Wang

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8605

Paper Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation.

Hiroshige Yoshioka; Hiroaki Akamatsu; Shinya Sakata et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation.

Authors: Hiroshige Yoshioka; Hiroaki Akamatsu; Shinya Sakata; K. Azuma; Takehiro Uemura; Y. Tsuchiya-Kawano; M. Osuga; Yasuhiro Koh; S. Morita; N. Yamamoto

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8616

Paper KRAS mutation subtypes responded differently to combination immunotherapy via disturbing myeloid-derived suppressor cells in non-small cell lung cancer.

Caifeng Gong; Xu Yang; Jinsong Zhang et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: KRAS mutation subtypes responded differently to combination immunotherapy via disturbing myeloid-derived suppressor cells in non-small cell lung cancer.

Authors: Caifeng Gong; Xu Yang; Jinsong Zhang; R. Wan; Jia Zhong; Zhijie Wang; Jie Wang

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8635

Paper Next-generation sequencing in patients with lung cancer undergoing immunotherapy: Retrospective analysis.

Akshee Batra; A. Khosla; David Alejos et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Next-generation sequencing in patients with lung cancer undergoing immunotherapy: Retrospective analysis.

Authors: Akshee Batra; A. Khosla; David Alejos; Jinah Kim; Sienna Searles; Akshit Chitkara; Karan Jatwani; Abhinav Vyas; H. Rehman; Shahid Sattar Ahmed; Rohit Singh

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15071

Paper Effect of targeting FAK by ifebemtinib and immunogenic cell death of Kras G12C/G12D inhibition on the efficacy of PD1 blockade.

Baoyuan Zhang; Jiaming Gao; Ran Pang et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Effect of targeting FAK by ifebemtinib and immunogenic cell death of Kras G12C/G12D inhibition on the efficacy of PD1 blockade.

Authors: Baoyuan Zhang; Jiaming Gao; Ran Pang; Ping Zhang; Jingwen Cheng; Natasha Qin; Leo Liu; Zaiqi Wang

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15102

Paper Characterization of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader for the treatment of KRAS- and RTK-driven cancers.

Kyle Begovich; Angela Schoolmeesters; Elena Martinez-Terroba et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Characterization of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader for the treatment of KRAS- and RTK-driven cancers.

Authors: Kyle Begovich; Angela Schoolmeesters; Elena Martinez-Terroba; Navin Rajapakse; Qiao Liu; Arvind Shakya; Akinori Okano; Venkat Mali; Shenlin Huang; Aparajita H Chourasia; Leah Fung

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15192

Paper Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).

Anne Therese Keating; K. Papadopoulos; Eleni Hloros et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).

Authors: Anne Therese Keating; K. Papadopoulos; Eleni Hloros; A. Spira; W. McKean; A. Krivoshik

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.tps3184

Paper SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.

M. Negrão; K. Arbour; Timothy F. Burns et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.

Authors: M. Negrão; K. Arbour; Timothy F. Burns; F. Cappuzzo; A. Dingemans; N. Girard; B. H. Gronberg; M. Hochmair; Ticiana A. Leal; Colin R Lindsay; Shun Lu; M. Nishio; L. Paz-Ares; Martin Reck; J. Sabari; A. Spira; W. N. William; Aaron Chen; C. M. Visseren Grul; S. Peters

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.tps8649

Paper Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).

F. Barlesi; E. Felip; Sanjay Popat et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).

Authors: F. Barlesi; E. Felip; Sanjay Popat; B. Solomon; J. Wolf; Bob T. Li; Yi‐Long Wu; Keith Kerr; Hiroaki Akamatsu; D. Camidge; Ravi G. Gupta; A. Meloni; Tian Dai; H. Borghaei

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.tps8653

Paper KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

V. Gregorc; M. González-Cao; S. Salvagni et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

Authors: V. Gregorc; M. González-Cao; S. Salvagni; A. Koumarianou; Ignacio Gil-Bazo; M. Maio; Santiago Viteri; M. Majem; Vanesa Gutiérrez; R. Bernabé Caro; Miguel F. Sanmamed; Hua-Qiang Zhu; Haige Shen; Yu Wang; R. Rosell

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba8511

Paper Quantitative evaluation of oncogenic KRAS signaling and therapeutic effects of molecular-targeted drugs in living cells by single-molecule imaging.

Ryoma Yokoi; J. Tajima; Shigeru Kiyama et al. · 2024 · Journal of Clinical Oncology · DOI

Full title: Quantitative evaluation of oncogenic KRAS signaling and therapeutic effects of molecular-targeted drugs in living cells by single-molecule imaging.

Authors: Ryoma Yokoi; J. Tajima; Shigeru Kiyama; Yoshihiro Tanaka; K. Murase; Manabu Futamura; Kenichi G. N. Suzuki; N. Matsuhashi

Year: 2024

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2024.42.23_suppl.76

Paper Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.

Yunpeng Yang; Li Zhang; Yuxiang Ma et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.

Authors: Yunpeng Yang; Li Zhang; Yuxiang Ma; Yuanyuan Zhao; W. Fang; Hongyun Zhao; Yan Huang; Likun Chen; X. Hou; Yongsheng Li; Yongsheng Wang; Zhiyong He; S. Xiao; Hai Zhu; Yi Zhu

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.3001

Paper Initial results of a screening trial for evaluating oncogenic drivers in Japanese patients with surgically resected early-stage non-small cell lung cancer: LC-SCRUM-Advantage.

Yuki Matsumura; K. Yoh; Y. Zenke et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Initial results of a screening trial for evaluating oncogenic drivers in Japanese patients with surgically resected early-stage non-small cell lung cancer: LC-SCRUM-Advantage.

Authors: Yuki Matsumura; K. Yoh; Y. Zenke; Shingo Kitagawa; Joji Samejima; T. Kasugai; H. Saijo; Takafumi Hashimoto; Ryu Kanzaki; Ikue Kamei; Gaku Yamamoto; Yu Tanaka; H. Izumi; Tetsuya Sakai; E. Sugiyama; S. Umemura; Shingo Matsumoto; Masahiro Tsuboi; Koichi Goto

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8065

Paper First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.

P. Jänne; W. Theelen; M. Garassino et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.

Authors: P. Jänne; W. Theelen; M. Garassino; A. Spira; J. Laskin; Filippo de Marinis; F. Badin; Lisenka Boom; C. Aguado de la Rosa; Izabela Chmielewska; E. Felip; G. Ostoros; L. Jimenez-Kurlander; C.M. Lane; A. Sachdeva; Laura J. Eccles; Shun Lu

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8500

Paper S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).

S. Padda; M.W. Redman; David E. Gerber et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).

Authors: S. Padda; M.W. Redman; David E. Gerber; K. Minichiello; D. Mehta; S. Mashru; Hosam Hakim; J. Brahmer; Jeffrey D. Bradley; T. Stinchcombe; J.E. Gray; Karen Kelly; D. Kozono; K. Reckamp; Martin J Edelman; Hossein Borghaei; Jyoti D. Patel; Roy S. Herbst; Suresh S. Ramalingam; J. Neal

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8518

Paper Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with

Konstantin Dragnev, Y. Murciano-Goroff, N. Ammakkanavar, Shinji Takeuchi, Yutaka Fujiwara, Timothy F. Burns, A. Spira, Melissa L. Johnson, A. Sacher, Joanne Lundy, T. Koyama, A. Patnaik, G. Sherwood, Cesar A Perez, M. Chisamore, A. Fink, Aaron Chen, Geoff Oxnard, Melinda D Willard, Nimit Singhal · 2025 · Journal of Clinical Oncology · DOI

Full title: Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with

Authors: Konstantin Dragnev, Y. Murciano-Goroff, N. Ammakkanavar, Shinji Takeuchi, Yutaka Fujiwara, Timothy F. Burns, A. Spira, Melissa L. Johnson, A. Sacher, Joanne Lundy, T. Koyama, A. Patnaik, G. Sherwood, Cesar A Perez, M. Chisamore, A. Fink, Aaron Chen, Geoff Oxnard, Melinda D Willard, Nimit Singhal

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8519

Paper Impact of standard vs reduced dosing of sotorasib on efficacy and toxicity in KRAS G12C–mutated advanced non-small cell lung cancer: A systematic review and meta-analysis.

Aung, Wint Yan; Neumann, Melissa Francoise; Wang, Kevin et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Impact of standard vs reduced dosing of sotorasib on efficacy and toxicity in KRAS G12C–mutated advanced non-small cell lung cancer: A systematic review and meta-analysis.

Authors: Aung, Wint Yan; Neumann, Melissa Francoise; Wang, Kevin; Chukkalore, Divya; Morales, Jaclyn; Seetharamu, Nagashree

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8593

Paper MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.

A. Sacher; M. Şendur; Anastasios Stathis et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.

Authors: A. Sacher; M. Şendur; Anastasios Stathis; Maya Gottfried; Shun Lu; R. Juergens; Laiyu Liu; Carlos Rojas; J. Bar; V. Moreno; Yun Fan; Mustafa Erman; N. Peled; E. Felip; Mark Ayers; T. Jemielita; L. R. Molife; Y. Choi; R. Dziadziuszko

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8605

Paper Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC).

Zhengbo Song; Xingya Li; Rongbo Lin et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC).

Authors: Zhengbo Song; Xingya Li; Rongbo Lin; Ying Liu; Yongzhong Luo; Yuan Yuan; Huaqiu Shi; Tangfeng Lv; Yiping Zhang; Liming Zhu; Yinxin Zhu; Zaiqi Wang

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8629

Paper Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA- and machine learning–based patient classifier.

M. Uhlik; Klemen Žiberna; Luka Ausec et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA- and machine learning–based patient classifier.

Authors: M. Uhlik; Klemen Žiberna; Luka Ausec; Rafael Rosengarten; Miha Štajdohar; E. Cohen; Josh Wheeler

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e13614

Paper Exploring molecular resistance mechanisms in therapy naïve NSCLC patients: A retrospective 2 year Indian study.

Chirantan Bose; A. Joshi; Vashishth Maniar et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Exploring molecular resistance mechanisms in therapy naïve NSCLC patients: A retrospective 2 year Indian study.

Authors: Chirantan Bose; A. Joshi; Vashishth Maniar; Udip Maheshwari; K. Joshi; P. Kalaskar; K. Jobanputra; P. Kendre; Smith Sheth; C. Pethe; D. Morzaria; K. Todi; M. Mekha; T. Sethjiwala; Makarand Randive; S. Dhande; P. Devde; N. Bayas; Tushar Patil

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e15074

Paper Racial disparities in molecularly targeted trials of tyrosine kinase inhibitors (TKI) for the perioperative management of oncogene-driven non-small cell lung cancer (NSCLC): A systematic review.

O. Adebayo; Koosha Paydary · 2025 · Journal of Clinical Oncology · DOI

Full title: Racial disparities in molecularly targeted trials of tyrosine kinase inhibitors (TKI) for the perioperative management of oncogene-driven non-small cell lung cancer (NSCLC): A systematic review.

Authors: O. Adebayo; Koosha Paydary

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e20015

Paper Impact of mutant STK11, KEAP1, and KRAS on firstline chemoimmunotherapy survival outcomes in metastatic non-small cell lung cancer (NSCLC): A meta-analysis of randomized and comparative studies.

Suvarna Guvvala; Ankita Gupta; Sireesha Vutukuri et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Impact of mutant STK11, KEAP1, and KRAS on firstline chemoimmunotherapy survival outcomes in metastatic non-small cell lung cancer (NSCLC): A meta-analysis of randomized and comparative studies.

Authors: Suvarna Guvvala; Ankita Gupta; Sireesha Vutukuri; P. Haddad

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e20504

Paper Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS G12C mutant non-small-cell lung cancer.

B. Solomon; Wallace L. Akerley; Vinod Ganju et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS G12C mutant non-small-cell lung cancer.

Authors: B. Solomon; Wallace L. Akerley; Vinod Ganju; Jun Zhang; Alex A. Adjei; Melissa L. Johnson; A. Spira; Lei Deng; Edward B. Garon; So Yeon Kim; Richard Frank; Lyudmila Bazhenova; Rasha Cosman; Rachel Roberts-Thomson; C. Karapetis; Yong Ben; Foster Gonsalves

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps8649

Paper Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC).

F. Skoulidis; B. Solomon; N. Frost et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Authors: F. Skoulidis; B. Solomon; N. Frost; R. Heist; Caicun Zhou; Martina Zarak Crnkovic; Vladan Antic; Hen Prizant; M. C. Mayo; C. Meyenberg; Sophie Keufer-Le Gall; Sanjay Popat

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps8656

Paper Spatially resolved protein profiling in pancreatic adenosquamous carcinoma.

Adel Kardosh; Rosalie C. Sears; Zheng Xia et al. · 2025 · Journal of Clinical Oncology · DOI

Full title: Spatially resolved protein profiling in pancreatic adenosquamous carcinoma.

Authors: Adel Kardosh; Rosalie C. Sears; Zheng Xia; Eizabaru M Sasatomi; Brian Mau; Jonathan R Brody; Melissa Wong; Charles D. Lopez; E. Chen; Guillaume Pegna; Cristiane M Franca; John Muschler; Joanna Pucilowska; Shaun M Goodyear

Year: 2025

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.2025.43.4_suppl.760

Paper Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Tan, Aaron C.; Tan, Daniel S.W. · 2022 · Journal of Clinical Oncology · DOI

Full title: Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Authors: Tan, Aaron C.; Tan, Daniel S.W.

Year: 2022

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.21.01626

Paper Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

G. Dy; R. Govindan; V. Velcheti et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Authors: G. Dy; R. Govindan; V. Velcheti; G. Falchook; A. Italiano; J. Wolf; A. Sacher; Toshiaki Takahashi; S. Ramalingam; C. Dooms; Dong-Wan Kim; A. Addeo; Jayesh Desai; M. Schuler; P. Tomasini; David S. Hong; P. Lito; Q. Tran; Simon Jones; A. Anderson; A. Hindoyan; W. Snyder; F. Skoulidis; Bob T. Li

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.22.02524

Paper Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

Negrão, Marcelo V.; Spira, Alexander I.; Heist, Rebecca S. et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

Authors: Negrão, Marcelo V.; Spira, Alexander I.; Heist, Rebecca S.; Jänne, Pasi A.; Pacheco, Jose M.; Weiss, Jared; Gadgeel, Shirish M.; Velastegui, Karen; Yang, Wenjing; Der‐Torossian, Hirak; Christensen, James G.; Sabari, Joshua K.

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.23.00046

Paper Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation

Bekaii‐Saab, Tanios; Yaeger, Rona; Spira, Alexander I. et al. · 2023 · Journal of Clinical Oncology · DOI

Full title: Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation

Authors: Bekaii‐Saab, Tanios; Yaeger, Rona; Spira, Alexander I.; Pelster, Meredith; Sabari, Joshua K.; Hafez, Navid; Barve, Minal; Velastegui, Karen; Yan, Xiaohong; Shetty, Aditya; Der‐Torossian, Hirak; Pant, Shubham

Year: 2023

Venue: Journal of Clinical Oncology

DOI: https://doi.org/10.1200/jco.23.00434

Paper Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting.

Luiza Doro; G. Ozcan; James J. Vredenburgh et al. · 2024 · JCO Oncology Practice · DOI

Full title: Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting.

Authors: Luiza Doro; G. Ozcan; James J. Vredenburgh; Emily F. Collier

Year: 2024

Venue: JCO Oncology Practice

DOI: https://doi.org/10.1200/op.2024.20.10_suppl.316

Paper Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer

Schouten, Robert D.; Vessies, Daan C.L.; Bosch, Linda J.W. et al. · 2021 · JCO Precision Oncology · DOI

Full title: Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer

Authors: Schouten, Robert D.; Vessies, Daan C.L.; Bosch, Linda J.W.; Barlo, Nicole P.; Lindert, Anne S. R. van; Cillessen, Saskia A.G.M.; Broek, Daan van den; Heuvel, Michel M. van den; Monkhorst, Kim

Year: 2021

Venue: JCO Precision Oncology

DOI: https://doi.org/10.1200/po.20.00450

Paper Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.

L. Gerratana; Michael Movarek; F. Wehbe et al. · 2022 · JCO Precision Oncology · DOI

Full title: Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.

Authors: L. Gerratana; Michael Movarek; F. Wehbe; N. Katam; D. Mahalingam; J. Donahue; Ami N. Shah; Y. Chae; Megan Mulcahy; Dean Tsarwhas; V. Villaflor; A. Kalyan; M. Hussein; J. Patel; S. Chandra; L. Platanias; W. Gradishar; M. Cristofanilli; A. Behdad

Year: 2022

Venue: JCO Precision Oncology

DOI: https://doi.org/10.1200/po.21.00289

Paper Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

Arriola, Edurne; Bernabé, Reyes; Campelo, Rosario García et al. · 2023 · JCO Precision Oncology · DOI

Full title: Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

Authors: Arriola, Edurne; Bernabé, Reyes; Campelo, Rosario García; Biscuola, Michele; Enguita, Ana B.; López‐Ríos, Fernando; Martinez, Rafael C.; Mezquita, Laura; Palanca, Sarai; Pareja, María Jesús; Zugazagoitia, Jon; Arrabal, Natalia; Garcı́a, Juan F.; Carcedo, David; Álava, Enrique de

Year: 2023

Venue: JCO Precision Oncology

DOI: https://doi.org/10.1200/po.22.00546

Paper Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer

Thummalapalli, Rohit; Bernstein, Ezra; Herzberg, Benjamin et al. · 2023 · JCO Precision Oncology · DOI

Full title: Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer

Authors: Thummalapalli, Rohit; Bernstein, Ezra; Herzberg, Benjamin; Li, Bob T.; Iqbal, Afsheen N.; Preeshagul, Isabel R.; Santini, Fernando C.; Eng, Juliana; Ladanyi, Marc; Yang, Soo‐Ryum; Shen, Ronglai; Lito, Piro; Riely, Gregory J.; Sabari, Joshua K.; Arbour, Kathryn C.

Year: 2023

Venue: JCO Precision Oncology

DOI: https://doi.org/10.1200/po.23.00030

Paper Molecular inhibition of RAS signalling to target ageing and age-related health

Laskovs, Mihails; Partridge, Linda; Slack, Cathy · 2022 · Disease Models & Mechanisms · DOI

Full title: Molecular inhibition of RAS signalling to target ageing and age-related health

Authors: Laskovs, Mihails; Partridge, Linda; Slack, Cathy

Year: 2022

Venue: Disease Models & Mechanisms

DOI: https://doi.org/10.1242/dmm.049627

Paper Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer

Merve Aras; Özlem Yayıntaş · 2026 · Journal of Research in Pharmacy · DOI

Full title: Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer

Authors: Merve Aras; Özlem Yayıntaş

Year: 2026

Venue: Journal of Research in Pharmacy

DOI: https://doi.org/10.12991/jrespharm.1645818

Paper Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report.

Wang, Ming-Xing; Zhu, Pei; Shi, Yue et al. · 2024 · World journal of clinical cases · DOI

Full title: Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report.

Authors: Wang, Ming-Xing; Zhu, Pei; Shi, Yue; Sun, Qing-Ming; Dong, Wan-Hui

Year: 2024

Venue: World journal of clinical cases

DOI: https://doi.org/10.12998/wjcc.v12.i25.5805

Paper EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors

Sartori, Giuliana; Cavazza, Alberto; Sgambato, Alessandro et al. · 2009 · American Journal of Clinical Pathology · DOI

Full title: EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors

Authors: Sartori, Giuliana; Cavazza, Alberto; Sgambato, Alessandro; Marchioni, Alessandro; Barbieri, Fausto; Longo, Lucia; Bavieri, Mario; Murer, Bruno; Meschiari, Emmanuela; Tamberi, Stefano; Cadioli, Annamaria; Luppi, Fabrizio; Migaldi, Mario; Rossi, Giulio

Year: 2009

Venue: American Journal of Clinical Pathology

DOI: https://doi.org/10.1309/ajcph0trmpxvzw2f

Paper Distinctive Evaluation of Nonmucinous and Mucinous Subtypes of Bronchioloalveolar Carcinomas inEGFRand K-rasGene-Mutation Analyses for Japanese Lung Adenocarcinomas

Sakuma, Yuji; Matsukuma, Shoichi; Yoshihara, Mitsuyo et al. · 2007 · American Journal of Clinical Pathology · DOI

Full title: Distinctive Evaluation of Nonmucinous and Mucinous Subtypes of Bronchioloalveolar Carcinomas inEGFRand K-rasGene-Mutation Analyses for Japanese Lung Adenocarcinomas

Authors: Sakuma, Yuji; Matsukuma, Shoichi; Yoshihara, Mitsuyo; Nakamura, Yoshiyasu; Noda, Kazumasa; Nakayama, Haruhiko; Kameda, Yoichi; Tsuchiya, Eiju; Miyagi, Yohei

Year: 2007

Venue: American Journal of Clinical Pathology

DOI: https://doi.org/10.1309/wvxfgaflaux48du6

Paper Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.

Xinting Zheng; Jiamin Luo; Wei Liu et al. · 2022 · Drugs of Today · DOI

Full title: Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.

Authors: Xinting Zheng; Jiamin Luo; Wei Liu; C. Ashby; Zhe‐Sheng Chen; Lizhu Lin

Year: 2022

Venue: Drugs of Today

DOI: https://doi.org/10.1358/dot.2022.58.4.3400573

Paper Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

Sakai, Kazuko; Tsurutani, Junji; Yamanaka, Takeharu et al. · 2015 · PLoS ONE · DOI

Full title: Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

Authors: Sakai, Kazuko; Tsurutani, Junji; Yamanaka, Takeharu; Yoneshige, Azusa; Ito, Akihiko; Togashi, Yosuke; Velasco, Marco A. De; Terashima, Masato; Fujita, Yoshihiko; Tomida, Shuta; Tamura, Takao; Nakagawa, Kazuhiko; Nishio, Kazuto

Year: 2015

Venue: PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0121891

Paper Cell death in cancer therapy of lung adenocarcinoma

Zagryazhskaya, Anna; Gyurászová, Katarína; Zhivotovsky, Boris · 2015 · The International Journal of Developmental Biology · DOI

Full title: Cell death in cancer therapy of lung adenocarcinoma

Authors: Zagryazhskaya, Anna; Gyurászová, Katarína; Zhivotovsky, Boris

Year: 2015

Venue: The International Journal of Developmental Biology

DOI: https://doi.org/10.1387/ijdb.150044bz

Paper Biomarkers in the management of lung cancer: changing the practice of thoracic oncology

Melichar, Bohuslav · 2022 · Clinical Chemistry and Laboratory Medicine (CCLM) · DOI

Full title: Biomarkers in the management of lung cancer: changing the practice of thoracic oncology

Authors: Melichar, Bohuslav

Year: 2022

Venue: Clinical Chemistry and Laboratory Medicine (CCLM)

DOI: https://doi.org/10.1515/cclm-2022-1108

Paper Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis

X. Gu; J. Si; Y. Guan et al. · 2023 · Open Medicine · DOI

Full title: Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis

Authors: X. Gu; J. Si; Y. Guan; Yibing Xu; L. Shao; Yiping Zhang; Chun-wei Xu; Weiwei Pan; Yuanzhi Lu; Zhengbo Song; Wenxian Wang

Year: 2023

Venue: Open Medicine

DOI: https://doi.org/10.1515/med-2023-0653

Paper Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

Tomasini, Pascale; Walia, Preet; Labbé, Catherine et al. · 2016 · The Oncologist · DOI

Full title: Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

Authors: Tomasini, Pascale; Walia, Preet; Labbé, Catherine; Jao, Kevin; Leighl, Natasha B.

Year: 2016

Venue: The Oncologist

DOI: https://doi.org/10.1634/theoncologist.2015-0084

Paper Emerging Therapeutic Implications of STK11 Mutation: Case Series.

B. Laderian; Prabhjot S. Mundi; T. Fojo et al. · 2020 · The Oncologist · DOI

Full title: Emerging Therapeutic Implications of STK11 Mutation: Case Series.

Authors: B. Laderian; Prabhjot S. Mundi; T. Fojo; S. Bates

Year: 2020

Venue: The Oncologist

DOI: https://doi.org/10.1634/theoncologist.2019-0846

Paper 4E-BP1 as an oncotarget

Q. She · 2015 · Aging · DOI

Full title: 4E-BP1 as an oncotarget

Authors: Q. She

Year: 2015

Venue: Aging

DOI: https://doi.org/10.18632/aging.100794

Paper Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

Wang, Rui; Zhang, Yang; Pan, Yunjian et al. · 2015 · Oncotarget · DOI

Full title: Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

Authors: Wang, Rui; Zhang, Yang; Pan, Yunjian; Li, Yuan; Hu, Haichuan; Cai, Deng; Li, Hang; Ye, Ting; Luo, Xiaoyang; Zhang, Yiliang; Li, Bin; Shen, Lei; Sun, Yihua; Chen, Haiquan

Year: 2015

Venue: Oncotarget

DOI: https://doi.org/10.18632/oncotarget.5549

Paper Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice

Teixeira, Manuel R.; Oliveira, Júlio; Borralho, Paula et al. · 2022 · Acta Médica Portuguesa · DOI

Full title: Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice

Authors: Teixeira, Manuel R.; Oliveira, Júlio; Borralho, Paula; Fernandes, Gabriela; Almodôvar, Teresa; Fernandes, Isabel; Macedo, Daniela; Ferreira, Ana; Barroso, Ana; Teixeira, Encarnação; Machado, José Carlos

Year: 2022

Venue: Acta Médica Portuguesa

DOI: https://doi.org/10.20344/amp.17680

Paper Genome editing of LKB1 (STK11) mutation in A549 lung cancer cells using CRISPR/Cas9 system

A. P. Morelli; F. Simabuco; I. Pavan et al. · 2018 · Revista dos Trabalhos de Iniciação Científica da UNICAMP · DOI

Full title: Genome editing of LKB1 (STK11) mutation in A549 lung cancer cells using CRISPR/Cas9 system

Authors: A. P. Morelli; F. Simabuco; I. Pavan; M. Tavares; Luiz Guilherme Salvino; Nathalie F. P. Pereira; F. R. Silva; T. C. T. Junior; R. Chammas

Year: 2018

Venue: Revista dos Trabalhos de Iniciação Científica da UNICAMP

DOI: https://doi.org/10.20396/revpibic262018138

Paper Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report.

Jia, Xianglong; Liu, Meng; Cheng, Zhiqiang · 2024 · AME case reports · DOI

Full title: Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report.

Authors: Jia, Xianglong; Liu, Meng; Cheng, Zhiqiang

Year: 2024

Venue: AME case reports

DOI: https://doi.org/10.21037/acr-23-153

Paper Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?

A. Abhyankar; G. Dy · 2024 · AME Clinical Trials Review · DOI

Full title: Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?

Authors: A. Abhyankar; G. Dy

Year: 2024

Venue: AME Clinical Trials Review

DOI: https://doi.org/10.21037/actr-24-17

Paper Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies

Rashdan, Sawsan; Gerber, David E. · 2016 · Annals of Translational Medicine · DOI

Full title: Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies

Authors: Rashdan, Sawsan; Gerber, David E.

Year: 2016

Venue: Annals of Translational Medicine

DOI: https://doi.org/10.21037/atm.2016.12.57

Paper Emerging application of genomics-guided therapeutics in personalized lung cancer treatment

Zaman, Aubhishek; Bivona, Trever G. · 2018 · Annals of Translational Medicine · DOI

Full title: Emerging application of genomics-guided therapeutics in personalized lung cancer treatment

Authors: Zaman, Aubhishek; Bivona, Trever G.

Year: 2018

Venue: Annals of Translational Medicine

DOI: https://doi.org/10.21037/atm.2018.05.02

Paper Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells.

Donghua Geng; Huiying Wu · 2021 · Journal of Gastrointestinal Oncology · DOI

Full title: Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells.

Authors: Donghua Geng; Huiying Wu

Year: 2021

Venue: Journal of Gastrointestinal Oncology

DOI: https://doi.org/10.21037/jgo-22-341

Paper Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

Chalela, Roberto; Curull, Víctor; Enríquez, César et al. · 2017 · Journal of Thoracic Disease · DOI

Full title: Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

Authors: Chalela, Roberto; Curull, Víctor; Enríquez, César; Pijuán, Lara; Bellosillo, Beatríz; Gea, Joaquim

Year: 2017

Venue: Journal of Thoracic Disease

DOI: https://doi.org/10.21037/jtd.2017.06.20

Paper An annual review of the remarkable advances in lung cancer clinical research in 2019

Cheng, Bo; Xiong, Shan; Li, Caichen et al. · 2020 · Journal of Thoracic Disease · DOI

Full title: An annual review of the remarkable advances in lung cancer clinical research in 2019

Authors: Cheng, Bo; Xiong, Shan; Li, Caichen; Liang, Hengrui; Zhao, Yi; Li, Jianfu; Shi, Jiang; Ou, Limin; Chen, Zisheng; Peng, Liang; Liang, Wenhua; He, Jianxing

Year: 2020

Venue: Journal of Thoracic Disease

DOI: https://doi.org/10.21037/jtd.2020.03.11

Paper Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival

Amanam, Idoroenyi; Mambetsariev, Isa; Gupta, Rohan et al. · 2020 · Journal of Thoracic Disease · DOI

Full title: Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival

Authors: Amanam, Idoroenyi; Mambetsariev, Isa; Gupta, Rohan; Achuthan, Srisairam; Wang, Yingyu; Pharaon, Rebecca; Massarelli, Erminia; Koczywas, Marianna; Reckamp, Karen L.; Salgia, Ravi

Year: 2020

Venue: Journal of Thoracic Disease

DOI: https://doi.org/10.21037/jtd.2020.04.18

Paper ATR expression as a prognostic biomarker in KRAS-mutated non-small cell lung cancer

Li Jiang; Chao Luo; Peng Zhang et al. · 2025 · Journal of Thoracic Disease · DOI

Full title: ATR expression as a prognostic biomarker in KRAS-mutated non-small cell lung cancer

Authors: Li Jiang; Chao Luo; Peng Zhang; Renyu Wang; Lili Tang; Xufeng Deng; Anna T. Allemann; A. Abhyankar; Hong Zheng; Jigang Dai

Year: 2025

Venue: Journal of Thoracic Disease

DOI: https://doi.org/10.21037/jtd-2025-1113

Paper The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer with driver or non-driver gene alterations: a retrospective cohort study

Qi He; Xiaobei Guo; Yu-Rou Chen et al. · 2026 · Journal of Thoracic Disease · DOI

Full title: The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer with driver or non-driver gene alterations: a retrospective cohort study

Authors: Qi He; Xiaobei Guo; Yu-Rou Chen; Xiao-xing Gao; Jing Zhao; W. Zhong; Min-Jiang Chen; Yan Xu; Meng-Zhao Wang

Year: 2026

Venue: Journal of Thoracic Disease

DOI: https://doi.org/10.21037/jtd-2025-1409

Paper Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations

K. Lu; H. Husain · 2021 · Journal of Thoracic Disease · DOI

Full title: Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations

Authors: K. Lu; H. Husain

Year: 2021

Venue: Journal of Thoracic Disease

DOI: https://doi.org/10.21037/jtd-22-312

Paper Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform

C. Mayo de las Casas; Mónica Garzón-Ibáñez; N. Jordana-Ariza et al. · 2018 · Translational Cancer Research · DOI

Full title: Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform

Authors: C. Mayo de las Casas; Mónica Garzón-Ibáñez; N. Jordana-Ariza; S. Viteri-Ramírez; I. Moya-Horno; N. Karachaliou; Z. Yeste; Raquel Campos; S. Villatoro; Ariadna Balada-Bel; B. García-Peláez; N. Reguart; C. Teixidó; E. Jantus; S. Calabuig; C. Aguado; A. Giménez-Capitán; Ruth Román-Lladó; Ana Pérez-Rosado; M. Catalan; J. Bertran-Alamillo; S. García-Román; S. Rodríguez; Lidia Alonso; E. Aldeguer; A. Martínez-Bueno; M. González-Cao; A. Aguilar Hernández; J. García-Mosquera; María de Los Llanos Gil; Manuel Fernández; R. Rosell; M. Molina-Vila

Year: 2018

Venue: Translational Cancer Research

DOI: https://doi.org/10.21037/tcr.2018.10.12

Paper Adagrasib in the treatment of KRASG12C-mutated non-small cell lung cancer: a cost-effectiveness analysis.

Huo, Gengwei; Song, Ying; Liu, Shenge et al. · 2025 · Translational cancer research · DOI

Full title: Adagrasib in the treatment of KRASG12C-mutated non-small cell lung cancer: a cost-effectiveness analysis.

Authors: Huo, Gengwei; Song, Ying; Liu, Shenge; He, Xiaoning; Chen, Peng

Year: 2025

Venue: Translational cancer research

DOI: https://doi.org/10.21037/tcr-2025-742

Paper KRAS and EGFR inhibitors: a new step in the management of colorectal cancer

Khalil Saleh; Rebecca Ibrahim; Rita Khoury et al. · 2023 · Translational Gastroenterology and Hepatology · DOI

Full title: KRAS and EGFR inhibitors: a new step in the management of colorectal cancer

Authors: Khalil Saleh; Rebecca Ibrahim; Rita Khoury; Zamzam Tikriti; N. Khalife

Year: 2023

Venue: Translational Gastroenterology and Hepatology

DOI: https://doi.org/10.21037/tgh-24-73

Paper Non-small cell lung cancer: current treatment and future advances

Zappa, Cecilia; Mousa, Shaker A. · 2016 · Translational Lung Cancer Research · DOI

Full title: Non-small cell lung cancer: current treatment and future advances

Authors: Zappa, Cecilia; Mousa, Shaker A.

Year: 2016

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr.2016.06.07

Paper KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients

Garzón, Mónica; Villatoro, Sergi; Teixidó, Cristina et al. · 2016 · Translational Lung Cancer Research · DOI

Full title: KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients

Authors: Garzón, Mónica; Villatoro, Sergi; Teixidó, Cristina; Mayo, Clara; Martínez, Alejandro; Gil, María de los Llanos; Viteri, Santiago; Morales-Espinosa, Daniela; Rosell, Rafael

Year: 2016

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr.2016.10.14

Paper Autochthonous murine models for the study of smoker and never-smoker associated lung cancers

Akbay, Esra A.; Kim, James · 2018 · Translational Lung Cancer Research · DOI

Full title: Autochthonous murine models for the study of smoker and never-smoker associated lung cancers

Authors: Akbay, Esra A.; Kim, James

Year: 2018

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr.2018.06.04

Paper Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Bersani, Francesca; Morena, Deborah; Picca, Francesca et al. · 2020 · Translational Lung Cancer Research · DOI

Full title: Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Authors: Bersani, Francesca; Morena, Deborah; Picca, Francesca; Morotti, Alessandro; Tabbò, Fabrizio; Bironzo, Paolo; Righi, Luisella; Taulli, Riccardo

Year: 2020

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-20-189

Paper Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer

Jiang-Xia Yuan; Yue Hao; Xianzi Dai et al. · 2023 · Translational Lung Cancer Research · DOI

Full title: Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer

Authors: Jiang-Xia Yuan; Yue Hao; Xianzi Dai; Jiaojiao Hong; Chengyu Chen; Zhengxing Huo; Jia Zhu; Qian Wang

Year: 2023

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-2025-164

Paper KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples

Loong, Herbert H.; Du, Nan; Cheng, Chunyan et al. · 2020 · Translational Lung Cancer Research · DOI

Full title: KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples

Authors: Loong, Herbert H.; Du, Nan; Cheng, Chunyan; Lin, Hanqing; Guo, Jian; Lin, Gen; Li, Mingjiang; Jiang, Tao; Shi, Zhihua; Cui, Yanzhi; Jin, Xianfeng; Yao, Jicheng; Xing, Yutong; Yao, Ming; Wang, Kai; Mok, Tony; Liu, Lunxu

Year: 2020

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-20-455

Paper Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome

Pavan, Alberto; Bragadin, Andrea Boscolo; Calvetti, Lorenzo et al. · 2021 · Translational Lung Cancer Research · DOI

Full title: Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome

Authors: Pavan, Alberto; Bragadin, Andrea Boscolo; Calvetti, Lorenzo; Ferro, Alessandra; Zulato, Elisabetta; Attili, Ilaria; Nardo, Giorgia; Maso, Alessandro Dal; Frega, S.; Menin, Andrea; Fassan, Matteo; Calabrese, Fiorella; Pasello, Giulia; Guarneri, Valentina; Aprile, Giuseppe; Conté, Pierfranco; Rosell, Rafael; Indraccolo, Stefano; Bonanno, Laura

Year: 2021

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-20-674

Paper Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Hualin Chen; Mei-lian Liu; Zhiwei Dai et al. · 2020 · Translational Lung Cancer Research · DOI

Full title: Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Authors: Hualin Chen; Mei-lian Liu; Zhiwei Dai; Shujun Li; Yiping Luo; Yongcun Wang; Wenmei Su; W. Cai; Donghong Yang; Jian Huang; Zhi-Xiong Yang

Year: 2020

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-20-679

Paper Immunotherapy in oncogene addicted non-small cell lung cancer

McLean, Luke; Leal, José Luis; Solomon, Benjamin et al. · 2021 · Translational Lung Cancer Research · DOI

Full title: Immunotherapy in oncogene addicted non-small cell lung cancer

Authors: McLean, Luke; Leal, José Luis; Solomon, Benjamin; John, Thomas

Year: 2021

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-20-772

Paper Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing—a single-center experience

Zacharias, Martin; Absenger, Gudrun; Kashofer, Karl et al. · 2021 · Translational Lung Cancer Research · DOI

Full title: Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing—a single-center experience

Authors: Zacharias, Martin; Absenger, Gudrun; Kashofer, Karl; Wurm, Robert; Lindenmann, Jörg; Terbuch, Angelika; Konjić, Selma; Sauer, Stefan; Gollowitsch, Franz; Gorkiewicz, Gregor; Brčić, Luka

Year: 2021

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-21-570

Paper The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review

A. Spagnuolo; P. Maione; C. Gridelli · 2021 · Translational Lung Cancer Research · DOI

Full title: The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review

Authors: A. Spagnuolo; P. Maione; C. Gridelli

Year: 2021

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-21-948

Paper A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab

Shen, Yinchen; Li, Jiaqi; Qiang, Huiping et al. · 2022 · Translational Lung Cancer Research · DOI

Full title: A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab

Authors: Shen, Yinchen; Li, Jiaqi; Qiang, Huiping; Lei, Yuqiong; Chang, Qing; Zhong, Runbo; Stella, Giulia Maria; Gelsomino, Francesco; Kim, Yeon Wook; Abed, Afaf; Qian, Jialin; Chu, Tianqing

Year: 2022

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-22-493

Paper Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer

Wang, Yadong; Peng, Ling; Zhao, Ming et al. · 2022 · Translational Lung Cancer Research · DOI

Full title: Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer

Authors: Wang, Yadong; Peng, Ling; Zhao, Ming; Xiong, Yuanyuan; Xue, Jianchao; Li, Bowen; Huang, Zhicheng; Liu, Xinyu; Yang, Xiaoying; Song, Yang; Bing, Zhongxing; Guo, Chao; Tian, Zhenhuan; Gao, Chao; Cao, Lei; Cao, Zhili; Li, Ji; Xu, Jiang; Si, Xiaoyan; Zhang, Li; Li, Xiaoguang; Zheng, Zhibo; Song, Mengmeng; Chen, Rongrong; Lim, Wan‐Teck; Pavan, Alberto; Romero, Atocha; Liang, Naixin; Yang, Huaxia; Li, Shanqing

Year: 2022

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-22-629

Paper Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.

Santarpia, Mariacarmela; Ciappina, Giuliana; Spagnolo, Calogera Claudia et al. · 2023 · Translational lung cancer research · DOI

Full title: Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.

Authors: Santarpia, Mariacarmela; Ciappina, Giuliana; Spagnolo, Calogera Claudia; Squeri, Andrea; Passalacqua, Maria Ilenia; Aguilar, Andrés; Gonzalez-Cao, Maria; Giovannetti, Elisa; Silvestris, Nicola; Rosell, Rafael

Year: 2023

Venue: Translational lung cancer research

DOI: https://doi.org/10.21037/tlcr-22-639

Paper KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China

Li, Qianni; Zhou, Qi; Zhao, Shicai et al. · 2022 · Translational Lung Cancer Research · DOI

Full title: KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China

Authors: Li, Qianni; Zhou, Qi; Zhao, Shicai; Wu, Peng; Shi, Ping; Zeng, Jia; Xiong, Xiaomin; Chen, Haiwen; Kittaneh, Muaiad; Bravaccini, Sara; Zanoni, Michele; Zhou, Chengzhi; Zhang, Jiexia

Year: 2022

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-22-655

Paper The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients

Yang, Ying; Shen, Shengping; Sun, Yingjia et al. · 2022 · Translational Lung Cancer Research · DOI

Full title: The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients

Authors: Yang, Ying; Shen, Shengping; Sun, Yingjia; Husain, Hatim; Zhou, Haiyan; Lü, Shun; Li, Ziming

Year: 2022

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-22-88

Paper KRAS G12C mutation: from undruggable target to potentially agnostic biomarker

Osta, Badi El · 2023 · Translational Lung Cancer Research · DOI

Full title: KRAS G12C mutation: from undruggable target to potentially agnostic biomarker

Authors: Osta, Badi El

Year: 2023

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-23-174

Paper Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?

Oya, Yuko; Mitsudomi, Tetsuya · 2023 · Translational Lung Cancer Research · DOI

Full title: Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?

Authors: Oya, Yuko; Mitsudomi, Tetsuya

Year: 2023

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-23-97

Paper Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review

Bin Liu; Ziyu Wang; Meng Gu et al. · 2024 · Translational Lung Cancer Research · DOI

Full title: Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review

Authors: Bin Liu; Ziyu Wang; Meng Gu; Jinghui Wang; Jinjing Tan

Year: 2024

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.21037/tlcr-24-592

Paper Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors.

Dongsheng He; R. Bai; N. Chen et al. · 2024 · Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · DOI

Full title: Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors.

Authors: Dongsheng He; R. Bai; N. Chen; Jiuwei Cui

Year: 2024

Venue: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

DOI: https://doi.org/10.21147/j.issn.1000-9604.2024.04.06

Paper Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers

S. Misale; R. Yaeger; Riccardo Mezzadra et al. · 2022 · DOI

Full title: Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers

Authors: S. Misale; R. Yaeger; Riccardo Mezzadra; Jenna Sinopoli; Yu Bian; M. Marasco; Esther Kaplun; Yijun Gao; Huiyong Zhao; A. Paula; Yingjie Zhu; Sydney Bowker; Q. Chang; Besnik Qeriqi; B. Weigelt; H. Der-Torossian; K. Anderes; N. Socci; J. Shia; Gregory Riely; Y. Murciano-Goroff; Bob T. Li; J. Christensen; J. Reis-Filho; D. Solit; E. de Stanchina; S. Lowe; Neal Rosen

Year: 2022

DOI: https://doi.org/10.21203/rs.3.rs-1236956/v1

Paper Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing et al. · 2024 · Nature · DOI

Full title: Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

Year: 2024

Venue: Nature

DOI: https://doi.org/10.1038/s41586-024-07205-6

Paper Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.

R. K. Harwansh; J. Hamid; Pranay Wal et al. · 2025 · Current pharmaceutical design · DOI

Full title: Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.

Authors: R. K. Harwansh; J. Hamid; Pranay Wal; Rohitas Deshmukh; P. K. Patra; Amin Gasmi

Year: 2025

Venue: Current pharmaceutical design

DOI: https://doi.org/10.2174/0113816128334659241223113743

Paper Recent developments, challenges and opportunities in targeting the KRAS pathway

M. Pothuganti; Sayan Mitra; Pravin Iyer et al. · 2022 · Letters in Drug Design & Discovery · DOI

Full title: Recent developments, challenges and opportunities in targeting the KRAS pathway

Authors: M. Pothuganti; Sayan Mitra; Pravin Iyer; N. Gowda

Year: 2022

Venue: Letters in Drug Design & Discovery

DOI: https://doi.org/10.2174/1570180819666220704104028

Paper Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.

Guo, Matthew Z; Marrone, Kristen A; Spira, Alexander et al. · 2023 · Future oncology (London, England) · DOI

Full title: Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.

Authors: Guo, Matthew Z; Marrone, Kristen A; Spira, Alexander; Rosner, Samuel

Year: 2023

Venue: Future oncology (London, England)

DOI: https://doi.org/10.2217/fon-2022-1106

Paper Ras and Ras mutations in cancer

Rajasekharan, Satish; Raman, Thiagarajan · 2013 · Open Life Sciences · DOI

Full title: Ras and Ras mutations in cancer

Authors: Rajasekharan, Satish; Raman, Thiagarajan

Year: 2013

Venue: Open Life Sciences

DOI: https://doi.org/10.2478/s11535-013-0158-5

Paper Targeted Degradation of Oncogenic KRASG12C by VHL-recruiting PROTACs

Bond, Michael J.; Chu, Ling; Nalawansha, Dhanusha A. et al. · 2020 · DOI

Full title: Targeted Degradation of Oncogenic KRASG12C by VHL-recruiting PROTACs

Authors: Bond, Michael J.; Chu, Ling; Nalawansha, Dhanusha A.; Li, Ke; Crews, Craig M.

Year: 2020

DOI: https://doi.org/10.26434/chemrxiv.12091176.v1

Paper Mutation status and postresection survival of patients with non–small cell lung cancer brain metastasis: implications of biomarker-driven therapy

Shah, Pavan P.; Franke, Jennifer L.; Medikonda, Ravi et al. · 2021 · Journal of neurosurgery · DOI

Full title: Mutation status and postresection survival of patients with non–small cell lung cancer brain metastasis: implications of biomarker-driven therapy

Authors: Shah, Pavan P.; Franke, Jennifer L.; Medikonda, Ravi; Jackson, Christopher M.; Srivastava, Siddhartha; Choi, John; Forde, Patrick M.; Brahmer, Julie R.; Ettinger, David S.; Feliciano, Josephine; Levy, Benjamin; Marrone, Kristen A.; Naidoo, Jarushka; Redmond, Kristin J.; Kleinberg, Lawrence; Lim, Michael

Year: 2021

Venue: Journal of neurosurgery

DOI: https://doi.org/10.3171/2020.10.jns201787

Paper Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

Miyashita, Hirotaka; Hong, David S. · 2024 · Journal of Cancer Immunology · DOI

Full title: Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

Authors: Miyashita, Hirotaka; Hong, David S.

Year: 2024

Venue: Journal of Cancer Immunology

DOI: https://doi.org/10.33696/cancerimmunol.6.086

Paper Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness

Ursino, Chiara; Mouric, Cécile; Gros, Laurent et al. · 2023 · Frontiers in Immunology · DOI

Full title: Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness

Authors: Ursino, Chiara; Mouric, Cécile; Gros, Laurent; Bonnefoy, Nathalie; Faget, Julien

Year: 2023

Venue: Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2023.1170321

Paper RAS: Striking at the Core of the Oncogenic Circuitry

Gimple, Ryan C.; Wang, Xiuxing · 2019 · Frontiers in Oncology · DOI

Full title: RAS: Striking at the Core of the Oncogenic Circuitry

Authors: Gimple, Ryan C.; Wang, Xiuxing

Year: 2019

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2019.00965

Paper Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

Tartarone, Alfredo; Lapadula, Vittoria; Micco, Concetta Di et al. · 2021 · Frontiers in Oncology · DOI

Full title: Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

Authors: Tartarone, Alfredo; Lapadula, Vittoria; Micco, Concetta Di; Rossi, Gemma; Ottanelli, Carlotta; Marini, Andrea; Giorgione, Roberta; Ferrari, Katia; Catalano, Martina; Voltolini, Luca; Mini, Enrico; Roviello, Giandomenico

Year: 2021

Venue: Frontiers in Oncology

DOI: https://doi.org/10.3389/fonc.2021.632256

Paper miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential

Yan, Hang; Tang, Shengjie; Tang, Shoujun et al. · 2022 · Frontiers in Pharmacology · DOI

Full title: miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential

Authors: Yan, Hang; Tang, Shengjie; Tang, Shoujun; Zhang, Jun; Guo, Haiyang; Qin, Chao; Hu, Haiyang; Zhong, Chuan; Li, Yang; Zhu, Yunhe; Zhou, Haining

Year: 2022

Venue: Frontiers in Pharmacology

DOI: https://doi.org/10.3389/fphar.2022.949566

Paper Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry

Huang, Richard S.P.; Severson, Eric A.; Haberberger, James et al. · 2021 · Pathology & Oncology Research · DOI

Full title: Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry

Authors: Huang, Richard S.P.; Severson, Eric A.; Haberberger, James; Duncan, Daniel; Hemmerich, Amanda; Edgerly, Claire; Ferguson, N. Lynn; Frampton, Garrett M.; Owens, Clarence; Williams, Erik A.; Elvin, Julia A.; Vergilio, Jo‐Anne; Killian, Jonathan Keith; Lin, Douglas I.; Morley, Samantha; McEwan, Deborah; Holmes, Oliver; Danziger, Natalie; Cohen, Michael B.; Sathyan, Pratheesh; McGregor, Kimberly; Reddy, Prasanth; Venstrom, Jeffrey M.; Anhorn, Rachel; Alexander, Brian M.; Brown, Charlotte A.; Ross, Jeffrey S.; Ramkissoon, Shakti

Year: 2021

Venue: Pathology & Oncology Research

DOI: https://doi.org/10.3389/pore.2021.592997

Paper KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges

Moldvay, Judit; Tı́már, József · 2024 · Pathology & Oncology Research · DOI

Full title: KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges

Authors: Moldvay, Judit; Tı́már, József

Year: 2024

Venue: Pathology & Oncology Research

DOI: https://doi.org/10.3389/pore.2023.1611580

Paper Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways

Vanshika Garg; Raphael N. H. M. Hofmann; Moazzam Saleem et al. · 2026 · Cells · DOI

Full title: Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways

Authors: Vanshika Garg; Raphael N. H. M. Hofmann; Moazzam Saleem; Amin Mirzaiebadizi; Ghazaleh Sadat Hashemi; Tooba Hameed; Bahareh Jooyeh; Silke Pudewell; Mehrnaz Mehrabipour; Niloufar Mosaddeghzadeh; Roland P Piekorz; M. R. Ahmadian

Year: 2026

Venue: Cells

DOI: https://doi.org/10.3390/cells15020190

Paper Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

P. Ulivi; A. Delmonte; E. Chiadini et al. · 2014 · International Journal of Molecular Sciences · DOI

Full title: Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

Authors: P. Ulivi; A. Delmonte; E. Chiadini; D. Calistri; M. Papi; M. Mariotti; A. Verlicchi; A. Ragazzini; L. Capelli; A. Gamboni; M. Puccetti; A. Dubini; M. Burgio; C. Casanova; L. Crinò; D. Amadori; C. Dazzi

Year: 2014

Venue: International Journal of Molecular Sciences

DOI: https://doi.org/10.3390/ijms16010747

Paper [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)].

· 2025 · Zhonghua yi xue za zhi · DOI

Full title: [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)].

Year: 2025

Venue: Zhonghua yi xue za zhi

DOI: https://doi.org/10.3760/cma.j.cn112137-20250511-01152

Paper [Annual therapeutic advances in advanced non-small cell lung cancer in 2024].

T. Luan; P. X. Shen; Y. H. Zhang et al. · 2025 · Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · DOI

Full title: [Annual therapeutic advances in advanced non-small cell lung cancer in 2024].

Authors: T. Luan; P. X. Shen; Y. H. Zhang; X. Xie; X. Q. Lin; M. Liu; J. Peng; H. Deng; S. Y. Wang; C. C. Wang; C. Z. Zhou

Year: 2025

Venue: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

DOI: https://doi.org/10.3760/cma.j.cn112147-20241103-00655

Paper [Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer].

W. Xu; X. Zhuo; L. Liu et al. · 2023 · Zhonghua zhong liu za zhi [Chinese journal of oncology] · DOI

Full title: [Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer].

Authors: W. Xu; X. Zhuo; L. Liu; J. Zhao; X. Y. Lin; G. Fu

Year: 2023

Venue: Zhonghua zhong liu za zhi [Chinese journal of oncology]

DOI: https://doi.org/10.3760/cma.j.cn112152-20220310-00167

Paper Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma

Ruizhu Sun; Zhansheng Hou; Yankui Zhang et al. · 2022 · Oncology Letters · DOI

Full title: Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma

Authors: Ruizhu Sun; Zhansheng Hou; Yankui Zhang; B. Jiang

Year: 2022

Venue: Oncology Letters

DOI: https://doi.org/10.3892/ol.2022.13528

Paper Molecular biology of lung cancer.

Cooper, Wendy A.; Lam, David; O’Toole, Sandra et al. · 2013 · PubMed · DOI

Full title: Molecular biology of lung cancer.

Authors: Cooper, Wendy A.; Lam, David; O’Toole, Sandra; Minna, John D.

Year: 2013

Venue: PubMed

DOI: https://doi.org/10.3978/j.issn.2072-1439.2013.08.03

Paper Adaptive resistance to targeted therapies in cancer.

R. Rosell; N. Karachaliou; D. Morales-espinosa et al. · 2013 · Translational Lung Cancer Research · DOI

Full title: Adaptive resistance to targeted therapies in cancer.

Authors: R. Rosell; N. Karachaliou; D. Morales-espinosa; C. Costa; M. Molina; I. Sansano; A. Gascó; S. Viteri; B. Massutí; Jia Wei; M. Gonzalez Cao; A. Martínez Bueno

Year: 2013

Venue: Translational Lung Cancer Research

DOI: https://doi.org/10.3978/j.issn.2218-6751.2012.12.08

Paper Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group

Chang, Sun Hee; Shim, Hyo Sup; Kim, Tae Jung et al. · 2021 · Journal of Pathology and Translational Medicine · DOI

Full title: Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group

Authors: Chang, Sun Hee; Shim, Hyo Sup; Kim, Tae Jung; Choi, Yoon‐La; Kim, Wan Seop; Shin, Dong Hoon; Kim, Lucia; Park, Heae Surng; Lee, Geon Kook; Lee, Chang Hun; Group, Korean Cardiopulmonary Pathology Study

Year: 2021

Venue: Journal of Pathology and Translational Medicine

DOI: https://doi.org/10.4132/jptm.2021.03.23

Paper Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer

Yoon, Shinkyo; Yang, Hannah; Ryu, Hyun-Min et al. · 2021 · Cancer Research and Treatment · DOI

Full title: Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer

Authors: Yoon, Shinkyo; Yang, Hannah; Ryu, Hyun-Min; Lee, Eun Jin; Jo, Yu‐Jin; Seo, Seyoung; Kim, Deokhoon; Lee, Chang Hoon; Kim, Wanlim; Jung, Kyung Hae; Park, Sook Ryun; Choi, Eun Kyung; Kim, Sang‐We; Park, Kang‐Seo; Lee, Dae Ho

Year: 2021

Venue: Cancer Research and Treatment

DOI: https://doi.org/10.4143/crt.2021.651

Paper Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Rivera‐Concepción, Joel; Uprety, Dipesh; Adjei, Alex A. · 2022 · Cancer Research and Treatment · DOI

Full title: Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Authors: Rivera‐Concepción, Joel; Uprety, Dipesh; Adjei, Alex A.

Year: 2022

Venue: Cancer Research and Treatment

DOI: https://doi.org/10.4143/crt.2022.078

Paper PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience

Mitiushkina, Natalia V.; Kholmatov, Maksim; Venina, Aigul R. et al. · 2018 · Neoplasma · DOI

Full title: PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience

Authors: Mitiushkina, Natalia V.; Kholmatov, Maksim; Venina, Aigul R.; Tiurin, Vladislav I.; Yanus, Grigoriy A.; Sokolova, Tatyana N.; Yatsuk, Olga S.; Zaitseva, Olga A.; Ivantsov, Alexandr O.; Kuligina, Ekatherina Sh.; Togo, Alexandr V.; Imyanitov, Evgeny N.

Year: 2018

Venue: Neoplasma

DOI: https://doi.org/10.4149/neo_2018_171225n843

Paper Targeting the Achilles’ heel of drug-resistant cancer stem cells

L. Seguin; M. Gozo; S. Weis et al. · 2014 · Cell Cycle · DOI

Full title: Targeting the Achilles’ heel of drug-resistant cancer stem cells

Authors: L. Seguin; M. Gozo; S. Weis; D. Cheresh

Year: 2014

Venue: Cell Cycle

DOI: https://doi.org/10.4161/cc.29460

Paper Efficacy and immune modulation of KRAS G12C inhibitor sotorasib in murine KRAS G12C mutant non-small cell lung cancers with major co-occurring genomic alterations

Zhou, Teng; Truong, M.; Araújo, Haniel A. et al. · 2022 · DOI

Full title: Efficacy and immune modulation of KRAS G12C inhibitor sotorasib in murine KRAS G12C mutant non-small cell lung cancers with major co-occurring genomic alterations

Authors: Zhou, Teng; Truong, M.; Araújo, Haniel A.; Lee, Richard; Skoulidis, Ferdinandos

Year: 2022

DOI: https://doi.org/10.52519/00100

Paper Tumour-Derived Extracellular Vesicles in Chemotherapy Resistance: Molecular Pathways, Clinical Implications and Therapeutic Opportunities

Rupali J. Ghule; Priyal N. Jadhav; Yogeshwari N. Sanap et al. · 2025 · Asian Journal of Research in Pharmaceutical Sciences · DOI

Full title: Tumour-Derived Extracellular Vesicles in Chemotherapy Resistance: Molecular Pathways, Clinical Implications and Therapeutic Opportunities

Authors: Rupali J. Ghule; Priyal N. Jadhav; Yogeshwari N. Sanap; Mukund Pache; A. Darekar

Year: 2025

Venue: Asian Journal of Research in Pharmaceutical Sciences

DOI: https://doi.org/10.52711/2231-5659.2025.00055

Paper Advances in Targeted Therapies for Non-Small Cell Lung Cancer: Current Trends and Challenges

Akhter Ali Khan; Qasim Nawaz; Fazal Ghani et al. · 2024 · Pakistan Journal of Medical & Health Sciences · DOI

Full title: Advances in Targeted Therapies for Non-Small Cell Lung Cancer: Current Trends and Challenges

Authors: Akhter Ali Khan; Qasim Nawaz; Fazal Ghani; Samid Ur Rehman; Burhan ullah; Z. U. Rehman

Year: 2024

Venue: Pakistan Journal of Medical & Health Sciences

DOI: https://doi.org/10.53350/pjmhs02024181492

Paper KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

D. Owen; B. Konda; J. Sipos et al. · 2019 · The Journal of the National Comprehensive Cancer Network · DOI

Full title: KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

Authors: D. Owen; B. Konda; J. Sipos; Tom Liu; A. Webb; M. Ringel; C. Timmers; M. Shah

Year: 2019

Venue: The Journal of the National Comprehensive Cancer Network

DOI: https://doi.org/10.6004/jnccn.2019.7292

Paper New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer

Gregory Riely · 2024 · The Journal of the National Comprehensive Cancer Network · DOI

Full title: New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer

Authors: Gregory Riely

Year: 2024

Venue: The Journal of the National Comprehensive Cancer Network

DOI: https://doi.org/10.6004/jnccn.2024.5007

Paper Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer

Deming, Dustin A. · 2025 · Journal of the National Comprehensive Cancer Network · DOI

Full title: Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer

Authors: Deming, Dustin A.

Year: 2025

Venue: Journal of the National Comprehensive Cancer Network

DOI: https://doi.org/10.6004/jnccn.2024.7067

Paper Lung Cancer in the Era of Precision Oncology

Othman Othman · 2025 · International Journal of Pathology and Biomarkers · DOI

Full title: Lung Cancer in the Era of Precision Oncology

Authors: Othman Othman

Year: 2025

Venue: International Journal of Pathology and Biomarkers

DOI: https://doi.org/10.71428/ijpb.2025.0104

Paper How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

B. Ricciuti; Alessia Mira; Elisa Andrini et al. · 2022 · Drugs in Context · DOI

Full title: How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Authors: B. Ricciuti; Alessia Mira; Elisa Andrini; Pietro Scaparone; S. V. Michelina; F. Pecci; L. Cantini; A. De Giglio; G. Lamberti; C. Ambrogio; G. Metro

Year: 2022

Venue: Drugs in Context

DOI: https://doi.org/10.7573/dic.2022-7-4

Paper [Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].

Suda, Kenichi; Mitsudomi, Tetsuya · 2022 · Kyobu geka. The Japanese journal of thoracic surgery

Full title: [Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].

Authors: Suda, Kenichi; Mitsudomi, Tetsuya

Year: 2022

Venue: Kyobu geka. The Japanese journal of thoracic surgery

Paper COMBINATION WITH BCA101 IMPROVES THE EFFICACY OF KRAS-G12C INHIBITOR AND OVERCOMES G12C INHIBITOR-INDUCED RESISTANCE IN LUNG AND COLON CANCER CELL LINES

Reshmi Nair; Veena Somasundaram; S. Krishn et al.

Full title: COMBINATION WITH BCA101 IMPROVES THE EFFICACY OF KRAS-G12C INHIBITOR AND OVERCOMES G12C INHIBITOR-INDUCED RESISTANCE IN LUNG AND COLON CANCER CELL LINES

Authors: Reshmi Nair; Veena Somasundaram; S. Krishn; Rachel Salazar

Paper Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer

Full title: Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer

Thesis TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

Palmer, Daniel H; Valle, Juan W; Ting Ma, Yuk et al. · 2020 · University of Liverpool · DOI

Full title: TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

Authors: Palmer, Daniel H; Valle, Juan W; Ting Ma, Yuk; Faluyi, Olusola; Neoptolemos, John P; Jensen Gjertsen, Trine; Iversen, Berit; Amund Eriksen, Jon; Moller, Anne-Sophie; Aksnes, Anne-Kirsti; Miller, Robert; Dueland, Svein

Year: 2020

Venue: University of Liverpool

DOI: oai:livrepository.liverpool.ac.uk:3130240

Thesis Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS

Narvaez, Ana J; Ber, Suzan; Crooks, Alex et al. · 2017 · University of Liverpool · DOI

Full title: Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS

Authors: Narvaez, Ana J; Ber, Suzan; Crooks, Alex; Emery, Amy; Hardwick, Bryn; Almeida, Estrella Guarino; Huggins, David J; Perera, David; Roberts-Thomson, Meredith; Azzarelli, Roberta; Hood, Fiona E; Prior, Ian A; Walker, David W; Boyce, Richard; Boyle, Robert G; Barker, Samuel P; Torrance, Christopher J; McKenzie, Grahame J; Venkitaraman, Ashok R

Year: 2017

Venue: University of Liverpool

DOI: oai:livrepository.liverpool.ac.uk:3009121

Thesis Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.

Eser, S; Reiff, N; Messer, M et al. · 2013 · Technical University of Munich (TUM) · DOI

Full title: Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.

Authors: Eser, S;Reiff, N;Messer, M;Seidler, B;Gottschalk, K;Dobler, M;Hieber, M;Arbeiter, A;Klein, S;Kong, B;Michalski, CW;Schlitter, AM;Esposito, I;Kind, AJ;Rad, L;Schnieke, AE;Baccarini, M;Alessi, DR;Rad, R;Schmid, RM;Schneider, G;Saur, D

Year: 2013

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1210723

Thesis Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases.

Pfarr, Nicole; Penzel, Roland; Klauschen, Frederick et al. · 2016 · Technical University of Munich (TUM) · DOI

Full title: Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases.

Authors: Pfarr, Nicole;Penzel, Roland;Klauschen, Frederick;Heim, Daniel;Brandt, Regine;Kazdal, Daniel;Jesinghaus, Moritz;Herpel, Esther;Schirmacher, Peter;Warth, Arne;Weichert, Wilko;Endris, Volker;Stenzinger, Albrecht

Year: 2016

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1322881

Thesis Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.

Gröschel, Stefan; Bommer, Martin; Hutter, Barbara et al. · 2016 · Technical University of Munich (TUM) · DOI

Full title: Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.

Authors: Gröschel, Stefan;Bommer, Martin;Hutter, Barbara;Budczies, Jan;Bonekamp, David;Heining, Christoph;Horak, Peter;Fröhlich, Martina;Uhrig, Sebastian;Hübschmann, Daniel;Geörg, Christina;Richter, Daniela;Pfarr, Nicole;Pfütze, Katrin;Wolf, Stephan;Schirmacher, Peter;Jäger, Dirk;von Kalle, Christof;Brors, Benedikt;Glimm, Hanno;Weichert, Wilko;Stenzinger, Albrecht;Fröhling, Stefan

Year: 2016

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1341209

Thesis Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in KRAS-Mutant Cancer Cells.

Erber, Johanna; Steiner, Joachim D; Isensee, Jörg et al. · 2019 · Technical University of Munich (TUM) · DOI

Full title: Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in KRAS-Mutant Cancer Cells.

Authors: Erber, Johanna;Steiner, Joachim D;Isensee, Jörg;Lobbes, Leonard A;Toschka, André;Beleggia, Filippo;Schmitt, Anna;Kaiser, Rainer W J;Siedek, Florian;Persigehl, Thorsten;Hucho, Tim;Reinhardt, Hans C

Year: 2019

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1591269

Thesis Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.

Ruess, Dietrich A; Heynen, Guus J; Ciecielski, Katrin J et al. · 2018 · Technical University of Munich (TUM) · DOI

Full title: Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.

Authors: Ruess, Dietrich A;Heynen, Guus J;Ciecielski, Katrin J;Ai, Jiaoyu;Berninger, Alexandra;Kabacaoglu, Derya;Görgülü, Kivanc;Dantes, Zahra;Wörmann, Sonja M;Diakopoulos, Kalliope N;Karpathaki, Angeliki F;Kowalska, Marlena;Kaya-Aksoy, Ezgi;Song, Liang;van der Laan, Eveline A Zeeuw;López-Alberca, María P;Nazaré, Marc;Reichert, Maximilian;Saur, Dieter;Erkan, Mert M;Hopt, Ulrich T;Sainz, Bruno;Birchmeier, Walter;Schmid, Roland M;Lesina, Marina;Algül, Hana

Year: 2018

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1588457

Thesis KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

Sebastian, Martin; Eberhardt, Wilfried E E; Hoffknecht, Petra et al. · 2021 · Technical University of Munich (TUM) · DOI

Full title: KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

Authors: Sebastian, Martin;Eberhardt, Wilfried E E;Hoffknecht, Petra;Metzenmacher, Martin;Wehler, Thomas;Kokowski, Konrad;Alt, Jürgen;Schütte, Wolfgang;Büttner, Reinhard;Heukamp, Lukas C;Stenzinger, Albrecht;Jänicke, Martina;Fleitz, Annette;Zacharias, Stefan;Dille, Stephanie;Hipper, Annette;Sandberg, Marlen;Weichert, Wilko;Groschek, Matthias;von der Heyde, Eyck;Rauh, Jacqueline;Dechow, Tobias;Thomas, Michael;Griesinger, Frank

Year: 2021

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1600871

Thesis Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells

Koch, Heiner; Wilhelm, Mathias; Ruprecht, Benjamin et al. · 2016 · Technical University of Munich (TUM) · DOI

Full title: Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells

Authors: Koch, Heiner;Wilhelm, Mathias;Ruprecht, Benjamin;Beck, Scarlet;Frejno, Martin;Klaeger, Susan;Kuster, Bernhard

Year: 2016

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1617054

Thesis Pkc Isozymes in Lung Cancer Development and Therapy Resistance

Abera, Mahlet · 2023 · University of Pennsylvania · DOI

Full title: Pkc Isozymes in Lung Cancer Development and Therapy Resistance

Authors: Abera, Mahlet

Year: 2023

Venue: University of Pennsylvania

DOI: https://repository.upenn.edu/handle/20.500.14332/27971

Thesis TUMOR SUPPRESSOR GENOTYPE INFLUENCES THE EXTENT AND MODE OF IMMUNOSURVEILLANCE IN LUNG CANCER

Adler, Keren, Mia · 2025 · University of Pennsylvania · DOI

Full title: TUMOR SUPPRESSOR GENOTYPE INFLUENCES THE EXTENT AND MODE OF IMMUNOSURVEILLANCE IN LUNG CANCER

Authors: Adler, Keren, Mia

Year: 2025

Venue: University of Pennsylvania

DOI: https://repository.upenn.edu/handle/20.500.14332/61698

Thesis Cancer genomics approaches elucidate tumor mutational and microenvironmental landscapes and dynamics

Campbell, Katie · 2018 · Washington University in St. Louis · DOI

Full title: Cancer genomics approaches elucidate tumor mutational and microenvironmental landscapes and dynamics

Authors: Campbell, Katie

Year: 2018

Venue: Washington University in St. Louis

DOI: https://openscholarship.wustl.edu/art_sci_etds/1694

Thesis Tumor Cells As Organizers Of The Tumor Microenvironment: Tumor Cell-Intrinsic Regulation Of Anti-Tumor Immunity In Pancreatic Cancer

Li, Jinyang · 2023 · University of Pennsylvania · DOI

Full title: Tumor Cells As Organizers Of The Tumor Microenvironment: Tumor Cell-Intrinsic Regulation Of Anti-Tumor Immunity In Pancreatic Cancer

Authors: Li, Jinyang

Year: 2023

Venue: University of Pennsylvania

DOI: https://repository.upenn.edu/handle/20.500.14332/30881

Thesis A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Zhang, Ziyang; Rohweder, Peter J.; Ongpipattanakul, Chayanid et al. · 2022 · Technical University of Denmark (DTU) · DOI

Full title: A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Authors: Zhang, Ziyang; Rohweder, Peter J.; Ongpipattanakul, Chayanid; Basu, Koli; Bohn, Markus-Frederik; Dugan, Eli J.; Steri, Veronica; Hann, Byron; Shokat, Kevan M.; Craik, Charles S.

Year: 2022

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/3ba88759-3ca2-4237-913b-e876eb08fc9a

Thesis Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation

Lourenço, J · 2024 · University of Oxford - ORA · DOI

Full title: Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation

Authors: Lourenço, J

Year: 2024

Venue: University of Oxford - ORA

DOI: oai:ora.ox.ac.uk:uuid:51e38f56-ddd4-4271-af13-cc8f3a999b75

Thesis A novel platform for mutation detection in colorectal cancer using a PNA-LNA molecular switch

Islam, Md Sajedul; Aktar, Sharmin; id_orcid 0000-0001-9483-8960 et al. · 2025 · Charles Sturt University - Research Output · DOI

Full title: A novel platform for mutation detection in colorectal cancer using a PNA-LNA molecular switch

Authors: Islam, Md Sajedul; Aktar, Sharmin; id_orcid 0000-0001-9483-8960; Moetamedirad, Neda; Xie, Nan; Lu, Cu Tai; Gopalan, Vinod; Lam, Alfred K.; Shiddiky, Muhammad J.A.; id_orcid 0000-0003-4526-4109

Year: 2025

Venue: Charles Sturt University - Research Output

DOI: https://researchoutput.csu.edu.au/en/publications/9f6ce7ca-f689-44e8-8b8e-cfa9fb67ce07

Thesis Atropisomeric fragments in drug discovery and probe compound development

Danet, B · 2022 · University of Oxford - ORA · DOI

Full title: Atropisomeric fragments in drug discovery and probe compound development

Authors: Danet, B

Year: 2022

Venue: University of Oxford - ORA

DOI: oai:ora.ox.ac.uk:uuid:8da426c4-f05a-40cf-9427-75fc74b9deb7

Thesis Correlation between KRAS mutation and CTLA-4 mRNA expression in circulating tumour cells:Clinical implications in colorectal cancer

Aktar, Sharmin; id_orcid 0000-0001-9483-8960; Islam, Farhadul et al. · 2023 · Charles Sturt University - Research Output · DOI

Full title: Correlation between KRAS mutation and CTLA-4 mRNA expression in circulating tumour cells:Clinical implications in colorectal cancer

Authors: Aktar, Sharmin; id_orcid 0000-0001-9483-8960; Islam, Farhadul; Cheng, Tracie; Gamage, Sujani Madhurika Kodagoda; Choudhury, Indra Neil; id_orcid 0000-0002-1575-584X; Islam, Md Sajedul; Lu, Cu Tai; Hamid, Faysal Bin; Ishida, Hirotaka; Abe, Ichiro; Xie, Nan; Gopalan, Vinod; Lam, Alfred K.

Year: 2023

Venue: Charles Sturt University - Research Output

DOI: https://researchoutput.csu.edu.au/en/publications/40ef0781-89de-4a4c-be85-dccf971f906c

Thesis An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

Vallejo, Adrian; Perurena, Naiara; Guruceaga, Elisabet et al. · 2017 · University of Copenhagen · DOI

Full title: An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

Authors: Vallejo, Adrian; Perurena, Naiara; Guruceaga, Elisabet; Mazur, Pawel K; Martinez-Canarias, Susana; Zandueta, Carolina; Valencia, Karmele; Arricibita, Andrea; Gwinn, Dana; Sayles, Leanne C; Chuang, Chen-Hua; Guembe, Laura; Bailey, Peter; Chang, David K; Biankin, Andrew; Ponz-Sarvise, Mariano; Andersen, Jesper B; Khatri, Purvesh; Bozec, Aline; Sweet-Cordero, E Alejandro; Sage, Julien; Lecanda, Fernando; Vicent, Silve

Year: 2017

Venue: University of Copenhagen

DOI: https://researchprofiles.ku.dk/da/publications/99fbaa75-4d02-4c45-9495-82783ec483bc

Thesis The influence of the gut microbiome on immune checkpoint blockade therapy of cancer

Xu, Liqin · 2021 · Technical University of Denmark (DTU) · DOI

Full title: The influence of the gut microbiome on immune checkpoint blockade therapy of cancer

Authors: Xu, Liqin

Year: 2021

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/4adf4b3f-8a85-4e9d-8398-be1eeaf84109

Thesis Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing

Demuth, Christina; Spindler, Karen-Lise Garm; Johansen, Julia S et al. · 2018 · University of Copenhagen · DOI

Full title: Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing

Authors: Demuth, Christina; Spindler, Karen-Lise Garm; Johansen, Julia S; Pallisgaard, Niels; Nielsen, Dorte; Hogdall, Estrid; Vittrup, Benny; Sorensen, Boe Sandahl

Year: 2018

Venue: University of Copenhagen

DOI: https://researchprofiles.ku.dk/da/publications/07bb75ce-dfc3-4100-aabe-884230ffd452

Thesis Oncogenic signaling pathways in pancreatic ductal adenocarcinoma

Agrawal, Rahul; Natarajan, Kedar Nath; id_orcid 0000-0002-9264-1280 · 2023 · Technical University of Denmark (DTU) · DOI

Full title: Oncogenic signaling pathways in pancreatic ductal adenocarcinoma

Authors: Agrawal, Rahul; Natarajan, Kedar Nath; id_orcid 0000-0002-9264-1280

Year: 2023

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/a6462722-94fd-4576-905c-137a10f05e14

Thesis Advances in the Molecular Landscape of Lung Cancer Brain Metastasis

Souza, Vanessa G. P. [UNESP]; de Araújo, Rachel Paes [UNESP]; Santesso, Mariana R. [UNESP] et al. · 2023 · Universidade Estadual Paulista (UNESP) · DOI

Full title: Advances in the Molecular Landscape of Lung Cancer Brain Metastasis

Authors: Souza, Vanessa G. P. [UNESP]; de Araújo, Rachel Paes [UNESP]; Santesso, Mariana R. [UNESP]; Seneda, Ana Laura [UNESP]; Minutentag, Iael W. [UNESP]; Felix, Tainara Francini [UNESP]; Hamamoto Filho, Pedro Tadao [UNESP]; Pewarchuk, Michelle E.; Brockley, Liam J.; Marchi, Fábio A.; Lam, Wan L.; Drigo, Sandra A. [UNESP]; Reis, Patricia P. [UNESP]

Year: 2023

Venue: Universidade Estadual Paulista (UNESP)

DOI: http://dx.doi.org/10.3390/cancers15030722

Thesis Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer

Parra, Edwin Roger; Jiang, Mei; Machado-Rugolo, Juliana et al. · 2021 · Universidade Estadual Paulista (UNESP) · DOI

Full title: Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer

Authors: Parra, Edwin Roger; Jiang, Mei; Machado-Rugolo, Juliana; Yaegashi, Lygia Bertalha; Prieto, Tabatha; Farhat, Cecilia; Sa, Vanessa Karen de [UNESP]; Nagai, Maria Aparecida [UNESP]; Cordeiro de Lima, Vladmir Claudio; Takagaki, Tereza; Terra, Ricardo; Fabro, Alexandre Todorovic; Capelozzi, Vera Luiza

Year: 2021

Venue: Universidade Estadual Paulista (UNESP)

DOI: http://dx.doi.org/10.5858/arpa.2019-0419-OA

Thesis A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Zhang, Ziyang; Rohweder, Peter J.; Ongpipattanakul, Chayanid et al. · 2022 · Technical University of Denmark (DTU) · DOI

Full title: A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Authors: Zhang, Ziyang; Rohweder, Peter J.; Ongpipattanakul, Chayanid; Basu, Koli; Bohn, Markus-Frederik; Dugan, Eli J.; Steri, Veronica; Hann, Byron; Shokat, Kevan M.; Craik, Charles S.

Year: 2022

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/3ba88759-3ca2-4237-913b-e876eb08fc9a

Thesis KRAS driver mutations and DNA methylation profiling in pancreatic cancer: from association with the immune cell microenvironment to theranostic biomarkers

Barbosa, Barbara Mitsuyasu [UNESP] · 2024 · Universidade Estadual Paulista (UNESP) · DOI

Full title: KRAS driver mutations and DNA methylation profiling in pancreatic cancer: from association with the immune cell microenvironment to theranostic biomarkers

Authors: Barbosa, Barbara Mitsuyasu [UNESP]

Year: 2024

Venue: Universidade Estadual Paulista (UNESP)

DOI: https://hdl.handle.net/11449/256876

Thesis Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Ng, Kevin; Boumelha, Jesse; Enfield, Katey SS et al. · 2024 · Imperial College London · DOI

Full title: Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Authors: Ng, Kevin; Boumelha, Jesse; Enfield, Katey SS; Almagro, Jorge L; Cha, Hongui M; Pich, Oriol; Karasaki, Takahiro; Moore, David; Salgado, Roberto; Sivakumar, Monica; Young, George; Molina-Arcas, Miriam L; de Carne Trecesson, Sophie; Anastasiou, Panayiotis; Fendler, Annika C; Au, Lewis; Shepherd, Scott TC; Martinez-Ruiz, Carlos; Puttick, Clare; Black, James RM; Watkins, Thomas BK; Kim, Hyemin; Shim, Seohee; Faulkner, Nikhil; Attig, Jan A; Veeriah, Selvaraju; Magno, Neil J; Ward, Sophia T; Frankell, Alexander; Al Bakir, Maise; Lim, Emilia; Hill, Mark; Wilson, Gareth; Cook, Daniel; Birkbak, Nicolai; Behrens, Axel; Yousaf, Nadia; Popat, Sanjay; Hackshaw, Allan; TRACERx, Consortium; CAPTURE, Consortium; Hiley, Crispin T; Litchfield, Kevin; McGranahan, Nicholas; Jamal-Hanjani, Mariam; Larkin, James; Lee, Se-Hoon; Turajlic, Samra; Swanton, Charles; Downward, Julian; Kassiotis, George

Year: 2024

Venue: Imperial College London

DOI: https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000991048500006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb

Thesis Emerging drivers in non-small cell lung cancer, is there a role for immunotherapy?—a narrative review

Brunetti, Leonardo; Santo, Valentina; Russano, Marco et al. · 2024 · Imperial College London · DOI

Full title: Emerging drivers in non-small cell lung cancer, is there a role for immunotherapy?—a narrative review

Authors: Brunetti, Leonardo; Santo, Valentina; Russano, Marco; Cortellini, Alessio; Galletti, Alessandro; Citarella, Fabrizio; Di Fazio, Giuseppina-Rita; Vendittelli, Alessia; La Cava, Giulia; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele

Year: 2024

Venue: Imperial College London

DOI: http://dx.doi.org/10.21037/pcm-22-33

Thesis Peptide inhibitors: breaking cancer code

Coburn, Fleur; Nsereko, Yanyamba; Armstrong, Amy et al. · 2025 · Imperial College London · DOI

Full title: Peptide inhibitors: breaking cancer code

Authors: Coburn, Fleur; Nsereko, Yanyamba; Armstrong, Amy; Al Musaimi, Othman

Year: 2025

Venue: Imperial College London

DOI: https://hdl.handle.net/10044/1/122026

Thesis Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach

Pender, A; Garcia-Murillas, I; Rana, S et al. · 2016 · Imperial College London · DOI

Full title: Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach

Authors: Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J

Year: 2016

Venue: Imperial College London

DOI: http://hdl.handle.net/10044/1/36632

Thesis Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer

Haghgoo, SM; Allameh, A; Mortaz, E et al. · 2017 · Imperial College London · DOI

Full title: Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer

Authors: Haghgoo, SM; Allameh, A; Mortaz, E; Garssen, J; Folkerts, G; Barnes, PJ; Adcock, IM

Year: 2017

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000351953800012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Minchom, A; Thavasu, P; Ahmad, Z et al. · 2017 · Imperial College London · DOI

Full title: A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Authors: Minchom, A; Thavasu, P; Ahmad, Z; Stewart, A; Georgiou, A; O'Brien, MER; Popat, S; Bhosle, J; Yap, TA; de Bono, J; Banerji, U

Year: 2017

Venue: Imperial College London

DOI: http://hdl.handle.net/10044/1/51768

Thesis Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines

Varshavi, Dorna; Varshavi, Dorsa; McCarthy, Nicola et al. · 2020 · Imperial College London · DOI

Full title: Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines

Authors: Varshavi, Dorna; Varshavi, Dorsa; McCarthy, Nicola; Veselkov, Kirill; Keun, Hector C; Everett, Jeremy R

Year: 2020

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000526305000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer

Middleton, G; Crack, LR; Popat, S et al. · 2016 · Imperial College London · DOI

Full title: The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer

Authors: Middleton, G; Crack, LR; Popat, S; Swanton, C; Hollingsworth, SJ; Buller, R; Walker, I; Carr, TH; Wherton, D; Billingham, LJ

Year: 2016

Venue: Imperial College London

DOI: http://hdl.handle.net/10044/1/36630

Thesis Molecular Approaches to Targeting Oncogenic KRAS and Ferroptosis

Feng, Huizhong · 2019 · Columbia University · DOI

Full title: Molecular Approaches to Targeting Oncogenic KRAS and Ferroptosis

Authors: Feng, Huizhong

Year: 2019

Venue: Columbia University

DOI: https://doi.org/10.7916/d8-ra7q-1110

Thesis Probing Cancer Targets and Therapeutic Mechanisms using Small Molecules

Zhang, Yan · 2019 · Columbia University · DOI

Full title: Probing Cancer Targets and Therapeutic Mechanisms using Small Molecules

Authors: Zhang, Yan

Year: 2019

Venue: Columbia University

DOI: https://doi.org/10.7916/D8WM2XC5

Thesis Computational design, synthesis, and biological evaluation of small molecule anti-cancer therapeutics

Welsch, Matthew Ernest · 2015 · Columbia University · DOI

Full title: Computational design, synthesis, and biological evaluation of small molecule anti-cancer therapeutics

Authors: Welsch, Matthew Ernest

Year: 2015

Venue: Columbia University

DOI: https://doi.org/10.7916/D8P84B9P

Thesis Analysis of Oncogenic Signal Transduction with Application to KRAS Signaling Pathways

Broyde, Joshua · 2018 · Columbia University · DOI

Full title: Analysis of Oncogenic Signal Transduction with Application to KRAS Signaling Pathways

Authors: Broyde, Joshua

Year: 2018

Venue: Columbia University

DOI: https://doi.org/10.7916/D8NZ8M76

Thesis Signaling and Feedback Networks Underlying Senstivity and Resistance to Kinase Inhibitors in Oncogene Addicted Cancers

Schrock, Alexa · 2013 · Harvard University - DASH · DOI

Full title: Signaling and Feedback Networks Underlying Senstivity and Resistance to Kinase Inhibitors in Oncogene Addicted Cancers

Authors: Schrock, Alexa

Year: 2013

Venue: Harvard University - DASH

DOI: http://dissertations.umi.com/gsas.harvard:10007

Thesis Identifying therapeutic vulnerabilities in RAS pathway–driven melanoma

Situ, Lisa · 2025 · Harvard University - DASH · DOI

Full title: Identifying therapeutic vulnerabilities in RAS pathway–driven melanoma

Authors: Situ, Lisa

Year: 2025

Venue: Harvard University - DASH

DOI: https://dash.harvard.edu/handle/1/42719652

Thesis The effects of Gly12 KRAS oncogenes are mutation and context specific

Sheth, Shikha Sameer · 2022 · Harvard University - DASH · DOI

Full title: The effects of Gly12 KRAS oncogenes are mutation and context specific

Authors: Sheth, Shikha Sameer

Year: 2022

Venue: Harvard University - DASH

DOI: https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37372213

Thesis Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

Zimmer, Lisa; Barlesi, Fabrice; Martinez-Garcia, Maria et al. · 2014 · Utrecht University · DOI

Full title: Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

Authors: Zimmer, Lisa; Barlesi, Fabrice; Martinez-Garcia, Maria; Dieras, Veronique; Schellens, Jan H M; Spano, Jean-Philippe; Middleton, Mark R; Calvo, Emiliano; Paz-Ares, Luiz; Larkin, James; Pacey, Simon; Venturi, Miro; Kraeber-Bodéré, Françoise; Tessier, Jean J L; Eberhardt, Wilfried Ernst Erich; Paques, Michel; Guarin, Ernesto; Meresse, Valerie; Soria, Jean-Charles

Year: 2014

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/308528

Thesis Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice

Hinrichs, John W. J.; Van Blokland, W. T. Marja; Moons, Michiel J. et al. · 2015 · Utrecht University · DOI

Full title: Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice

Authors: Hinrichs, John W. J.; Van Blokland, W. T. Marja; Moons, Michiel J.; Radersma, Remco D.; Radersma-Van Loon, Joyce H.; de Voijs, Carmen M. A.; Rappel, Sophie B.; Koudijs, Marco J.; Besselink, Nicolle J. M.; Willems, Stefan M.; de Weger, Roel A.

Year: 2015

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/331338

Thesis Covalent targeting of acquired cysteines in cancer

Visscher, Marieke; Arkin, Michelle R.; Dansen, Tobias B. · 2016 · Utrecht University · DOI

Full title: Covalent targeting of acquired cysteines in cancer

Authors: Visscher, Marieke; Arkin, Michelle R.; Dansen, Tobias B.

Year: 2016

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/333302

Thesis Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

van Geel, Robin M J M; van Brummelen, Emilie M J; Eskens, Ferry A L M et al. · 2020 · Utrecht University · DOI

Full title: Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Authors: van Geel, Robin M J M; van Brummelen, Emilie M J; Eskens, Ferry A L M; Huijberts, Sanne C F A; de Vos, Filip Y F L; Lolkema, Martijn P J K; Devriese, Lot A; Opdam, Frans L; Marchetti, Serena; Steeghs, Neeltje; Monkhorst, Kim; Thijssen, Bas; Rosing, Hilde; Huitema, Alwin D R; Beijnen, Jos H; Bernards, René; Schellens, Jan H M

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/395955

Thesis ABCB1 limits brain exposure of the KRAS G12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

Loos, Nancy H C; Retmana, Irene A; Li, Wenlong et al. · 2022 · Utrecht University · DOI

Full title: ABCB1 limits brain exposure of the KRAS G12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

Authors: Loos, Nancy H C; Retmana, Irene A; Li, Wenlong; Martins, Margarida L F; Lebre, Maria C; Sparidans, Rolf W; Beijnen, Jos H; Schinkel, Alfred H

Year: 2022

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/418392

Thesis Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

van Geel, Robin M J M; van Brummelen, Emilie M J; Eskens, Ferry A L M et al. · 2020 · Utrecht University · DOI

Full title: Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/411157

Thesis Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Huijberts, Sanne C F A; van Geel, Robin M J M; van Brummelen, Emilie M J et al. · 2020 · Utrecht University · DOI

Full title: Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Authors: Huijberts, Sanne C F A; van Geel, Robin M J M; van Brummelen, Emilie M J; Opdam, Frans L; Marchetti, Serena; Steeghs, Neeltje; Pulleman, Saskia; Thijssen, Bas; Rosing, Hilde; Monkhorst, Kim; Huitema, Alwin D R; Beijnen, Jos H; Bernards, René; Schellens, Jan H M

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/439731

Thesis ABCB1 limits brain exposure of the KRAS G12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

Loos, Nancy H C; Retmana, Irene A; Li, Wenlong et al. · 2022 · Utrecht University · DOI

Full title: ABCB1 limits brain exposure of the KRAS G12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

Authors: Loos, Nancy H C; Retmana, Irene A; Li, Wenlong; Martins, Margarida L F; Lebre, Maria C; Sparidans, Rolf W; Beijnen, Jos H; Schinkel, Alfred H

Year: 2022

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/419717

Thesis Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants

Post, Jasmin B; Roodhart, Jeanine M L; Snippert, Hugo J G · 2020 · Utrecht University · DOI

Full title: Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants

Authors: Post, Jasmin B; Roodhart, Jeanine M L; Snippert, Hugo J G

Year: 2020

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/440558

Thesis Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling

Ponsioen, Bas; Post, Jasmin B; Buissant des Amorie, Julian R et al. · 2021 · Utrecht University · DOI

Full title: Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling

Authors: Ponsioen, Bas; Post, Jasmin B; Buissant des Amorie, Julian R; Laskaris, Dimitrios; van Ineveld, Ravian L; Kersten, Simone; Bertotti, Andrea; Sassi, Francesco; Sipieter, François; Cappe, Benjamin; Mertens, Sander; Verlaan-Klink, Ingrid; Boj, Sylvia F; Vries, Rob G J; Rehmann, Holger; Vandenabeele, Peter; Riquet, Franck B; Trusolino, Livio; Bos, Johannes L; Snippert, Hugo J G

Year: 2021

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/442564

Thesis An engineered protein antagonist of K-Ras/B-Raf interaction

Parker, Jillian A.; Kiefer, Jonathan D.; Knihtila, Ryan et al. · 2017 · Massachusetts Institute of Technology (MIT) · DOI

Full title: An engineered protein antagonist of K-Ras/B-Raf interaction

Authors: Parker, Jillian A.; Kiefer, Jonathan D.; Knihtila, Ryan; McGee, John; Verdine, Greg; Mattos, Carla; Kauke, Monique Jacqueline; Traxlmayr, Michael; Wittrup, Karl Dane

Year: 2017

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/112691

Thesis Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

van Brummelen, Emilie M.J.; Huijberts, Sanne; van Herpen, Carla et al. · 2021 · Utrecht University · DOI

Full title: Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

Authors: van Brummelen, Emilie M.J.; Huijberts, Sanne; van Herpen, Carla; Desar, Ingrid; Opdam, Frans; van Geel, Robin; Marchetti, Serena; Steeghs, Neeltje; Monkhorst, Kim; Thijssen, Bas; Rosing, Hilde; Huitema, Alwin; Beijnen, Jos; Bernards, Rene; Schellens, Jan

Year: 2021

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/456165

Thesis AMPK promotes tolerance to Ras pathway inhibition by activating autophagy

Sanduja, S; Feng, Y; Reinhardt, F et al. · 2018 · Massachusetts Institute of Technology (MIT) · DOI

Full title: AMPK promotes tolerance to Ras pathway inhibition by activating autophagy

Authors: Sanduja, S; Feng, Y; Reinhardt, F; Halaban, R; Mathis, Robert Austin; Sokol, Ethan Samuel; Gupta, Piyush

Year: 2018

Venue: Massachusetts Institute of Technology (MIT)

DOI: http://hdl.handle.net/1721.1/117558

Thesis Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling

Nguyen, Kim Bich; Spranger, Stefani · 2021 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling

Authors: Nguyen, Kim Bich; Spranger, Stefani

Year: 2021

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/135977

Thesis The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

Schoenfeld, Adam J.; Bandlamudi, Chai; Lavery, Jessica A. et al. · 2022 · Massachusetts Institute of Technology (MIT) · DOI

Full title: The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

Authors: Schoenfeld, Adam J.; Bandlamudi, Chai; Lavery, Jessica A.; Montecalvo, Joseph; Namakydoust, Azadeh; Rizvi, Hira; Egger, Jacklynn; Concepcion, Carla P.; Paul, Sonal; Arcila, Maria E.; Daneshbod, Yahya; Chang, Jason; Sauter, Jennifer L.; Beras, Amanda; Ladanyi, Marc; Jacks, Tyler; Rudin, Charles M.; Taylor, Barry S.; Donoghue, Mark T.A.; Heller, Glenn; Hellmann, Matthew D.; Rekhtman, Natasha; Riely, Gregory J.

Year: 2022

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/134622.2

Thesis The metabolic landscape of RAS-driven cancers from biology to therapy

Mukhopadhyay, Suman; Vander Heiden, Matthew G; McCormick, Frank · 2021 · Massachusetts Institute of Technology (MIT) · DOI

Full title: The metabolic landscape of RAS-driven cancers from biology to therapy

Authors: Mukhopadhyay, Suman; Vander Heiden, Matthew G; McCormick, Frank

Year: 2021

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/136166

Thesis Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy

Wang, Stephanie J; Li, Ran; Ng, Thomas SC et al. · 2022 · Massachusetts Institute of Technology (MIT) · DOI

Full title: Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy

Authors: Wang, Stephanie J; Li, Ran; Ng, Thomas SC; Luthria, Gaurav; Oudin, Madeleine J; Prytyskach, Mark; Kohler, Rainer H; Weissleder, Ralph; Lauffenburger, Douglas A; Miller, Miles A

Year: 2022

Venue: Massachusetts Institute of Technology (MIT)

DOI: https://hdl.handle.net/1721.1/136159.2

Thesis Combined Computational, Experimental, and Assay-Development Studies of Protein:Protein and Protein:Small Molecule Complexes, with Applications to the Inhibition of Enzymes and Protein:Protein Interactions

Frenkel, Marcel · 2020 · Duke University · DOI

Full title: Combined Computational, Experimental, and Assay-Development Studies of Protein:Protein and Protein:Small Molecule Complexes, with Applications to the Inhibition of Enzymes and Protein:Protein Interactions

Authors: Frenkel, Marcel

Year: 2020

Venue: Duke University

DOI: https://hdl.handle.net/10161/20091

Thesis Functional screening to define apoptosis-inducing precision cancer therapies

Anderson, Grace · 2019 · Duke University · DOI

Full title: Functional screening to define apoptosis-inducing precision cancer therapies

Authors: Anderson, Grace

Year: 2019

Venue: Duke University

DOI: https://hdl.handle.net/10161/18244

Thesis Overcoming Therapeutic Resistance by Targeting Oncogene-Driven and Targeted-Therapy Induced Cancer Dependencies

Ali, Moiez · 2021 · Duke University · DOI

Full title: Overcoming Therapeutic Resistance by Targeting Oncogene-Driven and Targeted-Therapy Induced Cancer Dependencies

Authors: Ali, Moiez

Year: 2021

Venue: Duke University

DOI: https://hdl.handle.net/10161/22949

Thesis Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient

Dazert, E.; Colombi, M.; Boldanova, T. et al. · 2025 · University of Basel - edoc Repository · DOI

Full title: Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient

Authors: Dazert, E.; Colombi, M.; Boldanova, T.; Moes, S.; Adametz, D.; Quagliata, L.; Roth, V.; Terracciano, L.; Heim, M. H.; Jenoe, P.; Hall, M. N.

Year: 2025

Venue: University of Basel - edoc Repository

DOI: http://hdl.handle.net/20.500.14716/5718

Thesis Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment

Kirchhammer, N; Trefny, MP; Auf, der Maur P et al. · 2025 · University of Basel - edoc Repository · DOI

Full title: Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment

Authors: Kirchhammer, N; Trefny, MP; Auf, der Maur P; Läubli, H; Zippelius, A

Year: 2025

Venue: University of Basel - edoc Repository

DOI: https://hdl.handle.net/20.500.14716/57799

Thesis Towards Tumor Cell Specific Proteolysis Targeting Chimeras: Identification of Oncogenic KRASG12C, DcpS, and MAGE-A3 Degraders

Bond, Michael Joseph · 2022 · Yale University · DOI

Full title: Towards Tumor Cell Specific Proteolysis Targeting Chimeras: Identification of Oncogenic KRASG12C, DcpS, and MAGE-A3 Degraders

Authors: Bond, Michael Joseph

Year: 2022

Venue: Yale University

DOI: https://elischolar.library.yale.edu/gsas_dissertations/455

Thesis Multimodal Characterization of Evolution of Resistance in Lung Cancer

Cech, Lauren · 2025 · University of California, San Francisco (UCSF) · DOI

Full title: Multimodal Characterization of Evolution of Resistance in Lung Cancer

Authors: Cech, Lauren

Year: 2025

Venue: University of California, San Francisco (UCSF)

DOI: https://escholarship.org/uc/item/1mn3t8gm

Thesis Novel Biosensor Designs to Report Endogenous Ras Activity in Living Cells

Weeks, Ryan Neal · 2024 · University of California, San Diego (UCSD) · DOI

Full title: Novel Biosensor Designs to Report Endogenous Ras Activity in Living Cells

Authors: Weeks, Ryan Neal

Year: 2024

Venue: University of California, San Diego (UCSD)

DOI: https://escholarship.org/uc/item/3913v3s7

Thesis ROR1 - a druggable target : preclinical studies of ROR1 and combinatorial partners in malignancies

Amineh Ghaderi (18665794) · 2021 · Karolinska Institutet · DOI

Full title: ROR1 - a druggable target : preclinical studies of ROR1 and combinatorial partners in malignancies

Authors: Amineh Ghaderi (18665794)

Year: 2021

Venue: Karolinska Institutet

DOI: oai:figshare.com:article/26947300

Thesis Unravelling Lung Cancer Heterogeneity and Associated Therapeutic Responses using in vivo and ex vivo Model Systems

Nagaraj, Ashwini Sakrepatna · 2018 · University of Helsinki (HELDA) · DOI

Full title: Unravelling Lung Cancer Heterogeneity and Associated Therapeutic Responses using in vivo and ex vivo Model Systems

Authors: Nagaraj, Ashwini Sakrepatna

Year: 2018

Venue: University of Helsinki (HELDA)

DOI: http://hdl.handle.net/10138/262131

Thesis The use of Affimers to explore RAS biology and inform small molecule design

Turner, Amy Louise · 2022 · White Rose eTheses (Leeds, Sheffield, York) · DOI

Full title: The use of Affimers to explore RAS biology and inform small molecule design

Authors: Turner, Amy Louise

Year: 2022

Venue: White Rose eTheses (Leeds, Sheffield, York)

DOI: oai:etheses.whiterose.ac.uk:32371

Thesis Precision medicine for lung cancer : models, functional assays and mechanisms

Talwelkar, Sarang · 2021 · University of Helsinki (HELDA) · DOI

Full title: Precision medicine for lung cancer : models, functional assays and mechanisms

Authors: Talwelkar, Sarang

Year: 2021

Venue: University of Helsinki (HELDA)

DOI: http://hdl.handle.net/10138/336006

Thesis Oncogenic mutations as biomarkers and therapeutic targets in lung cancer

Lam, Chi-leung, David; 林志良 · 2015 · University of Hong Kong · DOI

Full title: Oncogenic mutations as biomarkers and therapeutic targets in lung cancer

Authors: Lam, Chi-leung, David; 林志良

Year: 2015

Venue: University of Hong Kong

DOI: https://hub.hku.hk/handle/10722/207610

Thesis Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Kapoor, Avnish; Yao, Wantong; Ying, Haoqiang et al. · 2014 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Authors: Kapoor, Avnish; Yao, Wantong; Ying, Haoqiang; Hua, Sujun; Liewen, Alison; Wang, Qiuyun; Zhong, Yi; Wu, Chang-Jiun; Sadanandam, Anguraj; Hu, Baoli; Chang, Qing; Chu, Gerald C.; Al-Khalil, Ramsey; Jiang, Shan; Xia, Hongai; Fletcher-Sananikone, Eliot; Lim, Carol; Horwitz, Gillian I.; Viale, Andrea; Pettazzoni, Piergiorgio; Sanchez, Nora; Wang, Huamin; Protopopov, Alexei; Zhang, Jianhua; Heffernan, Timothy; Johnson, Randy L.; Chin, Lynda; Wang, Y. Alan; Draetta, Giulio; Depinho, Ronald A.

Year: 2014

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/107908

Thesis Targeting pathways downstream of KRAS in lung adenocarcinoma

Zhu, Zehua; Golay, Hadrien G.; Barbie, David A. · 2014 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Targeting pathways downstream of KRAS in lung adenocarcinoma

Authors: Zhu, Zehua; Golay, Hadrien G.; Barbie, David A.

Year: 2014

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/109577

Thesis COMBINATION IMMUNOTHERAPY TARGETING IMMUNOSUPPRESSIVE SIGNALS IN THE TUMOR MICROENVIRONMENT PREVENTS CANCER PROGRESSION IN BREAST AND PANCREATIC CANCER

Keenan, Bridget P. · 2015 · Johns Hopkins University · DOI

Full title: COMBINATION IMMUNOTHERAPY TARGETING IMMUNOSUPPRESSIVE SIGNALS IN THE TUMOR MICROENVIRONMENT PREVENTS CANCER PROGRESSION IN BREAST AND PANCREATIC CANCER

Authors: Keenan, Bridget P.

Year: 2015

Venue: Johns Hopkins University

DOI: http://jhir.library.jhu.edu/handle/1774.2/37977

Thesis Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases

Murone, Maximilien; Chessex, Anne Vaslin; Attinger, Antoine et al. · 2016 · École polytechnique fédérale de Lausanne (EPFL) · DOI

Full title: Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases

Authors: Murone, Maximilien; Chessex, Anne Vaslin; Attinger, Antoine; Ramachandra, Raghuveer; Shetty, Shankar J.; Daginakatte, Girish; Sengupta, Saumitra; Marappan, Sivapriya; Dhodheri, Samiulla; Rigotti, Stefania; Bachhav, Yogeshwar; Brienza, Silvano; Traxler, Peter; Lang, Marc; Aguet, Michel; Zoete, Vincent; Michielin, Olivier; Nicholas, Courtney; Johnson, Faye M.; Ramachandra, Murali; Mcallister, Andres

Year: 2016

Venue: École polytechnique fédérale de Lausanne (EPFL)

DOI: https://infoscience.epfl.ch/handle/20.500.14299/131436

Thesis Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma

Hyslop, SR; Alexander, M; Thai, AA et al. · 2020 · University of Melbourne · DOI

Full title: Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma

Authors: Hyslop, SR; Alexander, M; Thai, AA; Kersbergen, A; Kueh, AJ; Herold, MJ; Corbin, J; Gangatirkar, P; Ng, AP; Solomon, BJ; Alexander, WS; Sutherland, KD; Josefsson, EC

Year: 2020

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/240564

Thesis INVESTIGATING MECHANISMS OF TUMOR PROGRESSION AND RESISTANCE TO CHEMORADIOTHERAPY IN LUNG CANCER

Nguyen, Triet · 2025 · Johns Hopkins University · DOI

Full title: INVESTIGATING MECHANISMS OF TUMOR PROGRESSION AND RESISTANCE TO CHEMORADIOTHERAPY IN LUNG CANCER

Authors: Nguyen, Triet

Year: 2025

Venue: Johns Hopkins University

DOI: https://jscholarship.library.jhu.edu/handle/1774.2/71069

Thesis Targeting Ras Neoantigens with Novel Cancer Immunotherapies

DiNapoli, Sarah R · 2025 · Johns Hopkins University · DOI

Full title: Targeting Ras Neoantigens with Novel Cancer Immunotherapies

Authors: DiNapoli, Sarah R

Year: 2025

Venue: Johns Hopkins University

DOI: https://jscholarship.library.jhu.edu/handle/1774.2/70597

Thesis Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Cui, W; Franchini, F; Alexander, M et al. · 2021 · University of Melbourne · DOI

Full title: Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Authors: Cui, W; Franchini, F; Alexander, M; Officer, A; Wong, HL; IJzerman, M; Desai, J; Solomon, BJ

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/264445

Thesis KrAsG12C inhibition with sotorasib in advanced solid tumors

Hong, DS; Fakih, MG; Strickler, JH et al. · 2021 · University of Melbourne · DOI

Full title: KrAsG12C inhibition with sotorasib in advanced solid tumors

Authors: Hong, DS; Fakih, MG; Strickler, JH; Desai, J; Durm, GA; Shapiro, GI; Falchook, GS; Price, TJ; Sacher, A; Denlinger, CS; Bang, YJ; Dy, GK; Krauss, JC; Kuboki, Y; Kuo, JC; Coveler, AL; Park, K; Kim, TW; Barlesi, F; Munster, PN; Ramalingam, SS; Burns, TF; Meric-Bernstam, F; Henary, H; Ngang, J; Ngarmchamnanrith, G; Kim, J; Houk, BE; Canon, J; Russell Lipford, J; Friberg, G; Lito, P; Govindan, R; Li, BT

Year: 2021

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/281546

Thesis Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer

Best, SA; Gubser, PM; Sethumadhavan, S et al. · 2022 · University of Melbourne · DOI

Full title: Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer

Authors: Best, SA; Gubser, PM; Sethumadhavan, S; Kersbergen, A; Negrón Abril, YL; Goldford, J; Sellers, K; Abeysekera, W; Garnham, AL; McDonald, JA; Weeden, CE; Anderson, D; Pirman, D; Roddy, TP; Creek, DJ; Kallies, A; Kingsbury, G; Sutherland, KD

Year: 2022

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/310765

Thesis SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Jones, Greg G; del Rio, Isabel Boned; Sari, Sibel et al. · 2021 · Imperial College London · DOI

Full title: SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Authors: Jones, Greg G; del Rio, Isabel Boned; Sari, Sibel; Sekerim, Aysen; Young, Lucy C; Hartig, Nicole; Zubiaur, Itziar Areso; El-Bahrawy, Mona A; Hynds, Rob E; Lei, Winnie; Molina-Arcas, Miriam; Downward, Julian; Rodriguez-Viciana, Pablo

Year: 2021

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000470850000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis Severe immune checkpoint inhibitor hepatitis in KRAS G12C-mutant NSCLC potentially triggered by sotorasib: case report

Begum, Parvin; Goldin, Robert D; Possamai, Lucia A et al. · 2021 · Imperial College London · DOI

Full title: Severe immune checkpoint inhibitor hepatitis in KRAS G12C-mutant NSCLC potentially triggered by sotorasib: case report

Authors: Begum, Parvin; Goldin, Robert D; Possamai, Lucia A; Popat, Sanjay

Year: 2021

Venue: Imperial College London

DOI: https://www.ncbi.nlm.nih.gov/pubmed/34590053

Thesis Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Capelan, M; Roda, D; Geuna, E et al. · 2017 · Imperial College London · DOI

Full title: Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Authors: Capelan, M; Roda, D; Geuna, E; Rihawi, K; Bodla, S; Kaye, SB; Bhosle, J; Banerji, U; O'Brien, M; de Bono, JS; Popat, S; Yap, TA

Year: 2017

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411302900002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.

Guo, Christina; Chénard-Poirier, Maxime; Roda, Desamparados et al. · 2020 · University of Cambridge · DOI

Full title: Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.

Authors: Guo, Christina; Chénard-Poirier, Maxime; Roda, Desamparados; de Miguel, Maria; Harris, Samuel J; Candilejo, Irene Moreno; Sriskandarajah, Priya; Xu, Wen; Scaranti, Mariana; Constantinidou, Anastasia; King, Jenny; Parmar, Mona; Turner, Alison J; Carreira, Suzanne; Riisnaes, Ruth; Finneran, Laura; Hall, Emma; Ishikawa, Yuji; Nakai, Kiyohiko; Tunariu, Nina; Basu, Bristi; Kaiser, Martin; Lopez, Juanita Suzanne; Minchom, Anna; de Bono, Johann S; Banerji, Udai

Year: 2020

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/312255

Thesis Anticancer targeted agent combination

Braña García, Irene · 2017 · Universitat Autònoma de Barcelona (TDX) · DOI

Full title: Anticancer targeted agent combination

Authors: Braña García, Irene

Year: 2017

Venue: Universitat Autònoma de Barcelona (TDX)

DOI: http://hdl.handle.net/10803/457506

Thesis Inhibition of prenylated KRAS in a lipid environment

Jansen, Johanna M.; Wartchow, Charles; Jahnke, Wolfgang et al. · 2017 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: Inhibition of prenylated KRAS in a lipid environment

Authors: Jansen, Johanna M.; Wartchow, Charles; Jahnke, Wolfgang; Fong, Susan; Tsang, Tiffany; Zavorotinskaya, Tatiana; Bussiere, Dirksen; Cheng, Jan Marie; Crawford, Kenneth; Dai, Yumin; Dove, Jeffrey; Fang, Eric; Feng, Yun; Florent, Jean-Michel; Fuller, John; Gossert, Alvar Diego; id_orcid0000-0001-7732-495X; Hekmat-Nejad, Mohammad; Henry, Chrystèle; Klopp, Julia; Lenahan, William P.; Lingel, Andreas; Ma, Sylvia; Meyer, Arndt; Mishina, Yuji; Narberes, Jamie; Pardee, Gwynn; Ramurthy, Savithri; Rieffel, Sebastien; Stuart, Darrin; Subramanian, Sharadha; Tandeske, Laura; Widger, Stephania; Widmer, Armin; Winterhalter, Aurelie; Zaror, Isabel; Hardy, Stephen

Year: 2017

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/362530

Thesis Molecular homology between canine spontaneous oral squamous cell carcinomas and human head-and-neck squamous cell carcinomas reveals disease drivers and therapeutic vulnerabilities

Guscetti, Franco; https://orcid.org/0000-0002-3173-4811; Nassiri, Sina et al. · 2020 · Vetsuisse Faculty Bern and Zurich · DOI

Full title: Molecular homology between canine spontaneous oral squamous cell carcinomas and human head-and-neck squamous cell carcinomas reveals disease drivers and therapeutic vulnerabilities

Authors: Guscetti, Franco; https://orcid.org/0000-0002-3173-4811; Nassiri, Sina; Beebe, Erin; Rito Brandao, Inês; Graf, Ramona; Markkanen, Enni; https://orcid.org/0000-0001-7780-8233

Year: 2020

Venue: Vetsuisse Faculty Bern and Zurich

DOI: oai:www.zora.uzh.ch:20.500.14742/174159

Thesis $\textit{N}$MR$^2$-Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS

Bütikofer, Matthias; Torres, Felix; Kadavath, Harindranath et al. · 2025 · ETH Zurich (Swiss Federal Institute of Technology in Zurich) · DOI

Full title: $\textit{N}$MR$^2$-Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS

Authors: Bütikofer, Matthias; Torres, Felix; Kadavath, Harindranath; id_orcid0000-0002-4559-4389; Gämperli, Nina; Abi Saad, Marie Jose; Zindel, Daniel; id_orcid0000-0002-4559-4389; Coudevylle, Nicolas; Riek, Roland; id_orcid0000-0002-4559-4389; Orts, Julien

Year: 2025

Venue: ETH Zurich (Swiss Federal Institute of Technology in Zurich)

DOI: http://hdl.handle.net/20.500.11850/744839

Thesis Oncogenic Signaling Pathways in The Cancer Genome Atlas

Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua et al. · 2018 · Utrecht University · DOI

Full title: Oncogenic Signaling Pathways in The Cancer Genome Atlas

Authors: Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua; Chatila, Walid K.; Luna, Augustin; La, Konnor C.; Dimitriadoy, Sofia; Liu, David L.; Kantheti, Havish S.; Saghafinia, Sadegh; Chakravarty, Debyani; Daian, Foysal; Gao, Qingsong; Bailey, Matthew H.; Liang, Wen Wei; Foltz, Steven M.; Shmulevich, Ilya; Ding, Li; Heins, Zachary J.; Ochoa, Angelica; Gross, Benjamin E.; Gao, Jianjiong; Zhang, Hongxin; Kundra, Ritika; Kandoth, Cyriac; Bahceci, Istemi; Dervishi, Leonard; Dogrusoz, Ugur; Zhou, Wanding; Shen, Hui; Laird, Peter W.; Way, Gregory P.; Greene, Casey S.; Liang, Han; Xiao, Yonghong; Wang, Chen; Iavarone, Antonio; Berger, Alice H.; Bivona, Trever G.; Lazar, Alexander J.; Hammer, Gary D.; Giordano, Thomas; Kwong, Lawrence N.; McArthur, Grant; Huang, Chenfei; Tward, Aaron D.; Frederick, Mitchell J.; McCormick, Frank; Zhang, Jiashan (Julia); de Krijger, Ronald; The Cancer Genome Atlas Research Network

Year: 2018

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/363899

Thesis A pan-cancer analysis of the microbiome in metastatic cancer

Battaglia, Thomas W.; Mimpen, Iris L.; Traets, Joleen J.H. et al. · 2024 · Utrecht University · DOI

Full title: A pan-cancer analysis of the microbiome in metastatic cancer

Authors: Battaglia, Thomas W.; Mimpen, Iris L.; Traets, Joleen J.H.; van Hoeck, Arne; Zeverijn, Laurien J.; Geurts, Birgit S.; de Wit, Gijs F.; Noë, Michaël; Hofland, Ingrid; Vos, Joris L.; Cornelissen, Sten; Alkemade, Maartje; Broeks, Annegien; Zuur, Charlotte L.; Cuppen, Edwin; Wessels, Lodewyk; van de Haar, Joris; Voest, Emile

Year: 2024

Venue: Utrecht University

DOI: https://dspace.library.uu.nl/handle/1874/455119

Thesis Mutations of epidermal growth factor receptor (EGFR) pathway genes andMET in primary lung adenocarcinoma

Ho, Ka-yan, Rebecca Lucinda.; 何嘉茵. · 2012 · University of Hong Kong · DOI

Full title: Mutations of epidermal growth factor receptor (EGFR) pathway genes andMET in primary lung adenocarcinoma

Authors: Ho, Ka-yan, Rebecca Lucinda.; 何嘉茵.

Year: 2012

Venue: University of Hong Kong

DOI: https://hub.hku.hk/handle/10722/173950

Thesis ctDNA monitoring using patient-specific sequencing and integration of variant reads

Wan, JCM; Heider, K; Gale, D et al. · 2020 · University of Melbourne · DOI

Full title: ctDNA monitoring using patient-specific sequencing and integration of variant reads

Authors: Wan, JCM; Heider, K; Gale, D; Murphy, S; Fisher, E; Mouliere, F; Ruiz-Valdepenas, A; Santonja, A; Morris, J; Chandrananda, D; Marshall, A; Gill, AB; Chan, PY; Barker, E; Young, G; Cooper, WN; Hudecova, I; Marass, F; Mair, R; Brindle, KM; Stewart, GD; Abraham, JE; Caldas, C; Rassl, DM; Rintoul, RC; Alifrangis, C; Middleton, MR; Gallagher, FA; Parkinson, C; Durrani, A; McDermott, U; Smith, CG; Massie, C; Corrie, PG; Rosenfeld, N

Year: 2020

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/254094

Thesis CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Armstrong, AJ; Geva, R; Chung, HC et al. · 2024 · University of Melbourne · DOI

Full title: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Authors: Armstrong, AJ; Geva, R; Chung, HC; Lemech, C; Miller, WH; Hansen, AR; Lee, JS; Tsai, F; Solomon, BJ; Kim, TM; Rolfo, C; Giranda, V; Ren, Y; Liu, F; Kandala, B; Freshwater, T; Wang, JS

Year: 2024

Venue: University of Melbourne

DOI: https://hdl.handle.net/11343/348440

Thesis Biomarkers along the continuum of care in lung cancer

Holdenrieder, S · 2016 · Technical University of Munich (TUM) · DOI

Full title: Biomarkers along the continuum of care in lung cancer

Authors: Holdenrieder, S

Year: 2016

Venue: Technical University of Munich (TUM)

DOI: https://mediatum.ub.tum.de/1344596

Thesis PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis and Anoikis

Bean, Gregory · 2014 · Washington University in St. Louis · DOI

Full title: PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis and Anoikis

Authors: Bean, Gregory

Year: 2014

Venue: Washington University in St. Louis

DOI: https://openscholarship.wustl.edu/art_sci_etds/79

Thesis Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

Borch, Annie; Bjerregaard, Anne Mette; Araujo Barbosa de Lima, Vinicius et al. · 2023 · Technical University of Denmark (DTU) · DOI

Full title: Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

Authors: Borch, Annie; Bjerregaard, Anne Mette; Araujo Barbosa de Lima, Vinicius; Østrup, Olga; Yde, Christina Westmose; Eklund, Aron Charles; Mau-Sørensen, Morten; Barra, Carolina; id_orcid 0000-0002-6836-4906; Svane, Inge Marie; Nielsen, Finn Cilius; Funt, Samuel A.; Lassen, Ulrik; Hadrup, Sine Reker; id_orcid 0000-0002-5937-4344

Year: 2023

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/6f236ce4-64f3-4b8e-931d-050ca22e0acc

Thesis Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

Borch, Annie; Bjerregaard, Anne Mette; Araujo Barbosa de Lima, Vinicius et al. · 2023 · Technical University of Denmark (DTU) · DOI

Full title: Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

Year: 2023

Venue: Technical University of Denmark (DTU)

DOI: https://orbit.dtu.dk/en/publications/6f236ce4-64f3-4b8e-931d-050ca22e0acc

Thesis Advanced liquid biopsy technologies for circulating biomarker detection

Soda, Narshone; Rehm, Bernd H.A.; Sonar, Prashant et al. · 2019 · Charles Sturt University - Research Output · DOI

Full title: Advanced liquid biopsy technologies for circulating biomarker detection

Authors: Soda, Narshone; Rehm, Bernd H.A.; Sonar, Prashant; Nguyen, Nam Trung; Shiddiky, Muhammad J.A.; id_orcid 0000-0003-4526-4109

Year: 2019

Venue: Charles Sturt University - Research Output

DOI: https://researchoutput.csu.edu.au/en/publications/b52348da-8d4d-4ff7-8899-56cb3ddfd51a

Thesis Validation of surrogate endpoints used in clinical trials of immune checkpoint inhibitors and targeted therapies in advanced cancers

Kok, Peey Sei · 2023 · University of Sydney · DOI

Full title: Validation of surrogate endpoints used in clinical trials of immune checkpoint inhibitors and targeted therapies in advanced cancers

Authors: Kok, Peey Sei

Year: 2023

Venue: University of Sydney

DOI: https://hdl.handle.net/2123/31296

Thesis Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors

Pannuti, Antonio; Filipovic, Aleksandra; Hicks, Chindo et al. · 2018 · Imperial College London · DOI

Full title: Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors

Authors: Pannuti, Antonio; Filipovic, Aleksandra; Hicks, Chindo; Lefkowitz, Elliot; Ptacek, Travis; Stebbing, Justin; Miele, Lucio

Year: 2018

Venue: Imperial College London

DOI: https://www.ncbi.nlm.nih.gov/pubmed/29570743

Thesis Highlights in lung cancer in 2019.

Lim, Kok Haw Jonathan; Popat, Sanjay · 2020 · Imperial College London · DOI

Full title: Highlights in lung cancer in 2019.

Authors: Lim, Kok Haw Jonathan; Popat, Sanjay

Year: 2020

Venue: Imperial College London

DOI: https://www.ncbi.nlm.nih.gov/pubmed/32054634

Thesis Current highlights in lung cancer in 2021

Lim, KHJ; Solomon, BJ · 2021 · Imperial College London · DOI

Full title: Current highlights in lung cancer in 2021

Authors: Lim, KHJ; Solomon, BJ

Year: 2021

Venue: Imperial College London

DOI: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000704803800002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Thesis ctDNA monitoring using patient-specific sequencing and integration of variant reads.

Wan, Jonathan CM; Heider, Katrin; Gale, Davina et al. · 2020 · University of Cambridge · DOI

Full title: ctDNA monitoring using patient-specific sequencing and integration of variant reads.

Authors: Wan, Jonathan CM; Heider, Katrin; Gale, Davina; Murphy, Suzanne; Fisher, Eyal; Mouliere, Florent; Ruiz-Valdepenas, Andrea; Santonja, Angela; Morris, James; Chandrananda, Dineika; Marshall, Andrea; Gill, Andrew B; Chan, Pui Ying; Barker, Emily; Young, Gemma; Cooper, Wendy N; Hudecova, Irena; Marass, Francesco; Mair, Richard; Brindle, Kevin M; Stewart, Grant D; Abraham, Jean E; Caldas, Carlos; Rassl, Doris M; Rintoul, Robert C; Alifrangis, Constantine; Middleton, Mark R; Gallagher, Ferdia A; Parkinson, Christine; Durrani, Amer; McDermott, Ultan; Smith, Christopher G; Massie, Charles; Corrie, Pippa G; Rosenfeld, Nitzan

Year: 2020

Venue: University of Cambridge

DOI: https://www.repository.cam.ac.uk/handle/1810/307153

Patent us-2023339910-a1

· 2023

Full title: us-2023339910-a1

Year: 2023

Patent us-2024033266-a1

· 2024

Full title: us-2024033266-a1

Year: 2024

Patent us-2024082251-a1

· 2024

Full title: us-2024082251-a1

Year: 2024

Patent us-2024139193-a1

· 2024

Full title: us-2024139193-a1

Year: 2024

Patent us-2024226020-a1

· 2024

Full title: us-2024226020-a1

Year: 2024

Patent us-2024217982-a1

· 2024

Full title: us-2024217982-a1

Year: 2024

Patent us-2024287101-a1

· 2024

Full title: us-2024287101-a1

Year: 2024

Patent us-2024252490-a1

· 2024

Full title: us-2024252490-a1

Year: 2024

Patent us-2024285625-a1

· 2024

Full title: us-2024285625-a1

Year: 2024

Patent us-2024408089-a1

· 2024

Full title: us-2024408089-a1

Year: 2024

Patent us-2025041313-a1

· 2025

Full title: us-2025041313-a1

Year: 2025

Patent us-2025051394-a1

· 2025

Full title: us-2025051394-a1

Year: 2025

Patent us-2025114346-a1

· 2025

Full title: us-2025114346-a1

Year: 2025

Patent us-2025230193-a1

· 2025

Full title: us-2025230193-a1

Year: 2025

Patent us-2025281514-a1

· 2025

Full title: us-2025281514-a1

Year: 2025

Patent us-2025195533-a1

· 2025

Full title: us-2025195533-a1

Year: 2025

Patent us-2025313577-a1

· 2025

Full title: us-2025313577-a1

Year: 2025

Patent us-9532984-b2

· 2017

Full title: us-9532984-b2

Year: 2017

Patent us-2018072723-a1

· 2018

Full title: us-2018072723-a1

Year: 2018

Patent us-2018162812-a1

· 2018

Full title: us-2018162812-a1

Year: 2018

Patent us-2018289683-a1

· 2018

Full title: us-2018289683-a1

Year: 2018

Patent us-2018177767-a1

· 2018

Full title: us-2018177767-a1

Year: 2018

Patent us-2019388403-a1

· 2019

Full title: us-2019388403-a1

Year: 2019

Patent us-2020030324-a1

· 2020

Full title: us-2020030324-a1

Year: 2020

Patent us-2020360374-a1

· 2020

Full title: us-2020360374-a1

Year: 2020

Patent us-2021300920-a1

· 2021

Full title: us-2021300920-a1

Year: 2021

Patent us-2021220364-a1

· 2021

Full title: us-2021220364-a1

Year: 2021

Patent us-10532042-b2

· 2020

Full title: us-10532042-b2

Year: 2020

Patent us-10898473-b2

· 2021

Full title: us-10898473-b2

Year: 2021

Patent us-11161847-b2

· 2021

Full title: us-11161847-b2

Year: 2021

Patent us-11426404-b2

· 2022

Full title: us-11426404-b2

Year: 2022

Patent us-2022193077-a1

· 2022

Full title: us-2022193077-a1

Year: 2022

Patent us-2022186227-a1

· 2022

Full title: us-2022186227-a1

Year: 2022

Patent us-2022389021-a1

· 2022

Full title: us-2022389021-a1

Year: 2022

Patent us-2022378787-a1

· 2022

Full title: us-2022378787-a1

Year: 2022

Patent us-2023028414-a1

· 2023

Full title: us-2023028414-a1

Year: 2023

Patent us-2023107642-a1

· 2023

Full title: us-2023107642-a1

Year: 2023

Patent us-2023235327-a1

· 2023

Full title: us-2023235327-a1

Year: 2023

Patent us-2023248729-a1

· 2023

Full title: us-2023248729-a1

Year: 2023

Patent us-2023233568-a1

· 2023

Full title: us-2023233568-a1

Year: 2023

Patent us-2023321102-a1

· 2023

Full title: us-2023321102-a1

Year: 2023

Patent us-11845761-b2

· 2023

Full title: us-11845761-b2

Year: 2023

Patent us-11654145-b2

· 2023

Full title: us-11654145-b2

Year: 2023

Patent us-12448400-b2

· 2025

Full title: us-12448400-b2

Year: 2025

Patent us-12410212-b2

· 2025

Full title: us-12410212-b2

Year: 2025

Patent us-2012041070-a1

· 2012

Full title: us-2012041070-a1

Year: 2012

Patent us-2013280329-a1

· 2013

Full title: us-2013280329-a1

Year: 2013

Patent us-2014135370-a1

· 2014

Full title: us-2014135370-a1

Year: 2014

Patent us-2014113930-a1

· 2014

Full title: us-2014113930-a1

Year: 2014

Patent us-2013022970-a1

· 2013

Full title: us-2013022970-a1

Year: 2013

Patent us-2014288045-a1

· 2014

Full title: us-2014288045-a1

Year: 2014

Patent us-2016058751-a1

· 2016

Full title: us-2016058751-a1

Year: 2016

Patent us-2016287585-a1

· 2016

Full title: us-2016287585-a1

Year: 2016

Patent us-2016031898-a1

· 2016

Full title: us-2016031898-a1

Year: 2016

Patent us-2016166571-a1

· 2016

Full title: us-2016166571-a1

Year: 2016

Patent us-9227978-b2

· 2016

Full title: us-9227978-b2

Year: 2016

Patent us-9745319-b2

· 2017

Full title: us-9745319-b2

Year: 2017

Patent us-9926267-b2

· 2018

Full title: us-9926267-b2

Year: 2018

Patent us-11180506-b2

· 2021

Full title: us-11180506-b2

Year: 2021

Patent us-11345701-b1

· 2022

Full title: us-11345701-b1

Year: 2022

Patent us-11787811-b2

· 2023

Full title: us-11787811-b2

Year: 2023

Patent us-12195473-b2

· 2025

Full title: us-12195473-b2

Year: 2025

Patent us-2021040089-a1

· 2021

Full title: us-2021040089-a1

Year: 2021

Patent us-2021094919-a1

· 2021

Full title: us-2021094919-a1

Year: 2021

Patent us-2021292331-a1

· 2021

Full title: us-2021292331-a1

Year: 2021

Patent us-2022213109-a1

· 2022

Full title: us-2022213109-a1

Year: 2022

Patent us-2022298174-a1

· 2022

Full title: us-2022298174-a1

Year: 2022

Patent us-2023011726-a1

· 2023

Full title: us-2023011726-a1

Year: 2023

Patent us-2025115603-a1

· 2025

Full title: us-2025115603-a1

Year: 2025

Patent us-2025304601-a1

· 2025

Full title: us-2025304601-a1

Year: 2025

2. Data Extraction

0/1035 extracted

Paper

What Evidence Is There for the Reimbursement of Personalised Medicine?

P. Hall, C. McCabe · 2013

Full title: What Evidence Is There for the Reimbursement of Personalised Medicine?

Authors: P. Hall, C. McCabe

DOI: https://doi.org/10.1007/s40273-013-0025-x

Paper

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021

Kayki‐Mutlu, Gizem; Aksoyalp, Zinnet Şevval; Wojnowski, Leszek et al. · 2022

Full title: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021

Authors: Kayki‐Mutlu, Gizem; Aksoyalp, Zinnet Şevval; Wojnowski, Leszek; Michel, Martin C.

DOI: https://doi.org/10.1007/s00210-022-02250-2

Paper

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Chen, Nan; Fang, Wenfeng; Zhong, Lin et al. · 2017

Full title: KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Authors: Chen, Nan; Fang, Wenfeng; Zhong, Lin; Peng, Peijian; Wang, Juan; Zhan, Jianhua; Hong, Shaodong; Huang, Jiaxing; Liu, Lin; Jin, Sheng; Zhou, Ting; Chen, Ying; Zhang, Hongyu; Zhang, Li

DOI: https://doi.org/10.1007/s00262-017-2005-z

Paper

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

S. Piha-Paul; C. Tseng; H. Tran et al. · 2023

Authors: S. Piha-Paul; C. Tseng; H. Tran; Meng Gao; D. Karp; V. Subbiah; A. Tsimberidou; J. Kawedia; S. Fu; S. Pant; T. Yap; V. Morris; B. Kee; Mariela Blum Murphy; Joann Lim; F. Meric-Bernstam

DOI: https://doi.org/10.1007/s00280-023-04545-4

Paper

Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

Heinrich, Kathrin; Miller‐Phillips, Lisa; Ziemann, Frank et al. · 2022

Full title: Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

DOI: https://doi.org/10.1007/s00432-022-04165-0

Paper

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

Boonstra, Pieter A.; Wind, Thijs T.; Kruchten, Michel van et al. · 2020

Full title: Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

DOI: https://doi.org/10.1007/s10555-020-09876-9

Paper

Current therapy of KRAS-mutant lung cancer

Ghimessy, Áron; Radeczky, Péter; László, Viktória et al. · 2020

Full title: Current therapy of KRAS-mutant lung cancer

Authors: Ghimessy, Áron; Radeczky, Péter; László, Viktória; Hegedűs, Balázs; Rényi-Vámos, F; Fillinger, János; Klepetko, Walter; Lang, Christian; Döme, Balázs; Megyesfalvi, Zsolt

DOI: https://doi.org/10.1007/s10555-020-09903-9

Paper

Structure-based inhibitor design of mutant RAS proteins—a paradigm shift

Nyíri, Kinga; Koppány, Gergely; Vértessy, Beáta G. · 2020

Full title: Structure-based inhibitor design of mutant RAS proteins—a paradigm shift

Authors: Nyíri, Kinga; Koppány, Gergely; Vértessy, Beáta G.

DOI: https://doi.org/10.1007/s10555-020-09914-6

Paper

Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

Francescangeli, Federica; Angelis, Maria Laura De; Rossi, Rachele et al. · 2023

Full title: Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

Authors: Francescangeli, Federica; Angelis, Maria Laura De; Rossi, Rachele; Cuccu, Adriano; Giuliani, Alessandro; Maria, Ruggero De; Zeuner, Ann

DOI: https://doi.org/10.1007/s10555-023-10092-4

Paper

Advancements in gene therapies targeting mutant KRAS in cancers

Wang, Yuhang; Bùi, Thuỳ Anh; Yang, Xinpu et al. · 2025

Full title: Advancements in gene therapies targeting mutant KRAS in cancers

Authors: Wang, Yuhang; Bùi, Thuỳ Anh; Yang, Xinpu; Hutvàgner, György; Deng, Wei

DOI: https://doi.org/10.1007/s10555-025-10243-9

Paper

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.

Ku, Bo Mi; Bae, Yeon Hee; Lee, Kyoung Young et al. · 2020

Full title: Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.

Authors: Ku, Bo Mi; Bae, Yeon Hee; Lee, Kyoung Young; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Park, Keunchil; Ahn, Myung-Ju

DOI: https://doi.org/10.1007/s10637-019-00795-3

Paper

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer

Lee, Arnold · 2022

Full title: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer

Authors: Lee, Arnold

DOI: https://doi.org/10.1007/s11523-022-00922-w

Paper

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

Dorman, Klara; Zhang, Danmei; Heinrich, Kathrin et al. · 2023

Full title: Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

DOI: https://doi.org/10.1007/s11523-023-00950-0

Paper

Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Danielle Brazel; Misako Nagasaka · 2024

Full title: Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Authors: Danielle Brazel; Misako Nagasaka

DOI: https://doi.org/10.1007/s11523-024-01055-y

Paper

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Isla, Dolores; Lozano, María D.; Paz‐Ares, Luis et al. · 2022

Authors: Isla, Dolores; Lozano, María D.; Paz‐Ares, Luis; Salas, Clara; Castro, Javier de; Conde, Esther; Felip, Enriqueta; Gómez‐Román, Javier; Garrido, Pilar; Enguita, Ana B.

DOI: https://doi.org/10.1007/s12094-022-03046-9

Paper

Unraveling (K)RAS in pancreatic ductal adenocarcinoma

Bernhard Doleschal · 2024

Full title: Unraveling (K)RAS in pancreatic ductal adenocarcinoma

Authors: Bernhard Doleschal

DOI: https://doi.org/10.1007/s12254-024-01003-6

Paper

Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review

Mansinho, André; Fernandes, Ricardo M.; Carneiro, António Vaz · 2022

Full title: Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review

Authors: Mansinho, André; Fernandes, Ricardo M.; Carneiro, António Vaz

DOI: https://doi.org/10.1007/s12325-022-02362-4

Paper

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Khasraw, Mustafa; Yalamanchili, Priyanka; Santhanagopal, Anu et al. · 2024

Full title: Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Authors: Khasraw, Mustafa; Yalamanchili, Priyanka; Santhanagopal, Anu; Wu, Chuntao; Salas, Maribel; Meng, Jie; Karnoub, Maha; Esker, Stephen; Felip, Enriqueta

DOI: https://doi.org/10.1007/s12325-024-02799-9

Paper

Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion

C. Bestvina; Chul Kim; Nathalie Daaboul · 2025

Full title: Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion

Authors: C. Bestvina; Chul Kim; Nathalie Daaboul

DOI: https://doi.org/10.1007/s12325-025-03195-7

Paper

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.

Chopra, Divyan; Lan, Zhiyi; Waterhouse, David M et al. · 2025

Full title: Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.

Authors: Chopra, Divyan; Lan, Zhiyi; Waterhouse, David M; Wolf, Jürgen; Felip, Enriqueta; Moradian, Hoora; Karim, Nadia; Obiozor, Cynthia; Stollenwerk, Björn

DOI: https://doi.org/10.1007/s12325-025-03259-8

Paper

Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines

Plangger, Adelina; Rath, Barbara H.; Stickler, Sandra et al. · 2022

Full title: Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines

Authors: Plangger, Adelina; Rath, Barbara H.; Stickler, Sandra; Hochmair, Maximilian J.; Lang, Clemens; Weigl, Lukas; Funovics, Martin; Hamilton, Gerhard

DOI: https://doi.org/10.1007/s12672-022-00550-w

Paper

Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors

Wang, Lihao; Wei, Dandan; Li, Shanshan et al. · 2025

Full title: Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors

Authors: Wang, Lihao; Wei, Dandan; Li, Shanshan; Jiang, Shiqing

DOI: https://doi.org/10.1007/s12672-025-03569-x

Paper

Modern therapies of nonsmall cell lung cancer

Jachowski, Andrzej; Marcinkowski, Mikołaj; Szydłowski, Jakub et al. · 2023

Full title: Modern therapies of nonsmall cell lung cancer

Authors: Jachowski, Andrzej; Marcinkowski, Mikołaj; Szydłowski, Jakub; Grabarczyk, Oskar; Nogaj, Zuzanna; Marcin, L. Pekalski; Pławski, Andrzej; Jagodzińśki, Paweł P.; Słowikowski, Bartosz

DOI: https://doi.org/10.1007/s13353-023-00786-4

Paper

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Kleij, Maud B. A. van der; Guchelaar, Niels A.D.; Mathijssen, Ron H.J. et al. · 2023

Full title: Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Authors: Kleij, Maud B. A. van der; Guchelaar, Niels A.D.; Mathijssen, Ron H.J.; Versluis, Jurjen; Huitema, Alwin D. R.; Koolen, Stijn L.W.; Steeghs, Neeltje

DOI: https://doi.org/10.1007/s40262-023-01293-9

Paper

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Wilcox, Jessica; Boire, Adrienne · 2022

Full title: Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Authors: Wilcox, Jessica; Boire, Adrienne

DOI: https://doi.org/10.1007/s40263-022-00975-5

Paper

Sotorasib: First Approval

Blair, Hannah A. · 2021

Full title: Sotorasib: First Approval

Authors: Blair, Hannah A.

DOI: https://doi.org/10.1007/s40265-021-01574-2

Paper

External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges

Carrigan, Gillis; Bradbury, Brian D.; Brookhart, M. Alan et al. · 2022

Full title: External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges

Authors: Carrigan, Gillis; Bradbury, Brian D.; Brookhart, M. Alan; Capra, William B.; Chia, Victoria; Rothman, Kenneth J.; Sarsour, Khaled; Taylor, Michael D.; Brown, Jefferey S.

DOI: https://doi.org/10.1007/s40471-022-00305-9

Paper

Metabolic reprogramming in non-small cell lung cancer: unraveling therapeutic vulnerabilities and resistance mechanisms

T. Addissouky · 2026

Full title: Metabolic reprogramming in non-small cell lung cancer: unraveling therapeutic vulnerabilities and resistance mechanisms

Authors: T. Addissouky

DOI: https://doi.org/10.1007/s44162-026-00147-9

Paper

Innovative drugs promote precision cancer therapy

Huang, Xuan; Zhu, Mengxuan; Chen, Ruoxue et al. · 2023

Full title: Innovative drugs promote precision cancer therapy

Authors: Huang, Xuan; Zhu, Mengxuan; Chen, Ruoxue; Ni, Junjie; Zhao, Wenrui; Li, Song; Lü, Xiaoling; Jiao, Heng; Cao, Xin

DOI: https://doi.org/10.1007/s44272-023-00002-8

Paper

Oncogenic KRAS signalling in pancreatic cancer

EŞER, Serap; Schnieke, Angelika; Schneider, Günter et al. · 2014

Full title: Oncogenic KRAS signalling in pancreatic cancer

Authors: EŞER, Serap; Schnieke, Angelika; Schneider, Günter; Saur, Dieter

DOI: https://doi.org/10.1038/bjc.2014.215

Paper

Targeting molecular addictions in cancer

Vivanco, Igor · 2014

Full title: Targeting molecular addictions in cancer

Authors: Vivanco, Igor

DOI: https://doi.org/10.1038/bjc.2014.461

Paper

Combining targeted therapeutics in the era of precision medicine

D. Papadatos-Pastos; M. J. De Miguel Luken; T. Yap · 2015

Full title: Combining targeted therapeutics in the era of precision medicine

Authors: D. Papadatos-Pastos; M. J. De Miguel Luken; T. Yap

DOI: https://doi.org/10.1038/bjc.2014.558

Paper

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Jänne, Pasi A.; Smith, Ian C. P.; McWalter, Gael et al. · 2015

Full title: Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

DOI: https://doi.org/10.1038/bjc.2015.215

Paper

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

Chen, J; Bi, Hong‐Yan; Hou, Jincai et al. · 2013

Full title: Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

Authors: Chen, J; Bi, Hong‐Yan; Hou, Jincai; Zhang, X; Zhang, C; Yue, Liling; Wen, Xinyu; Liu, D; H, Shi; Yuan, Jingping; Liu, Jingke; Liu, B

DOI: https://doi.org/10.1038/cddis.2013.312

Paper

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

Wang, Jieqiong; Hu, Kewen; Guo, Jiawei et al. · 2016

Full title: Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

Authors: Wang, Jieqiong; Hu, Kewen; Guo, Jiawei; Cheng, Feixiong; Lv, Jing; Jiang, Wenhao; Lü, Weiqiang; Liu, Jinsong; Pang, Xiufeng; Liu, Mingyao

DOI: https://doi.org/10.1038/ncomms11363

Paper

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

Shin, Seungmin; Choi, Dong-Ki; Jung, Keun‐Ok et al. · 2017

Full title: Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

Authors: Shin, Seungmin; Choi, Dong-Ki; Jung, Keun‐Ok; Bae, Jeomil; Kim, Ji‐Sun; Park, Seong‐Wook; Song, Ki‐Hoon; Kim, Yong‐Sung

DOI: https://doi.org/10.1038/ncomms15090

Paper

Molecular targeted therapy for anticancer treatment

H. Min; Ho Young Lee · 2022

Full title: Molecular targeted therapy for anticancer treatment

Authors: H. Min; Ho Young Lee

DOI: https://doi.org/10.1038/s12276-022-00864-3

Paper

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

Shin, Dong Hoon; Jo, Jeong Yeon; Choi, Minyoung et al. · 2023

Full title: Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

Authors: Shin, Dong Hoon; Jo, Jeong Yeon; Choi, Minyoung; Kim, Kyung‐Hee; Bae, Young‐Ki; Kim, Sang Soo

DOI: https://doi.org/10.1038/s12276-023-01091-0

Paper

Targeting TGF-β–Smad2/3–JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer

Dongcheon Shin; Min-Gew Choi; Chungyong Han et al. · 2025

Full title: Targeting TGF-β–Smad2/3–JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer

Authors: Dongcheon Shin; Min-Gew Choi; Chungyong Han; Sang Soo Kim

DOI: https://doi.org/10.1038/s12276-025-01536-8

Paper

Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics

Sorolla, Anabel; Wang, Edina; Golden, Emily et al. · 2019

Full title: Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics

Authors: Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Henriques, Sónia Troeira; Redfern, Andrew; Blancafort, Pilar

DOI: https://doi.org/10.1038/s41388-019-1056-3

Paper

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Yu, Chune; Luo, Dan; Yu, Jing et al. · 2021

Full title: Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Authors: Yu, Chune; Luo, Dan; Yu, Jing; Zhang, Min; Zheng, Xiaobo; Xu, Guangchao; Wang, Jiaxin; Wang, Huiling; Xu, Yufei; Jiang, Ke; Xu, Jie; Ma, Xuelei; Jing, Jing; Shi, Hubing

DOI: https://doi.org/10.1038/s41388-021-02077-w

Paper

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Feng, Juanjuan; Hu, Zhongwei; Xia, Xinting et al. · 2023

Full title: Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Authors: Feng, Juanjuan; Hu, Zhongwei; Xia, Xinting; Liu, Xiaogu; Lian, Zhengke; Wang, Hui; Wang, Liren; Wang, Cun; Zhang, Xueli; Pang, Xiufeng

DOI: https://doi.org/10.1038/s41388-023-02676-9

Paper

Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer

Yu Zhang; Liang Liu; Jinpeng Pei et al. · 2024

Full title: Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer

Authors: Yu Zhang; Liang Liu; Jinpeng Pei; Zhiqiang Ren; Yan Deng; Ker Yu

DOI: https://doi.org/10.1038/s41388-023-02924-y

Paper

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Yuan, Min; Huang, Lili; Chen, Jianhua et al. · 2019

Full title: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Authors: Yuan, Min; Huang, Lili; Chen, Jianhua; Wu, Jie; Xu, Qing

DOI: https://doi.org/10.1038/s41392-019-0099-9

Paper

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Zhong, Lei; Li, Yueshan; Xiong, Liang et al. · 2021

Full title: Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Authors: Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong

DOI: https://doi.org/10.1038/s41392-021-00572-w

Paper

The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

Wang, Shun; Zheng, Yan; Feng, Yang et al. · 2021

Full title: The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

DOI: https://doi.org/10.1038/s41392-021-00659-4

Paper

Insights from the degradation mechanism of cyclin D into targeted therapy of the cancer cell cycle

Maïwen Caudron-Herger; S. Diederichs · 2021

Full title: Insights from the degradation mechanism of cyclin D into targeted therapy of the cancer cell cycle

Authors: Maïwen Caudron-Herger; S. Diederichs

DOI: https://doi.org/10.1038/s41392-021-00732-y

Paper

KRAS mutation: from undruggable to druggable in cancer

Lamei Huang; Zhixing Guo; Fang Wang et al. · 2021

Full title: KRAS mutation: from undruggable to druggable in cancer

Authors: Lamei Huang; Zhixing Guo; Fang Wang; Liwu Fu

DOI: https://doi.org/10.1038/s41392-021-00780-4

Paper

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, Ming; Cao, Chao-Guo; Ni, Zhihao et al. · 2022

Full title: PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

Authors: He, Ming; Cao, Chao-Guo; Ni, Zhihao; Liu, Yongbo; Song, Peilu; Hao, Shuang; He, Yuna; Sun, Xiuyun; Rao, Yu

DOI: https://doi.org/10.1038/s41392-022-00999-9

Paper

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Yang, Yang; Li, Shuo; Wang, Yujiao et al. · 2022

Full title: Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Authors: Yang, Yang; Li, Shuo; Wang, Yujiao; Zhao, Yi; Li, Qiu

DOI: https://doi.org/10.1038/s41392-022-01168-8

Paper

Patient-derived xenograft models in cancer therapy: technologies and applications

Liu, Yihan; Wu, Wantao; Cai, Changjing et al. · 2023

Full title: Patient-derived xenograft models in cancer therapy: technologies and applications

Authors: Liu, Yihan; Wu, Wantao; Cai, Changjing; Zhang, Hao; Shen, Hong; Han, Ying

DOI: https://doi.org/10.1038/s41392-023-01419-2

Paper

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Guowei Yin; Jing Huang; Johnny Petela et al. · 2023

Full title: Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Authors: Guowei Yin; Jing Huang; Johnny Petela; Hongmei Jiang; Yuetong Zhang; Siqi Gong; Jiaxin Wu; Bei Liu; Jianyou Shi; Yijun Gao

DOI: https://doi.org/10.1038/s41392-023-01441-4

Paper

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, Xin; Yu, Tingting; Li, Xiang et al. · 2023

Full title: Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Authors: Xie, Xin; Yu, Tingting; Li, Xiang; Zhang, Nan; Foster, Leonard J.; Peng, Cheng; Huang, Wei; He, Gu

DOI: https://doi.org/10.1038/s41392-023-01589-z

Paper

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Bahar, Md Entaz; Kim, Hyun Joon; Kim, Deok Ryong · 2023

Full title: Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Authors: Bahar, Md Entaz; Kim, Hyun Joon; Kim, Deok Ryong

DOI: https://doi.org/10.1038/s41392-023-01705-z

Paper

New clinical trial design in precision medicine: discovery, development and direction

Duan, Xiao-Peng; Qin, Bao‐Dong; Jiao, Xiao‐Dong et al. · 2024

Full title: New clinical trial design in precision medicine: discovery, development and direction

Authors: Duan, Xiao-Peng; Qin, Bao‐Dong; Jiao, Xiao‐Dong; Liu, Ke; Wang, Zhan; Zang, Yuan‐Sheng

DOI: https://doi.org/10.1038/s41392-024-01760-0

Paper

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Khalil Choucair; Hafsa Imtiaz; Md. Hafiz Uddin et al. · 2025

Full title: Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Authors: Khalil Choucair; Hafsa Imtiaz; Md. Hafiz Uddin; M. Nagasaka; M. N. Al-Hallak; P. Philip; B. El-Rayes; Boris C. Pasche; A. Azmi

DOI: https://doi.org/10.1038/s41392-025-02473-8

Paper

Direct Ras G12C inhibitors: crossing the rubicon

Lindsay, Colin R.; Blackhall, Fiona · 2019

Full title: Direct Ras G12C inhibitors: crossing the rubicon

Authors: Lindsay, Colin R.; Blackhall, Fiona

DOI: https://doi.org/10.1038/s41416-019-0499-1

Paper

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Geel, Robin M.J.M. van; Brummelen, Emilie M.J. van; Eskens, Ferry A.L.M. et al. · 2020

Full title: Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

DOI: https://doi.org/10.1038/s41416-020-0776-z

Paper

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors

Baranyi, Marcell; Molnár, Eszter; Hegedüs, Luca et al. · 2024

Full title: Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors

DOI: https://doi.org/10.1038/s41416-024-02586-x

Paper

The KRAS-G12C inhibitor: activity and resistance.

Liu, Jiao; Kang, Rui; Tang, Daolin · 2022

Full title: The KRAS-G12C inhibitor: activity and resistance.

Authors: Liu, Jiao; Kang, Rui; Tang, Daolin

DOI: https://doi.org/10.1038/s41417-021-00383-9

Paper

Glimmers of hope for targeting oncogenic KRAS-G12D

Tang, Daolin; Kang, Rui · 2022

Full title: Glimmers of hope for targeting oncogenic KRAS-G12D

Authors: Tang, Daolin; Kang, Rui

DOI: https://doi.org/10.1038/s41417-022-00561-3

Paper

Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity

Leung, Elaine Lai Han; Luo, Lian Xiang; Liu, Zhong Qiu et al. · 2018

Full title: Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity

DOI: https://doi.org/10.1038/s41419-017-0065-9

Paper

MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer

Zhang, Yuanzhou; Liang, Shunshun; Xiao, Bowen et al. · 2022

Full title: MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer

Authors: Zhang, Yuanzhou; Liang, Shunshun; Xiao, Bowen; Hu, Jingying; Pang, Yechun; Liu, Yuling; Yang, Juan; Ao, Junpin; Wei, Lin; Luo, Xiaoying

DOI: https://doi.org/10.1038/s41419-022-04709-9

Paper

Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells.

Lee, Chaeyoung; Yi, Jawoon; Park, Jihwan et al. · 2024

Full title: Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells.

Authors: Lee, Chaeyoung; Yi, Jawoon; Park, Jihwan; Ahn, Byungyong; Won, Young-Wook; Jeon, JiHeung; Lee, Byung Ju; Cho, Wha Ja; Park, Jeong Woo

DOI: https://doi.org/10.1038/s41419-024-06436-9

Paper

Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer.

Liu, Hongyu; Zhou, Chao; Lu, Jun et al. · 2025

Full title: Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer.

Authors: Liu, Hongyu; Zhou, Chao; Lu, Jun; Liu, Yuqing; Zou, Peichen; Zhu, Liang; Lei, Huimin; Han, Baohui

DOI: https://doi.org/10.1038/s41419-025-07687-w

Paper

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells

Maj-Britt Paulsohn; Klara Henrike Frahnert; Denise Schlösser et al. · 2025

Full title: Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells

DOI: https://doi.org/10.1038/s41419-025-08362-w

Paper

TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer

Ben Zhao; L. Dierichs; J. Gu et al. · 2020

Full title: TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer

DOI: https://doi.org/10.1038/s41420-020-0246-7

Paper

An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer

Karstedt, Silvia von; Walczak, Henning · 2020

Full title: An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer

Authors: Karstedt, Silvia von; Walczak, Henning

DOI: https://doi.org/10.1038/s41420-020-0249-4

Paper

Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer

Zhu, Jialong; Ji, Linlin; Chen, Yitian et al. · 2023

Full title: Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer

Authors: Zhu, Jialong; Ji, Linlin; Chen, Yitian; Li, Huiyu; Huang, Mengxi; Dai, Zhe; Wang, Jing; Xiang, Dan; Fu, Gongbo; Lei, Zengjie; Chu, Xiaoyuan

DOI: https://doi.org/10.1038/s41420-023-01354-9

Paper

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

Mao, Zhongwei; Xiao, Hongying; Shen, Pan‐Pan et al. · 2022

Full title: KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

DOI: https://doi.org/10.1038/s41421-021-00368-w

Paper

MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation

Wang, Yuan; Jia, Zhenchang; Liang, Chenxi et al. · 2023

Full title: MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation

DOI: https://doi.org/10.1038/s41421-022-00507-x

Paper

Assembling defined DNA nanostructures with anticancer drugs: a metformin/DNA complex nanoplatform with a synergistic antitumor effect for KRAS-mutated lung cancer therapy

Qian, Hang; Wang, Dong; He, Binfeng et al. · 2022

Full title: Assembling defined DNA nanostructures with anticancer drugs: a metformin/DNA complex nanoplatform with a synergistic antitumor effect for KRAS-mutated lung cancer therapy

Authors: Qian, Hang; Wang, Dong; He, Binfeng; Liu, Qian; Xu, Yü; Wu, Di; Chen, Chunfa; Zhang, Wen; Leong, David Tai; Wang, Guansong

DOI: https://doi.org/10.1038/s41427-022-00427-y

Paper

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

Quevedo, Camilo; Cruz-Migoni, Abimael; Béry, Nicolas et al. · 2018

Full title: Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

DOI: https://doi.org/10.1038/s41467-018-05707-2

Paper

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Kazi, Aslamuzzaman; Xiang, Shengyan; Yang, Hua et al. · 2018

Full title: GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Authors: Kazi, Aslamuzzaman; Xiang, Shengyan; Yang, Hua; Delitto, Daniel; Treviño, José G.; Jiang, Rays H. Y.; Ayaz, Muhammad; Lawrence, Harshani R.; Kennedy, Perry; Sebti, Saı̈d M.

DOI: https://doi.org/10.1038/s41467-018-07644-6

Paper

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Jones, Greg G.; Río, Isabel Boned del; Sarı, Sibel et al. · 2019

Full title: SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

DOI: https://doi.org/10.1038/s41467-019-10367-x

Paper

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS

Béry, Nicolas; Miller, Ami; Rabbitts, Terence H. · 2020

Full title: A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS

Authors: Béry, Nicolas; Miller, Ami; Rabbitts, Terence H.

DOI: https://doi.org/10.1038/s41467-020-17022-w

Paper

Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

Lundin, Anders; Porritt, Michelle J.; Jaiswal, Himjyot et al. · 2020

Full title: Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

DOI: https://doi.org/10.1038/s41467-020-18548-9

Paper

Immune modulatory effects of oncogenic KRAS in cancer

Hamarsheh, Shaima’a; Groß, Olaf; Brummer, Tilman et al. · 2020

Full title: Immune modulatory effects of oncogenic KRAS in cancer

Authors: Hamarsheh, Shaima’a; Groß, Olaf; Brummer, Tilman; Zeiser, Robert

DOI: https://doi.org/10.1038/s41467-020-19288-6

Paper

CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer

Zhang, Man; Yang, Wei; Wang, Peng et al. · 2020

Full title: CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer

Authors: Zhang, Man; Yang, Wei; Wang, Peng; Deng, Yu; Dong, Yuting; Liu, Fangfang; Huang, Rui; Zhang, Peng; Duan, Yaqi; Liu, Xindong; Lin, Dandan; Chu, Qian; Zhong, Bo

DOI: https://doi.org/10.1038/s41467-020-19973-6

Paper

Selective and noncovalent targeting of RAS mutants for inhibition and degradation

Teng, Kai Wen; Tsai, Steven T.; Hattori, Takamitsu et al. · 2021

Full title: Selective and noncovalent targeting of RAS mutants for inhibition and degradation

Authors: Teng, Kai Wen; Tsai, Steven T.; Hattori, Takamitsu; Fedele, Carmine; Koide, Akiko; Yang, Chao; Hou, Xuben; Zhang, Yingkai; Neel, Benjamin G.; O’Bryan, John P.; Koide, Shohei

DOI: https://doi.org/10.1038/s41467-021-22969-5

Paper

MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

Brägelmann, Johannes; Lorenz, Carina; Borchmann, Sven et al. · 2021

Full title: MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

DOI: https://doi.org/10.1038/s41467-021-25728-8

Paper

Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry

Maldegem, Febe van; Valand, Karishma; Cole, Megan et al. · 2021

Full title: Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry

DOI: https://doi.org/10.1038/s41467-021-26214-x

Paper

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Radia M. Johnson; X. Qu; Chu-Fang Lin et al. · 2022

Full title: ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

DOI: https://doi.org/10.1038/s41467-022-33172-5

Paper

Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine

Wang, Kai‐Bo; Liu, Yushuang; Li, Jinzhu et al. · 2022

Full title: Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine

Authors: Wang, Kai‐Bo; Liu, Yushuang; Li, Jinzhu; Xiao, Cheng‐Mei; Wang, Yingying; Gu, Wei; Li, Yipu; Xia, Yuan‐Zheng; Yan, Tingdong; Yang, Minghua; Kong, Lingyi

DOI: https://doi.org/10.1038/s41467-022-33761-4

Paper

Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity

Nguyen, Kim; Malik, Turnee N.; Chaput, John C. · 2023

Full title: Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity

Authors: Nguyen, Kim; Malik, Turnee N.; Chaput, John C.

DOI: https://doi.org/10.1038/s41467-023-38100-9

Paper

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma

Kostyrko, Kaja; Román, Marta; Lee, Alex G. et al. · 2023

Full title: UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma

DOI: https://doi.org/10.1038/s41467-023-39591-2

Paper

Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen

Wright, Katharine M.; DiNapoli, Sarah R.; Miller, Michelle S. et al. · 2023

Full title: Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen

DOI: https://doi.org/10.1038/s41467-023-40821-w

Paper

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma

Baltanás, Fernando C.; García‐Navas, Rósula; Rodríguez-Ramos, Pablo et al. · 2023

Full title: Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma

DOI: https://doi.org/10.1038/s41467-023-41583-1

Paper

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Macaya, Irati; Román, Marta; Welch, Connor et al. · 2023

Full title: Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

DOI: https://doi.org/10.1038/s41467-023-41828-z

Paper

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

Bulle, Ashenafi; Liu, Peng; Seehra, Kuljeet et al. · 2024

Full title: Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

DOI: https://doi.org/10.1038/s41467-024-46811-w

Paper

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

M. Nokin; Alessia Mira; Enrico Patrucco et al. · 2024

Full title: RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

DOI: https://doi.org/10.1038/s41467-024-51828-2

Paper

Precision drugging of the MAPK pathway in head and neck cancer

Ngan, Hoi-Lam; Law, Chun-Ho; Choi, Yannie Chung Yan et al. · 2022

Full title: Precision drugging of the MAPK pathway in head and neck cancer

Authors: Ngan, Hoi-Lam; Law, Chun-Ho; Choi, Yannie Chung Yan; Chan, Jenny Yu-Sum; Lui, Vivian Wai Yan

DOI: https://doi.org/10.1038/s41525-022-00293-1

Paper

Defining subpopulations of differential drug response to reveal novel target populations

N. Keshava; T. S. Toh; H. Yuan et al. · 2019

Full title: Defining subpopulations of differential drug response to reveal novel target populations

Authors: N. Keshava; T. S. Toh; H. Yuan; Bingxun Yang; Michael P. Menden; Dennis Wang

DOI: https://doi.org/10.1038/s41540-019-0113-4

Paper

A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses

Arbelaez, Carlos; Estrada, Juan; Gessner, Melissa A. et al. · 2020

Full title: A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses

Authors: Arbelaez, Carlos; Estrada, Juan; Gessner, Melissa A.; Glaus, Charles; Morales, Agnieszka B.; Mohn, Deanna; Phee, Hyewon; Lipford, J. Russell; Johnston, James A.

DOI: https://doi.org/10.1038/s41541-020-00253-9

Paper

A view on drug resistance in cancer

Vasan, Neil; Baselga, José; Hyman, David M. · 2019

Full title: A view on drug resistance in cancer

Authors: Vasan, Neil; Baselga, José; Hyman, David M.

DOI: https://doi.org/10.1038/s41586-019-1730-1

Paper

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing et al. · 2024

Full title: Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

DOI: https://doi.org/10.1038/s41586-024-07205-6

Paper

Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types

Gurung, Hem R.; Heidersbach, Amy; Darwish, Martine et al. · 2023

Full title: Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types

DOI: https://doi.org/10.1038/s41587-023-01945-y

Paper

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Jayesh Desai; G. Alonso; Se Hyun Kim et al. · 2023

Full title: Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

DOI: https://doi.org/10.1038/s41591-023-02696-8

Paper

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Skoulidis, Ferdinandos; Li, Bob T; de Langen, Adrianus Johannes et al. · 2025

Full title: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

DOI: https://doi.org/10.1038/s41591-025-03732-5

Paper

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

Caiola, Elisa; Frapolli, Roberta; Tomanelli, Michele et al. · 2018

Full title: Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

Authors: Caiola, Elisa; Frapolli, Roberta; Tomanelli, Michele; Valerio, Rossana; Iezzi, Alice; Garassino, Marina Chiara; Broggini, Massimo; Marabese, Mirko

DOI: https://doi.org/10.1038/s41598-017-18900-y

Paper

Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation

Weng, Tzu‐Yang; Wu, Hsuan Franziska; Li, Chung-Yen et al. · 2018

Full title: Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation

DOI: https://doi.org/10.1038/s41598-018-26454-w

Paper

An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

Hansen, Rasmus; Firdaus, Sarah J.; Li, Shuangwei et al. · 2018

Full title: An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

Authors: Hansen, Rasmus; Firdaus, Sarah J.; Li, Shuangwei; Janes, Matthew R.; Zhang, Jingchuan; Liu, Yi; Zarrinkar, Patrick P.

DOI: https://doi.org/10.1038/s41598-018-32683-w

Paper

KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations

Pantsar, Tatu · 2020

Full title: KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations

Authors: Pantsar, Tatu

DOI: https://doi.org/10.1038/s41598-020-68950-y

Paper

The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer

Moerland, Jessica A.; Zhang, Di; Reich, Lyndsey A. et al. · 2020

Full title: The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer

Authors: Moerland, Jessica A.; Zhang, Di; Reich, Lyndsey A.; Carapellucci, Sarah; Lockwood, Beth; Leal, Ana S.; Krieger-Burke, Teresa; Aleiwi, Bilal; Ellsworth, Edmund L.; Liby, Karen T.

DOI: https://doi.org/10.1038/s41598-020-79260-8

Paper

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Pairawan, Seyed; Akçakanat, Argun; Kopetz, Scott et al. · 2022

Full title: Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

DOI: https://doi.org/10.1038/s41598-022-05193-z

Paper

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

Vaclová, Tereza; Chakraborty, Atanu; Sherwood, James et al. · 2022

Full title: Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

Authors: Vaclová, Tereza; Chakraborty, Atanu; Sherwood, James; Ross, Sarah J.; Carroll, Danielle; Barrett, J. Carl; Downward, Julian; Bruin, Elza C. de

DOI: https://doi.org/10.1038/s41598-022-06369-3

Paper

The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors

Sakamoto, Kotaro; Lin, Bangzhong; Nunomura, Kazuto et al. · 2022

Full title: The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors

Authors: Sakamoto, Kotaro; Lin, Bangzhong; Nunomura, Kazuto; Izawa, Takeshi; Nakagawa, Shinsaku

DOI: https://doi.org/10.1038/s41598-022-12401-3

Paper

Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis

Zhou, Chu; Jing, Zhongying; Liu, Wei et al. · 2023

Full title: Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis

Authors: Zhou, Chu; Jing, Zhongying; Liu, Wei; Ma, Zihuan; Liu, Siyao; Fang, Yueyu

DOI: https://doi.org/10.1038/s41598-023-42851-2

Paper

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Cheng, Ke; Zhou, Zijian; Chen, Qiangxing et al. · 2024

Full title: CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Authors: Cheng, Ke; Zhou, Zijian; Chen, Qiangxing; Chen, Zixin; Cai, Yu; Cai, He; Wu, Shangdi; Gao, Pan; Cai, Yunqiang; Zhou, Jin; Wang, Xin; Zhong, Wu; Peng, Bing

DOI: https://doi.org/10.1038/s41598-024-57417-z

Paper

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential

Metin Eser; Gulam Hekimoğlu; M. Yarar et al. · 2024

Full title: KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential

Authors: Metin Eser; Gulam Hekimoğlu; M. Yarar; Sezin Canbek; M. Ozcelik

DOI: https://doi.org/10.1038/s41598-024-75208-4

Paper

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Gurule, Natalia J.; McCoach, Caroline E.; Hinz, Trista K. et al. · 2021

Full title: A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

DOI: https://doi.org/10.1038/s41698-021-00181-4

Paper

Comprehensive molecular profiling of pulmonary pleomorphic carcinoma

Nagano, Masaaki; Kohsaka, Shinji; Hayashi, Takuo et al. · 2021

Full title: Comprehensive molecular profiling of pulmonary pleomorphic carcinoma

DOI: https://doi.org/10.1038/s41698-021-00201-3

Paper

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes

Gabriela Palma; Faisal Khurshid; K. Lu et al. · 2021

Full title: Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes

Authors: Gabriela Palma; Faisal Khurshid; K. Lu; Brian D. Woodward; H. Husain

DOI: https://doi.org/10.1038/s41698-021-00237-5

Paper

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.

Farnsworth, Dylan A; Inoue, Yusuke; Johnson, Fraser D et al. · 2022

Full title: MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.

DOI: https://doi.org/10.1038/s41698-022-00328-x

Paper

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

Lee, Jessica; Sivakumar, Smruthy; Schrock, Alexa B. et al. · 2022

Full title: Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

DOI: https://doi.org/10.1038/s41698-022-00334-z

Paper

Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

Priest, Katherine; Le, Anh T.; Gebregzabheir, Amanuail et al. · 2023

Full title: Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

DOI: https://doi.org/10.1038/s41698-023-00349-0

Paper

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

B. Nelson; N. Reddy; J. Huse et al. · 2023

Full title: Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

Authors: B. Nelson; N. Reddy; J. Huse; B. Amini; M. Nardo; M. Gouda; S. Weathers; V. Subbiah

DOI: https://doi.org/10.1038/s41698-023-00398-5

Paper

Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma

Zhao, Ruiying; Xu, Yunhua; Chen, Yedan et al. · 2023

Full title: Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma

DOI: https://doi.org/10.1038/s41698-023-00430-8

Paper

ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

Timofeev, Oleg; Giron, Philippe; Lawo, Steffen et al. · 2024

Full title: ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

Authors: Timofeev, Oleg; Giron, Philippe; Lawo, Steffen; Pichler, Martin; Noeparast, Amir

DOI: https://doi.org/10.1038/s41698-024-00554-5

Paper

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization

Kohei Maruyama; Yuki Shimizu; Yumi Nomura et al. · 2025

Full title: Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization

Authors: Kohei Maruyama; Yuki Shimizu; Yumi Nomura; Tomoko Oh-hara; Yuki Takahashi; Satoshi Nagayama; Naoya Fujita; Ryohei Katayama

DOI: https://doi.org/10.1038/s41698-024-00793-6

Paper

Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A

H. Yanada; Ryohei Yoshida; Ryotaro Kida et al. · 2025

Full title: Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A

DOI: https://doi.org/10.1038/s41698-025-00953-2

Paper

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Maroni, Giorgia; Bassal, Mahmoud A.; Krishnan, Indira et al. · 2021

Full title: Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

DOI: https://doi.org/10.1038/s42003-021-01897-6

Paper

Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform

Xia, Yifeng; X, Ji; Jang, In Sock et al. · 2021

Full title: Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform

Authors: Xia, Yifeng; X, Ji; Jang, In Sock; Surka, Christine; Hsu, Christy; Wang, Kai; Rolfe, Mark; Bence, Neil; Lu, Gang

DOI: https://doi.org/10.1038/s42003-021-02352-2

Paper

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Chapeau, Emilie A.; Sansregret, Laurent; Galli, Giorgio Giacomo et al. · 2024

Full title: Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

DOI: https://doi.org/10.1038/s43018-024-00754-9

Paper

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Riediger, Anja Lisa; Dietz, Steffen; Schirmer, Uwe et al. · 2016

Full title: Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Authors: Riediger, Anja Lisa; Dietz, Steffen; Schirmer, Uwe; Meister, Michael; Heinzmann-Groth, Ingrid; Schneider, Marc A.; Muley, Thomas; Thomas, Michael; Sültmann, Holger

DOI: https://doi.org/10.1038/srep33505

Paper

Fragment-based covalent ligand discovery

Lu, Wenchao; Kostić, Milka; Zhang, Tinghu et al. · 2021

Full title: Fragment-based covalent ligand discovery

Authors: Lu, Wenchao; Kostić, Milka; Zhang, Tinghu; Che, Jianwei; Patricelli, Matthew P.; Jones, Lyn H.; Chouchani, Edward T.; Gray, Nathanael S.

DOI: https://doi.org/10.1039/d0cb00222d

Paper

KRasG12C inhibitors in clinical trials: a short historical perspective

Goebel, Lisa; Müller, Matthias; Goody, Roger S. et al. · 2020

Full title: KRasG12C inhibitors in clinical trials: a short historical perspective

Authors: Goebel, Lisa; Müller, Matthias; Goody, Roger S.; Rauh, Daniel

DOI: https://doi.org/10.1039/d0md00096e

Paper

Covalent inhibitors: a rational approach to drug discovery

Sutanto, Fandi; Konstantinidou, Markella; Dömlingꝉ, Alexander · 2020

Full title: Covalent inhibitors: a rational approach to drug discovery

Authors: Sutanto, Fandi; Konstantinidou, Markella; Dömlingꝉ, Alexander

DOI: https://doi.org/10.1039/d0md00154f

Paper

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation

Bond, Michael J.; Crews, Craig M. · 2021

Full title: Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation

Authors: Bond, Michael J.; Crews, Craig M.

DOI: https://doi.org/10.1039/d1cb00011j

Paper

Monobodies as tool biologics for accelerating target validation and druggable site discovery

Akkapeddi, Padma; Teng, Kai Wen; Koide, Shohei · 2021

Full title: Monobodies as tool biologics for accelerating target validation and druggable site discovery

Authors: Akkapeddi, Padma; Teng, Kai Wen; Koide, Shohei

DOI: https://doi.org/10.1039/d1md00188d

Paper

Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling

Lim, Shuhui; Boyer, N.; Boo, Nicole et al. · 2021

Full title: Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling

DOI: https://doi.org/10.1039/d1sc05187c

Paper

The era of high-quality chemical probes

Licciardello, Marco P.; Workman, Paul · 2022

Full title: The era of high-quality chemical probes

Authors: Licciardello, Marco P.; Workman, Paul

DOI: https://doi.org/10.1039/d2md00291d

Paper

Medicinal chemistry perspective of pyrido[2,3- d ]pyrimidines as anticancer agents

Kumar, Adarsh; Bhagat, Kuber Kumar; Singh, Ankit Kumar et al. · 2023

Full title: Medicinal chemistry perspective of pyrido[2,3- d ]pyrimidines as anticancer agents

Authors: Kumar, Adarsh; Bhagat, Kuber Kumar; Singh, Ankit Kumar; Singh, Harshwardhan; Angre, Tanuja; Verma, Amita; Khalilullah, Habibullah; Jaremko, Mariusz; Emwas, Abdul‐Hamid; Kumar, Pradeep

DOI: https://doi.org/10.1039/d3ra00056g

Paper

Management of Brain Metastases: A Review of Novel Therapies

Bellur, Shreyas; Khosla, Atulya Aman; Ozair, Ahmad et al. · 2023

Full title: Management of Brain Metastases: A Review of Novel Therapies

Authors: Bellur, Shreyas; Khosla, Atulya Aman; Ozair, Ahmad; Kotecha, Rupesh; McDermott, Michael; Ahluwalia, Manmeet S.

DOI: https://doi.org/10.1055/s-0043-1776782

Paper

The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12C

Vincent L. Cannataro; S. Gaffney; Carly Stender et al. · 2017

Full title: The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12C

Authors: Vincent L. Cannataro; S. Gaffney; Carly Stender; Zi-Ming Zhao; M. Philips; A. Greenstein; J. Townsend

DOI: https://doi.org/10.1101/149724

Paper

SHP2 Inhibition Abrogates Adaptive Resistance to KRAS G12C -Inhibition and Remodels the Tumor Microenvironment of KRAS -Mutant Tumors

Fedele, Carmine; Li, Shuai; Teng, Kai Wen et al. · 2020

Full title: SHP2 Inhibition Abrogates Adaptive Resistance to KRAS G12C -Inhibition and Remodels the Tumor Microenvironment of KRAS -Mutant Tumors

DOI: https://doi.org/10.1101/2020.05.30.125138

Paper

Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer

Y. Inoue; A. Nikolić; D. Farnsworth et al. · 2020

Full title: Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer

Authors: Y. Inoue; A. Nikolić; D. Farnsworth; A-L Liu; M. Ladanyi; R. Somwar; M. Gallo; W. Lockwood

DOI: https://doi.org/10.1101/2020.11.12.368522

Paper

An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

Boumelha, Jesse; Trécesson, Sophie de Carné; Law, Emily K. et al. · 2020

Full title: An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

DOI: https://doi.org/10.1101/2020.12.22.423126

Paper

Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

Tang, Kwan Ho; Li, Shuai; Khodadadi‐Jamayran, Alireza et al. · 2021

Full title: Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

DOI: https://doi.org/10.1101/2021.03.21.436338

Paper

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Haderk, Franziska; Fernández-Méndez, Celia; Čech, Lauren et al. · 2021

Full title: A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

DOI: https://doi.org/10.1101/2021.10.23.465573

Paper

Combined KRAS G12C and SOS1 inhibition enhances and extends the anti-tumor response in KRAS G12C -driven cancers by addressing intrinsic and acquired resistance

Thatikonda, Venu; Lu, Hengyu; Jurado, Sabine et al. · 2023

Full title: Combined KRAS G12C and SOS1 inhibition enhances and extends the anti-tumor response in KRAS G12C -driven cancers by addressing intrinsic and acquired resistance

DOI: https://doi.org/10.1101/2023.01.23.525210

Paper

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro et al. · 2023

Full title: Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

DOI: https://doi.org/10.1101/2023.03.27.534309

Paper

A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer

J. Foote; Tyler E Mattox; A. Keeton et al. · 2024

Full title: A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer

DOI: https://doi.org/10.1101/2023.05.17.541233

Paper

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

Vida Tajiknia; Maximilian Pinho-Schwermann; Praveen R Srinivasan et al. · 2023

Authors: Vida Tajiknia; Maximilian Pinho-Schwermann; Praveen R Srinivasan; Liz Hernandez Borrero; Leiqing Zhang; K. Huntington; W. El-Deiry

DOI: https://doi.org/10.1101/2023.09.13.557593

Paper

Targeting cancer with small molecule pan-KRAS degraders

Popow, Johannes; Farnaby, William; Gollner, Andreas et al. · 2023

Full title: Targeting cancer with small molecule pan-KRAS degraders

DOI: https://doi.org/10.1101/2023.10.24.563163

Paper

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma

Daley, Brianna R.; Sealover, Nancy E.; Sheffels, Erin et al. · 2023

Full title: SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma

DOI: https://doi.org/10.1101/2023.12.07.570642

Paper

Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling

Rachel Nakagawa; Andrew Beardsley; Sophia Durney et al. · 2024

Full title: Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling

Authors: Rachel Nakagawa; Andrew Beardsley; Sophia Durney; M. Hayward; Vishvak Subramanyam; Nathaniel P. Meyer; Harrison Wismer; Hani Goodarzi; Valerie M. Weaver; Daniel Van de Mark; Andrei Goga

DOI: https://doi.org/10.1101/2024.09.26.615226

Paper

Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells

Maj-Britt Paulsohn; Klara Henrike Frahnert; Xin Fang et al. · 2025

Full title: Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells

Authors: Maj-Britt Paulsohn; Klara Henrike Frahnert; Xin Fang; Carolin Schneider; Constanza Tapia Contreras; Günter Schneider; E. Hessmann; Matthias Dobbelstein

DOI: https://doi.org/10.1101/2025.01.11.632518

Paper

CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma

Kathleen M. McAndrews; Krishnan K. Mahadevan; Bingrui Li et al. · 2025

Full title: CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma

DOI: https://doi.org/10.1101/2025.01.29.635543

Paper

RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors

Beau Baars; Ana Orive-Ramos; Ziyue Kou et al. · 2025

Full title: RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors

Authors: Beau Baars; Ana Orive-Ramos; Ziyue Kou; Bijaya Gaire; Mathieu Desaunay; Christos Adamopoulos; Stuart A. Aaronson; Shaomeng Wang; E. Gavathiotis; Poulikos I. Poulikakos

DOI: https://doi.org/10.1101/2025.02.14.638317

Paper

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models

Daniela D. De Nobrega; Logan C. Eiler; Parmanand Ahirwar et al. · 2025

Full title: Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models

Authors: Daniela D. De Nobrega; Logan C. Eiler; Parmanand Ahirwar; Urvi P. Rawal; Chelsea L. Crawford; D. Buchsbaum; A. Keeton; Y. Maxuitenko; Xi Chen; G. Piazza; Allan Tsung; Karim I. Budhwani

DOI: https://doi.org/10.1101/2025.02.25.640132

Paper

Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1, a regulator of cap-dependent translation

I. Meraz; Shuhong Wu; Yi Xu et al. · 2025

Full title: Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1, a regulator of cap-dependent translation

Authors: I. Meraz; Shuhong Wu; Yi Xu; Lihui Gao; Meng Feng; Chenghui Ren; R. Song; Ran Zhang; Qi Wang; Yuanxin Xi; Sung Yun Jung; Jing Wang; Bingliang Fang; M. Majidi; Jack A Roth

DOI: https://doi.org/10.1101/2025.03.18.643954

Paper

Mechanisms of resistance to active state selective tri-complex RAS inhibitors

Ben Sang; Ling Feng Ye; Feng Hu et al. · 2025

Full title: Mechanisms of resistance to active state selective tri-complex RAS inhibitors

DOI: https://doi.org/10.1101/2025.04.24.649345

Paper

Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.

Daniel R. Principe; Jeffrey H Becker; Anastasia E. Metropulos et al. · 2026

Full title: Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.

Authors: Daniel R. Principe; Jeffrey H Becker; Anastasia E. Metropulos; Alejandra M Marinelarena; Thao D Pham; A. Aissa; H. Munshi

DOI: https://doi.org/10.1158/1535-7163.mct-25-0483

Paper

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRC.

Alonso, Salvador; Chu, Kevan; Parsons, Marie J et al. · 2025

Full title: Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRC.

Authors: Alonso, Salvador; Chu, Kevan; Parsons, Marie J; Granowsky, Elizabeth; Gunasinghe, Himari; Shia, Jinru; Yaeger, Rona; Dow, Lukas E

DOI: https://doi.org/10.1101/2025.08.05.668666

Paper

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation

Sung-Hyun Hwang; Mingyun Bae; Ji-Won Kim et al. · 2025

Full title: VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation

DOI: https://doi.org/10.1101/2025.09.16.676456

Paper

Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development

Estape, Anna Arnal; Foggetti, Giorgia; Starrett, Jacqueline H. et al. · 2021

Full title: Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development

Authors: Estape, Anna Arnal; Foggetti, Giorgia; Starrett, Jacqueline H.; Nguyen, Don X.; Politi, Katerina

DOI: https://doi.org/10.1101/cshperspect.a037820

Paper

Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47

Hu, Huanhuan; Cheng, Rongjie; Wang, Yanbo et al. · 2022

Full title: Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47

DOI: https://doi.org/10.1172/jci153470

Paper

Targeting mutations in cancer

Waarts, Michael R.; Stonestrom, Aaron J.; Park, Young C. et al. · 2022

Full title: Targeting mutations in cancer

Authors: Waarts, Michael R.; Stonestrom, Aaron J.; Park, Young C.; Levine, Ross L.

DOI: https://doi.org/10.1172/jci154943

Paper

Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition

Yihsuan S. Tsai; M. Woodcock; S. Azam et al. · 2022

Full title: Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition

Authors: Yihsuan S. Tsai; M. Woodcock; S. Azam; L. Thorne; K. Kanchi; J. Parker; B. Vincent; C. Pecot

DOI: https://doi.org/10.1172/jci155523

Paper

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

F. Nardi; N. Perurena; Amy E. Schade et al. · 2023

Full title: Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Authors: F. Nardi; N. Perurena; Amy E. Schade; Zecang Li; K. Ngo; E. Ivanova; Aisha Saldanha; Chendi Li; P. Gokhale; A. Hata; D. Barbie; C. Paweletz; P. Janne; K. Cichowski

DOI: https://doi.org/10.1172/jci167651

Paper

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

Vaccaro, Kyle; Allen, Juliet; Whitfield, Troy W. et al. · 2024

Full title: Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

DOI: https://doi.org/10.1172/jci169315

Paper

Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS–mutant cancer models

Shihui Shen; Qiansen Zhang; Yuhan Wang et al. · 2025

Full title: Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS–mutant cancer models

DOI: https://doi.org/10.1172/jci185278

Paper

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer

Padhye, Aparna; Konen, Jessica; Rodriguez, B. Leticia et al. · 2021

Full title: Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer

DOI: https://doi.org/10.1172/jci.insight.148392

Paper

Targeting the undruggable oncogenic KRAS: the dawn of hope

Asimgil, Hande; Ertetik, Utku; Çevik, Nedim Can et al. · 2022

Full title: Targeting the undruggable oncogenic KRAS: the dawn of hope

DOI: https://doi.org/10.1172/jci.insight.153688

Paper

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report

H. H. Rossing; M. Grauslund; E. Urbanska et al. · 2013

Authors: H. H. Rossing; M. Grauslund; E. Urbanska; L. C. Melchior; C. K. Rask; Junia C. Costa; B. Skov; J. Sørensen; E. Santoni-Rugiu

DOI: https://doi.org/10.1186/1756-0500-6-489

Paper

Oncogenic driver mutations in lung cancer

S. Luo; D. C. Lam · 2013

Full title: Oncogenic driver mutations in lung cancer

Authors: S. Luo; D. C. Lam

DOI: https://doi.org/10.1186/2213-0802-1-6

Paper

MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis

Chungui Xu; Weihao Lin; Qi Zhang et al. · 2024

Full title: MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis

Authors: Chungui Xu; Weihao Lin; Qi Zhang; Yarui Ma; Xue Wang; Ai Guo; Guiling Zhu; Zhendiao Zhou; Weiwei Song; Ziyi Zhao; Yuchen Jiao; Xiaobing Wang; Chunxia Du

DOI: https://doi.org/10.1186/s10020-024-00972-y

Paper

Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma

Sixian Chen; Aizhen Fu; Yuanli Lu et al. · 2022

Full title: Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma

Authors: Sixian Chen; Aizhen Fu; Yuanli Lu; W. Lu; Yongfeng Chen; S.-H. Hong; Suli Zhou; Tianmin Xiang; Zhenzhen Zhang; Yongguang Cai

DOI: https://doi.org/10.1186/s12864-021-08289-4

Paper

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

Araujo, Luiz H.; Souza, Bianca Mendes; Leite, Laura Rabelo et al. · 2021

Full title: Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

Authors: Araujo, Luiz H.; Souza, Bianca Mendes; Leite, Laura Rabelo; Parma, Sabrina A. F.; Lopes, Natália P.; Malta, Frederico Scott Varella; Freire, Maíra Cristina Menezes

DOI: https://doi.org/10.1186/s12885-021-07884-8

Paper

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice

Liu, Yanxia; Gao, Yuan; Wang, Ying et al. · 2022

Full title: A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice

Authors: Liu, Yanxia; Gao, Yuan; Wang, Ying; Zhao, Cong; Zhang, Zhiyun; Li, Baolan; Zhang, Tongmei

DOI: https://doi.org/10.1186/s12885-022-10236-9

Paper

Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

Julián, Cristina; Pal, Navdeep; Gershon, Anda et al. · 2023

Full title: Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

Authors: Julián, Cristina; Pal, Navdeep; Gershon, Anda; Evangelista, Marie; Purkey, Hans E.; Lambert, Peter; Shi, Zhen; Zhang, Qing

DOI: https://doi.org/10.1186/s12885-023-10778-6

Paper

Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis

Teppei Yamaguchi; J. Shimizu; Reiko Matsuzawa et al. · 2024

Full title: Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis

Authors: Teppei Yamaguchi; J. Shimizu; Reiko Matsuzawa; Naohiro Watanabe; Y. Horio; Yutaka Fujiwara

DOI: https://doi.org/10.1186/s12885-024-12554-6

Paper

The complex journey of targeting RAS in oncology

Katarzyna Wasiak; Damian Ciunowicz; Amelia Kierasińska-Kałka et al. · 2025

Full title: The complex journey of targeting RAS in oncology

Authors: Katarzyna Wasiak; Damian Ciunowicz; Amelia Kierasińska-Kałka; Marta Węgierska; Marcin Pacholczyk; Piotr Rieske; Ewelina Stoczyńska-Fidelus

DOI: https://doi.org/10.1186/s12885-025-14033-y

Paper

Comprehensive tumor molecular profile analysis in clinical practice

Özdoğan, Mustafa; Papadopoulou, Eirini; Τσούλος, Νικόλαος et al. · 2021

Full title: Comprehensive tumor molecular profile analysis in clinical practice

DOI: https://doi.org/10.1186/s12920-021-00952-9

Paper

CRISPR and KRAS: a match yet to be made

Bender, Guzide; Yamaci, Rezan Fahrioglu; Taneri, Bahar · 2021

Full title: CRISPR and KRAS: a match yet to be made

Authors: Bender, Guzide; Yamaci, Rezan Fahrioglu; Taneri, Bahar

DOI: https://doi.org/10.1186/s12929-021-00772-0

Paper

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer

Chiou, Li-Wen; Chan, Chien-Hui; Jhuang, Yu‐Ling et al. · 2023

Full title: DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer

Authors: Chiou, Li-Wen; Chan, Chien-Hui; Jhuang, Yu‐Ling; Yang, Ching‐Yao; Jeng, Yung‐Ming

DOI: https://doi.org/10.1186/s12929-023-00940-4

Paper

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

Kotani, Hiroshi; Oshima, Hiroko; Boucher, Justin C. et al. · 2024

Full title: Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

DOI: https://doi.org/10.1186/s12929-024-01060-3

Paper

Recent advances in non-small cell lung cancer targeted therapy; an update review

Araghi, Mahmood; Mannani, Reza; Maleki, Ali Heidarnejad et al. · 2023

Full title: Recent advances in non-small cell lung cancer targeted therapy; an update review

DOI: https://doi.org/10.1186/s12935-023-02990-y

Paper

The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis

Rui Zhao; Yang Shu; Wei Xu et al. · 2024

Full title: The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis

Authors: Rui Zhao; Yang Shu; Wei Xu; Fengxian Jiang; Pancen Ran; Liying Pan; Jingliang Wang; Weihao Wang; Jing Zhao; Yahui Wang; Guobin Fu

DOI: https://doi.org/10.1186/s12935-024-03498-9

Paper

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Xu, Ke; Park, Dongkyoo; Magis, Andrew T. et al. · 2019

Full title: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Authors: Xu, Ke; Park, Dongkyoo; Magis, Andrew T.; Zhang, Jun; Zhou, Wei; Sica, Gabriel; Ramalingam, Suresh S.; Curran, Walter J.; Deng, Xingming

DOI: https://doi.org/10.1186/s12943-019-1012-4

Paper

RNA-based therapies: A cog in the wheel of lung cancer defense

Κhan, Parvez; Siddiqui, Jawed A.; Lakshmanan, Imayavaramban et al. · 2021

Full title: RNA-based therapies: A cog in the wheel of lung cancer defense

Authors: Κhan, Parvez; Siddiqui, Jawed A.; Lakshmanan, Imayavaramban; Ganti, Apar Kishor; Salgia, Ravi; Jain, Maneesh; Batra, Surinder K.; Nasser, Mohd W.

DOI: https://doi.org/10.1186/s12943-021-01338-2

Paper

An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

F. Reggiani; E. Sauta; F. Torricelli et al. · 2021

Full title: An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

Authors: F. Reggiani; E. Sauta; F. Torricelli; E. Zanetti; E. Tagliavini; G. Santandrea; G. Gobbi; G. Damia; R. Bellazzi; D. Ambrosetti; A. Ciarrocchi; V. Sancisi

DOI: https://doi.org/10.1186/s12943-021-01357-z

Paper

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Tang, Daolin; Kroemer, Guido; Kang, Rui · 2021

Full title: Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Authors: Tang, Daolin; Kroemer, Guido; Kang, Rui

DOI: https://doi.org/10.1186/s12943-021-01422-7

Paper

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Chunxi Zhu; Xiaoqing Guan; Xinuo Zhang et al. · 2022

Full title: Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Authors: Chunxi Zhu; Xiaoqing Guan; Xinuo Zhang; X. Luan; Zhengbo Song; Xiangdong Cheng; Weidong Zhang; Jiangjiang Qin

DOI: https://doi.org/10.1186/s12943-022-01629-2

Paper

Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

Zhu, Zhi; McGray, AJ Robert; Jiang, Weijian et al. · 2022

Full title: Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

Authors: Zhu, Zhi; McGray, AJ Robert; Jiang, Weijian; Lu, Binfeng; Kaliński, Paweł; Guo, Zong Sheng

DOI: https://doi.org/10.1186/s12943-022-01664-z

Paper

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Wang, Penglei; Laster, Kyle Vaughn; Jia, Xuechao et al. · 2023

Full title: Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Authors: Wang, Penglei; Laster, Kyle Vaughn; Jia, Xuechao; Dong, Zigang; Liu, Kangdong

DOI: https://doi.org/10.1186/s12943-023-01903-x

Paper

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Puyalto, A.; Rodríguez‐Remírez, María; López, Inés et al. · 2024

Full title: Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

DOI: https://doi.org/10.1186/s12943-024-01991-3

Paper

Targeting KRAS: from metabolic regulation to cancer treatment

Shi, Yanyan; Zheng, Huiling; Wang, Tianzhen et al. · 2025

Full title: Targeting KRAS: from metabolic regulation to cancer treatment

Authors: Shi, Yanyan; Zheng, Huiling; Wang, Tianzhen; Zhou, Shaonan; Zhao, Shiqing; Li, Mo; Cao, Baoshan

DOI: https://doi.org/10.1186/s12943-024-02216-3

Paper

The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy

Ma, Qinglong; Zhang, Wenyang; Wu, Kongming et al. · 2025

Full title: The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy

Authors: Ma, Qinglong; Zhang, Wenyang; Wu, Kongming; Shi, Lei

DOI: https://doi.org/10.1186/s12943-024-02218-1

Paper

Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs

Xia Wang; Jing Wu; Aotian Xiao et al. · 2025

Full title: Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs

Authors: Xia Wang; Jing Wu; Aotian Xiao; Jie Wang; Jun Tian

DOI: https://doi.org/10.1186/s12943-025-02364-0

Paper

Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation

Dim, Nneka; Perepelyuk, Maryna; Gomes, Olukayode et al. · 2015

Full title: Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation

Authors: Dim, Nneka; Perepelyuk, Maryna; Gomes, Olukayode; Thangavel, Chellappagounder; Liu, Yi; Den, Robert B.; Lakshmikuttyamma, Ashakumary; Shoyele, Sunday

DOI: https://doi.org/10.1186/s12951-015-0124-2

Paper

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo

Yuchen Zhang; Cheukfai Li; Chenglai Xia et al. · 2022

Full title: Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo

Authors: Yuchen Zhang; Cheukfai Li; Chenglai Xia; Keneth Kin Wah To; Zhixing Guo; C. Ren; L. Wen; Fang Wang; Liwu Fu; N. Liao

DOI: https://doi.org/10.1186/s12964-022-00955-8

Paper

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions

Watterson, Alex; Coelho, Matthew A. · 2023

Full title: Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions

Authors: Watterson, Alex; Coelho, Matthew A.

DOI: https://doi.org/10.1186/s12964-023-01063-x

Paper

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

Rosell, R.; Jantus‐Lewintre, Eloísa; Cao, Peng et al. · 2024

Full title: KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

DOI: https://doi.org/10.1186/s12964-024-01667-x

Paper

Off-target engagement of sotorasib with PPARγ via FABP4: a novel mechanism driving interstitial lung disease.

Zhang, Jiaqi; Li, Jinjin; Cheng, Mengting et al. · 2025

Full title: Off-target engagement of sotorasib with PPARγ via FABP4: a novel mechanism driving interstitial lung disease.

Authors: Zhang, Jiaqi; Li, Jinjin; Cheng, Mengting; Zhou, Haiyang; Zhang, Xiaochen; Yan, Hao; Xu, Zhifei; Yang, Bo; He, Qiaojun; Gao, Zizheng; Chen, Xueqin; Luo, Peihua

DOI: https://doi.org/10.1186/s12964-025-02425-3

Paper

RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment

Liu, Yongting; Xie, Bin; Chen, Qiong · 2023

Full title: RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment

Authors: Liu, Yongting; Xie, Bin; Chen, Qiong

DOI: https://doi.org/10.1186/s12967-023-04486-9

Paper

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner

Laurent, Pierre-Antoine; Milić, Marina; Quevrin, Clément et al. · 2023

Full title: KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner

DOI: https://doi.org/10.1186/s12967-023-04619-0

Paper

KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors

Tian, Linyan; Liu, Chengming; Zheng, Sufei et al. · 2025

Full title: KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors

Authors: Tian, Linyan; Liu, Chengming; Zheng, Sufei; Shi, Huiyang; Fang, Wei; Jiang, Wenxin; Dong, Yucheng; Xu, Haiyan; Yin, Enzhi; Sun, Nan; He, Jie; Wang, Yan

DOI: https://doi.org/10.1186/s12967-025-06089-y

Paper

Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

Shen, Fangfang; Guo, Wei; Song, Xia et al. · 2023

Full title: Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

Authors: Shen, Fangfang; Guo, Wei; Song, Xia; Wang, Bei

DOI: https://doi.org/10.1186/s13000-023-01349-1

Paper

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Majeed, Umair; Manochakian, Rami; Zhao, Yujie et al. · 2021

Full title: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Authors: Majeed, Umair; Manochakian, Rami; Zhao, Yujie; Lou, Yanyan

DOI: https://doi.org/10.1186/s13045-021-01121-2

Paper

Emerging strategies to target RAS signaling in human cancer therapy

Chen, Kun; Zhang, Yalei; Qian, Ling et al. · 2021

Full title: Emerging strategies to target RAS signaling in human cancer therapy

Authors: Chen, Kun; Zhang, Yalei; Qian, Ling; Wang, Peng

DOI: https://doi.org/10.1186/s13045-021-01127-w

Paper

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Sajid Khan; Janet S. Wiegand; Peiyi Zhang et al. · 2022

Full title: BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

DOI: https://doi.org/10.1186/s13045-022-01241-3

Paper

Tumor organoids: applications in cancer modeling and potentials in precision medicine

Xu, Hanxiao; Jiao, Dechao; Liu, Aiguo et al. · 2022

Full title: Tumor organoids: applications in cancer modeling and potentials in precision medicine

Authors: Xu, Hanxiao; Jiao, Dechao; Liu, Aiguo; Wu, Kongming

DOI: https://doi.org/10.1186/s13045-022-01278-4

Paper

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Wu, Qing; Qian, Wei; Sun, Xiaoli et al. · 2022

Full title: Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Authors: Wu, Qing; Qian, Wei; Sun, Xiaoli; Jiang, Shaojie

DOI: https://doi.org/10.1186/s13045-022-01362-9

Paper

Drugging KRAS: current perspectives and state-of-art review

Parikh, Kaushal; Banna, Giuseppe Luigi; Liu, Stephen V. et al. · 2022

Full title: Drugging KRAS: current perspectives and state-of-art review

Authors: Parikh, Kaushal; Banna, Giuseppe Luigi; Liu, Stephen V.; Friedlaender, Alex; Desai, Aakash; Subbiah, Vivek; Addeo, Alfredo

DOI: https://doi.org/10.1186/s13045-022-01375-4

Paper

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Xiaojuan Yang; Hong Wu · 2024

Full title: RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Authors: Xiaojuan Yang; Hong Wu

DOI: https://doi.org/10.1186/s13045-024-01631-9

Paper

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.

Kwan, Albert K; Piazza, Gary A; Keeton, Adam B et al. · 2022

Full title: The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.

Authors: Kwan, Albert K; Piazza, Gary A; Keeton, Adam B; Leite, Caio A

DOI: https://doi.org/10.1186/s13046-021-02225-w

Paper

Research progress on non-protein-targeted drugs for cancer therapy

Zhang, Yiwen; Lu, Lu; Song, Feifeng et al. · 2023

Full title: Research progress on non-protein-targeted drugs for cancer therapy

Authors: Zhang, Yiwen; Lu, Lu; Song, Feifeng; Zou, Xiaozhou; Liu, Yujia; Zheng, Xiaowei; Qian, Jinjun; Gu, Chunyan; Huang, Ping; Yang, Ye

DOI: https://doi.org/10.1186/s13046-023-02635-y

Paper

Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2

Kim, Dasom; Min, Dongwha; Kim, Joohee et al. · 2023

Full title: Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2

Authors: Kim, Dasom; Min, Dongwha; Kim, Joohee; Kim, Jong Min; Seo, Yerim; Jung, Byung Hwa; Kwon, Seung‐Hae; Ro, Hyunju; Lee, Seoee; Jason, K.; Lee, Ji-Yun

DOI: https://doi.org/10.1186/s13046-023-02922-8

Paper

RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer

Jianzhuang Wu; Kexin Xie; Yixuan Zhang et al. · 2025

Full title: RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer

Authors: Jianzhuang Wu; Kexin Xie; Yixuan Zhang; Weiyi Zhang; Rongjie Cheng; Yaliang Zhang; Yugui Xia; Tongyan Liu; Rong Yin; Yudong Qiu; Tao Xu; Rutian Li; Qi Sun; Chao Yan

DOI: https://doi.org/10.1186/s13046-025-03369-9

Paper

Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target

Ajmal, Amar; Alkhatabi, Hind Ali; Alreemi, Roaa M. et al. · 2024

Full title: Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target

Authors: Ajmal, Amar; Alkhatabi, Hind Ali; Alreemi, Roaa M.; Alamri, Mubarak A.; Khalid, Asaad; Abdalla, Ashraf N.; Alotaibi, Bader S.; Wadood, Abdul

DOI: https://doi.org/10.1186/s13065-024-01152-z

Paper

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

Chan, Lok Seng; Liu, Jianzhong; Li, Molly et al. · 2023

Full title: Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

Authors: Chan, Lok Seng; Liu, Jianzhong; Li, Molly; Li, Lili; Tao, Qian; Mok, Tony

DOI: https://doi.org/10.1186/s13148-023-01454-4

Paper

Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.

Boby, Jeffrey Mathew; Mohd Ghazali, Nurul Nadia; Mani, Anita et al. · 2022

Full title: Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.

Authors: Boby, Jeffrey Mathew; Mohd Ghazali, Nurul Nadia; Mani, Anita; George, Mathew

DOI: https://doi.org/10.1186/s13256-022-03593-3

Paper

The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC

Firas Batrash; Mahmoud Kutmah; Jun Zhang · 2023

Full title: The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC

Authors: Firas Batrash; Mahmoud Kutmah; Jun Zhang

DOI: https://doi.org/10.1186/s40164-023-00453-8

Paper

Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling

Wang, Ya‐Fang; Yao, Mingyue; Li, Cheng et al. · 2023

Full title: Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling

Authors: Wang, Ya‐Fang; Yao, Mingyue; Li, Cheng; Yang, Kexin; Qin, Xiaolong; Xu, Lansong; Shi, Shangxuan; Yu, Chengcheng; Meng, Xiangjun; Xie, Chengying

DOI: https://doi.org/10.1186/s40164-023-00466-3

Paper

Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

Qiao, Meng; Zhou, Fei; Liu, Xinyu et al. · 2024

Full title: Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

Authors: Qiao, Meng; Zhou, Fei; Liu, Xinyu; Jiang, Tao; Wang, Haowei; Li, Xuefei; Zhao, Chao; Cheng, Lei; Chen, Xiaoxia; Ren, Shengxiang; Wang, Zaiqi; Zhou, Caicun

DOI: https://doi.org/10.1186/s40164-023-00471-6

Paper

Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer

Jeffrey Xiao; Joshua Kim; Brandon Park et al. · 2025

Full title: Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer

DOI: https://doi.org/10.1186/s40164-025-00669-w

Paper

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Liu, Si‐Yang Maggie; Sun, Hao; Zhou, Jiaying et al. · 2020

Full title: Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Authors: Liu, Si‐Yang Maggie; Sun, Hao; Zhou, Jiaying; Jie, Guang‐Ling; Xie, Zhi; Shao, Yang; Zhang, Xian; Ye, Junyi; Chen, Chunxiang; Zhang, Xu‐Chao; Zhou, Qing; Yang, Jin‐Ji; Wu, Yi‐Long

DOI: https://doi.org/10.1186/s40364-020-00199-z

Paper

Oncogenic alterations in advanced NSCLC: a molecular super-highway

Friedlaender, Alex; Pérol, M.; Banna, Giuseppe Luigi et al. · 2024

Full title: Oncogenic alterations in advanced NSCLC: a molecular super-highway

Authors: Friedlaender, Alex; Pérol, M.; Banna, Giuseppe Luigi; Parikh, Kaushal; Addeo, Alfredo

DOI: https://doi.org/10.1186/s40364-024-00566-0

Paper

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Pang, Xiufeng; Liu, Mingyao · 2016

Full title: A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Authors: Pang, Xiufeng; Liu, Mingyao

DOI: https://doi.org/10.1186/s40880-016-0154-7

Paper

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Zixi Wang; Yurou Xing; Bingjie Li et al. · 2022

Full title: Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Authors: Zixi Wang; Yurou Xing; Bingjie Li; Xiaoyu Li; Bin Liu; Yongsheng Wang

DOI: https://doi.org/10.1186/s43556-022-00107-x

Paper

KRASG12C inhibitors in lung cancer therapy

Maciej Jędrak; Karolina Niekurzak; Joanna Kania et al. · 2023

Full title: KRASG12C inhibitors in lung cancer therapy

Authors: Maciej Jędrak; Karolina Niekurzak; Joanna Kania; Maciej Józefiak; Piotr Sobkiewicz; Krzysztof Kania

DOI: https://doi.org/10.12775/jehs.2023.17.01.015

Paper

Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies

Valeryia Milasheuskaya; Katsiaryna Miraniuk; Mykola Sobchynskyi et al. · 2025

Full title: Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies

DOI: https://doi.org/10.12775/qs.2025.43.61191

Paper

Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

Perkins, Géraldine; Yap, Timothy A.; Pope, Lorna et al. · 2012

Full title: Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

DOI: https://doi.org/10.1371/journal.pone.0047020

Paper

Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome

Kerner, Gerald S. M. A.; Schuuring, Ed; Sietsma, Johanna et al. · 2013

Full title: Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome

DOI: https://doi.org/10.1371/journal.pone.0070346

Paper

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

R. Terragni; A. Casadei Gardini; S. Sabattini et al. · 2014

Full title: EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

Authors: R. Terragni; A. Casadei Gardini; S. Sabattini; G. Bettini; D. Amadori; C. Talamonti; M. Vignoli; L. Capelli; J. Saunders; M. Ricci; P. Ulivi

DOI: https://doi.org/10.1371/journal.pone.0085388

Paper

A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein

Carver, Joseph O.; Dexheimer, Thomas S.; Hsu, Dennis et al. · 2014

Full title: A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein

Authors: Carver, Joseph O.; Dexheimer, Thomas S.; Hsu, Dennis; Weng, Meng‐Tzu; Smith, Jordan L.; Guha, Rajarshi; Jadhav, Ajit; Simeonov, Anton; Luo, Ji

DOI: https://doi.org/10.1371/journal.pone.0103836

Paper

The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

Wada, Makoto; Horinaka, Mano; Yamazaki, Toshikazu et al. · 2014

Full title: The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

Authors: Wada, Makoto; Horinaka, Mano; Yamazaki, Toshikazu; Katoh, Norito; Sakai, Toshiyuki

DOI: https://doi.org/10.1371/journal.pone.0113217

Paper

A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress

Lee, Jong Woo; Park, Hee Sun; Park, Sin‐Aye et al. · 2015

Full title: A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress

Authors: Lee, Jong Woo; Park, Hee Sun; Park, Sin‐Aye; Ryu, Seung-Hee; Meng, Wuyi; Jürgensmeier, Juliane M.; Kurie, Jonathan M.; Hong, Waun Ki; Boyer, Julie L.; Herbst, Roy S.; Koo, Ja Seok

DOI: https://doi.org/10.1371/journal.pone.0122628

Paper

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression

Sato, Katsuaki; Suda, Kenichi; Shimizu, Shigeki et al. · 2016

Full title: Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression

Authors: Sato, Katsuaki; Suda, Kenichi; Shimizu, Shigeki; Sakai, Kazuko; Mizuuchi, Hiroshi; Tomizawa, Kenji; Takemoto, Toshiki; Nishio, Kazuto; Mitsudomi, Tetsuya

DOI: https://doi.org/10.1371/journal.pone.0154186

Paper

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers

Diána Brauswetter; Bianka Gurbi; A. Varga et al. · 2017

Full title: Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers

Authors: Diána Brauswetter; Bianka Gurbi; A. Varga; E. Várkondi; R. Schwáb; G. Bánhegyi; O. Fábián; G. Kéri; I. Vályi-Nagy; I. Peták

DOI: https://doi.org/10.1371/journal.pone.0185687

Paper

Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy

Fomchenko, Elena I.; Bayley, James C.; Alvarez‐Breckenridge, Christopher et al. · 2022

Full title: Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy

Authors: Fomchenko, Elena I.; Bayley, James C.; Alvarez‐Breckenridge, Christopher; Rhines, Laurence D.; Tatsui, Claudio E.

DOI: https://doi.org/10.14245/ns.2244290.145

Paper

ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer

Saad, Mohamed I.; Alhayyani, Sultan; McLeod, Louise et al. · 2019

Full title: ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer

DOI: https://doi.org/10.15252/emmm.201809976

Paper

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS ‐mutant cancer

Zhang, Yang; Liang, Shun‐Qing; Saliakoura, Maria et al. · 2021

Full title: Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS ‐mutant cancer

DOI: https://doi.org/10.15252/emmm.202013193

Paper

Targeting rare tumors: new focus for clinical research in China

Wang, Shuhang; Jiang, Yale; Miao, Huilei et al. · 2022

Full title: Targeting rare tumors: new focus for clinical research in China

DOI: https://doi.org/10.15252/emmm.202216415

Paper

[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice.]

L. Belluomini; Sara Pilotto · 2025

Full title: [Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice.]

Authors: L. Belluomini; Sara Pilotto

DOI: https://doi.org/10.1701/4619.46290

Paper

Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma

Peng, Xinyi; Xia, Zhenqi; Guo, Yong et al. · 2023

Full title: Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma

Authors: Peng, Xinyi; Xia, Zhenqi; Guo, Yong; Li, Yan

DOI: https://doi.org/10.18632/aging.204770

Paper

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells

A. Rouhi; Christina R. Miller; Sarah Grasedieck et al. · 2016

Full title: Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells

Authors: A. Rouhi; Christina R. Miller; Sarah Grasedieck; Stefanie Reinhart; B. Stolze; H. Döhner; F. Kuchenbauer; L. Bullinger; S. Fröhling; C. Scholl

DOI: https://doi.org/10.18632/oncotarget.13841

Paper

The proto-oncogene KRAS is targeted by miR-200c

Kopp, Florian; Wagner, Ernst; Roidl, Andreas · 2013

Full title: The proto-oncogene KRAS is targeted by miR-200c

Authors: Kopp, Florian; Wagner, Ernst; Roidl, Andreas

DOI: https://doi.org/10.18632/oncotarget.1427

Paper

In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics

Grundberg, Ida; Kiflemariam, Sara; Mignardi, Marco et al. · 2013

Full title: In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics

Authors: Grundberg, Ida; Kiflemariam, Sara; Mignardi, Marco; Imgenberg‐Kreuz, Juliana; Edlund, Karolina; Micke, Patrick; Sundström, Magnus; Sjöblom, Tobias; Botling, Johan; Nilsson, Mats

DOI: https://doi.org/10.18632/oncotarget.1527

Paper

Molecular pathways and therapeutic targets in lung cancer

Shtivelman, Emma; Hensing, Thomas A.; Simon, George R. et al. · 2014

Full title: Molecular pathways and therapeutic targets in lung cancer

Authors: Shtivelman, Emma; Hensing, Thomas A.; Simon, George R.; Dennis, Phillip A.; Otterson, Gregory A.; Bueno, Raphael; Salgia, Ravi

DOI: https://doi.org/10.18632/oncotarget.1891

Paper

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

Jun Zhang; S. Nannapaneni; Dongsheng Wang et al. · 2017

Full title: Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

Authors: Jun Zhang; S. Nannapaneni; Dongsheng Wang; Fakeng Liu; Xu Wang; R. Jin; Xiuju Liu; M. Rahman; Xiang-hong Peng; G. Qian; Z. Chen; Kwok-kin Wong; F. Khuri; Wei Zhou; D. Shin

DOI: https://doi.org/10.18632/oncotarget.19779

Paper

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

Said, Rabih; Yang, Ye; Falchook, Gerald S. et al. · 2014

Full title: Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

DOI: https://doi.org/10.18632/oncotarget.2339

Paper

Implications of KRAS mutations in acquired resistance to treatment in NSCLC

Re, Marzia Del; Rofi, Eleonora; Restante, Giuliana et al. · 2017

Full title: Implications of KRAS mutations in acquired resistance to treatment in NSCLC

Authors: Re, Marzia Del; Rofi, Eleonora; Restante, Giuliana; Crucitta, Stefania; Arrigoni, E.; Fogli, Stefano; Maïo, Massimo Di; Petrini, Iacopo; Danesi, Romano

DOI: https://doi.org/10.18632/oncotarget.23553

Paper

Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials

Wilkins, Jon F.; Cannataro, Vincent L.; Hu, Hai et al. · 2018

Full title: Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials

Authors: Wilkins, Jon F.; Cannataro, Vincent L.; Hu, Hai; Townsend, Jeffrey P.

DOI: https://doi.org/10.18632/oncotarget.25155

Paper

Targeted drug combination therapy design based on driver genes

Zsákai, Lilian; Sipos, Anna; Dobos, Judit et al. · 2019

Full title: Targeted drug combination therapy design based on driver genes

DOI: https://doi.org/10.18632/oncotarget.26985

Paper

Circulating tumor DNA analysis in the era of precision oncology

R. Said; N. Guibert; G. Oxnard et al. · 2020

Full title: Circulating tumor DNA analysis in the era of precision oncology

Authors: R. Said; N. Guibert; G. Oxnard; A. Tsimberidou

DOI: https://doi.org/10.18632/oncotarget.27418

Paper

Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations

Joshi, Asim; Mishra, Rohit; Desai, Sanket et al. · 2021

Full title: Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations

DOI: https://doi.org/10.18632/oncotarget.27905

Paper

Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Kaczmarczyk, Jan; Roberts, Rhonda R.; Luke, Brian T. et al. · 2021

Full title: Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Authors: Kaczmarczyk, Jan; Roberts, Rhonda R.; Luke, Brian T.; Chan, King C.; Wagoner, Carly M. Van; Felder, Robin A.; Saul, Richard G.; Colantonio, Simona; Blonder, Josip

DOI: https://doi.org/10.18632/oncotarget.28072

Paper

Activation of RAS family members confers resistance to ROS1 targeting drugs

M. Cargnelutti; S. Corso; M. Pergolizzi et al. · 2014

Full title: Activation of RAS family members confers resistance to ROS1 targeting drugs

Authors: M. Cargnelutti; S. Corso; M. Pergolizzi; L. Mevellec; D. Aisner; R. Dziadziuszko; M. Varella-Garcia; P. Comoglio; R. Doebele; J. Vialard; S. Giordano

DOI: https://doi.org/10.18632/oncotarget.3311

Paper

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade

Umelo, Ijeoma Adaku; Wever, Olivier De; Kronenberger, Peter et al. · 2015

Full title: Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade

Authors: Umelo, Ijeoma Adaku; Wever, Olivier De; Kronenberger, Peter; Deun, Jan Van; Noor, Alfiah; Singh, Kshitiz; Teugels, Erik; Chen, Gang; Bracke, Marc; Grève, Jacques De

DOI: https://doi.org/10.18632/oncotarget.3853

Paper

Mutant HRAS as novel target for MEK and mTOR inhibitors

Kießling, Michael K.; Curioni‐Fontecedro, Alessandra; Samaras, Panagiotis et al. · 2015

Full title: Mutant HRAS as novel target for MEK and mTOR inhibitors

Authors: Kießling, Michael K.; Curioni‐Fontecedro, Alessandra; Samaras, Panagiotis; Atrott, Kirstin; Cosín‐Roger, Jesús; Lang, Silvia; Scharl, Michael; Rogler, Gerhard

DOI: https://doi.org/10.18632/oncotarget.5619

Paper

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

Baldelli, Elisa; Bellezza, Guido; Haura, Eric B. et al. · 2015

Full title: Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

DOI: https://doi.org/10.18632/oncotarget.5941

Paper

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts

C. Lieu; Peter J. Klauck; Patrick K. Henthorn et al. · 2015

Full title: Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts

Authors: C. Lieu; Peter J. Klauck; Patrick K. Henthorn; J. Tentler; A. Tan; A. Spreafico; H. Selby; Blair C. Britt; S. Bagby; J. Arcaroli; W. Messersmith; T. Pitts; S. Eckhardt

DOI: https://doi.org/10.18632/oncotarget.5949

Paper

Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression

Wang, Qun; Tan, Rong; Zhu, Xin et al. · 2016

Full title: Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression

Authors: Wang, Qun; Tan, Rong; Zhu, Xin; Zhang, Yi; Tan, Zhiping; Su, Bing; Li, Yu

DOI: https://doi.org/10.18632/oncotarget.7134

Paper

Inhibiting the molecular evolution of cancer through HSP90

A. Martins; F. Davies; P. Workman · 2012

Full title: Inhibiting the molecular evolution of cancer through HSP90

Authors: A. Martins; F. Davies; P. Workman

DOI: https://doi.org/10.18632/oncotarget.738

Paper

KRAS above and beyond – EGFR in pancreatic cancer

J. Siveke; H. Crawford · 2012

Full title: KRAS above and beyond – EGFR in pancreatic cancer

Authors: J. Siveke; H. Crawford

DOI: https://doi.org/10.18632/oncotarget.750

Paper

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model

B. Danysh; Erin Y. Rieger; Deepankar Sinha et al. · 2016

Full title: Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model

Authors: B. Danysh; Erin Y. Rieger; Deepankar Sinha; Caitlin Evers; G. Cote; M. Cabanillas; M. Hofmann

DOI: https://doi.org/10.18632/oncotarget.9023

Paper

Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment

Cordover, Emma; Minden, Audrey · 2020

Full title: Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment

Authors: Cordover, Emma; Minden, Audrey

DOI: https://doi.org/10.20517/2394-4722.2020.101

Paper

Research progress on KRAS mutations in colorectal cancer

Cefalì, Marco; Epistolio, Samantha; Palmarocchi, Maria Celeste et al. · 2021

Full title: Research progress on KRAS mutations in colorectal cancer

Authors: Cefalì, Marco; Epistolio, Samantha; Palmarocchi, Maria Celeste; Frattini, Milo; Dosso, Sara De

DOI: https://doi.org/10.20517/2394-4722.2021.61

Paper

Emerging RAS-directed therapies for cancer

Conroy, Michael; Cowzer, Darren; Kölch, Walter et al. · 2021

Full title: Emerging RAS-directed therapies for cancer

Authors: Conroy, Michael; Cowzer, Darren; Kölch, Walter; Duffy, Austin G.

DOI: https://doi.org/10.20517/cdr.2021.07

Paper

Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study

Guo, Xiaojin; He, Du; Li, Jiayu et al. · 2022

Full title: Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study

Authors: Guo, Xiaojin; He, Du; Li, Jiayu; Yang, Meng‐Hang; Xiong, Anweng; Zhang, Haiping; Wu, Fengying

DOI: https://doi.org/10.20517/cdr.2021.85

Paper

Emerging insights to lung cancer drug resistance

Su, Chunxia · 2022

Full title: Emerging insights to lung cancer drug resistance

Authors: Su, Chunxia

DOI: https://doi.org/10.20517/cdr.2022.61

Paper

From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers

Saliani, Mahsa; Jalal, Razieh; Ahmadian, Mohammad Reza · 2019

Full title: From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers

Authors: Saliani, Mahsa; Jalal, Razieh; Ahmadian, Mohammad Reza

DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0530

Paper

Biological insights in non-small cell lung cancer

Rosell, Rafael; Jain, Anisha; Codony‐Servat, Jordi et al. · 2023

Full title: Biological insights in non-small cell lung cancer

Authors: Rosell, Rafael; Jain, Anisha; Codony‐Servat, Jordi; Jantus‐Lewintre, Eloísa; Morrison, Blake; Ginesta, Jordi Barretina; González‐Cao, María

DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0108

Paper

Cutting-Edge Therapies for Lung Cancer

La’ah, Anita Silas; Chiou, Shih‐Hwa · 2024

Full title: Cutting-Edge Therapies for Lung Cancer

Authors: La’ah, Anita Silas; Chiou, Shih‐Hwa

DOI: https://doi.org/10.3390/cells13050436

Paper

KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer

Kılgöz, Havva Ö.; Bender, Guzide; Scandura, Joseph M. et al. · 2016

Full title: KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer

Authors: Kılgöz, Havva Ö.; Bender, Guzide; Scandura, Joseph M.; Viale, Agnès; Taneri, Bahar

DOI: https://doi.org/10.2119/molmed.2016.00151

Paper

Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer

Y. Jing; Ruixin Cheng; H. Zeng et al. · 2024

Full title: Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer

Authors: Y. Jing; Ruixin Cheng; H. Zeng; Qin Huang; Dongyu He; Jiayi Sun; P. Tian; Yalun Li

DOI: https://doi.org/10.2147/ijgm.s484435

Paper

Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer

Shannon S Zhang; M. Nagasaka · 2021

Full title: Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer

Authors: Shannon S Zhang; M. Nagasaka

DOI: https://doi.org/10.2147/lctt.s334623

Paper

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Brazel, Danielle; Arter, Zhaohui; Nagasaka, Misako · 2022

Full title: A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Authors: Brazel, Danielle; Arter, Zhaohui; Nagasaka, Misako

DOI: https://doi.org/10.2147/lctt.s383662

Paper

CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code.

Zhang, Shannon S; Lee, Alexandria; Nagasaka, Misako · 2023

Full title: CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code.

Authors: Zhang, Shannon S; Lee, Alexandria; Nagasaka, Misako

DOI: https://doi.org/10.2147/LCTT.S403461

Paper

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

Brazel, Danielle; Kim, Jennifer; Ou, Sai‐Hong Ignatius · 2023

Full title: CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

Authors: Brazel, Danielle; Kim, Jennifer; Ou, Sai‐Hong Ignatius

DOI: https://doi.org/10.2147/lctt.s403614

Paper

Adagrasib in KRYSTAL-12 has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma.

Luo, Faustine X; Arter, Zhaohui Liao · 2024

Full title: Adagrasib in KRYSTAL-12 has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma.

Authors: Luo, Faustine X; Arter, Zhaohui Liao

DOI: https://doi.org/10.2147/LCTT.S490942

Paper

The Role Of Circulating Tumor DNA In Therapeutic Resistance

Xu, Chenxin; Cao, Haixia; Chen, Shi et al. · 2019

Full title: The Role Of Circulating Tumor DNA In Therapeutic Resistance

Authors: Xu, Chenxin; Cao, Haixia; Chen, Shi; Feng, Jifeng

DOI: https://doi.org/10.2147/ott.s226202

Paper

Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments.

Ji, Jingran; Wang, Chongkai; Fakih, Marwan · 2022

Full title: Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments.

Authors: Ji, Jingran; Wang, Chongkai; Fakih, Marwan

DOI: https://doi.org/10.2147/OTT.S340392

Paper

Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer

Yanning Sun; Li Ma; Xiaofei Zhang et al. · 2024

Full title: Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer

Authors: Yanning Sun; Li Ma; Xiaofei Zhang; Zhaoxia Wang

DOI: https://doi.org/10.2147/ott.s487870

Paper

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

Zheng, Difan; Chen, Haiquan; Wang, Rui et al. · 2016

Full title: The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

Authors: Zheng, Difan; Chen, Haiquan; Wang, Rui; Zhang, Yang; Pan, Yunjian; Cheng, Xinghua; Cheng, Chao; Zheng, Shanbo; Li, Hang; Gong, Ranxia; Li, Yuan; Shen, Xuxia; Sun, Yihua

DOI: https://doi.org/10.2147/ott.s96834

Paper

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Whitsett, Timothy G.; Richer, Amanda L.; Friel, Jacqueline M. et al. · 2015

Full title: Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Authors: Whitsett, Timothy G.; Richer, Amanda L.; Friel, Jacqueline M.; Carson, Vashti M.; Inge, Landon J.

DOI: https://doi.org/10.2147/pgpm.s52845

Paper

Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators

Check, Jerome H.; PORETTA, TRINA; Check, Diane et al. · 2023

Full title: Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators

Authors: Check, Jerome H.; PORETTA, TRINA; Check, Diane; Srivastava, Maya D.

DOI: https://doi.org/10.21873/anticanres.16240

Paper

Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment

Kataoka, Masahiro; Kitazawa, Masato; Nakamura, Satoshi et al. · 2023

Full title: Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment

Authors: Kataoka, Masahiro; Kitazawa, Masato; Nakamura, Satoshi; Koyama, Makoto; Yamamoto, Yuta; Miyazaki, Satoru; Hondo, Nao; Tanaka, Hirokazu; Soejima, Yuji

DOI: https://doi.org/10.21873/anticanres.16629

Paper

KRASMutations in Cholangiocarcinoma: Prevalence, Prognostic Value, andKRASG12/G13 Detection in Cell-Free DNA

THONGYOO, PITCHASAK; Chindaprasirt, Jarin; Aphivatanasiri, Chaiwat et al. · 2024

Full title: KRASMutations in Cholangiocarcinoma: Prevalence, Prognostic Value, andKRASG12/G13 Detection in Cell-Free DNA

DOI: https://doi.org/10.21873/cgp.20492

Paper

STABILITY INDICATING AND COST-EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SOTORASIB BY USING RP-HPLC

Yarlagadda, Subba Rao; Mannam, Subba Rao; Jampani, Baby Padmini · 2021

Full title: STABILITY INDICATING AND COST-EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SOTORASIB BY USING RP-HPLC

Authors: Yarlagadda, Subba Rao; Mannam, Subba Rao; Jampani, Baby Padmini

DOI: https://doi.org/10.22159/ijap.2021v13i5.42659

Paper

LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology

Irene A. Retmana

Full title: LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology

Authors: Irene A. Retmana

DOI: https://doi.org/10.33540/2425

Paper

Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach

Kumar, S. Udhaya; Varghese, Rinku Polachirakkal; Preethi, V. Anu et al. · 2023

Full title: Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach

Authors: Kumar, S. Udhaya; Varghese, Rinku Polachirakkal; Preethi, V. Anu; Doss, C. George Priya; Zayed, Hatem

DOI: https://doi.org/10.31083/j.fbl2811288

Paper

Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer

Shi, Jiajian; Chen, Yuchen; Peng, Chentai et al. · 2022

Full title: Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer

Authors: Shi, Jiajian; Chen, Yuchen; Peng, Chentai; Kuang, Linwu; Zhang, Zitong; Li, Yangkai; Huang, Kun

DOI: https://doi.org/10.32604/oncologie.2022.027545

Paper

Targeting KRAS in pancreatic cancer

Stickler, Sandra; Rath, Barbara H.; Hamilton, Gerhard · 2024

Full title: Targeting KRAS in pancreatic cancer

Authors: Stickler, Sandra; Rath, Barbara H.; Hamilton, Gerhard

DOI: https://doi.org/10.32604/or.2024.045356

Paper

p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors

Grassilli, Emanuela; Cerrito, Maria Grazia; Bonomo, Sara et al. · 2021

Full title: p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors

Authors: Grassilli, Emanuela; Cerrito, Maria Grazia; Bonomo, Sara; Giovannoni, Roberto; Conconi, Donatella; Lavitrano, Marialuisa

DOI: https://doi.org/10.3389/fcell.2021.690365

Paper

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Sun, Guoqiang; Rong, Dawei; Li, Zhouxiao et al. · 2021

Full title: Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Authors: Sun, Guoqiang; Rong, Dawei; Li, Zhouxiao; Sun, Guangshun; Wu, Fan; Li, Xiao; Cao, Hongyong; Cheng, Ye; Tang, Weiwei; Sun, Yangbai

DOI: https://doi.org/10.3389/fcell.2021.694363

Paper

The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

Cáceres-Gutiérrez, Rodrigo E.; Alfaro‐Mora, Yair; Andonegui, Marco A. et al. · 2022

Full title: The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

Authors: Cáceres-Gutiérrez, Rodrigo E.; Alfaro‐Mora, Yair; Andonegui, Marco A.; Díaz‐Chávez, José; Herrera, Luis A.

DOI: https://doi.org/10.3389/fcell.2022.751367

Paper

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

Zhang, Zining; Zhang, Heng; Liao, Xiang et al. · 2023

Full title: KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

Authors: Zhang, Zining; Zhang, Heng; Liao, Xiang; Tsai, Hsiang‐i

DOI: https://doi.org/10.3389/fcell.2023.1147676

Paper

Targeting alternative splicing in cancer immunotherapy

Han, Nan; Liu, Zhaoqi · 2023

Full title: Targeting alternative splicing in cancer immunotherapy

Authors: Han, Nan; Liu, Zhaoqi

DOI: https://doi.org/10.3389/fcell.2023.1232146

Paper

Transcription and Translation Inhibitors in Cancer Treatment

Laham-Karam, Nihay; Pinto, Gaspar; Poso, Antti et al. · 2020

Full title: Transcription and Translation Inhibitors in Cancer Treatment

Authors: Laham-Karam, Nihay; Pinto, Gaspar; Poso, Antti; Kokkonen, Piia

DOI: https://doi.org/10.3389/fchem.2020.00276

Paper

The Role of Glutamine and Glutaminase in Pulmonary Hypertension

Wang, Shang; Yan, Yi; Xu, Weijie et al. · 2022

Full title: The Role of Glutamine and Glutaminase in Pulmonary Hypertension

Authors: Wang, Shang; Yan, Yi; Xu, Weijie; Gong, Su‐Gang; Zhong, Xiu-Jun; An, Qin-Yan; Zhao, Ya‐Lin; Liu, Jinming; Wang, Lan; Yuan, Ping; Jiang, Rong

DOI: https://doi.org/10.3389/fcvm.2022.838657

Paper

Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic

L. Quiñones; Kuen S. Lee · 2015

Full title: Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic

Authors: L. Quiñones; Kuen S. Lee

DOI: https://doi.org/10.3389/fgene.2015.00195

Paper

Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer

Gao, Liyuan; Shen, Weizhang · 2022

Full title: Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer

Authors: Gao, Liyuan; Shen, Weizhang

DOI: https://doi.org/10.3389/fgene.2022.890247

Paper

Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates

Alcaráz-Sanabria, Ana; Morafraile, Esther Cabañas; Fernández-Hinojal, G. et al. · 2022

Full title: Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates

Authors: Alcaráz-Sanabria, Ana; Morafraile, Esther Cabañas; Fernández-Hinojal, G.; Velasco, Guillermo; Pérez‐Segura, Pedro; Pandiella, Atanasio; Győrffy, Balázs; Ocaña, Alberto

DOI: https://doi.org/10.3389/fimmu.2021.786069

Paper

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

Chen, Xun; Keller, S.; Hafner, Philipp et al. · 2024

Full title: Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

Authors: Chen, Xun; Keller, S.; Hafner, Philipp; Alrawashdeh, Asma; Avery, Thomas Yul; Norona, Johana; Zhou, Jinxue; Ruess, Dietrich Alexander

DOI: https://doi.org/10.3389/fimmu.2024.1340726

Paper

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Xiang, Yuchu; Liu, Xudong; Wang, Yifan et al. · 2024

Full title: Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Authors: Xiang, Yuchu; Liu, Xudong; Wang, Yifan; Zheng, Dawei; Meng, Qiuxing; Jiang, Lingling; Yang, Sha; Zhang, Sijia; Zhang, Xin; Liu, Yan; Wang, Bo

DOI: https://doi.org/10.3389/fimmu.2024.1366260

Paper

Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.

Zhang, Fan; Wang, Banglu; Wu, Menghuan et al. · 2025

Full title: Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.

Authors: Zhang, Fan; Wang, Banglu; Wu, Menghuan; Zhang, Liwen; Ji, Mei

DOI: https://doi.org/10.3389/fimmu.2025.1509173

Paper

Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy

Li Peng; Hongmei Li; Wencai Yan et al. · 2025

Full title: Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy

Authors: Li Peng; Hongmei Li; Wencai Yan; Yingjie Liu; Haihao Zhu; Yingcai Hong

DOI: https://doi.org/10.3389/fimmu.2025.1649445

Paper

Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma

Ramalingam, Prasanna Srinivasan; Priyadharshini, A.; Emerson, Isaac Arnold et al. · 2023

Full title: Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma

Authors: Ramalingam, Prasanna Srinivasan; Priyadharshini, A.; Emerson, Isaac Arnold; Arumugam, Sivakumar

DOI: https://doi.org/10.3389/fmed.2023.1107128

Paper

A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer

Hofmarcher, Thomas; Malmberg, Chiara; Lindgren, Peter · 2023

Full title: A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer

Authors: Hofmarcher, Thomas; Malmberg, Chiara; Lindgren, Peter

DOI: https://doi.org/10.3389/fmed.2023.1119506

Paper

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Linehan, Anna; O’Reilly, Mary; McDermott, Ray et al. · 2024

Full title: Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Authors: Linehan, Anna; O’Reilly, Mary; McDermott, Ray; O’Kane, Grainne M.

DOI: https://doi.org/10.3389/fmed.2024.1369136

Paper

Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity

Henkels, Karen M.; Rehl, Kristen M.; Cho, Kwang‐Jin · 2021

Full title: Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity

Authors: Henkels, Karen M.; Rehl, Kristen M.; Cho, Kwang‐Jin

DOI: https://doi.org/10.3389/fmolb.2021.673096

Paper

KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients

Wang, Shuhang; Li, Qin; Ma, Peiwen et al. · 2022

Full title: KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients

Authors: Wang, Shuhang; Li, Qin; Ma, Peiwen; Fang, Yuan; Yu, Yue; Jiang, Ning; Miao, Huilei; Tang, Qiyu; Yang, Yuqi; Xing, Shujun; Chen, Rongrong; Yi, Xin; Li, Ning

DOI: https://doi.org/10.3389/fmolb.2022.831382

Paper

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, Haitang; Liang, Shun‐Qing; Schmid, Ralph A. et al. · 2019

Full title: New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Authors: Yang, Haitang; Liang, Shun‐Qing; Schmid, Ralph A.; Peng, Ren‐Wang

DOI: https://doi.org/10.3389/fonc.2019.00953

Paper

Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models

Wan, Yuhua; Zhang, Yan; Wang, Gengchong et al. · 2020

Full title: Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models

Authors: Wan, Yuhua; Zhang, Yan; Wang, Gengchong; Mwangi, Patrick Malonza; Cai, Huaman; Li, Rongxiu

DOI: https://doi.org/10.3389/fonc.2020.01326

Paper

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations

M. Colombo; M. Marabese; Giulia Vargiu et al. · 2020

Full title: Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations

Authors: M. Colombo; M. Marabese; Giulia Vargiu; M. Broggini; E. Caiola

DOI: https://doi.org/10.3389/fonc.2020.532292

Paper

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

Xiang, Luochengling; Fu, Xiao; Wang, Xiao et al. · 2020

Full title: A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

Authors: Xiang, Luochengling; Fu, Xiao; Wang, Xiao; Li, Wenyuan; Zheng, Xiaoqiang; Nan, Kejun; Tian, Tao

DOI: https://doi.org/10.3389/fonc.2020.559896

Paper

DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer

Rayees Padder; Z. I. Bhat; Zaki Ahmad et al. · 2021

Full title: DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer

Authors: Rayees Padder; Z. I. Bhat; Zaki Ahmad; Neetu Singh; M. Husain

DOI: https://doi.org/10.3389/fonc.2020.592130

Paper

Targeting KRAS: The Elephant in the Room of Epithelial Cancers

V. Merz; M. Gaule; C. Zecchetto et al. · 2021

Full title: Targeting KRAS: The Elephant in the Room of Epithelial Cancers

Authors: V. Merz; M. Gaule; C. Zecchetto; A. Cavaliere; S. Casalino; Camilla Pesoni; Serena Contarelli; Fabio Sabbadini; M. Bertolini; Domenico Mangiameli; M. Milella; V. Fedele; D. Melisi

DOI: https://doi.org/10.3389/fonc.2021.638360

Paper

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

Zhao, Yiming; Wang, Shuyuan; Yang, Zhengyu et al. · 2021

Full title: Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

Authors: Zhao, Yiming; Wang, Shuyuan; Yang, Zhengyu; Dong, Yu; Wang, Yanan; Zhang, Lele; Hu, Hai; Han, Baohui

DOI: https://doi.org/10.3389/fonc.2021.665484

Paper

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

M. Xie; Xiaoling Xu; Yun Fan · 2021

Full title: KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

Authors: M. Xie; Xiaoling Xu; Yun Fan

DOI: https://doi.org/10.3389/fonc.2021.672612

Paper

The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience

Karol, Dalia; McKinnon, Mathieu; Mukhtar, Lenah E. et al. · 2021

Full title: The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience

Authors: Karol, Dalia; McKinnon, Mathieu; Mukhtar, Lenah E.; Awan, Arif; Lo, Bernard; Wheatley‐Price, Paul

DOI: https://doi.org/10.3389/fonc.2021.687730

Paper

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

Giampieri, Riccardo; Lupi, Alessio; Ziranu, Pina et al. · 2021

Full title: Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

DOI: https://doi.org/10.3389/fonc.2021.736104

Paper

Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway

Jain, Anisha; Prasad, Ashwini; Pradeep, Sushma et al. · 2021

Full title: Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway

DOI: https://doi.org/10.3389/fonc.2021.741326

Paper

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Mo Shen; Rong-Xin Qi; Justin Ren et al. · 2022

Full title: Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Authors: Mo Shen; Rong-Xin Qi; Justin Ren; D. Lv; Haihua Yang

DOI: https://doi.org/10.3389/fonc.2021.780655

Paper

Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer.

Blaquier, Juan Bautista; Cardona, Andrés Felipe; Recondo, Gonzalo · 2021

Full title: Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer.

Authors: Blaquier, Juan Bautista; Cardona, Andrés Felipe; Recondo, Gonzalo

DOI: https://doi.org/10.3389/fonc.2021.787585

Paper

KRAS Mutations in Squamous Cell Carcinomas of the Lung

Acker, Fabian; Stratmann, Jan; Aspacher, Lukas et al. · 2021

Full title: KRAS Mutations in Squamous Cell Carcinomas of the Lung

Authors: Acker, Fabian; Stratmann, Jan; Aspacher, Lukas; Nguyen, Thu; Wagner, Sebastian; Serve, Hubert; Wild, Peter J.; Sebastian, Martin

DOI: https://doi.org/10.3389/fonc.2021.788084

Paper

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

Ferrara, Miriam Grazia; Stefani, Alessio; Pilotto, Sara et al. · 2021

Full title: The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

DOI: https://doi.org/10.3389/fonc.2021.792385

Paper

Targeting KRAS in Non-Small Cell Lung Cancer

Elena Corral de la Fuente; M. E. Olmedo García; Ana Gómez Rueda et al. · 2022

Full title: Targeting KRAS in Non-Small Cell Lung Cancer

Authors: Elena Corral de la Fuente; M. E. Olmedo García; Ana Gómez Rueda; Yolanda Lage; P. Garrido

DOI: https://doi.org/10.3389/fonc.2021.792635

Paper

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

Cucurull, Marc; Notario, L.; Sánchez‐Céspedes, Montse et al. · 2022

Full title: Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

Authors: Cucurull, Marc; Notario, L.; Sánchez‐Céspedes, Montse; Hierro, Cinta; Estival, Anna; Carcereny, Enric; Saigí, Maria

DOI: https://doi.org/10.3389/fonc.2021.793121

Paper

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit

Ning, Wenjuan; Marti, Thomas M.; Dorn, Patrick et al. · 2022

Full title: Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit

Authors: Ning, Wenjuan; Marti, Thomas M.; Dorn, Patrick; Peng, Ren‐Wang

DOI: https://doi.org/10.3389/fonc.2022.1004669

Paper

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Bannoura, Sahar F.; Khan, Husain Yar; Azmi, Asfar S. · 2022

Full title: KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Authors: Bannoura, Sahar F.; Khan, Husain Yar; Azmi, Asfar S.

DOI: https://doi.org/10.3389/fonc.2022.1013902

Paper

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population

L. Peng; Jun Guo; L. Kong et al. · 2023

Full title: Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population

Authors: L. Peng; Jun Guo; L. Kong; Yong Huang; N. Tang; Juguang Zhang; Minglei Wang; Xiaohan He; Zhenzhen Li; Yonggang Peng; Zhehai Wang; Xiao Han

DOI: https://doi.org/10.3389/fonc.2022.1070761

Paper

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Hou, Jue; He, Zongsheng; Liu, Tian et al. · 2022

Full title: Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Authors: Hou, Jue; He, Zongsheng; Liu, Tian; Chen, Dongfeng; Wang, Bin; Wen, Qinglian; Zheng, Xi

DOI: https://doi.org/10.3389/fonc.2022.755053

Paper

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.

Désage, Anne-Laure; Léonce, Camille; Swalduz, Aurélie et al. · 2022

Full title: Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.

Authors: Désage, Anne-Laure; Léonce, Camille; Swalduz, Aurélie; Ortiz-Cuaran, Sandra

DOI: https://doi.org/10.3389/fonc.2022.796832

Paper

Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma

Gupta, Kshama; Jones, Jeremy; Farias, Virgínea et al. · 2022

Full title: Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma

Authors: Gupta, Kshama; Jones, Jeremy; Farias, Virgínea; Mackeyev, Yuri; Singh, Pankaj K.; Quiñones‐Hinojosa, Alfredo; Krishnan, Sunil

DOI: https://doi.org/10.3389/fonc.2022.840241

Paper

LKB1: Can We Target an Hidden Target? Focus on NSCLC

Ndembe, Gloriana; Intini, Ilenia; Perin, Elisa et al. · 2022

Full title: LKB1: Can We Target an Hidden Target? Focus on NSCLC

Authors: Ndembe, Gloriana; Intini, Ilenia; Perin, Elisa; Marabese, Mirko; Caiola, Elisa; Mendogni, Paolo; Rosso, Lorenzo; Broggini, Massimo; Colombo, Marika

DOI: https://doi.org/10.3389/fonc.2022.889826

Paper

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C.

Zhuang, Haiming; Fan, Jigang; Li, Mingyu et al. · 2022

Full title: Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C.

Authors: Zhuang, Haiming; Fan, Jigang; Li, Mingyu; Zhang, Hao; Yang, Xiuyan; Lin, Ligen; Lu, Shaoyong; Wang, Qing; Liu, Yaqin

DOI: https://doi.org/10.3389/fonc.2022.915512

Paper

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation

Avery, Thomas Yul; Köhler, Natalie; Zeiser, Robert et al. · 2022

Full title: Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation

Authors: Avery, Thomas Yul; Köhler, Natalie; Zeiser, Robert; Brummer, Tilman; Ruess, Dietrich Alexander

DOI: https://doi.org/10.3389/fonc.2022.931774

Paper

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer

Mussafi, Ofek; Mei, Jie; Mao, Wenjun et al. · 2022

Full title: Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer

Authors: Mussafi, Ofek; Mei, Jie; Mao, Wenjun; Wan, Yuan

DOI: https://doi.org/10.3389/fonc.2022.948405

Paper

State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer

Yao, Yongfang; Fareed, Rameesha; Zafar, Aliya et al. · 2022

Full title: State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer

Authors: Yao, Yongfang; Fareed, Rameesha; Zafar, Aliya; Saleem, Kalsoom; Huang, Tao; Duan, Yongtao; Rehman, Masood ur

DOI: https://doi.org/10.3389/fonc.2022.958505

Paper

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population

Fancelli, Sara; Caliman, Enrico; Mazzoni, Francesca et al. · 2022

DOI: https://doi.org/10.3389/fonc.2022.968064

Paper

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 <50%

I. Attili; C. Valenza; C. Santoro et al. · 2022

Authors: I. Attili; C. Valenza; C. Santoro; G. Antonarelli; P. Trillo Aliaga; E. Del Signore; C. Catania; G. Spitaleri; A. Passaro; F. de Marinis

DOI: https://doi.org/10.3389/fonc.2022.980765

Paper

Utilization of macrocyclic peptides to target protein-protein interactions in cancer

Yang, Jiawen; Zhu, Qiaoliang; Wu, Yifan et al. · 2022

Full title: Utilization of macrocyclic peptides to target protein-protein interactions in cancer

Authors: Yang, Jiawen; Zhu, Qiaoliang; Wu, Yifan; Xiao-juan, QU; Liu, Haixia; Jiang, Biao; Ge, Di; Song, Xiaoling

DOI: https://doi.org/10.3389/fonc.2022.992171

Paper

Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models

Meike Kaehler; Pia Osteresch; A. Künstner et al. · 2023

Full title: Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models

Authors: Meike Kaehler; Pia Osteresch; A. Künstner; Stella Juliane Vieth; Daniela Esser; Marius Möller; Hauke Busch; I. Vater; M. Spielmann; I. Cascorbi; I. Nagel

DOI: https://doi.org/10.3389/fonc.2023.1200897

Paper

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

Notario, L.; Cucurull, Marc; Cerdà, Gabriela et al. · 2023

Full title: Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

DOI: https://doi.org/10.3389/fonc.2023.1239000

Paper

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer

Qunaj, Lindor; May, Michael; Neugut, Alfred I. et al. · 2023

Full title: Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer

Authors: Qunaj, Lindor; May, Michael; Neugut, Alfred I.; Herzberg, Benjamin

DOI: https://doi.org/10.3389/fonc.2023.1252516

Paper

Lung cancer organoids: models for preclinical research and precision medicine

Liu, Yajing; Zhou, Yanbing; Chen, Pu · 2023

Full title: Lung cancer organoids: models for preclinical research and precision medicine

Authors: Liu, Yajing; Zhou, Yanbing; Chen, Pu

DOI: https://doi.org/10.3389/fonc.2023.1293441

Paper

Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer.

Chour, Ali; Toffart, Anne-Claire; Berton, Elodie et al. · 2024

Full title: Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer.

Authors: Chour, Ali; Toffart, Anne-Claire; Berton, Elodie; Duruisseaux, Michael

DOI: https://doi.org/10.3389/fonc.2024.1328728

Paper

KRAS G12C inhibitor combination therapies: current evidence and challenge.

Miyashita, Hirotaka; Kato, Shumei; Hong, David S · 2024

Full title: KRAS G12C inhibitor combination therapies: current evidence and challenge.

Authors: Miyashita, Hirotaka; Kato, Shumei; Hong, David S

DOI: https://doi.org/10.3389/fonc.2024.1380584

Paper

Assessment of KRASG12C inhibitors for colorectal cancer

G. Piazza; Preethi Chandrasekaran; Y. Maxuitenko et al. · 2024

Full title: Assessment of KRASG12C inhibitors for colorectal cancer

Authors: G. Piazza; Preethi Chandrasekaran; Y. Maxuitenko; Karim I. Budhwani

DOI: https://doi.org/10.3389/fonc.2024.1412435

Paper

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

Aliki Ntzifa; Theodoros Marras; G. Kallergi et al. · 2024

Full title: Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

Authors: Aliki Ntzifa; Theodoros Marras; G. Kallergi; Athanasios Kotsakis; V. Georgoulias; E. Lianidou

DOI: https://doi.org/10.3389/fonc.2024.1435537

Paper

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

Alessandro Tubita; S. Fancelli; Lorenzo Anela et al. · 2025

Full title: KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

DOI: https://doi.org/10.3389/fonc.2025.1654491

Paper

Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer

Jean Cabon; D. Lerouge; S. Thureau et al. · 2025

Full title: Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer

DOI: https://doi.org/10.3389/fonc.2025.1675825

Paper

Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors

Saeed Aslani; Owen McKay; L. Lipton et al. · 2025

Full title: Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors

Authors: Saeed Aslani; Owen McKay; L. Lipton; Vinod Ganju; Daniel Croagh

DOI: https://doi.org/10.3389/fonc.2025.1691760

Paper

Regulation of the Ras-Related Signaling Pathway by Small Molecules Containing an Indole Core Scaffold: A Potential Antitumor Therapy

Chen, Feiyu; Li, Xiang; Zhu, Hongping et al. · 2020

Full title: Regulation of the Ras-Related Signaling Pathway by Small Molecules Containing an Indole Core Scaffold: A Potential Antitumor Therapy

Authors: Chen, Feiyu; Li, Xiang; Zhu, Hongping; Huang, Wei

DOI: https://doi.org/10.3389/fphar.2020.00280

Paper

9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells

A. Poloznikov; Sergey Nikulin; L. Bolotina et al. · 2021

Full title: 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells

DOI: https://doi.org/10.3389/fphar.2021.777114

Paper

Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells

Xingduo Dong; Meng Zhang; Chaoyun Cai et al. · 2022

Full title: Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells

Authors: Xingduo Dong; Meng Zhang; Chaoyun Cai; Q. Teng; Jing-Quan Wang; Yigong Fu; Qingbin Cui; Ketankumar Patel; Dong-Tao Wang; Zhe-Sheng Chen

DOI: https://doi.org/10.3389/fphar.2022.843829

Paper

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Li, Jiaxin; Li, Runze; Ma, Lin-Rui et al. · 2022

Full title: Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Authors: Li, Jiaxin; Li, Runze; Ma, Lin-Rui; Wang, Peng; Xu, Donghan; Huang, Jie; Li, Li-Qi; Tang, Ling; Xie, Ying; Leung, Elaine Lai‐Han; Yan, Peiyu

DOI: https://doi.org/10.3389/fphar.2022.875330

Paper

Recent progress in targeted therapy for non-small cell lung cancer

Yao Xiao; Pu Liu; Jie Wei et al. · 2023

Full title: Recent progress in targeted therapy for non-small cell lung cancer

Authors: Yao Xiao; Pu Liu; Jie Wei; Xin Zhang; Jun Guo; Yajun Lin

DOI: https://doi.org/10.3389/fphar.2023.1125547

Paper

Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Li, Furong; Lin, Yanping; Li, Rong et al. · 2023

Full title: Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Authors: Li, Furong; Lin, Yanping; Li, Rong; Shen, Xin; Xiang, Mengying; Xiong, Guangrui; Zhang, Ke; Xia, Tingrong; Guo, Jiangyan; Miao, Zhonghui; Liao, Yedan; Zhang, Xuan; Xie, Lin

DOI: https://doi.org/10.3389/fphar.2023.1165666

Paper

Roles and inhibitors of FAK in cancer: current advances and future directions

Hu, Hui-Hui; Wang, Saiqi; Shang, Hai-Li et al. · 2024

Full title: Roles and inhibitors of FAK in cancer: current advances and future directions

Authors: Hu, Hui-Hui; Wang, Saiqi; Shang, Hai-Li; Lv, Huifang; Chen, Beibei; Gao, Shegan; Chen, Xiaobing

DOI: https://doi.org/10.3389/fphar.2024.1274209

Paper

Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond.

Huang, Renjie; Gong, Xian; Du, Jianting et al. · 2025

Full title: Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond.

Authors: Huang, Renjie; Gong, Xian; Du, Jianting; Xu, Guobing; Qian, Jiekun; Liao, Guoliang; Lin, Yuxing; Pan, Maojie; Zheng, Bin; Yuan, Wenjie; Huang, Qinzhao; Chen, Chun; Yang, Zhang

DOI: https://doi.org/10.3389/fphar.2025.1704347

Paper

The Research Progress of Direct KRAS G12C Mutation Inhibitors

Yang, Ai Li; Li, Min; Fang, Mingzhi · 2021

Full title: The Research Progress of Direct KRAS G12C Mutation Inhibitors

Authors: Yang, Ai Li; Li, Min; Fang, Mingzhi

DOI: https://doi.org/10.3389/pore.2021.631095

Paper

Targeted therapeutic options in early and metastatic NSCLC-overview

Gálffy, Gabriella; Mórocz, Éva; Korompay, Réka et al. · 2024

Full title: Targeted therapeutic options in early and metastatic NSCLC-overview

Authors: Gálffy, Gabriella; Mórocz, Éva; Korompay, Réka; Hécz, Réka; Bujdosó, Réka; Puskás, Rita; Lovas, Tímea; Gáspár, Eszter; Yahya, Kamel; Király, Péter Attila; Lohinai, Zoltán

DOI: https://doi.org/10.3389/pore.2024.1611715

Paper

Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions

Böldicke, Thomas · 2022

Full title: Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions

Authors: Böldicke, Thomas

DOI: https://doi.org/10.3390/antib11030049

Paper

An In Vivo Inflammatory Loop Potentiates KRAS Blockade

Arendt, Kristina A. M.; Ntaliarda, Giannoula; Armenis, Vasileios et al. · 2022

Full title: An In Vivo Inflammatory Loop Potentiates KRAS Blockade

DOI: https://doi.org/10.3390/biomedicines10030592

Paper

Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience

Anna K Rekowska; Piotr Rola; Agnieszka Kwiatkowska et al. · 2024

Full title: Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience

Authors: Anna K Rekowska; Piotr Rola; Agnieszka Kwiatkowska; M. Wójcik-Superczyńska; Michał Gil; P. Krawczyk; Janusz Milanowski

DOI: https://doi.org/10.3390/biomedicines12020325

Paper

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

Nollmann, Friederike I.; Ruess, Dietrich Alexander · 2020

Full title: Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

Authors: Nollmann, Friederike I.; Ruess, Dietrich Alexander

DOI: https://doi.org/10.3390/biomedicines8080281

Paper

Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR

Palacín-Aliana, Irina; Garcia‐Romero, Noemí; Asensi-Puig, Adriá et al. · 2021

Full title: Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR

Authors: Palacín-Aliana, Irina; Garcia‐Romero, Noemí; Asensi-Puig, Adriá; Carrión-Navarro, Josefa; González‐Rumayor, Víctor; Ayuso‐Sacido, Ángel

DOI: https://doi.org/10.3390/biomedicines9080906

Paper

A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer

M. Grzes; Magdalena Oroń; Z. Staszczak et al. · 2020

Full title: A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer

Authors: M. Grzes; Magdalena Oroń; Z. Staszczak; A. Jaiswar; M. Nowak-Niezgoda; Dawid Walerych

DOI: https://doi.org/10.3390/cancers12061532

Paper

Mechanisms of Resistance to KRASG12C Inhibitors

V. Dunnett-Kane; P. Nicola; F. Blackhall et al. · 2021

Full title: Mechanisms of Resistance to KRASG12C Inhibitors

Authors: V. Dunnett-Kane; P. Nicola; F. Blackhall; C. Lindsay

DOI: https://doi.org/10.3390/cancers13010151

Paper

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

D. König; S. Savic Prince; S. Rothschild · 2021

Full title: Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

Authors: D. König; S. Savic Prince; S. Rothschild

DOI: https://doi.org/10.3390/cancers13040804

Paper

Targeting KRAS in Cancer: Promising Therapeutic Strategies

Mustachio, Lisa Maria; Chelariu-Raicu, Anca; Székvölgyi, Lóránt et al. · 2021

Full title: Targeting KRAS in Cancer: Promising Therapeutic Strategies

Authors: Mustachio, Lisa Maria; Chelariu-Raicu, Anca; Székvölgyi, Lóránt; Roszik, Jason

DOI: https://doi.org/10.3390/cancers13061204

Paper

KRAS G12C Mutations in NSCLC: From Target to Resistance

A. Addeo; G. Banna; A. Friedlaender · 2021

Full title: KRAS G12C Mutations in NSCLC: From Target to Resistance

Authors: A. Addeo; G. Banna; A. Friedlaender

DOI: https://doi.org/10.3390/cancers13112541

Paper

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cabanos, Heidie Frisco; Hata, Aaron N. · 2021

Full title: Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Authors: Cabanos, Heidie Frisco; Hata, Aaron N.

DOI: https://doi.org/10.3390/cancers13112666

Paper

Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation

Pardo-Sánchez, José Miguel; Mancheño, Nuria; Cerón, J. M. Castro et al. · 2021

Full title: Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation

DOI: https://doi.org/10.3390/cancers13122980

Paper

Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma

Gow, Chien‐Hung; Hsieh, Min‐Shu; Liu, Yi-Nan et al. · 2021

Full title: Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma

Authors: Gow, Chien‐Hung; Hsieh, Min‐Shu; Liu, Yi-Nan; Lee, Yi‐Hsuan; Shih, Jin‐Yuan

DOI: https://doi.org/10.3390/cancers13164103

Paper

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Rodak, Olga; Peris‐Díaz, Manuel David; Olbromski, Mateusz et al. · 2021

Full title: Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Authors: Rodak, Olga; Peris‐Díaz, Manuel David; Olbromski, Mateusz; Podhorska‐Okołów, Marzenna; Dzięgiel, Piotr

DOI: https://doi.org/10.3390/cancers13184705

Paper

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

Yuta Adachi; Ryo Kimura; K. Hirade et al. · 2021

Full title: Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

Authors: Yuta Adachi; Ryo Kimura; K. Hirade; H. Ebi

DOI: https://doi.org/10.3390/cancers13205081

Paper

Oncogenic KRAS: Signaling and Drug Resistance

Kim, Hyeon Jin; Lee, Han Na; Jeong, Mi Suk et al. · 2021

Full title: Oncogenic KRAS: Signaling and Drug Resistance

Authors: Kim, Hyeon Jin; Lee, Han Na; Jeong, Mi Suk; Jang, Se Bok

DOI: https://doi.org/10.3390/cancers13225599

Paper

A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished.

Ning, Wenjuan; Yang, Zhang; Kocher, Gregor J et al. · 2022

Full title: A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished.

Authors: Ning, Wenjuan; Yang, Zhang; Kocher, Gregor J; Dorn, Patrick; Peng, Ren-Wang

DOI: https://doi.org/10.3390/cancers14020390

Paper

Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets

Karagiannakos, Alexandros; Adamaki, Maria; Tsintarakis, Antonis et al. · 2022

Full title: Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets

Authors: Karagiannakos, Alexandros; Adamaki, Maria; Tsintarakis, Antonis; Vojtěšek, Bořivoj; Fåhræus, Robin; Zoumpourlis, Vassilis; Karakostis, Konstantinos

DOI: https://doi.org/10.3390/cancers14030664

Paper

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Reita, Damien; Pabst, Lucile; Pencreach, Erwan et al. · 2022

Full title: Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Authors: Reita, Damien; Pabst, Lucile; Pencreach, Erwan; Guérin, Eric; Dano, Laurent; Rimelen, Valérie; Voegeli, Anne-Claire; Vallat, Laurent; Mascaux, Céline; Beau-Faller, Michèle

DOI: https://doi.org/10.3390/cancers14051321

Paper

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

Bontoux, Christophe; Hofman, Véronique; Brest, Patrick et al. · 2022

Full title: Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

Authors: Bontoux, Christophe; Hofman, Véronique; Brest, Patrick; Ilié, Marius; Mograbi, Baharia; Hofman, Paul

DOI: https://doi.org/10.3390/cancers14071628

Paper

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients

Ulivi, Paola; Urbini, Milena; Petracci, Elisabetta et al. · 2022

Full title: Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients

DOI: https://doi.org/10.3390/cancers14102352

Paper

Synthetic Vulnerabilities in the KRAS Pathway

Román, Marta; Hwang, Elizabeth; Sweet‐Cordero, E. Alejandro · 2022

Full title: Synthetic Vulnerabilities in the KRAS Pathway

Authors: Román, Marta; Hwang, Elizabeth; Sweet‐Cordero, E. Alejandro

DOI: https://doi.org/10.3390/cancers14122837

Paper

A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting

I. Terrenato; Cristiana Ercolani; A. di Benedetto et al. · 2022

Full title: A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting

DOI: https://doi.org/10.3390/cancers14122971

Paper

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

E. Cekani; Samantha Epistolio; Giulia Dazio et al. · 2022

Full title: Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

Authors: E. Cekani; Samantha Epistolio; Giulia Dazio; M. Cefalì; L. Wannesson; M. Frattini; P. Froesch

DOI: https://doi.org/10.3390/cancers14174103

Paper

Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines

Yixuan Ma; Benjamin Schulz; N. Trakooljul et al. · 2022

Full title: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines

Authors: Yixuan Ma; Benjamin Schulz; N. Trakooljul; Moosheer Al Ammar; Anett Sekora; S. Sender; F. Hadlich; D. Zechner; F. Weiss; M. Lerch; R. Jaster; Christian Junhanss; H. Murua Escobar

DOI: https://doi.org/10.3390/cancers14184467

Paper

KRAS in NSCLC: State of the Art and Future Perspectives

Cascetta, Priscilla; Marinello, Arianna; Lazzari, Chiara et al. · 2022

Full title: KRAS in NSCLC: State of the Art and Future Perspectives

Authors: Cascetta, Priscilla; Marinello, Arianna; Lazzari, Chiara; Gregorc, Vanesa; Planchard, David; Bianco, Roberto; Normanno, Nicola; Morabito, Alessandro

DOI: https://doi.org/10.3390/cancers14215430

Paper

Advances in the Molecular Landscape of Lung Cancer Brain Metastasis

Souza, Vanessa G. P.; Araújo, Rachel Paes de; Santesso, Mariana R. et al. · 2023

Full title: Advances in the Molecular Landscape of Lung Cancer Brain Metastasis

DOI: https://doi.org/10.3390/cancers15030722

Paper

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

Éabha O’Sullivan; A. Keogh; Brian Henderson et al. · 2023

Full title: Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

Authors: Éabha O’Sullivan; A. Keogh; Brian Henderson; S. Finn; S. Gray; K. Gately

DOI: https://doi.org/10.3390/cancers15061635

Paper

Precision Oncology: Evolving Clinical Trials across Tumor Types

Song, I-Wen; Vo, Henry Hiep; Chen, Ying‐Shiuan et al. · 2023

Full title: Precision Oncology: Evolving Clinical Trials across Tumor Types

Authors: Song, I-Wen; Vo, Henry Hiep; Chen, Ying‐Shiuan; Baysal, Mehmet A.; Kahle, Michael; Johnson, Amber M.; Tsimberidou, Apostolia M.

DOI: https://doi.org/10.3390/cancers15071967

Paper

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Li, Shenduo; Correia, Guilherme Sacchi de Camargo; Wang, Jing et al. · 2023

Full title: Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Authors: Li, Shenduo; Correia, Guilherme Sacchi de Camargo; Wang, Jing; Manochakian, Rami; Zhao, Yujie; Lou, Yanyan

DOI: https://doi.org/10.3390/cancers15112899

Paper

New Actions on Actionable Mutations in Lung Cancers

Le, Xiuning; Elamin, Yasir Y.; Zhang, Jianjun · 2023

Full title: New Actions on Actionable Mutations in Lung Cancers

Authors: Le, Xiuning; Elamin, Yasir Y.; Zhang, Jianjun

DOI: https://doi.org/10.3390/cancers15112917

Paper

Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment

Restrepo, Juan Carlos; Dueñas, Diana; Corredor, Zuray et al. · 2023

Full title: Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment

Authors: Restrepo, Juan Carlos; Dueñas, Diana; Corredor, Zuray; Liscano, Yamil

DOI: https://doi.org/10.3390/cancers15133474

Paper

Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience

Chmielewska, Izabela; Krawczyk, Paweł; Grenda, Anna et al. · 2023

Authors: Chmielewska, Izabela; Krawczyk, Paweł; Grenda, Anna; Wójcik-Superczyńska, Magdalena; Krzyżanowska, Natalia; Gil, Michał; Milanowski, Janusz

DOI: https://doi.org/10.3390/cancers15143732

Paper

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib

A. Nolan; C. Raso; W. Kolch et al. · 2023

Full title: Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib

Authors: A. Nolan; C. Raso; W. Kolch; A. Kriegsheim; Kieran Wynne; D. Matallanas

DOI: https://doi.org/10.3390/cancers15164141

Paper

Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams

Serra, Massimo; Rubes, Davide; Schinelli, Sergio et al. · 2023

Full title: Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams

Authors: Serra, Massimo; Rubes, Davide; Schinelli, Sergio; Paolillo, Mayra

DOI: https://doi.org/10.3390/cancers15164173

Paper

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure

Jesus, Victor Hugo Fonseca de; Mathias-Machado, Maria Cecília; Farias, João Paulo Fogacci de et al. · 2023

Full title: Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure

Authors: Jesus, Victor Hugo Fonseca de; Mathias-Machado, Maria Cecília; Farias, João Paulo Fogacci de; Aruquipa, Marcelo Porfírio Sunagua; Jácome, Alexandre A.; Peixoto, Renata D’Alpino

DOI: https://doi.org/10.3390/cancers15205015

Paper

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations

Attili, Ilaria; Corvaja, Carla; Spitaleri, Gianluca et al. · 2023

Full title: New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations

Authors: Attili, Ilaria; Corvaja, Carla; Spitaleri, Gianluca; Signore, Ester Del; Aliaga, Pamela Trillo; Passaro, Antonio; Marinis, Filippo de

DOI: https://doi.org/10.3390/cancers15205079

Paper

Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

Cian O’Leary; Grace Murphy; Yong Yeung et al. · 2023

Full title: Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

Authors: Cian O’Leary; Grace Murphy; Yong Yeung; Ming Tang; Vikram Jain; C.G. O’Leary

DOI: https://doi.org/10.3390/cancers15235582

Paper

KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

Fujimoto, Kazushi; Ikeda, Satoshi; Tabata, Erina et al. · 2024

Full title: KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

DOI: https://doi.org/10.3390/cancers16071327

Paper

Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

Anastasia Karachaliou; E. Kotteas; O. Fiste et al. · 2024

Full title: Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

Authors: Anastasia Karachaliou; E. Kotteas; O. Fiste; Konstantinos N. Syrigos

DOI: https://doi.org/10.3390/cancers16081447

Paper

Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials

T. Peng; Ta-Wei Wu; Tai-Yung Yi et al. · 2024

Full title: Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials

Authors: T. Peng; Ta-Wei Wu; Tai-Yung Yi; An-Jan Wu

DOI: https://doi.org/10.3390/cancers16213676

Paper

Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer

Dekker, Simone E.; Deng, Lei · 2024

Full title: Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer

Authors: Dekker, Simone E.; Deng, Lei

DOI: https://doi.org/10.3390/cancers16223885

Paper

Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways

Šereš, Mário; Spacayova, Katarina; Sulová, Zdena et al. · 2025

Full title: Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways

Authors: Šereš, Mário; Spacayova, Katarina; Sulová, Zdena; Špaldová, Jana; Breier, Albert; Pavlíková, Lucia

DOI: https://doi.org/10.3390/cancers17020248

Paper

Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)

Mina, Syeda A.; Shanshal, Mohamed; Leventakos, Konstantinos et al. · 2025

Full title: Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)

Authors: Mina, Syeda A.; Shanshal, Mohamed; Leventakos, Konstantinos; Parikh, Kaushal

DOI: https://doi.org/10.3390/cancers17030353

Paper

Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

Soumavo Mukherjee; D. Suresh; Ajit P. Zambre et al. · 2025

Full title: Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

Authors: Soumavo Mukherjee; D. Suresh; Ajit P. Zambre; Sairam Yadavilli; Shreya Ghoshdastidar; Anandhi Upendran; R. Kannan

DOI: https://doi.org/10.3390/cancers17030490

Paper

KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges

P. P. Vitiello; A. A. Valsecchi; Eleonora Duregon et al. · 2025

Full title: KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges

Authors: P. P. Vitiello; A. A. Valsecchi; Eleonora Duregon; Paola Francia di Celle; P. Cassoni; M. Papotti; A. Bardelli; M. Di Maio

DOI: https://doi.org/10.3390/cancers17172803

Paper

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?

Krzyżanowska, Natalia; Krawczyk, Paweł; Wojas‐Krawczyk, Kamila et al. · 2022

Full title: Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?

Authors: Krzyżanowska, Natalia; Krawczyk, Paweł; Wojas‐Krawczyk, Kamila; Kucharczyk, Tomasz; Milanowski, Janusz

DOI: https://doi.org/10.3390/cells11203280

Paper

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

Lam, Kuen Kuen; Wong, Siew Heng; Cheah, Peh Yean · 2023

Full title: Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

Authors: Lam, Kuen Kuen; Wong, Siew Heng; Cheah, Peh Yean

DOI: https://doi.org/10.3390/cells12040631

Paper

Cutting-Edge Therapies for Lung Cancer

La’ah, Anita Silas; Chiou, Shih‐Hwa · 2024

Full title: Cutting-Edge Therapies for Lung Cancer

Authors: La’ah, Anita Silas; Chiou, Shih‐Hwa

DOI: https://doi.org/10.3390/cells13050436

Paper

The Role of Oxidative Stress in Tumorigenesis and Progression

Li, Kexin; Deng, Zhangyuzi; Lei, Chunran et al. · 2024

Full title: The Role of Oxidative Stress in Tumorigenesis and Progression

Authors: Li, Kexin; Deng, Zhangyuzi; Lei, Chunran; Ding, Xiaoqing; Li, Jing; Wang, Changshan

DOI: https://doi.org/10.3390/cells13050441

Paper

Hippo Signaling at the Hallmarks of Cancer and Drug Resistance

Kumar, Ramesh; Hong, Wanjin · 2024

Full title: Hippo Signaling at the Hallmarks of Cancer and Drug Resistance

Authors: Kumar, Ramesh; Hong, Wanjin

DOI: https://doi.org/10.3390/cells13070564

Paper

Genetic Signature of Human Pancreatic Cancer and Personalized Targeting

Reshkin, Stephan J.; Cardone, Rosa Angela; Koltai, Tomas · 2024

Full title: Genetic Signature of Human Pancreatic Cancer and Personalized Targeting

Authors: Reshkin, Stephan J.; Cardone, Rosa Angela; Koltai, Tomas

DOI: https://doi.org/10.3390/cells13070602

Paper

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Degirmenci, Ufuk; Wang, Mei; Hu, Jiancheng · 2020

Full title: Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Authors: Degirmenci, Ufuk; Wang, Mei; Hu, Jiancheng

DOI: https://doi.org/10.3390/cells9010198

Paper

Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond

Shetu, Shaila A.; James, Nneoma; Rivera, Gildardo et al. · 2023

Full title: Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond

Authors: Shetu, Shaila A.; James, Nneoma; Rivera, Gildardo; Bandyopadhyay, Debasish

DOI: https://doi.org/10.3390/cimb45030124

Paper

Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery

Ramalingam, Prasanna Srinivasan; Balakrishnan, Purushothaman; Rajendran, Senthilnathan et al. · 2023

Full title: Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery

Authors: Ramalingam, Prasanna Srinivasan; Balakrishnan, Purushothaman; Rajendran, Senthilnathan; Arunachalam, J.; Rajasekaran, R.; Arumugam, Sivakumar

DOI: https://doi.org/10.3390/cimb45030137

Paper

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Mithoowani, Hamid; Febbraro, Michela · 2022

Full title: Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Authors: Mithoowani, Hamid; Febbraro, Michela

DOI: https://doi.org/10.3390/curroncol29030150

Paper

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Cho, Byoung Chul; Loong, Herbert H.; Tsai, Chun‐Ming et al. · 2022

Full title: Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Authors: Cho, Byoung Chul; Loong, Herbert H.; Tsai, Chun‐Ming; Teo, Man Lung P.; Kim, Hye Ryun; Lim, Sun Min; Jain, Suyog; Olsen, Steve; Park, Keunchil

DOI: https://doi.org/10.3390/curroncol29030174

Paper

The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis

McGuire, Anna; McConechy, Melissa K.; Melosky, Barbara et al. · 2022

Full title: The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis

DOI: https://doi.org/10.3390/curroncol29040215

Paper

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Cheema, Parneet; Banerji, Shantanu; Blais, Normand et al. · 2023

Full title: Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

DOI: https://doi.org/10.3390/curroncol30070476

Paper

Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer

Kano, Yoshihito; Suenaga, Mitsukuni; Uetake, Hiroyuki · 2023

Full title: Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer

Authors: Kano, Yoshihito; Suenaga, Mitsukuni; Uetake, Hiroyuki

DOI: https://doi.org/10.3390/curroncol30070480

Paper

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance

Leonard J. Ash; Ottavia Busia-Bourdain; Daniel Okpattah et al. · 2024

Full title: KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance

Authors: Leonard J. Ash; Ottavia Busia-Bourdain; Daniel Okpattah; Avrosina Kamel; Ariel N. Liberchuk; Andrew L. Wolfe

DOI: https://doi.org/10.3390/curroncol31040150

Paper

Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches.

Karki, Ramesh; Chen, Ru; Pan, Sheng · 2025

Full title: Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches.

Authors: Karki, Ramesh; Chen, Ru; Pan, Sheng

DOI: https://doi.org/10.3390/curroncol32110614

Paper

Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Wankhede, Durgesh; Bontoux, Christophe; Grover, Sandeep et al. · 2023

Full title: Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Authors: Wankhede, Durgesh; Bontoux, Christophe; Grover, Sandeep; Hofman, Paul

DOI: https://doi.org/10.3390/diagnostics13193043

Paper

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

Baldelli, Elisa; Gazzah, Emna El; Moran, John Conor et al. · 2021

Full title: Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

DOI: https://doi.org/10.3390/genes12091402

Paper

Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges

Meira, Débora Dummer; Caetano, Maria Clara de Castro e; Casotti, Matheus Correia et al. · 2023

Full title: Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges

DOI: https://doi.org/10.3390/genes14101906

Paper

Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation

Ni, Duan; Song, Kun; Zhang, Jian et al. · 2017

Full title: Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation

Authors: Ni, Duan; Song, Kun; Zhang, Jian; Lu, Shaoyong

DOI: https://doi.org/10.3390/ijms18112249

Paper

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

Rebuzzi, Sara Elena; Zullo, Lodovica; Rossi, Giovanni et al. · 2021

Full title: Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

DOI: https://doi.org/10.3390/ijms22052625

Paper

If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer

Köhler, Jens; Jänne, Pasi A. · 2021

Full title: If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer

Authors: Köhler, Jens; Jänne, Pasi A.

DOI: https://doi.org/10.3390/ijms22063025

Paper

Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives

Aleksakhina, Svetlana N.; Imyanitov, Evgeny N. · 2021

Full title: Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives

Authors: Aleksakhina, Svetlana N.; Imyanitov, Evgeny N.

DOI: https://doi.org/10.3390/ijms222010931

Paper

Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer

Lee, Jennifer J.; Jain, Vaibhav; Amaravadi, Ravi K. · 2021

Full title: Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer

Authors: Lee, Jennifer J.; Jain, Vaibhav; Amaravadi, Ravi K.

DOI: https://doi.org/10.3390/ijms222212402

Paper

The Role of EREG/EGFR Pathway in Tumor Progression

Cheng, Wanli; Feng, Po‐Hao; Lee, Kang‐Yun et al. · 2021

Full title: The Role of EREG/EGFR Pathway in Tumor Progression

Authors: Cheng, Wanli; Feng, Po‐Hao; Lee, Kang‐Yun; Chen, Kuan-Yuan; Sun, Wei-Lun; Hiệp, Nguyễn Văn; Luo, Ching-Shan; Wu, Sheng‐Ming

DOI: https://doi.org/10.3390/ijms222312828

Paper

KRAS: A Druggable Target in Colon Cancer Patients

F. Negri; L. Bottarelli; G. de’Angelis et al. · 2022

Full title: KRAS: A Druggable Target in Colon Cancer Patients

Authors: F. Negri; L. Bottarelli; G. de’Angelis; L. Gnetti

DOI: https://doi.org/10.3390/ijms23084120

Paper

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer

Calabrese, Fiorella; Pezzuto, Federica; Lunardi, Francesca et al. · 2022

Full title: Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer

Authors: Calabrese, Fiorella; Pezzuto, Federica; Lunardi, Francesca; Fortarezza, Francesco; Tzorakoleftheraki, Sofia‐Eleni; Resi, Maria Vittoria; Tinè, Mariaenrica; Pasello, Giulia; Hofman, Paul

DOI: https://doi.org/10.3390/ijms23084164

Paper

Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines

Oliveira, Renato José da Silva; Gomes, Izabela Natália Faria; Silva, Luciane Sussuchi da et al. · 2022

Full title: Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines

DOI: https://doi.org/10.3390/ijms23147774

Paper

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges

Serena Ceddia; L. Landi; F. Cappuzzo · 2022

Full title: KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges

Authors: Serena Ceddia; L. Landi; F. Cappuzzo

DOI: https://doi.org/10.3390/ijms23169391

Paper

In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis.

Tu, Gao; Liu, Qing; Qiu, Yue et al. · 2022

Full title: In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis.

Authors: Tu, Gao; Liu, Qing; Qiu, Yue; Leung, Elaine Lai-Han; Yao, Xiaojun

DOI: https://doi.org/10.3390/ijms232213845

Paper

Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study

Srisongkram, Tarapong; Weerapreeyakul, Natthida · 2022

Full title: Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study

Authors: Srisongkram, Tarapong; Weerapreeyakul, Natthida

DOI: https://doi.org/10.3390/ijms24010669

Paper

A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition

Barrios‐Bernal, Pedro; Lucio-Lozada, José; Ramos-Ramírez, Maritza et al. · 2023

Full title: A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition

Authors: Barrios‐Bernal, Pedro; Lucio-Lozada, José; Ramos-Ramírez, Maritza; Hernández‐Pedro, Norma; Arrieta, Óscar

DOI: https://doi.org/10.3390/ijms24054331

Paper

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy

E. Gurreri; G. Genovese; Luigi Perelli et al. · 2023

Full title: KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy

Authors: E. Gurreri; G. Genovese; Luigi Perelli; Antonio Agostini; G. Piro; C. Carbone; G. Tortora

DOI: https://doi.org/10.3390/ijms24119313

Paper

The Future of Precision Oncology

Rulten, Stuart L.; Grose, Richard; Gatz, Susanne A. et al. · 2023

Full title: The Future of Precision Oncology

Authors: Rulten, Stuart L.; Grose, Richard; Gatz, Susanne A.; Jones, J. Louise; Cameron, Angus J.M.

DOI: https://doi.org/10.3390/ijms241612613

Paper

Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers

Kim, Jimi · 2023

Full title: Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers

Authors: Kim, Jimi

DOI: https://doi.org/10.3390/ijms242316933

Paper

Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development

Ranđelović, Ivan; Nyíri, Kinga; Koppány, Gergely et al. · 2024

Full title: Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development

Authors: Ranđelović, Ivan; Nyíri, Kinga; Koppány, Gergely; Baranyi, Marcell; Tóvári, József; Kígyós, Attila; Tı́már, József; Vértessy, Beáta G.; Grolmusz, Vince

DOI: https://doi.org/10.3390/ijms25052572

Paper

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer

Xuan Wang; Johanna Breuer; S. Garbe et al. · 2024

Full title: Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer

Authors: Xuan Wang; Johanna Breuer; S. Garbe; Frank Giordano; Peter Brossart; Georg Feldmann; S. Bisht

DOI: https://doi.org/10.3390/ijms25116249

Paper

Emerging Targets in Non-Small Cell Lung Cancer

Liu, Louisa; Soler, Joshua; Reckamp, Karen L. et al. · 2024

Full title: Emerging Targets in Non-Small Cell Lung Cancer

Authors: Liu, Louisa; Soler, Joshua; Reckamp, Karen L.; Sankar, K. Nathan

DOI: https://doi.org/10.3390/ijms251810046

Paper

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer

Ki Lui; Kwok-Kuen Cheung; Winnie Wing Man Ng et al. · 2024

Full title: The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer

Authors: Ki Lui; Kwok-Kuen Cheung; Winnie Wing Man Ng; Yanping Wang; Doreen W. H. Au; W. C. Cho

DOI: https://doi.org/10.3390/ijms252211954

Paper

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

M. Cefalì; Samantha Epistolio; Giulia Ramelli et al. · 2022

Full title: Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

Authors: M. Cefalì; Samantha Epistolio; Giulia Ramelli; Dylan Mangan; F. Molinari; V. Martin; Stefania Freguia; L. Mazzucchelli; P. Froesch; M. Frattini; L. Wannesson

DOI: https://doi.org/10.3390/jcm11061627

Paper

KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration

Yunchen Yang; Huan Zhang; Shanshan Huang et al. · 2023

Full title: KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration

Authors: Yunchen Yang; Huan Zhang; Shanshan Huang; Q. Chu

DOI: https://doi.org/10.3390/jcm12020709

Paper

Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer

Stein, Matthew K.; Oluoha, Oluchukwu; Patel, Kruti et al. · 2021

Full title: Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer

Authors: Stein, Matthew K.; Oluoha, Oluchukwu; Patel, Kruti; Vanderwalde, Ari M.

DOI: https://doi.org/10.3390/jpm11060518

Paper

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

Šutić, Maja; Vukić, Ana; Baranašić, Jurica et al. · 2021

Full title: Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

Authors: Šutić, Maja; Vukić, Ana; Baranašić, Jurica; Försti, Asta; Džubur, Feđa; Samaržija, Miroslav; Jakopović, Marko; Brčić, Luka; Knežević, Jelena

DOI: https://doi.org/10.3390/jpm11111102

Paper

A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer

Manolakos, Peter; Ward, Linda · 2023

Full title: A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer

Authors: Manolakos, Peter; Ward, Linda

DOI: https://doi.org/10.3390/jpm13061010

Paper

Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors

Sara Cherri; Laura Melocchi; L. Gandolfi et al. · 2023

Full title: Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors

Authors: Sara Cherri; Laura Melocchi; L. Gandolfi; G. Rossi; A. Zaniboni

DOI: https://doi.org/10.3390/life13020395

Paper

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021

Sochacka-Ćwikła, Aleksandra; Mą̨czyński, Marcin; Regiec, Andrzej · 2022

Full title: FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021

Authors: Sochacka-Ćwikła, Aleksandra; Mą̨czyński, Marcin; Regiec, Andrzej

DOI: https://doi.org/10.3390/molecules27072259

Paper

New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine

Wang, Nana; Mei, Haibo; Dhawan, Gagan et al. · 2023

Full title: New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine

Authors: Wang, Nana; Mei, Haibo; Dhawan, Gagan; Zhang, Wei; Han, Jianlin; Soloshonok, Vadim A.

DOI: https://doi.org/10.3390/molecules28093651

Paper

A Deep-Learning Proteomic-Scale Approach for Drug Design

Overhoff, Brennan; Falls, Zackary; Mangione, William et al. · 2021

Full title: A Deep-Learning Proteomic-Scale Approach for Drug Design

Authors: Overhoff, Brennan; Falls, Zackary; Mangione, William; Samudrala, Ram

DOI: https://doi.org/10.3390/ph14121277

Paper

Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Lee, Jesang; Park, Seung Bum · 2022

Full title: Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Authors: Lee, Jesang; Park, Seung Bum

DOI: https://doi.org/10.3390/ph15121478

Paper

TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.

Tammaccaro, Salvina Laura; Prigent, Philippe; Le Bail, Jean-Christophe et al. · 2023

Full title: TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.

DOI: https://doi.org/10.3390/ph16040553

Paper

Recent Advances in Covalent Drug Discovery

Schaefer, D. M.; Cheng, Xinlai · 2023

Full title: Recent Advances in Covalent Drug Discovery

Authors: Schaefer, D. M.; Cheng, Xinlai

DOI: https://doi.org/10.3390/ph16050663

Paper

Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise.

Alanazi, Fawaz E; Alatawi, Yasser; Alattar, Abdullah et al. · 2025

Full title: Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise.

Authors: Alanazi, Fawaz E; Alatawi, Yasser; Alattar, Abdullah; Alshaman, Reem; Kotb, Ahmed A; Hetta, Helal F

DOI: https://doi.org/10.3390/ph18121788

Paper

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

A. Indini; E. Rijavec; M. Ghidini et al. · 2021

Full title: Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

Authors: A. Indini; E. Rijavec; M. Ghidini; A. Cortellini; F. Grossi

DOI: https://doi.org/10.3390/pharmaceutics13050653

Paper

Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer

Leone, Gian Marco; Candido, Saverio; Lavoro, Alessandro et al. · 2023

Full title: Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer

Authors: Leone, Gian Marco; Candido, Saverio; Lavoro, Alessandro; Vivarelli, Silvia; Gattuso, Giuseppe; Călina, Daniela; Libra, Massimo; Falzone, Luca

DOI: https://doi.org/10.3390/pharmaceutics15041252

Paper

The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers

Andrade, Fernanda; German-Cortés, Júlia; Montero‐Herradón, Sara et al. · 2023

Full title: The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers

DOI: https://doi.org/10.3390/pharmaceutics15061686

Paper

Emerging Treatment Options in Lung Cancer

Addeo, Alfredo · 2022

Full title: Emerging Treatment Options in Lung Cancer

Authors: Addeo, Alfredo

DOI: https://doi.org/10.36000/hbt.oh.2022.13.076

Paper

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer

Caputo, Vincenza; Ciardiello, Fortunato; Corte, Carminia M. Della et al. · 2023

Full title: Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer

Authors: Caputo, Vincenza; Ciardiello, Fortunato; Corte, Carminia M. Della; Martini, Giulia; Troiani, Teresa; Napolitano, Stefania

DOI: https://doi.org/10.37349/etat.2023.00125

Paper

Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies

Malik, Parth; Rani, Ruma; Solanki, Raghu et al. · 2023

Full title: Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies

Authors: Malik, Parth; Rani, Ruma; Solanki, Raghu; Patel, Vishal Haribhai; Mukherjee, Tapan K.

DOI: https://doi.org/10.37349/etat.2023.00171

Paper

Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer

Wu, Jingbo; Li, Xiaojing; Liu, Hui et al. · 2023

Full title: Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer

Authors: Wu, Jingbo; Li, Xiaojing; Liu, Hui; Liu, Yong-Juan; Liu, Xiuping

DOI: https://doi.org/10.3892/br.2023.1686

Paper

Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis

Liu, Xiaofeng; Hai, Yang; Dong, Jinqu et al. · 2022

Full title: Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis

Authors: Liu, Xiaofeng; Hai, Yang; Dong, Jinqu; Xu, Lan; Hou, Wenqian; Su, Jing; Ren, Weiyu; Liu, Dongling

DOI: https://doi.org/10.3892/ijo.2022.5447

Paper

Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL‑XL

Kitazawa, Masato; Miyagawa, Yusuke; Koyama, Makoto et al. · 2021

DOI: https://doi.org/10.3892/mco.2021.2310

Paper

Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.

Baoyin Zhao; Jing Wang; B. Song et al. · 2015

Full title: Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.

Authors: Baoyin Zhao; Jing Wang; B. Song; Hong Wei; Weipeng Lv; L. Tian; Mei Li; Shen Lv

DOI: https://doi.org/10.3892/mmr.2014.3058

Paper

Phenotypic screening using large‑scale genomic libraries to identify drug targets for the treatment of cancer (Review)

Sato, Mitsuo · 2020

Full title: Phenotypic screening using large‑scale genomic libraries to identify drug targets for the treatment of cancer (Review)

Authors: Sato, Mitsuo

DOI: https://doi.org/10.3892/ol.2020.11512

Paper

Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta‑analysis

Li, Shu; Wang, Xiaotong; Li, Qiuhong et al. · 2022

Full title: Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta‑analysis

Authors: Li, Shu; Wang, Xiaotong; Li, Qiuhong; Li, Chunli

DOI: https://doi.org/10.3892/ol.2022.13605

Paper

Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model

Hsu, Ping‐Chih; Tian, Bo; Yang, Yi‐Lin et al. · 2019

Full title: Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model

Authors: Hsu, Ping‐Chih; Tian, Bo; Yang, Yi‐Lin; Wang, Yucheng; Liu, Shu; Urisman, Anatoly; Yang, Cheng‐Ta; Xu, Zhidong; Jablons, David M.; You, Liang

DOI: https://doi.org/10.3892/or.2019.7207

Paper

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)

Zhang, Joshua; Darman, Lily; Hassan, Mohammad Rashedul et al. · 2023

Full title: Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)

Authors: Zhang, Joshua; Darman, Lily; Hassan, Mohammad Rashedul; Holzen, Urs von; Awasthi, Niranjan

DOI: https://doi.org/10.3892/or.2023.8643

Paper

Advances in targeting KRAS mutations: A promising approach for the treatment of non-small cell lung cancer (Review)

Upesh Sharma; Jincheng Song; Hemraj Kandu et al. · 2026

Full title: Advances in targeting KRAS mutations: A promising approach for the treatment of non-small cell lung cancer (Review)

Authors: Upesh Sharma; Jincheng Song; Hemraj Kandu; Yue Zhu; Zhaoxia Dai

DOI: https://doi.org/10.3892/or.2026.9044

Paper

Therapeutic Progress in Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer

Liu, Yi; HUANG, Zhen; CHEN, Lulu et al. · 2025

Full title: Therapeutic Progress in Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer

Authors: Liu, Yi; HUANG, Zhen; CHEN, Lulu; Song, Qibin

DOI: https://doi.org/10.3971/j.issn.1000-8578.2025.25.0438

Paper

Using Artificial Intelligence to select drug targets in oncology

Tudor I Oprea; Virgil Păunescu · 2024

Full title: Using Artificial Intelligence to select drug targets in oncology

Authors: Tudor I Oprea; Virgil Păunescu

DOI: https://doi.org/10.53011/jmro.2024.01.01

Paper

From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC

Hongyu Liu · 2025

Full title: From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC

Authors: Hongyu Liu

DOI: https://doi.org/10.54097/0trsfx05

Paper

Sotorasib and other drugs comparison in treating non-small cell lung cancer

Yueting Ren · 2022

Full title: Sotorasib and other drugs comparison in treating non-small cell lung cancer

Authors: Yueting Ren

DOI: https://doi.org/10.54097/hset.v8i.1256

Paper

Advancements in Targeted Therapies Based on the EGFR, and KRAS Genetic Mutations in Lung Cancer

Weiting Feng · 2024

Full title: Advancements in Targeted Therapies Based on the EGFR, and KRAS Genetic Mutations in Lung Cancer

Authors: Weiting Feng

DOI: https://doi.org/10.54254/2753-8818/2024.18031

Paper

A Novel Integrated Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma Based on Synergistic siRNA and Intelligent Nanocarriers

Yibing Li · 2026

Full title: A Novel Integrated Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma Based on Synergistic siRNA and Intelligent Nanocarriers

Authors: Yibing Li

DOI: https://doi.org/10.54254/2753-8818/2026.pj31652

Paper

KRAS Inhibition in Colorectal Cancer: Current Insights, Clinical Successes, and Ongoing Challenges

Furqan Memon; Momina Nadeem; C. Bah et al. · 2024

Full title: KRAS Inhibition in Colorectal Cancer: Current Insights, Clinical Successes, and Ongoing Challenges

Authors: Furqan Memon; Momina Nadeem; C. Bah; Muhammad Sulaiman; Umm-E- Hani; Ceaser Wankumbu Silumbwe; Muhammad Ali Amin Khan; Julius Mulumba; Jianjun Zou; Shengtao Yuan

DOI: https://doi.org/10.55561/ajhr.v3i3.180

Paper

Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human plasma: Implications for therapeutic drug monitoring

Hikita, Eri; Gando, Yoshito; Chubachi, Hideo et al. · 2023

Full title: Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human plasma: Implications for therapeutic drug monitoring

Authors: Hikita, Eri; Gando, Yoshito; Chubachi, Hideo; Shirota, Mikio; Kushiyama, Akifumi; Yasu, Takeo

DOI: https://doi.org/10.5582/ddt.2023.01043

Paper

PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Barua, Amrita; Kundu, Samrat T; Garza, Sofia G et al. · 2025

Full title: PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Authors: Barua, Amrita; Kundu, Samrat T; Garza, Sofia G; Fradette, Jared J; Choudhary, Bhagya Shree; Peng, David H; Diao, Lixia; Wang, Jing; Gibbons, Don L

DOI: https://doi.org/10.64898/2025.12.22.696060

Paper

Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

Lu, Yuqing; Yang, Yuewen; Zhu, Guanghao et al. · 2023

Full title: Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

Authors: Lu, Yuqing; Yang, Yuewen; Zhu, Guanghao; Zeng, Hairong; Fan, Yi‐Ming; Guo, Fujia; Xu, Dongshu; Wang, Boya; Chen, Dapeng; Ge, Guang‐Bo

DOI: https://doi.org/10.7150/ijbs.83026

Paper

Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks

Stravopodis, Dimitrios J.; Papavassiliou, Kostas A.; Papavassiliou, Athanasios G. · 2023

Full title: Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks

Authors: Stravopodis, Dimitrios J.; Papavassiliou, Kostas A.; Papavassiliou, Athanasios G.

DOI: https://doi.org/10.7150/ijbs.83574

Paper

S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance

Saptadwipa Ganguly; R. Burikhanov; Vitaliy M. Sviripa et al. · 2025

Full title: S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance

DOI: https://doi.org/10.7150/ijbs.96672

Paper

Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma

Wu, Xiaonan; Zhao, Jun; Yang, Ling et al. · 2022

Full title: Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma

DOI: https://doi.org/10.7150/jca.65370

Paper

Conquering oncogenic KRAS and its bypass mechanisms

Hou, Pingping; Wang, Yingshuang · 2022

Full title: Conquering oncogenic KRAS and its bypass mechanisms

Authors: Hou, Pingping; Wang, Yingshuang

DOI: https://doi.org/10.7150/thno.71260

Paper

KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review

Fatima, Sheereen; Pansuriya, Nirav; Lakhani, Alisha et al. · 2024

Full title: KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review

DOI: https://doi.org/10.7759/cureus.60061

Thesis

Adaptive resistance to EGFR-targeted therapy by calcium signaling in NSCLC cells

Mulder, Celine; Prust, Nadine; Van Doorn, Sander et al. · 2018

Full title: Adaptive resistance to EGFR-targeted therapy by calcium signaling in NSCLC cells

Authors: Mulder, Celine; Prust, Nadine; Van Doorn, Sander; Reinecke, Maria; Kuster, Bernhard; Van Bergen En Henegouwen, Paul; Lemeer, Simone

DOI: https://dspace.library.uu.nl/handle/1874/374409

Thesis

Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription

Kulkarni, A; Mohan, V; Tang, TT et al. · 2025

Full title: Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription

Authors: Kulkarni, A; Mohan, V; Tang, TT; Post, L; Chan, YC; Manning, M; Thio, N; Parker, BL; Dawson, MA; Rosenbluh, J; Vissers, JHA; Harvey, KF

DOI: https://hdl.handle.net/11343/358338

Thesis

Identification of therapeutic targets in canine bladder cancer: a translational model for MAPK pathway-targeted and immune-based therapies

Cronise, Kathryn Elizabeth, author; Duval, Dawn, advisor; Gustafson, Daniel, advisor et al. · 2021

Full title: Identification of therapeutic targets in canine bladder cancer: a translational model for MAPK pathway-targeted and immune-based therapies

Authors: Cronise, Kathryn Elizabeth, author; Duval, Dawn, advisor; Gustafson, Daniel, advisor; DeLuca, Jennifer, committee member; Page, Rodney, committee member; Thamm, Douglas, committee member

DOI: https://hdl.handle.net/10217/232608

Thesis

Aktuelle patientenindividuelle Behandlungsansätze beim metastasierten nicht-kleinzelligen Lungenkarzinom

Frost, Nikolaj · 2022

Full title: Aktuelle patientenindividuelle Behandlungsansätze beim metastasierten nicht-kleinzelligen Lungenkarzinom

Authors: Frost, Nikolaj

DOI: https://refubium.fu-berlin.de/handle/fub188/33608

Thesis

Hochdurchsatz-Sequenz-Analyse zur Identifikation von prädisponierenden sowie

Isau, Melanie · 2015

Full title: Hochdurchsatz-Sequenz-Analyse zur Identifikation von prädisponierenden sowie

Authors: Isau, Melanie

DOI: https://refubium.fu-berlin.de/handle/fub188/2221

Thesis

Perfil molecular do câncer de pulmão de não pequenas células em um hospital terciário no sul do Brasil

Andreis, Tiago Finger · 2023

Full title: Perfil molecular do câncer de pulmão de não pequenas células em um hospital terciário no sul do Brasil

Authors: Andreis, Tiago Finger

DOI: http://hdl.handle.net/10183/265098

Thesis

Carcinoma de pulmón no celula pequeña, con mutación de KRas: diferenciación y caracterización de subtipos, así como de los diferentes mecanismos de resistencia, para la elaboración de tratamientos dirigidos

Gil Moreno, María de los Llanos · 2019

Authors: Gil Moreno, María de los Llanos

DOI: http://hdl.handle.net/10803/665499

Thesis

FASTING-MIMICKING DIET-BASED NON-TOXIC COMBINATION THERAPY IN CANCER TREATMENT: FROM MOLECULES TO BEDSIDE

DI TANO, MAIRA · 2019

Full title: FASTING-MIMICKING DIET-BASED NON-TOXIC COMBINATION THERAPY IN CANCER TREATMENT: FROM MOLECULES TO BEDSIDE

Authors: DI TANO, MAIRA

DOI: http://hdl.handle.net/2434/609110

Thesis

SMAC-MIMETIC- AND TRAIL- BASED COMBINATIONS AS THERAPEUTIC STRATEGIES FOR KRAS-MUTATED CANCERS

A. Conti · 2015

Full title: SMAC-MIMETIC- AND TRAIL- BASED COMBINATIONS AS THERAPEUTIC STRATEGIES FOR KRAS-MUTATED CANCERS

Authors: A. Conti

DOI: http://hdl.handle.net/2434/249662

Thesis

Mechanisms of Resistance to MAPK Pathway Inhibition in RAS-Mutant Cancers

Wang, Belinda · 2017

Full title: Mechanisms of Resistance to MAPK Pathway Inhibition in RAS-Mutant Cancers

Authors: Wang, Belinda

DOI: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33493475

Thesis

Loss of Insulin Receptor Substrates 1 and 2 Suppresses Kras-Driven Non-Small Cell Lung Cancer

Xu, He (Clare) · 2019

Full title: Loss of Insulin Receptor Substrates 1 and 2 Suppresses Kras-Driven Non-Small Cell Lung Cancer

Authors: Xu, He (Clare)

DOI: http://nrs.harvard.edu/urn-3:HUL.InstRepos:39987870

Thesis

Co-targeting Translation Initiation and the RAS/ERK Pathway for the Treatment of KRAS-mutant Lung Cancer

Nardi, Francesca · 2024

Full title: Co-targeting Translation Initiation and the RAS/ERK Pathway for the Treatment of KRAS-mutant Lung Cancer

Authors: Nardi, Francesca

DOI: https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37377848

Thesis

Mapping the molecular mechanism of GTPases KRAS and RIT1 in lung cancer

Holmes, Kristin Dannielle · 2021

Full title: Mapping the molecular mechanism of GTPases KRAS and RIT1 in lung cancer

Authors: Holmes, Kristin Dannielle

DOI: http://hdl.handle.net/1773/47110

Thesis

The Molecular Epidemiology of Non-Small Cell Lung Cancer

Isaksson, Johan · 2023

Full title: The Molecular Epidemiology of Non-Small Cell Lung Cancer

Authors: Isaksson, Johan

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-497493

Thesis

Development of Combination Therapy with Anti-Cancer Drugs

Leijen, S. · 2013

Full title: Development of Combination Therapy with Anti-Cancer Drugs

Authors: Leijen, S.

DOI: https://dspace.library.uu.nl/handle/1874/267996

Thesis

Understanding Resistance to Targeted Anticancer Therapies

Sun, C. · 2015

Full title: Understanding Resistance to Targeted Anticancer Therapies

Authors: Sun, C.

DOI: https://dspace.library.uu.nl/handle/1874/304110

Thesis

Mutation and immune profiling of non-small cell lung cancer

La Fleur, Linnéa · 2019

Full title: Mutation and immune profiling of non-small cell lung cancer

Authors: La Fleur, Linnéa

DOI: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-390321

Thesis

Clinical Pharmacology of Genotype-Directed Anticancer Therapy: Towards Rational Combination Strategies

van Geel, Robin M J M · 2016

Full title: Clinical Pharmacology of Genotype-Directed Anticancer Therapy: Towards Rational Combination Strategies

Authors: van Geel, Robin M J M

DOI: https://dspace.library.uu.nl/handle/1874/341138

Thesis

Early clinical development of targeted anticancer agents

van Brummelen, E.M.J. · 2017

Full title: Early clinical development of targeted anticancer agents

Authors: van Brummelen, E.M.J.

DOI: https://dspace.library.uu.nl/handle/1874/356786

Thesis

A one-two punch model for cancer therapy

Wang, Liqin · 2018

Full title: A one-two punch model for cancer therapy

Authors: Wang, Liqin

DOI: https://dspace.library.uu.nl/handle/1874/364638

Thesis

From resistance to sensitivity and back – the full circle of resisting the inescapable

Šuštić, Tonći · 2020

Full title: From resistance to sensitivity and back – the full circle of resisting the inescapable

Authors: Šuštić, Tonći

DOI: https://dspace.library.uu.nl/handle/1874/396923

Thesis

Translational research of combined anticancer therapies targeting the MAPK pathway

Huijberts, Sanne Cornelia Francina Adriana · 2020

Full title: Translational research of combined anticancer therapies targeting the MAPK pathway

Authors: Huijberts, Sanne Cornelia Francina Adriana

DOI: https://dspace.library.uu.nl/handle/1874/406730

Thesis

Precision medicine in non-small cell lung cancer: Improving dosing strategies

Boosman, René Johan · 2022

Full title: Precision medicine in non-small cell lung cancer: Improving dosing strategies

Authors: Boosman, René Johan

DOI: https://dspace.library.uu.nl/handle/1874/420491

Thesis

All roads lead to SHP2

Mulero-Sánchez, Antonio · 2023

Full title: All roads lead to SHP2

Authors: Mulero-Sánchez, Antonio

DOI: https://dspace.library.uu.nl/handle/1874/430725

Thesis

Combine and conquer as a strategy to treat RAS-driven cancers

Jansen, Robin Alexandra · 2024

Full title: Combine and conquer as a strategy to treat RAS-driven cancers

Authors: Jansen, Robin Alexandra

DOI: https://dspace.library.uu.nl/handle/1874/437416

Thesis

Biomarker-driven treatment strategies in solid tumors: Insights from clinical and translational research

Embaby, Alaa · 2024

Full title: Biomarker-driven treatment strategies in solid tumors: Insights from clinical and translational research

Authors: Embaby, Alaa

DOI: https://dspace.library.uu.nl/handle/1874/451613

Thesis

LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology

Retmana, Irene Anindyajati · 2024

Full title: LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology

Authors: Retmana, Irene Anindyajati

DOI: https://dspace.library.uu.nl/handle/1874/455646

Thesis

Tumor cell-intrinsic signals promoting tolerance and adaptation to oncogenic kinase inhibition

Flower, Cameron Timothy · 2024

Full title: Tumor cell-intrinsic signals promoting tolerance and adaptation to oncogenic kinase inhibition

Authors: Flower, Cameron Timothy

DOI: https://hdl.handle.net/1721.1/156951

Thesis

Cross-species evaluation of Pan-RAF inhibitor LY3009120 or SOS1::KRAS inhibitor BI-3406 in human, canine, and equine malignant melanoma

Gao, Yu · 2024

Full title: Cross-species evaluation of Pan-RAF inhibitor LY3009120 or SOS1::KRAS inhibitor BI-3406 in human, canine, and equine malignant melanoma

Authors: Gao, Yu

DOI: https://nbn-resolving.org/urn:nbn:de:gbv:95-120575

Thesis

Investigating therapeutic chemotypes by merging functional genomics and drug design

Lou, Kevin · 2022

Full title: Investigating therapeutic chemotypes by merging functional genomics and drug design

Authors: Lou, Kevin

DOI: https://escholarship.org/uc/item/14s7p5tg

Thesis

Analysis of the initiation, progression and therapy of BRAF(V600E) and KRAS(G12D)- driven non-small cell lung adenocarcinoma using conditional mouse models

Trejo, Christy · 2012

Full title: Analysis of the initiation, progression and therapy of BRAF(V600E) and KRAS(G12D)- driven non-small cell lung adenocarcinoma using conditional mouse models

Authors: Trejo, Christy

DOI: https://escholarship.org/uc/item/1bv4t8kc

Thesis

Development of a scalable in-vivo drug discovery platform allows for deep interrogation of mechanisms of KRAS.G12C inhibitors.

Yu, John Xuzong · 2022

Full title: Development of a scalable in-vivo drug discovery platform allows for deep interrogation of mechanisms of KRAS.G12C inhibitors.

Authors: Yu, John Xuzong

DOI: https://escholarship.org/uc/item/17w596v6

Thesis

Investigation of Notch3-dependent mechanisms in KRAS-mutant lung adenocarcinoma

Hwang, Elizabeth Eujin · 2022

Full title: Investigation of Notch3-dependent mechanisms in KRAS-mutant lung adenocarcinoma

Authors: Hwang, Elizabeth Eujin

DOI: https://escholarship.org/uc/item/3204n09b

Thesis

Development of an Irreversible Mutant-Specific Inhibitor of Oncogenic K-Ras G12C

Ostrem, Jonathan Michael · 2013

Full title: Development of an Irreversible Mutant-Specific Inhibitor of Oncogenic K-Ras G12C

Authors: Ostrem, Jonathan Michael

DOI: https://escholarship.org/uc/item/23h9s068

Thesis

The cooperation of PIK3CA[H1047R] with BRAF[V600E] and KRAS[G12D] in lung tumorigenesis

Green, Shon · 2015

Full title: The cooperation of PIK3CA[H1047R] with BRAF[V600E] and KRAS[G12D] in lung tumorigenesis

Authors: Green, Shon

DOI: https://escholarship.org/uc/item/8fs8784n

Thesis

Tumor-Specific Therapies Targeting Antigen Presentation and Misregulated Proteolysis

Rohweder, Peter James · 2022

Full title: Tumor-Specific Therapies Targeting Antigen Presentation and Misregulated Proteolysis

Authors: Rohweder, Peter James

DOI: https://escholarship.org/uc/item/6nc3b40b

Thesis

Discovery and Design of Next Generation Inhibitors Targeting the HER2/HER3 heterodimer and K-Ras

Novotny, Chris J · 2016

Full title: Discovery and Design of Next Generation Inhibitors Targeting the HER2/HER3 heterodimer and K-Ras

Authors: Novotny, Chris J

DOI: https://escholarship.org/uc/item/8zz805wx

Thesis

Targeting oncogenic K-Ras G12C and G13C via covalent drug design

Nnadi, Chimno · 2019

Full title: Targeting oncogenic K-Ras G12C and G13C via covalent drug design

Authors: Nnadi, Chimno

DOI: https://escholarship.org/uc/item/8np2j0vr

Thesis

CHARACTERIZATION OF THE TUMOR AND SYSTEMIC IMMUNOMODULATORY EFFECTS OF MEK1 INHIBITION

Dennison, Lauren · 2021

Full title: CHARACTERIZATION OF THE TUMOR AND SYSTEMIC IMMUNOMODULATORY EFFECTS OF MEK1 INHIBITION

Authors: Dennison, Lauren

DOI: http://jhir.library.jhu.edu/handle/1774.2/64286

Thesis

Identification of drug resistance mechanisms induced in response to KRAS therapeutics

Warren, Hannah · 2021

Full title: Identification of drug resistance mechanisms induced in response to KRAS therapeutics

Authors: Warren, Hannah

DOI: https://livrepository.liverpool.ac.uk/3140729/1/201218160_Sep2021.pdf

Thesis

103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)

Barlesi, F; Felip, E; Popat, S et al. · 2024

Authors: Barlesi, F; Felip, E; Popat, S; Solomon, B; Wolf, J; Li, BT; Wu, Y-L; Kerr, KM; Akamatsu, H; Camidge, DR; Gupta, R; Meloni, A; Dai, T; Borghaei, H

DOI: https://hdl.handle.net/11343/351906

Thesis

A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

Roth, S; Wilson, KC; Ramsay, RG et al. · 2025

Full title: A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

DOI: https://hdl.handle.net/11343/359449

Thesis

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J; Alonso, G; Kim, SH et al. · 2025

Full title: Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

DOI: https://hdl.handle.net/11343/358247

Thesis

The importance of Ras in drug resistance in cancer

Healy, Fiona M; Prior, Ian A; MacEwan, David J · 2022

Full title: The importance of Ras in drug resistance in cancer

Authors: Healy, Fiona M; Prior, Ian A; MacEwan, David J

DOI: https://livrepository.liverpool.ac.uk/3116829/1/Healy%20et%20al%20BJP%20clean.pdf

Thesis

The Frequency of Ras Mutations in Cancer

Prior, Ian A; Hood, Fiona E; Hartley, James L · 2020

Full title: The Frequency of Ras Mutations in Cancer

Authors: Prior, Ian A; Hood, Fiona E; Hartley, James L

DOI: https://livrepository.liverpool.ac.uk/3093548/1/Prior%20CR2020.pdf

Thesis

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Warren, Hannah R; Ross, Sarah J; Smith, Paul D et al. · 2022

Full title: Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Authors: Warren, Hannah R; Ross, Sarah J; Smith, Paul D; Coulson, Judy M; Prior, Ian A

DOI: https://livrepository.liverpool.ac.uk/3164900/1/bcj-2022-0440.pdf

Thesis

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Branstrom, Art · 2021

Full title: Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Authors: Branstrom, Art

DOI: https://doi.org/10.1038/s42003-021-01897-6

Thesis

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

Verissimo, Carla S; Overmeer, René M; Ponsioen, Bas et al. · 2016

Full title: Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

DOI: https://dspace.library.uu.nl/handle/1874/343547

Thesis

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

Subbiah, Vivek; Kreitman, Robert J; Wainberg, Zev A et al. · 2018

Full title: Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

DOI: https://dspace.library.uu.nl/handle/1874/362469

Thesis

Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Retmana, Irene A; Loos, Nancy H C; Schinkel, Alfred H et al. · 2021

Full title: Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Authors: Retmana, Irene A; Loos, Nancy H C; Schinkel, Alfred H; Beijnen, Jos H; Sparidans, Rolf W

DOI: https://dspace.library.uu.nl/handle/1874/412114

Thesis

Pharmacokinetics of the KRAS G12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

Loos, Nancy H C; Retmana, Irene A; Rijmers, Jamie et al. · 2023

Full title: Pharmacokinetics of the KRAS G12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

Authors: Loos, Nancy H C; Retmana, Irene A; Rijmers, Jamie; Wang, Yaogeng; Gan, Changpei; Lebre, Maria C; Sparidans, Rolf W; Beijnen, Jos H; Schinkel, Alfred H

DOI: https://dspace.library.uu.nl/handle/1874/432858

Thesis

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study

Retmana, Irene A.; Çelebi, Nefise; Rijmers, Jamie et al. · 2024

Full title: Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study

Authors: Retmana, Irene A.; Çelebi, Nefise; Rijmers, Jamie; Schinkel, Alfred H.; Beijnen, Jos H.; Sparidans, Rolf W.

DOI: https://dspace.library.uu.nl/handle/1874/437527

Thesis

Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

Retmana, Irene A; Loos, Nancy H C; Schinkel, Alfred H et al. · 2023

Authors: Retmana, Irene A; Loos, Nancy H C; Schinkel, Alfred H; Beijnen, Jos H; Sparidans, Rolf W

DOI: https://dspace.library.uu.nl/handle/1874/432864

Thesis

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure

Rijmers, Jamie; Retmana, Irene A; Bui, Viët et al. · 2024

Full title: ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure

Authors: Rijmers, Jamie; Retmana, Irene A; Bui, Viët; Arguedas, Davinia; Lebre, Maria C; Sparidans, Rolf W; Beijnen, Jos H; Schinkel, Alfred H

DOI: https://dspace.library.uu.nl/handle/1874/452188

Thesis

A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells

Hoang, Trish T.; Tanrikulu, Ismet Caglar; Vatland, Quinn A. et al. · 2020

Full title: A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells

Authors: Hoang, Trish T.; Tanrikulu, Ismet Caglar; Vatland, Quinn A.; Hoang, Trieu M.; Raines, Ronald T

DOI: https://hdl.handle.net/1721.1/123520

Thesis

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Krall, Elsa B; Munoz, Diana M; Ilic, Nina et al. · 2017

Full title: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

DOI: http://hdl.handle.net/1721.1/109867

Thesis

A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer

Gu, Li; Deng, Zhou J.; Roy, Sweta et al. · 2021

Full title: A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer

Authors: Gu, Li; Deng, Zhou J.; Roy, Sweta; Hammond, Paula T

DOI: https://hdl.handle.net/1721.1/130536

Thesis

The metabolic landscape of RAS-driven cancers from biology to therapy

Mukhopadhyay, Suman; Vander Heiden, Matthew G; McCormick, Frank · 2022

Full title: The metabolic landscape of RAS-driven cancers from biology to therapy

Authors: Mukhopadhyay, Suman; Vander Heiden, Matthew G; McCormick, Frank

DOI: https://hdl.handle.net/1721.1/136166.2

Thesis

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

Liu, Qingsong; Xu, Chunxiao; Kirubakaran, Sivapriya et al. · 2015

Full title: Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

DOI: http://hdl.handle.net/1721.1/96764

Thesis

Selective Killing of K-ras Mutant Cancer Cells by Novel Small Molecule Inducers of Oxidative Stress

Shaw, Alice; Winslow, Monte Meier; Magendantz, Margaret et al. · 2011

Full title: Selective Killing of K-ras Mutant Cancer Cells by Novel Small Molecule Inducers of Oxidative Stress

Authors: Shaw, Alice; Winslow, Monte Meier; Magendantz, Margaret; Ouyang, Chensi; Dowdle, James; Subramanian, Aravind; Lewis, Timothy A.; Maglathin, Rebecca L.; Tolliday, Nicola; Jacks, Tyler E

DOI: http://hdl.handle.net/1721.1/67456

Thesis

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

Martz, C. A.; Ottina, Kathleen; Singleton, K. R. et al. · 2015

Full title: Systematic identification of signaling pathways with potential to confer anticancer drug resistance

DOI: http://hdl.handle.net/1721.1/97538

Thesis

Systems Biology Approaches for Identifying Synthetic Lethal Targets in Cancer

Ku, Angel Alejandro · 2019

Full title: Systems Biology Approaches for Identifying Synthetic Lethal Targets in Cancer

Authors: Ku, Angel Alejandro

DOI: https://escholarship.org/uc/item/0gj863n2

Thesis

DIRECT PP2A ACTIVATION FOR THE TREATMENT OF KRAS- AND EGFR-DRIVEN LUNG ADENOCARCINOMA

Tohme, Rita · 2018

Full title: DIRECT PP2A ACTIVATION FOR THE TREATMENT OF KRAS- AND EGFR-DRIVEN LUNG ADENOCARCINOMA

Authors: Tohme, Rita

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=case1526073628472942

Thesis

Discovery of small molecules blocking oncogenic K-Ras activity

Kovar, Sarah E. · 2018

Full title: Discovery of small molecules blocking oncogenic K-Ras activity

Authors: Kovar, Sarah E.

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=wright1533299266181661

Thesis

SENSITIZATION TO TRAIL-INDUCED APOPTOSIS IN K-RAS 12 MUTANT PANCREATIC CANCER CELLS BY BITC

Wicker, Christina Ann · 2008

Full title: SENSITIZATION TO TRAIL-INDUCED APOPTOSIS IN K-RAS 12 MUTANT PANCREATIC CANCER CELLS BY BITC

Authors: Wicker, Christina Ann

DOI: http://rave.ohiolink.edu/etdc/view?acc_num=wright1215556518

Thesis

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)

Mian, Afsar Ali; Haberbosch, Isabella; Khamaisie, Hazem et al. · 2021

DOI: https://infoscience.epfl.ch/handle/20.500.14299/179752

Thesis

Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors

Desai, J; Gan, H; Barrow, C et al. · 2020

Full title: Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors

DOI: https://hdl.handle.net/11343/245843

Thesis

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Tutuka, CSA; Andrews, MC; Mariadason, JM et al. · 2021

Full title: PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Authors: Tutuka, CSA; Andrews, MC; Mariadason, JM; Ioannidis, P; Hudson, C; Cebon, J; Behren, A

DOI: https://hdl.handle.net/11343/259639

Thesis

P21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

Wang, K; Baldwin, GS; Nikfarjam, M et al. · 2021

Full title: P21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

Authors: Wang, K; Baldwin, GS; Nikfarjam, M; He, H

DOI: https://hdl.handle.net/11343/271165

Thesis

Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway

Wormald, S; Milla, L; O'Connor, L · 2021

Full title: Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway

Authors: Wormald, S; Milla, L; O'Connor, L

DOI: https://hdl.handle.net/11343/261432

Thesis

Landscape of KRAS G12C, Associated Genomic Alterations, and Interrelation with Immuno-Oncology Biomarkers in KRAS -Mutated Cancers

Salem, ME; El-Refai, SM; Sha, W et al. · 2022

Full title: Landscape of KRAS G12C, Associated Genomic Alterations, and Interrelation with Immuno-Oncology Biomarkers in KRAS -Mutated Cancers

Authors: Salem, ME; El-Refai, SM; Sha, W; Puccini, A; Grothey, A; George, TJ; Hwang, JJ; O'Neil, B; Barrett, AS; Kadakia, KC; Musselwhite, LW; Raghavan, D; Van Cutsem, E; Tabernero, J; Tie, J

DOI: https://hdl.handle.net/11343/307179

Thesis

ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer

Saad, MI; Alhayyani, S; McLeod, L et al. · 2022

Full title: ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer

DOI: https://hdl.handle.net/11343/304295

Thesis

Developments in systemic therapies for the management of lung cancer

Heynemann, S; Mitchell, P · 2023

Full title: Developments in systemic therapies for the management of lung cancer

Authors: Heynemann, S; Mitchell, P

DOI: https://hdl.handle.net/11343/338045

Thesis

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Choi, Y; Dharia, NV; Jun, T et al. · 2025

Full title: Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Authors: Choi, Y; Dharia, NV; Jun, T; Chang, J; Royer-Joo, S; Yau, KK; Assaf, ZJ; Aimi, J; Sivakumar, S; Montesion, M; Sacher, A; LoRusso, P; Desai, J; Schutzman, JL; Shi, Z

DOI: https://hdl.handle.net/11343/358323

Thesis

CRAF dimerization with ARAF regulates KRAS-driven tumor growth

Venkatanarayan, A; Liang, J; Yen, I et al. · 2022

Full title: CRAF dimerization with ARAF regulates KRAS-driven tumor growth

DOI: https://hdl.handle.net/11343/322098

Thesis

Major milestones in translational oncology.

Dragani, Tommaso A; Castells, Antoni; Kulasingam, Vathany et al. · 2016

Full title: Major milestones in translational oncology.

Authors: Dragani, Tommaso A; Castells, Antoni; Kulasingam, Vathany; Diamandis, Eleftherios P; Earl, Helena; Iams, Wade T; Lovly, Christine M; Sedelaar, JP Michiel; Schalken, Jack A

DOI: https://www.repository.cam.ac.uk/handle/1810/260591

Thesis

DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.

Majrashi, Taghreed A; Sabt, Ahmed; Almahli, Hadia et al. · 2024

Full title: DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.

DOI: https://www.repository.cam.ac.uk/handle/1810/365512

Thesis

The influence of the EGFR pathway in modulating the efficacy of gemcitabine

Luk, Peter Ping-Kit · 2011

Full title: The influence of the EGFR pathway in modulating the efficacy of gemcitabine

Authors: Luk, Peter Ping-Kit

DOI: http://hdl.handle.net/1959.4/50384

Thesis

Small RNA combination therapy for lung cancer

Tammela, Tuomas; Xue, Wen; Dahlman, James E. et al. · 2015

Full title: Small RNA combination therapy for lung cancer

DOI: http://hdl.handle.net/1721.1/95771

Thesis

Vývoj a validace nové metodiky pro obohacení a detekci cirkulující nádorové DNA u onkologických pacientů

Pláničková, Lenka · 2017

Full title: Vývoj a validace nové metodiky pro obohacení a detekci cirkulující nádorové DNA u onkologických pacientů

Authors: Pláničková, Lenka

DOI: http://hdl.handle.net/20.500.11956/91800

Thesis

The validity and predictive value of blood-based biomarkers in prediction of response in the treatment of metastatic non-small cell lung cancer: A systematic review

van Delft, F; Koffijberg, H; Retèl, V et al. · 2020

Full title: The validity and predictive value of blood-based biomarkers in prediction of response in the treatment of metastatic non-small cell lung cancer: A systematic review

Authors: van Delft, F; Koffijberg, H; Retèl, V; van den Heuvel, M; Ijzerman, M

DOI: https://hdl.handle.net/11343/246343

Thesis

Current highlights in lung cancer in 2021

Lim, KHJ; Solomon, BJ · 2021

Full title: Current highlights in lung cancer in 2021

Authors: Lim, KHJ; Solomon, BJ

DOI: https://hdl.handle.net/11343/287770

Thesis

Circulating tumour DNA to guide precision medicine in solid malignancies

Tan, Lavinia Tsia Yi · 2023

Full title: Circulating tumour DNA to guide precision medicine in solid malignancies

Authors: Tan, Lavinia Tsia Yi

DOI: https://hdl.handle.net/11343/326332

Thesis

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Basu, B; Krebs, MG; Sundar, R et al. · 2018

Full title: Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Thesis

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

Earl, Helena; Molica, Stefano; Rutkowski, Piotr · 2017

Full title: Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

Authors: Earl, Helena; Molica, Stefano; Rutkowski, Piotr

DOI: https://www.repository.cam.ac.uk/handle/1810/264598

Patent

us-2023346790-a1

· 2023

Full title: us-2023346790-a1

Patent

us-2023373999-a1

· 2023

Full title: us-2023373999-a1

Patent

us-2023372340-a1

· 2023

Full title: us-2023372340-a1

Patent

us-2023310436-a1

· 2023

Full title: us-2023310436-a1

Patent

us-2023357277-a1

· 2023

Full title: us-2023357277-a1

Patent

us-2023374042-a1

· 2023

Full title: us-2023374042-a1

Patent

us-2024016781-a1

· 2024

Full title: us-2024016781-a1

Patent

us-2023374036-a1

· 2023

Full title: us-2023374036-a1

Patent

us-2024025907-a1

· 2024

Full title: us-2024025907-a1

Patent

us-2024058321-a1

· 2024

Full title: us-2024058321-a1

Patent

us-2023383359-a1

· 2023

Full title: us-2023383359-a1

Patent

us-2023406860-a1

· 2023

Full title: us-2023406860-a1

Patent

us-2024108630-a1

· 2024

Full title: us-2024108630-a1

Patent

us-2024058441-a1

· 2024

Full title: us-2024058441-a1

Patent

us-2024050430-a1

· 2024

Full title: us-2024050430-a1

Patent

us-2024059703-a1

· 2024

Full title: us-2024059703-a1

Patent

us-2024082218-a1

· 2024

Full title: us-2024082218-a1

Patent

us-2024101553-a1

· 2024

Full title: us-2024101553-a1

Patent

us-2024091230-a1

· 2024

Full title: us-2024091230-a1

Patent

us-2024083913-a1

· 2024

Full title: us-2024083913-a1

Patent

us-2024101573-a1

· 2024

Full title: us-2024101573-a1

Patent

us-2024124478-a1

· 2024

Full title: us-2024124478-a1

Patent

us-2024140948-a1

· 2024

Full title: us-2024140948-a1

Patent

us-2024141353-a1

· 2024

Full title: us-2024141353-a1

Patent

us-2024159756-a1

· 2024

Full title: us-2024159756-a1

Patent

us-2024173392-a1

· 2024

Full title: us-2024173392-a1

Patent

us-2024148733-a1

· 2024

Full title: us-2024148733-a1

Patent

us-2024158446-a1

· 2024

Full title: us-2024158446-a1

Patent

us-2024165208-a1

· 2024

Full title: us-2024165208-a1

Patent

us-2024190885-a1

· 2024

Full title: us-2024190885-a1

Patent

us-2024173328-a1

· 2024

Full title: us-2024173328-a1

Patent

us-2024139196-a1

· 2024

Full title: us-2024139196-a1

Patent

us-2024101557-a1

· 2024

Full title: us-2024101557-a1

Patent

us-2024174660-a1

· 2024

Full title: us-2024174660-a1

Patent

us-2024182470-a1

· 2024

Full title: us-2024182470-a1

Patent

us-2024238294-a1

· 2024

Full title: us-2024238294-a1

Patent

us-2024190862-a1

· 2024

Full title: us-2024190862-a1

Patent

us-2024173329-a1

· 2024

Full title: us-2024173329-a1

Patent

us-2024238397-a1

· 2024

Full title: us-2024238397-a1

Patent

us-2024197711-a1

· 2024

Full title: us-2024197711-a1

Patent

us-2024156821-a1

· 2024

Full title: us-2024156821-a1

Patent

us-2024216546-a1

· 2024

Full title: us-2024216546-a1

Patent

us-2024246954-a1

· 2024

Full title: us-2024246954-a1

Patent

us-2024219403-a1

· 2024

Full title: us-2024219403-a1

Patent

us-2024247000-a1

· 2024

Full title: us-2024247000-a1

Patent

us-2024228510-a1

· 2024

Full title: us-2024228510-a1

Patent

us-2024263146-a1

· 2024

Full title: us-2024263146-a1

Patent

us-2024287066-a1

· 2024

Full title: us-2024287066-a1

Patent

us-2024261289-a1

· 2024

Full title: us-2024261289-a1

Patent

us-2024293558-a1

· 2024

Full title: us-2024293558-a1

Patent

us-2024254122-a1

· 2024

Full title: us-2024254122-a1

Patent

us-2024279206-a1

· 2024

Full title: us-2024279206-a1

Patent

us-2024327425-a1

· 2024

Full title: us-2024327425-a1

Patent

us-2024358702-a1

· 2024

Full title: us-2024358702-a1

Patent

us-2024245686-a1

· 2024

Full title: us-2024245686-a1

Patent

us-2024352028-a1

· 2024

Full title: us-2024352028-a1

Patent

us-2024344136-a1

· 2024

Full title: us-2024344136-a1

Patent

us-2024343742-a1

· 2024

Full title: us-2024343742-a1

Patent

us-2024299392-a1

· 2024

Full title: us-2024299392-a1

Patent

us-2024287068-a1

· 2024

Full title: us-2024287068-a1

Patent

us-2024325363-a1

· 2024

Full title: us-2024325363-a1

Patent

us-2024307395-a1

· 2024

Full title: us-2024307395-a1

Patent

us-2024343735-a1

· 2024

Full title: us-2024343735-a1

Patent

us-2024374525-a1

· 2024

Full title: us-2024374525-a1

Patent

us-2024300964-a1

· 2024

Full title: us-2024300964-a1

Patent

us-2024335447-a1

· 2024

Full title: us-2024335447-a1

Patent

us-2024343813-a1

· 2024

Full title: us-2024343813-a1

Patent

us-2024374597-a1

· 2024

Full title: us-2024374597-a1

Patent

us-2024390340-a1

· 2024

Full title: us-2024390340-a1

Patent

us-2024368192-a1

· 2024

Full title: us-2024368192-a1

Patent

us-2024383922-a1

· 2024

Full title: us-2024383922-a1

Patent

us-2024400557-a1

· 2024

Full title: us-2024400557-a1

Patent

us-2024366567-a1

· 2024

Full title: us-2024366567-a1

Patent

us-2024376127-a1

· 2024

Full title: us-2024376127-a1

Patent

us-2024398815-a1

· 2024

Full title: us-2024398815-a1

Patent

us-2025032497-a1

· 2025

Full title: us-2025032497-a1

Patent

us-2024368156-a1

· 2024

Full title: us-2024368156-a1

Patent

us-2024366608-a1

· 2024

Full title: us-2024366608-a1

Patent

us-2024408098-a1

· 2024

Full title: us-2024408098-a1

Patent

us-2024417408-a1

· 2024

Full title: us-2024417408-a1

Patent

us-2024398814-a1

· 2024

Full title: us-2024398814-a1

Patent

us-2025009748-a1

· 2025

Full title: us-2025009748-a1

Patent

us-2025009753-a1

· 2025

Full title: us-2025009753-a1

Patent

us-2025049810-a1

· 2025

Full title: us-2025049810-a1

Patent

us-2024423987-a1

· 2024

Full title: us-2024423987-a1

Patent

us-2025108055-a1

· 2025

Full title: us-2025108055-a1

Patent

us-2025019387-a1

· 2025

Full title: us-2025019387-a1

Patent

us-2025082648-a1

· 2025

Full title: us-2025082648-a1

Patent

us-2025032494-a1

· 2025

Full title: us-2025032494-a1

Patent

us-2025099461-a1

· 2025

Full title: us-2025099461-a1

Patent

us-2025109147-a1

· 2025

Full title: us-2025109147-a1

Patent

us-2025042922-a1

· 2025

Full title: us-2025042922-a1

Patent

us-2025057817-a1

· 2025

Full title: us-2025057817-a1

Patent

us-2025049792-a1

· 2025

Full title: us-2025049792-a1

Patent

us-2025136582-a1

· 2025

Full title: us-2025136582-a1

Patent

us-2025136609-a1

· 2025

Full title: us-2025136609-a1

Patent

us-2025122210-a1

· 2025

Full title: us-2025122210-a1

Patent

us-2025108050-a1

· 2025

Full title: us-2025108050-a1

Patent

us-2025101042-a1

· 2025

Full title: us-2025101042-a1

Patent

us-2025127782-a1

· 2025

Full title: us-2025127782-a1

Patent

us-2025059208-a1

· 2025

Full title: us-2025059208-a1

Patent

us-2025136615-a1

· 2025

Full title: us-2025136615-a1

Patent

us-2025051365-a1

· 2025

Full title: us-2025051365-a1

Patent

us-2025129103-a1

· 2025

Full title: us-2025129103-a1

Patent

us-2025136621-a1

· 2025

Full title: us-2025136621-a1

Patent

us-2025154156-a1

· 2025

Full title: us-2025154156-a1

Patent

us-2025145589-a1

· 2025

Full title: us-2025145589-a1

Patent

us-2025188162-a1

· 2025

Full title: us-2025188162-a1

Patent

us-2025177399-a1

· 2025

Full title: us-2025177399-a1

Patent

us-2025154133-a1

· 2025

Full title: us-2025154133-a1

Patent

us-2025179077-a1

· 2025

Full title: us-2025179077-a1

Patent

us-2025205238-a1

· 2025

Full title: us-2025205238-a1

Patent

us-2025213579-a1

· 2025

Full title: us-2025213579-a1

Patent

us-2025188085-a1

· 2025

Full title: us-2025188085-a1

Patent

us-2025215087-a1

· 2025

Full title: us-2025215087-a1

Patent

us-2025249019-a1

· 2025

Full title: us-2025249019-a1

Patent

us-2025250286-a1

· 2025

Full title: us-2025250286-a1

Patent

us-2025221989-a1

· 2025

Full title: us-2025221989-a1

Patent

us-2025228834-a1

· 2025

Full title: us-2025228834-a1

Patent

us-2025262211-a1

· 2025

Full title: us-2025262211-a1

Patent

us-2025206759-a1

· 2025

Full title: us-2025206759-a1

Patent

us-2025213563-a1

· 2025

Full title: us-2025213563-a1

Patent

us-2025270206-a1

· 2025

Full title: us-2025270206-a1

Patent

us-2025282799-a1

· 2025

Full title: us-2025282799-a1

Patent

us-2025262213-a1

· 2025

Full title: us-2025262213-a1

Patent

us-2025268900-a1

· 2025

Full title: us-2025268900-a1

Patent

us-2025276982-a1

· 2025

Full title: us-2025276982-a1

Patent

us-2025276968-a1

· 2025

Full title: us-2025276968-a1

Patent

us-2025312333-a1

· 2025

Full title: us-2025312333-a1

Patent

us-2025295665-a1

· 2025

Full title: us-2025295665-a1

Patent

us-2025295664-a1

· 2025

Full title: us-2025295664-a1

Patent

us-2025270225-a1

· 2025

Full title: us-2025270225-a1

Patent

us-2025312343-a1

· 2025

Full title: us-2025312343-a1

Patent

us-9029089-b2

· 2015

Full title: us-9029089-b2

Patent

us-2018118757-a1

· 2018

Full title: us-2018118757-a1

Patent

us-2017197945-a1

· 2017

Full title: us-2017197945-a1

Patent

us-2018015087-a1

· 2018

Full title: us-2018015087-a1

Patent

us-2018273523-a1

· 2018

Full title: us-2018273523-a1

Patent

us-2018086753-a1

· 2018

Full title: us-2018086753-a1

Patent

us-2018155348-a1

· 2018

Full title: us-2018155348-a1

Patent

us-2018273515-a1

· 2018

Full title: us-2018273515-a1

Patent

us-2018127396-a1

· 2018

Full title: us-2018127396-a1

Patent

us-2018141927-a1

· 2018

Full title: us-2018141927-a1

Patent

us-2018194748-a1

· 2018

Full title: us-2018194748-a1

Patent

us-2018319775-a1

· 2018

Full title: us-2018319775-a1

Patent

us-2019070191-a1

· 2019

Full title: us-2019070191-a1

Patent

us-2018334454-a1

· 2018

Full title: us-2018334454-a1

Patent

us-2018273577-a1

· 2018

Full title: us-2018273577-a1

Patent

us-2018153919-a1

· 2018

Full title: us-2018153919-a1

Patent

us-2019055211-a1

· 2019

Full title: us-2019055211-a1

Patent

us-2019092767-a1

· 2019

Full title: us-2019092767-a1

Patent

us-2019270743-a1

· 2019

Full title: us-2019270743-a1

Patent

us-2019262342-a1

· 2019

Full title: us-2019262342-a1

Patent

us-2019062314-a1

· 2019

Full title: us-2019062314-a1

Patent

us-2018282308-a1

· 2018

Full title: us-2018282308-a1

Patent

us-2019077801-a1

· 2019

Full title: us-2019077801-a1

Patent

us-2018282307-a1

· 2018

Full title: us-2018282307-a1

Patent

us-2019367489-a1

· 2019

Full title: us-2019367489-a1

Patent

us-2019160148-a1

· 2019

Full title: us-2019160148-a1

Patent

us-2019345158-a1

· 2019

Full title: us-2019345158-a1

Patent

us-2019062330-a1

· 2019

Full title: us-2019062330-a1

Patent

us-2019343838-a1

· 2019

Full title: us-2019343838-a1

Patent

us-2019284144-a1

· 2019

Full title: us-2019284144-a1

Patent

us-2019144444-a1

· 2019

Full title: us-2019144444-a1

Patent

us-2019389796-a1

· 2019

Full title: us-2019389796-a1

Patent

us-2019375749-a1

· 2019

Full title: us-2019375749-a1

Patent

us-2019345169-a1

· 2019

Full title: us-2019345169-a1

Patent

us-2020010454-a1

· 2020

Full title: us-2020010454-a1

Patent

us-2019367534-a1

· 2019

Full title: us-2019367534-a1

Patent

us-2019389851-a1

· 2019

Full title: us-2019389851-a1

Patent

us-2019336514-a1

· 2019

Full title: us-2019336514-a1

Patent

us-2020181123-a1

· 2020

Full title: us-2020181123-a1

Patent

us-2020033346-a1

· 2020

Full title: us-2020033346-a1

Patent

us-2020010904-a1

· 2020

Full title: us-2020010904-a1

Patent

us-2020115363-a1

· 2020

Full title: us-2020115363-a1

Patent

us-2020069657-a1

· 2020

Full title: us-2020069657-a1

Patent

us-2020207766-a1

· 2020

Full title: us-2020207766-a1

Patent

us-2019374542-a1

· 2019

Full title: us-2019374542-a1

Patent

us-2020055845-a1

· 2020

Full title: us-2020055845-a1

Patent

us-2020308170-a1

· 2020

Full title: us-2020308170-a1

Patent

us-2020165231-a1

· 2020

Full title: us-2020165231-a1

Patent

us-2020239479-a1

· 2020

Full title: us-2020239479-a1

Patent

us-2020253868-a1

· 2020

Full title: us-2020253868-a1

Patent

us-2020222407-a1

· 2020

Full title: us-2020222407-a1

Patent

us-2020237758-a1

· 2020

Full title: us-2020237758-a1

Patent

us-2020262837-a1

· 2020

Full title: us-2020262837-a1

Patent

us-2021009577-a1

· 2021

Full title: us-2021009577-a1

Patent

us-2020325234-a1

· 2020

Full title: us-2020325234-a1

Patent

us-2020339554-a1

· 2020

Full title: us-2020339554-a1

Patent

us-2020331911-a1

· 2020

Full title: us-2020331911-a1

Patent

us-2021024501-a1

· 2021

Full title: us-2021024501-a1

Patent

us-2021115063-a1

· 2021

Full title: us-2021115063-a1

Patent

us-2021230162-a1

· 2021

Full title: us-2021230162-a1

Patent

us-2021032293-a1

· 2021

Full title: us-2021032293-a1

Patent

us-2021085683-a1

· 2021

Full title: us-2021085683-a1

Patent

us-2021188869-a1

· 2021

Full title: us-2021188869-a1

Patent

us-2021177844-a1

· 2021

Full title: us-2021177844-a1

Patent

us-2021198255-a1

· 2021

Full title: us-2021198255-a1

Patent

us-2021269434-a1

· 2021

Full title: us-2021269434-a1

Patent

us-2021355125-a1

· 2021

Full title: us-2021355125-a1

Patent

us-2021269432-a1

· 2021

Full title: us-2021269432-a1

Patent

us-2021230170-a1

· 2021

Full title: us-2021230170-a1

Patent

us-2021355141-a1

· 2021

Full title: us-2021355141-a1

Patent

us-2021261532-a1

· 2021

Full title: us-2021261532-a1

Patent

us-2021355121-a1

· 2021

Full title: us-2021355121-a1

Patent

us-10125134-b2

· 2018

Full title: us-10125134-b2

Patent

us-10111874-b2

· 2018

Full title: us-10111874-b2

Patent

us-10246424-b2

· 2019

Full title: us-10246424-b2

Patent

us-10144724-b2

· 2018

Full title: us-10144724-b2

Patent

us-10273207-b2

· 2019

Full title: us-10273207-b2

Patent

us-10414757-b2

· 2019

Full title: us-10414757-b2

Patent

us-10633381-b2

· 2020

Full title: us-10633381-b2

Patent

us-10428064-b2

· 2019

Full title: us-10428064-b2

Patent

us-10519146-b2

· 2019

Full title: us-10519146-b2

Patent

us-10398696-b2

· 2019

Full title: us-10398696-b2

Patent

us-10351550-b2

· 2019

Full title: us-10351550-b2

Patent

us-10640504-b2

· 2020

Full title: us-10640504-b2

Patent

us-10689377-b2

· 2020

Full title: us-10689377-b2

Patent

us-10829458-b2

· 2020

Full title: us-10829458-b2

Patent

us-10646488-b2

· 2020

Full title: us-10646488-b2

Patent

us-10723738-b2

· 2020

Full title: us-10723738-b2

Patent

us-10441587-b2

· 2019

Full title: us-10441587-b2

Patent

us-10711014-b2

· 2020

Full title: us-10711014-b2

Patent

us-10875842-b2

· 2020

Full title: us-10875842-b2

Patent

us-10858343-b2

· 2020

Full title: us-10858343-b2

Patent

us-10882847-b2

· 2021

Full title: us-10882847-b2

Patent

us-10647715-b2

· 2020

Full title: us-10647715-b2

Patent

us-10689356-b2

· 2020

Full title: us-10689356-b2

Patent

us-10919850-b2

· 2021

Full title: us-10919850-b2

Patent

us-11045484-b2

· 2021

Full title: us-11045484-b2

Patent

us-10730867-b2

· 2020

Full title: us-10730867-b2

Patent

us-11053226-b2

· 2021

Full title: us-11053226-b2

Patent

us-11090304-b2

· 2021

Full title: us-11090304-b2

Patent

us-10975071-b2

· 2021

Full title: us-10975071-b2

Patent

us-11096939-b2

· 2021

Full title: us-11096939-b2

Patent

us-10888559-b2

· 2021

Full title: us-10888559-b2

Patent

us-10888568-b2

· 2021

Full title: us-10888568-b2

Patent

us-10982287-b2

· 2021

Full title: us-10982287-b2

Patent

us-11091481-b2

· 2021

Full title: us-11091481-b2

Patent

us-10988485-b2

· 2021

Full title: us-10988485-b2

Patent

us-11285156-b2

· 2022

Full title: us-11285156-b2

Patent

us-11155879-b2

· 2021

Full title: us-11155879-b2

Patent

us-11352370-b2

· 2022

Full title: us-11352370-b2

Patent

us-11285135-b2

· 2022

Full title: us-11285135-b2

Patent

us-11439645-b2

· 2022

Full title: us-11439645-b2

Patent

us-11306087-b2

· 2022

Full title: us-11306087-b2

Patent

us-11390626-b2

· 2022

Full title: us-11390626-b2

Patent

us-11267812-b2

· 2022

Full title: us-11267812-b2

Patent

us-11548888-b2

· 2023

Full title: us-11548888-b2

Patent

us-11274093-b2

· 2022

Full title: us-11274093-b2

Patent

us-11434231-b2

· 2022

Full title: us-11434231-b2

Patent

us-11739102-b2

· 2023

Full title: us-11739102-b2

Patent

us-2022040182-a1

· 2022

Full title: us-2022040182-a1

Patent

us-2021290633-a1

· 2021

Full title: us-2021290633-a1

Patent

us-2022002298-a1

· 2022

Full title: us-2022002298-a1

Patent

us-2022064188-a1

· 2022

Full title: us-2022064188-a1

Patent

us-2022054492-a1

· 2022

Full title: us-2022054492-a1

Patent

us-2021379007-a1

· 2021

Full title: us-2021379007-a1

Patent

us-2022079947-a1

· 2022

Full title: us-2022079947-a1

Patent

us-2022112205-a1

· 2022

Full title: us-2022112205-a1

Patent

us-2022040181-a1

· 2022

Full title: us-2022040181-a1

Patent

us-2022112178-a1

· 2022

Full title: us-2022112178-a1

Patent

us-2022064696-a1

· 2022

Full title: us-2022064696-a1

Patent

us-2022168280-a1

· 2022

Full title: us-2022168280-a1

Patent

us-2022054491-a1

· 2022

Full title: us-2022054491-a1

Patent

us-2022096482-a1

· 2022

Full title: us-2022096482-a1

Patent

us-2022170909-a1

· 2022

Full title: us-2022170909-a1

Patent

us-2021380570-a1

· 2021

Full title: us-2021380570-a1

Patent

us-2022112192-a1

· 2022

Full title: us-2022112192-a1

Patent

us-2022106309-a1

· 2022

Full title: us-2022106309-a1

Patent

us-2022152026-a1

· 2022

Full title: us-2022152026-a1

Patent

us-2022154189-a1

· 2022

Full title: us-2022154189-a1

Patent

us-2022152030-a1

· 2022

Full title: us-2022152030-a1

Patent

us-2022175782-a1

· 2022

Full title: us-2022175782-a1

Patent

us-2022177531-a1

· 2022

Full title: us-2022177531-a1

Patent

us-2022153741-a1

· 2022

Full title: us-2022153741-a1

Patent

us-2022184179-a1

· 2022

Full title: us-2022184179-a1

Patent

us-2022177603-a1

· 2022

Full title: us-2022177603-a1

Patent

us-2022227738-a1

· 2022

Full title: us-2022227738-a1

Patent

us-2022267857-a1

· 2022

Full title: us-2022267857-a1

Patent

us-2022257599-a1

· 2022

Full title: us-2022257599-a1

Patent

us-2022227883-a1

· 2022

Full title: us-2022227883-a1

Patent

us-2022213101-a1

· 2022

Full title: us-2022213101-a1

Patent

us-2022194961-a1

· 2022

Full title: us-2022194961-a1

Patent

us-2022273643-a1

· 2022

Full title: us-2022273643-a1

Patent

us-2022340641-a1

· 2022

Full title: us-2022340641-a1

Patent

us-2022323446-a1

· 2022

Full title: us-2022323446-a1

Patent

us-2022306633-a1

· 2022

Full title: us-2022306633-a1

Patent

us-2022306688-a1

· 2022

Full title: us-2022306688-a1

Patent

us-2022395504-a1

· 2022

Full title: us-2022395504-a1

Patent

us-2022323614-a1

· 2022

Full title: us-2022323614-a1

Patent

us-2022401436-a1

· 2022

Full title: us-2022401436-a1

Patent

us-2022331324-a1

· 2022

Full title: us-2022331324-a1

Patent

us-2022395507-a1

· 2022

Full title: us-2022395507-a1

Patent

us-2022389013-a1

· 2022

Full title: us-2022389013-a1

Patent

us-2022402971-a1

· 2022

Full title: us-2022402971-a1

Patent

us-2022389033-a1

· 2022

Full title: us-2022389033-a1

Patent

us-2023124492-a1

· 2023

Full title: us-2023124492-a1

Patent

us-2023023023-a1

· 2023

Full title: us-2023023023-a1

Patent

us-2023072276-a1

· 2023

Full title: us-2023072276-a1

Patent

us-2023000867-a1

· 2023

Full title: us-2023000867-a1

Patent

us-2023103007-a1

· 2023

Full title: us-2023103007-a1

Patent

us-2023077225-a1

· 2023

Full title: us-2023077225-a1

Patent

us-2023128824-a1

· 2023

Full title: us-2023128824-a1

Patent

us-2023061083-a1

· 2023

Full title: us-2023061083-a1

Patent

us-2023114765-a1

· 2023

Full title: us-2023114765-a1

Patent

us-2023099858-a1

· 2023

Full title: us-2023099858-a1

Patent

us-2023183235-a1

· 2023

Full title: us-2023183235-a1

Patent

us-2023099204-a1

· 2023

Full title: us-2023099204-a1

Patent

us-2023121955-a1

· 2023

Full title: us-2023121955-a1

Patent

us-2023233569-a1

· 2023

Full title: us-2023233569-a1

Patent

us-2023201198-a1

· 2023

Full title: us-2023201198-a1

Patent

us-2023192696-a1

· 2023

Full title: us-2023192696-a1

Patent

us-2023143938-a1

· 2023

Full title: us-2023143938-a1

Patent

us-2023226040-a1

· 2023

Full title: us-2023226040-a1

Patent

us-2023233567-a1

· 2023

Full title: us-2023233567-a1

Patent

us-2023203018-a1

· 2023

Full title: us-2023203018-a1

Patent

us-2023257374-a1

· 2023

Full title: us-2023257374-a1

Patent

us-2023339981-a1

· 2023

Full title: us-2023339981-a1

Patent

us-2023338384-a1

· 2023

Full title: us-2023338384-a1

Patent

us-2023285498-a1

· 2023

Full title: us-2023285498-a1

Patent

us-2023174555-a1

· 2023

Full title: us-2023174555-a1

Patent

us-2023233558-a1

· 2023

Full title: us-2023233558-a1

Patent

us-2023303586-a1

· 2023

Full title: us-2023303586-a1

Patent

us-11723891-b2

· 2023

Full title: us-11723891-b2

Patent

us-11766436-b2

· 2023

Full title: us-11766436-b2

Patent

us-11878985-b2

· 2024

Full title: us-11878985-b2

Patent

us-11767320-b2

· 2023

Full title: us-11767320-b2

Patent

us-11932633-b2

· 2024

Full title: us-11932633-b2

Patent

us-11918584-b2

· 2024

Full title: us-11918584-b2

Patent

us-11939328-b2

· 2024

Full title: us-11939328-b2

Patent

us-11697657-b2

· 2023

Full title: us-11697657-b2

Patent

us-11905281-b2

· 2024

Full title: us-11905281-b2

Patent

us-12016862-b2

· 2024

Full title: us-12016862-b2

Patent

us-11890285-b2

· 2024

Full title: us-11890285-b2

Patent

us-11999753-b2

· 2024

Full title: us-11999753-b2

Patent

us-12059421-b2

· 2024

Full title: us-12059421-b2

Patent

us-12049483-b2

· 2024

Full title: us-12049483-b2

Patent

us-11945803-b2

· 2024

Full title: us-11945803-b2

Patent

us-11993597-b2

· 2024

Full title: us-11993597-b2

Patent

us-12077539-b2

· 2024

Full title: us-12077539-b2

Patent

us-12083121-b2

· 2024

Full title: us-12083121-b2

Patent

us-12128048-b2

· 2024

Full title: us-12128048-b2

Patent

us-12121519-b2

· 2024

Full title: us-12121519-b2

Patent

us-11999752-b2

· 2024

Full title: us-11999752-b2

Patent

us-12168058-b2

· 2024

Full title: us-12168058-b2

Patent

us-12208099-b2

· 2025

Full title: us-12208099-b2

Patent

us-12110289-b2

· 2024

Full title: us-12110289-b2

Patent

us-12280055-b2

· 2025

Full title: us-12280055-b2

Patent

us-12291539-b2

· 2025

Full title: us-12291539-b2

Patent

us-12383503-b2

· 2025

Full title: us-12383503-b2

Patent

us-12280056-b2

· 2025

Full title: us-12280056-b2

Patent

us-12180220-b2

· 2024

Full title: us-12180220-b2

Patent

us-12409178-b2

· 2025

Full title: us-12409178-b2

Patent

us-12378243-b2

· 2025

Full title: us-12378243-b2

Patent

us-12377101-b2

· 2025

Full title: us-12377101-b2

Patent

us-12391692-b2

· 2025

Full title: us-12391692-b2

Patent

us-12441742-b2

· 2025

Full title: us-12441742-b2

Patent

us-12398154-b2

· 2025

Full title: us-12398154-b2

Patent

us-12440491-b2

· 2025

Full title: us-12440491-b2

Patent

us-12336995-b2

· 2025

Full title: us-12336995-b2

Patent

us-12421253-b2

· 2025

Full title: us-12421253-b2

Patent

us-2012004116-a1

· 2012

Full title: us-2012004116-a1

Patent

us-2011262920-a1

· 2011

Full title: us-2011262920-a1

Patent

us-2012064175-a1

· 2012

Full title: us-2012064175-a1

Patent

us-2011269640-a1

· 2011

Full title: us-2011269640-a1

Patent

us-2013252831-a1

· 2013

Full title: us-2013252831-a1

Patent

us-2014350022-a1

· 2014

Full title: us-2014350022-a1

Patent

us-2013029336-a1

· 2013

Full title: us-2013029336-a1

Patent

us-2015239900-a1

· 2015

Full title: us-2015239900-a1

Patent

us-2016022680-a1

· 2016

Full title: us-2016022680-a1

Patent

us-2016108019-a1

· 2016

Full title: us-2016108019-a1

Patent

us-2015238515-a1

· 2015

Full title: us-2015238515-a1

Patent

us-2015184250-a1

· 2015

Full title: us-2015184250-a1

Patent

us-2016143906-a1

· 2016

Full title: us-2016143906-a1

Patent

us-2016159738-a1

· 2016

Full title: us-2016159738-a1

Patent

us-2016297774-a1

· 2016

Full title: us-2016297774-a1

Patent

us-2016120876-a1

· 2016

Full title: us-2016120876-a1

Patent

us-2017022184-a1

· 2017

Full title: us-2017022184-a1

Patent

us-9862701-b2

· 2018

Full title: us-9862701-b2

Patent

us-9884047-b1

· 2018

Full title: us-9884047-b1

Patent

us-re50490-e

· 2025

Full title: us-re50490-e

Patent

us-re50527-e

· 2025

Full title: us-re50527-e

Patent

us-10053737-b2

· 2018

Full title: us-10053737-b2

Patent

us-10329627-b1

· 2019

Full title: us-10329627-b1

Patent

us-10556906-b2

· 2020

Full title: us-10556906-b2

Patent

us-10774082-b2

· 2020

Full title: us-10774082-b2

Patent

us-11007183-b2

· 2021

Full title: us-11007183-b2

Patent

us-11141418-b1

· 2021

Full title: us-11141418-b1

Patent

us-11186878-b2

· 2021

Full title: us-11186878-b2

Patent

us-11312724-b2

· 2022

Full title: us-11312724-b2

Patent

us-11510919-b2

· 2022

Full title: us-11510919-b2

Patent

us-11859252-b2

· 2024

Full title: us-11859252-b2

Patent

us-11865182-b2

· 2024

Full title: us-11865182-b2

Patent

us-11965162-b2

· 2024

Full title: us-11965162-b2

Patent

us-12122787-b2

· 2024

Full title: us-12122787-b2

Patent

us-12168006-b2

· 2024

Full title: us-12168006-b2

Patent

us-12251383-b2

· 2025

Full title: us-12251383-b2

Patent

us-12447152-b2

· 2025

Full title: us-12447152-b2

Patent

us-2009202989-a1

· 2009

Full title: us-2009202989-a1

Patent

us-2011081651-a1

· 2011

Full title: us-2011081651-a1

Patent

us-2011319415-a1

· 2011

Full title: us-2011319415-a1

Patent

us-2013102595-a1

· 2013

Full title: us-2013102595-a1

Patent

us-2013203788-a1

· 2013

Full title: us-2013203788-a1

Patent

us-2015197814-a1

· 2015

Full title: us-2015197814-a1

Patent

us-2016040252-a1

· 2016

Full title: us-2016040252-a1

Patent

us-2016228451-a1

· 2016

Full title: us-2016228451-a1

Patent

us-2016317517-a1

· 2016

Full title: us-2016317517-a1

Patent

us-2019117596-a1

· 2019

Full title: us-2019117596-a1

Patent

us-2019352723-a1

· 2019

Full title: us-2019352723-a1

Patent

us-2020078360-a1

· 2020

Full title: us-2020078360-a1

Patent

us-2020140437-a1

· 2020

Full title: us-2020140437-a1

Patent

us-2020190596-a1

· 2020

Full title: us-2020190596-a1

Patent

us-2020246338-a1

· 2020

Full title: us-2020246338-a1

Patent

us-2020276189-a1

· 2020

Full title: us-2020276189-a1

Patent

us-2020338205-a1

· 2020

Full title: us-2020338205-a1

Patent

us-2021040564-a1

· 2021

Full title: us-2021040564-a1

Patent

us-2021230174-a1

· 2021

Full title: us-2021230174-a1

Patent

us-2021324383-a1

· 2021

Full title: us-2021324383-a1

Patent

us-2021401845-a1

· 2021

Full title: us-2021401845-a1

Patent

us-2022213100-a1

· 2022

Full title: us-2022213100-a1

Patent

us-2022235356-a1

· 2022

Full title: us-2022235356-a1

Patent

us-2022389029-a1

· 2022

Full title: us-2022389029-a1

Patent

us-2022395508-a1

· 2022

Full title: us-2022395508-a1

Patent

us-2023011378-a1

· 2023

Full title: us-2023011378-a1

Patent

us-2023023009-a1

· 2023

Full title: us-2023023009-a1

Patent

us-2023026856-a1

· 2023

Full title: us-2023026856-a1

Patent

us-2023105745-a1

· 2023

Full title: us-2023105745-a1

Patent

us-2023118795-a1

· 2023

Full title: us-2023118795-a1

Patent

us-2023158019-a1

· 2023

Full title: us-2023158019-a1

Patent

us-2023174526-a1

· 2023

Full title: us-2023174526-a1

Patent

us-2023203060-a1

· 2023

Full title: us-2023203060-a1

Patent

us-2023212170-a1

· 2023

Full title: us-2023212170-a1

Patent

us-2023226061-a1

· 2023

Full title: us-2023226061-a1

Patent

us-2023227472-a1

· 2023

Full title: us-2023227472-a1

Patent

us-2023357231-a1

· 2023

Full title: us-2023357231-a1

Patent

us-2023365563-a1

· 2023

Full title: us-2023365563-a1

Patent

us-2023406849-a1

· 2023

Full title: us-2023406849-a1

Patent

us-2024174690-a1

· 2024

Full title: us-2024174690-a1

Patent

us-2024180912-a1

· 2024

Full title: us-2024180912-a1

Patent

us-2024200146-a1

· 2024

Full title: us-2024200146-a1

Patent

us-2024246968-a1

· 2024

Full title: us-2024246968-a1

Patent

us-2024252664-a1

· 2024

Full title: us-2024252664-a1

Patent

us-2024300942-a1

· 2024

Full title: us-2024300942-a1

Patent

us-2024325394-a1

· 2024

Full title: us-2024325394-a1

Patent

us-2024342285-a1

· 2024

Full title: us-2024342285-a1

Patent

us-2024376107-a1

· 2024

Full title: us-2024376107-a1

Patent

us-2024390379-a1

· 2024

Full title: us-2024390379-a1

Patent

us-2024409558-a1

· 2024

Full title: us-2024409558-a1

Patent

us-2025002504-a1

· 2025

Full title: us-2025002504-a1

Patent

us-2025019385-a1

· 2025

Full title: us-2025019385-a1

Patent

us-2025034169-a1

· 2025

Full title: us-2025034169-a1

Patent

us-2025051333-a1

· 2025

Full title: us-2025051333-a1

Patent

us-2025051361-a1

· 2025

Full title: us-2025051361-a1

Patent

us-2025064946-a1

· 2025

Full title: us-2025064946-a1

Patent

us-2025066386-a1

· 2025

Full title: us-2025066386-a1

Patent

us-2025122211-a1

· 2025

Full title: us-2025122211-a1

Patent

us-2025129096-a1

· 2025

Full title: us-2025129096-a1

Patent

us-2025161305-a1

· 2025

Full title: us-2025161305-a1

Patent

us-2025163064-a1

· 2025

Full title: us-2025163064-a1

Patent

us-2025255868-a1

· 2025

Full title: us-2025255868-a1

Patent

us-2025262194-a1

· 2025

Full title: us-2025262194-a1

Patent

us-2025313553-a1

· 2025

Full title: us-2025313553-a1

Patent

us-9861623-b1

· 2018

Full title: us-9861623-b1

3. Authors & Profiles

Run data extraction first

Find authors first. Run extraction before finding authors.

4. Email Outreach

Generate emails first. Find authors, then generate emails.

Kras G12C Inhibitors In Nsclc Efficacy Resistance

1. Documents

Full text available

Metadata only

2. Data Extraction

3. Authors & Profiles

4. Email Outreach

Settings

Edit Email